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The interactions between chronic lymphocytic leukaemia (CLL) cells and the CLL 
microenvironment play an important role in the disease progression and development of 
resistance to therapies. CD40 stimulation of CLL cells by T cells represents a major 
interaction in vivo, contributing to the survival and proliferation of CLL cells. However, the 
molecular mechanisms mediating these effects of CD40 stimulation are not fully 
understood. Through the proteomics approach, this project aimed to identify 
molecules/pathways associated with the pro-survival effect of CD40 stimulation by studying 
the global changes in protein expression in CD40 stimulated CLL cells. Herein, it was 
independently confirmed that CD40 stimulation protected CLL cells from spontaneous and 
drug-induced cell death, which are in accordance with the previously published work. Mass 
spectrometry-based proteomic study identified 552 proteins that were differentially 
expressed in the CD40 stimulated CLL cells in comparison with their unstimulated 
counterparts. Bioinformatics analysis showed that these differentially expressed proteins 
were involved in a variety of biological processes. The functional enrichment analysis of the 
significantly up-regulated proteins identified the ‘cell-cell adhesions’ at the top of a list of 
the most enriched functional clusters. This cluster included 38 differentially expressed 
proteins, 17 of them with over 2-fold changes in protein expression. Among the proteins 
with over 2-fold changes in expression was the ATP-dependent RNA helicase DDX3X. The 
preliminary functional study suggested that DDX3X potentially plays a role in the CD40 
stimulation-mediated survival of CLL cells. Taken together, these data indicated that CD40 
stimulation produced the pro-survival effect by enhancing the cell adhesion properties of 
CLL cells. Therefore, the findings from this study have provided a reasonable foundation for 
future studies to investigate the molecular mechanisms responsible for the CD40 
stimulation-mediated survival of CLL cells, which could help identify potential targets for 
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Chapter 1. Introduction 
 
1.1 Chronic lymphocytic leukaemia 
1.1.1 Epidemiology 
Chronic lymphocytic leukaemia, CLL for short, is the most common leukaemia in adults in 
the Western world with 4.9/100,000 newly diagnosed cases every year in the United 
Kingdom (UK) and the United States of America (USA) (von Tresckow et al., 2019, Milne et 
al., 2020, Bosch and Dalla-Favera, 2019). It tends to affect the older adults with a median 
age of 74 at diagnosis and a male to female ratio of 1.3:1 (Bosch and Dalla-Favera, 2019). In 
comparison with Western countries, the incidence of CLL is relatively lower in Asian, African, 
and Caribbean countries, which indicates a racial disparity of CLL (Wu et al., 2010, Wu et al., 
2016). It has been reported that exposure to herbicides and pesticides, reduced recreational 
sun exposure, medical history of atopic health conditions, exposure to hepatitis C virus, and 
common infections may increase the risk of CLL (Slager et al., 2014, Landgren et al., 2007). 
Meanwhile, around 10% of the patients diagnosed with CLL have a family history of the 
disease, indicating CLL as one of the inherited haematological malignancies (Cerhan and 
Slager, 2015).  
 
1.1.2 The clinical features 
CLL is now defined as a malignancy of clonal expansion of B lymphocytes accumulating in 
the peripheral blood, bone marrow, lymph nodes, and other lymphoid tissues (Fabbri and 
Dalla-Favera, 2016). The diagnostic criteria of CLL require the presence of ≥ 5000 clonal B 
lymphocytes per microlitre in the peripheral blood persisting for more than 3 months 
(Hallek et al., 2018, Hallek, 2019). Together with small lymphocytic lymphoma (SLL), CLL is 
classified as the mature B cell neoplasm by the World Health Organization (WHO) and CLL is 
preceded by monoclonal B cell lymphocytosis (MBL) with a rate of 1-2% every year (Rossi 
and Gaidano, 2013). Based on the mutation status of the immunoglobulin heavy chain 
variable region (IGHV) genes, CLL is clinically classified into two subtypes, known as the 
IGHV-mutated (IGHV-M) and unmutated (IGHV-UM) CLL (Vardi et al., 2014). The clinical 
outcomes of patients with IGHV-M CLL are usually better than those with IGHV-UM CLL 
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(Damle et al., 1999, Hamblin et al., 1999). Currently, there are two staging systems, the Rai 
staging system (Rai et al., 1975) and the Binet staging system (Binet et al., 1981), which are 
used to clinically stratify CLL patients to direct therapy and predict survival. The Rai staging 
system (Table 1.1), together with the revised edition (Table 1.2), is commonly used in the 
USA, whereas the Binet staging system (Table 1.3) is widely applied in Europe (Eichhorst et 
al., 2015).  
Table 1.1 Rai staging system 
Stage Characteristics Median survival 
0 Only lymphocytosis in the peripheral blood and bone 
marrow infiltration 
> 150 months 
I Presence of lymphadenopathies 101 months 
II Presence of hepatosplenomegaly 71 months 
III Presence of anemia (defined as Hb < 11 g/dl) 19 months 
IV Presence of thrombocytopenia (Plt < 100,000/mm3) 19 months 
 
Table 1.2 Revised Rai staging system 
Stage Characteristics 
Low risk Only lymphocytosis in the peripheral blood and bone marrow 
infiltration (same as stage 0) 
Intermediate risk Presence of lymphadenopathies (same as stage I) and/or 
hepatosplenomegaly (same as stage II) 
High risk Presence of anemia (same as stage III) and/or thrombocytopenia 
(same as stage IV) 
 
Table 1.3 Binet staging system 
Stage Characteristics 
A No anemia (Hb > 10 g/dl) or thrombocytopenia (Plt > 100,000/mm3) and 
up to 2 lymphoid sites involved 
B No anemia (Hb > 10 g/dl) or thrombocytopenia (Plt > 100,000/mm3) and 
more than 2 lymphoid sites involved 
C Presence of anemia (Hb < 10 g/dl) or thrombocytopenia (Plt < 
100,000/mm3) regardless of the number of lymphoid sites involved 
 
Since the beginning of the 21st century, several genomic aberrations have been used as 
independent risk factors to direct the choice of therapy and briefly predict survival. The 
most frequent genetic lesions detected in the patients with CLL include the deletion of the 
long arm of chromosome 13 (del13q14), trisomy 12 (+12), the deletion of the long arm of 
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chromosome 11 (del11q22-q23), and the deletion of the short arm of chromosome 17 
(del17p13) (Hallek et al., 2018).  
Del13q14 has been found in 50-60% of patients with CLL and it is more frequently in 
patients with IGHV-M CLL (Döhner et al., 2000). Del13q14 is usually associated with a 
favourable prognosis compared with other genomic aberrations. It has been shown that the 
acquisition of del13q14 leads to the loss of microRNA (miR) clusters 15 and 16, both of 
which regulate the expression of the B cell lymphoma 2 (BCL-2) gene (Calin et al., 2002). The 
loss of miR15 and miR16 results in the upregulation of anti-apoptotic BCL-2 protein, which 
contributes to the proliferation and expansion of CLL B cells and the development of the 
disease (Calin et al., 2002, Klein et al., 2010).  
Trisomy 12 has been found in 10-20% of patients with CLL, which is indiscriminate among 
patients with IGHV-M CLL or IGHV-UM CLL (Döhner et al., 2000). Patients with trisomy 12 
are considered to have an intermediate prognosis but they are more likely to have the 
Richter transformation (Strati et al., 2015).  
Del11q22-23 can be detected in up to 20% of patients with CLL at diagnosis (Stankovic and 
Skowronska, 2014) and it frequently occurs the IGHV-UM CLL patients with the nodal 
disease (Döhner et al., 1997). Del11q22-23 disrupts the ataxia-telangiectasia mutated (ATM) 
gene encoding a kinase involved in DNA damage response (Shiloh and Ziv, 2013) and the 
disruption of the baculoviral IAP repeat-containing 3 (BIRC3) gene, a negative regulator of 
the non-canonical NF-κB pathway (Rossi et al., 2012). The prognosis of the patients with 
del11q22-23 is worse than the patients with del13q14 or trisomy 12 (Stankovic and 
Skowronska, 2014).  
Del17p13 occurs in less than 10% of the patients with CLL at diagnosis and more frequently 
in patients with IGHV-UM CLL (Döhner et al., 2000). It has reported that Del17p13 may lead 
to the loss of the TP53 gene, a tumour suppressor gene associated with the initiation of cell 
cycle arrest and apoptosis in cells with DNA damages (Chen, 2016). The frequency of 
Del17p13 increases in chemotherapy-resistant and refractory CLL patients (Gaidano et al., 
1991, Landau et al., 2015). The presence of del17p13 represents a poor prognosis and 
directly impacts the clinical choice of therapy (Zenz et al., 2008). TP53 mutations have been 
found in most of the CLL patients with Del17p13 and taken as an independent factor for the 
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poor prognosis resulting from the impaired p53 pathway (Scarfò et al., 2016). TP53 
mutations show preference in the IGHV-UM CLL patients (Campo et al., 2018). Studies have 
demonstrated that TP53 mutations play a role in the pathogenesis and progression of CLL 
and its incidence is increased with the progression of the disease (Rossi et al., 2014, Scarfò 
et al., 2016). 
Recently, several novel gene mutations have been identified including NOTCH1, Splicing 
factor 3b subunit 1 (SF3B1), BIRC3, myeloid differentiation primary response 88 (MYD88), 
and NFκ light polypeptide gene enhancer in B cells inhibitor-  (NFKBIE).  
NOTCH1 mutations have been found in around 10-15% of CLL patients at diagnosis with a 
higher preference in the patients with IGHV-UM CLL (Fabbri et al., 2011, Landau et al., 
2015). It has been reported that one-third of the CLL patients with NOTCH1 mutations also 
have trisomy 12 and that the presence of those two aberrations leads to poor prognosis (Del 
Giudice et al., 2012, Riches et al., 2014). The biological significance of NOTCH1 mutations in 
CLL Cells has not been fully understood but the preliminary investigation demonstrates that 
it may play a role in regulating the survival, proliferation, and migration of CLL cells (Rosati 
et al., 2009, López-Guerra et al., 2019). Clinically, it has been reported that CLL patients with 
NOTCH1 mutations exhibit unsatisfactory responses to the anti-CD20 monoclonal antibody 
(Stilgenbauer et al., 2014). Later, researchers found that patients with NOTCH1 mutated CLL 
have low expression levels of CD20 (Pozzo et al., 2016), which may be the reason for the 
poor response to the therapy with the anti-CD20 antibody.  
SF3B1 mutations have been found in 10-15% CLL patients, with a higher incidence in the 
patients of IGHV-UM CLL (Quesada et al., 2012). SF3B1 gene encodes an RNA-protein 
complex, U2 snRNP, and it is involved in the initial stage of RNA splicing (Quesada et al., 
2012, Landau et al., 2015, Allen and Parsons, 2015). SF3B1 mutations are associated with 
Del11q22-23 in CLL patients who have a poor prognosis (Wang et al., 2011a). It has been 
reported that SF3B1 mutated CLL cells without ATM and TP53 aberrations show impaired 
ATM/p53 transcriptional responses when they are treated by DNA damaging agents such as 
fludarabine (Te Raa et al., 2015).  
Mutations of the BIRC3 gene have been found in 4% of CLL patients at diagnosis (Rossi et al., 
2012). BIRC3 mutations have been more frequently found in patients with fludarabine-
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refractory CLL but it seems that BIRC3 mutations are independent of the TP53 aberration 
(Rossi et al., 2012). It has been shown that BIRC3 mutations result in an elimination of the C-
terminal RING domain of the BIRC3 protein, leading to a loss of its function for the 
degradation of a negative regulator of the non-canonical NF-κB signalling pathway, which 
causes sustained activation of this pathway (Keats et al., 2007). The age at diagnosis of the 
patients with BIRC3 mutated CLL is lower than the average age of CLL patients at diagnosis 
(Puente et al., 2015).  
MYD88 mutations have been found in around 5% of CLL patients with a higher prevalence in 
IGHV mutated CLL (Puente et al., 2011, Puente et al., 2015). MYD88 protein is a cytosolic 
adaptor protein participating in the Toll-like receptor pathway, which can further activate 
the NF-κB signalling pathway in normal B cells (Rawlings et al., 2012). Further studies are 
needed to establish the role of MYD88 mutations in CLL (Maleki et al., 2019).  
Besides BIRC3 and MYD88, NFKBIE mutations have been found as one more aberration 
involved in the aberrant activation of NF-κB signalling in CLL. NFKBIE gene encodes IκB , a 
negative regulator of the NF-κB signalling pathway, in normal B cells (Mansouri et al., 2015). 
It has been reported that NFKBIE mutations are accumulated during the pathogenesis and 
progression of CLL (Damm et al., 2014, Mansouri et al., 2015, Alves et al., 2014). These 
genetic aberrations related to the NF-κB signalling pathway may explain the constitutive 
activation of this pathway in CLL but the precise mechanisms and their functions in CLL 
remain to be fully characterized. 
 
1.1.3 Current treatment 
Despite the impressive advances in the understanding of the pathophysiology of the disease 
and the introduction of novel molecularly-targeted therapeutics in recent years, CLL remains 
an incurable disease (Bosch and Dalla-Favera, 2019, Milne et al., 2020).  
Chlorambucil with or without the steroid was used as the preferred drug for the treatment 
of patients with CLL in early time (Han et al., 1973, Knospe and Loeb, 1980). At the 
beginning of the 21st century, the combination of fludarabine (F) and cyclophosphamide (C) 
plus rituximab (R), an anti-CD20 monoclonal antibody, (the so-called FCR), became the 
front-line therapy, as it significantly improves the outcome of the patients with CLL 
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comparing with the previous management (Eichhorst et al., 2006, Catovsky et al., 2007, 
Hallek et al., 2010). This combination is still a front-line therapy for the untreated, del(17p) 
negative, TP53 unmutated, IGHV-mutated patients, with age less than 65 years old and 
without any significant comorbidities, according to the National Comprehensive Cancer 
Network (NCCN) Guidelines version 2.2021.  
A better understanding of the pathogenesis of CLL does lead to a new era and tremendously 
change the clinical management of this disease. A group of small molecular inhibitors have 
become the preferred regimens for CLL patients. With the understanding of the signalling 
induced by the B cell receptor (BCR) in CLL cells, small molecule inhibitors targeting the 
components of the BCR signalling pathway have been introduced in the clinical 
management for CLL patients (Burger, 2012b). It has been shown that the inhibitor of 
Bruton tyrosine kinase (BTK) including ibrutinib and acalabrutinib, and the inhibitor of 
phosphatidylinositol-3-kinase (PI3K-𝛿) including idelalisib and duvelisib, display impressive 
efficacy in the treatment of CLL patients, including those with high-risk CLL such as 
deletion/mutation in TP53 (O'Brien et al., 2016, Ghia et al., 2020). As monotherapy 
(reported by the RESONATE2 study), ibrutinib exhibited a significantly higher overall 
response rate (ORR) and longer progress-free survival (PFS) rate, compared to that of 
chlorambucil (Burger et al., 2015; Burger et al., 2020). In the ELEVATE-TN phase III study, 
acalabrutinib both as monotherapy and a combination with anti-CD20 antibody resulted in 
better ORR compared with the combination of chlorambucil and anti-CD20 antibody 
(Sharman et al., 2019). Those two types of inhibitors have been used as the first-line 
therapies for previously untreated patients with/without del(17p)/TP53 mutation, according 
to the latest version of NCCN Guidelines. The discovery of the abnormal expression status of 
the proteins belonging to the BCL-2 family in CLL cells contributed to creation of the 
inhibitors targeting these proteins (Kang and Reynolds, 2009, Balakrishnan and Gandhi, 
2013). Venetoclax, known as ABT-199, is a highly selective BCL-2 inhibitor and it has been 
approved to be used for the treatment of CLL patients with 17p deletion since 2016 
(Lampson and Davids, 2017). These inhibitors become the main treatment options for 
patients with CLL according to the NCCN Guidelines version 2.2021.  
Figure 1.1 is a flow chart providing general guidelines on the preferred choice of therapies 
for medical professionals treating patients with CLL.  
7 
 
                           
Figure 1.1 Clinical management of CLL and the preferred regimens. This flow chart shows 
the clinical options for the previously untreated CLL patients. The workflow and 
corresponding preferred therapy are recommended by NCCN Guidelines version 2.2021. 
 
1.2 The pathogenesis of CLL 
As mentioned above, the improved clinical management of CLL depends heavily on a better 
understanding of the pathogenesis of this disease. Below I will provide an overview of the 
current understanding of the pathogenesis of CLL. 
 
1.2.1 The origin of CLL cells 
Although the understanding of CLL pathogenesis has been improved drastically over the last 
decades, the origin of CLL cells is still a matter of debate.  
In the earlier days, CLL B cells were thought to derive from the B1 lineage of B cells weakly 
secreting immunoglobulin M (IgM), which was based on the observation that many 
phenotypic properties of this type of B cells were shared by CLL B cells (Caligaris-Cappio et 
8 
 
al., 1982, Stall et al., 1988). Recently, an alternative theory has emerged that the cellular 
origin of CLL could be linked to the haematopoietic stem cells (HSCs) (Husby and Grønbæk, 
2017). In 2011, Yoshikane Kikushige and colleagues reported that immunodeficient mice 
transplanted with purified HSCs from patients diagnosed with CLL generate clonal B cells 
with CLL-like phenotype (Kikushige et al., 2011), supporting the theory that the presence of 
genetic and epigenetic alterations in HSCs can lead to the occurrence of CLL. In 2014, 
Frederik Damm and colleagues reported that the genetic and epigenetic lesions related to 
CLL, such as NOTCH1, SF3B1, could be found in the pluripotent HSCs in patients with CLL 
(Damm et al., 2014). These reports indicate that the genetic abnormalities leading to the 
onset of CLL may have occurred in the multipotent HSCs, which further supports the HSCs 
theory. 
The clonal rearrangements of immunoglobulin genes together with cell surface markers on 
CLL B cells lead to the theory that CLL cells come from the mature B cells which express a 
low amount of surface membrane immunoglobulins (Ig), CD19, CD20, and co-express CD23, 
CD5, CD200 (Swerdlow et al., 2017). With the identification of the mutation status of the 
IGHV genes, it has been proposed that the IGHV-M CLL cells and the IGHV-UM CLL cells have 
different cell origins (Figure 1.2). In 2001, it was reported by Klein and colleagues that the 
gene expression profile of CLL cells showed a certain amount of homogeneity with that of 
CD27+ memory B cells (Klein et al., 2001). In humans, the CD27+ memory B cells have been 
found to possess both IGHV-M and IGHV-UM genes (Klein et al., 1998). Basing on those 
findings, the IGHV-M CLL cells were considered to derive from the post-germinal centre B 
cells that have experienced antigen-presenting process, and they are CD5 and CD27 positive 
(Klein et al., 2001, Seifert et al., 2012). The situation about the origin of the IGHV-UM CLL 
cells is more complicated and there are currently two proposals. One is that the IGHV-UM 
CLL cells derive from the naïve B cells which are pre-GC B cells expressing CD5, but not 
CD27. Another one is that the IGHV-UM CLL cells originate from the GC- and T cell-
independent, antigen-experienced B cells which may directly derive from a lineage of 
precursor B cells (Klein et al., 2001, Seifert et al., 2012). Over the last decade, evidence 
emerges that antigen selection plays a role in the pathogenesis of CLL (Stamatopoulos et al., 
2017). It is reported that both IGHV-UM and IGHV-M CLL cells showed a highly restricted 
expression of certain immunoglobulin genes (Agathangelidis et al., 2012, Vardi et al., 2014). 
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In 2012, a study showed that IGHV-UM CLL cells express low-affinity, poly-reactive, and self-
reactive BCRs, and the IGHV-M CLL cells express oligo-reactive and mono-reactive BCRs 
(Agathangelidis et al., 2012). Meanwhile, another study reported that IGHV-UM and IGHV-M 
CLL cells may rely on antigen-independent, cell-autonomous BCR signalling (Dühren-von 
Minden et al., 2012).  
Collectively, the origin of CLL cells is still uncertain and further studies are needed to 
characterize the cell origin of CLL. Figure 1.2 summarises a briefly current consensus 













                      
Figure 1.2 The cellular origin of CLL. Based on the evidence published in the literature so 
far, one theory suggests that CLL cells may derive from the haematopoietic stem cells 
(HSCs). The accumulation of certain genetic and epigenetic lesions may lead to the 
transformation of the HSCs to ‘CLL’ HSCs and further expansion of polyclonal B cell 
progenitors. However, this theory is still debatable. IGHV-M CLL cells seem to derive from 
the post-GC CD5+ CD27+ B cells. The IGHV-UM CLL cells may originate from the pre-GC 
CD5+ CD27- B cells, which could arise from the naïve B cells or from a lineage of B cells that 
have experienced antigens independently of T cells. With the further accumulation of 
genetic and epigenetic lesions, these progenitor cells transform and expand, developing 
monoclonal B-cell lymphocytosis (MBL) and finally resulting in the occurrence of CLL. GC: 
germinal centre; TD: T cell-dependent antigen; TI: T cell-independent antigen. This figure is 
modified from the paper published by Giulia Fabbri et al. (2016). 
 
1.2.2 CLL microenvironment 
The tumour microenvironment is known to be critically involved in establishing many 
hallmarks of cancers and is important in the pathogenesis of cancers (Hanahan and 
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Weinberg, 2011). Emerging evidence also indicates that the microenvironment plays an 
important role in the survival and expansion of CLL cells.  
Firstly, it has been observed that CLL cells isolated from patients cannot survive alone ex 
vivo unless they were co-cultured with bone marrow stromal cells (BMSCs) or nurse-like 
cells (NLCs) (Panayiotidis et al., 1996, Lagneaux et al., 1998, Burger et al., 2000), which 
indicates that the extracellular signals from the microenvironment support the survival of 
CLL cells. Then, it has been noticed that there are various chemokine receptors expressed on 
CLL cells, which helps the cell trafficking and homeostasis in-between the bone marrow, 
lymphoid tissues, and peripheral blood in response to cytokines/chemokines secreted by 
the accessory cells within the microenvironment (Burger and Kipps, 2002). Later, a seminal 
study published in 2005 reinforced the role of the microenvironment in the development of 
CLL (Messmer et al., 2005). Before 2005, based on the observation that CLL cells were non-
dividing, cell-cycle arrested cells, CLL was considered as an accumulative disease as the 
leukaemia cells failed to undergo the programmed cell death and accumulated in the bone 
marrow, lymphoid tissues, and peripheral blood in patients (Dameshek, 1967). However, by 
using the deuterated water to measure the DNA replication in CLL cells in vivo, Bradley 
Messmer and colleagues demonstrated that CLL cells proliferated at a rate of 0.1% to 1% of 
the entire clone every day in the patients with CLL (Messmer et al., 2005). The higher the 
proliferation rate the CLL patients had, the more aggressive the disease became (Messmer 
et al., 2005). This report redefined CLL as a proliferative disease and, from then on, CLL 
researchers have become more interested in the study of the compartments where CLL cells 
proliferate. Further studies have confirmed that CLL cells proliferate mainly in the lymph 
node microenvironment (Calissano et al., 2011).  
It is now established that the microenvironment plays a significant role in the pathogenesis 
and the disease progression of CLL (Burger, 2012b, Ramsay and Rodriguez‐Justo, 2013, 
Burger and Gribben, 2014, Fabbri and Dalla-Favera, 2016). 
The CLL microenvironment consists of the bone marrow and secondary lymphoid organs, 
where CLL cells are interacting with groups of accessory cells including bone marrow stromal 
cells (BMSCs), monocyte-derived nurse-like cells (NLCs), and T cells (Burger, 2012b), as 
shown in Figure 1.3.  
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The BMSCs is the first type of accessory cells that have been found to rescue CLL cells from 
spontaneous apoptosis when those two types of cell are co-cultured in vitro (Lagneaux et 
al., 1998). It has also been reported that co-culturing with BMSCs also protects CLL cells 
from drug-induced cell death, which seems to rely on the increased expression of MCL-1 
(Kurtova et al., 2009). The interaction between CLL cells and BMSCs activates the NF-κB 
signalling pathway through protein kinase C – β (PKC-β) in BMSCs themselves, which further 
makes BMSCs indispensable for the survival of CLL cells (Lutzny et al., 2013). The high 
affinity of CLL cells for BMSCs relies on the CXCR4-CXCL12 axis. It has been found that the 
chemokine (C-X-C motif) receptor 4 (CXCR4) (also known as CD184) is expressed at a high 
level on the surface of CLL cells that circulates in the peripheral blood (Burger et al., 1999, 
Burger and Bürkle, 2007, Pasikowska et al., 2016). CLL cells with high expression of CXCR4 
are attracted to the corresponding ligand (CXCL12) that are expressed by BMSCs and 
migrate to the bone marrow (Burger et al., 1999, Möhle et al., 1999). Once there, the 
expression level of CXCR4 in CLL cells decreases, enabling the retention of CLL cells within 
the bone marrow and promoting the survival and expansion of the leukaemia cells (Burger 
and Bürkle, 2007, Pasikowska et al., 2016). CLL cells express the very late activation 
antigens-4 (VLA-4), also termed as CD49d, which interacts with the vascular cell adhesion 
protein 1 (VCAM1) expressed by BMSCs (Fabbri and Dalla-Favera, 2016). 
NLCs has been found in the secondary lymphoid tissues and spleen of the CLL patients 
(Burger et al., 2000, Tsukada et al., 2002) and NLCs can be developed in vitro by culturing 
the peripheral blood mononuclear cells (PBMCs) isolated from patients with CLL for one to 
two weeks (Burger et al., 2000). Similar to BMSCs, co-culturing with the NLCs protect CLL 
cells from spontaneous apoptosis (Burger et al., 2000). Co-culturing with the NLCs also 
activates the BCR signalling and the NF-κB pathways in CLL cells and the gene expression 
profile of CLL cells co-cultured with NLCs is similar to that of CLL cells isolated from the 
lymph nodes of CLL patients (Burger et al., 2009). NLCs secret CXCL12 and CXCL13 to attract 
CLL cells and induce pro-survival signals to support the survival of CLL cells by binding to 
many receptors expressed on CLL cells with their corresponding ligands (Burger et al., 2000, 
Bürkle et al., 2007). Co-culturing with NLCs can activate the BCR signalling pathways and 
stimulate the interaction between CD100 on CLL cells and plexin B1 expressed by NLCs and 
activate NOTCH1 signalling in CLL cells as well (Fabbri and Dalla-Favera, 2016). 
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In the meantime, the role of T cells in the development of CLL has long been documented. It 
has been shown that co-culturing CLL cells with activated CD4+ T cells can reverse the cell 
cycle resting status of the CLL cells from peripheral blood to proliferation status in vitro and 
induced the differentiation of CLL cells into IgM secreting cells (Tretter et al., 1998, Os et al., 
2013). It has also been observed that CD40 stimulated CLL cells can secrete CCL22 that 
attracted CD4+, CD154+ T cells in the microenvironment of CLL such as lymph nodes and 
bone marrow (Ghia et al., 2002). Definitive evidence for T cell involvement in CLL was 
provided by a seminal study employing an adoptive transfer model. In the study, the 
authors transplanted purified human CLL cells alone into the immunodeficient mice and the 
animals did not develop CLL; however, when CLL cells and autologous T cells were co-
transplanted, the transplanted mice develop CLL-like leukaemia (Bagnara et al., 2011). They 
also showed that eliminating CD4+ T cells in the transfer model abrogated the survival and 
proliferation of CLL cells (Bagnara et al., 2011). This proves that the autologous T cells were 
necessary for the survival and expansion of CLL cells in the transplanted mice. The successful 
induction of CLL in the adoptive transfer model shows that the components of the 
microenvironment including T cells are crucial for the development of CLL. It is also reported 
that the CD4+ and CD8+ T cells isolated from the patients with CLL are dysfunctional with 
impaired synapse formation and this abnormal formation can be induced by CLL cells on T 
cells from healthy persons (Ramsay et al., 2008). T cells from the patients with CLL display 
the characteristics of T-cell exhaustion with increased expression of exhaustion markers 
CD244, CD160, and PD1, especially on CD8+ T cells, resulting in the functional defects in 
cytotoxicity (Riches et al., 2013). Oligoclonal expansion of T cells that express activation 
marker CD57 in the patients with CLL indicates that these T cells may undergo chronic 
activation during their development (Burger and Gribben, 2014). It has also been shown 
that the migration, immunological synapse signalling, and interactions with tumour cells of 
autologous CD4+ T cells can be enhanced by exposure to the extracellular vesicles secreted 
by CD40/IL-4 stimulated CLL cells (Smallwood et al., 2016).  
Based on the evidence, it is reasonable to suggest that the interaction between CLL cells and 
T cells mutually influences each other. On one hand, it supports the survival and 
proliferation of CLL cells. On the other hand, it alters the function of T cells amenable to the 
development of the disease. Although the exact underlying mechanisms are still not fully 
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understood, it is accepted that the interaction between CLL cells and T cells is mainly 
mediated by the ligation of CD40 on CLL cells by CD154 on T cells (Caligaris‐Cappio, 2003, 
Burger and Gribben, 2014, Fabbri and Dalla-Favera, 2016). Studies have also shown that the 
gene expression profile of CLL cells stimulated by CD40L is highly similar to that of CLL cells 
stimulated by autologous T cells and that gene expression of such stimulated CLL cells 
closely resemble that of the CLL cells isolated from lymph nodes of CLL patients (Herishanu 
et al., 2011, Pascutti et al., 2013). Therefore, it is the study of the interaction between CLL 




                       
Figure 1.3 Main components of the microenvironment of CLL. Bone marrow stromal cells 
(BMSCs), monocyte-derived nurse-like cells (NLCs) and T cells are the main components 
within the microenvironment of CLL. CLL cells express VLA-4, also termed as CD49d, which 
interacts with VCAM1 expressed by BMSCs. Besides, CLL cells also interact with BMSCs 
through the CXCR4-CXCL12 axis. NLCs secret CXCL12 and CXCL13 to attract CLL cells and 
induce pro-signals to support the survival of CLL cells by the ligation of CD38 with CD31, 
binding to the BCMA/TACI/BAFFR receptors on CLL cells via ligands including APRIL/BAFF on 
NCLs. The interaction between CLL cells and T cells is mainly mediated by the ligation of 
CD40 with CD154 (also known as CD40L). CD40 stimulated CLL cells secret CCL22 that 
attracted CD4+, CD154+ T cells. This figure was modified from a review paper by Fabbri and 
Dalla-Favera (2016). APRIL, a proliferation-inducing ligand; BAFF, B cell activating factor; 
BAFFR, BAFF receptor; BCMA, B cell maturation antigen; TACI, transmembrane activator, 
and Ca2+ modulator and CAML (calcium-modulating cyclophilin ligand) interactor; VLA-4, 
very late activation antigens-4; VCAM1, vascular cell adhesion protein 1. 
 
1.3 CD40-CD154 interaction 
1.3.1 CD40 signalling in normal B cells 
As mentioned above, CD40-CD154 interaction is regarded as the main mode of 
communication between CLL cells and T cells. CD40 is a 43-50kDa transmembrane protein, a 
cell surface receptor of the tumour necrosis factor receptor (TNF-R) family (van Kooten and 
Banchereau, 2000). CD40 is first identified on B lymphocytes and it is shown to play an 
important role in the humoral immune system (van Kooten and Banchereau, 2000, Qu, 
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2009). CD40 is widely expressed on B lymphocytes, monocytes, dendritic cells (DCs), 
endothelial cells (van Kooten and Banchereau, 1997). CD40 ligand, also termed as CD40L or 
CD154, is a 39 kDa type II transmembrane protein that belongs to the tumour necrosis 
factor (TNF) family (Smith et al., 1994). CD40 ligand is expressed not only on activated CD4+ 
T cells but also on different types of cells such as B cells, DCs, basophils, monocytes, 
macrophages, natural killer (NK) cells, fibroblasts (van Kooten and Banchereau, 1997, van 
Kooten and Banchereau, 2000).  
When CD154 binds to CD40, CD40 needs to form a trimer and the acidic domain in the 
receptor interacts with the basic domain of CD154 (Schonbeck and Libby, 2001). The signals 
induced by the engagement of CD40 by CD154 need to be transduced via the recruitment of 
adapter proteins, TNFR-associated factors (TRAFs) (Bishop et al., 2007). So far, six proteins 
have been identified, which constitute the TRAF family, and they are named from TRAF1 to 
TRAF6, which can be directly and indirectly recruited upon the CD40-CD154 ligation 
transducing signals for cellular biological processes (Elgueta et al., 2009) (Figure 1.4). The 
signalling pathways which can be activated by CD40-CD154 engagement include the 
canonical and non-canonical nuclear factor 𝜅B (NF-κB)-signalling pathways, the mitogen-
activated protein kinases (MAPKs), phosphoinositide-3-kinase (PI3K), phospholipase C𝛾 
(PLC𝛾) pathway, and Janus family kinase 3 (JAK3)-phosphorylation of signal transducer and 
activator of transcription 5 (STAT5) pathways (Bishop et al., 2007, Säemann et al., 2003, 
Säemann et al., 2002).  
It has been reported that TRAF1 deficient B cells exhibit an increasing degradation of TRAF2 
and TRAF3 (Xie et al., 2006) and this phenomenon can be found in the antigen-presenting 
cells (APCs) (Arron et al., 2002). The recruitment of TRAF1 together with TRAF2 transduces 
signalling leading to the activation of the canonical NF-κB pathway, as deficiency of those 
two TRAF proteins abolishes the activation of the NF-κB signalling pathway and this 
abolishment cannot be achieved by the deletion of TRAF1 and TRAF2 individually (Xie et al., 
2006). The recruitment of TRAF2 upon CD40-CD40L ligation plays a role in the activation of 
p38, JNK, and Akt signalling, as CD40-CD40L ligation is unable to activate these in TRAF2 
deficient B cells and mouse embryonic fibroblasts (Hostager et al., 2003, Yeh et al., 1997, 
Lee et al., 1997). 
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Together with TRAF3, TRAF2 has also been shown to negatively regulate the non-canonical 
NF-κB signalling pathway in B cells (Gardam et al., 2008, Vallabhapurapu et al., 2008, 
Zarnegar et al., 2008). To be specific, CD40-CD40L ligation leads to the recruitment of TRAF2 
and TRAF3 together with the cellular inhibitor of apoptosis (cIAP) to the cytoplasmic tail of 
CD40 transmembrane receptor and the NF-κB-inducing kinase (NIK). NIK is usually degraded 
by the cIAP, which, following interacting with TRAR2 and TRAF3, loses its degradation 
function, resulting in the accumulation of NIK and the activation of the non-canonical NF-κB 
signalling pathway (Zarnegar et al., 2008, Vallabhapurapu et al., 2008, Bishop et al., 2007). 
The role of TRAF3 in the NF-κB signalling appears to be a negative one, at least in B cells (He 
et al., 2007). Thus, CD40 signalling is almost intact in TRAF3 deficient B cells (He et al., 2007, 
Xie et al., 2004). Reinforced expression and recruitment of TRAF3 upon CD40-CD154 ligation 
has been shown to suppresses the canonical NF-κB signalling pathway in B cells (He et al., 
2007). However, contrasting results are observed in epithelial cells where TRAF3 is essential 
for the CD40-mediated activation of NF-κB signalling (Urbich et al., 2001, Propst et al., 
2002). It indicates a distinct function of TRAF3 in different types of cells.  
The role of TRAF5 in positively regulating CD40 signalling has been reported. It has been 
shown that the recruitment of TRAF5 to the cytoplasmic domain of CD40 upon receptor 
ligation is indirect as it requires the presence of TRAF3 (Bishop et al., 2007, Hauer et al., 
2005). However, knocking down TRAF5 in B cells disables the activation of the canonical and 
non-canonical NF-κB signalling pathways, down-regulates the expression of co-stimulators 
and decreases the proliferation, and the production of antibodies in B cells (Nakano et al., 
1999, Elgueta et al., 2009).  
TRAF6 has been shown to bind directly and indirectly to the cytoplasmic domain of the CD40 
receptor upon CD40-CD40L engagement (Davies et al., 2005, Rowland et al., 2007). When 
directly recruited upon CD40-CD40L ligation, TRAF6 induces Akt phosphorylation by forming 
a complex with Casitas B-lineage lymphoma b (Cbl-b), Casitas B-lineage lymphoma (c-Cbl), 
and PI3K (Arron et al., 2001, Davies et al., 2004) (Figure 1.4). When indirectly recruited, 
TRAF6 interacts with TRAF2 to complete the signalling transduction induced by CD40-CD40L 
ligation (Bishop et al., 2007, Elgueta et al., 2009).  
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The signalling transduction activated by CD40-CD40L engagement through TRAFs has yet to 
be fully understood, which still needs further study to fully characterize the biological 
functions of individual TRAFs.           
            
Figure 1.4 CD40 signalling in B cells. CD40-CD40L ligation recruits TRAFs to the cytoplasmic 
domain of CD40 transmembrane receptor in B cells and transduces signalling through 
individual TRAFs or the combination of TRAFs. TRAF1 together with TRAF2 transduces the 
signals in the canonical NF-κB signalling pathway. The recruitment of TRAF2 upon CD40-
CD40L ligation plays a role in the activation of p38, JNK, and Akt signalling. TRAF2 and TRAF3 
together with cIAP regulate the non-canonical NF-κB signalling pathway by controlling the 
degradation of NIK. The recruitment of TRAF3 upon CD40-CD40L ligation suppresses the 
canonical NF-κB signalling pathway. The recruitment of TRAF5 with the combination of 
TRAF3 transduces the activation of the canonical and non-canonical NF-κB signalling 
pathways. Directly recruited TRAF6 induces the signalling for the Akt phosphorylation by 
forming a complex with Casitas B-lineage lymphoma b (Cbl-b), Casitas B-lineage lymphoma 
(c-Cbl), and PI3K. Indirectly recruited TRAF6 interacts with TRAF2 to complete the signalling 
transduction induced by CD40-CD40L ligation. This figure is modified from two papers 
published by Elgueta et al. (2009) and Hobeika et al. (2015). 
 
CD40-CD154 interaction has attracted intense interest from researchers due to its 
significant role in the haematopoiesis and the immune system. CD40 signalling induced 
upon CD40-CD154 engagement is crucial for the differentiation, apoptosis, proliferation, 
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and isotype switching for B lymphocytes (Kehry, 1996, Greiner et al., 1997, Seijkens et al., 
2010). The differentiation of B lymphocytes is regulated not only by the signal from surface 
immunoglobulins but also by the signals induced by activated T cells. The signal induced by T 
cells is mainly based on the engagement of the CD40 receptor expressed on B lymphocytes 
with the CD154 expressed on activated T cells (Bishop and Hostager, 2003). CD40-mediated 
signalling is also important for the differentiation from germinal centre B cells to memory B 
cells, as abrogating CD40 ligand cancels the differentiate from germinal centre B cells into 
the cells with the features of plasma cells (Arpin et al., 1995). It has been reported that 
CD40-mediated signalling can rescue B cells from surface Ig-induced apoptosis (Wang et al., 
1995, Choi et al., 1995, Merino et al., 1995). Via CD40-CD154 engagement, activated CD4+ T 
cells stimulate the precursor of B cells to proliferate in vitro (Renard et al., 1994). The 
inhibition of the CD40-CD154 interaction abolishes the proliferation and production of Ig by 
B cells (Clark and Ledbetter, 1994, Marshall et al., 1993).  
In addition, CD40-CD154 interaction is also indispensable for the development and functions 
of other types of cells including T lymphocytes, DCs, NK cells (Seijkens et al., 2010). For the 
differentiation of T lymphocytes, CD40-CD154 interaction plays important role in the 
development of T-help cells including the T-helper 1, T-helper 2, and T-helper 17 (Pilon et 
al., 2009, Straw et al., 2003, Jenkins et al., 2008, Iezzi et al., 2009). Knocking out respective 
genes encoding CD40 and CD154 in mice leads to an obvious reduction of CD4 and CD25 
double-positive T regulatory cells in the peripheral blood, spleen, and thymus (Guiducci et 
al., 2005, Smook et al., 2005). CD40-CD154 ligation in the haematopoietic stem and 
progenitor cells (HSPCs) recruits TRAF6 and activates NF-𝜅B signalling pathway resulting in 
the formation of mature DCs (Ouaaz et al., 2002, Kobayashi et al., 2003). In-vitro studies 
show that CD40-mediated signalling up-regulates the level of Flt3 ligand and 
thrombopoietin secreted by bone marrow stromal cells, which facilitates the differentiation 
of HSPCs towards NK cells (Fu et al., 2002). CD40-CD154 engagement between the NK cells 
and APCs promotes the cytotoxicity of NK cells (Sartorius et al., 2003, Tomihara et al., 2007). 
Accumulating evidence supports the notion that CD40-CD154 interaction plays a critical role 
in the immune system. It has been known for a long time that CD40-CD154 engagement is 
important for the formation of the germinal centre (Foy et al., 1994). Abolishment of CD40-
mediated signalling leads to a loss of GC activity, while restoration of the CD40-mediated 
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signalling enables the initiation and maturation of the GC activity (Elgueta et al., 2009). 
Inhibition of the CD40-CD154 interaction either by using the blocking antibodies or 
genetically abrogating the genes encoding CD40 or CD154 results in the deletion of thymus-
dependent humoral immunity (Banchereau et al., 1994). It is now known that the 
interaction between T cells and B cells constitutes an essential part of humoral immunity 
(Mitchison, 2004). In addition to its role in the differentiation and mediating interaction of 
these two types of cells, CD40-CD154 engagement is involved in the differentiation and 
functions of the APCs such as DCs (described above). Meanwhile, evidence exhibits the 
significant role of CD40-CD154 crosstalk in cellular immunity, especially its role in the donor-
specific transfusion tolerance (Quezada et al., 2003). It has been reported that CD40-CD154 
engagement induces the activation of CD8+ T cells, which leads to allograft rejection (Larsen 
et al., 1996, Jones et al., 2000). Blocking this engagement results in T cell tolerance by 
suppressing the CD4+ and CD8+ T cells (Honey et al., 1999, Jones et al., 2000). It, in turn, 
helps the persistence of allograft tolerance (Parker et al., 1995, Zheng et al., 1999, Lehnert 
et al., 2001, Jarvinen et al., 2003, Chalermskulrat et al., 2006). These observations together 
highlight the therapeutic potential in targeting or activating CD40-CD154 interaction in 
immunotherapy. 
 
1.3.2 Activation of the CD40 signalling pathway in CLL cells 
The CD40-CD154 crosstalk between CLL cells and activated CD4+ CD154+ T cells constitutes 
one of the major forms of communication between cells within the CLL microenvironment. 
The functional effects of CD40 stimulation have been studied by many research groups, 
especially its pro-survival role in CLL. In 1998, using an agonistic anti-CD40 monoclonal 
antibody (G28-5), Maria Romano and colleagues reported that the activation of CD40 
receptors on CLL cells can reduce the amount of apoptosis induced by fludarabine and that 
this pro-survival effect was due to the activation of NF-κB signalling pathway in CD40 
stimulated CLL cells (Romano et al., 1998a). In line with this observation, Richard Furman 
and colleagues reported that, comparing with normal B cells, CLL cells exhibit a higher level 
of NF-κB activity which can be further activated by CD40 stimulation and that blocking the 
CD40-CD154 engagement on CLL inhibited the activity of NF-κB and induced apoptosis 
(Furman et al., 2000). Furthermore, there is no difference between M-CLL and UM-CLL cells 
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in terms of the activation of the NF-κB signalling pathway and proliferation induced by 
CD40-CD154 ligation (Tromp et al., 2010). Later, it has been found that CD40-CD154 
engagement can induce the expression of both anti-apoptotic and pro-apoptotic proteins in 
CLL cells. CD40 stimulation regulates the expression profile of a group of the apoptosis-
regulatory proteins, including the members of the BCL-2 superfamily, in CLL cells (Willimott 
et al., 2011, Smit et al., 2007, Kater et al., 2004). The proteins of the BCL-2 family can be 
classified into three groups: the anti-apoptotic proteins including BCL-2, BCL-XL, MCL-1, BCL-
W, and Bfl-1; the pro-apoptotic proteins including BAX, BAK, and BOK; the BH3-only pro-
apoptotic proteins such as BAD, BID, BIK, BIM, BMF, HRK, Noxa, Puma, and so on (Kale et al., 
2018).  
Although the overall influence induced by CD40 activation in CLL cells is pro-survival and the 
inhibition of cell death, CD40 stimulation also produces seemingly contradictory effects in 
the expression of the individual proteins involved in apoptosis. For example, CD40 
stimulation induces the expression of anti-apoptotic proteins such as BCL-XL, MCL-1, Bfl-1 
and down-regulates the expression of pro-apoptotic proteins like BH3-only proteins Noxa 
and Harakiri in CLL cells; at the same time, it also upregulates the expression of the protein 
BID that is a pro-apoptotic BH3-only protein (Kater et al., 2004, Smit et al., 2007). Besides, 
CD40 stimulation increases the expression of CD95, a death receptor belonging to the TNF-R 
superfamily (Nagata and Golstein, 1995), but it does not sensitize CLL cells to death-
receptor-induced cell death (Wang et al., 1997, Kater et al., 2004). Although it does not 
sensitize CLL cells to CD95-induced cell death immediately, the up-regulation of the 
expression of CD95 induces the up-regulation of the Fas-associated death domain protein 
(FADD) and DAP3 (a FADD-binding molecule ) 5 days after CD40 stimulation and 
consequently the CD40-stimulated CLL cells respond to CD95-induced apoptosis (Chu et al., 
2002).   
Besides its influences on survival, CD40 activation seems to help CLL cells interact with other 
bystander cells within the microenvironment. CD40 stimulated CLL cells produce 
chemokines including CCL2, CCL3, CCL4, CCL5, CCL7, CCL24, CXCL5, CXCL10, and IL4, and 
those chemokines can attract monocytes (van Attekum et al., 2017). Also, it has been found 
that CD40-CD154 engagement increases the level of CD44 in CLL cells and enhances the 
binding of CD44 to its extracellular matrix ligand hyaluronan present on stromal cells (Girbl 
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et al., 2013). As a result, CD44-HA adhesion restrains the motility of CLL cells, thus retaining 
the leukemic cells within the lymph node microenvironment (Girbl et al., 2013).  
CD40 stimulation also works together with other co-stimulators to induce the proliferation 
of CLL cells. CD40 stimulation, in the presence of BMSCs and CpG-oligodeoxynucleotides 
(ODNs), activated the non-cycling CLL cells to enter into the cell cycle and induces 
proliferation as measured by the expression of Ki-67 (Purroy et al., 2015). It was also shown 
that the proliferation effect was more pronounced in cells induced by the combined stimuli 
than by individual stimulus (Purroy et al., 2015). Moreover, the co-stimulation induced by 
the combined stimuli increases the expression of ZAP-70 and causes the resistance of 
stimulated cells to the induction of apoptosis by fludarabine and bendamustine (Purroy et 
al., 2015). It was reported that compared with IL-2, IL-15, anti-IgM, and CpG-ODNs, the IL-21 
produced by activated T cells shows the highest potency to work synergistically with CD40 
stimulation to induce proliferation on CLL cells (Pascutti et al., 2013). The co-stimulation by 
CD40 and IL-4 has been shown to promote DNA damage repair by up-regulating the 
expression of ATM and increasing the phosphorylation of the downstream targets of ATM 
(Lezina et al., 2018). Those data indicate that CD40 activation induces a range of biological 
effects including the induction of the expression of many genes and altering signal 
transduction pathways, ultimately promoting the survival and proliferation of CLL cells. The 
clinical significance of the in-vitro response of CLL cells to CD40 stimulation has also been 
highlighted by the observation that not all CLL cells isolated from patients with CLL respond 
to CD40 stimulation by CD40 ligand (Scielzo et al., 2011). Significantly, CLL patients with CLL 
cells not responding to the CD40 stimulation tends to lead a more aggressive disease course 
than the patients whose CLL cells respond to the CD40 stimulation (Scielzo et al., 2011). It 
further indicates that CD40-CD154 interaction is likely involved in the pathogenesis and 
progress of the disease course of CLL. 
In the meanwhile, in-vitro studies employing inhibitors to inhibit CD40 stimulation also show 
that they can overcome the pro-survival effect induced by CD40 stimulation on CLL cells. It is 
shown that HCD122, an antagonist anti-CD40 monoclonal antibody, abrogates the pro-
survival signals induced by CD40 stimulation and inhibits the secretion of IL-6, IL-8, IL-10, 
TNF-α, and GM-CSF by CLL cells (Luqman et al., 2008). It also induces cell death of CLL cells 
possibly by targeting antibody-dependent cellular cytotoxicity (ADCC) (Luqman et al., 2008). 
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It has also been reported that the c-Abl inhibitors, dasatinib, and imatinib, abolish the pro-
survival effect induced by CD40 stimulation on CLL cells and restores the sensitivity of CLL 
cells to the killing of cytotoxic drugs (Hallaert et al., 2008). The treatment of CLL cells with 
chlorambucil cancels the pro-survival effect induced by CD40 stimulation, which can be 
further enhanced by the combination of bezafibrate and medroxyprogesterone acetate 
through generating reactive oxygen species (ROS) and mitochondrial superoxide (Hayden et 
al., 2009, Calissano et al., 2011). Besides, treating CLL cells with NVP-AUY922 (a heat shock 
protein-90 inhibitor) together with fludarabine overcomes the fludarabine-resistance 
induced by CD40 stimulation (Best and Mulligan, 2012).  
Given the critical role of CD40-CD154 interaction in the immune system, it is important to 
characterize the effect of inhibiting CD40 signalling on other immune cells before the clinical 
application of therapeutics targeting pro-survival signals induced by CD40 stimulation in CLL. 
A comprehensive understanding of the influence induced by CD40 stimulation on the 
immune system as well as on CLL cells is required so that more precise targets can be 
identified for therapeutic intervention in the clinical management of CLL patients in the 
future.  
 
1.4 Proteomics study in CLL 
The accomplishment of the Human Genome Project (HGP) provides us a blueprint for the 
entire genetic information of human beings (Gannett, 2008). However, HGP also reveals a 
further biological complexity involving the transmission processes of the genetic 
information within the human organism as there are only about 20,000 protein-coding 
genes identified (Moraes and Góes, 2016), whereas the number of proteins within the 
human organism is estimated to be as many as 500,000 (Pray, 2008). The wide difference 
makes the multi-omics studies, especially at the protein level, significant in the investigation 
of biological activities of individual genes in a human body. The DNAs carry the genetic 
information and direct the development of different types of cells, while the proteins are 
the executors to perform the function of the individual genes. Following the concept of 
‘genome’, the ‘proteome’ is defined as the entire constituent of proteins expressed by a 
specific cell or organism (Wasinger et al., 1995, Poon and Johnson, 2001). As mentioned 
above, compared with the genome, the proteome is more complex and deserves further 
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investigations. This is because, first of all, the number of genes for a specific cell or organism 
is constant and relative stable (Ermini et al., 2008), whereas the number of proteins is 
different from cell to cell due to the different biological function (Walsh, 2002, Elguoshy et 
al., 2017). Secondly, even for a specific cell within an organism, the number of proteins is 
changeable from time to time, which is influenced not only by the changes in gene 
expression but also by the environmental factors such as changes in the pH, exposure to 
stimuli, and inflammatory condition (Walsh, 2002, Lundberg and Borner, 2019). Thirdly, 
working as the bridging molecules, messenger RNA (mRNA) can be transcribed from the 
same gene by different transcription starting locus or alternative splicing resulting in more 
than one peptides being translated, which leads to the diversity of proteoforms (Sperling et 
al., 2008). In addition, the existence of the post-translational modifications (PTMs) including 
the methylation, ubiquitylation, phosphorylation, and glycosylation magnifies the difference 
between the number of genes and the number of proteoforms in a cell or organism (Niall, 
1973, Walsh, 2006). These phenomena indicate that the proteome provides more accurate 
and up-to-date information on the functional status of a cell or organism, although technical 
challenges have held back researchers from investigating a large number of proteins 
simultaneously.  
The techniques such as genome microarrays, in situ hybridization, polymerase chain 
reaction (PCR), and RNA sequencing (RNA-seq) have been comprehensively applied in 
research (Griffiths et al., 2018), which all depends on the complementary characteristics of 
the paired purine base: guanine to cytosine and adenine to thymine (A-T) for DNA (Pullman 
and Pullman, 1959), guanine to cytosine and adenine to uracil (A-U) for RNA (Tobias et al., 
2011). However, proteins are comprised of chains of the 20 common amino acids linked via 
peptide bonds and there has been no technology so far that exist to amplify these chains 
directly. One traditional technique relies on electrophoresis to separate proteins based on 
their molecular weight (O'Farrell, 1975, Hames, 1998). The proteins separated are then 
transferred onto nitrocellulose membrane and probed with enzyme-conjugated antibodies; 
the relative abundance of the identified proteins is then measured against the relatively 
stable proteins such as β-actin and GAPDH (Kurien and Scofield, 2006). These processes are 
term as ‘Western blotting’. So far, Western blotting is still a useful method for in-cell protein 
analysis but the number of proteins that can be investigated simultaneously is limited by its 
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principle (Moritz, 2020). Later on, the emerging techniques for protein characterization such 
as enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and 
immunofluorescence are all based on the interaction between a specific protein or epitope 
of interest and the corresponding antibodies (Engvall et al., 1971, Lequin, 2005, Ramos-Vara 
and Miller, 2014, Odell and Cook, 2013). Like Western blotting, the number of proteins that 
can be studied simultaneously by these methods is limited as well. Attempts have been 
made to use antibodies to construct the protein microarray, also termed as the ‘protein 
chips’, which is based on the ideas of the genome microarrays (MacBeath et al., 1999, 
MacBeath, 2002, Templin et al., 2003). Now protein microarray techniques can be divided 
into the following categories: analytical protein microarray, reverse-phase protein 
microarray, and functional protein microarray (Sutandy et al., 2013). Similar to the genome 
microarrays, protein microarrays essentially assemble thousands of miniaturized assays on a 
small plate to detect many proteins simultaneously from the same sample (Sutandy et al., 
2013). The analytic protein microarrays are widely used for protein quantification, in which 
the plate contains different antibodies that capture the proteins in a sample and the bound 
proteins are then detected by reporter antibodies directly or indirectly (Gupta et al., 2016). 
The reverse-phase protein microarrays are opposite to the steps involved in the analytic 
protein microarrays, in which protein samples are immobilized on the plate and then 
detected by antibodies (Gupta et al., 2016). As the analytic protein microarrays are 
performed in the so-called sandwich way (antibodies in plates; proteins in samples; 
antibodies added further for detection), the reverse-phase protein microarrays involve 
immobilizing proteins from samples onto the plates, following which antibodies are used for 
detection. The functional protein microarrays are mainly applied in the study of protein 
interactions and useful to detect binding between protein-protein, protein-DNA, protein-
RNA, and so on, with the plate containing known proteins or peptides which are then mixed 
with to be analysed samples with any binding molecules detected as a result of the 
interaction (Gupta et al., 2016). Although the technique of protein microarrays increases the 
number of proteins detected simultaneously, the results are strongly influenced by the 
specificity and sensitivity of the corresponding antibodies (Gupta et al., 2016). The limited 
number of miniaturized assays and the number of antibodies or samples that can be 
immobilized on one plate restricts the number of proteins to be identified (MacBeath, 2002, 
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Templin et al., 2003, Gupta et al., 2016), which makes this type of technique suitable for the 
study of targeted proteins. 
The application of mass spectrometry (MS) techniques provides a new opportunity for 
proteomics studies (Aebersold and Mann, 2003). Instead of using antibodies to detect 
proteins, MS identifies proteins by measuring the mass-to-charge (m/z) ratio of the peptides 
from a protein, from which the specific molecular weight can be accurately calculated and 
ultimately the sequence of the specific amino acids of the peptide chain or chains that form 
the protein can be obtained (Koomen et al., 2005). With the rapid development, MS-based 
techniques can be applied not only to accurately measure the level of proteins in samples 
but also to detect the PTMs of the proteins (Kirkpatrick et al., 2005, Nita‐Lazar et al., 2008, 
Pan et al., 2011, Mischerikow and Heck, 2011, Afjehi-Sadat and Garcia, 2013). The classic 
procedures of MS-based proteomics study have now been well established concerning the 
extraction of proteins from cell/tissue samples, digesting proteins into peptides, separating 
the peptides by high-performance liquid chromatography (HPLC), detecting peptides by 
mass spectrometers, searching on database and data analysis (Walker, 2005).  
Over the last two decades, MS-based proteomic techniques have also been applied in CLL 
research including the studies of the distinct expression of proteins by CLL cells from 
patients of different CLL subgroups. In 2003, a study using two-dimensional gel 
electrophoresis followed with MS showed that the pattern of PTMs of nucleophosmin was 
different between M-CLL and UM-CLL and that the expression levels of  F-actin-capping 
protein β subunit, 14-3-3 β protein, laminin-binding protein precursor were significantly up-
regulated in M-CLL cells comparing with that in UM-CLL cells (Cochran et al., 2003). The 
difference in expression and localization of proteins between M-CLL and UM-CLL has also 
been reported by others employing various proteomic approaches (Barnidge et al., 2005, 
Rees‐Unwin et al., 2010, Admoni-Elisha et al., 2016). The proteomic study from our 
research group has also identified migration defects as a feature associated with UM-CLL 
cells (Eagle et al., 2015). In that study, among a total number of 3521 identified proteins, 
274 proteins were found to be differentially expressed between UM-CLL and M-CLL cells. 
The functional enrichment analysis of the differentially expressed proteins showed that the 
migration/adhesion pathways were significantly enriched by 39 differentially expressed 
proteins, 35 of them were significantly under-expressed in UM-CLL, thus indicating a 
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migration defect and/or enhanced adhesive capacity in these cells. Clinical correlation 
analysis also confirmed that patients with UM-CLL are likely to develop bulky lymph nodes, a 
well-known indicator for poor prognosis of the disease (Eagle et al., 2015).  
Meanwhile, MS-based proteomics techniques have been used to investigate novel 
biomarkers as well as the pathogenetic factors for CLL. In 2003, Boyd and colleagues used 
plasma-membrane-based proteomic analysis to identify new prognostic and therapeutic 
targets and found that two novel proteins (MIG2B and B-cell novel protein#1, BCNP1) were 
expressed preferentially in CLL B cells (Boyd et al., 2003). In a separate study, by comparing 
CLL B cells to the B cells from young and elderly healthy donors, Rupert Mayer and 
colleagues reported that CLL cells share protein expression profile of B cells from elderly 
healthy donors, thus suggesting that aging may predispose B cells to CLL cells (Mayer et al., 
2018). In another study, by comparing CLL B cells from 14 patients with CLL to B cells from 
healthy donors, authors identified a total number of 8694 proteins with 544 of them 
significantly up-regulated in CLL B cells including some established markers such as BCL-2, 
CD5, CD23 and several previously unreported proteins that are involved in B-cell receptor 
signalling (e.g. LAX1, CLEC17A, APT2B4) (Johnston et al., 2018). A recent study using a 
quantitative label-free proteomics technique showed that the activities of metabolic 
pathways of CLL B cells were different from healthy B cells with the overexpression of 
proteins involved in the metabolism of lipid and cholesterol in CLL cells (Thurgood et al., 
2019). Studies of histone proteome in CLL cells also revealed a distinct expression and 
diverse post-translation modifications of histone proteins. Thus, comparing to normal B 
cells, the expression of histone H2A variants (H2AFL and H2AFA/M) was significantly 
decreased in CLL cells (Su et al., 2009). However, the expression of a histone H2A variant 
with a molecular mass of 14,063 Da was associated with a significantly shorter time to 
treatment (Singh et al., 2015). Another study investigated the proteomic profile of plasma-
derived exosomes from patients with CLL and found that CLL cells from patients with 
progressive disease secreted exosomes with high levels of S100-A9 which in turn activated 
the NF-κB pathway during CLL progression (Prieto et al., 2017). 
MS-based proteomics techniques have also been used to investigate activities of specific 
signalling pathways. A study investigating the signalosomes of BCR reported that the 
activation of BCR led to the phosphorylation and ubiquitylation of the receptor-proximal 
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signalling components and that two novel components of BCR signalling, RAB7A, and BCL10, 
were identified (Satpathy et al., 2015). It is also showed that the ubiquitylation of BCL10 was 
required for the BCR-mediated activation of the NF-κB signalling pathway (Satpathy et al., 
2015). Another study reported that a protein known as kininogen was up-regulated upon 
BCR activation and that its expression was associated with shorter median survival (Kashuba 
et al., 2013). MS-based proteomic techniques have also been used to explore the alteration 
of CXCR4/CXCL12 signalling pathways of CLL cells. Morgan O’Hayre and colleagues reported 
that the activation of CXCR4 by CXCL12 induced phosphorylation and degradation of 
programmed cell death factor 4 (PDCD4), which functions as a tumour suppressor (O'Hayre 
et al., 2010). CXCL12 stimulation also led to phosphorylation of heat shock protein 27 
(HSP27), an anti-apoptosis protein (O'Hayre et al., 2010). In addition, a study employing the 
quantitative MS technique revealed that mutations in ribosomal protein S15 (RPS15) led to 
an alteration in global protein synthesis and translational fidelity in CLL cells (Bretones et al., 
2018). 
MS-based proteomic techniques have also been used to investigate the on/off-target effects 
of kinase inhibitors and other therapeutic agents in CLL. In 2013, Yiping Che and colleagues 
reported that SNX-7081, an HSP90 inhibitor, decreased the expression of proteins involved 
in cell cycle and DNA replication and repair in CLL cells, demonstrating an on-target effect of 
SNX-7081 (Che et al., 2013). Later, they showed that SNX7081 induced cell death 
synergistically with fludarabine by inhibiting the DNA repair and increasing the expression of 
pro-apoptotic molecules such as BID in CLL cells lacking functional p53 (Kaufman et al., 
2015). In another study, Chiara Agnoletto and colleagues reported that cell death induced 
by a mitochondria-targeting small molecule, sodium dichloroacetate, in p53 mutated CLL 
cells was associated with the activation of transcription factor interleukin enhancer binding 
factor 3 (IEF3) and p21 (Agnoletto et al., 2015). By screening protein-protein interaction 
using MS-based techniques together with co-immunoprecipitation, Zhuojun Liu and 
colleagues reported that the receptor tyrosine kinase-like orphan receptor 1 (ROR1) 
interacted with HSP90 to promote the survival of CLL cells and that targeting HSP90 led to 
the degradation of ROR1 through ubiquitin-proteasome pathway, resulting in improved 
cytotoxicity of ibrutinib in CLL cells (Liu et al., 2020). Therefore, MS-based proteomic 
techniques help us achieve a better understanding of the effects of drugs in the protein 
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expression at a global level and the precise mechanism of drugs, which will benefit the 
development and synergistic study of drugs. 
MS-based proteomic techniques provide us a way to investigate the pathogenesis of CLL at a 
global protein expression level. So far, there has not been any proteomic study in the CD40 
stimulation on CLL cells. 
 
1.5 The rationale underlying this project 
Although novel therapeutic agents such as inhibitors of BCR or BCL-2 significantly improve 
the clinical management of patients, CLL remains an incurable disease. One major challenge 
in the clinical management of CLL is that almost all patients receiving therapies eventually 
develop drug resistance, resulting in mortalities (Hallek, 2019). In addition to the intrinsic 
factors such as certain genetic mutations that cause drug resistance, the extrinsic signals 
from the microenvironment also protect CLL cells from drug-induced cell death, resulting in 
resistance to therapy (Ramsay and Rodriguez‐Justo, 2013, Arruga and Deaglio, 2017). 
Therefore, over the past decades, understanding how CLL cells interact with the 
microenvironment has been the focus of the CLL research community worldwide to find a 
novel therapeutic strategy to overcome the microenvironment-mediated drug resistance 
(Burger, 2012b, Ramsay and Rodriguez‐Justo, 2013, Crassini et al., 2015). T cells are one of 
the major components in the CLL microenvironment and their significant role in the 
pathogenesis and development of CLL has been well documented. The interaction between 
CLL cells and T cells is mainly mediated via CD40-CD154 crosstalk (Caligaris‐Cappio, 2003, 
Burger and Gribben, 2014). In vitro simulating the interactions of CLL cells with the 
microenvironment by co-culturing or stimulating CLL cells with the components from the 
microenvironment provides a useful model to study the pro-survival signals induced by the 
microenvironment (Purroy et al., 2015, Boissard et al., 2017, Pascutti et al., 2013, Crassini et 
al., 2017). Previous work in this research group has shown that co-culturing CLL cells with 
transfected mouse fibroblasts expressing human CD154 protected CLL cells not only from 
spontaneous cell death but also from drug-induced cell death (Zhuang et al., 2014, Chapman 
et al., 2017). Despite the clear cytoprotective effects observed at the cellular level by us and 
others, the underlying molecular mechanisms are still not well characterized. In addition, 
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there has been no published MS-based proteomic studies of the CD40 stimulation in CLL. 
Since MS-based proteomic techniques have the potential to unravel the changes in protein 
expression at a global level, this project was initiated to investigate the molecular 
mechanisms mediating pro-survival effects induced specifically by CD40 stimulation in CLL 
cells through the proteomics approach.  
 
1.6 Hypothesis and aims 
The hypothesis of this project was that CD40 stimulation alters the protein expression at a 
global level, resulting in the survival and drug resistance of CLL cells.  
The aim of this study was therefore to investigate the molecular mechanisms underlying the 
CD40 stimulation-mediated cytoprotective effect in CLL cells by studying the global changes 
in protein expression induced by CD40 stimulation through the MS-based proteomic 
approach. Ultimately, it was hoped that the protein(s)/pathways that are critically involved 
in mediating the pro-survival effect of CD40 stimulation in CLL can be identified and that the 
therapeutic strategy of intervention can subsequently be developed to overcome CD40 
stimulation-induced drug resistance in CLL. 
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Chapter 2. Methodology 
 
2.1 Introduction 
This chapter contains information about the techniques applied in this project and consists 
of two parts. The first part includes the description of the principles of the techniques and 
explains the reasons why they were selected for this project. These techniques include flow 
cytometry, mRNA sequencing, mass spectrometry, and RNA interference (Figure 2.1). 
Western blotting has been commonly used throughout this project to investigate individual 
protein targets, so it is included in this chapter. The second part is the description of the 
operational procedures of the methods used throughout the project.  
         
    Figure 2.1 Main techniques applied in this project to measure the biological outcomes  
 
2.2 The principles of the key techniques applied in this project 
2.2.1 Flow cytometry 
In this project, flow cytometry has been applied for the cell death analysis and the cell 
surface marker assay (to test the phenotype of fibroblasts and the percentage of primary 
CLL cells co-expressing CD5 and CD19). With flow cytometry, it is possible to simultaneously 
measure and analyse (even sorting) the multiple physical characteristics of the single cell in 
a mixture of a sample (Givan, 2001). The flow cytometer generally consists of three 
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components, the fluidics system, the optics system, and the electronics system (Biosciences, 
2000). The fluidics system transports analytes to the laser beam for interrogation. The optics 
system includes the lasers to illuminate the analytes and optical filters to direct the resulting 
light signals to the correlated detectors (DaC, 2000). The electronics system then converts 
the detected light signals into electronic signals for further analysis. The analytes for flow 
cytometry should be in a fluid stream and the suitable size of analytes ranges from 0.2 to 
150μm (Biosciences, 2000). All the analytes in the fluid stream will pass through the laser 
intercept and scatter laser light, and the fluorescent molecules presenting on the analytes 
will fluoresce. The scattered laser light is collected by appropriately positioned lenses and 
finally detected with the help of beam splitters and filters. The scattering light travels in two 
directions, namely the forward-scattered light (FSC) and the side-scattered light (SSC) 
(Figure 2.2). FSC is mainly affected by the size of analytes and the SSC is mainly affected by 
the internal complexity of analytes. SSC is collected at approximately 90 degrees to the FSC 
(Biosciences, 2000).  
                
            Figure 2.2 Simple schematic diagram of the optics system of a flow cytometer 
            FSC: forward-scattered light; SSC: side-scattered light. 
 
Fluorescent compounds absorb light energy, and the absorbed energy raises the fluorescent 
compound to a higher energy level. The excited electron quickly decays to its original status 
and emits excess energy in the form of a photon of light (Givan, 2011). This transition of 
energy gives out fluorescence (Givan, 2011). Based on this principle, labelling analytes with 
different fluorochromes can help to identify and quantify targets on the analytes for 
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biological analysis on the condition that the combination of the fluorochromes will emit 
distinguishable wavelengths for individual identification. The most commonly used laser is 
the argon-ion laser as its light of 488 nm wavelength can excite versatile fluorochromes. The 
most popular fluorochrome for individual applications is the fluorescein isothiocyanate 
(FITC) which usually works in the combination with another fluorochrome phycoerythrin 
(PE) (Shapiro, 2005). With the fast development of the flow cytometer, the maximum 
number of fluorochromes in combination can reach eighteen.  
Here in this project, the fluorochrome combination used for cell death detection was FITC 
Annexin V together with propidium iodide (PI) or 7-aminoactinomycin (7-AAD). Annexin V is 
a 35-36 kDa Ca2+ dependent phospholipid-binding protein and has a high affinity for 
phosphatidylserine (PS) (Pharmingen). In a healthy cell, PS residues are usually retained in 
the inner leaflet of the cell membrane. When cells undergo apoptosis, the PS will 
translocate to the outer side of the cell membrane and the Annexin V can bind to the 
exposed PS to identify the apoptotic cells at an early stage (Abedin et al., 2007, Turcotte et 
al., 1994). PI is used as a fluorescent reagent to stain the nucleic acids (DNA) of the cells 
(Ormerod, 1998). PI is cell membrane impermeant and thus excluded from viable cells with 
intact membranes. However, when the cell membrane becomes permeabilised or disrupted 
during late apoptosis or necrosis, PI will enter the cells and bind to DNA with high affinity. PI 
is used together with Annexin V to identify apoptotic cells in the late stage. Alternatively, 7-
AAD is also used as a fluorescent dye to identify apoptotic cells in the late stage. 7-AAD has 
a high binding affinity with DNA when the cell membrane becomes permeabilized or 
disrupted by apoptosis or necrosis (Zimmermann and Meyer, 2011). In this way, the 
combination of FITC Annexin V with PI/7-AAD works together to identify cells that undergo 
early and late-stage apoptosis. The FITC Annexin V positive and PI/7-AAD negative cells are 
under the early apoptotic stage. The FITC Annexin V and PI/7-AAD double-positive cells are 
under the late apoptotic stage whereas cells double negative for FITC Annexin V and PI/7-









B.                         
Figure 2.3 Schematic diagram of cell death detection by flow cytometry using Annexin V 
and PI/7-AAD. (A) shows how the Annexin V and PI/7-AAD binding to the dying and dead 
cells. PS residues are usually retained in the inner leaflet of the healthy cell membrane. 
When cells undergo apoptosis, the PS translocates to the outer side of the cell membrane 
and the Annexin V can bind to the exposed PS to identify the apoptotic cells at an early 
stage. When the cell membrane becomes permeabilised or disrupted during the late 
apoptosis or necrosis, PI will enter the cells and bind to DNA with high affinity. 7-AAD also 
has a high binding affinity with DNA and it works like PI. (B) shows an example of the results 
of cell death detection using the combination of FITC Annexin V with PI/7-AAD works 
together to identify cells that undergo early and late-stage apoptosis. The FITC Annexin V 
positive and PI/7-AAD negative cells are under the early apoptotic stage as shown in the 
lower-right corner. The FITC Annexin V and PI/7-AAD double-positive cells are under the late 
apoptotic stage as shown in the upper-right corner. Cells double negative for FITC Annexin V 
and PI/7-AAD are considered to be viable as shown in the lower-left corner. 
 
Comparing with other techniques to identify the apoptotic cells, flow cytometry is quicker 
and more efficient with the minimum amount of cells needed (Olson et al., 1993). It is 
particularly suitable in assays where the aim of the experiments is to quickly measure the 
percentage of cell death in response to drug treatment. 
Flow cytometry was also applied in this project for monitoring the surface expression of 
human CD154 in the transfected mouse fibroblasts and the percentage of CLL cells co-
expressing CD5 and CD19 among the peripheral blood mononuclear cells (PBMCs) samples 
from individual patients with CLL. In the former case, stably transfected mouse embryonic 
fibroblasts expressing human CD154 were used in the co-culture experiments for CD40 
stimulation of CLL cells. The parental mouse fibroblasts which were also stably transfected 
with an empty vector were used as a control in co-culture experiments. The phenotypes of 
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the fibroblasts were thus regularly checked by flow cytometry to ensure that the correct 
fibroblasts were used for CD40 stimulation. In the case of CLL samples, as the proportion of 
CD5 and CD19 double-positive CLL cells among the PBMC samples varies from individual 
patients, the percentage of CLL cells co-expressing CD5 and CD19 in every PBMC samples 
used in the study was monitored by flow cytometry to ascertain the level of contamination 
from other types of cells such as T cells and monocytes. 
  
2.2.2 mRNA sequencing 
The mRNA sequencing technique applied in this project was the RNA-seq, a next-generation 
sequencing (NGS) technique that has become the method of choice for RNA sequencing 
analysis after 2012. The entire process for sequencing applied in this project consisted of 
preparation of biological samples, RNA extraction, RNA sample quality, and quantity test, 
library construction, sequencing, data processing (quality control, mapping, quantification), 
and data analysis (Conesa et al., 2016). To be specific, biological sample preparation and 
RNA extraction together with the quantification and purity tests for all the RNA samples 
were conducted in this laboratory before sending them to a commercial company 
(NOVOGENE plc, Hong Kong, China) for sequencing. The sequencing data analysis was 
supported by the bioinformatics group at the Computational Biology Facility at the 
University of Liverpool. 
For the NGS technique, the mRNA isolated from the whole RNA extracted from biological 
samples is fragmented and converted to the complementary DNA (cDNA). The cDNA is then 
combined with adaptors and further amplified. The adaptor ligated to the cDNA includes the 
sequencing primer binding site, the index, and the region complementary to the flow cell 
oligo. Each part has two types that fit the two ends of cDNA separately. The following 
process is the cluster generation where prepared cDNA binds to the oligos within the flow 
cell and generates the correlated complementary strand. The original strand cDNA is 
washed away leaving the complementary strand for bridge amplification. During the bridge 
amplification, the left strand bends over, binds to the complementary oligo, and works as 
the template to generate the double-stranded cDNA with each of the strands attached to 
the flow cell with their different end oligo. The double strands denature and generate one 
forward strand and one reverse strand. The bridge amplification is repeated with millions of 
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clusters simultaneously resulting in the clonal amplification for all the clusters. After the 
bridge amplification, the reverse strands are washed off leaving only the forward strands in 
the flow cell and all the forward strands work as the template for sequencing synthesis and 
paired-end sequencing synthesis to read out the forward and reverse strands. The whole 
process description was derived from the online information provided by Illumina and the 
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Figure 2.4 Schematic diagram of the NGS principle. mRNA isolated from the whole RNA 
extracted from biological samples is fragmented and converted to cDNA. The cDNA is then 
added with adaptors and amplified. The original strand cDNA is washed away leaving the 
complementary strand for bridge amplification. During the bridge amplification, the left 
strand bends over, binds to the complementary oligo, and works as the template to 
generate the double strands cDNA. The double strands denature and generate one forward 
strand and one reverse strand. The bridge amplification is repeated with millions of clusters 
simultaneously resulting in the clonal amplification for all the clusters. Then, the reverse 
strands are washed off leaving only the forward strands in the flow cell and all the forward 
strands work as the template for sequencing synthesis and paired-end sequencing synthesis 




NGS is the latest sequencing technique that has been commonly used nowadays. Comparing 
with the microarray sequencing, NGS does not need prior knowledge for the design of probe 
sets, which makes it more economic and efficient. 
 
2.2.3 Mass spectrometry-based proteomic approaches 
Liquid chromatography mass spectrometry (LC-MS/MS) technique provides a sensitive and 
efficient way to analyse proteins both qualitatively and quantitatively. The key aim of this 
project was to investigate the CD40 stimulation-induced pro-survival effect on primary CLL 
cells mediated through changes in protein expression. To identify the changes in protein 
expression induced by CD40 stimulation at a global level, the protein expression of CD40 
stimulated primary CLL cells was compared with that of their unstimulated counterparts.  
Mass spectrometry (MS)-based proteomics is an advanced technique, and its application 
leads to comprehensive identification and quantification of proteins expressed in a 
cell/tissue-specific manner. The advantage of MS-based discovery proteomics techniques is 
that they require no prior knowledge of what proteins are presenting in a particular 
cell/tissue sample and that they can identify and quantify hundreds and thousands of 
proteins simultaneously (Schulze and Usadel, 2010). MS-based approaches have been 
shown to detect the changes in protein expression associated with different stages of a 
disease or different treatments (Han, 2010, Zhang et al., 2019).  
Basically, there are two forms of proteomics study which are also called the ‘top-down’ and 
the ‘bottom-up’ approaches (Chait, 2006). The ‘top-down’ type of proteomics study refers 
to identifying and quantifying proteins by analysing the intact proteins, such as analysing the 
intact proteins using a mass spectrometer, tandem mass spectrometry, and two-
dimensional gel electrophoresis in combination with tandem mass spectrometry (Kelleher, 
2004, Sze et al., 2002, Wright et al., 2014). This is a relatively slow process and it requires 
proteins to be presented to the mass spectrometer in a semi-pure state. In contrast, the 
‘bottom-up’ type of proteomics study means identifying and quantifying proteins by 
analysing the sequence of amino acids of peptides that are generated from digested 
proteins (Chait, 2006, Aebersold and Mann, 2003). In this project, we use a bottom-up 
proteomics approach to identify and relatively quantify proteins: the complexity of samples 
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from the CD40 stimulated and unstimulated primary CLL cells makes this relatively high 
throughput approach more suitable. 
The entire process performed by a mass spectrometer consists of three parts which are the 
sample ionisation, ion selection, and ion/mass detection (Gross, 2006). In this project, the 
instrument of mass spectrometry used was the TripleTOF6600 (Sciex) (Figure 2.5). 
Specifically, samples of mixed peptides are suspended in solution and these in-solution 
peptides are sprayed into the instrument by electrospray ionisation (Klein et al., 1997, 
Hopfgartner et al., 2004). During the spray, the peptides are heated and ionised, from which 
the peptides adopt 1 or more protons (Awad et al., 2015, Koomen et al., 2005). The ionised 
peptides then enter the instrument and via a mini-quadrupole (QJet) and a slightly larger 
quadrupole Q zero (Q0), they reach the chamber of Q1 that has four parallel metal rods 
arranged in a circle. By adjusting the voltages of the device of Q1, it is manageable to select 
the range of mass-to-charge ratio (m/z) for analytes (Hunter and Seymour, 2015). Generally 
speaking, researchers will set the voltage to cover the entire range firstly. Then, if the 
researchers will target at any special analytes, they will adjust the settings of Q1 with 
specific m/z range to select analytes of interest (Chernushevich et al., 2001, Chernushevich 
and Thomson, 2003). The ionised peptides coming out from the Q1 enter the next chamber, 
linear accelerator (LINAC), in which the collision-induced dissociation (CID) happens to 
further fragment the peptides for the purpose of amino acid sequencing read out. In the 
chamber of LINAC, ionised peptides are bombarded with high energy nitrogen for further 
fragmentation and the sequence of amino acids can be determined due to the places of 
breakage induced by CID on the peptide backbone can be reasonably predictable (Koomen 
et al., 2005). The last part of the TripleTOF6600 is the time-of-flight (TOF) tube where the 
m/z of peptides are measured based on the principle that the time an ion takes to travel the 
reflected distance in the instrument is proportional to its m/z (Cotter, 1999, Koomen et al., 
2005). When it comes to the calculation of the mass of peptides from its m/z, it can be 
explained by taking the positive ion mode as an example. The charge is conferred by the 
adoption of a proton or protons H+ and an H+ has a mass of amu (atomic mass unit, 1 amu = 
1 Da = 1g/mol). Taking a peptide of 1529.8204 Da as an example, the singly charged ion of 
this peptide will have an m/z of (1529.8204+1)/1 = 1530.8204; the doubly charged ion of 
this peptide will have an m/z of (1529.8204+2)/2 = 765.9102; the triply charged ion of this 
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peptide will have an m/z of (1529.8204+3)/3 = 510.9401. When the MS presents the 
spectrum results as Figure 2.6, the first peak in Figure 2.6 A will be identified as the doubly 
charged ion of the peptide 1529.8204 Da and the first peak in Figure 2.6 B will be identified 
as the triply charged ion of the peptide 1529.8204 Da. The mass spectrometer can identify 
the isotopic series as well. Taken the 12C and 13C as an example, it has been known that 99% 
of the carbon atoms occur as 12C and only 1% of the carbon atoms occur as 13C in nature and 
13C is 1 amu heavier than 12C (O'Leary, 1988). If all the carbon atoms in the peptide of 
1529.8204 Da turn out to be 12C, the doubly charged ion of this peptide will have an m/z of 
765.9102 as the first peak from the left in Figure 2.7. If one of the carbon atoms in this 
peptide turns out to be 13C, the doubly charged ion of this peptide will have an m/z of 
766.4116 as the second peak from the left in Figure 2.7. If two of the carbon atoms in this 
peptide turn out to be 13C, the doubly charged ion of this peptide will have an m/z of 
766.9118 as the third peak from the left in Figure 2.7. The proteins can be identified using a 
mass spectrometer by searching the peptide and fragment ion m/z values against a publicly 
available database such as SwissProt.  
               
Figure 2.5 Schematic diagram of the QqTOF process of the Triple TOF○R 6600 machine. 
Peptides in solution are sprayed through a very fine needle and are heated and ionised at 
the same time. Via the QJet and the Q0, ions enter the Q1. The voltages can be adjusted to 
select the range of mass or m/z according to the aim of the study. Then, ions enter the 
chamber of LINAC where the process of collision-induced dissociation (CID) takes place. The 
ionised peptides are bombarded with high energy nitrogen gas for fragmentation. The last 
part of the TripleTOF6600 is the time-of-flight (TOF) tube where the m/z of peptides are 
measured based on the principle that the time an ion takes to travel the reflected distance 





Figure 2.6 An example of the spectrum result of MS. The x-axis represents the number of 
m/z; the y-axis represents the intensity of peptides. (A) The spectrum is identified as the 
doubly charged ion of the peptide of 1529.8024. (B) The spectrum is identified as the triply 
charged ion of the peptide of 1529.8204. 
 
                                      
Figure 2.7 An example of the identification of isotopic series results of MS. The x-axis 
represents the number of m/z; the y-axis represents the intensity of peptides. The first peak 
from the left side is identified as the doubly charged ion of the peptide of 1529.8204 Da in 
which all the carbon atoms in it occur as 12C and it is a monoisotopic peptide. The second 
peak from the left side is identified as the doubly charged ion of this peptide in which one of 
the carbon atoms in it occurs as 13C. The third peak from the left side is identified as the 
doubly charged ion of this peptide in which two of the carbon atoms in it occur as 13C. 
 
The method of quantitative MS-based proteomics applied in this project was the isobaric 
tags for relative and absolute quantification (iTRAQ). The protein quantification methods 
based on mass spectrometry can be divided into two forms, label-free and label-based 
approaches (Patel et al., 2009). The labelling techniques depending on cell division, such as 
stable isotope labelling by amino acids in cell culture (SLIAC), are not appropriate for this 
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project because the primary CLL cells obtained from the peripheral blood of the patients are 
in cell-cycle arrest and they do not proliferate in vitro. Meanwhile, the limitation of the 
numbers and amount of primary CLL samples makes the label-free approaches such as 
SWATH (Sequential Windowed Acquisition of All Theoretical fragments) inappropriate as 
they require a certain amount of samples to establish a specific library for the global protein 
expression of the tissue in question (for example the protein expression profiles of the 
CD40-stimulated and unstimulated primary CLL cells) (Pham et al., 2012). Also, the statistical 
power of these types of approaches requires analysing a large number of samples. The 
iTRAQ labelling approach allows proteins/peptides from different samples to be analysed 
simultaneously and it increases the sensitivity of peptides detection by its additive effect in 
the mass spectrometer. Generally speaking, the same liquid chromatography mass 
spectrometry (LC-MS) method can be run to achieve reliable data across a cohort of 
samples. However, in reality, the more times of running the samples, the more variations 
will generate (Musenga and Cowan, 2013, Nováková, 2013). The multiplexed labelling 
principle of iTRAQ decreases the number of LC-MS acquisitions, which further reduces the 
technical-generated variations. Considering the minimum number of biological replicates 
(referring to the number of primary CLL cases) required, as suggested by bioinformaticians 
to achieve statistical confidence with the data generated, iTRAQ 8-plex was selected as the 
suitable option for this project.  
The principle of iTRAQ was established by Thompson et al. in 2003. iTRAQ is a tandem mass 
spectrometry-based quantification technique that requires the peptides to be fragmented 
before being quantified. iTRAQ-labelled peptides from several samples are pooled and 
analysed simultaneously, and this process provides information on peptide amino acid 
sequence and the relative abundance across labelled samples (Thompson et al., 2003). The 
4-plex version of iTRAQ was further described by Ross PL and colleagues in 2004 (Ross et al., 
2004) and three years later, iTRAQ was developed into the 8-plex version, which increases 
the utility of this technique. The 8-plex multiplexing labelling technique is very efficient 
when studying the protein expression in different biological conditions simultaneously and it 
enhances the accuracy of statistical analysis (Choe et al., 2007).  
All of the iTRAQ labelling tags have the same mass, that is they are isobaric, and they consist 
of three parts (Figure 2.8): a reporter group, a mass balance group, and an amine reactive 
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group (Thompson et al., 2003). The reactive group binds to peptides through the N-terminus 
and lysine side chains. The mass of the balance group varies depending on the different 
mass of the corresponding reporter group in order to keep the overall mass of the tags the 
same. The reporter and the balance groups will be released from peptides during the 
fragmentation process in the mass spectrometer (labelled with red arrows in Figure 2.8), 
and the difference in abundance of the reporter ions provides relative quantitation of that 
peptide across all the samples. The relative quantitation of proteins is extrapolated from the 
average ratio of the released reporter ions from all the peptides derived from an individual 
protein. At the same time, the spectra detected by the tandem mass spectrometry process 
provide the information of the amino acid sequence of peptides, which reveals the identity 
of the peptide/protein (Ross et al., 2004).  
    
Figure 2.8 Schematic diagram of the iTRAQ 8-plex labelling tags. The isobaric mass tags of 
iTRAQ consist of three parts: a reporter group, a mass balance group, and an amine reactive 
group. They label peptides at the N-terminus and lysine side chains by the reactive groups. 
During the fragmentation, the reporter and the balance groups will be released from 
peptides (labelled with red arrows) and the relative abundance of the reporter is used to 




After labelling samples using iTRAQ 8-plex, two stages of pre-fractionation were performed 
on the labelled peptides to increase proteome coverage and accuracy of the analysis. The 
principles for the pre-fractionation applied in this project were the high-performance liquid 
chromatography (HPLC), the ion exchange chromatography, and the gradient analysis.  
HPLC is a commonly used automatic technique with high efficiency and sensitivity and it 
usually consists of four parts, the pump with high pressure, the injection and loading 
system, the separation process by running through the column, and the detection (Snyder et 
al., 2012). There are three major modes of HPLC separation that are based on polarity, 
charge, or size. For the separation based on polarity, there is the normal phase (Figure 2.9 
A) and the reverse phase (Figure 2.9 B) HPLC. The column plays the role of the stationary 
phase and the molecules in the mobile phase run through the column to be separated. In 
the normal phase, the column is polar hydrophilic, which delays the polar molecules and 
helps the non-polar molecules run through faster. In contrast, in the reverse phase, the 
column is non-polar hydrophobic, which delays the non-polar molecules and helps the polar 
molecules run faster from the column (Gilar et al., 2005). Comparing with the normal phase, 
the reverse phase HPLC has a wider range of molecule applications and is more commonly 













                       
A. Normal phase 
                         
B. Reverse phase 
Figure 2.9 Schematic diagrams of the normal and reverse phase separation. Blue spots: the 
non-polar molecules. Yellow spots: the polar molecules. (A) the normal phase column is 
polar hydrophilic, which delays the polar molecules and helps the non-polar molecules run 
through faster. (B) the reverse phase column is non-polar hydrophobic, which delays the 
non-polar molecules and helps the polar molecules run faster from the column. 
 
Cation exchange chromatography is one type of ion exchange chromatography. Ion 
exchange chromatography is a process that separates or purifies ions and polar molecules 
based on their affinity to the ion exchanger applied and it has been widely applied in the 
charged molecules including proteins, peptides, nucleic acids, and nucleotides (Acikara, 
2013, Yamamoto et al., 1988). The cation exchange chromatography contains a negatively 
charged stationary phase and positively charged molecules in the mobile phase will be 
attracted (Cummins et al., 2017), which makes it usually applied in the molecules of interest 
that are positively charged (Figure 2.10 A). The other type of ion exchange chromatography 
is the anion exchange chromatography. Inversely to cation exchange, the anion exchange 
chromatography contains a positively charged stationary phase and negatively charged 
molecules will be attracted (Cummins et al., 2017), which makes this type of ion exchange 
chromatography applied in the molecules of interest are negatively charged (Figure 2.10 B). 
Here in this project, we used the cation exchange chromatography (column: 200×4.6mm, 
5μm, 300A, Poly LC, Columbia, MD) resulting from the fact that we used trypsin to digest 
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proteins. Trypsin is a commonly used protease that hydrolyzes proteins by cleaving the 
peptides on the C-terminal side of the amino acid residues lysine and arginine (Olsen et al., 
2004) and fully tryptic peptides are usually positively charged under acidic conditions, which 
makes cation exchange chromatography appropriate for this project. 
            A.                 B.  
Figure 2.10 Schematic diagrams of the two types of ion exchange chromatography. Red 
spots: positively charged molecules; blue spots: negatively charged molecules. (A) shows the 
process of cation exchange chromatography. The stationary phase, the column, of cation 
exchange chromatography is negatively charged. Positively charged molecules in the mobile 
phase will be attracted and the negatively charged molecules will pass through. (B) shows 
the process of anion exchange chromatography. The stationary phase of anion exchange 
chromatography is positively charged. Negatively charged molecules in the mobile phase 
will be attracted and positively charged molecules will pass through. 
 
Another key principle commonly applied in the separation is the gradient analysis. The 
gradient analysis is the process that using buffers consist of two or more solvents and the 
composition of the components in the buffers are programmed to change during the 
elution, which manages to further separate a specific type of molecules (the polar/non-
polar molecules, the positively/negatively charged molecules) (Schoenmakers, 1986, Patil, 
2017). Taking cation exchange as an example, firstly, the positively charged molecules are 
attracted by the negatively charged column and the negatively charged molecules pass 
through the column directly. The application of the gradient analysis can further separate 
the positively charged molecules binding to the column by eluting with the special buffer 
increasing the concentration of the positively charged components sequentially (Figure 
2.11). The positively charged components in the buffer will displace the positively charged 
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molecules binding to the column. The higher the concentration of the positively charged 
components, the more positively charged molecules can be eluted from the column.  
A.         B.  
Figure 2.11 Schematic diagrams of the gradient analysis. The red spots represent the 
positively charged molecules from the samples to be analysed and they are binding to the 
negatively charged column of the cation exchange chromatography. The purple spots 
represent the positively charged components from the elution buffer. The green spots 
represent the negatively charged components in the elution buffer. (A) With relatively lower 
concentrations of the positively charged components in the elution buffer, the positively 
charged molecules binding to the column are eluted with the positively charged 
components from the elution buffer taking place in the column. (B) With a higher 
concentration of the positively charged components in the elution buffer, more positively 
charged molecules are eluted from the column. 
 
Due to the complexity of the organic analytes in biology study, using only one simple 
separation is absolute not enough to separate the abundant mixture of peptides. As 
mentioned above, there were two stages of the pre-fractionation of the peptides applied in 
this project. The iTRAQ labelled protein samples were digested by using trypsin. The first 
stage peptides separation was performed by using cation exchange chromatography. When 
loaded the mixture samples of the positively charged tryptic peptides into the column of 
cation exchange chromatography, they were first attracted to the column with the 
negatively charged passing through the stationary phase. The elution buffer applied here 
was a gradient buffer with different levels of positively charged ions that took place the 
positively charged peptides in the column during the elution. With the increasing 
concentration of the positively charged ions in the elution buffer, the positively charged 
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peptides binding to the column were gradually eluted from the column based on their 
charges. The fractions of peptides obtained from the first stage separation were then 
desalted by a reversed phase cartridge and dried. The second stage of separation was 
performed by using the Eksigent NANO LC 415 (Eksigent) in-line with the mass 
spectrometer. The dried fragments of peptides were resuspended and submitted to the 
Eksigent NanoLC 415. The Eksigent NanoLC 415 automatically separated the analysed the 
peptides with gradient analysis together with the reverse phase HPLC processes. The 
sequential separation reduces the complexity of the peptide mixture presented to the MS at 
any one time, which increases the number and dynamic range of the peptides that can be 
captured. 
The LC-MS/MS-based iTRAQ technique is selected for the proteomics study in this project as 
it can accommodate the characteristics of primary CLL cells and fulfil the aims and design of 
the proteomics study for this project. However, the LC-MS/MS-based iTRAQ technique still 
has limitations. As described above, the entire procedure of this LC-MS/MS-based iTRAQ 
technique consists of multiple steps, and the operation of each step influences the final 
proteomics analysis. The condition of sample preparation is fundamental for MS-based 
proteomics study. Primary CLL cells are mostly non-proliferative cells and the high level of 
spontaneous apoptosis of these cells in culture conditions affects the repertoire of proteins 
extracted. The efficiency of iTRAQ labelling is a significant factor for the quality of the 
proteomics data. During the iTRAQ labelling in this study, a manufacturing issue with the 
iTRAQ reagents was encountered, which leads to the consequence that a group of samples 
was unlabelled. It was unpredictable and this step was redone after the manufacture 
provided a new kit. The LC-MS/MS-based iTRAQ technique cannot capture all the proteins 
expressed in samples. The quality of the protein samples to be analysed was checked by 
two-dimensional peptide separation before mass spectrometry processes to avoid the loss 
of protein identification due to the complexity of samples. Special types of proteins may be 
poorly captured and identified by mass spectrometry, such as membrane proteins (protein 
solubility), cytokines and chemokines (protein abundance), and protein expelled from cells. 
The degradation during every step of the entire procedure is another issue affecting the 
proteomics analysis. It is necessary to point out that the design of the LC-MS/MS-based 
iTRAQ technique applied in this project is not appropriate to capture the post-translationally 
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modified proteins. With prudent design and carefully operating in all steps, it was confident 
that obtaining a comprehensive understanding of the influences induced by CD40-
stimulation in primary CLL cells at the translational level was reliable by using the LC-
MS/MS-based iTRAQ technique.  
 
2.2.4 siRNA knockdown 
The knockdown technique applied in this project was small interfering RNA (siRNA) knocking 
down which is one of the RNA interference (RNAi) techniques. Upon entering cells, the long 
dsRNA will be processed by DICER (a dsRNA-specific RNase III enzyme) which produces the 
double-strand RNA of 21-23 bases (JAGLA et al., 2005). These RNAs then incorporate into 
the RNA-induced silencing complex (RISC) where one of the strands will be removed 
(Birmingham et al., 2007). The remaining strand of the RNA binds to the mRNA of the target 
gene through the complementary sequence and induces its degradation, effectively 
stopping the mRNA from being translated into proteins (Carthew and Sontheimer, 2009). 






               
Figure 2.12 Schematic diagram of the siRNA knockdown process. The long double-strand 
(ds) RNA firstly enters the cells through the cell membrane. The long dsRNA is then cut by 
DICER, which produces siRNAs of 21-23 bases. These siRNAs then incorporate into RISC with 
one of the strands removed. The remaining strand of siRNA binds to the mRNA of the target 
gene through the complementary sequence and induces its degradation, effectively 
stopping the mRNA from being translated into proteins. 
 
With the rapid development of the RNAi techniques, there are many other tools which can 
be used for gene silencing experiment such as short hairpin RNAs (shRNAs) and clustered 
regularly interspaced short palindromic repeats (CRISPRs). shRNA is an artificial RNA 
molecule that has a hairpin turn (Paddison et al., 2002, Brummelkamp et al., 2002). When it 
is delivered into targeted cells, it will generate siRNAs stably to silence target gene 
expression (Brummelkamp et al., 2002). Using shRNAs to silence target gene expression 
requires help with plasmids or viral/bacterial vectors to deliver the shRNAs into cells 
(Brummelkamp et al., 2002, Wang et al., 2011b). CRISPR is a family of DNA sequences that 
have been found in the genomes of prokaryotic organisms such as bacteria and it can detect 
and destroy DNA from similar bacteriophages during infections (Barrangou, 2015). Together 
with an enzyme, CRISPR-associated protein 9 (Cas9), CRISPR is now applied in scientific 
research to edit genes in organisms (Zhang et al., 2014, Hsu et al., 2014). Using shRNA or 
CRISPR-Cas9 to silence target gene expression may achieve a long-term effect but to 
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produce the specific constructs and generate cells consistently not expressing the target 
gene take a lot of time (Boettcher and McManus, 2015). Considering the experimental 
design, the cost, and benefit effectiveness, siRNAs knockdown is selected for this project.  
 
2.2.5 Western blotting 
So far, Western blotting is still the most frequently used method for the identification of 
specific in-cell proteins and relative quantification because of its relatively low cost and easy 
to use. It has been used through all this project to investigate the expression level of specific 
proteins. The basic process of Western blotting analysis (Figure 2.13) consists of protein 
extraction from biological samples, protein quantification, separation by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), protein transfer to the membrane, 
antibodies probing detection, visualized detection, imaging, and densitometry analysis.  
   
Figure 2.13 The workflow of the process of Western blotting. Proteins are extracted from 
the targeted cellular samples and quantified to calculate the same amount of proteins for 
SDS-PAGE separation. The proteins separated in gels are then transferred to PVDF 
membranes and be detected for visualization. The relative amount of the expression of 





In practice, cells are first lysed for protein extraction. Protein samples are quantified by 
different biochemical methods to work out the concentrations of protein for individual 
samples. A set amount of proteins from each sample are loaded on the pre-set gel usually 
made of an acrylamide solution. 
In-gel protein separation by electrophoresis is the key process in which proteins can be 
separated according to their molecular weight and be identified with the help of the pre-
stained protein marker. Usually, the polyacrylamide gels with different concentrations are 
used as the supporting medium and sodium dodecyl sulphate (SDS) is used to denature the 
proteins, a process known as SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis) (Kurien and Scofield, 2006). When the gel is placed under an electric field, 
the charged molecules within the gel will run from one end to the other. The SDS within the 
gel binds to proteins and form a negatively charged layer around proteins regardless of their 
inherent charge (Kurien and Scofield, 2006). In this way, when proteins travel on the gel 
under electrophoresis, they will be separated depending only on their molecular weight 
(Figure 2.14). 
                        
Figure 2.14 Schematic diagram of SDS-PAGE. A set amount of proteins from each sample 
(the purple lines) are loaded on the pre-set gel made of an acrylamide solution. The wells 
for loading protein samples are made by a comb. When gel loaded with protein samples is 
placed under an electric field, the charged molecules within the gel will run from one end to 
the other end, and then the proteins will be separated depending on their molecular weight. 
 
Separated proteins in gels need to be transferred to supporting membranes for further 
probing using an antibody specific to the protein of interest. The membrane commonly used 
is the polyvinylidene difluoride (PVDF) membrane. Comparing with other types of 
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membranes such as nitrocellulose and nylon, the PVDF membrane is more stable, thus less 
brittle and the hydrophobic nature of PVDF provides higher protein binding capacity (Gorr 
and Vogel, 2015). By placing the gel with PVDF membrane in-between the sponges and filter 
papers (Figure 2.15), proteins in the gel transfer from the gel to the PVDF membrane under 
electrophoresis. Wet transfer with all the components completely submersing in transfer 
buffer usually provides higher resolution and more distinct bands in final image acquisition 
(Mahmood and Yang, 2012). 
                
Figure 2.15 Schematic diagram of the transfer. The transferring usually uses a ‘sandwich 
style’ unit, which consists of a sponge on the top, a filter paper, a PVDF membrane, the gel, 
a filter paper, and a sponge at the bottom. This unit will be put in a cassette submersing in 
the transfer buffer to transfer the proteins from the gel to the PVDF membrane. 
 
Proteins transferred onto the membrane are further probed with primary antibody and 
corresponding secondary antibody in blocking solution to block the non-specific bindings. 
The blocking solution is usually comprised of an unrelated protein such as non-fat milk or 
bovine serum albumin in Tris Buffered Saline plus 0.1% detergent Tween-20 (TBS-T). Finally, 
after the membrane is incubated with the secondary antibody conjugated with horseradish 
peroxidase (HRP), the protein-primary antibody-secondary antibody complex is visualised 
using the commercially available HRP substrates such as ImmobilonTM Western 
Chemiluminescent HRP substrate (catalogue number P36599, Merck/MILLIPORE, UK). 
Chemiluminescent detection uses an enzyme to catalyse a chemical reaction that results in 
the generation of visible light (Stewart et al., 2015). The HRP chemiluminescent reaction is 
based on the catalysed oxidation of luminol by peroxide. Oxidized luminol emits light as it 
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decays to its ground state (User Guide for ImmobilonTM Western, MILLIPORE). This process 
has been shown in Figure 2.16. The imaging is then acquired by using a charged-coupled 
device (CCD) to capture the emitted light. 
             
Figure 2.16 Schematic diagram of protein identification and exposure. The protein-primary 
antibody-secondary antibody complex is detected by Chemiluminescent HRP substrates 
which then catalyse a reaction resulting in the generation of visible light. 
 
Western blot is an inexpensive and established method for protein identification and 
relative quantification. So far, the parallel techniques for protein identification and relative 
quantification are flow cytometry, immunofluorescence, enzyme-linked immunosorbent 
assay (ELISA), and immunohistochemistry. As described earlier, flow cytometry is an 
efficient technique for detecting proteins expresses on the surface of cells but is not the 
best option for analysing the molecules inside cells (Falkmer, 1992, Nüsse and Marx, 1997). 
Immunofluorescence and immunohistochemistry are better choices for analysis of protein 
expression in situ (Rojo et al., 2009, Sullivan and Chung, 2008). Those two techniques can 
identify and provide relative quantification of the expression of target proteins in tissue but 
are not the appropriate methods for protein identification in suspension cells. ELISA has a 
relatively easier process comparing with the complex process of Western blot and is the 
choice of methods for detecting the molecules suspended in supernatant such as 
chemokines and cytokines (Yolken, 1980). Therefore, for the in-cell protein analysis, 





2.3 Methods used throughout this project 
2.3.1 Cell culture 
2.3.1.1 Primary CLL cells culture 
The majority of the work in this project was based on the use of primary CLL cells. The 
process to prepare primary CLL cells for the experiment consists of isolation and 
cryopreservation, recovery of frozen cells, and cell culture. The following part will describe 
in this order.  
 
2.3.1.1.1 Isolation of CLL cells from blood samples and storage 
The peripheral blood samples from patients with CLL were obtained with informed consent 
and approval from Liverpool (Adult) Local Research Ethics Committee and transferred to the 
Liverpool Blood Disease Biobank. The procedure to isolate CLL cells was immediately carried 
out in a class II bio-safety tissue culture cabinet to maintain the sterile condition.  
Blood samples were slowly poured on top of the Lymphoprep (catalogue number 1114544, 
Axis-Shield PoC AS, Oslo, Norway), as shown in Figure 2.17. The samples were spun at 800g 
at room temperature for 30 minutes and the mononuclear cells layer was collected into new 
tubes. The mononuclear cells were washed with pre-warmed RPMI-1640 medium 
(catalogue number 22409015, Gibco/Life Technologies, UK) and centrifuged 550g for 10 
minutes. The supernatant was then removed and the cells were resuspended. Following the 
cell count, 20 million cells in 1ml freezing medium were aliquoted into the labelled cryotube 
and stored at -80℃ freezer initially and transferred to -150℃ freezer for long-term storage. 
                        
Figure 2.17 The process of lymphocyte extraction using Lymphoprep. Blood samples will be 
slowly flowed onto the top of the Lymphoprep and then centrifuged at 800g, room 
temperature, for 30 minutes. After the centrifuge, the sample in the tube will be separated 




2.3.1.1.2 Recovery of frozen primary CLL cells 
The frozen sample was thawed in 37℃ water-bath firstly and transferred into a 20ml 
universal tube on ice. Ice-cold RPMI-1640 medium with 10% heat-inactivated qualified fetal 
bovine serum (FBS) (catalogue number 16000044, Gibco/Life Technologies, UK), 1% L-
Glutamine (catalogue number G7513, Sigma-Aldrich, UK) and 1% Penicillin/Streptomycin 
(catalogue number P4333, Sigma-Aldrich, UK) were added drop by drop until it reached 
10ml for one vial of cells thawed. Then, the sample was centrifuged at 550g, 4℃ for 5 
minutes. The supernatant was removed and the pellet was washed with the ice-cold 
medium. The sample was centrifuged again in the same setting and the supernatant was 
removed. The pellet was resuspended with the ice-cold medium in appropriate volumes 
depending on the size of the cell pellet. The sample was then incubated in an incubator with 
the atmosphere containing 5% CO2 at 37℃ for 1h to recover. After the recovery, the number 
of cells was counted using an automated cell counter (Cellometer) and the initial viability of 
the sample was tested by flow cytometer before the further experiment. 
 
2.3.1.1.3 The analysis of the percentage of CD5 and CD19 double-positive primary CLL cells 
by flow cytometry 
The analysis of the percentage of CD5 and CD19 double-positive primary CLL cells for each 
primary sample is performed in order to determine the level of contamination of other 
types of blood cells in each CLL PBMC samples. Therefore, CD5 and CD19 antibodies and the 
corresponding isotype-control antibodies (Table 2.1) were used for staining. The stained 
primary CLL cells were analysed by flow cytometry. 
Table 2.1 Antibodies used for purity test using flow cytometry 
 Company Catalogue No. Description 
CD5 (FITC) BD 345781 Monoclonal mouse anti-human reagent for 
identification of cells expressing CD5 antigen 
Mouse IgG1 (FITC) BD 345815 Fluorescence controls for use with human cells 
CD19 (PE) BD 345777 Monoclonal mouse anti-human reagent for 
identification of cells expressing CD19 antigen 




2 million primary CLL cells were collected and transferred into 1.5ml Eppendorf tubes with 1 
million cells for test antibodies and 1 million for corresponding control antibodies. Each 
sample was centrifuged at 500rcf, room temperature, for 5min. The medium was removed 
and the cell pellet was washed with PBS. Then, the sample was centrifuged again in the 
same setting. The supernatant was removed and the pellet was resuspended with Staining 
Buffer (PBS with 0.1% BSA), 100μl per 1 million cells.  
20μl of CD5 antibody (FITC) and 20μl of CD19 antibody (PE) were added into the test group 
tubes and mixed well. 20μl of the mouse IgG1 (FITC) and 20μl of the mouse IgG1 (PE) were 
added into the control group tubes and mixed well. The detailed information about the 
antibodies used for the purity test by flow cytometry has been listed in Table 2.1. The 
testing samples were incubated in the dark for 10min. Then, samples were centrifuged at 
the previous setting and the supernatants of the samples were removed. The cell pellets 
were resuspended with 350-400μl Staining Buffer and analysed on the flow cytometer.   






            A.             
 
            B.              
Figure 2.18 An example of the results of the purity test of primary CLL sample by flow 
cytometer A. CLL cells were stained with negative control antibodies; B. CLL cells were 
stained with both FITC-labelled CD5 and PE-labelled CD19 antibodies. The BL1-A channel is 
for FITC (CD5) and the BL2-A channel is for PE (CD19).  
 
2.3.1.1.4 Culture of primary CLL cells 
For the standard cell culture condition, primary CLL cells were cultured in the RPMI medium 
with 10% heat-inactivated FBS, 1%L-Glutamine, and 1% Penicillin/Streptomycin at the 
density of 4×106 cells/ml in tissue culture plates (Falcon, BD Biosciences, UK). 
For the co-culture cell condition, primary CLL cells were resuspended in the DMEM medium 
(catalogue number D6546, Sigma-Aldrich, UK) with 10% heat-inactivated FBS and 1% 
Penicillin/Streptomycin at the density of 3×106 cells/ml. Primary CLL cells were then co-
cultured with adherent mouse fibroblasts that were 𝛾-irradiated and seeded at 3×105 
cells/ml the day before the co-culture experiment. 
 
Isotype control antibodies 
CD5, CD19 antibodies 
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2.3.1.2 MEFs used for the co-culture CD40 stimulation system 
Mouse embryonic fibroblasts (MEFs) stably transfected with the expression vector 
containing human CD154 cDNA were expressing human CD154 on the plasma membrane, 
which were used to co-culture with primary CLL cells to imitate the CD40-CD154 interaction 
between CD4+ T cells and CLL cells in the lymph nodes. The parental MEFs transfected with 
an empty vector, which were not expressing CD154, were used as a control. Both fibroblasts 
were provided by Professor Gerry Cohen within the Department at the University of 
Liverpool and maintained as described (Vogler et al., 2009b). 
 
2.3.1.2.1 Maintenance of MEFs 
Both the MEFs expressing CD154 and the parental control MEFs were cultured in DMEM 
medium with 10% heat-inactivated FBS and 1% Penicillin/Streptomycin and incubated in the 
incubator with an atmosphere containing 5% CO2 at 37℃. 
MEFs were routinely passaged every 3-4 days according to the density. Each time when 
passaged, the culture medium was removed from the adhering fibroblasts. The MEFs were 
trypsinised for 3-5 minutes in the incubator before being collected and centrifuged at 250g, 
room temperature, for 5 minutes. The cell pellet was resuspended with the pre-warmed 
fresh culture medium. The resuspended fibroblasts were then cultured in new flasks. 
 
2.3.1.2.2 Preparation for co-culture experiments 
Before the co-culture experiment, the MEFs need to be 𝛾-irradiated to inhibit their 
proliferation. The culture medium was removed and the monolayer of the fibroblasts was 
trypsinised for 3-5 minutes before being collected and spun at 250g, room temperature, for 
5 minutes. Then, the cell pellet was resuspended with an appropriate volume of pre-
warmed culture medium to obtain the cell density of 6×105 cells/ml. The fibroblasts were 𝛾-
irradiated at 75Gy to inhibit the proliferation. The irradiated fibroblasts were then diluted 
with pre-warmed culture medium to the density of 3×105 cells/ml and cultured in plates in 
the incubator with an atmosphere containing 5% CO2 at 37℃ for over 12h allowing them to 
recover and adhere. The irradiated fibroblasts were ready for co-culturing with primary CLL 
cells when they were confluent. After gently removing the culture medium over the 
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fibroblasts, primary CLL cells at the density of 3×106 cells/ml were plated on the top of the 
confluent monolayer of fibroblasts for co-culture. 
 
2.3.1.2.3 Detection of CD154 expression on MEFs 
The expression of CD154 on fibroblasts was monitored using the flow cytometer once a 
month to ensure that the correct type of fibroblasts was used for co-culture experiments. 
Thus, the culture medium was removed from the adhering fibroblasts and the monolayer 
was washed with pre-warmed PBS. The monolayer of fibroblasts was detached using Cell 
Dissociation Solution (catalogue number C5789, Sigma-Aldrich) and collected into a labelled 
universal tube. The fibroblasts were centrifuged at 200g, room temperature, for 5 minutes 
and the cell pellet was washed with PBS and spun again. The cell pellet was resuspended in 
0.5ml staining buffer (PBS containing 0.1% BSA) and aliquoted 1×106 cells from each type of 
fibroblasts and divided into two 1.5ml Eppendorf tubes with each one containing 5×105 
cells. 10μl of FITC mouse anti-human CD154 (catalogue number 555699, BD Biosciences) 
was added into one tube of each type of fibroblasts as a test. 10μl of FITC mouse IgG1 κ 
isotype control antibody (catalogue number 555748, BD Biosciences) was added into the 
other one tube of each type of fibroblasts as a control. The fibroblasts were incubated at 
room temperature in the dark for 10 minutes and analysed by flow cytometer. 
The diagrams in Figure 2.19 are an example of the results of detecting CD154 expression on 




A.                                 B.                       
 
C.                                       D.                                      
Figure 2.19 An example of the results of testing the phenotype of fibroblasts. The left diagram in each paired example shows the cells 
selected for detection, which are the cells in the red gate. The corresponding histograms on the right show the percentage of cells expressing 
CD154 in all the selected cells. The threshold was set according to the results of the control antibody in each type of fibroblasts. A. The results 
of the parental fibroblasts stained with the negative control antibody. B. The results of the parental fibroblasts stained with CD154 antibody. C. 
The results of the CD154 expressing fibroblasts stained with negative control antibody. D. The results of the CD154 expressing fibroblasts 
stained with CD154 antibody. BL1-A channel in histograms is for FITC-CD154.                                                                                                                                                                                                                        
Isotype control - CD154 expressing fibroblasts CD154 antibody - CD154 expressing fibroblasts 
CD154 antibody - control fibroblasts Isotype control - control fibroblasts 
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2.3.1.2.4 Cryopreservation of MEFs 
The culture medium was removed from the monolayer of fibroblasts and the monolayer 
was trypsinised for 3-5 minutes. The fibroblasts were collected and centrifuged at 250g, 
room temperature for 5 minutes. The supernatant was discarded and the cell pellet was 
resuspended with an appropriate volume of ice-cold medium with 10% DMSO to obtain a 
cell density of 1×106 cells/ml. Then, the fibroblasts were aliquoted 1ml per vial into each 
cryopreservation tube and kept at -80℃. 
 
2.3.1.3. CLL cell lines 
HG-3 CLL cell line was established in 1998 from a 70-year-old Caucasian male patient with 
CLL (see the information of HG-3 cell line on the website: 
https://www.dsmz.de/collection/catalogue/details/culture/ACC-765), Rai stage II. MEC1 CLL 
cell line was originally established in 1993 from a 61-year-old Caucasian male diagnosed 
with CLL in prolymphocytoid transformation to B-PLL (Stacchini et al., 1999).  
Both CLL cell lines were obtained from the Leibniz Institute (DSMZ) German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). The catalogue number of the 
HG-3 cell line and MEC1 cell line were ACC 765 and ACC497, respectively. The cells with a 
low number of passages were kept in cryopreservation.  
 
2.3.1.3.1 Culture and passage of CLL cell lines 
Both HG-3 cells and MEC1 cells were cultured in RPMI medium with 10% heat-inactivated 
FBS, 1%L-Glutamine, and 1% Penicillin/Streptomycin and incubated in the incubator with an 
atmosphere containing 5% CO2 at 37℃. 
HG-3 cells and MEC1 cells were passaged every 4-5 days depending on the cell density. Cells 
were collected from flasks and centrifuged at 550g, at room temperature, for 5 minutes. 
Then, the cell pellet was resuspended in an appropriate amount of pre-warmed culture 





2.3.1.3.2 Culture of CLL cell lines for the experiment 
When used for experiments, both HG-3 cells and MEC1 cells were cultured in RPMI medium 
with 10% heat-inactivated FBS, 1% L-Glutamine, and 1% Penicillin/Streptomycin with the cell 
density of 0.5×106 cells/ml in plates in the presence or absence of the test reagents at the 
indicated concentrations and kept in the incubator with an atmosphere containing 5% CO2 
at 37℃. 
 
2.3.1.3.3 Cryopreservation of CLL cell lines 
To avoid the genetic and phenotypic changes of the two CLL cell lines, I expanded the cell 
number in culture first after receiving them and cryopreserved a stock of vials for 
subsequent experiments. The two cell lines were maintained in culture for only three 
months before a new cryopreserved vial of cells was used.  
Cells for the cryopreservation were collected from the flasks and centrifuged the cells at 
550g, at room temperature, for 5 minutes. The cell pellet was resuspended with an 
appropriate volume of ice-cold medium to obtain a cell density of 2×106 cells/ml. Operating 
on ice, an appropriate volume of the ice-cold medium with 20% DMSO was slowly added 
into the tube with cells. The cells were aliquoted 1ml per vial into each cryo-tube and kept 
at -80℃. 
 
2.3.1.4 Mycoplasma test of cell lines to avoid contamination in lab 
To avoid contamination, the mycoplasma test has been conducting every month for all the 
cell lines cultured in the tissue culture room of the department. For each type of cell lines, at 
least 5×104 cells were collected from culture flasks into the correlated 1.5ml Eppendorf tube 
and centrifuged at 7000rpm, room temperature for 5 minutes. The cell pellet was washed 
twice and resuspended in 100μl sterile PBS. Each sample was heated for 10 minutes at 95℃ 
and vortexed for 5-10 seconds. The sample was then centrifuged at 13000rpm for 2 minutes 
and an aliquot (~100μl) of the heated supernatant was transferred into a fresh tube. The 
technician in the department tested the samples using a commercial PCR kit according to 
the manufacturer’s instructions. Only the cell lines which passed the mycoplasma tests can 
be used in the tissue culture room.  
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2.3.2 Cell death detection 
Cell death detection was analysed by flow cytometer using FITC Annexin V (catalogue 
number 556420, BD Pharmingen) and propidium iodide (PI) solution (catalogue number 
556463, BD Biosciences) or 7-AAD (catalogue number 2032240, Invitrogen).  
For each sample to be tested, 1 million cells were collected and transferred into a 1.5ml 
Eppendorf tube. The cells were centrifuged at 500rcf at room temperature for 5 minutes. 
The supernatant was removed and the cell pellet was resuspended with PBS. The cells were 
centrifuged again in the same setting. The supernatant was removed and the cell pellet was 
resuspended with 500μl Annexin V Binding Buffer (constituents of 10mM Hepes/NaOH, 
140mM NaCl, 2.5mM CaCl2, pH 7.4). 5μl of FITC Annexin V was added to each sample and 
incubated in the dark for 10 minutes. 10μl of PI or 5μl of 7-AAD was then added into the 
sample before analysed by flow cytometry. 
 
2.3.3 Western blotting 
2.3.3.1 Cell lysis and protein quantification 
Cell samples were first washed with ice-cold PBS three times and centrifuged at 1000g, 4℃, 
three times, 5 minutes each. Cell pellets were then lysed with RIPA buffer containing 
protease inhibitor (catalogue number P8439, Sigma-Aldrich) and phosphatase inhibitor 
(catalogue number 524625, Millipore, UK) and kept on ice for 10 minutes. Then, the CLL 
samples were further sonicated for 5 cycles (30 seconds on plus 30 seconds off) on a high 
setting using a sonicator (Bioruptor® Standard, B01010001, Diagenode). The process of 
sonication was only applied to primary CLL cells. After sonication, cell debris was centrifuged 
at 14000rpm, 4℃, for 20 minutes and the supernatant of each sample was transferred into 
new 1.5mL Eppendorf tubes. Extracted protein samples were kept at -20℃ before use.  
The total protein from each sample was quantified using the Bio-Rad DC™ Protein Assay 
Reagents Package (catalogue number 500-0116, Bio-Rad, UK) (Table 2.2). A serial dilution of 
BSA protein standard samples with protein concentrations from 0mg/ml to 3mg/ml were 
located into a multi-well plate together with samples to be tested. 5μl of lysates was 
collected from each sample and added into one well of a 96-well plate. The protein 
quantification was duplicated for each sample to avoid technical bias. After plated all the 
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duplicates of BSA standard samples and samples to be tested, 25μl of reagent A plus 
reagent S (consist of 1ml of reagent A and 20μl of reagent S) and 200μl of reagent B were 
added into each well. The plate was incubated for 15 minutes before placing it into a plate 
reader for scanning at 650nm. The protein concentrations of samples were calculated by 
comparing with the standard curve generated by BSA standard protein samples.  
Table 2.2 Information about the reagents for protein quantification 
Reagent Company Catalogue Number 
DCTM Protein Assay Reagent A BIO-RAD 500-0113 
DCTM Protein Assay Reagent S BIO-RAD 500-0115 
DCTM Protein Assay Reagent B BIO-RAD 500-0114 
Methanol, >=99.8% FisherChemical 1666182 
PBS Laboratory scope - 
 
2.3.3.2 SDS-PAGE running and transferring 
The running gel and stacking gel were prepared in advance and 10μg of protein sample from 
each sample was calculated according to the protein quantification and collected into a 
1.5ml Eppendorf tube. The rest of the samples were at -20℃. An appropriate volume of 
Laemmli sample buffer was added into each sample according to the protein concentrations 
(the maximum volume for each sample was 30μl for 15-well comb and 40μl for 10-well 
comb). Samples were then heated at 90℃ for 5 minutes and loaded on the gel. The 
electrophoresis was conducted in apparatus filling the running buffer under 115V for 90 
minutes. After separation by the electrophoresis, the gel was taken out and washed with 
the pre-cold transfer buffer. The transfer sandwich was prepared in the order of sponge, 
filter paper, membrane, gel, filter paper, and sponge in a cassette (Figure 2.15). The proteins 
were transferred from gel to PVDF membrane under 400mA for 60 minutes.  
 
2.3.3.3 Protein targets probing with antibodies 
The PVDF membrane was taken out after transferring and washed with 1×TBST for 10 
minutes. The membrane was then blocked with 5% milk/1×TBST for 30 minutes and 
incubated with primary antibody (1:1000 dilution) with continuous agitation at 4℃ 
overnight. Then the other day, the membrane was washed with 1×TBST for 10 minutes and 
blocked with 5% milk/1×TBST for 30 minutes. Finally, the membrane was incubated with 
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correlated secondary antibody (1:2000 dilution) at room temperature for 1h and visualized 
using an imaging machine (Bio-RAD).  
Here in this project, β-actin (1:10000 dilution) was probed as the protein loading control for 
Western blot analysis. After the probing for the target protein, the membrane was washed 
with 1×TBST for 10 minutes and blocked with 5% milk/1×TBST for 30 minutes. Then, the 
membrane was incubated with the β-actin antibody at room temperature for 1h and 
washed with 1×TBST for 10 minutes and blocked with 5% milk/1×TBST for 30 minutes. 
Finally, the membrane was incubated with the correlated secondary antibody for 1h and 
visualized. 
The visualization for the protein of interest or β-actin was detected by using the 
ImmobilonTM Western Chemiluminescent horseradish peroxidase (HRP) substrate (catalogue 
number P36599, Merck/MILLIPORE, UK). Densitometry analysis was performed by using 
ImageJ analysis software (National Institutes of Health, USA). 
The detailed information of materials and the component of reagents used to complete the 
process of Western blotting have been listed in Appendix 1. 
 
2.4 Statistical analysis 
In this project, pooled data generated from the results of independent experiments were 
shown in the format of mean ± standard deviation (mean ± SD). The statistical significance 
of the difference between the two groups was determined using the Student’s t-test (two-
tailed, paired) by either Microsoft ExcelTM or GraphPad Prism 8. LC50 of agents was 
calculated using the non-linear analysis by GraphPad Prism 8. 
68 
 
Chapter 3. CD40 stimulation protects primary CLL cells from drug-induced cell 
death  
 
3.1 Background and aims 
This chapter will be divided into two parts: the first part is focused on characterizing the 
biological effect of CD40 stimulation on drug-induced cell death of primary CLL cells and the 
second part is a comparison study to find out if CLL cells stimulated by the soluble CD40 
ligand system display similar biological responses to those stimulated by co-culture system. 
When the biological effects are confirmed, CLL cells stimulated by the soluble ligand system 
will be used in the proteomics study to examine the effect of CD40 stimulation on the 
protein expression of CLL cells at a global level, which will be described in the next chapter.  
For the first part, as described in the introduction chapter, although most evidence indicates 
that CD40 stimulation induces the pro-survival signal that leads to chemo-resistance in CLL 
cells, there are still some discrepancies in reporting the effect of CD40 stimulation largely 
due to the differences in the methods of stimulation used in different studies (De Totero et 
al., 2003, Söderberg et al., 1997). Therefore, it is necessary to independently confirm the 
biological effect of CD40 stimulation on primary CLL cells under the experimental conditions 
used in this study. The method of CD40 stimulation applied in the first part of the study 
described in this chapter was the established co-culture system in which primary CLL cells 
were cultured on the monolayer of mouse embryonic fibroblasts (MEFs) that were stably 
transfected with an expression vector containing human CD154 cDNA so they expressed 
human CD154 on the cell membrane continuously (Vogler et al., 2009a). In parallel, CLL cells 
that were cultured with the MEFs stably transfected with the empty vector were used as 
controls. Such a co-culture system is a robust, reproducible model to mimic the CD40 
stimulation within the microenvironment to support the survival and proliferation of CLL 
cells, and this system has been widely used by many CLL research groups worldwide (Patten 
et al., 2008, Buggins et al., 2010, Pepper et al., 2011, Hamilton et al., 2012). In addition, 
Pascutti and colleagues showed that the gene expression profile of CLL cells co-cultured 
with CD154-expressing fibroblasts was similar to that induced by autologous activated T 
cells, and such gene expression profile was also detected in CLL samples taken from the 
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lymph nodes of the patients with CLL (Pascutti et al., 2013), thus further validated the utility 
of the co-culture system to simulate the CD40 stimulation of CLL cells by activated T cells in 
vivo at the level of gene expression of mRNA. Previous work from this research group has 
shown that the CD40 stimulation induced by the co-culture system can protect CLL cells 
from cell death induced by cytotoxic agents that activate cell death through either death 
receptor (extrinsic) or mitochondrial (intrinsic) apoptosis pathway (Zhuang et al., 2014, 
Chapman et al., 2017). The aim of this part of the study is to independently investigate how 
CD40 stimulation influences the sensitivity of primary CLL cells to cell death induced by 
cytotoxic drugs that are currently used in CLL clinics. 
Four different drugs were used to induce cell death, including fludarabine, bendamustine, 
ABT-199 (venetoclax), and ibrutinib. Fludarabine is an important component of 
chemotherapy consisting of fludarabine, cyclophosphamide, and rituximab (FCR) that is a 
front-line therapy for the untreated, del(17p) negative, TP53 unmutated, IGHV-mutated 
patients with the age of less than 65 years old and without any significant comorbidities, 
according to the National Comprehensive Cancer Network (NCCN) Guidelines version 
2.2021. Fludarabine is a purine analogue and it induces apoptosis in cell cycle arresting cells 
such as CLL cells by interfering with the DNA repair process, which leads to the overloading 
of unrepaired DNA, triggering p53-dependent apoptosis (Pettitt, 2003). Bendamustine is a 
DNA damage agent as well but the cytotoxic mechanism is different in comparison with 
fludarabine. Bendamustine induces apoptosis by crosslinking DNA bases between the 
double-stranded DNA and inhibiting the replication and repair of DNA (Gandhi and Burger, 
2009, Cheson and Leoni, 2011). ABT-199 and ibrutinib are relatively new therapeutics for 
CLL, but they already show impressive efficiency in the treatment of CLL (Itchaki and Brown, 
2016, Kaur and Swami, 2017). ABT-199 is a selective inhibitor specific for BCL-2, which was 
developed upon improvement from ABT-737 that had a severe side-effect of causing 
thrombocytopenia due to its inhibition of BCL-XL (Souers et al., 2013).  
The second part of this chapter is to investigate whether using the soluble CD40 ligand 
system can reproduce the biological effect of the CD40 stimulation using the co-culture 
system. This is out of the consideration that, if CD40-stimulated CLL cells via the co-culture 
were used for the proteomics study, the fibroblasts from the co-culture system will 
inevitably mix with CLL cells, thus potentially contaminating the cellular protein contents 
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from the CLL cells used for protein expression analysis. Consequently, CD40 stimulation 
induced by the soluble CD40 ligand was explored in this project to ensure that the proteins 
from primary CLL cells were used for proteomics analysis. CD40 stimulation induced by the 
soluble CD40 ligand has been applied in many studies to imitate the CD40-CD154 ligation 
between T cells and CLL cells (Younes et al., 1998, Jacob et al., 1998, Grdisa, 2003, Plander 
et al., 2009, Smallwood et al., 2016). Although it has been reported that CD40 stimulation 
induced by the soluble CD40 ligand together with interleukin (IL)-4 can rescue CLL cells from 
apoptosis (Grdisa, 2003), it is unclear how similar or different the effect of CD40 stimulation 
induced by the soluble ligand versus by the co-culture system is. It is thus important to 
compare these two methods of stimulation to link the previous work carried out using the 
co-culture system to the proposed proteomics study of CLL cells stimulated by the soluble 
CD40 ligand. The analysis of mRNA expression of CD40-stimulated CLL cells using the co-
culture system has been reported (Pascutti et al., 2013), which can be used as a reference to 
compare the mRNA expression of CLL cells stimulated with the soluble CD40 ligand system. 
Therefore, in this study, the mRNA expression from the CLL cells stimulated by the soluble 
CD40 ligand system was analysed using RNA-seq technology. The differential gene 
expression profile of CLL cells stimulated by the soluble CD40 ligand was also compared to 
that of CLL cells isolated from bone marrow, lymph node, and peripheral blood of patients 
with CLL (Herishanu et al., 2011). 
 
3.2 Materials and Methods 
3.2.1 Materials 
Cryopreserved primary CLL samples were obtained from the Liverpool Blood Disease 
Biobank. Before further experiments, the percentage of CD5 and CD19 double-positive cells 
(i.e. real CLL cells) of each primary CLL case was analysed by flow cytometry. The detailed 
procedures of the analysis have been described in Chapter 2. Primary CLL samples with less 
than 60% of CD5 and CD19 double-positive CLL cells were excluded from the study. The 
details of the percentage of the double-positive cells of each primary CLL sample applied in 
the study was shown in Appendix 2. The clinical information of the applied cases has been 
described in Appendix 3. 
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The source of the transfected fibroblasts expressing CD154 and the control fibroblasts has 
been described in Chapter 2. The phenotype of the fibroblasts expressing or not expressing 
CD154 was tested by flow cytometry once a month throughout the duration of experiments 
involving CD40 stimulation using the co-culture system. 
Fludarabine (catalogue number F2773, Sigma-Aldrich), ABT-199 (catalogue number S8048-
SEL, Selleck Chemicals), and bendamustine (catalogue number B5437, Sigma-Aldrich) were 
applied in the study for the induction of cell death experiments. All three drugs were 
suspended in dimethyl sulfoxide (DMSO) (catalogue number 1371913, Fisher Chemical, UK) 
to make the stock concentrations of 50mM, 10mM, 100mM for fludarabine, ABT-199, 
bendamustine, respectively. Stocks of the individual drugs were aliquoted into 0.5ml 
Eppendorf tubes with small quantities and stored in a -20℃ freezer to avoid repeated thaw-
freeze cycles. The range of concentrations used in fludarabine treatment was based on 
previous studies from our research group in which time- and concentration-dependent 
induction of cell death in CLL cells by fludarabine were established (Zhuang et al., 2014). The 
choice of concentrations applied for ABT-199 treatment was based on the findings of a 
published study in which ABT-199 was shown to induce apoptosis in primary CLL cells with 
LC50 of 3nM (Souers et al., 2013). The concentrations of bendamustine were based on the 
previous study from our research group (Chapman et al., 2017). 
The hemagglutinin (HA)-tagged recombinant human (rh) CD40 ligand/TNFSF5 was 
purchased from the R&D Systems (Oxford, UK). The lyophilised rhCD40 ligand/TNFSF5 was 
resuspended in PBS with 0.1% BSA at a stock concentration of 100ng/μl. The rhCD40 
ligand/TNFSF5 solution was aliquoted into 0.5ml Eppendorf tubes with the aliquot size of 
5μl or 10μl and kept at -80℃ before use. The lyophilised anti-HA antibody was resuspended 
in PBS at a stock concentration of 500ng/μl and kept at 4℃.  
RNeasy Mini Kit and QIAshredder Kit were all purchased from the company of QIAGEN 
(Manchester, UK).  The Qubit microRNA Assay kit was purchased from the company of Life 
Technologies/Thermo Fisher Scientific (Paisley, UK). The process of RNA extraction and 




The detailed information about the suppliers of these reagents and products has been 
shown in Table 3.1.  
Table 3.1 Products and reagents used in Chapter 3 
Reagents/products Company Catalogue No. 
HA-tagged rhCD40 Ligand/TNFSF5 R&D SYSTEMS TFE1316121 
Anti-HA Antibody R&D SYSTEMS CDCV0517051 
RNeasy Mini Kit and QIAshredder Kit QIAGEN 74104, 79654 
Qubit microRNA Assay Kit Life Technologies Q32880, Q32881 
 
3.2.2 Cell culture 
3.2.2.1 Standard culture condition 
Thawed primary CLL cells were re-suspended at the concentration of 4×106 cells/ml in 
complete RPMI-1640 medium and plated to multi-well plates and cultured in the incubator 
with an atmosphere containing 5% CO2 at 37℃ before use. 
 
3.2.2.2 Co-culture of primary CLL cells 
The monolayers were prepared as described in the section 2.3.1.2.2 in Chapter 2 and the 
procedures of thawing and recovery of frozen primary CLL cells have been described in the 
section 2.3.1.1.2 in Chapter 2. After thawing, CLL cells were checked for viability following 
Trypan blue dye staining using a Cellometer. Cells were then adjusted to a density of 3×106 
cells/ml and plated over the monolayers of the pre-prepared fibroblasts to ensure that the 
ratio of primary CLL cells to fibroblasts was kept at 10:1. The primary CLL cells in co-culture 
were kept in the incubator with an atmosphere containing 5% CO2 at 37℃ for 24h for CD40 




        
Figure 3.1 Schematic diagram of the co-culture system. The division of fibroblasts was 
inhibited by irradiation with a dose of 75Gy. The irradiated fibroblasts were plated at a 
concentration of 3×105 cells/ml into 24-well plates and kept in the incubator with an 
atmosphere containing 5% CO2 at 37℃ overnight. When the fibroblasts were confluent, the 
thawed primary CLL cells were plated on the top of the confluent fibroblasts at the 
concentration of 3×106 cells/ml. 
 
3.2.2.3 CD40 stimulation induced by the soluble CD40 ligand system 
The method of CD40 stimulation using the soluble HA-tagged CD40 ligand was essential as 
described (Lezina et al., 2018). Briefly, 0.1µg/ml HA-tagged rhCD40 ligand/TNFSF5 was 
incubated with 0.5µg/ml anti-HA antibody for 30 minutes. Then, the mixture was added to 
the culture of thawed primary CLL cells and incubated for 24h for CD40 stimulation. In 
parallel, thawed primary CLL cells were incubated with 0.5µg/ml anti-HA antibody alone as 
the unstimulated control. The density of primary CLL cells was maintained at 4×106 cells/ml 
in the 24-well plate or 5×106 cells/ml in the 6-well plate. 
 
3.2.3 Drug treatments 
Induction of cell death by drugs was performed on primary CLL cells that have been co-
cultured with the CD154-expressing or control fibroblasts for 24h. Once CLL cells were 
gently collected from the monolayers, their numbers were counted on the Cellometer. The 
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cell density of both CD40-stimulated and unstimulated CLL cells was then adjusted to 4×106 
cells/ml in fresh complete medium and a fixed number of CLL cells were plated into a new 
multi-well plate, and cultured under standard conditions with or without the cytotoxic 
drugs. The duration of incubation with the drugs varied according to the type of drugs (see 
details below). At the end of incubation, CLL cells were collected and the percentage of cell 
death of each sample was detected by flow cytometry. The detailed procedure of cell death 
detection by flow cytometer has been described in the Methodology chapter (Chapter 2).  
 
3.2.4 Preparation of the mRNA sequencing samples 
3.2.4.1 Cell preparation 
To meet the minimum requirement of statistical and bioinformatics analysis, primary CLL 
samples from six individual patients with CLL were used as the biological replicates for the 
mRNA sequencing experiment. The criteria for the selection of CLL cases were that over 90% 
of CLL PBMCs are positive for both CD5 and CD19, which was measured by flow cytometry, 
and that CLL cells respond to CD40 stimulation induced by the soluble CD40 ligand method. 
The expression of BCL-XL measured by Western blotting was used to confirm CD40 
stimulation status resulting from that CD40 stimulation has been reported to up-regulate 
the expression of BCL-XL in CLL cells (Vogler et al., 2009a). With these criteria in mind, six 
primary CLL cases had been chosen for the mRNA sequencing study (the purity information 
of the six CLL cases has been provided in Appendix 2 and the clinical information of the CLL 
cases has been provided in Appendix 3).  
To generate a sufficient number of CD40 stimulated and unstimulated primary CLL cells 
from each CLL case for the RNA extraction and the subsequent sequencing study, thawed 
primary CLL cells were cultured at a concentration of 5×106/ml with 3ml of cell suspension 
per well in a 6-well plate in the presence or absence of the soluble CD40 ligand, as shown in 
Figure 3.2. Cells were harvested after 12h and 24h, respectively. In total, there were twenty-
four mRNA samples generated from six primary CLL cases. 
At each time point, in addition to cells harvested for RNA extraction, 1 million cells were 
collected for the viability test by flow cytometry and 4 million cells were collected for the 
detection of the BCL-XL expression by western blotting. The viabilities and the status of 
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CD40 stimulation of these samples were detected before further study (results have been 
shown in Figure 3.12 and 3.13). 
              
Figure 3.2 Schematic diagram of RNA sequencing sample preparation.                        
12h/24h sti: CD40 stimulated primary CLL cells with HA-tagged CD40 ligand + anti-HA 
antibody for 12h/24h; 12h/24h unsti: primary CLL cells cultured with anti-HA antibody for 
12h/24h as controls. FACS: flow cytometry; WB: Western blotting. 
 
3.2.4.2 RNA extraction 
RNA extraction was conducted using the RNeasy Mini Kit and QIAshredder Kit (both from 
QIAGEN). During the process of RNA extraction, all the samples were kept on ice to reduce 
the risk of RNA degradation. Cell pellets were lysed with 700µl per sample of Buffer RLT 
from the commercial kit containing β-mercaptoethanol. The lysate of each sample was 
transferred directly into the QIAshredder column and spun for 2 minutes at room 
temperature. The flow-through liquids were collected and mixed with 600µl of 70% ethanol, 
and then transferred to the RNeasy mini-column and spun for 15-20 seconds at 11,000g. 
The flow-through liquids were discarded and the remaining RNeasy mini-columns were spun 
again for 15-20 seconds at 11,000g. Each RNeasy mini-column was loaded with 700µl of 
Buffer RW1 and left on the bench for 5 minutes before being spun for 15-20 seconds at 
11,000g. With the flow-through discarded, the columns were loaded with 500µl Buffer RPE 
and centrifuged for 15 seconds at 11,000g. This step was repeated before transferring the 
columns to the 2ml collection tubes and centrifuged at 11,000g for 1 minute to dry the 
membrane. Finally, the RNeasy spin column was transferred to new 1.5ml collection tubes 
and loaded 30µl RNase-free water directly to the column membrane and centrifuged for 1 
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minute at 11,000g to elute the RNA. 5µl out of each sample was used for the purity and 
concentration test (diluted the sample in 1:5 with RNase-free water when the concentration 
was too high). All the exacted RNA samples were then stored at -80℃ before sent to 
NOVOGENE for RNAseq analysis. 
 
3.2.4.3 The purity and concentration of the RNA samples 
According to the requirement for sequencing from NOVOGENE, the purity of the RNA 
samples determined by the optical density reading at 260nm and 280nm wavelengths 
should be with the ratio of 260/280 over 1.8, together with the minimum quantity of 
2000ng for the total RNA. The purity was also confirmed by Nanodrop using 1μl from each 
RNA sample.  
The concentration was tested by Qubit with the Qubit® microRNA Assay Kits (catalogue 
number Q32880, Q32881, Molecular Probes of Life Technologies of Thermo Fisher Scientific, 
UK). The kits included the stock buffer, fluorescent dyes S1 and S2. The stock buffer and 
fluorescent dyes were mixed at the ratio of 199:1 in an appropriate volume for two standard 
samples and the test RNA samples. The mixed buffer should be kept in dark for 2 minutes 
before further steps. 190μl of the prepared mixed buffer was loaded to standard samples 
and 199μl of the mixed buffer was loaded to the test RNA samples. 10μl of S1 was added to 
the standard sample 1 and 10μl of S2 was added to the standard sample 2. 1μl from each 
RNA sample was added to the corresponding tube separately and mixed well with the 
buffer. The samples were incubated at room temperature for 2 minutes and measured the 
concentrations on the Qubit apparatus connecting with a computer.  
The information of the RNA samples sent to NOVOGENE has been shown in Table 3.2.
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Table 3.2 The information of the RNA samples 










#3684 12h unsti 2.09 147.5 59 8702.5 
 12h sti 2.1 133 59 7847 
 24h unsti 1.87 284 29 8236 
 24h sti 1.82 176 29 5104 
#3679 12h unsti 1.91 90 29 2610 
 12h sti 1.92 205 29 5945 
 24h unsti 1.93 159 29 4611 
 24h sti 1.86 224 29 6496 
#3640 12h unsti 1.9 396 29 11484 
 12h sti 1.94 680 29 19720 
 24h unsti 1.98 230 29 6670 
 24h sti 1.96 266 29 7714 
#3564 12h unsti 1.98 92 59 5428 
 12h sti 2.04 117 59 6903 
 24h unsti 1.92 114 59 6726 
 24h sti 1.9 176 59 10384 
#3568 12h unsti 1.98 101.5 59 5988.5 
 12h sti 1.96 100 59 5900 
 24h unsti 1.93 116 59 6844 
 24h sti 1.99 41.7 59 2460.3 
#3585 12h unsti 2.02 97.5 59 5752.5 
 12h sti 1.9 104 59 6136 
 24h unsti 1.92 114 59 6726 
 24h sti 1.91 139 59 8201 
Note: 12h/24h unsti: primary CLL cells cultured with 0.5ng/ml anti-HA antibody for 12h or 
24h; 12h/24h sti: primary CLL cells cultured with 0.1ng/ml HA-tagged CD40 ligand and 
0.5ng/ml anti-HA antibody for 12h or 24h. 
 
3.2.5 Data analysis 
The mRNA sequencing was performed by a commercial company NOVOGENE Ltd 
(Cambridge, UK). The differential expression analysis of the mRNA sequencing data between 
the CD40 stimulated and the unstimulated samples were performed using the DESeq2 
package in the R computer statistical environment. The comparison between data induced 
by the two CD40 stimulation methods and the comparison between the data of the soluble 
CD40 ligand system with the data of the primary CLL cells isolated from different in vivo 
tissues were performed by using GSEA 4.0.3. The omics data analysis was completed with 





3.3.1 CD40 stimulation protects primary CLL cells from drug-induced cell death 
3.3.1.1 CD40 stimulation protects primary CLL cells from fludarabine-induced cell death 
The first drug applied in this part of the study was fludarabine. The concentrations of 
fludarabine used were 0µM, 1µM, 3µM, 10µM, and 30µM. This was based on the findings of 
a previous study from this group in which time- and concentration-dependent induction of 
cell death on CLL cells by fludarabine was established (Zhuang et al., 2014).  
As previously stated, fludarabine is a purine analogue and it induces apoptosis in CLL cells by 
interfering with the DNA repair process, which leads to the overloading of unrepaired DNA, 
triggering p53-dependent apoptosis (Pettitt, 2003). However, CLL cells with 17p deletion or 
TP53 mutation exhibits resistance to fludarabine (Stilgenbauer et al., 2015). Considering 
there would be a certain amount samples harbouring 17p deletion and TP53 mutation, it 
was reasonable to screen samples to select fludarabine-response CLL samples for this part 
of study. Analysing the results using the drug-induced cell death formula of drug-induced 
cell death = [(% cell death of drug-treated cells - % cell death of untreated cells)/(100 - % cell 
death of untreated cells)] × 100 (Figure 3.3), the primary CLL cells from the six cases were 
observed to respond to fludarabine in a concentration-dependent manner when incubated 
for 48h at standard culture conditions.  
Although the results of drug-induced cell death showed that the primary CLL cells from the 
six cases responded to fludarabine (Figure 3.3), this data was generated by not factoring in 
the basal (spontaneous) cell death observed in control CLL cells. Therefore, this figure was 
modified to further reflect the extent of spontaneous cell death in these cells (Figure 3.4). 
Using this approach, it can be found that primary CLL cells from #3637 and #3642 were not 
very sensitive to fludarabine, compared with the results from other cases. This may be 
caused by the high percentage of spontaneous cell death. The extent of spontaneous cell 
death was different from case to case and it reflected the heterogeneity of CLL. In order to 
avoid the effect caused by high spontaneous cell death, only the primary CLL cells of the 
cases with initial viability (after recovery from freeze-thaw) over 80% were used for 
fludarabine treatment (Appendix 2). However, even though the initial viability of those six 
cases were satisfactory, the percentage of spontaneous cell death after 48h was excessive 
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(as observed in #3637 and #3642), which affected the results to some degree. Results of 
#3640 showed that the percentage of drug-induced cell death did not increase with the 
escalating concentrations from 3μM to 30μM (Figure 3.3 E), which can be explained by the 
results of the original cell death, with almost all of the cells under these concentrations 
were dead (Figure 3.4 E). Results of #3396 showed a lower percentage of cell death induced 
by 1μM fludarabine compared with that of the untreated cells (Figure 3.3 C and 3.4 C), 
which could have been due to technical error. Taken together, the primary CLL cells from 







                  
                  
                  
Figure 3.3 Fludarabine-induced cell death in primary CLL cells. For each CLL sample, thawed 
primary CLL cells were re-suspended at the concentration of 4×106 cells/ml in complete 
RPMI-1640 medium and loaded into 5 wells of a 24-well plate with 1ml per well. Fludarabine 
of each working concentration was diluted from the stock concentration with DMSO before 
the treatment. 1µl of each working concentration of fludarabine was added into one well of 
primary CLL cells and mixed well. One well was taken as the control and the primary CLL 
cells in this well were treated with 1µl of DMSO. After 48h incubation, the cells were 
collected and the cell death was analysed by flow cytometry following staining cells with 
FITC labelled annexin V and PI as described in Methods. Drug-induced cell death = [(% cell 
death of drug-treated cells - % cell death of untreated cells)/(100 - % cell death of untreated 
cells)] × 100. 
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Figure 3.4 The extent of spontaneous and fludarabine-induced cell death in primary CLL 
cells. For each CLL sample, thawed primary CLL cells were re-suspended at the 
concentration of 4×106 cells/ml in complete RPMI-1640 medium and loaded into 5 wells of a 
24-well plate with 1ml per well. Fludarabine of each working concentration was diluted 
from the stock concentration with DMSO before the treatment. 1µl of each working 
concentration of fludarabine was added into one well of primary CLL cells and mixed well. 
One well was taken as the control and the primary CLL cells in this well were treated with 
1µl of DMSO. After 48h incubation, the cells were collected and the cell death was analysed 





These six fludarabine-responsive CLL samples were thus taken forward for the co-culture 
experiments. Primary CLL cells were co-cultured with CD154 expressing fibroblasts for 24h 
for CD40 stimulation. CLL cells co-cultured with parental fibroblasts not expressing CD154 
for 24h were used as the controls. The CD40 stimulated and unstimulated primary CLL cells 
were then collected from the co-culture system, respectively, and incubated with 
fludarabine at standard culture conditions for another 48h.  
The results of individual CLL samples (#3369, #3396, #3637, #3640, and #3642) treated with 
fludarabine showed that there were differences in the fludarabine-induced cell death 
between the CD40 stimulated and unstimulated cells (Figure 3.5 A, C, D, E and F). Results of 
case #3637 showed that both CD40 stimulated and unstimulated cells exhibited a relatively 
lower percentage of cell death compared with the results of other cases (Figure 3.5 D). 
Resulting from the same procedure of the experiment, the situation was considered due to 
the heterogeneous features of CLL cells from different cases. The incomplete clinical 
information of those cases made no address for the explanation. Comparing the results of 
case #3637 with the results of this case under the standard culture condition (Figure 3.4 D), 
it can be found that the co-culture system may greatly improve viability of the primary CLL 
cells. Results of CLL case #3381 showed no difference in fludarabine-induced cell death 
between the stimulated and unstimulated cells (Figure 3.4 B). At the same time, it can be 
found that primary CLL cells from case #3381 were not sensitive to fludarabine as they had 
been treated under the standard condition. The treatment experiment on case #3381 was 
repeated twice and the results were similar. These results suggested that the co-culture 
condition may alter the sensitivity of the CLL cells from case #3381 to fludarabine. Again, no 




       
       
       
Figure 3.5 Cell death induced by fludarabine in CD40 stimulated and unstimulated CLL 
cells. CD154: CLL cells co-cultured with CD154 expressing fibroblasts for 24h for CD40 
stimulation. Parental: CLL cells co-cultured with parental fibroblasts for 24h. CLL cells were 
co-cultured for 24h and collected from the co-cultures to be incubated with fludarabine for 
another 48h at standard culture conditions. Cell death was analysed by flow cytometry 




When pooled the cell death data from the six cases and performed statistical analysis to 
determine if the difference in cell death between the CD40 stimulated and unstimulated 
cells, the average of those data showed that the differences were statistically significant at 
the concentrations of 0μM, 3μM, 10μM, 30μM, respectively. The pooled results showed 
that CD40 stimulation decreased the percentage of cell death induced by fludarabine on 
primary CLL cells (Figure 3.6) and the differences in cell death of the average data across six 
cases between CD40 stimulated cells and unstimulated cells were statistically significant at 
3μM (with 49.83% ± 30.17 for the unstimulated and 19.97% ± 13.62 for the CD40 stimulated 
cells), 10μM (with 53.14% ± 32.13 for the unstimulated and 20.50% ± 12.13 for the CD40 
stimulated cells), 30μM (with 62.02% ± 27.86 for the unstimulated and 25.81% ± 12.41 for 
the CD40 stimulated cells), respectively. Importantly, the difference in cell death between 
the CD40 stimulated and unstimulated cells that were treated without fludarabine was also 
statistically significant (Figure 3.5, average data for 0μM fludarabine with 42.34% ± 26.91 for 
the unstimulated and 13.66% ± 11.17 for the CD40 stimulated cells). Although the pooled 
data showed there were statistical significance between the cell death induced by 
fludarabine in CD40 stimulated and unstimulated primary CLL cells, the high standard errors 
indicated that there were obvious variation across the primary CLL cells from different 
cases, which made the results of individual cases more valuble than the pooled results. 
These results thus demonstrated that CD40 stimulation protected primary CLL cells from 




                                                            
Figure 3.6 Pooled results of fludarabine-induced cell death in CD40 stimulated and 
unstimulated CLL cells. CD154: primary CLL cells co-cultured with CD154 expressing 
fibroblasts for 24h for CD40 stimulation. Parental: primary CLL cells co-cultured with 
parental fibroblasts for 24h. CLL cells were co-cultured for 24h and collected from the co-
cultures to be incubated with fludarabine for another 48h under standard culture 
conditions. At the end of incubation, CLL cells were harvested and cell death was analysed 
by flow cytometry following staining cells with FITC labelled annexin V and PI as described in 
Methods.  
 
3.3.1.2 CD40 stimulation protects primary CLL cells from ABT-199-induced cell death 
The next drug tested for this part of study was ABT-199. The experiment with ABT-199 was 
directly taken forward under the co-culture system without the response test under 
standard culture condition due to the reason that the resistance to ABT-199 in CLL cells was 
reported to be caused by the abnormal expression of the BCL-2 family proteins induced by 
the signals from the CLL microenvironment (Klanova et al., 2020). The concentrations of 
ABT-199 used were 0nM, 1nM, 10nM, 100nM, 1000nM. The choice of the concentrations 
was based on the findings of a published study in which ABT-199 was shown to effectively 
induce apoptosis in primary CLL cells with the LC50 of 3nM (Souers et al., 2013). Primary CLL 
cells were first co-cultured with CD154 expressing fibroblasts for 24h for CD40 stimulation 
and the cells co-cultured with the parental fibroblasts were used as the unstimulated 
controls. Both CD40 stimulated cells and the unstimulated cells were then collected from 
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the co-cultures separately and treated with different concentrations of ABT-199 for another 
6h under standard culture conditions, respectively. There were three different CLL samples 
applied.  
The results of individual CLL samples treated with ABT-199 showed an obvious difference in 
ABT-199-induced cell death between CD40 stimulated and unstimulated cells (Figure 3.7). 
For all three CLL samples, the percentages of cell death of the CD40 stimulated cells (Figure 
3.7 A-C, orange lines) were dramatically lower than those of the unstimulated cells (Figure 
3.7 A-C, blue lines).  
     
Figure 3.7 Cell death induced by ABT-199 in CD40 stimulated and unstimulated CLL cells. 
CD154: primary CLL cells co-cultured with CD154 expressing fibroblasts for 24h for CD40 
stimulation. Parental: primary CLL cells co-cultured with parental fibroblasts that were used 
as unstimulated controls. CLL cells were co-cultured for 24h and collected from the co-
cultures to be incubated with ABT-199 for another 6h under standard conditions. At the end 
of incubation, CLL cells were harvested and cell death was analysed by flow cytometry 




The pooled data showed that the differences in ABT-199-induced cell death between CD40 
stimulated and unstimulated cells were statistically significant at 10nM (with 90.72% ± 6.56 
for the unstimulated and 28.76% ± 7.24 for the CD40 stimulated cells), 100nM (with 93.19% 
± 5.74 for the unstimulated and 35.54% ± 14.53 for the CD40 stimulated cells), and 1000nM 
(with 93.76% ± 5.94 for the unstimulated and 41.78% ± 13.85 for the CD40 stimulated cells), 
respectively (Figure 3.8). Although the decrease was not statistically significant, the cell 
death of the CD40 stimulated cells without ABT-199 treatment was lower than that of the 
unstimulated cells without ABT-199 treatment. 
These results clearly show that CD40 stimulation protects primary CLL cells from ABT-199-
induced cell death. 
                                                                      
Figure 3.8 Pooled data of ABT-199-induced cell death in CD40 stimulated and 
unstimulated CLL cells. CD154: primary CLL cells co-cultured with CD154 expressing 
fibroblasts for 24h for CD40 stimulation. Parental: primary CLL cells co-cultured with 
parental fibroblasts that were used as unstimulated controls. Primary CLL cells were co-
cultured for 24h and collected from the co-cultures to be incubated with ABT-199 at the 
indicated concentrations for another 6h under standard conditions. At the end of 
incubation, CLL cells were harvested and cell death was analysed by flow cytometry 
following staining cells with FITC labelled annexin V and PI as described in Methods. Mean ± 
SD of the results of 3 cases are shown. Statistical analysis was performed using the two-






3.3.1.3 CD40 stimulation protects primary CLL cells from bendamustine-induced cell death 
The third drug tested the effect of CD40 stimulation on primary CLL cells was bendamustine. 
Based on the findings from a previous study by our research group (Chapman et al., 2017), 
the final concentrations of bendamustine used in this study were 0μM, 1μM, 3μM, 10μM, 
30μM, 100μM. Primary CLL cells were first co-cultured for 24h with the CD154-expressing or 
parental fibroblasts, as described previously. Co-cultured CLL cells were then collected and 
incubated with different concentrations of bendamustine for another 24h under standard 
culture conditions. Three individual CLL samples were applied in this part of the study.  
The results of individual CLL samples showed an obvious difference in bendamustine-
induced cell death between CD40 stimulated and unstimulated CLL cells (Figure 3.9 A-C). 
CD40 stimulation decreased the percentage of cell death induced by bendamustine for all 
three CLL samples. Considering that the LC50 of bendamustine in primary CLL cells at 
standard culture condition is 27.48μM (Purroy et al. 2015), the results of case #3259 and 
case #3436 showed that the unstimulated CLL cells from those two cases did not as sensitive 
to bendamustine as reported. However, considering that the unstimulated primary CLL cells 
were co-cultured with the parental fibroblasts and that the cell adhesion status may alter 
the response pattern of primary CLL cells to some degree, those results were explicable.  
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Figure 3.9 Cell death induced by bendamustine in CD40 stimulated and unstimulated CLL 
cells. CD154: primary CLL cells co-cultured with CD154 expressing fibroblasts for 24h for 
CD40 stimulation. Parental: primary CLL cells co-cultured with parental fibroblasts that were 
used as unstimulated controls. Primary CLL cells were co-cultured for 24h and collected 
from the co-cultures to be incubated with bendamustine at the indicated concentrations for 
another 24h under standard conditions. At the end of incubation, CLL cells were harvested 
and cell death was analysed by flow cytometry following staining cells with FITC labelled 
annexin V and PI as described in Methods.  
 
The pooled data showed that the differences between CD40 stimulated and CD40 
unstimulated cells were statistically significant at each concentration of bendamustine 
(Figure 3.10). The percentage of cell death at 1μM was 41.76% ± 4.58 for the unstimulated 
cells and 18.04% ± 4.12 for the CD40 stimulated cells. The percentage of cell death at 3μM 
was 43.19% ± 5.27 for the unstimulated cells and 18.52% ± 2.25 for the CD40 stimulated 
cells. The percentage of cell death at 10μM was 45.17% ± 3.79 for the unstimulated cells 
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and 20.35% ± 2.59 for the CD40 stimulated cells. The percentage of cell death at 30μM was 
51.52% ± 3.64 for the unstimulated cells and 23.30% ± 2.00 for the CD40 stimulated cells. 
Finally, the percentage of cell death at 100μM was 72.07% ± 6.80 for the unstimulated and 
28.52% ± 5.89 for the CD40 stimulated cells. The difference in cell death between the CD40 
stimulated and unstimulated cells that were treated without bendamustine was also 
statistically significant (Figure 3.10, data for 0μM bendamustine: 40.23% ± 5.68 for the 
unstimulated and 17.78% ± 3.35 for the CD40 stimulated cells). 
These results suggest that CD40 stimulation protects primary CLL cells from spontaneous 
and bendamustine-induced cell death. 
                                                                      
Figure 3.10 Pooled data of bendamustine-induced cell death in CD40 stimulated and 
unstimulated CLL cells. CD154: primary CLL cells co-cultured with CD154 expressing 
fibroblasts for 24h for CD40 stimulation. Parental: primary CLL cells co-cultured with 
parental fibroblasts that were used as unstimulated controls. Primary CLL cells were co-
cultured for 24h and collected from the co-cultures to be incubated with bendamustine at 
the indicated concentrations for another 24h under standard conditions. At the end of 
incubation, CLL cells were harvested and cell death was analysed by flow cytometry 
following staining cells with FITC labelled annexin V and PI as described in Methods. Mean ± 
SD for 3 cases is shown. Statistical analysis was performed using the two-tailed, paired 
Student’s t-test. * indicate p-value < 0.05. 
 
The results obtained clearly showed that CD40 stimulation protected primary CLL cells from 
spontaneous and drug-induced cell death by fludarabine, ABT-199, and bendamustine. It 
has been reported that CD40 stimulation up-regulated the expression of a group of anti-
apoptotic proteins such as BCL-XL and MCL-1 in CLL cells (Kater et al., 2004), which was 
considered one possible reason for the resistance to ABT-199 induced by CD40 stimulation 
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(Klanova et al., 2020). However, CD40 stimulation also up-regulates the expression of pro-
apoptotic proteins such as BID in CLL cells (Kater et al., 2004, Smit et al., 2007). Considering 
the bi-directional effect in survival caused by CD40 stimulation, the molecular mechanism 
mediating the pro-survival effect and the multi-drug resistance induced by CD40 stimulation 
need further study to clarify. The overall aim of this study was to unravel the CD40 
stimulation-induced pro-survival signals by investigating the changes in protein expression 
at a global level.  
 
3.3.2 Comparison of two CD40 stimulation methods (the co-culture system versus the 
soluble CD40 ligand system) 
As stated earlier, the soluble CD40 ligand system is a preferred method to induce CD40 
stimulation in primary CLL cells for the proteomics study. Therefore, it was necessary to 
figure out whether the soluble CD40 ligand can reproduce the biological effect as that 
induced by the co-culture system on primary CLL cells. The soluble CD40 ligand stimulation 
method was optimised based on the published method (Lezina et al., 2018). Viability results 
showed that CD40 stimulation induced by the soluble CD40 ligand method protected 
primary CLL cells from spontaneous cell death (Figure 3.11). Considering the high level of 
cell death in samples that may affect the analysis, the viability tests were performed to 
ensure the quality of samples to be used for RNA-seq analysis. Originally, the criteria of 
initial viability over 70% and the 24h viability over 30% was chosen. However, since the 
primary CLL cells could not maintain such viability in culture, the samples used for RNA-seq 
were the six showed here (with the viability lower than the desired criteria).  
As stated previously, the up-regulated expression of BCL-XL was chosen as the marker for 
the successful establishment of CD40 stimulation in primary CLL cells (Kater et al., 2004, 
Vogler et al., 2009a). The results of western blot of the BCL-XL expression level in primary 
CLL cells treated with and without the soluble CD40 ligand were showed in Figure 3.12 with 





                               
Figure 3.11 Viability of the samples used for RNA-seq. Initial: the viability detected after 
the recovery of the primary CLL cells from the cryopreservation. 24h unsti: the viability of 
the primary CLL cells incubated with 0.5ng/ml anti-HA antibody for 24h; 24h sti: the viability 
of the primary CLL cells incubated with 0.1ng/ml HA-tagged CD40 ligand and 0.5ng/ml anti-
HA antibody for 24h.  
 
    
Figure 3.12 Induction of BCL-XL in CLL cells treated with or without the soluble CD40 ligand 
as detected by Western blotting. The plus sign ‘+’ represents the CD40 stimulated cells of 
each CLL sample, in which primary CLL cells were incubated with 0.1ng/ml HA-tagged CD40 
ligand and 0.5ng/ml anti-HA antibody for 24h. The minus sign ‘-‘ represents the 
unstimulated cells of each CLL sample, in which primary CLL cells were incubated with 
0.5ng/ml anti-HA antibody for 24h. 
 
As described previously, six primary CLL samples were used as the biological replicates, and 
two groups of cells were prepared from those six samples, i.e. CD40 stimulated and 
unstimulated CLL cells. In addition, two time points were considered for the duration of 
stimulation (12h and 24h). Consequently, there should be a total of twenty-four RNA 
samples to be sent for mRNA sequencing. After the re-examination by NOVOGENE, two of 
the RNA samples from the unstimulated CLL cells of case #3679 at 12h and case #3684 at 
24h did not meet the requirement of the minimum amount of mRNA for sequencing. In the 
end, mRNA sequencing was performed on twenty-two RNA samples. 33,126 genes were 
identified from these samples in total. The raw sequencing data provided by NOVOGENE 
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was then analysed by the bioinformatics group led by Professor Francesco Falciani in the 
University of Liverpool, who filtered the genes and produced a new list of 33121 genes. 
Then, they performed a normalization in DESeq2 on the filtered data to put more emphasis 
on the moderately expressed genes (Anders and Huber, 2010). Further analyses were all 
based on the filtered and normalized data. 
 
3.3.2.1 CD40 stimulation induced by the soluble CD40 ligand system causes changes in the 
gene expression in primary CLL cells 
Due to missing data from unstimulated CLL cells of cases #3679 at 12h and #3684 at 24h, 
the sequencing data from the corresponding CD40 stimulated samples at the 12h and 24h 
had to be excluded from the data analysis of the paired samples between the CD40 
stimulated and unstimulated cells. The principal component analysis (PCA) of all the genes 
basing on the filtered and normalised data showed that the CD40 stimulated samples were 
distributed separately from the unstimulated samples for both time points (Figure 3.13 A 
and B).  
Based on the filtered and normalized data, the differential expression analysis was 
performed between the CD40 stimulated and unstimulated samples for the two time points 
using DESeq2. Genes with the adjusted p-value less than 0.01 and false discovery rate (FDR) 
1% (Benjamini-Hochberg correction) were considered to be significantly differentially 
expressed. The results of the differential expression analysis showed that, for the 12h time 
point, there were 2029 significantly up-regulated genes and 1988 significantly down-
regulated genes (Appendix 4, 5). For the 24h time point, there were 2046 significantly up-
regulated genes and 1986 significantly down-regulated genes (Appendix 6.7). The 
separations between the CD40 stimulated samples and the unstimulated samples for two 
time points, respectively, were observed by the PCA analyses of the significantly 
differentially expressed genes (Figure 3.14 A and B).  
The results of the differential expression analysis showed that the CD40 stimulation induced 
by the soluble CD40 ligand system caused a significant difference in gene expression on 
primary CLL cells at the transcriptional level. 
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                           A.  
                            B.  
Figure 3.13 PCA for all genes. (A) the results of 12h data. (B) the results of 24h data. Black 
spots labelled with s represent the CD40 stimulated samples. Green spots labelled with u 




                       A.  
                       B.  
Figure 3.14 PCA for significantly differentially expressed genes (padjusted value < 0.01, FDR 
1%). (A) the results of 12h data. (B) the results of 24h data. Black spots labelled with s 
represent the CD40 stimulated samples. Green spots labelled with u represent the CD40 
unstimulated samples.  
 
3.3.2.2 The changes in gene expression at the transcriptional level induced by the soluble 
CD40 ligand system do not differ significantly from 12h to 24h 
To figure out whether the changes in gene expression induced by the soluble CD40 ligand 
differ significantly with time, the differentially expressed genes identified at the two time 
points were compared. For 12h time point, the number of significantly differentially 
expressed genes was 4017 with 2029 genes up-regulated and 1988 genes down-regulated. 
For 24h time point, the number of significantly differentially expressed genes was 4032 with 
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2046 genes up-regulated and 1986 genes down-regulated. The results of the comparison 
showed that there were 3269 genes consistently presenting at both lists and the 
percentages of consistency were 81% for both (Figure 3.15 A). The numbers of the 
consistent gene targets for significantly up-regulated and significantly down-regulated were 
1671 and 1598 and they made up over 80% of all the significantly differentially expressed 
gene targets (Figure 3.15 B and C).  
      
Figure 3.15 Comparing the significantly differentially expressed genes detected between 
12h and 24h time points. (A) Comparison of all the significantly differentially expressed 
genes detected; (B) Comparison of the significantly up-regulated genes detected; (C) 
Comparison of the significantly down-regulated genes. 
 
Based on the results of the comparison (summarized in Table 3.3), it was clear that the 
majority constituents of the 12h data and the 24h data were similar, which suggested that 
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the changes in gene expression induced by the soluble CD40 ligand on primary CLL cells at 
the transcriptional level have not altered much from 12h to 24h. Because of the similarity, 
further analysis will be focused on the differentially expressed genes obtained at the 24h 
time point for simplicity. 
Table 3.3 Summary of the data comparison between 12h and 24h 
 12h data 24h data Consistency
* 
%** 
All the genes detected 17231 17487 16856 98%/96% 
All significant (Padj<0.01) 4017 4032 3269 81%/81% 
Significantly up-regulated (Padj<0.01) 2029 2046 1671 82%/82% 
Significantly down-regulated (Padj<0.01) 1988 1986 1598 80%/80% 
*: Consistency means the genes consistently present on both lists; 
**%: the percentage of consistent genes in 12h data/ the percentage of consistent genes in 
24h data. 
 
3.3.2.3 The changes in gene expression of CLL cells activated by the soluble CD40 ligand 
method are similar to that of the CLL cells activated by the co-culture method  
The gene expression profile obtained from this study was compared with the published 
dataset of differentially expressed genes induced by the co-culture system (Pascutti et al., 
2013). The data obtained with 24h stimulation from both studies were compared. Using the 
adjusted p-value less than 0.05 as a cut-off, 6306 genes were found to be significantly 
differentially expressed with 2804 up-regulated and 3502 down-regulated in the published 
study. In this study with the adjusted p-value less than 0.01 and the False discovery rate 
(FDR) of 1%, 4032 genes were found to be differentially expressed in CLL cells induced by 
the soluble CD40 ligand, with 2046 up-regulated and 1986 down-regulated.  
The comparison between the soluble CD40 ligand and the co-culture system was analysed 
using GSEA 4.0.3. The results showed that the up-regulated gene targets induced by the 
soluble CD40 ligand were very similar to those up-regulated by the co-culture CD40 system. 
The enrichment score (Figure 3.16 A) of the up-regulated gene targets was strongly positive, 
which indicated a strong overlap of the up-regulated gene targets between the two sets of 
data. A similar conclusion was drawn with the analysis of the down-regulated gene targets 
(Figure 3.16 B). The false discovery rate q-values (shorten as FDR q-val in Table 3.4) of the 
up-regulated and down-regulated (Table 3.4) were both less than 0.0005, indicating they 
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were highly significant. Based on the results, the high level of similarity in gene expression 
induced by the soluble CD40 ligand and co-culture system was unlikely caused by random 
chance. The results of GSEA therefore show that the changes in gene expression induced by 
the soluble CD40 ligand on primary CLL cells were very similar to that induced by the co-
culture system.  
A. B. 
Figure 3.16 Enrichment plots of the comparison for the up-regulated targets and down-
regulated targets between the two sets of data. 
 
Table 3.4 The FDR q-value of the comparison of the up/down regulated gene targets.   
 
 
Note: The GSEA software only uses 3 decimal places. The FDR q-value here for the up-
regulated and down-regulated are both reported as 0, which means the values are less than 
0.0005 indicating they are highly significant. p-val: p-value; q-val: q-value. 
99 
 
3.3.2.4 Gene expression profile of CLL cells treated with the soluble CD40 ligand is similar 
to that of CLL cells localised in the lymph node 
The paper published by Herishanu and colleagues in 2011 reported the differential gene 
expression profiles of the CLL cells in lymph nodes, bone marrow, and peripheral blood as 
well (Herishanu et al., 2011). To determine whether the gene expression profile of CLL cells 
induced by the soluble CD40 ligand resembles that of CLL cells localised from any of the 
tissue sites, assisted by bioinformaticians from Prof. Falciani’s group, the gene expression 
data from this study was compared to the data from the published study. The gene 
expression data induced by the soluble CD40 ligand were divided into four groups, ‘12h up’, 
‘12h down’, ‘24h up’, and ‘24h down’. The four sets of data were further compared 
separately with the three ranked lists of the differentially expressed genes in CLL cells 
located between the different tissues (lymph node versus bone marrow, lymph node versus 
peripheral blood, bone marrow versus peripheral blood). The GSEA results have been shown 
in Table 3.5, Table 3.6, and Table 3.7. 
Table 3.5 The positive retrieved enrichment in the comparison between the gene 
expression data induced by the soluble CD40 ligand and the ranked list of lymph node vs 
bone marrow 
 
Note: The GSEA software only uses 3 decimal places. The FDR q-val here for the up-
regulated and down-regulated are both reported as 0, which means the values are less than 
0.0005 indicating they are highly significant. p-val: p-value; q-val: q-value. 
 
Table 3.6 The positive and negative retrieved enrichment in the comparison between the 
gene expression data induced by the soluble CD40 ligand and the ranked list of lymph 
node vs peripheral blood 
   
Note: The GSEA software only uses 3 decimal places. The FDR q-val here for the up-
regulated and down-regulated are both reported as 0, which means the values are less than 
0.0005 indicating they are highly significant. p-val: p-value; q-val: q-value. 
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Table 3.7 The negative retrieved enrichment in the comparison between the gene 
expression data induced by the soluble CD40 ligand and the ranked list of bone marrow vs 
peripheral blood 
 
Note: The GSEA software only uses 3 decimal places. The FDR q-val here for the up-
regulated and down-regulated are both reported as 0, which means the values are less than 
0.0005 indicating they are highly significant. p-val: p-value; q-val: q-value. 
 
The results of the comparison showed that gene targets up-regulated at 12h and 24h by the 
soluble CD40 ligand were also up-regulated in the ranked list of lymph nodes versus bone 
marrow. This indicated that the genes up-regulated by the soluble CD40 ligand can also be 
found in CLL cells located in the lymph node.  
Results also showed that gene targets up-regulated at 12h and 24h by the soluble CD40 
ligand were up-regulated in the ranked list of lymph nodes versus peripheral blood. At the 
same time, gene targets down-regulated by the soluble CD40 ligand at 24h were down-
regulated in the ranked list of lymph nodes versus peripheral blood as well. It further 
suggests that CD40 stimulation by the soluble CD40 ligand simulated the interaction of CLL 
cells with the lymph node microenvironment. 
The results of the comparison analysis showed that gene targets down-regulated by the 
soluble CD40 ligand at 24h were also down-regulated in the ranked list of bone marrow 
versus peripheral blood. This indicated that genes down-regulated by the soluble CD40 
ligand can also be found in CLL cells located in the bone marrow. It suggested that the 
soluble CD40 ligand simulated the negative influences in gene expression of CLL cells by the 
bone marrow.  
In summary, the main results from the RNA sequencing study showed that: (1) changes to 
gene expression induced by the soluble CD40 ligand were similar to the changes induced by 
the co-culture system; (2) gene expression profile of CLL cells treated with the soluble CD40 
ligand were similar to that of CLL cells localised in the lymph nodes, indicating that CD40 
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stimulation induced by the soluble CD40 ligand imitated the interaction of CLL cells with T 
cells within lymph nodes. 
 
3.4 Discussion 
The experiments of cell death induction in primary CLL cells showed that CD40 stimulation 
protected primary CLL cells from both spontaneous and drug-induced cell death, indicating 
that CD40 stimulation induced pro-survival signals on CLL cells. Ideally, it was preferable to 
repeat the treatment of each case three times separately for technical replicates, but the 
limited supply of primary CLL samples restricted the repeat of experiments for each case for 
the research project. To obtain a reliable result, at least three primary CLL cases were 
applied for each drug treatment except for fludarabine treatment. The primary CLL cases 
were taken randomly from the biobank to avoid selection bias. Those considerations above 
help to make the results more persuasive. The variation from case to case in response to 
each drug largely reflects the heterogeneity of CLL.  
The results of fludarabine treatment were consistent with previously published data 
showing that CD40 stimulated CLL cells resist to the induction of cell death by fludarabine 
(Romano et al., 1998b, Kitada et al., 1999, Kater et al., 2004). One paper reported that CD40 
stimulation sensitized CLL cells to fludarabine treatment in 2003 (De Totero et al., 2003), 
which seems contradictory to the data present here in this study. However, there were 
several issues mainly related to different methodologies. Firstly, in their study, the cells used 
as controls to the CD40 stimulated CLL cells were CLL cells cultured under standard 
conditions, the so-called ‘resting cells’. In contrast, in this study, the primary CLL cells co-
cultured with the parental fibroblasts were used as the controls. It is known that the co-
culture condition can influence CLL cells through, in addition to CD40 stimulation, ‘cell-to-
cell’ contacts and exposing CLL cells to secreted chemokines and cytokines by the fibroblasts 
(Ghia et al., 2002, Pascutti et al., 2013), which may affect their response to drug treatment. 
Therefore, it is more rigorous to use the same culture condition consistently throughout the 
experiments to accurately determine the response of CD40-stimulated CLL cells to 
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fludarabine. This was also the reason that the drug treatment following the CD40 
stimulation was conducted on the primary CLL cells that collected from the co-culture 
system. From this point of view, the soluble CD40 ligand stimulation method is a better 
choice to study the specific influence of CD40 stimulation. Therefore, soluble CD40 ligand 
stimulation method was chosen for the proteomics study in this project. Secondly, the ratio 
of the CD40-expressing fibroblasts and primary CLL cells in the co-culture system was 1:100 
in the study reported by De Totero and colleagues, which was different from this study 
where the ratio at 1:10 applied here. Besides, the duration of CD40 stimulation, the 
concentration of fludarabine and the duration of fludarabine treatment used in their study 
were all different from this study. Therefore, it is likely that the discrepancy of the results is 
caused by the different methods used in the studies. 
Regarding the responses of CD40-stimulated CLL cells to the treatment with ABT-199 and 
bendamustine, the results were consistent among the cases comparing with the results of 
fludarabine, even though variations in response was still observed across CLL cases. CD40 
stimulation protects CLL cells from cell death induced by these two cytotoxic drugs. Given 
the heterogeneous nature of CLL, these variations are not unexpected. These results from 
this study thus are consistent with the previously published data (Thijssen et al., 2015, 
Bojarczuk et al., 2016, Chapman et al., 2017, Jayappa et al., 2017, Brocco et al., 2017, 
Thijssen et al., 2013). For bendamustine, the results of two cases showed that the 
unstimulated primary CLL cells from #3259 and #3436 were not as sensitive to 
bendamustine, as previously reported in other studies (Purroy et al., 2015). In the published 
paper, the LC50 of bendamustine in primary CLL cells maintained in standard culture 
condition was 27.48μM (Purroy et al., 2015). The decreased sensitivity to bendamustine 
may partly be attributed to the co-culture system, in which parental fibroblasts may have 
lower the cell responsiveness due to changes in cell adhesion status. 
The investigation of the effect of CD40 stimulation on the drug-induced cell death indicates 
that CD40 stimulation induces pro-survival signals on primary CLL cells. The drugs applied in 
this study, namely fludarabine, ABT-199, and bendamustine, have different cytotoxic 
mechanisms. This suggests that the pro-survival signals induced by CD40 stimulation can 
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lead to chemo-resistance for CLL cells. The theory that the chemo-resistance phenomenon 
induced by CD40 stimulation may be mediated through common pro-survival 
signals/pathways can be supported by evidence. Many studies have shown that the ligation 
of CD40 on CLL cells results in increased expression of several anti-apoptotic proteins, such 
as BCL-XL (Granziero et al., 2001, Kitada et al., 1999, Pedersen et al., 2002, Kater et al., 
2004), MCL-1 (Scielzo et al., 2011, MCCaig et al., 2011, Smit et al., 2007), Bfl-1 (Kater et al., 
2004, Tromp et al., 2010) and BCL-2  (Scielzo et al., 2011) and decreased expression of pro-
apoptotic proteins such as BH3-only proteins Noxa (Smit et al., 2007) and Harakiri (Hrk) 
(Kater et al., 2004). In addition, CD40 stimulation activates the NF-κB signalling pathways, 
which promotes the survival and proliferation of CLL cells (Furman et al., 2000, Lee et al., 
1999, Romano et al., 1998b).  
The analysis of mRNA sequencing data showed that stimulating primary CLL cells using the 
soluble CD40 ligand system can induce similar changes at the gene expression level to that 
induced by the co-culture system. The gene expression profile of CLL cells treated with the 
soluble CD40 ligand can resemble that of the CLL cells residing in the lymph nodes. Thus, the 
results of the gene expression study provided the reassurance that the soluble CD40 ligand 
can be used in the proposed proteomics study. 
The gene expression profile obtained from CLL cells stimulated by the soluble CD40 
stimulation was not exactly the same as that from the CLL cells stimulated by the co-culture 
system. The differences are not unexcepted. First of all, the methods of the two CD40 
stimulation are different. During the experiment, it has been noticed that compared with 
CD40 stimulation induced by the soluble CD40 ligand, the co-culture system was better in 
sustaining the high viability of primary CLL cells, which indicates that there are some 
additional factors providing support to primary CLL cell besides CD40 stimulation. As 
mentioned above, it is obvious that the co-culture system causes not only the direct 
activation of the CD40 receptor on CLL cells by CD154 ligand expressed on the fibroblasts 
but also the cell-to-cell contacts which could activate other signalling pathways (Samuel et 
al., 2016, Nikitaki et al., 2016). The different forms of stimulation will thus inevitably cause 
differences in results, which makes reasonable to use the soluble CD40 ligand stimulation 
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method to study the specific influence induced by CD40 stimulation. Secondly, the gene 
profiles induced by the two CD40 stimulation systems were generated using the primary CLL 
samples from different patients, which could explain, at least in part, the differences in the 
gene expression. CLL is a heterogeneous disease so the variation in response to CD40 
stimulation across samples from different patients is unsurprising. It is, however, clear that 
the more biological replicates were used, the more accuracy of results could be achieved. 
With the limitation in the supply of the primary CLL cases, 6 cases were considered to be the 
minimum number for the study of gene expression profiling. Due to the low quantity of RNA 
in 2 out of the 24 RNA samples, RNA sequencing data was generated from only 22 samples. 
Moreover, the final bioinformatics analysis for comparison of gene expression between 
CD40-stimulated and unstimulated cells had to rely on sequencing data from 20 paired 
samples from 5 primary CLL cases. The reduction in the number of cases from 6 to 5 affects 
the results as well.  
In summary, in this part of study, the cytoprotective effect of CD40 stimulation against 
spontaneous and drug-induced cell death in CLL cells was independently confirmed. 
Comparing the gene expression profiles of CLL cells stimulated by the soluble CD40 ligand to 
that induced by the co-culture system, it was demonstrated that stimulation induced by the 
soluble CD40 ligand produced similar changes in gene expression in primary CLL cells that 
were stimulated by the co-culture system. Furthermore, the results revealed that the gene 
expression profile of CLL cells treated with the soluble CD40 ligand shared a high degree of 
similarity to that of CLL cells localised in the lymph nodes of patients with CLL. This novel 
finding thus indicates that CD40 stimulation induced by the soluble CD40 ligand can mimic 
the interaction of CLL cells with T cells in the lymph node microenvironment. Therefore, 
altogether, the above results provided reassurance that the soluble CD40 ligand can be used 
in the proposed proteomics study to study global changes in protein expression induced by 
CD40 stimulation on primary CLL cells.
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Chapter 4. CD40 stimulation changes the protein expression in primary CLL 
cells at a global level, affecting a variety of biological processes  
 
4.1 Background 
Analysing the differentially expressed proteins induced by CD40 stimulation on primary CLL 
cells at a global level is the key part of this project. Mass spectrometry techniques have 
been applied to the study of CLL for several years (Thurgood et al., 2017, Eagle et al., 2015, 
Johnston et al., 2018), but they have not been used to study the effect of CD40 stimulation 
on CLL cells. Proteins perform the functions of individual genes. However, the imperfect 
correlation between the level of transcription (mRNA) and the level of protein translation 
makes it necessary to study the gene expression at the level of protein expression (de Sousa 
Abreu et al., 2009, Chen et al., 2002). The biological effects of CD40 stimulation at the 
cellular level presented in the previous chapter indicate that CD40 stimulation induces pro-
survival signals that protect primary CLL cells from spontaneous and drug-induced 
apoptosis. It is thus possible that the levels of expression of many proteins are altered by 
CD40 stimulation, leading to the manifestation of the anti-apoptotic phenotype in CLL cells. 
The latest technique of mass spectrometry allows us to measure the change in the 
expression of proteins induced by CD40 stimulation comprehensively. Analysing those 
differentially expressed proteins can provide us with a better view of the influence of CD40 
stimulation in primary CLL cells at the protein translational level, which in turn helps to 
identify the molecules/pathways mediating the pro-survival signals. 
To achieve a good signal-to-noise ratio in protein samples used for the mass spectrometry 
analysis, I used the soluble CD40 ligand stimulation method to induce the CD40 stimulation 
on primary CLL cells. As described in the previous chapter, the co-culture method of CD40 
stimulation requires primary CLL cells to be co-cultured with CD154-expressing fibroblasts, 
which could result in the contamination of the protein extracts from the co-cultured primary 
CLL cells with variable amounts of proteins from the fibroblast, thus obscuring the accuracy 
of the proteomic analysis. The analysis of the mRNA sequencing data described in the 
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previous chapter confirms that CLL cells stimulated by the soluble CD40 ligand have a similar 
gene expression profile to that of CLL cells stimulated by the co-culture CD40 stimulation 
system. The technique of mass spectrometry (MS) applied here was the isobaric tags for 
relative and absolute quantitation (iTRAQ). The principle of this technique has been 
provided in the Methodology Chapter. 
 
4.2 Aims 
This part of the study aims at identifying differentially expressed proteins induced by CD40 
stimulation in primary CLL cells using iTRAQ-MS and investigating the biological significance 
of the differentially expressed proteins through bioinformatic analysis. 
 
4.3 Methods 
The workflow of iTRAQ-MS is shown in Figure 4.1. with each step described in the following 
sections. 
                                                    




4.3.1 The design of the iTRAQ experiment 
As recommended by the collaborators at the Bioinformatics Team at the University of 
Liverpool, a minimum number of six primary CLL cases is required to produce sufficient 
statistical power for the meaningful analysis of the proteomics data. The cellular proteins 
extracted from the primary CLL cells incubated with or without the soluble CD40 ligand for 
12h and 24h were generated for the iTRAQ-MS analysis. Besides, the cellular proteins 
extracted from the primary CLL cells at 0h time point were also prepared. Thus, five protein 
samples were generated from each primary CLL case. In total, there were thirty protein 
samples generated from six primary CLL cases. 
The kit applied to this part was the iTRAQ® Reagents - 8plex (AB SCIEX, USA), which provides 
eight channels to analyse eight protein samples for each iTRAQ assay. Therefore, it needs at 
least four iTRAQ assays to complete the analysis of all thirty protein samples. To compare 
the results generated from all the iTRAQ assays, it is necessary to generate a common 
comparator. Accordingly, the design for analysing all thirty protein samples by iTRAQ-MS 
was described as follows: 
1) To produce the common comparators, master pools were generated by collecting 50μg of 
proteins from each protein sample with the concentration of 100μg/20μl;  
2) To have technical replicates, each iTRAQ assay had two channels for the master pools 
leaving the other six channels for protein samples to be analysed in each assay (as a result, 
five iTRAQ assays were performed to complete the analysis of all thirty samples); 
3) To avoid operational bias, thirty protein samples from six primary CLL cases were 
allocated randomly across the five iTRAQ assays. 
 
According to the above design, the detailed information of the sample allocation for each 
iTRAQ assay was generated randomly, as shown in Table 4.1.
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               Table 4.1. Grouping information of five iTRAQ experiments 
iTRAQ No.1 iTRAQ No.2 iTRAQ No.3 iTRAQ No.4 iTRAQ No.5 
Pool 1 Pool 1 Pool 1 Pool 1 Pool 1 
Pool 2 Pool 2 Pool 2 Pool 2 Pool 2 
3650-24t 3587-0 3607-12t 3640-12t 3606-24c 
3587-24c 3605-12c 3650-24c 3607-0 3607-24c 
3640-24t 3650-12t 3640-12c 3587-24t 3607-12c 
3640-0 3587-12t 3605-0 3607-24t 3606-12c 
3606-12t 3587-12c 3606-24t 3605-24t 3650-12c 
3605-24c 3640-24c 3606-0 3605-12t 3650-0 
Note: The four-digit number is the case number of the primary CLL samples used in this study. 
‘-0’ represents the samples collected at 0h time point; ‘-12c’ represents the 12h CD40 
unstimulated samples; ‘-12t’ represents the 12h CD40 stimulated samples; ‘-24c’ represents 
the 24h CD40 unstimulated samples; ‘-24t’ represents the 24h CD40 stimulated samples.  
 
4.3.2 Cellular protein sample preparation 
The criteria for primary CLL case selection were: 
1) the percentage of the CLL cells expressing both CD5 and CD19 should be at least 80%;  
2) the initial viability of the primary CLL cells at 0h should be over 70% and the viability at 
24h should be over 30%;  
3) the minimum number of primary CLL cells used in each sample should be 40 million (to 
generate a minimum of 100μg of proteins needed for iTRAQ analysis). 
 
The schematic of the sample preparation for each primary CLL case is shown in Figure 4.2. 
For each CLL case, the cell sample at 0h time point was harvested immediately after the 
thawing and recovery of the cryopreserved primary sample. The rest of the cells were 
cultured in the 6-well plate with a density of 5×106/ml. For CD40 stimulation, the primary 
CLL cells were treated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml anti-HA antibody 
for 12h or 24h, respectively. For the unstimulated controls, CLL cells were treated with 
0.5μg/ml anti-HA antibody for 12h or 24h, respectively. 
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Figure 4.2 Schematic diagram of the preparation of each CLL sample for iTRAQ assay. 0h 
control: CLL cells harvested immediately after recovery without any manipulations; 12h/24h 
sti: CD40 stimulated CLL cells with 0.1μg/ml HA-tagged CD40 ligand + 0.5μg/ml anti-HA 
antibody for 12h/24h; 12h/24h unsti: CLL cells cultured with 0.5μg/ml anti-HA antibody for 
12h/24h as unstimulated controls. 
 
The viability of each sample was monitored by flow cytometry to meet the criteria of sample 
selection and the stimulation status was checked by Western blotting for BCL-XL with a 
specific BCL-XL antibody. The results of the six cases that passed all the tests are shown in 
Table 4.2, Figure 4.3, and Figure 4.4, respectively. 
Table 4.2 The percentage of CD5 and CD19 double-positive CLL cells of the primary CLL 
samples used for iTRAQ assays 









                                      
Figure 4.3 Viability of the samples used for iTRAQ assays. Initial: the viability of primary CLL 
cells after recovery. 12h/24h unsti: the viability of primary CLL cells incubated with 0.5μg/ml 
anti-HA antibody for 12h/24h. 12h/24h sti: the viability of primary CLL cells incubated with 
0.1μg/ml HA-tagged CD40 ligand and 0. 5μg/ml anti-HA antibody for 12h/24h.  
   
Figure 4.4 Confirmation of the CD40 activation status of primary CLL cells incubated with 
or without the soluble CD40 ligand. Western blotting was used to monitor the induction of 
the expression of BCL-XL as a marker for CD40 activation status. Unsti: 0h un-stimulated 
control, proteins extracted from the primary CLL cells were harvested after recovery; 12-
/24-C: proteins extracted from the un-stimulated primary CLL cells that incubated with 
0.5μg/ml anti-HA antibody for 12h/24h; 12-/24-T: proteins extracted from the stimulated 
primary CLL cells incubated with 0.1μg/ml HA-tagged CD40 ligand and 0. 5μg/ml anti-HA 
antibody for 12h/24h. 
 
4.3.3 Protein extraction, quantification, and qualification 
The entire procedure of the protein extraction was performed on ice. The primary CLL cells 
used for protein samples were washed three times using PBS, pH7.4 (0.89g KH2PO4 and 
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4.42g Na2HPO4 dissolved in 500ml ddH2O) with centrifugation and removal of the 
supernatant between each wash. After washing, 50μl of 0.5M TEAB with 0.1% SDS was 
added to each sample and each sample was gently vortexed to mix well. The samples were 
sonicated three times using a probe sonicator and centrifuged at 20,000g, 4℃, for 15 
minutes. After the centrifugation, the supernatant was transferred to the corresponding 
new labelled tubes. For each sample, 30μl was taken out for protein quantification using 
Bradford assay and the rest of the protein samples were stored at -80℃. 
The 30μl of each sample taken out for the protein quantification was further diluted in 1:1, 
1:5, 1:10, and 1:20 with phosphate buffer. The dilutions were plated on the 96-well plate 
with replicates. A standard curve of bovine serum albumin (BSA) in PBS was prepared from 
0.1-2mg/ml and this was also plated in duplicate. Into each well was then added 250μl 
Bradford Reagent (Sigma Aldrich, Gillingham, UK), and the absorbance at 540nm was read 
on a spectrophotometer (Molecular Devices). The quantity of each sample was calculated 
according to the formula generated from the standard curve.  
The quality of the samples was checked by running SDS-PAGE. For each sample, the volume 
of extract containing 10μg proteins was calculated and this volume was placed into a new 
0.5ml Eppendorf tube. LC-MS-grade H2O was added to make the volume up to 9μl. Then 3μl 
of 4× Laemmli sample buffer (8% SDS, 40% glycerol, 0.008% bromophenol blue, 0.25M Tris-
HCl pH6.8, 5% -mercaptoethanol) was added to the samples and they were heated for 10 
minutes at 100℃. The samples were loaded onto a freshly-made 12% SDS-PAGE gel 
together with the SEEBLUE2 marker (the process of gel making has been described in 
chapter 2). After electrophoresis, the stacking gel was removed and the resolving gel was 
transferred into a plastic box with freshly made fix-solution (40% Methanol with 7% Acetic 
Acid). The gels were fixed for 30 minutes and then stained with 80% Coomassie Brilliant Blue 
solution (0.1% Coomassie Blue, 2% phosphoric acid, 10% ammonium sulphate) containing 
20% HPLC grade methanol overnight at room temperature. Before being scanned, the gels 
were de-stained in 10% Acetic Acid with 25% Methanol for 60 seconds, rinsed with 25% 
methanol once, and then agitated overnight in 25% methanol to complete destaining. The 
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gels were scanned using a GS800 calibrated imaging densitometer (Bio-Rad). The results are 
shown in Figure 4.5.  
            
Figure 4.5 Protein quality determination by SDS-PAGE for all 30 protein samples used for 
iTRAQ-MS assays. For each gel, the first column of protein bands on the left was generated 
by SEEBLUE2 markers and the rest columns of protein bands were generated by the protein 
samples to be studied. The last sample on gel #3587, the first sample on gel #3605, and the 
last sample on gel #3607 were the samples from other cases that failed. The graph of 
#3587(sample 1-5) shows a lighter view comparing with the other five graphs because the 
staining duration was only 2h for that gel and the duration of the other 5 was overnight.  
 
4.3.4 Generation of the master pool from thirty samples 
According to the design and the number of iTRAQ assays, there should be 10 pools for five 
iTRAQ assays. Depending on the observed quantification of each sample, the volume 
required for 50µg was calculated and aliquots from all samples were pooled together. The 
final concentration was adjusted to 100µg/20µl using 0.5M TEAB with 0.1% SDS and 






4.3.5 Reduction, digestion, and labelling 
Aliquots of 100μg of protein from each sample were reduced with tris(2-carboxyethyl) 
phosphine (TCEP), the cysteine residues were capped with methyl methanethiosulfate 
(MMTS) and the proteins were digested with sequencing grade modified trypsin (catalogue 
number 0000276726, Promega, USA). After the overnight digestion, peptides were labelled 
with individual isobaric tags using 8plex reagents. The samples were then pooled and 
diluted to 4ml with 10mM KH2PO4 + 25% ACN. The pH value of the pool was adjusted to 
less than 3 with 500mM phosphoric acid.  
 
4.3.6 Sample fractionation 
Sample fractionation was achieved via the strong cation exchange chromatography using a 
Polysulfoethyl A column (200×4.6mm, 5μm, 300A, Poly LC, Columbia, MD) at a flow rate of 
1ml/min. The gradient was from 10mM potassium dihydrogen phosphate and 25% (w/v) 
ACN to 0.5M potassium chloride, 10mM potassium dihydrogen phosphate, and 25% (w/w/v) 
ACN for 90 minutes. After the fractionation, 17 fractions were collected for each iTRAQ 
assay and the fractions were dried overnight by centrifugation under the vacuum condition. 
Then, the fractions were reconstituted with 1ml of 0.1% trifluoroacetic acid (TFA) and 
desalted by using the high-recovery protein column (4.6×50mm, Agilent, Berkshire, UK) on 
an Agilent 1260 HPLC system. The operations of this step were performed with the help of 
my secondary supervisor Dr. Rosalind Jenkins.  
 
4.3.7 LC-MS analysis of iTRAQ samples 
The desalted fractions were reconstituted in 40µl of 0.1% formic acid and aliquots of 5µl 
were delivered into a TripleTOF 6600 system (SCIEX) via an Eksigent NanoLC 400 system 
(SCIEX) mounted with a NanoAcquity 5μm, 180μm × 20mm C18 trap and 1.7μm, 75μm × 
250mm analytical column (Water). A NanoSpray III source was fitted with a 10 µm inner 
diameter PicoTip emitter (New Objective, Woburn, MA). The trap column was washed with 
2% ACN/0.1% formic acid for 10 minutes at 2.5 µl/min before switching in-line with the 
analytic column. A gradient of 2-50% ACN/0.1% (v/v) formic acid over 90 minutes was 
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applied to the column at a flow rate of 300nl/min. Spectra were acquired automatically in 
positive ion mode using information-dependent acquisition powered by Analyst TF 1.7 
software (SCIEX), with survey scans of 250ms, MS/MS accumulation time of 100ms, and 
with monitoring of 25 most intense ions (total cycle time 2.75s). MS/MS spectra were 
acquired using a threshold of 100 counts/s and with the dynamic exclusion for 12s. The 
rolling collision energy was increased automatically by selecting the iTRAQ check box in 
Analyst and manually by increasing the collision energy intercepts by 5. This helps to ensure 
that the peptide precursor ions are efficiently fragmented leading to more consistent 
quantitative signals from the iTRAQ reporter ions. The operations of this step were 
performed with the help of my secondary supervisor Dr. Rosalind Jenkins.  
 
4.3.8 iTRAQ data readout and data analysis 
The data searching was performed using ProteinPilot 5.0 and the Paragon Algorithm (SCIEX) 
against the Swiss-Prot database (2017-4, 20201 human entries), with MMTS as a fixed 
modification of cysteine residues and biological modifications allowed. Mass tolerance for 
precursor and fragment ions was 10ppm. In addition, the data searching was also performed 
against a reversed decoy database and only proteins lying with a 1% global false discovery 
rate were taken forward for analysis (Shilov, I.V et al., 2007; Tang W.H. et al., 2008). This 
helps to exclude false-positive protein identifications. The protein identification was by 
several constituent peptides with at least 90% confidence in the correct sequence 
assignment.  
Ratios for each iTRAQ label were obtained, using the master pools as the denominator. Data 
from the five iTRAQ experiments were merged using RStudio (v 1.0.143, RStudio Inc). Ratios 
were converted to their natural log and data analysis was performed using Partek Genomic 
Suite software (v.7.18.0518, Partek Inc.St.Louis, MO, USA). Hierarchical cluster analysis and 
principal component analysis (PCA) were performed on data batch corrected for the iTRAQ 
experiment. Proteins that were differentially expressed between the unstimulated and 
stimulated samples for 12h and 24h were revealed using a 2-way ANOVA on the non-
corrected data, with both the stimulation status and the cases of primary CLL samples as 
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factors. Relevant volcano plots were derived from these data. The functional data analysis 
was performed by using the Protein Analysis Through Evolutionary Relationships (PANTHER) 
and Database for Annotation, Visualization, and Integrated Discovery (DAVID) online. 
 
4.4 Results 
The results will be divided into three parts (Figure 4.6): an overview of the proteomics data 
using hierarchical cluster analysis and principal component analysis (PCA), the differential 
expression analysis using the analysis of variance (ANOVA), and the functional enrichment 
analysis performed using the PANTHER and DAVID. 
            
                                   Figure 4.6 The workflow of iTRAQ-MS data analysis. 
 
The raw data from the iTRAQ-MS assay was generated from 27 samples. Three samples 
(#3650-12h stimulated, #3650-24h unstimulated, and #3650-24h stimulated) failed to be 
labelled and processed well for analysis due to the quality of the iTRAQ 8plex kit.  
There were 5583 proteins identified in five iTRAQ assays with a 1% false discovery rate (FDR) 
and 5303 proteins had been identified in all 27 iTRAQ samples. Among the 5303 proteins, 
4093 proteins were quantified in all samples and these proteins were analysed further. 
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The master pool in each iTRAQ assay was used as a common comparator so that the five 
iTRAQ experiments could be merged. As described, there were two master pools in each 
iTRAQ experiment, and they were used as technical replicates. The raw data based on the 
master pool labelled with the iTRAQ reagent of 113-mass reporter group was called the 113-
dataset and the raw data based on the master pool labelled with the iTRAQ reagent of 114-
mass reporter group was called the 114-dataset. Theoretically, the protein data based on 
the 113-master pool and that based on the 114-master pool should be the same. However, 
in reality, there were some differences between 113 and 114 datasets. Based on whether 
the mean ratio of all the proteins to the pool is close to 1 as the criteria of the quality for the 
datasets, the 113-dataset was considered to be better than the 114-dataset. That is the 
reason why the 113-dataset was taken for further analysis. 
 
4.4.1 The heterogeneity of CLL cases predominates the difference in the overall protein 
expression across CLL samples 
Hierarchical cluster analysis and PCA were performed to get a visualized overview of the 
extent of the dispersion of the data. Initially, the hierarchical cluster analysis and the PCA 
were performed on the iTRAQ data minus the pools with no correction applied (Figure 4.7). 
The hierarchical clustering showed that samples from the same primary CLL case were 
assembled together (Figure 4.7 A). When performing the PCA, the variables were changed 
by using the incubation time (Figure 4.7 B), the incubation time together with the 
stimulation status (Figure 4.7 C), the iTRAQ experiment number (Figure 4.7 D), and the 
number of primary CLL cases (Figure 4.7 E), respectively. Comparing the PCA labelled with 
different variables, the results showed that samples separated based on the number of 
primary CLL cases and there was no clear separation when taking the other three variables. 
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Figure 4.7 Hierarchical cluster analysis and PCA of the proteomics data generated by 
iTRAQ-MS assay without any correction. (A) the results of the hierarchical cluster show that 
samples from the same primary CLL case are assembled. (B) the PCA taking the incubation 
time as the variable shows no separation of the samples. (C) the PCA taking the incubation 
time together with the stimulation status as the variable shows no separation. (D) the PCA 
taking the iTRAQ experiment number as the variable shows no separation. (E) the PCA 




The initial analysis indicated that it was necessary to perform a batch correction to remove 
the effect of the source of the samples, the number of primary CLL cases. Based on the data 
minus the pools with batch correction for the cases of the primary CLL samples, the 
hierarchical clustering showed that the CD40 stimulated and unstimulated samples were 
partially assembled (Figure 4.8 A), which indicated some separation between the CD40 
stimulated and the unstimulated samples. However, the results of PCA showed that the 
separation based on the number of primary CLL cases, which observed previously, became 
blurry (Figure 4.8 B). Instead, samples were separated to a certain degree based on the 
iTRAQ experiment number (Figure 4.8 C). 
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Figure 4.8 Hierarchical cluster analysis and PCA of the proteomics data with the correction 
for the cases of primary CLL samples. (A) the result of hierarchical cluster analysis shows 
that the CD40 stimulated and unstimulated samples are partially assembled. (B) the PCA 
taking the number of primary CLL cases as the variable shows no clear separation. (C) the 
PCA taking the iTRAQ experiment number as the variable shows a separation to a certain 
degree. (D) the PCA taking the incubation time as the variable shows no separation. (E) the 




Based on the above results, it was reasonable to perform batch correction for both the 
cases of primary CLL samples and the iTRAQ experiment number. The results showed that 
the correction for both variables mixed the samples up and removed any obvious clusters 
(Figure 4.9). Under this circumstance, reviewing the distribution of all samples across five 
iTRAQ experiments, quite by chance, the iTRAQ experiment 4 was dominated by CD40 
unstimulated samples and iTRAQ experiment 5 was dominated by CD40 stimulated samples 
(Table 4.1). Therefore, correcting for the iTRAQ experiment would remove much of the true 
differences between CD40 unstimulated samples and CD40 stimulated samples. It was thus 
reasonable to take the cases of primary CLL samples as a variable alongside the stimulation 
status: only the batch correction for the cases should be performed for the analysis. 
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Figure 4.9 Hierarchical cluster analysis and PCA of the proteomics data with the correction 
for both the number of primary CLL cases and the number of the iTRAQ experiments. The 
results of the hierarchical cluster analysis (A) and the PCA (B, C, D, E) show no clear 




To get a further view, the data with batch correction for the cases of primary CLL samples 
were replotted with the two time points respectively taking the CD40 stimulation status as 
the variable (Figure 4.10). Results displayed the separation between the CD40 stimulated 
and the unstimulated samples, among which the separation was more obvious at the 24h 
time point (Figure 4.10 B) compared with that of the 12h time point (Figure 4.10 A). 
  
Figure 4.10 PCA of the proteomics data generated from two separate time points (data 
with batch correction for the number of primary CLL cases). (A) the PCA of the data 
generated from the 12h time point shows a separation between the CD40 stimulated and 
the unstimulated samples. (B) the PCA of the data generated from the 24h time point shows 
an obvious separation between the CD40 stimulation and the unstimulated samples. 
 
The results of hierarchical cluster analysis and PCA showed that: 
1) within 24h stimulation, the influence of heterogeneity, which is a comprehensively 
accepted trait of CLL, was predominant for the differences across different primary CLL 
cases. The changes caused by soluble CD40 stimulation did not conquer the influence of 
heterogeneity.  
2) After removing the effect of the source of primary CLL cells (the cases of primary CLL 
cells), the results showed that the soluble CD40 stimulation induced differential expression 





4.4.2 CD40 stimulation causes significant changes in the protein expression of primary CLL 
cells at a global level, and the number of the differentially expressed proteins induced by 
the soluble CD40 stimulation increases with the time of stimulation 
 
The statistical method used to identify the differentially expressed proteins was the analysis 
of variance (ANOVA) with the 2-way ANOVA on the non-corrected data, with both the 
stimulation status and the cases of primary CLL samples as factors due to the results of the 
hierarchical cluster analysis and PCA. The statistically significant expressed proteins were 
determined by a p-value of less than 0.05 with 1% FDR. With ANOVA analysis, 158 proteins 
were differentially expressed with 12h CD40 stimulation (Appendix 8). 552 proteins were 
differentially expressed with 24h CD40 stimulation (Appendix 9). Volcano plots were used to 
get a visualized view of the difference induced by the soluble CD40 stimulation method in 
primary CLL cells at the protein expression level (Figure 4.11). 
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Figure 4.11 Visualizing the differentially expressed proteins induced by the soluble CD40 
ligand in primary CLL cells. Red dots: differential expression with p-value < 0.05; Blue dots: 
differential expression with p-value > 0.05. (A) the volcano plot based on the 12h 
proteomics data generated by iTRAQ-MS assay with the batch correction for the number of 
primary CLL cases; (B) the volcano plot based on the 24h proteomics data generated by 
iTRAQ-MS assay with the batch correction for the number of primary CLL cases; (C) the 
volcano plot based on the 12h and 24h data generated by iTRAQ-MS assay with the batch 




Comparing the differential expression lists of the two time points, 57 proteins were present 
on both lists (Figure 4.12). 
                                                 
Figure 4.12 Comparison of the differentially expressed proteins in CD40 stimulated CLL 
cells between 12h and 24h. The yellow circle represents the 158 differentially expressed 
proteins at 12h; the green circle represents the 552 differentially expressed proteins at 24h. 
The 57 proteins include 35 proteins present on both of the significantly up-regulated lists, 
19 proteins present on both of the significantly down-regulated lists, and 3 proteins present 
on both lists but the directions of regulation induced by CD40 stimulation were different at 
two time points. 
 
When it comes to the up-regulated and down-regulated proteins, the 12h differential 
expression list showed that there were 158 proteins significantly differentially expressed 
with 66 proteins up-regulated and 92 proteins down-regulated. The 24h differential 
expression list showed that there were 552 proteins significantly differentially expressed 
with 448 proteins up-regulated and 104 proteins down-regulated. Comparing the up and 
down regulated proteins between 12h and 24h, there were 35 proteins present on both of 
the significantly up-regulated lists (Table 4.3) and there were 19 proteins present on both of 
the significantly down-regulated lists (Table 4.4). There were 3 proteins present on both lists 
but the directions of regulation induced by CD40 stimulation were different at two time 
points (O43707, Q9NRL2, P41212). For the 35 proteins consistently present on both up-
regulated lists, the fold-change of 32 individual proteins stayed at a similar level from 12h to 
24h with that of several proteins increases. For the 19 proteins consistently present on both 
down-regulated lists, the fold-change of the individual proteins stayed at a similar level from 
12h to 24h. 
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Table 4.3 Thirty-five concurrently up-regulated proteins at 12h and 24h (ranking by the 
first alphabet of the accession of proteins in the order of A-Z) 




O00471 Exocyst complex component 5 2.07 2.14 
O00764 Pyridoxal kinase 2.37 2.37 
O14579 Coatomer subunit epsilon 1.63 1.87 
O43172 U4/U6 small nuclear ribonucleoprotein Prp4 1.45 1.66 
O43847 Nardilysin 1.97 2.09 
O60499 Lymphocyte antigen 75 1.42 1.70 
O60508 Pre-mRNA-processing factor 17 1.76 2.01 
O75694 Nuclear pore complex protein Nup155 1.43 1.66 
O95163 Elongator complex protein 1 1.59 1.83 
O95298 NADH dehydrogenase [ubiquinone] 1 subunit C2 1.89 2.15 
P16070 CD44 antigen 2.15 2.36 
P19838 Nuclear factor NF-kappa-B p105 subunit 1.73 2.75 
P30050 60S ribosomal protein L12 1.23 1.23 
P31153 S-adenosylmethionine synthase isoform type-2 1.53 1.54 
P40763 Signal transducer and activator of transcription 3 1.44 1.47 
P48960 CD97 antigen 1.62 2.48 
P49588 Alanine—tRNA ligase, cytoplasmic 1.45 2.42 
P52292 Importin subunit alpha-1 2.32 2.67 
P52294 Importin subunit alpha-5 2.36 2.40 
Q13077 TNF receptor-associated factor 1 8.35 10.10 
Q13501 Sequestosome-1 1.74 2.20 
Q14137 Ribosome biogenesis protein BOP1 1.50 2.33 
Q14699 Raftlin 2.87 4.05 
Q3LXA3 Triokinase/FMN cyclase 1.55 1.69 
Q6BCY4 NADH-cytochrome b5 reductase 2 1.62 2.56 
Q86X10 Ral GTPase-activating protein subunit beta 1.52 1.63 
Q8IVM0 Coiled-coil domain-containing protein 50 2.01 1.95 
Q8IWA4 Mitofusin-1 1.81 1.93 
Q92900 Regulator of nonsense transcripts 1 1.39 1.37 
Q92918 Mitogen-activated protein kinase kinase 1 1.87 1.77 
Q96RU3 Formin-binding protein 1 1.66 1.86 
Q9H334 Forkhead box protein P1 1.41 1.49 
Q9H444 Charged multivesicular body protein 4b 2.70 3.67 
Q9NX20 39S ribosomal protein L16, mitochondrial 1.58 2.36 
Q9UJX3 Anaphase-promoting complex subunit 7 2.78 2.27 
Note: Fold-change 12h: The ratio of protein expression level between CD40 
stimulated/unstimulated at 12h time point; Fold-change 24h: The ratio of protein 





Table 4.4 Nineteen concurrently down-regulated proteins at 12h and 24h (ranking by the 
first alphabet of the accession of proteins in the order of A-Z) 




O75475 PC4 and SFRS1-interacting protein -2.16 -2.21 
P02768 Serum albumin -2.93 -3.38 
P20674 Cytochrome c oxidase subunit 5A, mitochondrial -2.05 -2.07 
P23443 Ribosomal protein S6 kinase beta-1 -2.00 -1.98 
P49321 Nuclear autoantigenic sperm protein -1.53 -1.47 
P61803 Dolichyl-diphosphooligasaccharide—protein 
glycosyltransferase subunit DAD1 
-1.62 -1.82 
P62341 Selenoprotein T -1.90 -2.76 
Q13033 Striatin-3 -1.59 -1.78 
Q13610 Periodic tryptophan protein 1 homolog -3.03 -2.66 
Q15031 Probable leucine--tRNA ligase, mitochondrial -2.35 -2.00 
Q15075 Early endosome antigen 1 -1.43 -1.46 
Q5VZK9 F-actin-uncapping protein LRRC16A -2.31 -1.92 
Q86SX6 Glutaredoxin-related protein 5, mitochondrial -1.58 -2.32 
Q8N442 Translation factor GUF1, mitochondrial -1.67 -1.92 
Q969F9 Hermansky-Pudlak syndrome 3 protein -1.98 -2.72 
Q96P31 Fc receptor-like protein 3 -2.33 -2.72 
Q9HAV7 GrpE protein homolog 1, mitochondrial -1.60 -1.92 
Q9NUP1 Biogenesis of lysosome-related orgenelles complex 1 
subunit 4 
-1.99 -2.46 
Q9UK58 Cyclin-L1 -1.83 -2.30 
Note: Fold-change 12h: The negative ratio of protein expression level between CD40 
stimulated/unstimulated at 12h time point; Fold-change 24h: The negative ratio of protein 
expression level between CD40 stimulated/unstimulated at 24h time point. 
 
The results of the comparison showed that CD40 stimulation changed the protein 
expression in primary CLL cells at a global level and that the changes induced by the CD40 
stimulation increased with time. As a result, further functional analysis was focused on the 
differential expression data of the 24h time point. The reasons were explained as follows. 
Firstly, the hierarchical cluster analysis and the PCA results showed that the influence of 
CD40 stimulation became more obvious with 24h stimulation, which suggested that the 
influence of CD40 stimulation increased with time. Secondly, the data showed that the 
number of the differentially expressed proteins at 24h (552) was much more than that at 
12h (158), which, once again, indicated that the influence of CD40 stimulation on the 
protein expression was greater at 24h than 12h. The data obtained at 24h can provide more 
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information compared with that at 12h. In addition, the effect of CD40 stimulation-induced 
protection on primary CLL cells was observed at 24h following CD40 stimulation, as 
described previously. Based on the above reasons, further analysis will focus on the 
differentially expressed proteins at the 24h time point. 
 
4.4.3 Functional analysis of the differentially expressed proteins induced by CD40 
stimulation 
4.4.3.1 The classification of the differentially expressed proteins by PANTHER classification 
system 
 
The protein classification analysis by PANTHER version 14.1 gave a brief view of the 552 
statistically differentially expressed proteins induced by the soluble CD40 stimulation 
system in primary CLL cells. Among the 552 significantly differentially expressed proteins, 
there were 550 proteins which can be mapped by Panther version14.1 with 2 unmapped 
proteins (I3L1I5 and Q9NUQ7). Meanwhile, the classification analysis was performed by 
PANTHER on all the proteins quantified (4093 proteins) as well. Among the 4093 identified 
proteins, there were 4080 proteins were identified and applied in the PANTHER analysis 
with 13 proteins unable to map (I3L1I5, Q9NUQ7, P04229, P58557, P30042, P09669, 
Q96HY6, P62861, P04439, P42167, Q9BT23, L0R6Q1, Q9NRK6). 
Classified by cellular component, the 550 identified proteins were grouped into fourteen 
categories (Table 4.5). Comparing with that of all proteins quantified (Table 4.6), the 
constituents and the rank were similar with a slight difference. Situations were similar in the 
classification by molecular function (Table 4.7 and 4.8) and biological process (Table 4.9 and 
4.10). The constituents of the classification for all the proteins quantified were a little more 
than that of the classification for the differentially expressed proteins. The ranks were 





Table 4.5 Classification by the cellular component of the differentially expressed proteins 
at 24h time point (550 of 552 proteins were mapped by PANTHER 14.1) 
 Category names Number % in 550 
1 Cell 316 57.50% 
2 Cell part 316 57.50% 
3 Organelle 215 39.10% 
4 Protein-containing complex 139 25.30% 
5 Organelle part 118 21.50% 
6 Membrane 69 12.5% 
7 Membrane-enclosed lumen 41 7.5% 
8 Membrane part 35 6.4% 
9 Extracellular region part 9 1.60% 
10 Extracellular region 9 1.60% 
11 Synapse part 7 1.30% 
12 Synapse 7 1.30% 
13 Supramolecular complex 7 1.30% 
14 Cell junction 3 0.50% 
Note: Number: the number of proteins in the correlated term;  
     % in 550: the percentage of (the number of proteins in each term/550). 
 
Table 4.6 Classification by the cellular component of all the proteins quantified in 27 
samples (4080 of 4093 proteins were mapped by PANTHER 14.1) 
 Category names Number % in 4080 
1 Cell 2264 55.50% 
2 Cell part 2264 55.50% 
3 Organelle 1732 42.50% 
4 Protein-containing complex 1051 25.80% 
5 Organelle part 1041 25.50% 
6 Membrane 614 15.00% 
7 Membrane-enclosed lumen 392 9.60% 
8 Membrane part 320 7.80% 
9 Extracellular region part 52 1.30% 
10 Extracellular region 52 1.30% 
11 Supramolecular complex 48 1.20% 
12 Synapse 38 0.90% 
13 Synapse part 36 0.90% 
14 Cell junction 22 0.50% 
Note: Number: the number of proteins in the correlated term;  






Table 4.7 Classification by the protein class of the differentially expressed proteins at 24h 
time point (550 of 552 proteins were mapped by PANTHER 14.1) 
 Category names Number  % in 550 
1 Metabolite interconversion enzyme 63 11.50% 
2 Translational protein 43 7.80% 
3 Nucleic acid binding protein 42 7.60% 
4 Protein modifying enzyme 29 5.30% 
5 Cytoskeletal protein 20 3.60% 
6 Protein-binding activity modulator 19 3.50% 
7 Membrane traffic protein 19 3.50% 
8 Gene-specific transcriptional regulator 17 3.10% 
9 Scaffold/adaptor protein 15 2.70% 
10 Transporter 12 2.20% 
11 Chromatin/chromatin-binding, or -regulatory protein 9 1.60% 
12 Chaperone 9 1.60% 
13 Defense/immunity protein 4 0.70% 
14 Extracellular matrix protein 2 0.40% 
15 Transfer/carrier protein 2 0.40% 
16 Transmembrane signal receptor 2 0.40% 
17 Intercellular signal molecule 1 0.20% 
18 Calcium-binding protein 1 0.20% 
19 Storage protein 1 0.20% 
Note: Number: the number of proteins in the correlated term;  














Table 4.8 Classification by the protein class of all the proteins quantified in 27 samples 
(4080 of 4093 proteins were mapped by PANTHER 14.1) 
 Category names Number  % in 4080 
1 Metabolite interconversion enzyme 472 11.60% 
2 Nucleic acid binding protein 404 9.90% 
3 Protein modifying enzyme 260 6.40% 
4 Translational protein 209 5.10% 
5 Membrane traffic protein 147 3.60% 
6 Protein-binding activity modulator 125 3.10% 
7 Cytoskeletal protein 121 3.00% 
8 Transporter 119 2.90% 
9 Gene-specific transcriptional regulator 113 2.80% 
10 Scaffold/adaptor protein 85 2.10% 
11 Chromatin/chromatin-binding, or -regulatory protein 80 2.00% 
12 Chaperone 46 1.10% 
13 Defense/immunity protein 29 0.70% 
14 Calcium-binding protein 22 0.50% 
15 Transfer/carrier protein 14 0.30% 
16 Intercellular signal molecule 12 0.30% 
17 Transmembrane signal receptor 9 0.20% 
18 Extracellular matrix protein 6 0.10% 
19 Cell adhesion molecule 3 0.10% 
20 Storage protein 2 0.00% 
21 Cell junction protein 1 0.00% 
22 Structural protein 1 0.00% 
Note: Number: the number of proteins in the correlated term;  















Table 4.9 Classification by the biological process of the differentially expressed proteins at 
24h time point (550 of 552 proteins were mapped by PANTHER 14.1) 
 Category names Number % in 550 
1 Cellular process 268 48.70% 
2 Metabolic process 193 35.10% 
3 Biological regulation 108 19.60% 
4 Cellular component organization or biogenesis 106 19.30% 
5 Localization 68 12.40% 
6 Response to stimulus 47 8.50% 
7 Signaling 32 5.80% 
8 Developmental process 16 2.90% 
9 Multicellular organismal process 9 1.60% 
10 Immune system process 8 1.50% 
11 Multi-organism process 7 1.30% 
12 Locomotion 6 1.10% 
13 Biological adhesion 6 1.10% 
14 Cell population proliferation 4 0.70% 
15 Reproductive process 2 0.40% 
16 Reproduction 2 0.40% 
Note: Number: the number of proteins in the correlated term;  
     % in 550: the percentage of the number of proteins in each term in 550. 
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Table 4.10 Classification by the molecular function of all the proteins identified in 27 
samples (4080 of 4093 proteins were mapped by PANTHER 14.1) 
 Category names Number % in 4080 
1 Cellular process 1929 47.30% 
2 Metabolic process 1448 35.50% 
3 Biological regulation 846 20.70% 
4 Cellular component organization or biogenesis 724 17.70% 
5 Localization 478 11.70% 
6 Response to stimulus 408 10.00% 
7 Signaling 231 5.70% 
8 Developmental process 115 2.80% 
9 Multicellular organismal process 92 2.30% 
10 Immune system process 67 1.60% 
11 Locomotion 42 1.00% 
12 Multi-organism process 39 1.00% 
13 Reproduction 26 0.60% 
14 Reproductive process 26 0.60% 
15 Biological adhesion 26 0.60% 
16 Cell population proliferation 21 0.50% 
17 Biological phase 6 0.10% 
18 Growth 5 0.10% 
19 Pigmentation 3 0.10% 
Note: Number: the number of proteins in the correlated term;  
     % in 4080: the percentage of the number of proteins in each term in 4080. 
 
These results showed that the differentially expressed proteins induced by CD40 stimulation 
were involved in a variety of biological activities in primary CLL cells, which suggested that 
CD40 stimulation changed the features of primary CLL cells in broad aspects. Based on the 
results of the comparison, the influences induced by CD40 stimulation did not aggregate on 
any particular class of proteins at the protein translational level. 
 
4.4.3.2 CD40 stimulation regulates a variety of biological processes of primary CLL cells 
The functional annotation analysis of the significantly differentially expressed proteins was 
analyzed by DAVID version 6.8. The 448 proteins that were significantly upregulated 
following 24h CD40 stimulation were submitted to DAVID 6.8 with all the proteins 
quantified in the iTRAQ experiment (4093) used as the background proteome. The 
functional annotation analysis gave out a list of 82 annotation clusters ranking by the 
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highest to lowest enrichment scores with the EASA threshold set to 1.0. A summary of the 
categories with FDR less than 0.5 is shown in Table 4.11. For the 104 down-regulated 
proteins (with one of the proteins, I3L1I5 cannot be mapped), the results of the functional 
annotation gave out 16 functional annotation clusters with the EASE threshold of 1.0 but 
none of these revealed a significant enrichment (the categories with FDR less than 1.0 is 
shown in Table 4.12).  
To catch an overall view of the functional overrepresentation of biological processes for the 
differentially expressed proteins induced by CD40 stimulation, the statistically significantly 
up and down regulated differentially expressed proteins were inputted respectively to the 
Reactome Pathway Database version 73 released on June 17, 2020. The biological processes 
overrepresented with a p-value less than 0.05 are highlighted in yellow in the Figure 4.13 
and 4.14. 
The results of the functional annotation analysis were not particularly conclusive as the 
enrichment scores were not high. However, they do suggest that cell-cell adhesion may be 
altered by CD40 stimulation. Previously in Chapter 3, the differentially expressed genes 
induced by the soluble CD40 ligand method in primary CLL cells had been obtained by the 
RNA sequencing analysis. To make a comparison of the effect induced by the CD40 
stimulation between the protein expression level and the transcriptional level, the 
functional annotation analysis of the significantly differentially expressed genes of the RNA-
seq data at 24h time point was performed using DAVID. The results of the functional 
annotation analysis of the 2046 significantly up-regulated genes gave out 271 clusters 
ranking by the highest to lowest enrichment scores with the EASA threshold set to 1.0 and 
the top one cluster on the list was the cell-cell adhesion (Appendix 10). It indicated that 
CD40 stimulation regulated cell-cell adhesion in primary CLL cells at the transcriptional level 
as well. Among the 82 clusters obtained by the statistically significantly up-regulated 
proteins induced by CD40 stimulation in primary CLL cells, 73 clusters can be found on the 
list of the 271 clusters obtained by the significantly up-regulated genes. The results of the 
functional annotation analysis of the 1986 significantly down-regulated genes showed 227 
clusters ranking by the enrichment scores with the EASA threshold set to 1.0 (Appendix 11). 
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For the 16 clusters obtained by the statistically significantly down-regulated proteins 
induced by CD40 stimulation in primary CLL cells, 15 clusters were present on the list of the 
227 clusters obtained by the significantly down-regulated genes. 
The comparison of the functional annotation clusters between the iTRAQ data and the RNA-
seq data showed similar biological alterations induced by CD40 stimulation, which increased 
the confidence of the iTRAQ data. In addition, it was encouraging that the cell-cell adhesion 
ranks on the top of both up-regulated functional annotation cluster lists. The results at both 
transcriptional level and protein expression level synergistically suggested that the biological 
process of the cell-cell adhesion in primary CLL cells was changed by the CD40 stimulation. 
Based on this finding, further investigation was focused on the proteins in the cell-cell 
adhesion cluster.  
38 proteins of the differentially up-regulated proteins induced by CD40 stimulation were 
allocated in the cluster of cell-cell adhesion (Table 4.13). Classifying the 38 proteins 
according to the molecular function by PANTHER, 15 proteins perform as binding molecules 
(Table 4.14), 7 proteins are involved in catalytic activity, and the other 4 proteins are 
classified in the categories of translation regulator activity, transcription regulator activity, 
and molecular function regulator. Classifying the 38 proteins according to the protein class 
by PANTHER, 8 proteins are cytoskeletal protein (Table 4.15); 5 proteins are metabolite 
interconversion enzyme; others are classified into the categories of the membrane traffic 
protein, the scaffold/adaptor protein, chaperone, the calcium-binding protein, the protein-
binding activity modulator, the gene-specific transcriptional regulator and the translation 
protein. 8 proteins can be mapped into pathways by PANTHER and the detailed information 
is shown in Table 4.16.                                         
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Table 4.11 The DAVID functional annotation categories (with the FDR<0.5) of the 448 statistically up-regulated proteins induced by CD40 
stimulation in primary CLL cells at 24h time point 
Annotation Cluster 1 Enrichment Score: 
3.4362324490527985 
     
Category Term Count % Genes Benjamini FDR 
GOTERM_BP_DIRECT GO:0098609~cell-cell 
adhesion 
37 8.26 Q9NYL9, Q7KZF4, P06733, P26641, Q92616, P14618, Q9Y266, Q9Y6W5, Q96C19, Q9H444, 
Q04637, P63244, P42224, Q7L1Q6, P40121, Q9Y6E2, P31939, Q9Y5X1, P22234, P55010, 
Q9Y5X3, P62258, P42566, P46060, P07737, O75874, P26196, O00571, P37802, Q16181, 




38 8.48 Q9NYL9, Q7KZF4, P06733, P26641, Q92616, P14618, Q9Y266, Q9Y6W5, P07948, Q96C19, 
Q9H444, Q04637, P63244, P42224, Q7L1Q6, P40121, Q9Y6E2, P31939, Q9Y5X1, P22234, 
P55010, Q9Y5X3, P62258, P42566, P46060, P07737, O75874, P26196, O00571, P37802, 
Q16181, P00338, Q99497, P49327, Q15691, P08238, P60228, P62424 
0.05 0.05 
GOTERM_MF_DIRECT GO:0098641~cadherin 
binding involved in 
cell-cell adhesion 
37 8.26 Q9NYL9, Q7KZF4, P06733, P26641, Q92616, P14618, Q9Y266, Q9Y6W5, Q96C19, Q9H444, 
Q04637, P63244, P42224, Q7L1Q6, P40121, Q9Y6E2, P31939, Q9Y5X1, P22234, P55010, 
Q9Y5X3, P62258, P42566, P46060, P07737, O75874, P26196, O00571, P37802, Q16181, 
P00338, Q99497, P49327, Q15691, P08238, P60228, P62424 
0.36 0.36 
Annotation Cluster 2 Enrichment Score: 
2.042696846327676 
     
Category Term Count % Genes Benjamini FDR 
UP_KEYWORDS Protein biosynthesis 28 6.25 P54577, P26641, P26640, O43776, O00267, Q04637, O60841, Q9P2J5, P26639, P41250, 
P23588, P55010, P15170, O15371, O15372, O43583, P49591, P49411, P23381, P14868, 





13 2.90 P54577, P26640, P49591, P23381, P14868, O43776, Q9P2J5, P26639, Q15181, P41250, 









12 2.68 P54577, P49591, P26640, Q9P2J5, P26639, P41250, P23381, P14868, P49589, P49588, 
O43776, P56192 
0.41 0.41 
Annotation Cluster 3 Enrichment Score: 
1.906322068791872 
     
Category Term Count % Genes Benjamini FDR 
UP_KEYWORDS Nucleotide-binding 89 19.87 P25098, A3KMH1, P54577, Q08AF3, P07900, Q8IY21, P07948, Q86YS6, Q3LXA3, P51149, 
O00148, P42025, O60841, Q9P2J5, P62195, P41250, P15170, P55072, Q8IYB8, P05771, 
Q13043, Q92930, P07437, Q9UL25, P51151, O75414, P49411, Q9GZZ9, P26196, P23919, 
O00159, Q9UJ70, P68104, Q8WV93, P22102, Q8IWA4, O15523, P00973, Q15477, Q13131, 




O43776, P36404, O00764, O60942, P49915, Q9H4B7, Q6DD88, P26639, O94804, P55010, 
P78371, P22234, Q92598, P40227, P22314, P49591, Q8WYJ6, P20591, P23381, P31749, 
P14868, O00571, P17980, Q8TD19, Q9HCC0, P34932, Q7L014, Q16181, Q5T9A4, Q92620, 
P23458, P49589, P49588, P45985, P49903, Q92900, P08238, Q9NRF8, P56192 
UP_KEYWORDS ATP-binding 69 15.40 P25098, A3KMH1, P54577, Q08AF3, P07900, Q8IY21, P07948, Q3LXA3, O00148, P42025, 
Q9P2J5, P62195, P41250, P55072, Q8IYB8, P05771, Q13043, O75414, Q9GZZ9, P26196, 
P23919, O00159, Q9UJ70, Q8WV93, P22102, O15523, P00973, Q15477, Q13131, P51003, 
P26640, P14618, Q92918, Q9UN37, P31153, Q8N3C0, O00442, Q13418, O43776, O00764, 
P49915, P26639, O94804, P78371, P22234, Q92598, P40227, P22314, P49591, P23381, 
P31749, P14868, O00571, P17980, Q8TD19, Q9HCC0, P34932, Q7L014, Q5T9A4, Q92620, 
P23458, P49589, P49588, P45985, P49903, Q92900, P08238, Q9NRF8, P56192 
0.41 0.41 
Annotation Cluster 5 Enrichment Score: 
1.5960740052665232 
     
Category Term Count % Genes Benjamini FDR 
UP_KEYWORDS GTPase activation 14 3.13 P50395, P46060, Q9H2M9, Q86YV0, O43665, Q9BTW9, Q8TC07, Q86TI0, Q86X10, Q68EM7, 
Q9P107, P31150, Q8N264, P98171 
0.42 0.42 
Annotation Cluster 8 Enrichment Score: 
1.2506074698725398 
     
Category Term Count % Genes Benjamini FDR 
UP_KEYWORDS TPR repeat 12 2.68 P49792, P19878, O76094, Q9BXJ9, O15550, Q13042, P50502, Q9H3S7, Q9UJX3, Q08752, 
Q13451, Q02790 
0.47 0.46 
Annotation Cluster 10 Enrichment Score: 
1.2029888687808314 
     
Category Term Count % Genes Benjamini FDR 
KEGG_PATHWAY hsa03013:RNA 
transport 
23 5.13 P49792, O15371, P46060, O15372, Q14974, Q86V81, Q96J01, P11940, Q9BTX1, O75694, 
Q7L576, P51114, Q04637, O60841, P68104, P23588, P55010, P20042, Q92900, P60228, 









Table 4.12 The DAVID functional annotation categories (with the FDR<1.0) of the 104 statistically down-regulated proteins induced by CD40 
stimulation in primary CLL cells at 24h time point 
Annotation Cluster 1 Enrichment Score: 1.7999646816124586 
     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FEATURE site:Not glycated 3 2.91 P68871, P02768, P69905 0.40 0.40 
UP_SEQ_FEATURE glycosylation site:N-linked (Glc) (glycation) 3 2.91 P68871, P02768, P69905 0.40 0.40 
GOTERM_MF_DIRECT GO:0019825~oxygen binding 3 2.91 P68871, P02768, P69905 0.74 0.74 
UP_KEYWORDS Glycation 3 2.91 P68871, P02768, P69905 0.67 0.67 













Figure 4.13 Illustrations of the functional overrepresentation analysis of the 448 up-regulated proteins by Reactome version 72. The yellow 









Figure 4.14 Illustrations of the functional overrepresentation analysis of the 104 down-regulated proteins by Reactome version 72. The 
yellow color represents the degree of overrepresentation with a p-value of less than 0.05.
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Table 4.13 The 38 proteins in the cell-cell adhesion cluster identified by DAVID functional 
annotation analysis (ranking by the fold-change of ANOVA) 
Protein Accession Fold-change p-value 
Charged multivesicular body protein 4b Q9H444 3.67 0.01 
EF-hand domain-containing protein D2 Q96C19 3.09 0.01 
ATP-dependent RNA helicase DDX3X O00571 2.89 0.00 
Protein DJ-1 Q99497 2.48 0.03 
Eukaryotic translation initiation factor 4 gamma 1 Q04637 2.45 0.01 
60S ribosomal protein L7a P62424 2.30 0.01 
Fatty acid synthase P49327 2.30 0.00 
Basic leucine zipper and W2 domain-containing protein 2 Q9Y6E2 2.30 0.03 
Wiskott-Aldrich syndrome protein family member 2 Q9Y6W5 2.25 0.00 
Bifunctional purine biosynthesis protein PURH P31939 2.25 0.00 
Ran GTPase-activating protein 1 P46060 2.22 0.00 
Septin-7 Q16181 2.22 0.00 
Tyrosine-protein kinase Lyn P07948 2.20 0.00 
14-3-3 protein epsilon P62258 2.20 0.00 
Multifunctional protein ADE2 P22234 2.15 0.01 
Elongation factor 1-gamma P26641 2.13 0.00 
Heat shock protein HSP 90-beta P08238 1.92 0.01 
Profilin-1 P07737 1.88 0.01 
Eukaryotic translation initiation factor 3 subunit E P60228 1.80 0.00 
Macrophage-capping protein P40121 1.80 0.04 
Microtubule-associated protein RP/EB family member 1 Q15691 1.78 0.03 
Basic leucine zipper and W2 domain-containing protein 1 Q7L1Q6 1.76 0.02 
eIF-2-alpha kinase activator GCN1 Q92616 1.76 0.00 
Epidermal growth factor receptor substrate 15 P42566 1.75 0.02 
Sorting nexin-9 Q9Y5X1 1.75 0.04 
Sorting nexin-5 Q9Y5X3 1.72 0.04 
Alpha-enolase P06733 1.68 0.02 
L-lactate dehydrogenase A chain P00338 1.67 0.03 
Isocitrate dehydrogenase [NADP] cytoplasmic O75874 1.64 0.04 
Pyruvate kinase PKM P14618 1.64 0.01 
Staphylococcal nuclease domain-containing protein 1 Q7KZF4 1.64 0.02 
Transgelin-2 P37802 1.62 0.00 
Receptor of activated protein C kinase 1 P63244 1.57 0.01 
Eukaryotic translation initiation factor 5 P55010 1.57 0.03 
Probable ATP-dependent RNA helicase DDX6 P26196 1.55 0.02 
Signal transducer and activator of transcription 1-
alpha/beta 
P42224 1.51 0.03 
Nuclear migration protein nudC Q9Y266 1.41 0.02 
Tropomodulin-3 Q9NYL9 1.38 0.02 
Note: Fold-change: the expression of the protein in CD40 stimulated/the expression of the 




Table 4.14 The 15/38 proteins that classified into the binding category according to the 
molecular function by PANTHER (ranking by the first alphabet of the accession of proteins 
in the order of A-Z) 
Accession Name of the protein PANTHER Protein Class 
P07737 Profilin-1 (PFN-1 ortholog) non-motor actin binding_protin 
P07948 Tyrosine-protein kinase Lyn  - 
P08238 Heat shock protein HSP90-beta Hsp90 family chaperone 
P26196 Probable ATP-dependent RNA helicase 
DDX6 
- 




P55010 Eukaryotic translation initiation factor 5  translation initiation factor 
P62424 60S ribosomal protein L7a ribosomal protein 
P63244 Receptor of activated protein C kinase 1  - 
Q04637 Eukaryotic translation initiation factor 4 
gamma 1 
translation initiation factor 
Q15691 Microtubule-associated protein RP/EB 
family member 1 
non-motor microtubule 
binding_protein 
Q16181 Septin-7 cytoskeletal protein 
Q7KZF4 Staphylococcal nuclease domain-
containing protein 1 
- 
Q9NYL9 Tropomodulin-3 actin or actin-binding 
cytoskeletal protein 
Q9Y266 Nuclear migration protein nudC microtubule or microtubule-
binding cytoskeletal protein 















Table 4.15 The 8/38 proteins that classified into the cytoskeletal protein category 
according to the protein class by PANTHER (ranking by the first alphabet of the accession of 
proteins in the order of A-Z) 
Accession Name of the protein PANTHER Protein Class 
P07737 Profilin-1  non-motor actin binding_protin 
P37802 Transgelin-2 non-motor actin binding_protin 
P40121 Macrophage-capping protein non-motor actin binding_protin 
Q15691 Microtubule-associated protein 
RP/EB family member 1 
non-motor microtubule 
binding_protein 
Q16181 Septin-7 cytoskeletal protein 
Q9NYL9 Tropomodulin-3 actin or actin-binding cytoskeletal 
protein 
Q9Y266 Nuclear migration protein nudC  microtubule or microtubule-binding 
cytoskeletal protein 
Q9Y6W5 Wiskott-Aldrich syndrome protein 
family member 2  




Table 4.16 The 8/38 proteins that mapped into the pathways by PANTHER 
Accession Name of the protein PATHER protein class Mapped pathways 
P42224 Signal transducer and activator of transcription-1 
alpha/beta  
DNA-binding transcription factor EGF receptor signaling pathway 
PDGF signaling pathway 
JAK/STAT signaling pathway 
Ras Pathway 
Angiogenesis 
Interleukin signaling pathway 
Interferon-gamma signaling pathway 
Inflammation mediated by chemokine and cytokine signaling pathway 
p53 pathway feedback loops 2 
Oxidative stress response 
P07948 Tyrosine-protein kinase Lyn  - B cell activation 
Cadherin signaling pathway 
CCKR signaling map 
Parkinson disease 
P62258 14-3-3 protein epsilon  scaffold/adaptor protein EGF receptor signaling pathway 
FGF signaling pathway 
Parkinson disease 
P14618 Pyruvate kinase PKM  - Glycolysis 
Pyruvate metabolism 
P07737 Profilin-1  non-motor actin binding protein Cytoskeletal regulation by Rho GTPase 
P06733 Alpha-enolase  lyase Glycolysis 
P31939 Bifunctional purine biosynthesis protein PURH  hydrolase transferase De novo purine biosynthesis 
P40121 Macrophage-capping protein  non-motor actin binding protein FAS signaling pathway 
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In summary, the iTRAQ data showed that CD40 stimulation regulated a variety of biological 
processes in primary CLL cells by changing the protein expression at a global level. The 
results of the functional analysis of the iTRAQ data suggested that CD40 stimulation up-
regulated the expression of proteins involved in the cell adhesion in primary CLL cells, which 
can be supported by the functional analysis of the RNA-seq data. Therefore, the proteins in 
the cell-cell adhesion cluster became the candidates of the functional study for this project. 
 
4.5 Discussion 
The aim of this part of the study was to investigate the influence of CD40 stimulation 
induced by the soluble CD40 ligand method on gene expression at the translational level in 
primary CLL cells. Although the reliability of mass spectrometry is generally good, there are 
several issues that need to be pointed out when interpreting the data. 
Firstly, there were six primary CLL cases applied in this part of the study and this was 
actually the minimum number of cases required for meaningful analysis of the proteomics 
data. It was mainly due to the limited access to primary CLL samples available in large 
quantities for sufficient protein extraction. From the statistics point of view, a higher 
number of primary CLL cases will make the study more powerful. However, the acquisition 
of the iTRAQ-MS data including the preliminary tests, sample preparation, mass 
spectrometry processes, and data analysis already took 10 months of study. The loss of 
three protein samples resulting from a manufacturing problem with the iTRAQ reagent also 
reduces the confidence to draw any clear conclusion directly from these data, thus making 
the validation by independent method necessary for the selected candidates before 
conducting the further study.  
Secondly, the difficulty in maintaining the good viability of primary CLL cells cultured in vitro 
affected the analysis of the proteomics data. Although it was desirable to collect CLL cells in 
culture at multiple time points over a period of time in order to obtain dynamic information 
on protein expression influenced by the CD40 stimulation, it was impossible to keep the 
viability of primary CLL cells at a satisfactory level for longer than 24h in vitro. It was shown 
that the viabilities of the primary CLL cells from the six cases already decreased to an 
average of 43.1% (ranging from 25.79%-52.0%) after 24h in culture. In order to obtain a 
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relative better viability for the samples used for iTRAQ assays, the samples generated from 
primary cases were selected with the criteria that the initial viability should be over 70% and 
that the viability after incubation should be over 30%. Although the viability of several 
samples did not meet the criteria, the six cases used for iTRAQ assays were the optimum 
cases that exhibited acceptable viability compared to the cases excluded. Basing on the data 
obtained, 24h time point was thus chosen as the end of incubation with the soluble CD40 
ligand method. 
Finally, some proteins known to be up-regulated by CD40 stimulation were not identified by 
iTRAQ-MS in the data obtained in this study. The total number of proteins identified here 
was 5303 with 4093 of them being quantified for analysis. So far, the maximum number of 
identified proteins for primary CLL cells by mass spectrometry study has been 8694 with 
nearly 6000 of these proteins being relatively quantitated (Johnston et al., 2018). The 
proteins that have not been detected by iTRAQ-MS in this study include BCL-XL, MCL-1, BID, 
and CD95. The expression of BCL-XL (Q07817) has been known to be up-regulated by CD40 
stimulation in CLL cells (Vogler et al., 2009a, Kitada et al., 1999, Kater et al., 2004) and it has 
been used as a marker for the activation of the CD40 signalling pathway in CD40-stimulated 
CLL cells in this study. MCL-1 (Q07820) is a pro-survival member of the proteins belonging to 
the BCL-2 family and BID (P55957) is a pro-apoptotic BH3-only protein in the family as well. 
As described earlier, the expression of these two proteins can be upregulated by CD40 
stimulation (Kater et al., 2004, Kitada et al., 1999). The expression of the death receptor 
CD95 (also known as FAS, P25445), a member of the TNF-R superfamily, was also reported 
to be up-regulated by CD40 stimulation in CLL cells (Chu et al., 2002, Kater et al., 2004). The 
method used to detect the four proteins from the above studies was Western blotting. 
According to the published information, it was noticed that these four proteins were absent 
from the lists of identified proteins in the data obtained in this study. Several reasons can be 
possibly responsible for this outcome, which are explained below.  
1) Capturing proteins with low molecular weight and with a low abundance of expression is 
a recognised challenge for mass spectrometry (Penno et al., 2009, Rzagalinski and Volmer, 
2017). The smaller the molecular weight of a protein, the lower the number of peptides 
constituting this protein, which leads to less chance for this protein to be identified by MS-
based techniques. This may be one of the reasons for the loss of the protein BCL-XL and BID 
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in the data. Protein BCL-XL and BID are relatively small proteins according to their molecular 
weight (26.049kDa for BCL-XL and 21.995kDa for BID, provided by Uniprot). Using the 
theoretical digestion tools provided online by ExPASy (Swiss Institute of Bioinformatics), 20 
peptides can be digested from the protein BCL-XL using Trypsin but only 9 of the 20 peptides 
fall into the m/z range that can be identified by iTRAQ-MS with the m/z setting used in this 
study from 400 m/z to 1800 m/z. This further reduces the chance of BCL-XL to be caught by 
the iTRAQ-MS, which is similar to the situation for BID. Using the online tool, Protein Atlas, 
to check the abundance of the protein BCL-XL, MCL-1, BID, and CD95 in human tissue, it can 
be found that no detected expression level of these four proteins in the normal B cells in the 
blood. Although these proteins have been observed at a higher level in CLL cells, to what 
extent, the level of their expressions increases under the background of the tremendous 
number of proteins expressed in CLL cells is uncertain. 
2) Membrane proteins and the proteins located in specific organelles are difficult to be 
extracted depending on the protein extraction methods used for MS-based proteomics 
analysis. It has been reported that the identification of membrane proteins is a recognised 
challenge for mass spectrometer analysis due to their intrinsic feature that they consist of 
both hydrophilic and hydrophobic regions and that they are amphipathic to water (Santoni 
et al., 2000). Researchers have been trying to improve the methods to identify membrane 
proteins using mass spectrometers (Prados-Rosales et al., 2019), but, here in this study, 
there was no specific procedures performed to maintain the cell membrane-bound proteins 
as the aim was to investigate the effect of CD40 stimulation at a global protein expression 
level. This may be one reason for the loss of membrane-bound proteins such as the cell 
surface receptor protein CD95 (Peter et al., 2015, Hjalmar et al., 2002). BCL-XL, MCL-1, and 
BID are the mitochondrial membrane-associated proteins (Vander Heiden et al., 1997, Bae 
et al., 2000, Renshaw et al., 2004). Besides the hydrophobic features of the membrane-
bound proteins mentioned above, it should be noted that the proteins located in the 
organelles are relatively difficult to be extracted based on the extraction methods used for 
MS-based analysis, whereas a more rigorous extraction method was used for the Western 
blotting. The extraction of proteins used in MS-based analysis is short of the process of 
heating the samples at 95℃ in Laemmli sample buffer, which may reduce the chance of 
some organelle proteins to be detected by MS-based techniques. 
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3) The instability of proteins affects their chance to be caught by MS-based techniques 
(Goodwin, 2012). Unstable proteins may be lost during the process of the experiment due to 
their instability. The website ExPASy provides a method to automatically estimate the 
stability of proteins in vitro by calculating the instability index of proteins. ExPASy uses an 
instability index formula published by Kunchur Guruprasad and colleagues in 1990 
(Guruprasad et al., 1990). The authors compared the stable and unstable proteins and found 
that the dipeptides of the unstable proteins were significantly different from those of the 
stable proteins. Depending on the instability, they gave out weight values for each 
dipeptide, and the instability index is determined according to the dipeptides and their 
weight values of the protein to be studied. Using this method, the protein MCL-1 and BID 
are classified as unstable proteins, which may be another reason for their absence in the 
data present in this study.   
4) The intrinsic chemistry of the proteins affects the possibility of them being identified by 
MS-based techniques. The iTRAQ-MS analysis was performed in a positive ion mode and the 
peptides positively charged are easier to be detected. Taking the four proteins as an 
example, analysing the amino acid composition of these proteins using ExPASy, the 
information of the four proteins showed that the ratio of the positively charged residues to 
the negatively charged residues of BCL-XL, MCL-1, BID, and CD95 are 20:30, 41:47, 22:29, 
and 48:43, respectively. It can be found that the positively charged residues in the protein 
BCL-XL, MCL-1, and BID are less than the negatively charged residues, which indicates that 
the peptides of these proteins may not ionise as readily. The chemistry of the peptides will 
also affect how they behave during the two different chromatography separations. This may 
further reduce the possibility of these proteins to be detected based on the accumulating 
factors discussed above. 
These are some possible reasons for the missing proteins in the data present here. It is 
notable that some Western blotting detectable proteins, such as BCL-XL, are missing to be 
identified by MS-based techniques. Excepted for the different strengths of the protein 
extraction methods as mentioned above, the principles of these two methods should be 
responsible for the conflict phenomenon as well. Western blotting is used to detected 
individual protein targets. As long as using a good antibody, Western blotting can sensitively 
probe the target protein and disregard the others, improving the potential dynamic range of 
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detection. However, the aim of using the discovery MS-base technique is to capture all the 
protein expressed in samples by analysing the peptides generated from the hundreds and 
thousands of proteins. Under the background of the huge signals, the sensitivity to detect 
one protein is decreased. 
For this part of the study, all these issues were considered, and considerable effort was 
made to avoid bias affecting the data analysis. The iTRAQ-MS data reported here provide 
preliminary and interesting information about the influence on protein expression induced 
by CD40 stimulation in primary CLL cells. Although the functional analysis of the RNA-seq 
data provides support to the iTRAQ data, further study is needed to validate and confirm 
the findings reported in this study. 
Using mass spectrometry-based techniques, 158 and 552 differentially expressed proteins 
induced by CD40 stimulation were identified at 12h and 24h time points, respectively. The 
increase in the number of significantly differentially expressed proteins in this period 
suggests that the effect of CD40 stimulation on protein expression becomes greater as time 
passes by. Studies have reported that the influences on the expression of some known 
target proteins induced by CD40 stimulation changes over time (Scielzo et al., 2011, Girbl et 
al., 2013). The PANTHER classification analysis shows that the 552 differentially expressed 
proteins induced by CD40 stimulation exhibit a range of molecular functions that are 
involved in a variety of biological processes. Results obtained in this study are thus in line 
with the published reports, which increases the confidence for the further functional studies 
of those differentially expressed proteins.  
The NF-κB signalling pathway is involved in many essential biological processes of cells 
including cell survival, proliferation, and apoptosis. It is known that CD40 stimulation can 
induce strong activation of the NF-κB signalling pathway in primary CLL cells, through both 
canonical and non-canonical activation pathways (Gasparini et al., 2014, Mansouri et al., 
2016, Vallabhapurapu et al., 2008). The canonical pathway is mediated by the formation of 
RelA with p50 complex which translocates into the nucleus to activate the gene 
transcription of the downstream targets (Gasparini et al., 2014). p50 and its precursor p105 
are also called NF-κB1. The non-canonical pathway is mediated by the formation of RelB 
with p50 and p52, with both complexes of RelB with p50 and RelB with p52 then 
translocating into the nucleus for the activation (Gasparini et al., 2014). p52 and its 
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precursor p100 are also known as NF-κB2. In proteomics data, it has been shown that the 
NF-κB p105 subunit and the NF-κB p100 subunit are significantly up-regulated by CD40 
stimulation by over 2-fold for both proteins (2.47 and 2.11, respectively). Meanwhile, 
TRAF1, one of the members of TRAF family proteins mediating the activation of the 
canonical NF-κB signaling pathway (Xie et al., 2006, Bishop et al., 2007), is also on the list of 
the differentially expressed proteins and is up-regulated by CD40 stimulation with over 10-
fold increase as detected by iTRAQ-MS in this study. Also, a negative regulator of NF-κB 
signalling, TRAF family member-associated NF-κB activator (TANK) (Bonif et al., 2006), is 
significantly down-regulated by CD40 stimulation with a 1.5-fold decrease in expression. 
These data are consistent with the published results that CD40 stimulation activates the 
canonical and non-canonical activation of NF-κB signalling pathways.  
The tyrosine protein kinase LYN is up-regulated by CD40 stimulation in CLL cells after 24h 
incubation with a 2.2-fold increase in expression, as detected in this study. It is known that 
the BCR signalling pathway is chronically activated in CLL B cells (Packham and Stevenson, 
2010, Quiroga et al., 2009). The expression of LYN, a critical component of the BCR signalling 
network, is also abnormally overexpressed when compared with normal B cells (Contri et 
al., 2005). The expression level of LYN is inversely correlated with the treatment-free 
survival of CLL patients (Wang et al., 2013). It has also been reported that CD40 signalling 
and BCR signalling can crosstalk with each other. It has thus been shown that CD40 
stimulation up-regulates the expression of CD79b (one of the proximal components 
mediating BCR signalling pathways) and BCR on primary CLL cells (Minuzzo et al., 2005). 
Some pathways can be regulated by both CD40 signalling and BCR activation including 
phosphatidylinositol 3-kinase (PI3K) pathway, phospholipase C𝛾2 (PLC𝛾2), and NF-κB 
pathways (Ren et al., 1994, Amrein, 2011, Ten Hacken and Burger, 2014). Some targets 
modulated by BCR signaling can also be regulated by CD40 stimulation on primary CLL cells 
such as the B cell activating factor (BAFF), the proliferation-inducing ligand (APRIL), and their 
receptors (Ferrer et al., 2014). The data obtained in this study thus add further evidence 
that the crosstalk between CD40 signalling and BCR signalling pathways occurs in CD40-
stimulated CLL cells. 
The expression of CD5 has been known as one of the characteristics of CLL cells (Friedman 
et al., 2018). Comparing with the CLL cells from the peripheral blood of patients, the CLL 
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cells from the lymph nodes express a higher level of CD5 (Pasikowska et al., 2016). This 
suggests that the expression of CD5 is induced by the microenvironment factors in vivo. The 
data obtained here that CD40 stimulation increases the expression of CD5 by 2.46-fold 
suggests that the increase in CD5 expression in CLL cells from lymph nodes may be mediated 
by CD40 stimulation. Meanwhile, the expression of CD44 is also up-regulated by CD40 
stimulation at the 24h time point with a 2.36-fold in this study. The function of CD44 in CLL 
is still under investigation. It has two forms in CLL, the soluble form and the cell membrane-
bound form. Several studies have reported that the soluble form is upregulated by CD40 
stimulation from the microenvironment, which in turn helps the proliferation of CLL cells, 
and that the expression level of the protein is associated with the disease progression 
(Eisterer et al., 2004, Gutjahr et al., 2018). It has also been shown that the expression of the 
cell membrane-bound form of CD44 increased during the disease progression in a murine 
model of CLL and that its expression can be up-regulated by the signals from the CLL 
microenvironment including the CD40 plus IL-4 stimulation on primary CLL cells 
(Fedorchenko et al., 2013). In 2017, Yandong Shen and colleagues reported that CD40 
stimulation changed the expression of surface proteins depicting the immunophenotypes of 
CLL cells and that one of the proteins was CD97 that was found to be upregulated by CD40 
stimulation in the CLL cells from the patients with progressive disease (Shen et al., 2018b). 
Consistent with that, the data present here show that the expression of CD97 is upregulated 
by the CD40 ligand stimulation method with a 2.48-fold increase. Therefore, the proteomics 
data in this study have confirmed many previously published results. 
Furthermore, the proteomics data in this study also provide some interesting insight into 
the role of some proteins in the survival of CLL cells, which could be potentially promising 
targets for therapeutic intervention. Several heat shock proteins (HSP) (HSP90-beta, HSO90-
alpha, HSP105, and HSP70 protein 4) were at higher expression level CD40 stimulated 
primary CLL cells comparing with unstimulated cells. HSP inhibition has been introduced into 
the research of CLL ever since the beginning of the 21st century (Jones et al., 2004) but the 
mechanisms of how the inhibitors of the heat shock proteins work are still unclear.  
The role of HSP90 in CLL has been studied by many research groups. It has been reported 
that HSP90 functions as a part of the support network for the correct folding of proteins 
involved in the essential signal transduction including the signalling for cell survival and 
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proliferation (Neckers, 2002, Bruserud et al., 2006). A high-affinity conformation of Hsp90 
that is commonly found in cancerous but not in normal cells is a chaperone protein that 
interacts with client proteins to inhibit the degradation (Goetz et al., 2003, Kamal et al., 
2003). In CLL, it has been reported that the inhibition of Hsp90 abolished the NF-κB 
signalling and that Hsp90 inhibitors can inhibit the pro-survival signalling provided by the 
CLL microenvironment and induce apoptosis of CLL cells (Hertlein et al., 2010, Walsby et al., 
2012). Previous work from our laboratory has shown that Hsp90 inhibitors have promising 
therapeutic potential as they are effective in inducing apoptosis of CLL cells with 
dysfunctional p53 (Lin et al., 2008). It was found that geldanamycin, an HSP90 inhibitor, 
exhibited different effects on the wild-type p53 and mutated p53 and killed CLL cells 
through promoting the degradation of mutant p53 whilst upregulating the expression of 
wild-type p53 (Lin et al., 2008). Besides, it has been demonstrated that HSP90 inhibitors are 
cytotoxic to primary CLL cells regardless of the functional status of p53 in these cells (Lin et 
al., 2008, Best et al., 2010) and that HSP90 inhibitors can work synergistically with 
fludarabine by interfering with the DNA damage repair (Best et al., 2012, Kaufman et al., 
2015). In 2016, Timothy Chen and colleagues reported that the HSP90 inhibitor can activate 
p38 signalling and inhibit the phosphorylation of AKT/STAT3, which further interferes with 
the migration and survival of CLL cells (Chen et al., 2016). In addition, it was reported that 
inhibiting HSP90 led to the destabilization of several BCR kinases including LYN, spleen 
tyrosine kinase, Bruton tyrosine kinase, and AKT, and induced apoptosis in CLL cells with and 
without survival support from co-culture with stromal cells or soluble CD40 ligand plus IL-4 
(Guo et al., 2017). These data indicate that HSP90 may be involved in a variety of biological 
signalling processes. The proteomics data obtained in this study show that the expression of 
both HSP90-alpha and HSP90-beta is up-regulated by CD40 stimulation, linking the 
expression of HSP90 to CD40 activation, which provides a rationale for further investigation 
into the role of HSP90 in CD40 stimulation-mediated survival in CLL.  
The proteomics data present here also show that HSP70 is upregulated by CD40 stimulation 
in CLL cells. It has been reported that HSP70 was overexpressed in CLL cells and critical in 
the survival of CLL cells, and its expression was correlated to poor prognosis of the patients 
with CLL (Frezzato et al., 2019, Rosati et al., 2012). Altogether, the data obtained in this 
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study and that of others implicate an important role of HSPs in the survival of CLL cells 
mediated by the microenvironmental factors, which merits further investigation. 
According to the functional enrichment analysis by DAVID, the cluster with the highest 
enrichment score is the cell-cell adhesion, which is supported by the functional analysis of 
the RNA-seq data obtained previously in Chapter 3. Cell adhesion molecules are involved in 
the interaction between malignant cells and the surrounding cells/tissues (the 
microenvironment) and play an important role in cell differentiation, survival, proliferation, 
and migration (Makrilia et al., 2009, Farahani et al., 2014). Owing to the characteristics of 
CLL cells, CLL has been regarded as a good model for the investigation of the functional role 
of cell adhesion molecules in the disease progression (Burger, 2013, Burger and Gribben, 
2014). In 2015, by analyzing the differentially expressed proteins between UM-CLL and U-
CLL, we reported that the cell migration pathways in UM-CLL cells were defective compared 
to M-CLL cells and that UM-CLL cells expressed an increased level of adhesion molecules 
(Eagle et al., 2015). This suggests that UM-CLL cells are being preferentially retained in the 
lymph node microenvironment. The clinical correlation analysis confirms that patients with 
UM-CLL were twice likely to develop lymphadenopathy (Eagle et al., 2015), which explains, 
at least in part, why patients with UM-CLL have a poor clinical outcome. It is likely that many 
other molecules involved in cell migration and trafficking are also dysregulated in CLL cells. 
The improved understanding of the tumor microenvironment and the biological processes 
that cell adhesion molecules are involved in is starting to inform the strategy for developing 
novel cancer therapies (Klonisch et al., 2008, Floor et al., 2011). It has been demonstrated 
that the novel small molecular inhibitors, ibrutinib, and idelalisib, can disrupt the cell 
migration into lymph nodes and/or mobilize CLL cells from the microenvironment to re-
enter the circulation so to make leukemic cells susceptible to the cytotoxic agents (Tissino et 
al., 2018, Herman et al., 2015, Burger, 2012a). The antagonists of CXCR4 have been under 
intense investigation and some of them are currently undergoing clinical evaluation (Burger 
et al., 2005, Andritsos et al., 2010, Andritsos et al., 2019). These data indicate that agents 
targeting cell-cell adhesion and cell migration are promising strategies for the treatment of 
CLL patients. 
In vivo, CLL cells migrate between the peripheral blood, lymph nodes, bone marrow, and 
secondary lymphoid tissues. The trafficking and homing of CLL cells depend on the 
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interaction with different adhesion molecules and chemokines such as CXCR4/CXCL12, 
CXCR5/CXCL13, CCL3, CCL4, and CD49d (Nadkarni et al., 1998, Ramsay and Rodriguez‐Justo, 
2013, Burger and Gribben, 2014). It has been known that the cell adhesion molecules are 
differentially expressed on CLL cells localized in different tissue components in vivo (Han et 
al., 2014, Dürig et al., 2001). CLL cells from the peripheral blood of patients exhibit a higher 
level CXCR4 comparing with those from lymph nodes (Möhle et al., 1999, Barretina et al., 
2003, Pasikowska et al., 2016), which is consistent with the finding that the cell-cycle 
arrested, quiescent CLL cells express a higher level of CXCR4 and CXCR5 comparing with the 
proliferating CLL cells (Bennett et al., 2007). These early findings indicate a significant role of 
the microenvironment in regulating the expression of the cell adhesion molecules in CLL. 
CD40-CD154 interaction represents important crosstalk between CLL cells and T cells in the 
lymph nodes and evidence shows that it regulates the expression of molecules involved in 
cell migration and trafficking exists. It has been reported that together with IL-4, CD40 
stimulation up-regulates the expression of adhesion-related molecule CD38 as well as ZAP-
70 in CLL cells (Willimott et al., 2007).  
The proteomics data obtained here in this study provides evidence for the notion that the 
CD40-CD154 crosstalk between CLL cells and T cells within the microenvironment regulates 
the cell adhesion in CLL cells. Alpha-enolase is one of the 38 proteins in the cell-cell 
adhesion cluster. It is a tumor-derived antigen and its expression has been reported to be 
up-regulated in proliferating CLL cells in the lymph nodes and also associated with a shorter 
time to first treatment (Griggio et al., 2017). The iTRAQ-MS data showed that the expression 
of alpha-enolase was regulated by CD40 stimulation. 
The results of the classification of the 38 proteins in the cell-cell adhesion cluster show that 
15 of them have been classified into the binding category according to their molecular 
function (Table 4.15) and 8 proteins have been classified into cytoskeletal proteins (Table 
4.16), which indicates that CD40 stimulation may regulate the cell adhesion of CLL cells via 
changing the cytoskeletal proteins and binding capability. In the 38 proteins, 8 proteins can 
be mapped into pathways by PANTHER (Table 4.17). Tyrosine kinase LYN was classified into 
this cell-cell adhesion cluster and it was mapped into the pathways of B cell activation and 
cadherin signalling pathway. The role of BCR signalling in the cell migration of CLL cells has 
been studied by many researchers with conflicting findings (Packham and Stevenson, 2010). 
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The iTRAQ-MS data indicate that the crosstalk between CD40 stimulation and the BCR 
signalling pathway may also regulate cell adhesion collectively. For instance, signal 
transducer and activator of transcription-1 (STAT-1) alpha/beta and 14-3-3 protein epsilon 
were mapped into the EGF receptor signalling pathway that is involved in the growth, 
survival, proliferation, and differentiation of cells (Oda et al., 2005). STAT-1 alpha/beta was 
also mapped in the JAK/STAT signalling pathway in this study. One paper has demonstrated 
that targeting JAKs inhibited the CD40L/IL-21 induced proliferation in CLL cells (Slinger et al., 
2017).  
Based on its important role in CLL and the results of the iTRAQ-MS data, the proteins in the 
cell-cell adhesion cluster were taken as the candidates for further study. The protein, ATP-
dependent RNA helicase DDX3X (O00571), was mapped into the JAK/STAT signalling 
pathway and up-regulated by CD40 stimulation with a 2.89-fold increase (Table 4.14). 
However, the biological function of DDX3X in CLL has not been investigated, which will form 
the topic of the next chapter. 
In summary, the iTRAQ-MS analysis identified the differentially expressed proteins that 
were involved in a variety of biological activities in CD40-stimulated CLL cells. Further 
studies are required to uncover the specific mechanisms of the regulation of these 
differentially expressed proteins induced by CD40 stimulation and their functional 
significance in CLL. 
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Chapter 5. DDX3X potentially plays a role in the CD40 stimulation induced 
pro-survival signals in CLL cells 
 
5.1 Background 
As described in the previous chapter, according to the functional analysis of the 448 
significantly up-regulated proteins induced by CD40 stimulation on CLL cells, the top-scored 
category (with the highest enrichment score) on the DAVID functional annotation clusters 
list is the ‘cell-cell adhesion’ (Table 4.12 in Chapter 4). This category includes 38 proteins 
and the expression of sixteen out of the 38 proteins was upregulated by CD40 stimulation 
by over two folds compared to that in the unstimulated cells. The ATP-dependent RNA 
helicase DDX3X (O00571) is one of them with its expression up-regulated by CD40 
stimulation by 2.89 folds. 
DDX3X is a member of the DEAD (Asp-Glu-Ala-Asp)-box RNA helicases superfamily that 
present in almost all organisms and plays a crucial role in many biological processes (Li et al., 
2014). In humans, DDX3X has a homolog, DDX3Y, which shares a 92% protein sequence 
identity with DDX3X (Kim et al., 2001). However, DDX3X and DDX3Y show different functions 
in various organs (Kim et al., 2001). DDX3X is located on the X-chromosome and it is 
ubiquitously transcribed in all human tissues (Park et al., 1998).  
The biological functions of the protein DDX3X have so far not been extensively studied. In 
recent years, it has been shown that DDX3X may play a role in the biology of cancer. It was 
initially reported that the mRNA level of DDX3X increases by 64% of hepatocellular 
carcinoma (Huang et al., 2004). However, other research groups reported that levels of 
DDX3X expression decrease in most patients with liver cancer (50-73%), as detected by 
qPCR and immunohistochemistry, and that its expression has a positive association with the 
expression of p21 (Chao et al., 2006, Chang et al., 2006). The contradictory findings indicate 
a complex role DDX3X plays in different types of cancer. Later, DDX3X has been studied in 
breast cancer, lung cancer, gall bladder cancer, colorectal cancer. It has been shown that the 
increased expression level of DDX3X in breast cancer is correlated to poor survival (Bol et al., 
2013). Besides, several studies reported that the inhibitors of DDX3X induced apoptosis in 
breast cancer cell lines (Xie et al., 2015, van Voss et al., 2017, Van Voss et al., 2018). 
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Similarly, it has been reported that the overexpression of DDX3X correlates to aggressive 
lung cancer (Bol et al., 2015). The expression level of DDX3X is a promising biomarker that 
positively correlates with the WHO pathologic grading and poor survival outcome in human 
gliomas (Hueng et al., 2015). In a study of colon cancer, however, DDX3X shows a different 
role, as the level of its expression indicates a good prognosis for the survival of the patients 
(Su et al., 2015).  
In CLL, the gene DDX3X was reported to be one of the most mutated genes, with the 
mutations detected in 3% of the patients with the disease (Wang et al., 2011a). Similar 
results were also reported by another study that DDX3X is mutated in 2.4% of the patients 
with CLL (Puente et al., 2011). In 2015, DDX3X mutations were reported to be a recurrent 
event during the convergent evolution of CLL (Ojha et al., 2015a). The incidence of DDX3X 
mutation in IGHV-UM CLL was reported to be significantly higher than that of IGHV-M CLL 
(24% versus 3%, respectively); moreover, DDX3X mutation was found to be more common 
in the patients with the relapsed disease (17%) than those with stable disease (4%) (Ojha et 
al., 2015b). Importantly, CLL cells with DDX3X mutations have lost the expression of DDX3X 
protein (Ojha et al., 2015b), indicating that mutations can lead to the inactivation of the 
function of DDX3X. Taken together, the above results suggest that DDX3X functions as a 
tumour suppressor in CLL. DDX3X mutations have also been founded in the natural killer/T 
cell lymphoma (NK/T cell lymphoma) and were linked to poor prognosis (Jiang et al., 2015).  
Functional studies have shown that DDX3X is involved in the biological processes of cell 
survival, apoptosis, cell cycle, and proliferation (Chao et al., 2006, Lai et al., 2010, Sun et al., 
2013, Bol et al., 2015). In a study of breast cancer, DDX3X was reported to be localised in 
the mitochondria and an inhibitor of DDX3X can reduce the mitochondrial translocation 
which consequently leads to the decrease in the oxygen consumption rates and the 
intracellular ATP concentrations and the increase in reactive oxygen species (ROS) and 
finally induces apoptosis (Van Voss et al., 2018). It was also reported that, together with 
GSK3 and cIAP, DDX3X was involved in the formation of an anti-apoptotic protein complex 
that counterbalances the extrinsic apoptotic signalling cascade initiated by the activation of 
death receptors (Sun et al., 2008). Furthermore, it was reported that DDX3X can increase 
the expression level of the transcription factor SNAIL, leading to increased migration and 
metastasis of breast cancer cells and that knocking down DDX3X using shRNA decreased 
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proliferation and migration of breast cancer cells (Sun et al., 2011). In addition, DDX3X has 
been reported to regulate the DNA-damage-induced apoptosis by directly interacting with 
p53, resulting in the accumulation of p53 inside the cells (Sun et al., 2013). It was also 
reported that p53 was a direct transcriptional activator of DDX3X and that the inactivation 
of p53 down-regulated DDX3X, resulting in the increased cell proliferation of lung cancer 
cells (Wu et al., 2011). Inhibiting DDX3X also caused cell cycle arrest and apoptosis of lung 
cancer cells (Bol et al., 2015). However, in hepatocellular carcinoma, it was reported that 
increased expression of DDX3X led to the down-regulation in the expression of Cyclin D1 
and up-regulation in the level of p21, causing cell death and G1 phase cell cycle arrest of the 
hepatocellular carcinoma cells (Wang et al., 2018).  
Therefore, studies have indicated a complicated, yet not fully characterized, the role of 
DDX3X in many biological processes, which requires further study to clarify its functions in 
different types of cancer cells. The results generated from the proteomics study in this 
project, together with the background information described above, make DDX3X a suitable 
candidate for the functional study of its role in mediating CD40 stimulation induced pro-
survival signals in CLL cells. 
 
5.2 Hypothesis 




5.3.1 Cells and cell culture 
Thawed primary CLL cells were cultured in RPMI 1640 medium with 10% heat-inactivated 
FBS, 1%L-Glutamine, and 1% Penicillin/Streptomycin at a cell density of 4×106/ml.  
Human HG-3 and MEC1 cell lines were cultured in T-75 culture flasks with RPMI 1640 
medium with 10% FBS, 1%L-Glutamine, and 1% Penicillin/Streptomycin. The cells were 
passaged every 4-5 days. Before the experiment, HG-3 and MEC1 cells were cultured at a 




RK-33 (an inhibitor of DDX3X) was purchased from the Selleckchem (catalogue number 
S8246, Houston, USA) and, once received, dissolved at a stock concentration of 100mM in 
DMSO and kept at -20℃ in the aliquot size of 10µl. On the day of the experiment, RK-33 
stock was further diluted to the required concentrations in DMSO. 
FITC Annexin V was purchased from the BD Pharmingen (catalogue number 556420, BD 
Biosciences, Oxford, UK). Fluorescent viability dye 7-AAD was purchased from Invitrogen 
(catalogue number 2032240, Life Technologies, UK). The information about the antibodies 
used for Western blot within this chapter has been listed in Table 5.1. 
Table 5.1 Antibodies used for Western blot in Chapter 5 
Antibodies Company Catalogue No. Isotype 
DDX3X (D19B4) Rabbit mAb Cell Signalling #8192 Rabbit IgG 
BCL-XL Cell Signalling #2762 Rabbit 
TRAF2 (C192) Antibody Cell Signalling #4724 Rabbit 
Anti-rabbit IgG, HRP-linked Antibody Cell Signalling #7074 Anti-rabbit IgG 
Anti-mouse IgG, HRP-linked Antibody Cell Signalling #7076 Anti-mouse IgG 
 
The siRNA reagents were purchased from the Dhmarmacon (Horizon, Cambridge, UK) 
including the ON-TARGETplus Human DDX3X (1654) siRNA-SMARTpool (catalogue number L-
006874-02-0005), the ON-TARGETplus Non-targeting Pool (catalogue number D-001810-10-
05), the DhmarmaFECT 1 Transfection Reagent (catalogue number T-2001-02) and the 5× 
siRNA Buffer (catalogue number B-002000-UB-100). The ON-TARGETplus Human DDX3X 
(1654) siRNA-SMARTpool consists of 4 siRNA targets of DDX3X. The detailed information of 
the ON-TARGETplus Human DDX3X (1654) siRNA-SMARTpool and the ON-TARGETplus Non-
targeting Pool has been shown in Table 5.2. After being delivered, the ON-TARGETplus 
Human DDX3X (1654) siRNA-SMARTpool was resuspended in 1× siRNA Buffer (diluted from 
the 5× siRNA Buffer) according to the recommended protocol from the Dharmocaon 
Horizon. The resuspended siRNA-SMARTpool was aliquoted into smaller volumes and kept 





Table 5.2 Detailed information on the ON-TARGETplus Human DDX3X (1654) siRNA-
SMARTpool 
Name Target sequence 
ON-TARGETplus SMARTpool siRNA J-006874-06 CAGAUUUAGUGGAGGGUUU 
ON-TARGETplus SMARTpool siRNA J-006874-07 GCAACACUGGGAUUAAUUU 
ON-TARGETplus SMARTpool siRNA J-006874-08               GAUGCUGGCUCGUGAUUC 
ON-TARGETplus SMARTpool siRNA J-006874-18 GGUAUUAGCACCAACGAGA 
 
 







5.3.3 RK-33 treatment 
For experiments on primary CLL cells, thawed primary CLL cells were cultured at a cell 
density of 4×106/ml in the 24 or 6-well plates with 1ml per well and treated with RK-33 at a 
range of concentrations. After 24h, primary CLL cells were harvested for cell death assay by 
flow cytometry or cell number count using the trypan blue exclusion method. 
For the experiment on HG-3 and MEC1 cell lines, cells were cultured at a cell density of 
0.5×106/ml in the 24 or 6-well plates with 1ml per well and treated with RK-33 at a range of 
concentrations. After incubation for 24h, 48h, or 72h, cells were harvested separately at 
each time point for cell death assay by flow cytometry or cell number count using the trypan 
blue exclusion method. 
 
5.3.4 CD40 stimulation on HG-3 and MEC1 cell lines 
HG-3 or MEC1 cells were cultured at a cell density of 0.5×106/ml in the 6-well plates with 
5ml cell suspension in each well. For CD40 stimulation, cells were treated with 0.1μg/ml 
soluble HA-tagged CD40 ligand and 0.5μg/ml anti-HA antibody. As the unstimulated control, 
cells were treated with 0.5μg/ml anti-HA antibody. Cells were harvested after 12h or 24h 




5.3.5 Cell death assay 
For monitoring cell death in primary CLL cells or cell lines, the cell death assay by flow 
cytometry was used throughout the study. The detailed procedures of cell death assay have 
been described in section 2.3.2 of the Methodology Chapter. 
To monitor the number of viable cells, cell count was performed using the Cellometer 
following staining the cells with Trypan blue dye. In brief, at the end of incubation, 20μl of 
cells were collected from each sample and mixed with 20μl of 0.1% Trypan Blue solution 
(catalogue number T8154, Sigma-Aldrich, UK). Cells excluding Trypan blue dye from each 
sample were counted on the Cellometer.  
 
5.3.6 Western blot 
The processes of Western blot have been described in section 2.3.3 of the Methodology 
Chapter. Recommended by the manufacture, the HeLa cell line and K256 cell line were used 
as the positive control for the antibody of DDX3X.  
 
5.3.7 siRNA knockdown 
siRNA knockdown experiment was performed using HG-3 and MEC1 cell lines. Briefly, 2×105 
cells per well were plated in the 48-well plates. The siRNA and the siControl were diluted 
using the serum-free RPMI medium, respectively. The DharmaFECT transfection reagent was 
also diluted using the serum-free RPMI medium. The diluted reagents were incubated for 5 
minutes. Then, the diluted siRNA or the siControl were added into the diluted DharmaFECT 
transfection reagent with gently pipetting to mix well. The mixed reagents were incubated 
for another 20 minutes. The knocking down and control reagents were then loaded into the 
suspending cells in corresponding wells. The volume of each well was then topped with 
RPMI culture medium (with 10% heat-inactivated FBS, 1%L-Glutamine, and 1%, 
Penicillin/Streptomycin) to reach 1ml per well. The cells with knocking down reagents were 
kept in an incubator with the atmosphere containing 5% CO2 at 37℃. The workflow of the 
processes has been shown in Figure 5.1. 
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Figure 5.1 The workflow of siRNA knockdown experiment using the ON-TARGETplus 
SMARTpool siRNAs specific to DDX3X  
 
5.4 Results 
5.4.1 CD40 stimulation up-regulates the expression of DDX3X in primary CLL cells 
To validate data from the iTRAQ-MS analysis, the Western blotting method was used to 
examine the expression of DDX3X using the same CLL cases that were applied in the 
proteomics study. Due to the unavailability of one case, the other five primary CLL cases 
were used for validation. Primary CLL cells were incubated with and without the soluble 
CD40 ligand for 24h and the CD40 stimulated and unstimulated cells were then harvested 
for Western blotting analysis.  
Results of Western blotting showed that CD40 stimulation upregulated the expression of 
DDX3X in the primary CLL cells from five cases, individually (Figure 5.2). The pooled results 
showed that the up-regulated expression of DDX3X induced by CD40 stimulation was 
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statistically significant (p-value < 0.01) (Figure 5.2 B). Results of validation were consistent 
with the iTRAQ-MS data that CD40 stimulation increases the expression of DDX3X with the 
incubation for 24h.      
               
Figure 5.2 Validation of the iTRAQ data for the up-regulated expression of DDX3X induced 
by CD40 stimulation. For CD40 stimulation, cells were incubated with 0.1μg/ml HA-tagged 
CD40 ligand and 0.5μg/ml anti-HA antibody. For the unstimulated control, cells were 
incubated with 0.5μg/ml anti-HA antibody. After 24h, cells were collected for Western 
blotting. (A) Western blotting of DDX3X expression in primary CLL cells from 5 cases. Hela 
and K562 cells were used as positive controls for the antibody. (B) pooled densitometry 
analysis of DDX3X expression in 5 cases. The difference of the averaged DDX3X expression 
between the CD40 stimulated and unstimulated primary CLL cells is statistically significant 
with p-value < 0.01 (using the two-tailed, paired Student’s t-test). 
 
5.4.2 Inhibitor of DDX3X, RK-33, induces cell death in primary CLL cells 
After the validation, the investigation moved on to the role of DDX3X in the survival of CLL 
cells. For this purpose, a novel inhibitor of DDX3X, RK-33, was introduced in this part of the 
study. It has been reported that RK-33 can inhibit the expression of DDX3X and induce cell 
death in different types of cancer cells (Bol et al., 2015, van Voss et al., 2015, Xie et al., 
2016). By incubating CLL cells with RK-33 at a range of concentrations for 24h, the results 
showed that RK-33 induced cell death in the primary CLL cells from 4 primary cases 
individually in a concentration-dependent manner (Figure 5.3). Pooled data showed that RK-
33 induced cell death in primary CLL cells with the LC50 of 3.89µM (Figure 5.4). 
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Figure 5.3 Results of the cell death induced by RK-33 in individual primary CLL cases. 
Thawed primary CLL cells were cultured at a density of 4×106/ml and treated with RK-33 for 
24h. Then, cells were harvested for cell death assay using flow cytometry. Drug-induced cell 
death = [(% cell death of drug-treated cells - % cell death of untreated cells)/(100 - % cell 
death of untreated cells)] × 100. (A)-(D) results of RK-33 induced cell death for four 
individual CLL samples.  
                                                
Figure 5.4 Pooled results of the cell death induced by RK-33 in primary CLL cells. Results of 
analysing the data of RK-33 induced cell death generated by four primary CLL cases using 
GraphPad Prism 8 and the LC50 is calculated from this nonlinear statistical analysis. 
 
Meanwhile, to see whether RK-33 inhibited the expression of DDX3X, the expression of 
DDX3X in primary cells treated with RK-33 was monitored using Western blotting. No results 
for primary case #3375 because of the insufficient number of primary cells obtained. As 
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shown in Figure 5.5, the expression of DDX3X remained largely unaffected by the treatment 
of RK-33 till at the concentration of 10000nM (Figure 5.5 A and B). However, the 
corresponding expression of β actin decreased concurrently with the expression of DDX3X, 
which indicated that the decrease of DDX3X expression may be caused by the degradation 
of all the proteins in dead cells induced by RK-33.  
These results of RK-33 on primary CLL cells suggest that DDX3X protein may play a role in 
the survival of primary CLL cells. However, whether or not RK-33 induces cell death by 
interfering with the DDX3X expression in CLL cells is not clear. Due to the difficulty in 
maintaining the good viability of primary CLL cells in vitro, further functional studies were 
performed using two CLL cell lines, the HG-3 and MEC1 cells.                 
       
Figure 5.5 Level of DDX3X expression in primary CLL cells treated with RK-33. Thawed 
primary CLL cells were cultured at a cell density of 4×106/ml and treated with RK-33. CLL 
cells were harvested after 24h for Western blotting. (A) and (B) shows the expression of 
DDX3X in primary CLL cells from three primary CLL cases treated with indicated 
concentrations of RK-33.  
 
5.4.3 HG-3 cells and MEC1 cells express DDX3X 
To use the HG-3 cells and MEC1 cells for the functional study of DDX3X, it is necessary to 
investigate whether these two types of CLL cell lines express the protein DDX3X at a similar 
level to that of primary CLL cells, whether the soluble CD40 ligand can activate the CD40 
signalling pathway in these cells, and whether the DDX3X expression can be up-regulated by 
CD40 stimulation using the soluble CD40 ligand. Therefore, the expression of DDX3X and 
BCL-XL in HG-3 cells and MEC1 cells with and without CD40 stimulation for 12h and 24h, 
respectively, were investigated using western blot. Meanwhile, the expression of DDX3X in 
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the primary CLL cells from three cases was tested to make a comparison with that in HG-3 
cells and MEC1 cells.  
Results of Western blotting showed that the basal level of expression of DDX3X in HG-3 cells 
was similar to that in primary CLL cells (Figure 5.6). Under the same concentration of soluble 
CD40 ligand stimulation method, the expression of DDX3X in HG-3 cells was not visually up-
regulated by CD40 stimulation. Meanwhile, the expression of BCL-XL was mildly up-
regulated by CD40 stimulation in HG-3 cells.  
                              
Figure 5.6 The expression of DDX3X in HG-3 cells with or without CD40 stimulation. 
12h/24h sti: HG-3 cells were incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml 
anti-HA antibody for 12h/24h. 12h/24h unsti: HG-3 cells were incubated with 0.5μg/ml anti-
HA antibody for 12h/24h. In the end of the incubation, cells were collected for Western 
blotting. 
 
Similar results were also seen in MEC1 cells. MEC1 cells expressed DDX3X as well and its 
basal expression level was similar to that in primary CLL cells (Figure 5.7). The expression of 
DDX3X in MEC1 cells were not visually up-regulated by CD40 stimulation. The expression of 
BCL-XL in MEC1 cells was obviously up-regulated by CD40 stimulation. 
                             
Figure 5.7 The expression of DDX3X in MEC1 cells with or without CD40 stimulation. 
12h/24h sti: MEC1 cells were incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml 
anti-HA antibody for 12h/24h. 12h/24h unsti: MEC1 cells were incubated with 0.5μg/ml 





These results showed that both HG-3 and MEC1 cells expressed DDX3X similarly to that in 
primary CLL cells. The mildly up-regulated expression of BCL-XL indicated that HG-3 and 
MEC1 cells responded to CD40 stimulation using the soluble CD40 ligand method. However, 
the expression of DDX3X was not upregulated by soluble CD40 ligand with the same dosage 
used in primary CLL cells. This suggested that the dosage of soluble CD40 ligand method 
should be further optimized to obtain a more obvious effect of CD40 stimulation.  
 
5.4.4 RK-33 induces cell death in HG-3 and MEC1 cells 
To investigate the effect of RK-33 on HG-3 cells and MEC1 cells, cells were treated with RK-
33 at a range of concentrations (0µM, 0.1µM, 1µM, 10µM, 100µM). The cell death after RK-
33 treatment was monitored at three time points, 24h, 48h, and 72h.  
The results of three independent experiments have been shown in Figure 5.8. RK-33 
induced cell death in both HG-3 cells and MEC1 cells in a concentration-dependent manner, 
which is similar to that observed in primary CLL cells. There was no obvious difference in cell 
death across three time points (24h, 48h, and 72h). The LC50 was calculated using GraphPad 
prism 8.0. The LC50 remained largely unchanged across 24h, 48h, and 72h time points (Table 
5.3). Since HG-3 cells express wild type p53 whereas MEC1 cells do not (Ravikrishnan et al., 
2019, Carrà et al., 2017), the similar response pattern in both cell lines indicates that RK-33 
may induce cell death independently of the status of p53.                
 
Figure 5.8 Induction of cell death by RK-33 in HG-3 and MEC1 cells. (A) results of analysing 
the data of RK-33 induced cell death in HG-3 cells generated by three independent 
experiments using GraphPad Prism 8. (B) results of analysing the data of RK-33 induced cell 
death in MEC1 cells generated by three independent experiments using GraphPad Prism 8. 
The LC50 of RK-33 in HG-3 cells and MEC1 cells at each time is calculated from this nonlinear 
statistical analysis.  
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Table 5.3 LC50 of RK-33 in HG-3 and MEC1 cells at three time points 
 24h 48h 72h 
LC50 of HG-3 2.64µM 4.10µM 3.85µM 
LC50 of MEC1 3.44µM 4.44µM 4.69µM 
 
 
5.4.5 RK-33 inhibits the expression of DDX3X in HG-3 and MEC1 cells 
To figure out whether RK-33 affects the expression of DDX3X in HG-3 cells and MEC1 cells, 
the two types of cells were treated with 0μM, 1μM, 3μM, 10μM for 24h and harvested for 
the detection of DDX3X expression by Western blotting. As shown in Figure 5.9, the 
expression of DDX3X was inhibited by RK-33 at concentrations between 3μM and 10μM.  
           
Figure 5.9 DDX3X expression after RK-33 treatment in HG-3 and MEC1 cells. (A) Western 
blotting of DDX3X expression in HG-3 and MEC1 cells after 24h RK-33 treatment. (B) 
densitometry analysis of DDX3X expression from three independent experiments after RK-
33 treatment in HG-3 cells. The difference of the averaged DDX3X expression between the 
control cells and the cells treated with 10μM of RK-33 is statistically significant with the p-
value < 0.05. (C) densitometry analysis of DDX3X expression from three independent 
experiments after RK-33 treatment in MEC1 cells. The difference of the averaged DDX3X 
expression between the control cells and the cells treated with 10μM of RK-33 is statistically 
significant with the p-value < 0.05. Statistical significance was determined by the two-tailed, 





5.4.6 RK-33 has no effect on the proliferation of HG-3 and MEC1 cells 
To investigate whether RK-33 affects the proliferation of HG-3 or MEC1 cells, HG-3 cells and 
MEC1 cells were incubated with RK-33 under the cytotoxicity concentration and counted 
the absolute number of viable cells using Trypan blue dye at the end of incubation.  
The results showed that RK-33 did not affect the number of viable cells in both HG-3 cells 
and MEC1 cells with the concentrations of 0.1µM and 1µM which are all below the LC50 of 
RK-33 for both types of cells (Figure 5.10 and Figure 5.11). There seemed a decrease in the 
number of viable cells at 48h in results from HG-3 cells but the decrease was not statistically 
significant.  
Based on these results, RK-33 at the concentrations that do not induce a significant level of 
cell death does not affect the proliferation of HG-3 and MEC1 cells. 
                                     
Figure 5.10 Effect of RK-33 under the cytotoxic concentration on the proliferation of HG-3 
cells. HG-3 cells were cultured at a cell density of 0.5×106/ml and treated with RK-33 at the 
indicated concentrations. After incubation for 24h, 48h, or 72h, cells were harvested 
separately at each time point and the absolute number of viable cells that exclude Trypan 
blue dye of each sample was counted using the Cellometer. These results were generated 
by three independent experiments (mean ± SD). No statistical significance was achieved 
using a two-tailed, paired Student’s t-test. 
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Figure 5.11 Effects of RK-33 under the cytotoxic concentration on the proliferation of 
MEC1 cells. MEC1 cells were cultured at a cell density of 0.5×106/ml and treated with RK-33 
at the indicated concentrations. After incubation for 24h, 48h, or 72h, cells were harvested 
separately at each time point and the absolute number of viable cells that exclude Trypan 
blue dye of each correlated sample was counting using the Cellometer. These results were 
generated by three independent experiments (mean ± SD). No statistical significance was 
achieved using a two-tailed, paired Student’s t-test. 
 
5.4.7 RK-33 partially abrogates CD40 stimulation mediated protection against fludarabine-
induced cell death in CLL cells  
The data in Chapter 3 showed that CD40 stimulation protected primary CLL cells from drug-
induced cell death. To investigate whether DDX3X inhibitor can affect the CD40 stimulation 
induced cytoprotection, firstly, it was necessary to figure out whether CD40 stimulation can 
protect CLL cell lines from drug-induced cell death. The drug used in this part was 
fludarabine. Since fludarabine induces cell death in a p53-dependent manner (Pettitt, 2003), 
MEC1 cells that do not express wild type p53 are not appropriate for the fludarabine-
involved experiments (Stacchini et al., 1999). Therefore, fludarabine-involved experiments 
were only performed on HG-3 cells.  
To know the response-pattern of HG-3 cells to fludarabine, HG-3 cells were treated with 
fludarabine at the concentrations of 0.3μM, 1μM, 3μM, 10μM, 30μM and incubated for 24h, 
48h, and 72h. As shown in Figure 5.12, fludarabine induced cell death in HG-3 cells in a time- 
and concentration-dependent manner.  
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Figure 5.12 Fludarabine treatment on HG-3 cells. Cells were cultured at a cell density of 
0.5×106/ml and incubated with fludarabine at concentrations of 0.3μM, 1μM, 3μM, 10μM, 
30μM for 24h, 48h, and 72h. Cells were harvested separately at each time point for cell 
death assay using flow cytometry. Drug-induced cell death = [(% cell death of drug-treated 
cells - % cell death of untreated cells)/(100 - % cell death of untreated cells)] × 100. (A) 
pooled results of fludarabine induced cell death in HG-3 cells by three independent 
experiments (mean ± SD). 
 
Previously data in section 5.4.3 has shown that the expression of BCL-XL in HG-3 cells can be 
up-regulated by the soluble CD40 ligand and the up-regulation of the expression of BCL-XL 
was more obvious with the incubation of 24h comparing to that of 12h (Figure 5.6 A), which 
proved that HG-3 cells respond to CD40 stimulation. To determine whether CD40 
stimulation can protect HG-3 cells from fludarabine-induced cell death, HG-3 cells were 
incubated with and without the soluble CD40 ligand for 24h, respectively, and then the 
CD40 stimulated and the unstimulated HG-3 cells were treated with fludarabine with a 
range of concentrations for a further 48h. Cells were harvested at the end of incubation for 
cell death assay using flow cytometry.  
Results showed that CD40 stimulation protected HG-3 cells from fludarabine-induced cell 
death (Figure 5.13), a result consistent with what we have observed on primary CLL cells. 
The difference in cell death between the CD40 stimulated and unstimulated cells was 




                                       
Figure 5.13 Effect of CD40 stimulation on fludarabine-induced cell death in HG-3 cells. For 
CD40 stimulation, HG-3 cells were incubated with 0.1μg/ml HA-tagged CD40 ligand and 
0.5μg/ml anti-HA antibody for 24h. As unstimulated controls, HG-3 cells were treated with 
0.5μg/ml anti-HA antibody alone for 24h. Both the CD40 stimulated and unstimulated cells 
were treated with fludarabine for another 48h. *: p-value < 0.05 (using the two-tailed, 
paired Students’ t-test). 
 
In order to investigate whether RK-33 affects the cytoprotective effect of CD40 stimulation 
against fludarabine-induced cell death in HG-3 cells, HG-3 cells were treated in four ways as 
the following: HG-3 cells incubated with 0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-HA 
antibody and 3μM of RK-33 (CD40 sti+ RK-33+); HG-3 cells incubated with 0.5μg/ml anti-HA 
antibody and 3μM of RK-33 (CD40 sti- RK-33+); HG-3 cells incubated with 0.1μg/ml HA-
tagged CD40 ligand and 0.5μg/ml anti-HA antibody (CD40 sti+ RK-33-); HG-3 cells incubated 
with 0.5μg/ml anti-HA antibody (CD40 sti- RK-33-). The HG-3 cells in the former two types of 
treatments (with the treatment of RK-33) are taken as the observation group and the HG-3 
cells in the latter two types of treatments (without RK-33 treatment) are taken as the 
control group. After the incubation of 24h, cells from each group with different treatments 
were harvested for Western blotting and further fludarabine treatment, respectively. 
Western blotting was used to check the expression of BCL-XL to confirm the CD40 
stimulation in cells treated with the soluble CD40 ligand, and to check the expression level 
of DDX3X in CD40-stimulated cells. Cells harvested from each type of treatment for further 
fludarabine treatment were treated with 3μM of fludarabine for another 48h and finally 
collected for cell death assay in the end. The concentration of fludarabine at 3μM was used 
as the previous results showed that CD40 stimulation has exhibited a significantly 
cytoprotective effect in HG-3 cells treated with 3μM of fludarabine (Figure 5.13). 
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The first concentration of RK-33 used in this experiment was 3μM, which was based on the 
LC50 of RK-33 in HG-3 cells. After 24h incubation, CD40 stimulation was successfully 
established in the HG-3 cells both in the observation and control groups with the expression 
of BCL-XL up-regulated in the CD40 stimulated HG-3 in each group (Figure 5.14 A and B). The 
increased expression of BCL-XL induced by CD40 stimulation in the control group is 
statistically significant (p-value < 0.01) but that in the observation group is not.  
For the expression of DDX3X, comparing to that of the cells without RK-33 treatment, the 
expression of DDX3X in the cells treated with 3μM of RK-33 was inhibited (Figure 5.14 A and 
C). However, the corresponding expression of β actin in those cells declines at the same 
time. The results of DDX3X expression with 3µM of RK-33 presented here were different 
from that of the previous results on HG-3 cells (Figure 5.9). This can be explained by the 
poor viability after 24h incubation in the observation groups (Figure 5.14 D), in which 3μM 
of RK-33 induced fierce cell death in almost all of the cells and led to all proteins degraded in 
the dead cells. 
The results of cell death after 24h incubation showed that, for the cells incubated without 
RK-33, the viability of the CD40 stimulated HG-3 cells (76.92% ± 3.82) was higher than that 
of the unstimulated cells (71.97% ± 2.52), and the difference was statistically significant (p-
value < 0.05) (Figure 5.14 D, columns labelled with ‘-RK33 (3μM)’ on the left side). Similar 
results were seen for the cells incubated with RK-33. The viability of the CD40 stimulated 
HG-3 cells treated with 3μM of RK-33 (8.02% ± 0.78) was higher than that of the 
unstimulated cells treated with 3μM of RK-33 (3.76% ± 0.09), and the difference was 
statistically significant (p-value < 0.01) (Figure 5.14 D, columns labelled with ‘+RK33 (3μM)’ 
on the right side).  
However, due to the low viability in the HG-3 cells treated with 3μM of RK-33 as a result of 
its cytotoxic effect, cells treated with 3μM of RK-33 cannot be used for further treatment 
with fludarabine.  
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Figure 5.14 Results of the CD40 stimulated and unstimulated HG-3 cells treated with or 
without 3μM of RK-33. HG-3 cells were incubated with four different types of interferences: 
incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml anti-HA antibody (CD40 sti+ 
RK-33-), incubated with 0.5μg/ml anti-HA antibody (CD40 sti- RK-33-), incubated with 
0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-HA antibody and 3μM of RK-33 (CD40 sti+ 
RK-33+), incubated with 0.5μg/ml anti-HA antibody and 3μM of RK-33 (CD40 sti+ RK-33+). 
Cells from each type were harvested after 24h for Western blotting and cell death assay. (A) 
Western blotting of the expression of BCL-XL and DDX3X in HG-3 cells. (B) densitometry 
analysis of the BCL-XL expression. (C) densitometry analysis of the DDX3X expression. (D) 
the viability of the cells incubated with four types of interferences after 24h incubation. 
Results were generated from the data of three independent experiments (mean ± SD). 
Statistical significance was determined using the two-tailed, paired Students’ t-test. *: p-
value < 0.05; **: p-value < 0.01. 
 
To reduce the cell death induced by RK-33 for HG-3 cells in the observation group before 
further treatment of fludarabine, the concentration of RK-33 was reduced to 1μM with 
other conditions kept unchanged in the experiment.  
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Under this condition, the results of Western blotting after 24h incubation showed that the 
expression of BCL-XL in the CD40 stimulated HG-3 cells in both the control and the 
observation group was higher than that in the corresponding unstimulated HG-3 cells 
(Figure 5.15 A and B). The up-regulated expression of BCL-XL induced by CD40 stimulation in 
the cells incubated without 1μM of RK-33 was statistically significant (p-value < 0.05) but 
that in the cells incubated with 1μM of RK-33 was not (Figure 5.15 B). The decrease caused 
by 1μM of RK-33 in the up-regulated expression of BCL-XL induced by CD40 stimulation 
indicated that the effect of CD40 stimulation may be affected by 1μM of RK-33.  
However, no inhibition of the DDX3X expression in cells treated with 1μM of RK-33 was 
observed (Figure 5.15 A). In addition, although CD40 stimulation increased the expression of 
DDX3X in the cells incubated with and without 1μM of RK-33, no statistical significance was 














          
Figure 5.15 Results of the expression of BCL-XL and DDX3X in the CD40 stimulated and 
unstimulated HG-3 cells treated with or without 1μM of RK-33. The expression of BCL-XL 
and DDX3X were investigated in HG-3 cells with four different types of interferences: cells 
incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml anti-HA antibody, cells 
incubated with 0.5μg/ml anti-HA antibody, cells incubated with 0.1μg/ml HA-tagged CD40 
ligand, 0.5μg/ml anti-HA antibody and 1μM of RK-33, cells incubated with 0.5μg/ml anti-HA 
antibody and 1μM of RK-33. (A) western blotting results of the BCL-XL and DDX3X 
expression in HG-3 cells. (B) densitometry analysis results of the expression of BCL-XL. (C) 
densitometry analysis results of the expression of DDX3X. Results were generated from the 
data of three independent experiments (mean ± SD). Statistical significance was determined 
using the two-tailed, paired Students’ t-test. *: p-value < 0.05; **: p-value < 0.01. 
 
The results of viability after 24h incubation showed that the cytoprotective effect of CD40 
stimulation was reduced by the treatment of 1μM of RK-33 (Figure 5.16 A). In the absence 
of 1μM of RK-33, the viability of the CD40 stimulated HG-3 cells (69.96% ± 2.80) was 
significantly higher than that of the unstimulated HG-3 cells (66.23% ± 2.20) (p-value < 0.01). 
In the presence of 1μM of RK-33, the difference in viability between the CD40 stimulated 
and unstimulated HG-3 cells was not statistically significant (66.66% ± 2.15 for CD40 
stimulated cells and 63.98% ± 0.56 for unstimulated cells). 
Based on the above observations, the CD40 stimulated and unstimulated HG-3 cells in the 




After further fludarabine treatment, the results showed that the protection induced by 
CD40 stimulation against fludarabine-induced cell death was partially abolished by 1μM of 
RK-33 (Figure 5.16 B). Without the treatment of 1μM of RK-33, the cell death of the CD40 
stimulated HG-3 cells treated with fludarabine was significantly lower (45.27% ± 0.73) than 
that of the unstimulated cells (55.80% ± 2.08) (p-value < 0.05). However, with the treatment 
of 1μM of RK-33, fludarabine-induced cell death of CD40 stimulated HG-3 cells (47.98% ± 
1.74) was similar to that in the unstimulated HG-3 cells (49.19% ± 0.83). 
        
Figure 5.16 RK-33 (1μM) affects the survival protection induced by CD40 stimulation in 
HG-3 cells. (A) 24h results of viabilities of the cells incubated with 0.5μg/ml anti-HA 
antibody, the cells incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml anti-HA 
antibody, the cells incubated with 0.5μg/ml anti-HA antibody and 1μM of RK-33, the cells 
incubated with 0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-HA antibody and 1μM of RK-
33. (B) cell death of the above cells treated with fludarabine for a further 48h. Results were 
generated from the data of three independent experiments (mean ± SD). Statistical 
significance was analysing using the two-tailed, paired Student’s t-test. *: p-value < 0.05; **: 
p-value < 0.01. 
 
The above experiment was then performed on primary CLL cells. The concentration of RK-33 
applied was 1μM and the concentration of fludarabine applied was 3μM. The procedure 
was the same as that performed on HG-3 cells.  
After 24h, the status of CD40 stimulation was confirmed by the up-regulation of the 
expression of BCL-XL in the primary CLL cells from three CLL cases (Figure 5.17 A and B). The 
treatment of 1μM of RK-33 made no difference in the increased expression of BCL-XL 
induced by CD40 stimulation in primary CLL cells (Figure 5.17 A, B, C). Similar to the results 
of HG-3 cells, 1μM of RK-33 did not inhibit the expression of DDX3X in these primary CLL 
cells and had no effect on the up-regulated expression of DDX3X (Figure 5.17 A, B, D, E; 
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Figure E was further normalized from Figure D with the up-regulation of DDX3X being 
normalized to be visualized more clearly). 
                 
Figure 5.17 Results of the expression of BCL-XL and DDX3X in the CD40 stimulated and 
unstimulated primary CLL cells treated with or without 1μM of RK-33. The expression of 
BCL-XL and DDX3X were investigated in the primary CLL cells of each case with four different 
types of interferences: cells incubated with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml 
anti-HA antibody (CD40 sti+ RK-33-), cells incubated with 0.5μg/ml anti-HA antibody (CD40 
sti- RK-33-), cells incubated with 0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-HA 
antibody and 1μM of RK-33 (CD40 sti+ RK-33+), cells incubated with 0.5μg/ml anti-HA 
antibody and 1μM of RK-33 (CD40 sti+ RK-33+). Cells from each type were harvested after 
the incubation of 24h for Western blotting. (A) and (B) Western blotting of the BCL-XL and 
DDX3X expression in primary CLL cells from three cases. (C) and (D) densitometry analysis of 
BCL-XL and DDX3X expression. (E) normalized up-regulated DDX3X expression. Statistical 
significance was analysing using the two-tailed, paired Student’s t-test. *: p-value < 0.05.
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The results of viability after 24h incubation showed that the treatment with 1µM of RK-33 
made no difference in the cytoprotective effect induced by CD40 stimulation in primary CLL 
cells based on the results of cells from individual cases and the pooled results (Figure 5.18).  
      
Figure 5.18 Viability of the CD40 stimulated and unstimulated CLL cells with or without 
incubation with RK-33(1μM) for 24h. Viabilities were detected in cells incubated with 
0.5μg/ml anti-HA antibody for 24h, cells incubated with 0.1μg/ml HA-tagged CD40 ligand 
and 0.5μg/ml anti-HA antibody for 24h, cells incubated with 0.5μg/ml anti-HA antibody and 
1μM of RK-33 for 24h, cells incubated with 0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-
HA antibody and 1μM of RK-33 for 24h. (A), (B), (C) are results of individual cases. (D) pooled 
results of three cases (mean ± SD). No statistically significant difference was observed 
between the CD40 stimulated and the unstimulated primary CLL cells neither with nor 
without the treatment of 1μM of RK-33. 
 
Then, the CD40 stimulated and unstimulated primary CLL cells treated with or without 1μM 
of RK-33 were further treated with 3μM of fludarabine for another 48h. Results of the 
primary CLL cells from case #3411 and #3587 showed that the cytoprotective effect induced 
by CD40 stimulation against the fludarabine-induced cell death was partially reduced by 
1μM of RK-33 (Figure 5.19 A and B). However, the results of case #3605 showed that 1μM of 
RK-33 made no influence on the cytoprotective effect (Figure 5.19 C). Despite the variation, 
the pooled results showed that the statistically significant decrease of fludarabine-induced 
cell death caused by CD40 stimulation was negated by 1μM of RK-33 (Figure 5.19 D).  
180 
 
These results suggest that RK-33 partially abrogated the cytoprotective effect induced by 
CD40 stimulation against fludarabine-induced cell death in primary CLL cells, but there may 
be a variation in primary CLL cells from different cases.  
    
Figure 5.19 Effect of RK-33 on fludarabine-induced cell death in the CD40 stimulated and 
unstimulated CLL cells. Cell death was detected in: cells incubated with 0.5μg/ml anti-HA 
antibody for 24h and incubated with 3μM of fludarabine for another 48h, cells incubated 
with 0.1μg/ml HA-tagged CD40 ligand and 0.5μg/ml anti-HA antibody for 24h and incubated 
with 3μM of fludarabine for another 48h, cells incubated with 0.5μg/ml anti-HA antibody 
and 1μM of RK-33 for 24h and incubated with 3μM of fludarabine for another 48h, cells 
incubated with 0.1μg/ml HA-tagged CD40 ligand, 0.5μg/ml anti-HA antibody and 1μM of RK-
33 for 24h and incubated with 3μM of fludarabine for another 48h. (A), (B), (C) are results of 
individual cases. (D) pooled results of three cases (mean ± SD). The difference between the 
CD40 stimulated and the unstimulated primary CLL cells without the treatment of 1μM of 
RK-33 is statistically significant (p-value < 0.01, using the two-tailed, paired Student’s test).  
 
Collectively, the data on both primary CLL cells and CLL cell lines showed that the DDX3X 
inhibitor, RK-33, induced cell death on CLL cells and partially abrogated the survival 
protection induced by CD40 stimulation against fludarabine-induced cell death, which 
indicates that DDX3X may potentially play a role in the survival of CLL cells and may be 
involved in mediating the CD40 stimulation induced pro-survival signals. Based on these 
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Western blot results, the expression of DDX3X was not inhibited obviously by RK-33 of 1µM 
in both primary CLL cells and HG-3 cells, which led to the question whether RK-33 induced 
cell death in CLL cells by inhibiting the expression of DDX3X protein. To answer this 
question, the siRNAs knockdown experiments were performed using CLL cell lines to 
investigate whether inhibiting the expression of DDX3X affected the survival of CLL cells. 
 
5.4.8 The effect of DDX3X knockdown by siRNAs on HG-3 and MEC1 cells  
The knockdown experiments were performed using siRNAs specific to DDX3X on HG-3 cells 
and MEC1 cells. Non-specific targeting siRNA was used as a control. Non-transfected cells 
(referred to as the ‘wild type’ cells) were also included in each knockdown experiment. Cell 
death was monitored at the end of treatment by flow cytometry.  
Results from HG-3 cells showed that, comparing with that in the siControl cells, knocking 
down DDX3X in HG-3 cells led to no statistically significant increase in cell death (Figure 
5.20).  
      
Figure 5.20 Effect of knocking down DDX3X in HG-3 cells. HG-3 cells were transfected with 
the SMARTpool siRNAs of DDX3X at 100nM and incubated for 48h. As a control, HG-3 cells 
were transfected with the SMARTpool control siRNA at 100nM for 48h. Untransfected cells 
were used for comparison. (A) Western blotting of the DDX3X expression in HG-3 cells. (B) 
effect of knocking down DDX3X on cell death as measured by flow cytometry using Annexin 
V and 7-AAD. The difference in cell death between the DDX3X knocking down cells and the 
siControl cells was not statistical significance. 
 
Similar results were found in MEC1 cells that knocking down DDX3X using siRNAs in MEC1 
cells caused no statistically significant increase in cell death (Figure 5.21).  
182 
 
          
Figure 5.21 Effect of knocking down DDX3X in MEC1 cells. MEC1 cells were transfected 
with the SMARTpool siRNAs of DDX3X at 100nM and incubated for 48h. As a control, cells 
were also transfected with the SMARTpool control siRNA at 100nM for 48h. Untransfected 
cells were also used in the experiments for comparison. (A) Western blotting results of 
DDX3X expression in MEC1 cells. (B) Effect of DDX3X siRNAs on cell death as measured by 
flow cytometry using Annexin V and 7-AAD. The difference in cell death between the DDX3X 
knocking down cells and the siControl cells was not statistical significance. 
 
Based on the above results that the increases in cell death caused by knocking down DDX3X 
in HG-3 and MEC1 cells were not statistically significant, no definitive conclusion can be 
drawn that inhibiting the expression of DDX3X affects the survival of CLL cells. The 
optimization of DDX3X knockdown has continued till the sudden outbreak of the COVID-19 
pandemic that caused the cessation of the knockdown experiments.  
 
In summary, DDX3X appears to play a role in the pro-survival effects mediated by CD40 
stimulation on CLL cells. The function of DDX3X may vary across different primary CLL cases. 
DDX3X inhibitor RK-33 induced apoptosis on both HG-3 cells and MEC1 cells, indicating that 
RK-33-induced cell death does not involve p53. 
 
5.5 Discussion 
The functional results from the preliminary study suggest that DDX3X is an interesting 
molecule to study in the context of CD40 stimulation-mediated survival in CLL cells.  
The results showed that the inhibitor of DDX3X, RK-33, induces cell death of both primary 
CLL cells (LC50=3.89μM at 24h) and two types of CLL cell lines (HG-3 cells: LC50=2.64μM at 
24h, 4.1μM at 48h, 3.85μM at 72h, respectively; MEC1 cells: LC50=3.44μM at 24h, 4.44μM at 
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48h, 4.69μM at 72h, respectively) with similar LC50s for each type of cells. These results are 
in line with published reports of RK-33 on other types of cancer cells. As a specific inhibitor 
of DDX3X, RK-33 inhibits the viability of several lung cancer cell lines highly expressing 
DDX3X with LC50 between 4.4 and 8.4μM (Bol et al., 2015). RK-33 shows cytotoxicity on 
colorectal cancer cell lines with LC50 ranging from 3μM to 7μM, and at the same time, it also 
inhibits the survival of patient-derived colorectal cancer spheroid cell lines with LC50 ranging 
from 3μM to 9μM (van Voss et al., 2015). For breast cancer, RK-33 induces cell death of 
breast cancer cell lines with LC50 between 2.8 and 4.5μM (Van Voss et al., 2018). The LC50 of 
RK-33 on medulloblastoma cell lines ranges from 2.5μM to 3.5μM (Tantravedi et al., 2019). 
Results also showed that RK-33 partially abrogated the cytoprotective effect induced by 
CD40 stimulation against fludarabine-induced cell death in both HG-3 cells and primary CLL 
cells from two cases but RK-33 made no difference on the primary CLL cells from case 
#3605. It may suggest a variation of RK-33 on primary CLL cells from different cases, which is 
in line with other reports. It has been reported that the expression level of DDX3X on 
different types of cells affects their sensitivity to RK-33 (Van Voss et al., 2018, Xie et al., 
2016, Bol et al., 2015). Due to the fact that CLL is a highly heterogeneous disease, it is 
possible that the expression level of DDX3X protein is different in individual patients. In 
addition to the heterogeneous expression status of DDX3X, the mutation status may also 
influence the sensitivity of RK-33 in primary CLL cell and the occurrence of DDX3X mutation 
has been reported in various type of diseases (Kellaris et al., 2018, Jiang et al., 2015, Pugh et 
al., 2012) including CLL. It was reported that nine genes were mutated at significant 
frequencies including five genes with unestablished roles in CLL and that one of them was 
DDX3X (Wang et al., 2011a). Later in 2015, DDX3X mutation was identified by analysing 
peripheral blood samples from 136 patients with CLL (Vollbrecht et al., 2015). Furthermore, 
it has been reported by Juhi Ojha and colleagues that DDX3X mutations were associated 
with the progression of CLL and play a role in the convergent evolution of CLL (Ojha et al., 
2015a, Ojha et al., 2015b). These findings indicate DDX3X expression varies across different 
patients and even in the same patient in different stages of CLL, which may be the reason 
for the variation of the sensitivity to RK-33 among the primary CLL cells from different cases. 
Although some interesting results with RK-33 were obtained in this part of study, it is clear 
that these results are not enough to generate strong conclusions for the role of DDX3X in 
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the pro-survival effect induced by CD40 stimulation due to undefined mechanism of RK-33 
and unsatisfied DDX3X knocking results based on the results present here in this part. For 
the function of RK-33 on inhibiting DDX3X protein, it has been reported that RK-33 induces 
cell death and decreases the expression of DDX3X protein on lung cancer cells (Bol et al., 
2015) and medulloblastoma cells (Tantravedi et al., 2019). Guus M Bol and colleagues 
reported that  50nM of RK-33 can specifically inhibit the expression of DDX3X by reducing 
the unwinding activity of the homolog of DDX3X in yeast (Bol et al., 2015). However, results 
in this study did not show a clear inhibition of DDX3X expression by RK-33 in primary CLL 
cells when it induced cell death in these cells. In primary CLL cells, the expression of DDX3X 
in cells treated with 10µM of RK-33 decreased but the correlated expression of β-actin 
decreased at the same time, which suggested that this decrease was likely caused by the cell 
death induced by RK-33 with all the proteins degraded. Results on the effect of RK-33 from 
HG-3 and MEC1 cells showed that RK-33 inhibited the expression of DDX3X in these cells 
gradually with the increasing concentrations and there were clear declines in the DDX3X 
expression in the cells treated by 3µM and 10 µM of RK-33 with the correlated β-actin 
expression unaffected. However, in the later experiments in HG-3 cells, the expression of 
DDX3X was inhibited by 3µM of RK-33 with the decreased expression of β-actin 
simultaneously. Based on these contradictory results, it is inconclusive to say that RK-33 
induces cell death by inhibiting the expression of DDX3X in HG-3 cells. Together with the 
results obtained from primary CLL cells, although RK-33 induced cell death in CLL cells, the 
data in this part of study did not clarify the mechanism underlying RK-33-induced cell death. 
Furthermore, results from the siRNAs knockdown experiments did not provide clear 
evidence for the role of DDX3X in the survival of CLL cells as well.  
In conclusion, the results obtained from this preliminary study indicate that DDX3X protein 
may be potentially involved in the CD40 stimulation-induced cytoprotective effect against 
fludarabine-induced cell death. However, further study is required to underpin the specific 







Chapter 6. General discussion 
 
This study aimed to investigate the molecular mechanisms of the pro-survival effect induced 
by CD40 stimulation in primary CLL cells using the proteomic approach. The hypothesis of 
the study was that CD40 stimulation altered the protein expression at a global level, 
resulting in the survival and drug resistance of CLL cells. The first part of this study 
confirmed that CD40 stimulation induced by co-culture method exhibited cytoprotective 
effect in primary CLL cells. The comparison between the gene expression profile of CLL cells 
stimulated by the soluble CD40 ligand and that induced by the co-culture method showed 
that the soluble CD40 ligand method produced similar changes in the gene expression in 
primary CLL cells to that induced by the co-culture method. This finding validated the use of 
the soluble CD40 ligand in proteomics study to investigate the global changes in protein 
expression induced by CD40 stimulation in primary CLL cells. Using the iTRAQ-MS technique, 
the differentially expressed proteins induced by CD40 stimulation in primary CLL cells were 
identified. Based on the iTRAQ data obtained, the functional annotation analysis and the 
further functional study was aimed at figuring out the key molecules/pathways that 
mediated the cytoprotective effect of CD40 stimulation based on the iTRAQ data. Here in 
this part, the discussion will be focused on the main findings from this research project. 
 
6.1 Independent confirmation of the pro-survival effect induced by the CD40 stimulation 
in primary CLL cells 
Using the co-culture system for CD40 stimulation, the results confirmed that CD40 
stimulation protected primary CLL cells from spontaneous and drug-induced cell death. The 
drugs used in this part of the study include fludarabine, ABT-199, and bendamustine, which 
are currently used in the CLL clinic. The results of the treatment experiment with each drug 
were generated from at least 3 primary CLL samples.  
With the variation across different samples, the pooled results of fludarabine, ABT-199, and 
bendamustine showed that CD40 stimulated primary CLL cells exhibited a decreased 
sensitivity to those drugs comparing with the unstimulated primary CLL cells. These results 
are consistent with most published papers (Kater et al., 2004, Thijssen et al., 2013) including 
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those reported by our research group (Chapman et al., 2017, Zhuang et al., 2014). These 
results support the notion that the signals from the CLL microenvironment promote the 
survival and drug resistance of CLL cells (Burger, 2013). Although there are instances where 
these results contradict the reported finding, the discrepancy of the results was possibly 
caused by the different methods used in the studies. Taking the paper published by De 
Totero and colleagues in 2003 as an example, they reported that CD40 stimulation 
sensitized CLL cells to fludarabine treatment by using the CLL cells cultured under standard 
conditions as the control cells and using the ratio of 1:100 for the CD40-expressing 
fibroblasts and primary CLL cells in the co-culture system (De Totero et al., 2003), which are 
different from the experiments conducted in this study. Here in this study, the cells taken as 
the control were the primary CLL cells co-cultured with the parental fibroblasts that were 
not expressing CD154, which was more comparable as both sets of primary CLL cells were 
kept at the same co-culture condition. Besides, the ratio used for the CD40-expressing 
fibroblasts and primary CLL cells in the co-culture system in this study was 1:10.  
The independent confirmation of the predominantly pro-survival effects caused by the CD40 
stimulation in primary CLL cells is the foundation of this study. 
 
6.2 The soluble CD40 ligand method can mimic the CD40-CD154 crosstalk within the lymph 
nodes as the co-culture method 
The co-culture method was not appropriate for the proteomics study in this project due to 
the inevitable mixture of fibroblasts when harvesting the primary CLL cells from the co-
culture system. It was thus replaced by the soluble CD40 ligand method to be used for the 
proteomics study. Although using the soluble CD40 ligand method to activate the CD40 
signalling pathways in CLL cells has been well documented (Smallwood et al., 2016, Lezina et 
al., 2018), whether the effect induced by CD40 activation in primary CLL cells via the co-
culture system versus the soluble CD40 ligand is comparable has not been examined 
previously. To obtain a degree of certainty in the comparability of the two stimulation 
methods before using the soluble CD40 ligand method for the proteomics study was 
necessary. The mRNA expression data of the CD40-stimulated primary CLL cells using the co-
culture method (Pascutti et al., 2013) provided the reference to compare the effect induced 
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by the two methods at the transcriptional level. Therefore, the gene expression study in CLL 
cells stimulated with the soluble CD40 ligand was performed using the RNA sequencing 
technology. 
The results of the comparison analysis showed that the changes in gene expression at the 
transcriptional level induced by the soluble CD40 ligand in primary CLL cells were similar to 
that induced by the co-culture system. Furthermore, using the published gene expression 
profile of CLL cells isolated from the microenvironment of CLL as a comparator (Herishanu et 
al., 2011), the data analysis showed that the gene expression profile of primary CLL cells 
treated with the soluble CD40 ligand resembled that of CLL cells residing in the lymph 
nodes. These results suggested that the soluble CD40 ligand was effective in activating the 
CD40 signalling pathway in CLL cells in a similar fashion to the co-culture system, which 
provided the confidence to use it in the proteomics study. In addition, the functional 
analysis of these RNA-seq data provided support for the results of iTRAQ-MS data. The 
consistent finding at both the protein expression level and the transcriptional level for the 
CD40 stimulation-induced effect on primary CLL cells increased the stringency of this study.  
 
6.3 CD40 stimulation up-regulates the expression of proteins involved in the cell adhesion 
of primary CLL cells 
The results of the iTRAQ-MS analysis showed that CD40 stimulation induced a significant 
change in the levels of protein expression in primary CLL cells. There were 552 significantly 
differentially expressed proteins detected between the CD40 stimulated and unstimulated 
primary CLL cells at the 24h time point with 448 of them up-regulated and 104 down-
regulated. Based on the results of the PANTHER classification analysis, these differentially 
expressed proteins were involved in various biological processes with different functions. 
The DAVID functional annotation analysis of the iTRAQ-MS data was supported by that of 
the RNA-seq data with most of the categories mapped by the differentially expressed 
proteins presenting of the lists of categories mapped by the differentially expressed genes 
of the RNA-seq data. According to the DAVID functional annotation analysis of the 448 
significantly up-regulated proteins, the category with the highest enrichment score on the 
DAVID functional annotation clusters list was the cell-cell adhesion that ranked on the top of 
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the list of the up-regulated RNA-seq data. These results suggest that CD40 stimulation up-
regulates the expression of the proteins involved in the cell adhesion in CLL cells.   
Based on the results of the functional annotation analysis of the iTRAQ-MS data and the 
important role of cell adhesion in CLL, the cell-cell adhesion was taken as the focus of the 
functional study. The aim was to find a novel target mediating the pro-survival effect of 
CD40 stimulation in the cell-cell adhesion categories. Looking into the proteins in this 
category, DDX3X was chosen for further validation and functional study. 
 
6.4 DDX3X may play a role in the pro-survival signals induced by CD40 stimulation in CLL 
cells 
The protein ATP-dependent RNA helicase DDX3X is one of the 38 proteins in the category of 
cell-cell adhesion and it was up-regulated by CD40 stimulation by over two folds compared 
to that in the unstimulated cells. The result of Western blotting validated the iTRAQ-MS 
results that CD40 stimulation induced by the soluble CD40 ligand up-regulated the 
expression of DDX3X in primary CLL cells from the same five primary CLL samples used in the 
proteomic study.  
To study its role in the survival of primary CLL cells, a selective inhibitor of DDX3X, RK-33, 
was used in the experiments and found that RK-33 induced cell death in primary CLL cells in 
a concentration-dependent manner. Due to the difficulty in maintaining the good viability of 
primary CLL cells in vitro, two CLL cell lines, HG-3 and MEC1, was used in the subsequent 
experiments. CD40 stimulation induced by the soluble CD40 ligand can up-regulate the 
expression of DDX3X and BCL-XL in both cell lines, a result that was observed in primary CLL 
cells. Results from the CLL cell lines showed that RK-33 induced cell death in HG-3 and MEC1 
cells in a dose-dependent manner, similar to that in primary CLL cells. Furthermore, it was 
found that RK-33 can partially abrogate the CD40 stimulation mediated protection against 
fludarabine-induced cell death in HG-3 cells. Similar results can be observed in the primary 
CLL cells from two primary CLL samples, but the results of the primary CLL cells from the 
other primary sample showed that RK-33 made no change in the CD40 stimulation mediated 
protection against fludarabine-induced cell death. Although the pooled results of the 
primary CLL cells from three primary samples showed that RK-33 partially abrogates the 
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CD40 stimulation mediated protection against fludarabine-induced cell death, the results 
from individual cases showed a variation across primary CLL samples.  
These results suggest that DDX3X may play a role in the survival of CLL cells and that DDX3X 
could be potentially involved in the pro-survival signals induced by CD40 stimulation in CLL 
cells. However, with the inconclusive results from experiments to knockdown DDX3X in HG-
3 and MEC1 cells, definitive conclusions cannot be generated based on these preliminary 
results.  
 
6.5 Future work 
Cell adhesion is a hot topic in cancer research as molecules in this category are involved in 
the differentiation, proliferation, migration, metastasis, and chemo-resistance of malignant 
cells (Farahani et al., 2014, Makrilia et al., 2009, Damiano et al., 1999). Cell adhesion is 
important in the pathogenesis and disease progression of CLL (Burger, 2013). In 2015, by 
analysing the profiles of differentially expressed proteins between the UM-IGHV and U-IGHV 
CLL cells, our research group demonstrated that the cell adhesion and migration pathways 
in the UM-IGHV CLL cells were defective compared to those in M-IGHV CLL cells, rendering 
UM-IGHV CLL cells being retained in the lymph nodes (Eagle et al., 2015), which indicates 
that the aberration of the cell trafficking may participate in the pathogenesis of CLL. The CLL 
microenvironment especially the lymph nodes support the survival and proliferation of CLL 
cells and the cell trafficking of CLL cells between the peripheral blood and the 
microenvironment is crucial for the disease progression, which is the reason that 
therapeutic investigation has been trying to interrupt the cell homing and the crosstalk 
between the CLL cells and the accessory cells in the past decades (Delgado et al., 2020). The 
clinical observations that the small molecular inhibitors targeting BCR signalling exhibit 
impressive clinical efficacy by disrupting the cell adhesion and redistributing CLL cells from 
the tissue microenvironment to peripheral blood (Tissino et al., 2018, Herman et al., 2015) 
highlighted the importance of targeting the cell-cell adhesion in CLL.  
The cell adhesion of CLL cells is directed by the interaction of CLL cells with the accessory 
cells via regulating the chemokines such as CXCR4/CXCL12, CXCR5/CXCL13, CCL3, CCL4, 
CCL22, and CD49d (Burger and Gribben, 2014, Han et al., 2014). Among these chemokines, it 
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has been reported that the secretion of CCL22 by CLL cells can be promoted by the CD40 
stimulation (Ghia et al., 2002). CLL cells localized in the lymph nodes express a higher level 
of CD38 comparing with the CLL cells circulating in the peripheral blood and CD38 is 
considered involved in the cell adhesion due to its ligand, the platelet endothelial cell 
adhesion molecule-1 (PECAM1) (Jaksic et al., 2004, Suricoc et al., 2000). It has been reported 
that CD40 stimulation promoted the cell adhesion of CLL cells by up-regulating the 
expression of CD38 (Willimott et al., 2007). So far, the cell adhesion of CLL cells has not been 
fully understood. Considering its important role in CLL, further studies are needed to 
address the details of the cell adhesion molecules and characterize their role in the disease 
progression and drug resistance in CLL. 
The results of the functional analysis of the iTRAQ-MS data obtained here in this study 
showed that CD40 stimulation up-regulated the expression of proteins involved in the 
biological process of the cell adhesion in primary CLL cells, which provides evidence for the 
notion that CD40-CD154 ligation between CLL cells and T cells within the microenvironment 
may regulate the cell adhesion status of CLL cells and enable CLL cells to persist in the tissue 
microenvironment. The proteomics data not only provides a comprehensive view of the 
effect of CD40 stimulation in primary CLL cells at the global protein expression level but also 
indicates that targeting the cell-cell adhesion could be an effective therapeutic strategy in 
CLL. Although the results of the functional study of the protein DDX3X obtained so far are 
short of stringency to make it a promising target, this study does broaden the mind in the 
pro-survival signals induced by CD40 stimulation in CLL cells.  
Based on the results obtained in this study, further work would be suggested to carry out on 
the following points. 
Firstly, continuing the functional study of the protein DDX3X in CLL cells would be necessary 
in order to clarify the role of DDX3X in the survival of CLL cells. It would be crucial to 
optimize the knockdown experiments and to observe the effect of knocking down DDX3X in 
HG-3 and MEC1 cells, which would provide clear evidence for the role of DDX3X in CLL cells. 
Obtaining the DDX3X-knockdown HG-3 and MEC1 cells would pave the way to perform the 
drug treatments on the CD40 stimulated and unstimulated, DDX3X-knockdown, cells to 




As the inhibitor of DDX3X, RK-33, can partially abrogate the cytoprotective effect induced by 
CD40 stimulation against the fludarabine-induced cell death in CLL cells, it would be 
interesting to figure out whether RK-33 can abrogate the CD40 stimulation-mediated 
cytoprotection against the cell death induced by other drugs such as ABT-199 and 
bendamustine (the drugs used in the investigation of the cytoprotective effect of CD40 
stimulation in CLL cells at the beginning of this study). In addition, it would be necessary to 
confirm the mechanism by which RK-33 inhibits the function of DDX3X. Since DDX3X is a 
RNA helicase protein, RNA duplex formation and unwinding can be studied following 
increasing concentration of RK-33 (Bol et al., 2015, Sengoku et al., 2006). Besides, 
introducing at least one more DDX3X inhibitor to see whether similar observation could be 
obtained would strengthen the finding with RK-33. 
Secondly, it would be meaningful to carry on the proteomics study for the CD40 stimulation 
in CLL cells. On one hand, the proteomic data obtained in this study did provide tremendous 
information. It is accountable to dig out more message from the data obtained. Besides 
DAVID, PANTHER, and Reactome, there have been other bioinformatics analysis tools such 
as Ingenuity Pathway Analysis (IPA) can be used for the data analysis, which may provide 
more specific information of the pathways changed by CD40 stimulation in primary CLL cells 
and may exhibit more potential targets to overcome the pro-survival signals and drug 
resistance caused by CD40 stimulation. On the other hand, to further validate the findings 
from the obtained data by increasing the number of the primary CLL cases in the study and 
using different techniques such as SWATH would give more stringency to the findings 
generated from the omics data.  
Thirdly, it would be interesting to compare the RNA-seq data and the proteomics data. 
Comparing the effect of CD40 stimulation in primary CLL cells between the mRNA level and 
protein expression level could help to reveal more information on the effect of CD40 
stimulation at both transcriptional and translational levels, which potentially advance the 







In summary, this study shows that CD40 stimulation induces predominantly pro-survival 
signalling in primary CLL cells, which protects CLL from spontaneous and drug-induced cell 
death. By using the MS-based techniques, this study has shown that CD40 stimulation not 
only changes the expression of proteins in primary CLL cells at a global level but also 
regulates specifically the expression of proteins that are involved in the biological process of 
cell adhesion. Based on the data provided here, it is reasonable to suggest that CD40 
stimulation produces a pro-survival effect by enhancing the cell adhesion properties of CLL 
cells and that DDX3X is likely one of the molecules involved in mediating the pro-survival 
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Appendix 1. The information about the materials and the component of reagents used to 
complete Western blotting 
RIPA buffer for lysis (100ml) 
Components Quantum Company Catalogue NO. 
50mM Tris pH7.6 5ml of 1M stock SIGMA 77861 
1% (w/v) Triton-X100 1ml of 100% SIGMA 9002931 
150mM NaCl 3ml of 5M stock SIGMA 7647145 
0.1% (w/v) SDS 0.5ml of 20% stock SIGMA 151213 
0.5%(w/v) Na Deoxycholate 5ml of 10% stock SIGMA 302954 
dH2O 85.5ml Laboratory scope - 
Protease inhibitors (before use) 10μl/ml SIGMA P8430 
Phosphatase inhibitor 10μl/ml Millipore 524625 
 
4×Sample buffer (50ml) 
Components Quantum Company Catalogue NO. 
250mM Tris-HCl (pH6.8) 12.5ml of 500mM Tris-HCl  SIGMA 1185531 
SDS 20ml 20%SDS SIGMA 151213 
Glycerol 17.5ml for 20%SDS Fisher Chemical 56815 
Bromophenol blue 0.07g Fisher BioReagents 115399 
Note: Add 25μl/ml β-mercaptoethanol (catalogue number 60242, SIGMA) before use. 
 
2×Sample buffer (100ml) 
Components Quantum Company Catalogue NO. 
125mM Tris-HCl (pH6.8) 6.25ml of 1M Tris-HCl SIGMA 1185531 
SDS 10ml 20%SDS SIGMA 151213 
Glycerol 15ml Fisher Chemical 56815 
Bromophenol blue 50mg Fisher BioReagents 115399 
20mM EDTA 2ml of 500mM EDTA stock SIGMA 6004 
dH2O 16.75ml  Laboratory scope - 
Note: Add 50μl/ml β-mercaptoethanol (catalogue number 60242, SIGMA) before use.  
1×Sample buffer consists of 1:1 2×Sample buffer and dH2O adding 100μl/ml β-
mercaptoethanol (catalogue number 60242, SIGMA) before use. 
 
Resolving gel (12%) 
Components 10ml 20ml Company Catalogue NO. 
30% Acrylamide 4ml 8ml National Diagnostics EC890 
4×ProtoGel®Resolving Buffer 2.5ml 5ml National Diagnostics EC892 
dH2O 3.4ml 6.8ml Laboratory scope - 
10% APS 100μl 200μl SIGMA 7727540 




Stacking gel (5%) 
Components 5ml 10ml Company Catalogue NO. 
30% Acrylamide 830μl 1.7ml National Diagnostics EC890 
ProtoGel®Stacking Buffer 1.25ml 2.5ml National Diagnostics EC892 
dH2O 2.9ml 5.7ml Laboratory scope - 
10% APS 50μl 100μl SIGMA 7727540 
TEMED 5μl 10μl SIGMA T7024 
 
Running buffer (0.1%SDS) 
Components Quantum Company Catalogue NO. 
dH2O 900ml Laboratory scope - 
10×Tris 0.25M Glycine (1.92M) solution 100ml National Diagnostics EC880 
20%SDS 5ml SIGMA 151213 
 
Transfer buffer 
Components Quantum Company Catalogue NO. 
dH2O 900ml Laboratory scope - 
10×Tris 0.25M Glycine (1.92M) solution 100ml National Diagnostics EC880 
 
1M Tris-HCl (pH7.5) 
Components Quantum Company Catalogue NO. 
Tris-base 121.14g in 900ml dH2O Fisher BioReagents 77861 
Concentrated HCl to pH7.5 - SIGMA 7647010 
dH2O Add up to 1000ml Laboratory scope - 
 
10×TBST 
Components Quantum Company Catalogue NO. 
1M Tris-HCl (pH7.5) 200ml Fisher BioReagents EC890 
5M NaCl (292.2g in 1000ml dH2O) 300ml SIGMA 7647145 
dH2O 490ml Laboratory scope - 
Tween-20 10ml Fisher BioReagents 153087 
 
1×TBST 
Components Quantum Company Catalogue NO. 
10×TBST 100ml Laboratory scope - 
dH2O 900ml Laboratory scope - 
 
 
5% milk/1×TBST – Blocking solution 
Components Quantum Company Catalogue NO. 
Dried milk powder 5g - - 
1×TBST 100ml Laboratory scope - 
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Appendix 2. The percentage of the CD5 and CD19 double-positive cells and the initial 
viability of the CLL samples used in this project 
Case No. Purity (%) Iso-type control (%) Initial Viability (%) 
#3369 97.74 0.05 85.7 
#3381 97.05 0.09 89.4 
#3396 97.25 0.13 75.9 
#3637 84.15 0.05 87.4 
#3640 98.44 0.58 89.9 
#3642 94.97 2.99 83 
#3274 98.17 0.18 74.3 
#3368 98.24 0.43 77.1 
#3436 96.56 3.11 89.7 
#3259 91.82 0.04 63.6 
#3684 97.38 0.13 48.05 
#3679 97.12 0.09 60.1 
#3564 97.88 0.18 74.4 
#3568 99.54 0.26 78.45 
#3585 97.39 0.49 71.8 
#3587 99.16 0.15 74.8 
#3605 98.64 0.06 88.2 
#3607 93.64 0.22 76.1 
#3606 98.34 0.05 92.4 
#3650 82.63 0.33 76.3 
#3375 99.10 0.06 86.1 
#3724 92.57 0.14 75.9 
#3726 95.54 0.43 89.3 






































Treated or not 
when collected 
the sample 
#3369 male 37 39 NA 13q- NA NA 163.5 157 01.10.2013 untreated 
#3381 female 67 74 NA normal NA NA 157.4 149.7 13.01.2014 treated 
#3396 female 53 67 NA 17p- NA C 80.2 76.1 02.04.2014 treated 
#3637 male 66 69 unmutated 11q-, 13q- no A 144.6 134.9 24.01.2018 untreated 
#3640 male 78 82 unmutated 13q- equivocal no A 177.5 163.4 31.01.2018 untreated 
#3642 male 67 73 unmutated normal no C 129.4 122.8 31.01.2018 treated 
#3259 male NA 70 NA NA NA NA 209 123.1 20.07.2011 treated 
#3411 male NA 72 unmutated 11q-, 13q- NA C 167.3 155.6 15.05.2014 treated 
#3274 female NA 54 NA normal NA NA 167.6 157 12.12.2011 untreated 
#3368 male NA 78 NA NA NA NA 163.3 156.8 26.09.2013 NA 
#3436 male NA 72 NA 13q- NA B 144.3 137 27.11.2014 untreated 
#3684 male 75 84 mutated 13q- no A 230.1 220.8 28.06.2018 untreated 
#3679 male 53 54 NA 13q- no C 171.4 164.7 06.06.2018 untreated 
#3564 male 52 84 NA 11q-, 13q- NA C 63 58.7 28.06.2017 treated 
#3568 male 72 76 unmutated normal no C 155.8 148.9 20.06.2017 treated 
#3585 male 66 68 unmutated 11q-, 13q- no A 109 101.4 16.08.2017 untreated 
#3587 male 54 55 mutated 13q- no NA 257.2 >200 16.08.2017 untreated 
#3605 male 60 63 mutated 13q- no B 252.8 244 27.09.2017 untreated 
#3607 male 66 69 mutated normal no B 254.2 247.7 02.10.2017 untreated 
#3606 male 58 67 unmutated 13q- no B 109.2 103.6 28.09.2017 treated 
#3650 female 63 70 mutated normal no B 119.6 110 17.03.2018 untreated 
#3375 male NA 54 NA 17p- NA C 227.4 222.9 04.11.2013 untreated 
#3724 female 51 55 mutated normal no NA 112.8 104.5 12.02.2019 untreated 
#3726 male 68 76 unmutated normal no C 178.8 173.5 04.03.2019 untreated 
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Appendix 4. Significantly up-regulated genes induced by the soluble CD40 ligand in 



















AAGAB 9.256011 9.003318 GRHPR 9.263214 8.051995 PSIMCT-1 5.663009 5.191410 
AAR2 9.346214 9.043955 GRIK4 4.191847 2.609938 PSMA1 9.173545 8.666355 
AARS 10.189509 9.466772 GRINA 10.725953 9.835385 PSMA2 8.088428 7.656642 
ABCC4 7.577703 6.366143 GRN 11.603842 11.054979 PSMA4 9.321643 8.750837 
ABCD2 6.118235 5.544507 GRSF1 9.977703 9.312355 PSMA7 9.199402 8.917967 
ABCE1 9.538806 8.855400 GRWD1 9.628595 9.145817 PSMB2 9.203474 8.699490 
ABCF1 9.648649 9.232733 GSPT1 10.112179 9.852286 PSMB3 6.115053 5.685184 
ABCF2 9.019185 8.551853 GSTP1 11.064527 10.677623 PSMB5 9.151188 8.483791 
ABHD17C 6.495063 5.805425 GTDC1 6.793932 6.161983 PSMC4 8.483435 8.116819 
ABTB2 10.337517 7.844249 GTF2A1 10.411366 10.130684 PSMD1 7.306777 6.737840 
AC003665.1 3.863562 3.282114 GTF2E1 8.760415 8.530163 PSMD11 9.784806 9.450524 
AC147651.4 8.334240 7.436902 GTF2F2 7.653450 7.297758 PSMD14 7.390923 6.938708 
ACADVL 11.497702 11.178647 GTF2H5 7.710751 7.369063 PSMD3 10.259729 9.908698 
ACBD6 8.238478 7.806272 GTF3C4 8.928162 8.528596 PSMD7 9.957423 9.617296 
ACHE 5.969000 4.618249 GTF3C6 7.343403 6.659632 PSMD8 9.781932 9.529896 
ACKR3 6.145289 5.514225 GTPBP4 8.651006 8.069171 PSME3 11.131769 10.562255 
ACOT2 8.391101 8.064345 GTPBP6 10.100292 9.819894 PSMG3 9.665421 9.190929 
ACOT4 6.680733 5.664072 GYS1 8.930057 8.652322 PTEN 10.552010 10.303792 
ACSL1 9.308463 8.628872 H6PD 10.279945 9.982420 PTENP1 9.654346 9.440832 
ACSL4 9.858334 8.975369 HAPLN3 6.956224 4.845370 PTGER4 10.307080 9.694277 
ACTB 15.611714 14.544635 HBS1L 8.458305 8.160482 PTGES2 9.749565 9.078002 
ACTG1 13.781399 13.105393 HCG18 9.258225 8.985932 PTGES3 11.574262 11.244639 
ACTN4 9.903357 9.553102 HCG26 7.979811 7.382561 PTGIR 9.471067 6.483238 
ACTR1B 10.333735 9.905625 HCG4B 7.620615 7.255750 PTGS1 6.158393 5.604180 
ACTR2 12.645088 12.368916 HCLS1 10.231580 9.949346 PTK2B 10.358451 9.838244 
ACTR3 11.783228 11.116749 HCP5 11.245443 10.386545 PTMS 9.088485 8.380509 
ACTR3B 6.620526 5.803147 HDAC9 9.212388 8.619653 PTP4A2 11.968089 11.790436 
ADA 7.510680 6.880008 HDGF 11.181015 10.970992 PTP4A3 6.091216 5.120392 
ADAM8 10.023564 9.518922 HEATR1 7.315771 6.918060 PTPN1 12.384293 11.933975 
ADAMDEC1 7.139362 5.494089 HEATR2 8.174699 7.661946 PTPN11 10.495493 10.165320 
ADAMTS7 8.372208 7.057737 HEG1 8.154099 7.793908 PTRH1 5.771048 5.102195 
ADAT2 7.506210 7.022905 HERPUD1 11.852293 10.925377 PTRH2 8.369742 7.835384 
ADCY3 7.367668 6.614701 HIAT1 9.147558 8.890987 PUF60 9.613488 9.203292 
ADIRF 5.459807 4.518399 HIGD1A 8.853699 8.319363 PUS7 6.807199 5.913644 
ADM2 6.670071 4.766879 HIGD2A 8.967330 8.698724 PVR 6.680267 6.066827 
ADO 10.428206 9.974932 HILPDA 7.315397 6.554359 PVRL1 9.909654 8.370234 
ADPRH 10.892489 9.994082 HIRA 9.409655 9.051076 PVT1 7.064409 6.352451 
ADRBK2 10.557090 10.352690 HIVEP1 11.485925 11.126778 PYCR1 8.638816 6.002589 
ADSL 7.307228 6.733004 HIVEP3 7.975547 7.613628 PYCRL 8.085164 7.635504 
AEN 10.299696 9.916067 HK2 8.531849 7.539227 QTRT1 9.320957 8.823283 
AFG3L2 9.051034 8.689496 HLA-A 13.677543 13.340863 QTRTD1 9.511574 9.207938 
AGFG1 10.009360 9.659038 HLA-B 14.117028 13.747961 RAB10 11.057099 10.704691 
AGMAT 7.326662 6.461741 HLA-C 13.145320 12.789693 RAB11A 10.027781 9.487014 
AGPAT3 11.094415 10.518510 HLA-DQA1 9.679669 8.821028 RAB12 8.461320 8.164088 
AGPAT6 10.819073 10.601589 HLA-DQA2 7.565875 6.877922 RAB13 9.178755 7.820693 
AGRN 7.658349 6.870882 HLA-E 14.520928 14.114734 RAB1B 11.118396 10.908575 
AGTRAP 7.559562 6.952701 HLA-F 12.100771 11.262980 RAB21 10.936219 10.175567 
AHCY 9.067913 8.563794 HLA-L 7.627063 6.676007 RAB27A 8.808915 8.542725 
AIFM2 8.010675 7.703569 HMGA1 11.177178 10.310230 RAB39A 6.862118 6.327111 
AIMP1 8.654396 8.369632 HMGCR 8.646798 8.294940 RAB39B 9.035531 8.767330 
AIMP2 7.421053 6.589969 HMGCS1 9.778085 9.124515 RAB3GAP2 9.918136 9.432611 
AK2 10.338549 9.931328 HMGN1 10.352153 10.142080 RAB3IP 8.467985 8.105754 
AKAP1 8.527040 8.204112 HN1L 10.357663 9.736927 RAB7L1 11.870498 10.686606 
AKR1A1 8.924394 8.286027 HNF1B 4.627412 3.670208 RAB8B 11.235435 10.795309 
ALCAM 9.038592 8.403593 HNRNPAB 10.413653 10.101189 RAB9A 9.916596 8.491283 
ALDH18A1 8.759973 8.432149 HNRNPC 11.462771 11.222112 RABEPK 6.766994 6.382401 
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ALDH1B1 9.099338 7.815578 HNRNPF 12.396139 12.105977 RABL3 8.484302 7.895676 
ALDH2 6.961776 5.831180 HNRNPK 11.623456 11.322897 RAC1 10.275315 9.999725 
ALDH4A1 6.654372 6.231954 HNRNPLL 7.591413 7.250920 RAD21 11.033243 10.813024 
ALKBH2 7.718734 7.127971 HNRNPM 11.406021 11.009740 RAD23A 10.131143 9.916437 
ALPK1 7.502941 7.119979 HNRNPR 10.850992 10.423518 RAD23B 10.682054 10.396216 
ALYREF 8.775687 8.407182 HNRNPU 12.194361 11.892015 RAD50 8.573766 8.162928 
AMMECR1L 9.493709 9.223611 HOMEZ 9.007058 8.332257 RAD51B 6.044670 5.321608 
ANAPC11 7.895185 7.549517 HOXB9 4.551969 3.080923 RAD51D 7.913949 7.301516 
ANAPC16 11.135178 10.762998 HPRT1 7.360438 6.971148 RAET1K 4.338818 3.715513 
ANAPC7 9.127265 8.755856 HSD17B10 8.216727 7.845982 RALA 9.870172 9.231925 
ANKLE2 12.083160 10.907245 HSD17B12 8.641750 8.266814 RAN 10.377104 9.969764 
ANKRD10 11.778189 10.869217 HSF5 7.213046 6.802449 RANBP1 8.168864 7.876727 
ANKRD33B 11.104928 8.242676 HSP90AA1 12.917488 12.640526 RANGAP1 11.138740 10.729797 
ANKRD40 9.615788 9.282026 HSP90AB1 12.604690 11.961245 RAP1A 9.332633 9.091226 
ANO9 10.394148 9.739824 HSP90B1 9.788531 9.102982 RAP1B 8.631704 8.280213 
ANP32A 10.473727 9.857048 HSP90B2P 10.339330 9.604162 RAP2A 10.020897 9.219124 
ANP32AP1 9.102031 8.555915 HSPA5 12.301816 11.354424 RAPGEF1 13.301506 12.868224 
ANP32B 10.169018 9.875351 HSPA8 12.762689 12.236699 RARA 10.845141 10.328107 
ANP32C 6.587065 5.946851 HSPA9 10.062931 9.789998 RASGRP1 8.091857 7.474283 
ANP32E 11.299989 10.875229 HSPBP1 8.313820 7.547349 RASGRP3 9.913317 9.497151 
ANXA2 8.797058 8.205150 HTATIP2 8.818797 8.502679 RASSF2 12.255757 11.682624 
ANXA2P2 11.836475 11.233888 HTRA2 10.016193 9.249324 RASSF4 8.931454 7.446972 
ANXA5 9.631339 9.051796 HUS1 7.610643 7.206752 RAVER1 10.353988 9.923348 
ANXA6 7.482076 6.572545 HUWE1 10.671940 10.202379 RBBP9 9.774705 9.058142 
ANXA7 9.959067 8.971183 HYAL2 7.959797 7.585948 RBM12 10.648325 10.110669 
AP1AR 9.312161 8.877617 HYLS1 7.736969 7.160555 RBM19 9.577846 9.113838 
AP1S2 8.850973 8.568426 HYOU1 11.616451 10.406065 RBM3 11.180729 10.528096 
AP1S3 10.968400 10.257385 IARS 8.423948 7.618998 RBMXL1 9.528496 9.204034 
AP2B1 10.936047 10.748371 IBTK 8.826112 8.541871 RBPJ 10.978764 10.374523 
APEX1 11.024108 10.685236 ICAM1 11.377633 9.065293 RCC1 8.652468 8.175380 
API5 10.435192 10.148789 ICAM5 6.102511 5.132353 RCC2 11.205569 10.812909 
APLF 5.985820 5.389928 IDI2 6.209045 5.770746 RCCD1 8.032754 7.586998 
APMAP 10.202233 9.932862 IER2 12.421553 12.071578 RCL1 7.190208 6.729486 
APOA1BP 7.912845 7.582394 IER3 10.689677 9.128214 RCN1 6.725084 5.087660 
APOBEC3C 10.846960 10.343415 IER5 13.697152 13.211522 RELB 11.598600 10.944967 
APOBEC3G 11.322227 10.632457 IFFO2 9.133017 8.815325 RELT 10.642824 10.077155 
APOL1 8.169604 7.603972 IFIH1 9.329084 8.589873 REXO4 9.533940 9.244496 
APPL1 10.483406 10.127446 IFNGR1 9.698731 9.245856 RFC2 7.262540 6.848776 
APRT 8.941912 8.376543 IFNGR2 10.815312 10.107537 RFFL 7.529424 6.785458 
AREL1 9.629572 9.358834 IFNLR1 11.041222 10.581757 RFK 8.569090 8.244520 
ARF3 11.519796 11.034853 IFRD2 7.584502 7.202052 RFTN1 12.584965 10.744772 
ARFRP1 9.072079 8.778852 IGF2BP3 5.211991 4.525232 RFX5 11.238357 10.548310 
ARHGAP17 9.706396 9.202335 IGSF3 11.560030 9.803718 RGS1 9.324597 8.801499 
ARHGAP23 4.808932 4.095887 IKBKE 7.360930 6.830859 RHBDF1 5.966780 5.436807 
ARHGAP24 10.694199 10.195834 IKZF1 12.063314 11.511552 RHBDF2 9.482415 9.124876 
ARHGAP31 10.764561 9.336045 IL10 7.423423 6.552633 RHOA 12.784304 12.584038 
ARHGDIA 12.299706 11.937890 IL13RA1 10.317806 8.445946 RHOF 6.291897 4.477722 
ARHGEF12 9.398122 8.931677 IL17REL 6.892092 5.005894 RHOG 11.426735 10.489954 
ARHGEF2 11.415668 10.830021 IL21R 11.914741 10.152103 RIMS3 7.841725 6.773615 
ARID5A 10.768647 10.160957 IL21R-AS1 5.121855 4.215186 RIOK1 7.981105 7.484223 
ARL1 8.869260 8.554881 IL23A 7.345607 6.931515 RIPK2 7.752799 7.330298 
ARL13B 7.506652 7.206905 IL2RA 11.510583 10.888850 RND1 7.749141 7.372651 
ARL14EP 8.799172 8.536348 IL2RG 12.174424 11.625127 RNF115 8.311515 7.933530 
ARL2 8.169176 7.592133 IL4I1 9.182611 6.512612 RNF121 8.841872 8.359273 
ARL8B 10.578694 10.207872 IL6R 9.633417 8.808908 RNF145 10.609933 9.442461 
ARMC5 9.337959 9.046180 IL7 7.890480 6.909876 RNF19B 10.113722 9.451164 
ARMC6 8.355739 7.663511 ILDR1 3.839730 3.153503 RNF207 6.488288 4.867717 
ARNTL2 7.814163 4.868201 ILF2 9.924035 9.605054 RNF208 4.823199 3.920208 
ARPC1B 9.608316 9.340805 IMP4 8.086554 7.755140 RNGTT 8.651627 8.377867 
ARPC2 10.455337 9.994432 IMPACT 5.946046 5.484599 RNU105A 3.887342 3.094583 
ARPC4 11.537078 11.051833 INADL 8.196151 7.877720 ROMO1 8.724796 8.349268 
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ARPC5 11.400014 10.879719 INTS3 9.108029 8.603054 RP1-
249H1.4 
3.569691 2.675058 





5.177772 4.507539 INTS9 7.471791 7.102505 RP11-
356I2.4 
5.782077 4.850655 
RSB 7.943820 7.618619 IPO4 6.667753 6.164576 RP11-
465B22.5 
4.348011 3.287398 
ASCC3 8.136109 7.742027 IPO5 9.795220 9.227020 RP11-
536C5.7 
5.267217 4.611505 
ASNA1 8.430965 8.118900 IPO7 9.893182 9.630484 RP11-
829H16.3 
4.845581 3.865848 
ASNS 8.234373 7.811411 IQSEC1 11.201182 9.873240 RP11-
861A13.4 
9.578296 9.051459 
ASUN 6.774301 6.362086 IRAK1 11.102710 10.533361 RP3-
395M20.9 
7.080828 6.211177 
ASXL1 11.910294 11.533720 IREB2 9.619440 9.384924 RP -
1071N3.1 
6.062545 5.460780 
ATAD3A 8.100628 7.808242 IRF4 12.468818 11.240521 RPAP2 7.395297 7.030706 
ATF3 8.731129 8.438866 IRF5 12.104352 11.180653 RPAP3 7.432205 7.061975 
ATF4 12.608717 12.376152 IRGQ 9.538916 9.227743 RPEL1 7.128120 6.736934 
ATF5 11.862233 10.532545 ISCU 11.317681 11.094557 RPF2 6.852316 6.051300 
ATF6 9.305916 9.029366 ISOC1 8.315318 8.041550 RPIA 8.697813 8.192367 
ATF7IP 10.827350 10.491456 ISOC2 7.597349 6.754931 RPL10 9.827840 9.613037 
ATIC 7.485868 7.013968 ITFG3 9.324040 8.718894 RPL10A 9.763781 9.493320 
ATOH8 2.984570 2.243190 ITPA 8.527174 8.161340 RPL13 10.508582 10.185761 
ATP2A2 10.576713 10.189415 ITPKC 8.929784 8.643198 RPL23P8 9.248619 8.904879 
ATP2B1 10.323781 10.020917 ITPR1 8.598943 8.218820 RPL36AL 10.943469 10.657415 
ATP2C1 7.998444 7.683370 IZUMO4 9.974277 9.171454 RPL4 10.628963 10.323989 
ATP5B 11.220849 10.935564 JADE2 12.297476 11.981609 RPL7L1 10.562698 10.204124 
ATP5EP2 11.265551 10.934503 JADE3 9.942357 9.411266 RPLP0 10.134589 9.799597 
ATP5F1 7.731070 7.442787 JAGN1 9.546085 9.142441 RPN1 10.593258 10.384773 
ATP5G2 8.036150 7.594922 JAK3 10.862289 9.651735 RPP25L 8.342257 7.959012 
ATP5S 7.818807 7.478195 JAM2 5.772376 5.110698 RPS19 7.416890 7.078945 
ATP6V0E1 10.699416 10.191436 JAZF1 10.033043 9.637496 RPS2 10.731486 10.362487 
ATP6V1C2 8.689475 7.891869 JMJD4 6.474725 5.982685 RPS27A 8.887305 8.303740 
ATXN10 8.447156 8.194055 JPH4 5.304516 2.997228 RPS6 11.516685 11.198891 
AURKAPS1 5.948796 5.424078 JRK 9.753419 9.542198 RPS6KA1 9.900873 9.208866 
AVEN 7.758568 6.987216 JUN 13.528094 13.021744 RPS6KC1 8.429745 8.066560 
AZIN1 11.533852 11.291753 JUNB 14.493838 13.939454 RPS6KL1 4.265310 3.304986 
B2M 15.184164 14.974225 KARS 7.793907 7.456427 RPSA 6.638492 6.252458 
B3GALT6 10.077850 9.099776 KATNBL1P6 8.416134 8.117025 RPSAP58 12.120815 11.737755 
B3GNT7 8.760188 7.896666 KCNK5 5.414365 4.197407 RPTOR 9.007456 8.411353 
B4GALNT1 3.574023 2.706582 KCNN1 8.062119 4.781480 RPUSD4 8.950144 8.701966 
B4GALT2 7.858132 7.161741 KCP 4.015421 3.365429 RQCD1 10.016496 9.704151 
B4GALT5 10.703519 9.185909 KCTD10 9.775679 9.497121 RRAS2 10.067127 9.770227 
B4GALT7 8.030696 7.679279 KCTD17 8.787078 8.508917 RRP1 8.104671 7.711420 
BAHD1 10.082192 9.852304 KDM2B 11.950407 10.703619 RRP12 7.845652 7.289168 
BAI2 2.977708 2.429234 KEAP1 9.948132 9.712928 RRP15 8.364454 7.672902 
BAIAP2L1 4.187723 3.327401 KHDRBS1 11.529163 10.932504 RRS1 9.214384 7.921808 
BANF1 9.675965 9.151806 KIAA0020 6.101271 5.305200 RSL1D1 10.928292 10.449668 
BASP1 12.503963 10.344033 KIAA0391 8.266833 7.945841 RSL24D1 9.918204 9.572991 
BATF 8.968438 7.950558 KIAA1211 3.531650 2.535657 RTCB 9.584050 8.791048 
BATF3 6.436584 4.849153 KIAA1430 10.230383 9.771561 RTFDC1 9.459008 9.134388 
BAZ1A 10.143439 9.550940 KIAA1524 5.129028 4.525288 RTKN 6.330375 5.424538 
BCAR3 8.383231 7.781202 KIF13A 8.132336 7.858804 RUFY3 10.023809 9.069223 
BCAT1 8.924151 7.216212 KIF1C 10.890506 9.819573 RUNX3 12.630383 11.857551 
BCL2 14.124109 13.136038 KIF21B 9.289600 8.848100 RUVBL1 7.609156 6.748104 
BCL2A1 9.708914 8.328437 KIF26B 5.680498 4.040075 S100A10 8.545113 8.053415 
BCL2L1 11.536553 9.211531 KIF3B 9.943679 9.165903 S100A11 7.785208 7.394681 
BCL2L10 4.667537 4.084619 KLC2 9.148853 8.779259 S100A14 7.092619 4.029068 
BCL2L13 9.726058 9.517907 KLF6 12.883064 12.609178 S100A2 4.336601 3.649564 
BCL7A 8.881724 8.314884 KNOP1 7.727935 7.135074 S100A6 10.545826 9.993454 
BEND3 7.425224 6.912900 KRAS 11.213271 10.992642 S1PR2 8.084482 7.340364 
BHLHE40 12.639737 11.252874 KYNU 6.054740 5.360301 SACS 9.432536 9.064015 
BHLHE40-
AS1 
3.463083 2.857035 L1CAM 8.564395 7.585918 SAMD14 7.033048 4.848988 
BID 8.543125 7.546188 LACTB 9.830454 8.810380 SAMSN1 10.039179 9.455172 
BIRC3 12.989007 12.430355 LAGE3 8.953112 8.587363 SAMSN1-
AS1 
4.851996 3.098236 
BLK 12.252541 11.967060 LAMP1 11.143929 10.773051 SAP30 5.767065 4.961487 
BLMH 7.896224 7.501864 LARP1 11.050886 10.787462 SARS 9.868655 9.632624 
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BLVRA 6.386454 5.499274 LARP4 9.443444 8.998273 SBF2-AS1 8.131558 7.734923 
BMP1 5.694350 5.185836 LARS 9.039013 8.439238 SCARF1 5.805059 5.211026 
BRI3 9.795800 9.158625 LARS2 7.396622 7.013992 SCD 8.131510 7.459929 
BRPF3 10.363012 10.027476 LAS1L 8.574630 8.245452 SCFD2 7.407688 6.330016 
BSG 11.701028 11.442830 LAT2 10.107925 9.094717 SCOC 9.143557 8.881550 
BSPRY 8.590347 7.979748 LCMT2 8.503889 7.935106 SCP2 10.290194 10.087677 
BST2 9.793400 9.487038 LCP1 13.642567 11.918107 SDC4 7.622864 5.850085 
BTBD19 7.051170 6.249555 LDHA 10.243880 9.658443 SDF2L1 8.983759 8.001779 
BTF3 9.501823 9.088413 LDHB 7.890874 7.344771 SDF4 10.947192 10.535492 
BTG3 7.775011 7.230484 LENG9 6.525069 6.059557 SEC11C 6.354326 5.566989 
BTLA 10.854749 10.406172 LHFP 5.918685 4.433218 SEC13 8.856370 8.568263 
BTN2A2 10.229816 9.130683 LHX2 3.602095 2.672178 SEC14L1P1 6.764362 6.383798 
BYSL 8.145960 7.064114 LIG3 7.762688 7.124744 SEC22A 7.699343 7.377751 
BZRAP1-AS1 9.591147 8.630263 LILRB2 8.589492 8.155210 SEC23B 8.207426 7.863279 
BZW2 6.329339 5.762125 LILRB4 8.981240 7.565176 SEC23IP 8.981885 8.687748 
C10orf10 7.225582 5.778357 LINC00158 5.113471 3.208406 SEC61A2 8.255381 7.915788 
C10orf2 9.257867 8.509199 LINC00173 4.972585 4.141330 SEC61B 7.859168 7.364735 
C10orf32 8.408186 8.021088 LINC00265 7.095712 6.581448 SEH1L 8.789817 8.308204 
C10orf55 4.242774 2.624682 LINC00338 8.078596 7.184333 SELT 10.710593 10.442661 
C11orf31 8.898228 8.608453 LINC00515 3.375319 2.878384 SEMA4C 7.354501 5.641354 
C11orf95 8.566578 8.059569 LINC00665 7.200113 6.855250 SEMA7A 11.446911 9.519861 
C12orf43 8.112581 7.649717 LINC00984 8.884088 8.426391 SENP1 8.634645 8.285477 
C12orf77 4.291059 3.341051 LINC00998 8.342215 7.839630 SEPT11 9.481165 8.717265 
C14orf1 8.386673 7.906342 LINC01104 3.433286 2.552604 SEPT8 8.461260 7.680134 
C14orf166 7.572469 7.163110 LINC01160 3.298697 2.617719 SERBP1 11.213197 10.802955 
C14orf169 9.414157 9.105280 LINC01181 2.927813 2.075934 SERPINB9 12.138071 11.578691 
C14orf80 8.151611 7.559685 LLPH 8.394391 7.995107 SERPINE2 4.371443 3.463739 
C15orf57 9.966143 9.403436 LMAN1 9.972987 9.691893 SESN2 8.055081 7.763078 
C17orf89 6.738522 6.202972 LMNB2 11.741368 10.294573 SET 12.433178 11.825314 
C17orf96 7.998565 6.797124 LOC10012903
4 
9.887750 9.474657 SF3B14 7.786237 7.456918 
C17orf99 6.683980 4.825585 LOC10012936
1 
9.184827 8.627339 SF3B3 10.099420 9.761348 
C19orf10 8.563781 8.120912 LOC10012969
7 
6.034883 5.531376 SF3B4 8.836720 8.494349 
C19orf24 8.952494 8.649309 LOC10013045
8 
8.644012 7.688259 SFPQ 11.915323 11.615860 
C19orf70 8.285816 7.698072 LOC10013074
4 
8.412395 7.930207 SFT2D1 8.363270 7.864996 
C1QBP 8.522942 7.878788 LOC10013211
1 
5.318803 4.025159 SFXN1 9.264127 8.764176 
C1orf200 5.897460 4.867423 LOC10013283
1 
5.575448 4.673991 SFXN2 6.778114 6.088841 
C22orf34 6.975432 6.337293 LOC10026816
8 
4.329737 3.679387 SGCB 7.426343 7.063479 
C4orf32 8.898191 8.372486 LOC10028817
5 
8.671765 7.646599 SGPP2 11.260688 10.068816 
C4orf46 8.480663 7.425944 LOC10050671
0 
11.798962 11.580043 SH2B3 11.193569 10.553447 
C5orf30 7.867079 7.423878 LOC10050763
4 
5.452930 4.628455 SH2D3A 8.259788 7.845933 
C6orf222 6.172351 5.487354 LOC10050765
6 
6.320200 5.451051 SH3BP2 9.947772 9.667107 
C7orf73 8.554600 8.185282 LOC10099657
3 
6.669391 6.014196 SH3KBP1 9.906799 9.508552 
C8orf33 9.700158 9.381583 LOC10106026
4 
5.360342 3.680770 SHFM1 6.649517 6.055358 
C9orf117 5.244279 4.688096 LOC10192768
6 
4.057834 2.955250 SHMT2 9.618174 9.233861 
CA2 5.761211 5.075693 LOC10192769
6 
3.760280 2.735708 SIAH2 10.977517 10.351597 
CACNA1G 3.873093 3.095910 LOC10192784
1 
6.084834 5.490044 SIRPA 10.626592 9.389811 
CAD 8.257997 7.913038 LOC10192797
1 
3.971225 2.618329 SLAMF7 11.211327 9.256657 
CALM3 11.063039 10.790890 LOC10192848
5 
6.114238 5.385114 SLC12A3 4.259711 3.568015 
CALR 12.911045 11.921672 LOC10192876
7 
4.065058 3.529402 SLC12A4 9.141707 8.673835 
CAMKK2 9.376300 9.051778 LOC10192934
0 
5.054254 4.194839 SLC15A4 9.982382 9.550010 
CAMSAP3 5.437607 4.927204 LOC10192940
1 
3.267133 2.797563 SLC16A9 2.991449 2.380868 
CAND1 10.423039 10.113435 LOC10192975
8 
6.785038 6.196743 SLC1A4 10.355945 9.651182 
CANX 11.787964 11.188812 LOC10192975
9 
2.836179 2.289221 SLC1A5 10.474659 9.660735 
CAP1 11.102680 10.826547 LOC10272372
6 
6.687577 4.418400 SLC20A1 10.220572 9.495860 
CAPN2 9.714372 9.274573 LOC10272382
6 
4.629105 3.214623 SLC24A1 7.819292 7.185680 
CAPNS1 10.435700 10.069202 LOC10272399
6 
6.942992 6.481115 SLC25A11 8.686647 8.197967 
CAPRIN1 10.609125 10.377276 LOC10272453
6 
9.109907 8.572991 SLC25A15 6.321422 5.845051 
CAPZA1 11.511840 11.225360 LOC115110 6.646704 6.103659 SLC25A24 8.879852 8.593323 
CAPZB 9.476251 9.123694 LOC152225 2.587676 1.942877 SLC25A25 9.147710 8.878830 
CARM1 9.654080 9.095533 LOC284454 8.590412 8.098747 SLC25A32 9.083862 8.766953 
CARS 7.690638 7.267942 LOC339192 13.402807 12.592124 SLC25A33 7.080930 6.572980 
238 
 
CASP7 9.731238 9.034232 LOC341056 8.731934 8.494729 SLC25A39 9.543027 9.261028 
CASZ1 9.914726 8.823517 LOC388813 5.108670 3.457616 SLC25A4 8.148023 7.865793 
CAV1 8.682713 6.502447 LOC389834 5.586548 5.089561 SLC25A43 8.802400 8.132264 
CBX1 10.165120 9.491544 LOC644189 4.496397 3.982172 SLC25A5 10.569954 10.366539 
CBX6 11.879689 11.142314 LOC730101 7.047545 6.181732 SLC25A51 7.668999 7.375275 
CCDC102A 6.509152 5.407948 LOC80154 6.446572 5.700951 SLC26A2 9.299678 9.081315 
CCDC103 4.901644 3.695815 LONRF1 8.948800 8.590309 SLC27A4 7.943434 7.531247 
CCDC106 8.847660 8.490678 LOR 3.377930 2.802276 SLC29A1 8.873356 7.895483 
CCDC12 8.413108 7.783854 LPCAT1 11.397116 10.509205 SLC2A13 8.544210 7.598399 
CCDC124 9.719717 9.089945 LRCH3 8.761516 8.415594 SLC2A6 8.991125 7.905587 
CCDC167 6.512192 5.657411 LRP8 7.507688 6.548363 SLC35A4 10.661640 10.272316 
CCDC28B 7.722293 6.859425 LRPPRC 8.541675 8.181947 SLC35B2 11.534850 10.706688 
CCDC50 12.013091 10.825192 LRRC59 9.885167 9.585542 SLC35F2 9.836964 9.060814 
CCDC71 8.668626 7.920502 LRRFIP2 8.268118 7.715765 SLC37A1 9.821182 9.243690 
CCDC82 8.801616 8.536577 LSM1 8.481004 8.179143 SLC38A1 12.929844 12.495711 
CCDC86 8.677921 7.677374 LSM3 8.008086 7.654207 SLC38A7 7.680050 7.319995 
CCL17 5.145427 2.921747 LSP1 11.642754 10.588470 SLC39A1 11.214945 10.520578 
CCL22 12.494669 8.329182 LSP1P3 6.114087 5.367595 SLC39A14 9.337536 8.518891 
CCL24 5.235802 4.605691 LTA 8.622104 7.118318 SLC39A6 9.487601 9.056463 
CCND1 9.477733 8.187206 LTV1 7.724918 7.244915 SLC41A2 8.293492 7.345430 
CCND2 10.572196 10.008827 LY75 10.308267 9.447374 SLC43A3 10.261226 8.259404 
CCNI2 6.720067 5.914530 LYPLA2 9.439847 9.183354 SLC45A3 7.752959 5.771268 
CCR7 14.898123 13.786232 LYPLAL1 6.512243 6.070089 SLC4A5 7.115923 6.701782 
CCT3 9.946289 9.332549 LYRM2 9.434610 9.045490 SLC50A1 10.358006 9.796564 
CCT4 9.669446 9.269484 LYRM4 8.159721 7.298678 SLC6A6 11.986711 11.073272 
CCT5 8.643892 7.969060 MAATS1 4.803499 4.004052 SLC6A9 5.221606 4.489325 
CCT6A 9.814161 9.365851 MACF1 10.036319 9.223320 SLC7A1 11.049844 10.089773 
CCT7 10.471522 9.864100 MACROD2 5.517062 4.856001 SLC9A7 11.918241 11.133172 
CD1C 4.684411 3.504720 MAGI2 5.023555 4.448702 SLC9A7P1 6.148104 5.436999 
CD200 11.044718 10.508780 MAGOH2 8.011581 7.655332 SLC9A8 9.936136 9.547615 
CD40 11.670835 10.007706 MAK16 7.603438 7.202031 SLCO5A1 5.691275 4.560033 
CD58 9.755725 8.310571 MALSU1 7.488097 6.956944 SLMO2 10.060536 9.790847 
CD59 10.510348 9.808142 MAML2 9.053602 8.551818 SMARCA4 8.742818 8.476650 
CD70 10.389670 9.473074 MANBAL 8.210854 7.831417 SMARCAD1 8.431871 8.170924 
CD80 7.828150 5.955129 MANF 8.612142 7.812189 SMARCC1 10.402872 10.124210 
CD82 12.849682 11.651063 MAP3K8 9.886350 8.899934 SMARCE1 9.720444 9.481551 
CD83 13.652377 12.484969 MAP4 11.184566 10.567141 SMC3 7.714293 7.382313 
CD84 11.621804 11.274538 MAP6 6.232511 5.826159 SMC6 8.982377 8.510471 
CD86 8.781821 7.720265 MAP7D1 9.887230 9.669886 SMG1 11.696785 11.151671 
CD97 11.487555 10.603464 MAP7D3 6.791853 6.413169 SMG7 10.240103 9.956829 
CDC42 11.821705 11.069530 MAPK11 8.765926 7.565920 SMG9 8.911703 8.519468 
CDC42EP2 6.987545 5.926480 MAPK13 10.131777 9.686028 SMIM12 10.048967 9.637967 
CDC42EP3 10.807343 10.447605 MAPKAP1 10.288910 9.815600 SMIM13 8.347857 8.048732 
CDC42SE1 12.214796 11.661197 MAPKBP1 9.195404 8.584036 SMIM15 9.043093 8.671185 
CDK17 9.777131 9.469233 MAPRE1 10.497813 10.097130 SMKR1 5.675721 5.073154 
CDK18 5.822684 4.624855 MARCKS 11.280039 9.350658 SMO 4.705386 4.200066 
CDK2AP1 9.113586 8.711323 MARCKSL1 11.982586 10.934436 SMPD2 7.283505 6.875675 
CDK4 8.921973 8.334912 MARS2 8.737303 8.448389 SMPD5 4.795881 4.058754 
CDKAL1 7.358088 6.997379 MARVELD2 4.849846 4.318869 SMS 7.724484 7.035880 
CDKN1A 12.182156 11.307742 MAT2A 10.974501 10.684514 SMYD5 9.067977 8.552394 
CDKN2A 7.913435 7.396754 MATR3 11.696912 11.481704 SNAP23 10.656311 10.365396 
CDKN2B 7.699946 6.937670 MB21D1 8.369321 7.963686 SND1 9.478363 9.009270 
CEBPG 10.851503 10.420744 MBD3 10.616658 10.355241 SNHG10 8.698803 8.376436 
CEP135 8.049326 7.339968 MCCC2 9.368760 8.724262 SNHG15 8.053105 7.600824 
CEP170B 6.583437 5.965674 MDFIC 12.319648 11.306853 SNHG16 9.377654 8.469271 
CEP19 7.902229 7.464534 MDH1 7.784923 7.410557 SNHG3 9.727811 9.075386 
CERS4 8.544056 7.254510 MDH2 8.688961 8.385943 SNHG4 6.718329 5.530204 
CETN2 7.381665 7.062865 MED1 10.538592 10.251143 SNN 12.625588 11.291943 
CETP 5.312108 4.430854 MED22 10.293709 9.716431 SNORA73A 4.455523 3.799926 
CFL1 12.485507 12.054871 MEF2C 10.981940 10.520573 SNORD80 6.196790 5.685461 
CFLAR 13.311085 12.067622 MESDC1 11.272117 10.756322 SNRPB 8.933357 8.627669 
239 
 
CFLAR-AS1 4.161791 3.487543 MEST 6.262334 5.686833 SNRPD1 7.136582 6.460304 
CHAC1 6.910119 5.486986 METAP1D 5.001095 4.404794 SNRPD3 10.774062 10.459643 
CHAC2 6.267317 5.587548 METAP2 8.924867 8.612290 SNX11 11.762398 9.753592 
CHCHD1 7.471256 7.154834 METTL1 6.824001 5.354088 SNX12 9.736112 9.416188 
CHCHD2 7.876265 7.475073 METTL2B 8.065076 7.764473 SNX17 9.730636 9.386740 
CHCHD3 8.649964 8.210045 MEX3C 12.395017 12.059848 SNX20 9.946492 9.309721 
CHMP4B 11.703399 10.610259 MFN2 10.385053 10.119394 SNX8 11.224229 10.940229 
CHMP6 7.986943 7.405995 MFSD1 7.835040 7.470045 SOCS1 9.698435 8.316994 
CHRNA6 6.020930 4.077555 MFSD10 9.686419 9.277547 SP2 9.466367 9.199842 
CHST10 9.036059 8.528021 MFSD2A 7.189336 6.142415 SPAG7 8.399184 8.090969 
CHST7 9.939214 8.009777 MGAT2 11.133809 10.695157 SPATA31D1 3.272763 2.264391 
CHTF8 10.704600 10.499848 MGC70870 6.218303 5.127459 SPATC1 4.600958 3.832915 
CHTOP 10.915804 10.673459 MGC72080 6.044529 5.586713 SPCS1 8.920904 8.655552 
CIAPIN1 8.213618 7.850654 MGLL 9.822260 7.647067 SPCS3 11.198919 10.995147 
CIB2 6.543973 5.946269 MICAL3 10.451809 9.943934 SPECC1 7.217105 6.006451 
CILP2 4.108292 3.467930 MIIP 9.935980 8.994541 SPHK1 7.851412 6.973475 
CINP 7.855419 7.182084 MINA 7.326604 6.725157 SPI1 10.589254 10.213813 
CIRH1A 7.081357 6.637570 MIPEP 5.433849 4.882014 SPIB 12.026962 10.874213 
CKB 8.665482 7.241171 MIR155HG 12.757305 10.086014 SPIN3 8.815260 8.485990 
CLCF1 6.634531 5.763222 MIR17HG 7.293608 6.434861 SPINT2 11.113093 10.642085 
CLCN5 7.560657 6.528655 MIR22HG 9.024159 8.551916 SPPL2A 8.183646 7.671443 
CLECL1 8.664612 8.216446 MIR4444-2 8.835368 8.585389 SPR 6.606046 5.642969 
CLIC1 11.522770 11.207350 MKNK2 13.183453 12.598034 SPRYD3 9.276411 9.009356 
CLIC2 5.341926 4.343794 MLH3 8.536051 8.206959 SPRYD4 7.795652 7.407690 
CLIP2 9.294735 7.104494 MLLT11 6.880012 6.399215 SQLE 9.745765 8.271877 
CLN6 8.913165 8.083001 MLST8 8.347630 7.774104 SQRDL 7.762558 7.449478 
CLNS1A 8.671966 8.281588 MMAB 6.668573 6.206132 SRC 10.234945 9.163659 
CLPB 7.121259 6.497751 MMD 9.215053 8.135761 SRFBP1 7.839910 7.222369 
CLSPN 5.303277 4.781041 MMP9 8.068881 7.614915 SRGN 13.815140 12.455413 
CLTA 9.933284 9.615444 MMRN2 6.479455 5.746661 SRM 7.888093 7.170912 
CLUH 9.768784 9.529628 MOB3A 11.707178 11.448120 SRP14 10.845261 10.597441 
CMTM6 11.906102 11.035585 MOCS3 8.691873 8.408015 SRP54 8.002305 7.602252 
CNN3 6.820960 6.206765 MON1A 7.413187 7.071667 SRP72 9.179310 8.894731 
CNOT11 9.709498 9.408008 MORC2 7.705041 7.409334 SRP9 9.967364 9.680590 
CNP 10.937742 10.466064 MORF4L1 10.596830 10.206773 SRPK1 9.797016 9.274638 
COA1 8.012314 7.741720 MOSPD2 7.756927 7.397681 SRSF1 11.964795 11.642513 
COA3 8.287246 7.821741 MPDU1 8.430558 7.922400 SRSF3 11.775462 11.517350 
COA4 8.991358 8.394548 MREG 7.117557 5.181648 SSNA1 10.592804 10.302425 
COA7 7.579890 6.927995 MRP63 9.529458 9.225579 SSRP1 9.809276 9.349716 
COBLL1 8.973517 8.495395 MRPL11 8.322521 7.917183 ST3GAL1 10.486214 9.973642 
COCH 9.078915 7.588296 MRPL12 8.062596 7.357958 ST3GAL2 10.486006 10.061668 
COL1A1 6.857237 5.215448 MRPL14 9.168564 8.284072 ST8SIA4 10.843849 9.545750 
COLGALT2 4.685596 4.058487 MRPL15 8.627101 8.153648 STAP2 2.961430 2.451475 
COMMD1 8.959038 7.707865 MRPL17 8.207521 7.880207 STARD10 9.096085 8.154828 
COMMD5 9.871237 9.548700 MRPL19 8.804502 8.530259 STARD4 8.162209 7.843439 
COMT 8.701420 8.316849 MRPL24 7.731779 7.050431 STAT1 9.574033 9.158250 
COPG2 6.497973 5.974801 MRPL27 7.580221 7.122976 STAT5A 11.260231 10.026999 
COPRS 7.994143 7.443738 MRPL28 8.666877 8.245364 STEAP3 6.180058 4.477834 
COPZ1 10.285138 10.034126 MRPL3 8.714764 7.919215 STOML1 6.726405 5.811719 
CORO6 11.326468 9.427760 MRPL32 8.764322 8.483957 STPG1 7.281647 6.644455 
COX17 5.823426 5.370415 MRPL36 7.846684 7.515602 STRAP 9.597562 9.372553 
COX5A 6.973045 6.557911 MRPL37 9.389296 9.049630 STX11 9.973688 9.446696 
COX7A2L 9.487810 9.261207 MRPL39 6.557266 6.047090 STX3 7.829944 7.467894 
CPEB1 7.223028 6.629153 MRPL40 7.746094 7.440217 SUB1 8.829184 8.215384 
CPNE2 6.813111 5.054804 MRPL42 8.386018 8.079644 SUMO2 10.377199 10.051161 
CPNE5 9.438786 8.176859 MRPL45 7.265070 6.915338 SUMO3 10.027051 9.665123 
CPNE7 5.106484 4.110497 MRPL47 5.847583 5.295347 SUPT16H 10.124193 9.755732 
CPSF2 9.391464 9.009151 MRPL51 8.165865 7.801180 SUPT3H 6.186837 5.488567 
CR2 6.738845 6.267896 MRPL54 7.966280 7.678616 SURF4 11.443944 11.243865 
CRIP1 9.296509 8.634115 MRPS10 9.432713 9.037823 SVIP 8.340869 8.051238 
CRIP2 8.525555 7.370123 MRPS12 8.916956 8.502359 SWAP70 12.675376 12.150692 
240 
 
CRLS1 8.638347 8.323464 MRPS16 9.692154 9.287874 SYMPK 9.642911 9.255631 
CRSP8P 8.388007 8.076656 MRPS17 7.119269 6.710258 SYNCRIP 10.469994 10.163489 
CRTC2 10.589636 10.314304 MRPS23 7.432696 7.047559 SYNE3 8.207979 7.745970 
CRYZ 7.827242 7.390413 MRPS28 7.806816 6.994973 SYNGR2 13.464185 12.528527 
CSF1 8.588056 6.895638 MRPS33 7.751515 7.189834 SYNJ2 7.782166 7.020278 
CSF2 3.451823 2.519772 MRPS35 8.508645 8.079009 SYNPO 10.153722 6.053756 
CSF2RB 9.883117 9.054114 MRTO4 9.376004 8.341824 SYT17 9.050578 8.232258 
CSF3 2.606239 2.029545 MS4A1 12.410872 11.717764 SZRD1 11.298148 10.933748 
CSK 11.623607 11.186092 MSANTD4 8.795737 8.440738 TAB2 11.698378 11.232393 
CSNK1G3 9.468515 8.941899 MSMO1 9.264134 8.547382 TAF15 9.916657 9.692615 
CSTF2T 10.428796 10.232224 MST1R 6.111841 4.128007 TAF4B 8.064006 7.610541 
CTPS1 7.377039 6.450445 MTA1 9.388249 9.103762 TAF5L 9.516795 9.237243 
CTSC 9.199341 8.659425 MTAP 8.241751 7.850007 TAF9 9.081695 8.683228 
CTSH 11.163654 10.291645 MTFP1 8.452006 7.512362 TAGLN2 13.733980 12.258672 
CTTNBP2NL 7.716314 6.905920 MTHFD1L 6.363676 5.366743 TANK 10.302654 9.919676 
CX3CL1 2.437301 1.690263 MTHFD2 9.586608 8.622228 TAP1 11.298724 10.679740 
CXCR5 12.877559 12.456348 MTMR2 8.146492 7.740246 TAP2 10.642251 10.327914 
CYB561 7.340160 5.860772 MTMR4 11.463440 10.080724 TAPBP 12.220394 11.749237 
CYB5A 6.638878 5.441235 MTMR9 9.645543 8.858495 TARS 8.906904 8.242432 
CYB5B 10.242533 9.825445 MTSS1 10.668071 10.013121 TBC1D22B 8.561056 8.138291 
CYB5R2 7.796194 6.022419 MTX2 6.815552 6.325500 TBC1D2B 10.032208 9.049683 
CYBRD1 10.000142 8.534640 MVP 10.797627 10.067148 TBCB 9.020743 8.769184 
CYC1 9.632930 9.306122 MYB 7.228954 6.209127 TBL1XR1 10.805846 10.543076 
CYCS 10.174257 9.733597 MYBBP1A 7.726272 7.146765 TBRG4 9.772698 9.482597 
CYFIP1 7.757823 7.233206 MYBL2 8.380864 7.945249 TCF12 9.723818 9.501486 
CYLD 11.957030 11.459893 MYC 10.521312 8.832113 TCF20 10.742757 10.514774 
CYP27B1 4.688566 4.015042 MYCBP2 10.096442 9.827925 TCF7 10.890489 9.567722 
CYP51A1 9.487350 9.021214 MYH11 7.425173 6.732373 TCFL5 10.794507 10.201306 
CYTH1 13.210518 12.945769 MYH9 12.357891 11.893985 TCTN1 7.198530 6.707298 
DAD1 10.362795 9.889217 MYL12B 10.701749 10.474596 TDRD7 8.141130 7.637010 
DAP 10.800324 10.443981 MYL9 8.638088 8.191431 TDRKH 6.205373 5.778333 
DARS 9.018839 8.580734 MYO1C 10.545967 9.401048 TELO2 8.992727 8.566623 
DARS2 8.004923 7.481526 MYO1D 7.995384 7.436831 TET3 10.009276 9.606236 
DAZAP1 10.447024 10.004127 MYOCD 3.657431 2.533665 TFAM 9.661708 9.330951 
DBI 10.096713 9.038786 NAA15 9.488540 9.182523 TFB2M 8.398647 8.089942 
DBNL 9.770108 9.464781 NAA20 8.178708 7.849925 TFEB 11.050039 10.468347 
DCAF13 5.692635 5.084592 NAA25 8.398306 8.090280 TFG 8.981978 8.521861 
DCAF13P3 6.161997 5.648552 NAA50 11.571565 11.348541 TFRC 10.875171 10.233623 
DCAF7 11.113488 10.896294 NABP1 9.322625 8.761503 THEM4 6.952775 6.442299 
DCTD 10.147021 9.838452 NAF1 7.874467 7.579441 THEM5 7.933563 6.165744 
DCTN5 10.351948 10.115690 NAGLU 8.847153 8.407871 THG1L 8.080807 7.399275 
DCTN6 6.581235 6.112838 NAMPT 9.799490 9.291278 THOP1 10.122039 9.236033 
DCTPP1 9.675015 9.134683 NAP1L1 11.102057 10.511211 THUMPD3-
AS1 
8.230218 7.867865 
DCUN1D1 8.303378 8.003244 NARS2 7.495338 7.082037 TICAM1 10.124846 9.717919 
DDB1 9.601359 9.378747 NAT10 8.685440 8.303054 TIFA 10.326543 9.891646 
DDHD2 8.081965 7.778292 NAT9 9.488378 9.222720 TIGIT 10.130076 9.547364 
DDOST 8.633030 8.317007 NBEAL2 10.685164 9.337119 TIMM10 7.241020 6.844844 
DDR1 9.958871 9.027884 NBN 9.422974 8.639423 TIMM13 8.198853 7.844592 
DDX10 7.309083 6.929355 NCBP2 10.543839 10.243878 TIMM17A 8.482745 8.088809 
DDX18 9.840314 9.497607 NCF2 10.544384 8.471848 TIMM23 7.829759 7.283416 
DDX21 11.354940 10.516788 NCK2 10.857647 10.043718 TIMM8A 7.164370 6.811764 
DDX47 8.749479 8.405781 NCL 11.857741 11.436288 TIMM9 6.431036 5.881282 
DEGS1 10.233627 9.841084 NCOA4 10.550600 10.346336 TIMMDC1 9.760773 9.382093 
DENND4A 10.185760 9.134229 NCOA5 10.103580 9.816639 TINF2 10.837482 10.442720 
DENND5A 9.334771 8.511276 NCOA7 9.079821 8.786396 TIPRL 9.533614 9.004596 
DENR 9.495007 9.261046 NDE1 10.433147 8.952034 TJP2 6.968203 6.295178 
DESI1 9.162396 8.748994 NDFIP1 10.218709 9.801049 TLCD1 6.183977 5.369223 
DFFA 8.578228 8.229136 NDFIP2 7.916157 7.351055 TLE1 9.250661 8.652293 
DFNB31 12.965166 12.582890 NDUFA4 7.849776 7.466117 TLR1 7.695650 7.363802 
DGAT2 8.420599 7.389074 NDUFA8 7.055210 6.704298 TLR10 8.833414 7.895474 
DHCR24 7.689489 6.633202 NDUFAF1 8.254683 7.990096 TLR6 9.700161 9.213184 
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DHCR7 7.657594 7.147511 NDUFAF3 8.050014 7.717489 TMA16 8.416628 7.794665 
DHRS12 7.029881 6.604067 NDUFAF4 7.651546 7.346801 TMCC1-AS1 5.051503 4.224050 
DHRS7 9.016918 8.721945 NDUFB3 7.048868 6.634061 TMCC3 8.939670 8.105878 
DHRS7B 6.798910 6.345372 NDUFB7 8.515000 8.078525 TMED3 9.304947 8.902384 
DHX33 8.625903 8.232490 NDUFB9 7.974564 7.627240 TMED9 10.200919 9.959840 
DHX34 8.613748 8.309339 NDUFS6 6.611317 6.201486 TMEM102 8.747298 8.423509 
DHX37 8.631942 8.050883 NECAP2 10.720064 10.045006 TMEM106A 8.104373 7.752912 
DIMT1 7.908405 7.598020 NEDD4L 7.856244 7.346799 TMEM120A 8.223630 6.802074 
DIS3L2 7.451744 7.104865 NEDD9 8.872628 8.002982 TMEM120B 8.766664 8.008669 
DKC1 9.030074 8.693965 NEIL2 8.164141 7.794952 TMEM14A 6.556240 5.909211 
DLD 8.198101 7.707401 NEK6 8.522214 7.881888 TMEM14B 8.346705 7.950855 
DLGAP3 7.776070 6.578548 NEK9 10.641730 10.426091 TMEM164 8.397424 7.731006 
DLGAP4 11.236919 10.845215 NETO2 8.717319 8.291630 TMEM168 8.593803 8.129816 
DNAJA1 9.689130 9.205302 NFAT5 11.029340 10.612006 TMEM170B 9.024246 7.910410 
DNAJB11 8.367030 7.820572 NFE2L1 12.212051 11.444550 TMEM177 6.759224 5.987786 
DNAJB5 7.687672 6.629075 NFIX 5.820519 5.088990 TMEM185B 10.036960 9.460988 
DNAJC14 9.930186 9.698660 NFKB1 11.887017 10.673714 TMEM192 8.626213 8.184823 
DNAJC30 8.179926 7.565202 NFKB2 11.847562 10.689427 TMEM205 9.535070 9.033125 
DNLZ 8.142304 7.767429 NFKBIA 13.378991 11.513359 TMEM230 10.439878 9.974428 
DNMT3A 9.282571 8.547111 NFKBID 10.603088 10.218152 TMEM241 6.025012 5.339959 
DNPH1 7.860551 7.261405 NFKBIE 11.680319 10.479515 TMEM254 7.613192 7.184004 
DOCK10 9.786693 8.975882 NFKBIZ 11.660519 10.729128 TMEM261 8.443876 7.971988 
DOHH 8.596377 8.292136 NHP2 9.171962 8.453737 TMEM5 7.576723 7.102482 
DOK4 5.091302 4.290893 NIFK 7.896608 7.378999 TMEM54 5.223252 3.972289 
DOT1L 10.395443 10.009420 NINJ1 9.387193 8.372370 TMEM63B 8.501244 7.546992 
DPF3 3.827762 3.278327 NIP7 8.965383 8.337970 TMEM69 8.385371 7.863926 
DPH2 9.731684 9.148639 NIPA2 10.501131 10.189379 TMEM97 6.977199 6.424672 
DPH3 9.000870 8.755716 NIPAL2 9.465169 9.153351 TMOD3 10.140120 9.905852 
DPH3P1 7.145036 6.629473 NIPAL4 7.144390 6.044852 TMSB4X 13.337793 12.755582 
DPH6 5.474051 4.809115 NKAP 8.576469 8.306636 TMTC2 7.454597 7.016989 
DPP3 8.044724 7.468552 NKIRAS2 9.462384 9.088322 TNF 9.313076 8.862826 
DPP4 5.615889 4.437248 NLE1 7.255620 6.826055 TNFAIP2 10.123882 7.738956 
DRAM1 8.535357 7.883267 NLN 8.157936 7.562048 TNFAIP3 12.626986 11.050334 
DTD2 8.233984 7.657512 NLRC5 11.336702 10.857789 TNFAIP8 12.002535 11.279374 
DUS3L 8.094284 7.819374 NMD3 8.468278 8.166291 TNFRSF10B 11.718629 11.153782 
DUSP2 11.610133 11.226466 NME1 6.761669 5.270193 TNFRSF14 11.110170 10.422705 
DUSP22 11.308190 10.526991 NME3 9.507197 8.954945 TNFRSF18 11.484693 9.588800 
DUSP23 8.116866 7.778484 NOB1 8.640507 8.214267 TNFRSF1B 12.974022 12.670121 
DUSP5 11.353803 10.364759 NOL10 7.529011 7.168125 TNFRSF4 9.518841 7.287392 
DYNLT3 9.098009 8.730422 NOL3 4.347847 3.758208 TNFRSF8 7.803850 5.861107 
E2F3 8.954177 8.588114 NOL6 9.050206 8.539976 TNFRSF9 11.446292 8.237760 
E2F4 9.943281 9.738082 NOL7 9.426097 9.052982 TNFSF14 6.944501 6.183331 
EARS2 8.127183 7.245363 NOLC1 10.483801 9.874967 TNFSF4 9.415078 6.609572 
EBI3 9.269462 5.199360 NOM1 9.161347 8.917194 TNIP1 11.138068 10.849795 
EBNA1BP2 7.371788 6.830576 NONO 11.351430 11.131721 TNIP2 10.909777 9.939449 
ECE1 12.490048 11.491398 NOP10 9.136509 8.700580 TNKS1BP1 9.322958 8.241286 
ECE2 6.384320 5.681868 NOP14 8.139814 7.697511 TNPO2 10.021142 9.756997 
ECHDC3 6.021558 5.100659 NOP14-AS1 7.353937 6.881610 TOMM22 9.647716 8.906735 
EDARADD 11.561143 10.386043 NOP16 7.879438 7.267071 TOMM34 8.587237 8.157183 
EED 8.292183 7.855362 NOP2 9.022405 8.726353 TOMM40 8.906000 8.460348 
EEF1A1 9.740196 8.878996 NPAT 9.223587 8.738073 TOMM40L 6.324965 5.933175 
EEF1B2 7.747933 7.397113 NPEPPS 9.915555 9.691010 TOMM5 8.988147 8.653162 
EEF1E1 6.170963 5.640734 NPLOC4 11.049301 10.794901 TOMM6 9.479941 9.042533 
EEF2K 10.179386 9.494892 NPM1 8.798452 8.370647 TOMM70A 9.835480 9.575854 
EEFSEC 8.009831 7.581077 NPRL3 7.515490 7.011852 TOR4A 9.770530 9.540890 
EFHD2 11.458127 10.770600 NR6A1 6.438676 4.427152 TP53 9.936214 9.541956 
EFNA1 3.699841 3.097234 NRAS 10.748267 10.003370 TP53BP2 9.720210 9.213191 
EFNB1 7.483093 6.948633 NRBF2 9.150481 8.589771 TP53I11 11.218256 10.448119 
EFTUD2 8.188129 7.859283 NRIP1 7.584296 7.070123 TP63 3.847818 3.262194 
EGOT 4.023727 2.740179 NRP2 7.944364 6.181097 TPI1 10.360010 10.071867 
EHD1 13.106831 12.220688 NRXN2 4.326183 3.380007 TPRN 8.811648 8.338478 
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EHD4 10.141257 9.688717 NSDHL 6.806515 6.336584 TRADD 10.377793 9.619065 
EID1 10.358631 10.086009 NSRP1 9.017231 8.740755 TRAF1 14.294991 11.341724 
EIF1 12.563976 12.269308 NSUN4 9.346961 8.979846 TRAF2 9.516173 9.124961 
EIF2A 8.742341 8.377545 NT5DC1 8.300796 7.820537 TRAF3 11.424986 11.066430 
EIF2B1 8.841053 8.600033 NT5DC2 7.116475 6.560155 TRAF4 12.142777 11.327350 
EIF2D 7.484642 7.052035 NT5DC3 7.832365 7.522877 TRAF7 8.410695 8.090477 
EIF2S1 9.730198 9.233359 NTN1 5.032037 4.376422 TRAPPC1 9.070315 8.796528 
EIF2S2 8.864998 8.479561 NTNG1 5.265678 4.719032 TRDMT1 6.346366 5.903685 
EIF2S3 10.714865 10.400510 NUCKS1 11.297647 10.977246 TRIM44 11.335897 11.069679 
EIF3B 10.155828 9.744755 NUDCD1 7.423995 6.911040 TRIP10 10.328015 8.631040 
EIF3J 9.591579 9.283072 NUDT19 8.425106 8.086554 TRIP12 10.483927 10.166014 
EIF4E2 9.651182 9.400125 NUDT9P1 4.622940 3.894760 TRIP13 3.809468 3.191958 
EIF4G1 10.600627 10.091480 NUP153 10.555562 10.143840 TRIP6 6.714911 6.301206 
EIF4H 10.932307 10.715490 NUP35 5.801097 5.359713 TRMT1 9.275649 8.942430 
EIF5A 10.928464 10.310727 NUP62 12.430531 11.549157 TRMT10C 8.994675 8.661997 
EIF5B 9.245331 8.854386 NUP93 6.984993 6.568522 TRMT2A 8.804333 8.515659 
EIF6 8.885419 8.439548 NUPL1 9.101593 8.679578 TRMT5 7.927207 7.415474 
ELAC1 6.580964 6.120649 NUS1 7.913726 7.485205 TRMT6 8.254027 7.896044 
ELAVL1 10.664109 10.131774 NUTF2 9.234528 8.672746 TRMT61A 9.628466 8.746008 
ELK1 9.563684 9.201237 NXPH3 3.903172 2.837690 TRMT61B 7.857321 7.447324 
ELK3 9.482506 8.724017 OAS3 8.327328 7.615395 TRPM7 10.135779 9.830924 
ELL2 9.172741 8.682189 OGFOD1 8.756864 8.499564 TRUB2 7.778759 7.374902 
ELMO2 8.806734 8.553729 OLA1 7.206073 6.796271 TSC22D2 10.582004 10.134665 
ELP6 7.239468 6.887568 OPA3 10.086520 9.543271 TSEN15 9.129782 8.495589 
EMC3-AS1 6.760477 6.230543 ORAI1 11.274131 10.287912 TSN 10.132302 9.924649 
EMG1 7.243880 6.647704 ORMDL2 8.166927 7.615106 TSPAN18 7.017012 5.534969 
EMILIN2 10.098620 9.302277 OSBPL9 8.013765 7.529188 TSPAN31 8.068237 7.702755 
EMP3 9.613166 8.990700 OSGIN2 9.166562 8.832662 TSPAN33 12.303193 10.283235 
ENO1 10.994280 9.882808 OSTC 8.496213 8.177574 TSPAN9 5.325559 4.601334 
ENPP4 9.647524 8.756243 OTUD4 10.477484 10.069244 TSR1 8.312162 7.795862 
ENPP5 4.598702 3.988937 OTUD6B 7.685564 7.349359 TTC27 6.512870 5.873235 
ENSA 10.999292 10.527974 OTUD7B 7.250872 6.303337 TTC7A 10.331215 9.996718 
EPHB4 5.191450 4.449017 OXTR 5.635789 3.807741 TTC7B 4.275766 3.605484 
EPM2AIP1 10.810939 10.164185 P4HA1 8.528242 8.203408 TTF2 9.356586 8.327812 
EPRS 8.982949 8.643499 PA2G4 9.775445 9.552060 TTLL12 8.444566 8.069751 
EPS15 11.036546 10.059130 PA2G4P4 10.020433 9.623298 TTPAL 9.322595 8.937734 
ERAL1 8.685289 8.213674 PABPC4 10.547606 10.317212 TUBA1B 10.848457 10.210065 
ERAP1 9.887675 9.659699 PAICS 9.134846 7.699182 TUBA1C 9.199981 8.133569 
ERH 10.043745 9.677365 PAK1 8.545398 8.048614 TUBB 12.707796 11.604997 
ERI3 8.424851 8.126820 PAK1IP1 6.522006 5.764698 TUBB2B 2.841586 2.242760 
ESAM 6.254439 4.830313 PANDAR 9.177343 8.838755 TUBB4B 11.643196 11.331979 
ESF1 8.003242 7.484752 PANK3 8.602533 8.328188 TVP23A 7.276266 6.155615 
ESPL1 6.890428 5.672931 PANX1 9.027620 8.586872 TWISTNB 8.683693 8.169561 
ESR1 6.083984 5.631277 PAOX 8.214119 7.750512 TXLNA 10.989458 10.664550 
ETFA 7.017212 6.201779 PAQR7 8.854436 8.368501 TXLNB 9.126221 8.634355 
ETFDH 6.581891 6.143651 PAQR8 9.523847 8.904218 TXN 7.501624 5.910335 
ETS1 12.672549 12.313324 PARK7 9.891294 9.018842 TXNDC9 7.556201 7.197992 
ETV3 10.436978 10.066657 PARP1 9.838794 9.506090 TXNL4A 10.294624 9.937864 
ETV3L 3.139902 2.375260 PARP12 9.786372 9.523261 TYK2 11.027574 10.565079 
EXO5 8.017360 7.665233 PARP14 11.659602 11.181127 TYMP 9.613168 9.319997 
EXOC4 8.561517 8.246410 PASK 10.532334 10.087788 TYW3 8.768483 8.371809 
EXOSC4 8.307846 7.899326 PATL1 9.429255 9.108881 UBAP2 7.856436 7.548913 
EZH2 8.067831 7.127078 PAX5 13.281801 12.240065 UBAP2L 9.294265 9.043515 
F13A1 4.777664 4.247873 PBRM1 9.651934 9.380841 UBE2A 9.629728 9.370900 
FAIM 5.940826 5.505305 PCK2 8.463421 7.692137 UBE2D1 7.966103 7.663846 
FAM105B 10.233823 9.556243 PCNX 10.172700 9.847484 UBE2E1 9.390119 9.127862 
FAM114A1 6.856539 6.263542 PDAP1 9.882140 9.475328 UBE2E2 6.433376 6.063342 
FAM118A 9.454661 9.173249 PDCD11 8.672859 8.281096 UBE2G2 10.688357 10.301486 
FAM129A 8.018693 6.484584 PDCD4 11.601370 10.813439 UBE2K 9.785201 9.528023 
FAM136A 9.539524 9.285749 PDCD4-AS1 8.760851 8.351390 UBE2N 10.234794 9.844370 
FAM168A 10.085239 9.682018 PDE7A 10.853305 10.387463 UBE2NL 4.539745 4.006996 
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FAM174B 7.258122 6.590849 PDF 7.073132 6.078748 UBE2Z 12.385105 11.696911 
FAM195B 9.788144 9.246058 PDIA3 10.376355 9.818654 UBE3A 10.384362 10.093619 
FAM208B 10.059183 9.785314 PDIA3P1 12.175497 11.522090 UBE3C 9.670613 9.272981 
FAM20B 9.954516 9.691905 PDIA4 10.011790 9.409025 UBFD1 10.022616 9.666346 
FAM213B 9.684299 8.760150 PDLIM5 8.511091 8.159868 UBIAD1 9.488096 9.175826 
FAM35A 7.508943 7.119892 PDZD11 6.104070 5.663184 UBLCP1 8.896982 8.258346 
FAM3C 7.973045 7.621746 PEA15 12.538113 11.685491 UBQLN4 9.046778 8.790737 
FAM49A 9.340787 8.167888 PEAK1 10.507036 10.196644 UBR4 10.074611 9.726865 
FAM60A 11.823095 10.838077 PEF1 10.190571 9.722666 UBTD2 8.570790 8.221371 
FAM83H 6.759413 6.014580 PELP1 9.694943 9.453192 UCK2 9.219775 8.467990 
FAM86C1 5.403617 4.853249 PES1 8.910037 8.361037 UEVLD 8.298677 7.907438 
FAM86DP 5.772754 5.354781 PET112 6.001971 5.504172 UGDH 8.709954 8.126218 
FAM98A 8.616719 8.277720 PEX10 6.814891 6.184313 UHRF1BP1L 8.453281 8.106538 
FAM98B 8.492891 7.809622 PEX26 9.951161 9.585986 UMPS 8.915494 8.425477 
FARSA 8.165520 7.818446 PFAS 8.629303 7.898671 UNC119 9.356146 8.784654 
FARSB 6.418428 5.728445 PFDN1 9.470067 9.173954 UPK3A 4.180361 3.508476 
FAS 9.197810 7.359137 PFKM 7.820353 7.215517 UPP1 6.751064 6.293203 
FASN 9.207352 8.398556 PFN1 13.246138 12.142713 UQCRFS1 8.515445 8.213243 
FASTKD2 8.354698 7.893753 PGAM1 8.294589 7.810328 URB1 7.981934 7.325966 
FBRS 11.729537 11.442207 PGAP2 8.055788 7.750183 URB2 8.758657 7.892362 
FBRSL1 10.796395 10.385901 PGBD4 6.822748 6.307238 URM1 9.819218 9.592057 
FBXL15 10.127009 9.766797 PGD 9.003495 8.531775 USP10 10.126587 9.710156 
FBXL19-AS1 7.033082 6.513874 PGK1 9.683183 9.293224 USP12 11.682897 10.871620 
FBXO22 7.664799 7.192479 PGLS 8.838932 8.504468 USP14 8.891787 8.585538 
FBXO45 8.387721 8.113579 PGM2 7.199569 6.787160 USP5 9.035419 8.741064 
FBXW5 10.932340 10.715262 PHAX 9.268312 8.965056 UST 7.062327 6.144689 
FBXW7 8.853351 8.559273 PHB 9.962317 9.057233 UTP14A 7.447608 7.028466 
FCER2 10.318987 10.035967 PHLDA2 6.007557 4.862256 UTP14C 9.591462 9.330928 
FCGBP 7.265702 6.453789 PHLDB1 6.510090 5.512804 UTP15 7.572322 7.072309 
FCHSD2 10.723601 10.153547 PHPT1 8.688569 8.163534 UTP20 7.013375 6.528684 
FDX1L 6.980084 6.397543 PICALM 9.668145 9.396461 UTP3 10.300720 10.022778 
FDXACB1 6.839687 6.361020 PIGV 8.421741 7.868879 UVRAG 10.386338 9.948415 
FEN1 8.812823 8.437314 PIGW 7.745143 6.997210 VAMP8 9.857040 9.588616 
FERMT3 9.918868 9.611577 PIGX 8.542610 8.144933 VARS 9.265724 8.390139 
FGF2 5.633130 4.946195 PIK3CA 8.865319 8.395123 VASP 10.456152 10.105105 
FH 6.161355 5.681020 PIK3CD 11.617311 11.079126 VBP1 9.011944 8.637342 
FHOD1 9.608529 8.593707 PIKFYVE 10.310258 10.060474 VCP 11.403338 10.968154 
FILIP1L 10.024974 9.362351 PIM1 13.276048 12.783845 VDAC1 10.325222 9.408011 
FJX1 2.225670 1.653672 PIM2 12.886344 12.433879 VIM 11.406069 10.003573 
FKBP11 7.156528 6.796760 PIM3 12.411253 11.934360 VKORC1 9.605630 9.241107 
FKBP1A 10.010083 9.582641 PINX1 7.452150 6.960361 VMP1 9.973448 9.603005 
FKBP2 8.786262 8.411954 PIP5K1A 9.705481 9.443053 VOPP1 11.044500 10.360267 
FKBP5 9.978102 9.121054 PIPSL 11.670281 11.174747 VPS13A 8.039587 7.533280 
FKRP 8.841880 8.550253 PISD 9.614068 9.317349 VPS25 7.829250 7.455321 
FKTN 8.045750 7.468121 PITPNB 10.088450 9.491887 VPS29 9.388680 9.118605 
FLAD1 9.399397 9.161590 PKIG 9.868467 9.327650 VPS37C 8.375623 8.012260 
FLJ13224 4.083211 3.421382 PKM 12.908717 11.664732 VTA1 8.785572 8.509943 
FLNA 12.291272 11.965005 PKN3 7.932098 7.163627 WARS 11.255112 9.945227 
FLNB 9.294826 8.372285 PLA2G4C 6.883091 5.884382 WARS2 7.562730 7.148344 
FLOT1 9.355959 8.883141 PLAGL1 9.337374 8.287766 WBP4 7.638530 7.336013 
FLVCR2 6.394650 5.805037 PLAGL2 9.527218 9.248221 WBSCR16 9.391856 9.172848 
FMNL1 12.574550 12.203994 PLAU 7.726272 4.957648 WDFY1 10.738492 10.317470 
FMNL3 10.860717 9.882385 PLCB3 8.134647 7.205018 WDR1 11.139408 10.718894 
FMO5 10.027877 9.648700 PLD2 8.173363 7.717127 WDR12 6.550665 5.934566 
FMOD 13.178568 12.568257 PLEC 13.370491 12.986661 WDR17 6.600760 6.090990 
FNBP1 13.141927 11.889397 PLEK 11.820043 9.573045 WDR3 7.292173 6.680622 
FNDC3B 7.093915 6.426965 PLEKHA7 8.607026 7.993442 WDR36 9.053057 8.678816 
FOXC1 5.387073 4.907138 PLEKHG1 12.249664 11.854104 WDR4 8.040739 7.295192 
FOXN3-AS1 4.972550 3.871487 PLEKHG5 5.008240 4.328656 WDR43 9.119591 8.469512 
FOXP1 12.063357 11.716763 PLEKHM2 11.087140 10.782799 WDR5 9.774212 9.451674 
FOXP4 11.156509 9.639759 PLEKHO2 10.310016 10.041502 WDR75 7.465193 7.071988 
244 
 
FPGS 9.716776 9.120571 PLGRKT 6.103763 5.401875 WDR77 8.785428 8.158238 
FRK 3.869077 3.168217 PLIN3 9.783327 9.188785 WDR89 9.285981 8.951965 
FSCN1 8.359925 6.735501 PLLP 4.001018 2.919481 WHAMMP3 6.578473 5.663220 
FSD1L 8.281042 7.202633 PLXNA1 10.758591 9.352370 WIZ 9.367094 8.938105 
FUNDC2 8.092592 7.666260 PMM2 9.268322 8.672864 WNK1 11.747667 11.503728 
FUT4 8.318240 7.819279 PNO1 8.648479 7.953727 WNT10B 4.978477 4.084999 
FUT8 8.026474 7.606743 PNP 8.329640 8.005619 WNT4 7.063380 4.618728 
FXN 7.258313 6.609287 PNPO 8.004336 7.676939 WSB2 10.060612 9.741505 
FXYD2 2.782408 2.256710 PNPT1 7.552026 7.033123 WWP2 9.087196 8.840427 
FXYD6 7.205289 5.942479 POFUT1 9.309040 8.884672 XBP1 10.632708 9.965839 
FZD6 6.214363 5.388860 POGLUT1 8.568576 8.275839 XPO1 10.469334 10.190956 
G3BP1 11.143771 10.642575 POLA2 7.857485 7.172694 XPO4 9.519483 9.236519 
G6PC3 7.975146 7.615333 POLD2 9.776221 9.264789 XPO5 8.153275 7.764126 
GABPB1 8.885364 8.405799 POLDIP2 9.423997 9.012998 XPOT 8.525360 8.078514 
GADD45GIP
1 
10.090108 9.624760 POLR1B 8.694538 8.201542 XRCC5 10.014226 9.708329 
GALNT10 9.378978 8.891046 POLR2D 9.295356 8.977444 XRCC6 9.717395 9.299643 
GALNT2 12.118198 11.268887 POLR2K 9.033526 8.749009 YARS 9.769455 9.167552 
GAR1 7.954412 7.419015 POLR2L 7.320525 6.961812 YARS2 8.390225 8.095343 
GARS 8.313743 7.556704 POLR3A 8.150369 7.840235 YBX1 10.934528 10.523804 
GART 8.854727 8.234206 POLR3H 8.591184 8.059028 YIF1A 8.449970 8.154144 
GBE1 7.387729 6.710232 POP1 6.897258 6.343253 YKT6 11.024983 10.791576 
GBGT1 8.448187 7.522117 POR 9.199681 8.743459 YWHAB 11.913422 11.649651 
GBP1 5.379221 4.595941 POU2F1 9.637037 9.358057 YWHAE 11.154669 10.601266 
GBP4 8.824976 8.277743 POU3F1 7.190971 6.161185 YWHAG 11.709213 11.358525 
GCDH 8.321036 7.721776 PPA1 6.537332 5.505475 YWHAQ 11.056517 10.743142 
GCFC2 7.693007 7.343095 PPAP2A 6.710423 6.196099 ZBED4 9.464340 9.093862 
GCN1L1 9.683952 9.389101 PPARA 10.093210 9.313365 ZBTB10 11.225886 10.497397 
GEMIN4 9.101899 8.702469 PPIA 10.499905 10.125560 ZBTB11-
AS1 
5.648287 5.168952 
GEMIN5 7.752069 7.283346 PPID 8.324802 7.786611 ZBTB17 9.735666 9.391653 
GEMIN8 8.124135 7.707728 PPIF 10.319382 9.493192 ZBTB32 11.885600 10.650887 
GEN1 9.346103 9.056499 PPIL1 9.005520 7.992625 ZBTB46 7.226931 6.371113 
GFI1 7.837560 6.999398 PPIP5K1 7.953659 7.645027 ZBTB5 11.128985 10.405202 
GFM1 7.864778 7.416451 PPP1R11 10.582639 10.322294 ZC3H15 9.313589 9.043010 
GGACT 6.640305 6.026339 PPP1R14B 9.603229 8.188461 ZC3H4 9.870583 9.507618 
GGCT 7.874824 7.361200 PPP1R15B 11.939538 11.607335 ZC3H7B 11.396274 10.516069 
GHITM 9.933420 9.662755 PPP1R7 7.434149 7.067590 ZCCHC7 10.033184 9.473843 
GHRL 4.229131 3.471176 PPP1R9B 12.979889 11.832230 ZCRB1 8.840581 8.547557 
GIPC1 8.136982 7.738207 PPP2CA 10.145646 9.941799 ZDHHC16 7.932238 7.625697 
GJD3 6.905464 6.134697 PPP2R1A 9.330812 9.096271 ZDHHC18 11.044687 10.241992 
GLB1 7.800182 7.449630 PPP2R2D 9.286233 9.011759 ZFAND3 10.798376 10.538253 
GLRX3 7.668560 7.301183 PPP3CB 8.820565 8.377265 ZFHX2 7.328407 5.512616 
GLUD1 10.372901 10.147006 PPP5C 7.701738 7.230559 ZFHX3 9.143519 8.888074 
GLYR1 10.728079 10.467554 PPRC1 10.246130 9.685230 ZFP36L1 14.349030 13.274213 
GMEB1 7.801590 7.378809 PPT1 9.488273 9.237922 ZFP41 8.097987 7.788214 
GMFB 9.864544 9.579812 PPTC7 10.941491 10.694623 ZFYVE26 9.225504 8.755941 
GNAI3 9.648212 9.389955 PRCC 10.425794 10.160781 ZMAT3 9.418587 9.135108 
GNB1 11.958349 11.788055 PRDX1 9.207868 8.227622 ZMIZ2 11.906237 11.381084 
GNB2L1 12.310337 12.078001 PRDX3 9.362231 8.959195 ZNF202 8.655611 8.328010 
GNG2 11.678765 11.280919 PRDX4 6.835312 6.228462 ZNF207 9.812598 9.378150 
GNG4 4.739941 4.084788 PRDX6 9.394917 9.109747 ZNF22 10.661479 10.172978 
GNG8 8.391163 5.687375 PRELID1 8.506013 7.992342 ZNF239 6.055177 5.323164 
GNL3 7.536946 7.196495 PREX1 10.426619 9.729047 ZNF260 9.919221 9.386619 
GNL3L 9.754527 9.397114 PRKAG2-AS1 6.090511 5.295968 ZNF267 10.561853 10.013919 
GNN 4.698072 4.074675 PRKAR1B 8.334243 7.426230 ZNF281 9.684547 9.186884 
GNPDA1 9.336072 8.919020 PRKCD 9.124562 8.249949 ZNF385C 7.040418 5.985955 
GNPNAT1 7.572381 7.212993 PRKDC 9.458682 9.076730 ZNF485 6.211379 5.618005 
GOLGA4 9.763829 9.549074 PRMT1 9.225952 8.859490 ZNF506 9.621447 9.188562 
GOSR1 9.676146 9.366938 PRMT2 10.085140 9.825305 ZNF593 7.719083 7.218397 
GOSR2 10.047498 9.622517 PRMT3 7.097821 6.597144 ZNF598 9.885906 9.611324 
GOT2 9.627328 8.727060 PRMT6 9.777467 9.460416 ZNF629 7.697979 7.345888 
GPATCH2L 10.070567 9.860935 PROB1 7.677366 7.223478 ZNF660 5.848110 5.393682 
245 
 
GPATCH4 9.435879 8.314691 PROSER1 9.590228 9.340378 ZNF706 8.578383 8.005280 
GPN1 8.166313 7.853822 PRPF19 9.700425 9.392673 ZNF710 10.424204 9.833169 
GPR132 11.048303 9.984089 PRPF40B 7.804841 7.209735 ZNF770 10.899827 10.656945 
GPR137 10.098102 9.431562 PRR18 7.312743 6.236891 ZNF780B 8.201468 7.877446 
GPR137B 8.429158 7.901980 PRRC2C 11.822686 11.491226 ZNF788 6.545033 5.402474 
GPR153 7.107124 6.219872 PRRG4 6.145901 4.992237 ZNFX1 11.231209 10.546836 
GPR157 8.054558 7.129877 PRRT2 6.903383 5.736598 ZNHIT6 8.797898 8.385863 
GPR55 6.507167 5.394587 PRRT3 8.165058 6.210247 ZRANB2 10.155034 9.850461 
GPRIN1 7.621375 7.216902 PRSS2 3.432196 2.727453 ZSCAN2 9.873474 8.701526 
GPSM3 11.010178 10.689030 PSAT1 5.512466 4.372260 ZSWIM4 9.725050 8.338401 
GRASP 9.295785 8.960126 




Appendix 5. Significantly down-regulated genes induced by the soluble CD40 ligand in 



















AATK 6.133189 6.749115 GRAP 7.997716 8.521510 PVRIG 7.588851 8.343843 
ABCA1 5.973675 6.767113 GRB7 5.092449 5.661817 PXK 9.158629 9.634712 
ABCA2 4.834033 5.429726 GRIK3 4.735380 5.422001 PYCARD 5.784908 6.638890 
ABCA7 8.470958 9.591706 GRIN3B 6.251483 6.785992 PYROXD2 6.510701 6.903359 
ABCB1 4.608725 5.705022 GRK5 7.025424 7.660943 QPCTL 8.435864 9.080690 
ABCB8 7.902289 8.198055 GRK6 8.537255 8.866517 QRICH2 6.436064 6.837585 
ABCC2 4.338211 5.000297 GSDMB 7.444153 8.253443 QSOX1 8.800525 9.081656 
ABCC5 6.844759 7.369519 GSDMD 10.032947 10.317981 QSOX2 10.224398 11.398356 
ABCD1 6.129854 6.797413 GSE1 9.230798 9.764541 RAB11FIP4 8.502227 9.462823 
ABCD4 8.529159 8.883973 GSTM4 5.032980 5.655547 RAB31 9.405049 9.663168 
ABCG1 7.634479 8.143359 GTPBP1 10.461498 10.877026 RAB33B 8.740516 9.003045 
ABHD10 7.903102 8.230830 GTSF1L 4.343880 5.072657 RAB37 7.181481 8.058940 
ABHD14A 5.573807 6.242763 GUCY2C 4.608779 5.179024 RAB3D 6.473006 6.985621 
ABHD14B 9.481911 9.789333 GUSBP11 7.849724 8.372132 RAB40B 4.759678 5.591309 
ABHD15 9.786064 10.645422 GYLTL1B 7.929450 8.834090 RAB40C 8.595411 9.091081 
ABHD16A 7.385525 7.768014 H1FX-AS1 5.423147 6.247697 RAB6B 4.842499 5.334095 
ABHD17A 8.948996 9.586660 H2AFJ 8.950285 9.317964 RABAC1 8.035641 8.395935 
ABHD3 8.060583 8.414214 HAGH 6.460491 6.965559 RABEP2 8.534016 8.861350 
ABHD4 9.061040 9.455371 HAS3 5.256872 5.797601 RAD9A 8.202491 8.918814 
ABI3 3.778964 4.313899 HAUS8 6.144151 6.599591 RALB 8.817555 9.109791 
ABLIM1 9.748820 10.694978 HBP1 8.898411 9.151143 RALGDS 9.134213 9.666851 
ABR 11.317246 11.597567 HCG23 4.415453 5.512879 RALGPS2 10.806984 11.195940 
ABTB1 9.307446 9.878499 HCG27 5.587147 6.395982 RANBP10 9.452674 9.759268 
AC074289.
1 
7.206153 7.675569 HCN2 4.392883 5.149239 RAP1GAP2 5.111532 6.322159 
ACACB 5.708070 6.748499 HDAC1 10.078287 10.293154 RAPGEF2 8.634316 9.171403 
ACAD8 8.048175 8.480083 HDAC10 8.231103 8.806651 RAPGEF3 8.043623 8.931204 
ACAP1 8.476415 9.175375 HDAC5 8.372640 9.020000 RARRES3 4.621867 5.298837 
ACAP2 9.802013 10.035609 HDAC7 11.285861 12.005942 RASA2 8.583111 8.897256 
ACAP3 6.602093 7.104923 HEATR5B 7.803049 8.126348 RASA3 7.596418 9.158674 
ACBD4 7.812576 8.132696 HEATR6 7.687235 8.085990 RASAL1 5.484986 6.417132 
ACD 8.113525 8.417379 HECA 10.358230 10.809660 RASAL3 9.404958 9.658980 
ACRC 6.074742 6.608365 HELZ2 9.761569 10.258493 RASD1 7.766963 8.503600 
ACSF2 6.390143 7.153407 HERC3 7.585876 8.051632 RASGRP2 9.196907 10.227206 
ACSM1 4.895042 5.486403 HEXDC 9.157525 9.399863 RASSF1 9.435357 9.904248 
ACSM3 4.017295 5.039782 HGSNAT 9.518951 9.873857 RASSF7 8.879235 9.337233 
ACSS1 9.222871 9.780176 HHEX 8.942484 9.837704 RB1CC1 9.114157 9.403434 
ACSS2 6.380653 6.953800 HIP1R 6.996844 8.418407 RBL2 9.777917 10.054221 
ADAM28 9.737601 10.376487 HIRIP3 7.458607 7.816084 RBM33 10.345634 10.727822 
ADAM29 5.385311 5.974511 HIST1H1C 8.711670 9.103416 RBM38 11.877033 12.676641 
ADAMTS6 6.647804 7.728968 HIST1H2AC 8.236810 8.697503 RBM39 11.110248 11.350753 
ADCK2 8.411243 8.872034 HIST1H2BD 7.363954 7.896124 RBM5 10.075314 10.370533 
ADCK3 8.548656 9.017088 HIST2H2BE 7.212281 7.621381 RBM5-AS1 5.972606 6.383502 
ADCY4 4.317554 4.947945 HLA-DMA 10.080573 10.818787 RBMS2 6.624578 7.343560 
ADCY9 5.019681 5.544475 HLA-DMB 9.846079 10.700509 RCN3 5.426221 5.993934 
ADD3 9.248780 9.835022 HMCES 8.225735 8.798913 RCOR1 9.009501 9.313104 
ADHFE1 4.018967 4.578741 HMGB2 8.689514 9.088870 RCOR3 9.132271 9.364035 
ADM 7.206325 7.943240 HMGN3 9.045223 9.501433 RCSD1 11.676576 12.496041 
ADPGK 10.376106 10.691632 HMOX1 9.911535 10.712648 REC8 6.538022 6.972879 
ADRB2 7.423097 8.212271 HNRNPU-
AS1 
8.211931 8.534725 REEP2 3.595279 4.407040 
ADRBK1 11.384728 11.803205 HOMER2 7.856529 8.502867 REEP5 9.301668 9.595123 
AES 12.083341 12.390484 HPCAL1 9.399352 10.476313 RELL1 3.943880 4.530999 
AFAP1L2 3.647477 4.286356 HPS3 7.432939 7.930086 REM2 6.095153 6.988161 
AFF1 8.847233 9.171482 HRK 5.464400 6.173399 RERE 9.971686 10.480111 
AFF3 10.330349 10.843432 HS2ST1 8.661962 9.014164 REST 9.748158 10.005614 
AFF4 10.322327 10.617507 HS3ST1 8.449186 8.879847 REV3L 8.634384 9.124888 
AGFG2 7.883589 8.290486 HSD17B11 8.652646 9.054799 RFC5 7.507528 7.822487 
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AGPAT5 10.697817 11.499960 HSDL1 8.751460 9.120977 RFX1 7.784084 8.219485 
AHCYL2 7.614685 7.963869 HSH2D 10.660703 11.128966 RFX7 9.086156 9.372220 
AHDC1 8.820625 9.295512 HSPA7 5.092305 5.930550 RGCC 7.958183 9.203274 
AHI1 7.636596 8.074539 HSPBAP1 7.207226 7.572417 RGL2 8.770918 9.185766 
AHNAK 13.658364 14.037162 HSPG2 5.190947 5.794598 RGL4 8.162692 8.618997 
AHSA2 10.403873 10.647037 HTATSF1P2 6.840287 7.750692 RGMB 7.489607 7.945997 
AK1 7.819495 8.673349 HTRA3 4.371417 5.920171 RGS14 8.029768 8.679525 
AKAP8L 9.251761 9.655961 ID3 12.476878 13.181651 RGS2 10.778911 11.784790 
AKAP9 9.309062 9.584024 IDS 11.809656 12.195561 RHBDL1 4.885492 5.547147 
AKIP1 7.234394 7.754659 IER5L 7.048551 7.416035 RHOB 10.155095 10.476382 
AKNA 11.266922 11.579818 IFFO1 8.633431 9.113453 RHOBTB2 9.402958 9.920320 
AKR7A2 7.257890 7.606683 IFI16 10.124042 10.362669 RHOH 11.236112 11.873766 
AKT2 11.004235 11.270433 IFIT2 6.578272 7.191054 RHPN1 8.879991 9.884127 
ALAD 8.242243 9.022849 IFITM1 6.108431 6.778861 RICTOR 9.018117 9.350232 
ALDH3A2 7.775564 8.442052 IFNAR2 9.190470 9.661205 RILPL1 4.963055 5.896285 
ALDH5A1 9.645917 10.360725 IFT57 8.997732 9.428015 RILPL2 10.178438 10.515205 
ALKBH4 7.197659 7.586700 IGIP 7.193167 7.532628 RIN3 10.258510 10.779131 
ALKBH5 10.837891 11.272378 IGSF8 8.058436 8.745264 RINL 9.676402 9.922413 
ALKBH6 7.683129 8.007853 IKZF3 12.008473 12.331165 RITA1 7.958093 8.398009 
ALOX15P1 4.436965 5.060935 IKZF5 8.992221 9.328012 RMI2 4.837376 5.547324 
ALOX5 10.358093 10.965044 IL10RB 9.010366 9.278254 RN7SK 8.219503 8.649636 
ALOX5AP 7.442012 8.387270 IL11RA 6.856667 7.520060 RNASE4 4.524366 5.149459 
ALX3 6.466696 6.913096 IL16 10.695893 11.405375 RNASE6 6.031679 7.370077 
AMDHD1 3.580233 4.193436 IL17RA 9.208831 9.597057 RNASEL 8.002411 8.429297 
AMFR 10.536876 10.977919 IL1R1 4.356608 4.935972 RNASET2 8.821844 10.586025 
AMH 4.670040 5.214378 IL1RAP 6.364588 6.906282 RNF113A 9.231032 9.645644 
AMN 5.042376 5.598243 IL24 6.719040 7.596447 RNF122 6.487833 6.928238 
AMT 6.262857 6.807356 IL27RA 8.351263 8.727791 RNF125 6.165343 7.037496 
AMY2B 5.907363 6.364947 ILF3-AS1 7.986957 8.335352 RNF130 8.178960 8.565446 
AMZ2 9.910971 10.318514 INF2 8.627624 9.473770 RNF135 8.199684 8.556753 
ANAPC4 7.038698 7.345787 ING1 9.620655 10.025611 RNF149 9.474679 9.936752 
ANK1 5.416342 6.521979 ING2 7.447629 7.820764 RNF166 8.269763 9.095731 
ANKMY1 7.176582 7.533414 ING4 8.103686 8.487843 RNF19A 9.449944 9.973906 
ANKMY2 7.085334 7.443162 INO80E 9.212549 9.568863 RNF213 10.486957 10.791491 
ANKRA2 7.974963 8.450435 INPP5A 8.173986 8.845767 RNF24 6.779816 7.421146 
ANKRD13A 10.421929 10.815246 INPP5D 10.341620 10.769307 RNF38 9.785074 10.120919 
ANKRD13D 7.863416 8.230662 INPPL1 9.920803 10.161482 RNF41 10.657678 11.335469 
ANKRD34A 4.391013 5.140965 INSIG2 8.323545 8.752144 RNF44 10.227713 10.776986 
ANKRD42 7.374457 7.930625 IP6K2 9.746680 10.207471 RNFT2 4.581723 5.197117 
ANKRD44 10.006203 10.561394 IPW 5.035797 5.624413 RNR1 13.322638 13.620757 
ANKZF1 9.184297 9.885873 IQCE 8.100087 8.540213 RNR2 16.127030 16.502298 
ANO8 5.481329 6.413373 IQGAP2 5.150194 5.789666 ROGDI 5.625195 6.119891 
ANTXR2 7.722352 9.011103 IRAK4 9.454629 9.715441 ROR1 9.412609 9.930454 
ANTXRLP1 2.827585 3.686061 IRF2BPL 10.990003 11.584495 RP11-
142C4.6 
2.838588 4.131693 





5.599763 6.333566 IRF7 9.297194 9.559710 RP11-
452H21.4 
3.694991 4.651188 
AP1B1 10.126709 10.538820 IRF8 11.915815 12.200497 RP11-
960L18.1 
3.880514 4.606785 
AP3S1 7.380994 7.822216 IRS1 8.189886 8.923291 RP6-
206I17.2 
4.606457 5.215655 
APAF1 8.727843 9.112861 IRS2 9.619933 10.178857 RPAIN 7.745849 8.071039 
APBB2 8.529929 10.117987 ISYNA1 6.993392 7.444557 RPL13A 11.723627 11.993568 
APBB3 7.955512 8.276893 ITGAL 7.932705 9.101738 RPL32P3 7.111743 7.457084 
APCDD1 2.869949 3.541978 ITGAX 9.077260 9.413319 RPRD2 9.355908 10.030800 
APOLD1 5.099555 5.731262 ITGB1 9.256280 9.755301 RPS27 8.498282 8.811310 
AQP3 4.670698 5.307525 ITGB1BP1 6.974638 7.338069 RPS6KB2 7.998226 8.366763 
ARAP1 9.487039 9.981271 ITGB5 5.256636 5.715976 RRBP1 8.702590 9.006995 
ARHGAP12 7.697412 8.201041 ITGB7 7.984086 9.077756 RRM2B 10.124019 10.450301 
ARHGAP19 8.562408 8.836825 ITIH4 6.579964 7.142359 RSBN1L 8.460275 8.841795 
ARHGAP27 9.984989 10.486292 ITM2B 10.258709 10.575394 RUNDC1 9.228970 9.684035 
ARHGAP33 6.583244 7.047364 ITPKB 12.283549 12.500566 RUNX1 8.964628 9.293885 
ARHGAP4 9.848457 10.203349 ITPR2 9.375663 9.858296 S1PR1 8.015101 9.325855 
ARHGAP9 9.102367 10.167333 ITPRIP 9.414289 9.769206 S1PR4 9.502185 10.159136 
248 
 
ARHGDIB 11.394938 11.754543 IVD 9.453667 9.721903 SAFB2 9.275459 9.686396 
ARHGEF1 9.557943 10.109026 JAG1 2.847352 3.483278 SAP25 7.771041 8.470685 
ARHGEF10L 7.384348 8.111379 JDP2 8.173256 8.777817 SAT1 10.331825 10.927009 
ARHGEF3 8.807645 9.582519 JHDM1D-
AS1 
6.730788 7.498769 SAT2 8.838371 9.206612 
ARHGEF6 8.434574 8.885534 JMJD1C 10.468769 10.921338 SATB1 6.972442 7.679454 
ARID4A 8.720744 9.108563 JMJD7 5.788096 6.591463 SBDSP1 8.442283 8.711127 
ARID5B 10.514759 11.239107 JMY 9.583949 10.093216 SBF1 10.045007 10.386280 
ARL15 6.864498 7.295578 JOSD1 11.283854 11.626243 SBK1 6.481650 7.170317 
ARL3 6.608880 6.998932 JPH3 4.012257 4.631160 SBNO1 9.893205 10.154252 
ARL4C 9.674513 10.242108 JUND 13.335080 13.761307 SC5D 9.097525 9.325229 
ARMCX3 9.984088 10.278971 KANK1 7.367444 7.969767 SCAI 7.557084 7.992673 
ARNT 8.950500 9.217360 KANK2 5.476894 6.586185 SCAMP1 7.640331 8.258352 
ARRB2 8.428264 9.072799 KAT2A 8.746278 9.109484 SCART1 5.128932 5.626940 
ARRDC2 11.517205 12.059445 KAT2B 8.268281 8.710569 SCIMP 7.686709 9.311069 
ARRDC3 9.743028 10.424728 KAT6B 8.790609 9.546522 SCML4 3.675990 4.568693 
ARSK 5.727405 6.191369 KBTBD3 5.889916 6.398685 SCN4A 3.122356 4.133780 
ASAP3 3.717792 4.396950 KBTBD6 7.702775 8.155164 SCXB 6.375952 7.587769 
ASF1A 8.732559 9.233229 KCNA3 9.610452 10.719469 SDC3 7.401552 8.158357 
ASIC3 5.476159 6.052770 KCNAB1 3.975992 4.512120 SDHA 7.098376 7.464381 
ASTE1 7.066390 7.439022 KCND1 5.867774 6.465886 SDK2 6.322866 7.019871 
ATAD2 7.308077 7.704549 KCNH2 5.187388 6.343969 SDR39U1 8.407852 8.747444 
ATG12 9.295285 9.573289 KCNJ11 8.692808 9.450228 SEC11A 9.160091 9.469592 
ATG16L2 7.473090 8.205298 KCNQ1 4.462993 5.298380 SEC31B 7.835716 8.169277 
ATG2B 8.924266 9.296832 KCTD7 8.847590 9.474136 SEC62 10.755305 10.992582 
ATG4B 9.487156 9.738683 KDELC2 6.014585 6.582624 SECISBP2L 10.270943 10.569468 
ATG9A 9.229815 9.621286 KDM3A 8.596695 9.075598 SEL1L3 9.733660 10.609882 
ATHL1 11.690117 12.409917 KDM6A 8.199089 8.498903 SELO 9.034261 9.655517 
ATM 10.043656 10.620575 KDM7A 9.415449 10.235622 SELP 4.927213 5.509226 
ATP10D 7.183621 7.575620 KHDRBS2 5.207042 5.748439 SELPLG 8.458654 9.100101 
ATP13A1 8.915959 9.183728 KHK 3.424715 3.920893 SEMA4B 8.937823 10.279032 
ATP2A3 11.316258 12.449012 KIAA0040 10.731834 11.448674 SEMA4D 9.149556 9.968537 
ATP2B4 9.565318 10.610168 KIAA0226 11.057331 11.692215 SENP7 7.538689 7.975237 
ATP6V0C 11.026993 11.355344 KIAA0355 9.152098 9.545492 SEPHS2 10.361755 10.708036 
ATP6V0E2 7.059980 7.633361 KIAA0430 11.033623 11.281939 SEPN1 8.902561 9.198027 
ATP6V1G2 4.124284 4.755513 KIAA0586 6.601041 7.023259 SEPT6 10.577185 11.325044 
ATP7A 7.036465 7.453913 KIAA1377 5.423529 6.120764 SEPT7P2 6.412185 6.832383 
ATPIF1 8.280458 8.644329 KIAA1407 8.318679 9.035598 SEPT9 12.723690 13.428689 
ATXN1L 10.316599 10.580783 KIAA1432 9.175176 9.433182 SEPW1 8.351059 8.720531 
ATXN7L1 6.469470 7.078136 KIAA1551 11.820386 12.186443 SERINC1 10.736066 11.000369 
AUH 6.407891 6.878557 KIAA1683 6.953866 8.185895 SERINC4 7.519847 8.415393 
AVPI1 5.260989 6.277919 KIF22 7.717690 8.147398 SERINC5 8.594518 9.000172 
AVPR2 3.846338 4.484104 KIF3C 6.440654 7.166535 SERPINF1 6.837941 7.299864 
AXIN1 9.975522 10.288741 KIFC2 9.098552 9.432321 SERPINI1 4.831047 5.367528 
AZI1 6.443477 6.863353 KISS1R 5.441094 5.882635 SERTAD3 9.743604 10.003438 
B3GNT1 6.521754 7.512429 KLC4 6.832759 7.294964 SESN1 7.680719 8.271992 
B4GALT1 11.057331 11.748091 KLF10 10.003246 10.526103 SESN3 11.635677 12.628836 
B4GALT3 9.136041 9.428957 KLF2 9.713611 10.789509 SESTD1 8.148186 8.865095 
BAG1 9.487159 9.813857 KLF3 7.303258 7.936228 SETBP1 8.739334 9.229075 
BAIAP3 6.487222 7.920626 KLF9 9.198526 9.700265 SETD2 10.489253 10.697485 
BAK1 6.755606 7.211618 KLHDC3 8.755676 9.102857 SETD7 7.894909 8.409998 
BANP 8.275387 8.969904 KLHL14 7.637533 8.470276 SETDB2 8.232586 8.656299 
BBS2 7.444461 7.881312 KLHL15 8.553740 8.865414 SF3B1 11.264831 11.480793 
BBS4 7.111482 7.443368 KLHL2 8.509271 9.103282 SFI1 7.438433 7.836599 
BBX 10.097629 10.348848 KLHL24 9.597484 10.352596 SFMBT1 10.056685 10.569356 
BCAS4 8.552594 9.140874 KLHL3 4.874261 5.372509 SFSWAP 9.059363 9.299176 
BCL11A 9.884017 10.699775 KLHL32 3.619751 4.454348 SFTPB 5.875039 7.490736 
BCR 7.667134 8.115698 KMT2E 10.716049 11.019854 SFXN3 8.093679 9.318320 
BDH2 5.117609 5.637664 KMT2E-AS1 8.385366 8.672159 SGK223 9.984047 10.391449 
BEND4 9.838418 10.098019 KNTC1 5.647240 6.181924 SGPP1 11.336000 11.716125 
BEST4 5.904869 6.353178 KPNA5 8.142312 8.451272 SGSH 7.886866 8.506549 
BET1L 10.075610 10.314348 KSR2 6.363684 7.204870 SGSM2 10.047012 10.602482 
249 
 
BICD2 10.053549 10.545566 LAG3 6.610896 7.093939 SGSM3 9.267024 9.517614 
BIN1 7.534472 8.123213 LAIR1 5.992883 6.606772 SH2B1 10.222514 10.575469 
BLNK 7.906647 8.303382 LAMA5 7.006159 7.898062 SH3BGRL2 8.464632 8.925289 
BMPR2 10.140846 10.764546 LAPTM4A 9.718665 10.065440 SH3BP5 8.644918 9.014126 
BNIP3L 9.498887 10.032303 LAPTM5 13.510297 14.136980 SH3BP5-AS1 7.644499 8.096543 
BRICD5 5.957509 6.629293 LATS2 7.591019 7.955483 SH3TC1 9.749393 10.219963 
BRWD1 9.552325 9.914410 LAX1 9.044887 10.114380 SHISA5 9.988748 10.656362 
BTBD2 9.709400 10.080100 LBH 11.966835 12.425985 SIAH1 8.678080 8.935949 
BTBD6 9.323592 9.800344 LCK 6.953137 7.939691 SIDT1 8.301978 9.105287 
BTG2 13.128953 13.773045 LCN10 6.819327 7.256991 SIDT2 8.401091 9.187241 
BTK 8.681938 9.067381 LCP2 6.022057 6.662608 SIGIRR 8.051068 8.540322 
BTN3A1 9.495923 9.975912 LDB1 10.572748 11.113378 SIGLEC10 7.358068 8.478397 
BTN3A2 9.727151 9.988034 LDLRAD4 9.299357 10.172818 SIK2 7.266443 7.655368 
BTNL2 2.015475 2.503942 LDLRAP1 7.862125 8.670102 SIK3 9.575045 10.074912 
BZRAP1 6.658635 7.499009 LENG8 12.470509 12.810973 SIMC1 7.939700 8.439132 
C10orf118 8.816477 9.063290 LEPRE1 8.528151 8.885571 SIPA1L1 10.313261 10.763285 
C11orf21 6.779389 7.385376 LEPREL4 5.199962 5.659600 SIPA1L3 9.928247 10.825237 
C11orf24 7.929042 8.455084 LEPROTL1 8.420653 8.819288 SIRT2 7.924211 8.524406 
C11orf30 8.218725 8.467697 LGALS8 7.261604 7.747817 SIT1 7.946372 8.813856 
C11orf35 6.691125 7.824103 LGI4 2.598308 3.232777 SKI 10.375295 10.815154 
C11orf68 9.745511 10.011099 LGMN 5.346517 5.856234 SKOR1 3.513173 4.222253 
C11orf80 6.129263 6.539421 LGR4 3.658812 4.402862 SLA 9.388119 10.491409 
C12orf10 7.210669 7.529462 LHFPL2 9.423371 9.775692 SLAMF6 10.172832 10.536176 
C12orf76 7.959098 8.436957 LHPP 7.394007 8.183721 SLBP 8.822573 9.160970 
C15orf62 6.828473 7.368949 LIG1 7.068479 7.848847 SLC12A6 10.489424 10.864599 
C16orf54 7.855526 8.891885 LIMD1 9.301848 9.763448 SLC12A9 8.924618 9.249591 
C16orf74 7.346644 8.496270 LIME1 6.815862 7.801970 SLC13A5 3.741783 4.723963 
C16orf86 6.603434 7.281723 LIMK2 8.709889 9.260004 SLC14A1 4.021864 5.467586 
C17orf103 7.932512 8.714264 LIN7B 5.808708 6.378225 SLC16A14 3.839525 4.476001 
C17orf59 9.444293 9.794674 LINC-PINT 8.667484 9.339054 SLC16A4 4.877353 5.443416 
C17orf62 10.959717 11.187681 LINC00202-
1 
2.772861 3.434054 SLC16A7 7.588971 8.554980 
C19orf38 4.778811 5.680146 LINC00304 4.280301 4.872751 SLC17A9 7.542427 8.140661 
C19orf66 7.895481 8.167819 LINC00324 4.974232 5.715572 SLC18B1 6.650567 7.670849 
C19orf68 8.221310 8.511236 LINC00339 6.864287 7.509756 SLC22A17 3.684763 4.635453 
C1QTNF6 6.641371 7.581241 LINC00426 4.565268 5.576078 SLC22A18 3.169111 3.733614 
C1orf162 6.245772 6.868669 LINC00525 4.145483 5.009445 SLC23A1 4.902925 5.661107 
C1orf35 8.187660 8.613026 LINC00593 2.579307 3.120593 SLC23A3 5.945808 6.387129 
C1orf95 6.202419 6.682193 LINC00672 5.383523 5.887674 SLC25A28 9.550996 10.128506 
C2CD2L 6.828760 7.402397 LINC00674 9.927943 10.367972 SLC25A29 10.069950 10.543024 
C2orf15 3.954130 4.475580 LINC00847 8.736562 9.427920 SLC25A36 9.568566 9.833864 
C2orf81 7.074453 7.483965 LINC00886 4.217689 4.843109 SLC25A42 7.342311 8.363375 
C3orf58 8.203456 8.636678 LINC00926 11.327949 11.874717 SLC26A11 7.300504 7.993456 
C5orf45 6.514378 7.265780 LINC00954 4.107383 4.609336 SLC26A6 6.692237 7.251190 
C6orf48 10.585965 11.062277 LINC01000 9.586914 9.941722 SLC27A1 6.970370 7.340541 
C9orf72 7.991252 8.436468 LINC01004 6.724918 7.570059 SLC27A3 7.213379 7.895621 
C9orf89 6.919767 7.374736 LINC01011 3.706255 4.701439 SLC29A3 7.199232 7.509684 
CA11 7.414319 8.099430 LINC01023 5.231918 5.874614 SLC2A11 6.873347 7.738123 
CA3 2.829509 3.306231 LINC01089 8.504520 8.956302 SLC2A3 8.337502 9.043030 
CABIN1 9.110351 9.403168 LINGO3 6.038788 8.115116 SLC2A4RG 7.898382 8.503660 
CABLES1 10.536549 11.134210 LLGL1 7.501637 7.851013 SLC30A1 7.583249 8.051347 
CABP4 3.465594 4.627525 LMBR1L 8.883465 9.266758 SLC35E2B 9.794951 10.187934 
CACNA1C 3.639025 4.162985 LMF2 9.646735 9.891559 SLC37A2 7.557893 8.000031 
CACNA2D2 5.298180 5.954232 LMNB1 7.195175 7.870435 SLC39A10 7.832414 8.315005 
CACNB2 4.977550 5.699816 LMO4 8.835106 9.340011 SLC44A2 9.713082 10.251933 
CALCOCO1 9.442995 10.127637 LMO7 7.753084 8.341336 SLC46A1 4.691173 5.285200 
CALHM2 8.630222 9.177471 LMTK2 8.496922 8.945184 SLC46A3 7.365075 7.776110 
CALM1 11.695785 12.059396 LNX2 7.877908 8.195083 SLC48A1 8.870225 9.474573 
CAMK2G 8.280636 8.660491 LOC100128
494 
5.006548 5.506546 SLC6A16 7.537872 7.906183 
CAMKK1 6.669715 8.221036 LOC100129
203 
5.596130 6.431284 SLC7A5P2 6.990005 7.353641 
CAPN14 5.387449 5.915812 LOC100129
550 
6.775283 7.833694 SLC7A7 8.611853 9.134587 
CAPN3 7.616348 8.168220 LOC100129
637 
8.824679 9.361364 SLC9A1 8.763880 9.459183 
250 
 
CAPRIN2 8.061746 8.497186 LOC100130
987 
4.451583 5.033736 SLCO4A1 9.483179 9.949996 
CAPS 7.632302 8.093126 LOC100287
072 
2.006616 2.473012 SLFN11 7.779146 8.210145 
CARD11 9.777374 10.257478 LOC100287
175 
3.985828 4.752101 SMAD3 7.534040 7.982787 
CARD14 5.447382 6.433126 LOC100289
230 
5.713850 6.248340 SMARCC2 10.272275 10.514635 
CARD8 9.749755 10.055272 LOC100294
145 
8.111829 8.386008 SMARCD3 5.558534 6.153761 
CARF 6.887429 7.326108 LOC100505
564 
6.469464 7.299439 SMC4 8.117439 8.389797 
CARHSP1 8.466389 9.186136 LOC100505
771 
7.937118 9.482197 SMCHD1 10.164578 10.913995 
CARNS1 7.247302 8.169913 LOC100506
060 
5.744349 6.228236 SMPD1 7.897605 8.291140 
CARS2 7.378284 7.791627 LOC100506
114 
4.570345 5.106827 SMPD3 5.451067 6.070002 
CASP10 5.884888 6.625319 LOC100506
634 
7.091323 7.458584 SNAI3 5.111714 6.153653 
CASP8 9.333403 9.739087 LOC100507
530 
3.703751 4.685603 SNED1 7.966414 8.934070 
CASP9 7.953873 8.354723 LOC100507
616 
8.278475 8.917009 SNPH 6.632093 7.497313 
CBFA2T2 9.241511 9.664118 LOC100652
768 
6.185091 7.446827 SNTB2 7.513429 8.540057 
CBLB 8.397134 8.832176 LOC100996
273 
5.759581 6.731520 SNX2 7.867927 8.244169 
CBX4 9.854180 10.659846 LOC100996
756 
4.473729 5.016734 SNX21 6.067108 6.454709 
CBX8 5.140850 6.211451 LOC101409
256 
2.789825 3.285763 SNX25 7.616554 7.929591 
CCBL1 5.281380 5.876164 LOC101927
245 
3.310262 4.083246 SNX27 8.947773 9.199316 
CCDC109B 6.897476 7.616563 LOC101927
371 
2.937039 3.466685 SNX30 8.045473 9.033860 
CCDC134 4.928386 5.500389 LOC101927
402 
6.925476 7.461688 SORBS3 7.455528 8.023162 
CCDC163P 5.339163 6.032296 LOC101927
759 
3.609486 4.271104 SOS1 9.200747 9.434358 
CCDC28A 7.121752 7.582698 LOC101927
902 
6.428085 7.684114 SOS2 9.155929 9.430400 
CCDC42B 3.131041 3.791425 LOC101928
092 
3.793462 4.445993 SOWAHD 8.046558 8.934843 
CCDC62 4.706058 5.249698 LOC101928
465 
6.429934 7.442057 SOX12 9.258273 10.091368 
CCDC64 10.616587 11.118721 LOC101928
572 
2.366138 2.880159 SP110 7.038412 7.864494 
CCDC69 11.178068 11.535165 LOC101928
719 
6.565578 7.446391 SP140 8.056782 8.740792 
CCDC88A 10.655747 11.002569 LOC101928
963 
5.735705 6.146271 SP140L 8.179918 8.435573 
CCDC88C 9.724954 10.036722 LOC101928
981 
3.202624 3.883143 SPAG4 6.879282 7.674200 
CCM2 8.899069 9.291149 LOC101929
005 
4.682490 5.634924 SPAG5 6.344714 6.729074 
CCND3 10.009725 10.419694 LOC101929
385 
6.504546 6.975361 SPATA13 7.869211 8.285432 
CCNDBP1 9.014298 9.324135 LOC101929
634 
2.653382 3.162111 SPATA2L 8.614765 9.160356 
CCNL1 11.080721 11.315489 LOC101929
698 
2.318216 2.932015 SPIN4 7.610884 8.388423 
CCNL2 11.703099 12.034827 LOC101930
307 
6.679957 7.105781 SPOCK2 12.798579 13.464626 
CCP110 8.050237 8.459314 LOC101930
332 
2.037691 2.486777 SPPL2B 8.481127 8.852237 
CCPG1 6.768492 7.270286 LOC102723
398 
3.919802 4.486758 SPSB3 10.008613 10.551214 
CCR6 5.784255 8.037080 LOC102723
521 
9.970197 10.214820 SPTAN1 9.253328 9.606988 
CCS 7.513089 7.904199 LOC102723
733 
4.001830 4.676058 SPTBN1 10.113406 10.760968 
CD163 6.782986 7.296012 LOC102723
801 
4.789183 5.513903 SPTBN5 5.826250 6.873031 
CD1D 5.021847 6.012555 LOC102723
874 
3.053626 3.552905 SRGAP3 4.472610 5.343256 
CD24 8.580865 9.722592 LOC102723
878 
3.030386 3.522537 SRPK2 8.600918 8.901380 
CD244 5.371056 6.401675 LOC102724
059 
3.458455 4.160720 SRRM2 13.492675 13.865527 
CD27 7.715420 9.417691 LOC102724
248 
5.680842 6.419666 SRSF5 11.811211 12.038195 
CD27-AS1 5.495974 6.097152 LOC102724
323 
6.620752 7.250678 SRSF7 10.826031 11.030349 
CD320 7.675861 8.002148 LOC102724
342 
5.803984 6.505117 SRSF8 9.962444 10.240890 
CD47 10.735401 10.983711 LOC102724
457 
2.106591 2.486267 SS18L1 8.104325 8.506481 
CD48 10.158133 10.590270 LOC102724
466 
6.118230 6.895854 SSBP2 4.143614 4.979442 
CD5 10.395187 11.328686 LOC102724
543 
8.500546 9.653967 SSH2 10.607338 11.222635 
CD52 9.192961 10.342752 LOC102724
965 
5.169001 5.628024 SSTR3 5.524803 6.578785 
CD6 9.120489 10.554378 LOC113230 5.096430 5.660594 ST6GAL1 12.494466 12.781821 
CD7 5.118054 5.647975 LOC146880 8.312966 8.844160 ST6GALNAC4 9.922308 10.528563 
CD72 6.843653 7.506895 LOC202181 6.476132 7.078305 ST6GALNAC6 11.395415 11.871134 




CD79B 9.796234 11.281623 LOC284023 6.870374 7.231821 STAMBPL1 8.213026 8.529536 
CD99 9.526941 9.824963 LOC390937 4.238015 5.017624 STAP1 7.621300 8.018389 
CDC16 8.400122 8.738531 LOC440461 5.292322 6.828100 STARD3 9.042874 9.363182 
CDC25B 8.532746 9.551281 LOC645638 6.639956 8.060997 STARD5 7.536206 8.174087 
CDC40 8.252916 8.589446 LOC646719 8.044764 8.318814 STARD9 7.139171 7.575869 
CDCA7L 7.453058 8.338330 LOC648987 7.029059 7.366113 STAT2 10.298652 10.967331 
CDIP1 9.522393 9.773124 LOC652276 7.189965 7.739955 STIM1 9.588252 9.981010 
CDIPT 9.811797 10.184619 LOC728392 7.596318 8.803020 STIM2 9.337549 9.772430 
CDK11A 7.707044 8.111582 LOC728743 9.203883 9.946768 STK24 9.630272 10.086029 
CDK11B 7.078542 7.420295 LOC728752 5.424280 6.076861 STMN3 7.601033 9.316920 
251 
 
CDK13 9.443027 9.681978 LPAR5 9.151384 9.521672 STOX1 4.359868 4.971877 
CDK19 8.826838 9.232589 LPCAT4 7.251341 8.287853 STRN 9.180262 9.444148 
CDK5RAP3 10.655117 10.853959 LPIN2 9.510103 10.002568 STX10 8.098501 8.505280 
CDKN1B 11.032895 11.541821 LPP 8.568942 9.218041 STX16 10.204798 10.478306 
CDKN2AIP 9.824935 10.142935 LRCH4 9.425170 9.917768 STX7 10.101785 10.468864 
CDKN2D 7.427991 8.441026 LRFN1 5.964269 6.845998 STXBP2 8.354013 8.639924 
CDS2 9.941087 10.144235 LRIG1 8.197405 8.898006 SUFU 7.070944 7.499309 
CEACAM21 6.461557 7.435726 LRMP 8.313274 8.924887 SUGP2 10.959042 11.221773 
CECR1 7.165762 8.761520 LRP10 11.904853 12.115187 SULF2 7.298565 7.809550 
CELF6 6.709803 7.182807 LRP5L 6.992365 7.349553 SUMF2 8.380406 8.661081 
CELSR2 3.702538 4.270571 LRRC16A 6.130468 6.580105 SUN2 10.733659 11.166879 
CEMP1 6.987224 7.703233 LRRC25 6.670252 7.392467 SUSD3 5.661222 7.059454 
CENPM 4.698199 5.330770 LRRC37A4P 7.036872 7.667730 SUV420H2 6.989784 7.560831 
CENPT 8.706960 9.182883 LRRC37B 5.933111 6.370908 SVILP1 3.342436 4.227689 
CEP250 8.758633 9.095521 LRRC45 6.707240 7.158559 SYCP3 4.167367 4.850989 
CEP57 9.026915 9.281149 LRRC56 6.201387 7.259129 SYK 11.737752 12.142039 
CEP85L 7.893762 8.528326 LRRC6 2.102782 2.789786 SYNE2 10.073920 10.614440 
CEP95 7.763478 8.324897 LRRC8A 8.397411 8.720788 SYNGAP1 8.507320 8.944885 
CERK 9.866232 10.691475 LRRC8C 7.203113 7.540662 SYNRG 10.006327 10.299365 
CHAD 4.183616 5.115969 LRRK2 7.744374 8.281870 SYPL1 9.384946 9.675221 
CHAMP1 8.687493 9.016092 LRRN2 5.417733 6.014979 SYTL1 8.848493 10.144967 
CHIT1 3.511815 4.153005 LRWD1 7.429239 8.092407 SYVN1 9.476113 9.829963 
CHMP1B 11.000911 11.284378 LSM4 9.172430 9.476143 TACC1 11.076986 11.434627 
CHPT1 8.021409 9.064773 LSM8 8.788368 9.077686 TACC3 7.507860 8.813970 
CHRNB1 7.579562 8.124073 LTBP3 7.959121 8.730428 TAF1 8.759301 9.040141 
CHST11 10.229200 10.843283 LUC7L 9.785128 10.183546 TAF1L 9.529254 9.805007 
CHST12 7.923714 8.331003 LUC7L3 10.594974 10.911650 TAF5 6.539663 6.944379 
CHST15 9.721904 10.770820 LY6G5B 7.171720 7.643920 TAGLN 7.359598 8.371188 
CHST2 11.599514 11.948950 LY86 6.368913 6.893939 TAOK2 9.971046 10.233067 
CHTF18 8.522656 8.824501 LY9 9.624283 10.852811 TAPSAR1 7.400627 7.770003 
CIB1 8.180158 8.938488 LYL1 8.308230 8.948321 TAPT1 8.148924 8.540689 
CIC 10.262561 10.483579 LZTS2 9.289296 9.937707 TARSL2 6.568438 7.040820 
CIPC 9.367726 9.833531 MAD1L1 7.580812 8.470846 TAZ 8.876652 9.214237 
CIRBP 11.811451 12.039045 MADD 9.241084 9.662561 TBC1D1 9.583678 9.939129 
CITED2 8.895305 9.234156 MAFK 10.225128 10.625033 TBC1D10C 9.186844 10.176337 
CKAP2 7.404835 8.084765 MAGEE1 6.469266 6.904612 TBC1D20 9.720120 9.983161 
CKAP4 10.853626 11.230284 MALAT1 12.597430 12.950099 TBC1D22A 9.380862 9.717821 
CLASRP 8.986964 9.443646 MAN1A1 9.581318 9.999139 TBC1D27 8.641089 9.906811 
CLCN4 7.288841 7.948054 MAN1B1 8.706183 9.202122 TBC1D9 9.781103 10.993644 
CLDN15 8.341075 8.698287 MAN1C1 3.144119 3.786059 TBCC 10.100865 10.316301 
CLDN23 5.824498 6.608888 MAN2A1 9.792644 10.180878 TBKBP1 7.349353 7.969075 
CLEC2B 4.974808 5.464554 MAN2A2 9.636863 10.304973 TBL1X 9.304990 9.734369 
CLEC4C 2.921898 3.665699 MAN2B2 9.039963 9.286362 TBX21 8.098130 8.583972 
CLK1 10.228920 10.795583 MAP3K1 10.920603 11.873896 TBXA2R 3.826945 4.517668 
CLK3 8.543011 8.878349 MAP3K12 6.078473 6.598834 TCAP 5.467370 6.043798 
CLK4 8.301336 8.609774 MAP3K2 10.397572 10.750544 TCEA2 7.048910 7.547909 
CLMN 7.878465 9.398409 MAP3K3 9.166757 9.533805 TCEAL1 7.881146 8.668981 
CLSTN1 10.257762 10.613994 MAP3K9 8.907502 9.506867 TCF25 9.083985 9.422348 
CLSTN3 8.562419 9.237768 MAP4K1 6.956381 7.375049 TCF7L1 3.861782 4.416825 
CMIP 9.030967 9.576185 MAP4K2 7.579930 8.167321 TCIRG1 9.652365 10.047758 
CMTM1 5.057069 5.613990 MAPK8IP3 11.151583 11.904048 TCL1B 2.586932 3.131696 
CNNM2 6.654556 7.127135 MAPKAPK5
-AS1 
8.103862 8.382750 TCL6 3.734490 4.250803 
CNNM3 9.841291 10.081511 MAPRE2 9.219004 9.943559 TCP11L2 8.351610 9.052751 
CNNM4 8.147668 8.627407 Mar-01 8.482444 9.765274 TECR 5.753189 6.449630 
CNOT6L 9.601298 9.854605 Mar-08 10.488795 10.808252 TEP1 9.196882 9.475405 
CNR2 9.880523 10.386521 Mar-09 9.666042 9.902850 TERF2IP 11.128875 11.460810 
CNTD2 3.706981 4.320371 MAST3 8.258654 9.324556 TEX264 8.553483 8.869833 
CNTRL 8.726680 8.997214 MAST4 6.038145 6.872776 TFAP4 6.578656 7.108260 
COG4 7.534305 7.900384 MAX 10.235421 10.506270 TFDP2 8.191075 8.574637 
COL4A3 6.424212 7.529103 MBD4 9.478290 10.101118 TGFBI 7.042415 8.237343 
COL4A4 6.411658 7.362059 MBNL3 9.788629 10.196104 THAP11 10.205827 10.639664 
252 
 
COL9A3 9.965914 11.288402 MBOAT1 6.279116 6.984269 THAP9-AS1 9.142882 9.405864 
COLCA1 4.754437 5.311942 MBP 11.395323 11.836426 THBS4 2.830321 3.673325 
COLGALT1 9.965321 10.280380 MC1R 6.404130 7.015503 THEM6 7.379659 7.831677 
COQ10A 7.893404 8.275718 MCEE 6.768637 7.186958 THEMIS2 10.854192 11.207629 
CORO1A 10.383930 10.642531 MCF2L 5.792562 6.246495 THRA 6.373520 7.357519 
CORO1B 8.742570 9.522160 MCM5 9.221746 9.511306 THYN1 6.111380 6.672098 
COTL1 11.783570 12.280302 MCM6 7.217107 7.967143 TIA1 10.312664 10.527240 
CPEB2 7.621976 8.180365 MDGA1 5.787426 6.286384 TIGD3 5.299538 6.031056 
CPLX1 1.893486 2.545885 MEAF6 9.157799 9.421569 TIMP2 9.058857 9.858665 
CPNE1 9.710866 9.989101 MECP2 10.893597 11.156827 TIPARP 8.586136 9.112358 
CRAMP1L 9.900517 10.293129 MED25 7.212427 7.587064 TIRAP 7.348063 7.706721 
CREB3L2 10.707116 11.213868 MEGF6 8.513138 9.467940 TLR4 5.995922 6.566219 
CREBRF 10.044355 10.374172 MEN1 9.713856 9.983476 TLR7 7.006870 7.701982 
CREBZF 10.844842 11.150669 METRNL 7.957091 8.537105 TLR9 9.506839 10.084130 
CREM 9.349922 10.268201 METTL7A 9.307567 10.800312 TM2D3 8.463589 8.710882 
CRIP3 4.455056 5.083313 METTL8 9.901449 10.179192 TM7SF2 6.074833 6.736677 
CRIPAK 6.999388 7.353361 MFN1 7.626940 8.086498 TMEM107 6.272864 6.908253 
CRLF3 9.637857 10.054475 MFSD8 7.971198 8.338008 TMEM109 10.311470 10.987433 
CROCC 7.577609 8.035353 MGAT1 11.642552 12.045841 TMEM110 8.903078 9.239143 
CRTAP 8.772007 9.386445 MGAT5 9.751593 10.264343 TMEM123 11.575513 12.097209 
CRTC1 8.299473 8.696913 MGEA5 11.338833 11.707436 TMEM129 9.634006 10.091432 
CRTC3 8.895620 9.175382 MGME1 8.624541 9.113526 TMEM134 7.953530 8.509004 
CRY2 9.390535 9.658577 MIA3 9.550832 9.843140 TMEM140 9.429598 9.869211 
CRYM 4.132480 5.741265 MIAT 7.292749 7.664577 TMEM143 6.169497 6.698871 
CRYM-AS1 4.569796 5.493053 MIB2 9.137959 9.608089 TMEM154 8.918909 9.221603 
CSNK1G2 10.321690 10.613929 MIDN 10.070354 10.824176 TMEM156 5.755893 6.459977 
CTBP1 9.970846 10.235085 MIF4GD 8.982288 9.891933 TMEM159 8.066358 8.647090 
CTD-
2201I18.1 
2.638331 3.253087 MINK1 8.885922 9.383830 TMEM175 7.624407 8.190126 
CTDSP2 11.448690 11.823138 MIR142 9.569555 9.902930 TMEM184B 8.684164 8.970579 
CTLA4 8.319957 9.805099 MIR1914 4.804915 5.592758 TMEM198B 6.726962 7.136176 
CTNNBIP1 6.765022 7.431659 MIR378I 7.562457 9.043994 TMEM2 8.232164 9.278559 
CTRL 6.087684 6.479509 MIR548AR 4.726354 5.330384 TMEM219 8.435957 8.753446 
CTSF 6.366085 7.692041 MIR600HG 9.056971 9.685791 TMEM236 5.434839 5.949172 
CTSK 4.636445 5.287705 MIR647 4.048867 4.700342 TMEM245 9.717601 9.934979 
CUL4B 8.983257 9.315246 MIR8071-2 7.630362 8.167606 TMEM259 12.327953 12.535098 
CUTA 9.491837 9.875794 MIS18BP1 8.133582 8.615109 TMEM38A 4.897349 5.913160 
CXCL16 8.563365 9.622004 MKRN1 10.243222 10.567629 TMEM55B 9.842896 10.089152 
CXCR4 13.788205 14.674559 MLKL 6.304095 6.874097 TMEM56 5.785460 6.688276 
CXXC1 9.382050 9.692023 MMP11 5.191982 5.737165 TMEM59 8.722783 9.098478 
CXXC5 11.195582 11.450360 MMP17 6.116928 7.048781 TMEM62 7.209867 7.725042 
CYFIP2 10.644416 11.312744 MNT 8.490941 9.190705 TMEM63A 8.057787 9.091134 
CYP4V2 7.719299 8.134709 MOAP1 9.234097 9.644762 TMEM66 11.821458 12.472671 
CYSLTR1 6.659844 7.415759 MORC3 10.315755 10.552976 TMEM71 4.966275 6.609253 
CYTH2 8.730151 9.157865 MOV10 7.678493 7.960820 TMEM79 7.498577 7.869021 
CYTIP 10.419754 11.234759 MPHOSPH8 10.130056 10.428958 TMEM80 7.682523 8.354477 
D2HGDH 8.009389 8.414620 MPPE1 5.980983 6.504518 TMEM86B 7.186929 7.635965 
DAAM1 7.236260 7.569053 MPRIP 9.736632 10.138820 TMF1 9.905193 10.184642 
DAB2IP 5.771159 6.602746 MPZ 5.449759 6.101168 TMPRSS6 5.361845 6.064534 
DACT1 6.790661 7.799970 MR1 8.893565 9.255973 TMUB2 9.956599 10.249848 
DAGLB 7.570560 7.906200 MRI1 9.300904 9.717919 TMX4 8.785616 9.630459 
DAPK2 6.148745 7.737531 MRO 1.837065 2.488249 TNFRSF13B 9.317777 10.292392 
DBF4 7.212483 7.561965 MROH1 7.861825 8.308971 TNFRSF13C 8.885864 10.327040 
DBNDD1 5.372409 6.356626 MROH6 6.809401 7.832574 TNFRSF17 2.574325 3.127818 
DBP 6.613576 7.704955 MRPL55 6.929850 7.417020 TNFSF10 5.458443 6.109876 
DCAF15 8.971239 9.392781 MSI2 11.521656 12.218268 TNFSF12 7.619045 8.349893 
DCLRE1C 8.671880 9.270166 MSL2 10.502427 10.885839 TNFSF9 9.444886 10.022440 
DCST2 2.889807 3.461429 MSL3 9.002215 9.435988 TNK2 10.188257 10.968269 
DDAH2 8.333439 8.909511 MST4 8.847440 9.188987 TNKS 9.148084 9.365072 
DDB2 8.188674 8.521329 MSTO2P 6.429657 6.989132 TNKS2 9.586367 9.984687 
DDX26B 8.256819 8.639834 MT1F 4.384969 5.299089 TNNI2 4.984266 5.719524 
DDX3Y 10.647068 10.865333 MTHFR 9.255777 9.614545 TNRC6B 9.464978 10.119326 
253 
 
DEAF1 7.151848 7.779319 MTIF3 8.166071 8.489706 TNRC6C 8.441728 8.732735 
DEDD2 10.821919 11.118184 MTMR9LP 7.018192 7.854352 TNRC6C-AS1 9.449427 9.776318 
DEF6 8.311369 8.962931 MTSS1L 6.385707 7.358071 TNS3 8.508114 9.209193 
DEF8 9.734321 10.329729 MTURN 8.159344 8.936546 TNXB 4.549803 5.071711 
DEGS2 7.365740 8.476399 MUC20 5.161903 5.722611 TOB1 9.268211 9.635260 
DENND1C 9.206569 9.504006 MUSTN1 4.119894 4.630889 TOM1 8.219136 8.871936 
DENND5B 8.863595 9.228488 MX2 7.370585 8.310612 TOP1MT 7.811753 8.602167 
DENND6A 7.758102 8.219350 MXD1 9.180741 9.553111 TP53I13 10.805405 11.541423 
DENND6B 6.022784 6.667104 MXD4 9.201469 9.935834 TP53INP1 8.764568 9.385653 
DEPDC5 7.484627 8.100128 MXI1 9.351173 10.045208 TP53INP2 8.179773 8.593881 
DFFB 6.969785 7.320959 MYH7B 5.568301 6.069894 TPCN1 9.176353 10.140333 
DGCR2 9.945031 10.210919 MYLIP 8.771121 9.166593 TPCN2 8.408690 8.920752 
DGKA 8.325350 9.222105 MYO15B 7.670066 8.018349 TPP1 10.609975 11.043185 
DGKD 9.684614 10.143825 MYO1F 7.148722 7.641951 TPST2 8.798822 9.152090 
DGKE 8.443803 8.837087 MYO5C 6.425863 6.913521 TRABD 9.525969 10.612266 
DGKQ 8.726985 9.030795 MYO9B 10.968806 11.351779 TRABD2A 6.195459 6.894272 
DHX58 5.935273 6.366604 MYOM1 5.085682 5.985240 TRAF3IP2 7.086646 7.625472 
DICER1-AS1 5.457935 6.024229 MZB1 7.816867 8.266659 TRAF3IP3 8.441620 8.994525 
DIP2B 8.689159 8.971859 N4BP2 8.570774 8.861567 TRAF5 8.843682 9.614448 
DIRAS1 5.635301 6.519214 NAA16 8.001647 8.401587 TRAM2 9.153824 9.878944 
DIRC2 5.796123 6.612837 NAA40 9.366986 9.699894 TRAPPC2L 8.068031 9.289385 
DLL1 6.066551 6.737970 NAAA 7.573153 8.181447 TRIB1 9.722994 10.486511 
DMPK 8.951945 9.265988 NAB2 8.932102 10.033203 TRIM14 8.300252 8.795054 
DMXL1 9.133693 9.435769 NADK 9.807504 10.099868 TRIM22 10.082894 10.546520 
DNAJB13 5.969942 6.666576 NAGK 9.196412 9.531616 TRIM25 9.132000 9.587603 
DNAJB2 11.261603 11.570218 NAGPA 7.824754 8.155919 TRIM38 9.648818 10.188216 
DNAJB9 9.023350 9.283826 NAPRT1 8.729793 9.194369 TRIM39 8.643815 8.895877 
DNAJC4 8.266069 8.821578 NAPSB 9.475912 9.800597 TRIM52 8.375634 8.793785 
DNASE1L2 4.905950 5.567506 NARF 7.774579 8.059265 TRIM65 8.923241 9.332526 
DNASE2 8.446791 8.845297 NASP 7.315813 7.670453 TRIM66 7.420658 7.737597 
DNHD1 8.532389 8.989070 NBPF11 7.460332 8.033317 TRIM7 4.946070 6.289501 
DNMBP 9.322892 10.020548 NBPF15 7.203546 7.531151 TRIM8 10.121835 10.513000 
DOK2 8.118200 8.403342 NCAPD2 7.299712 7.704941 TRNAA26 2.372849 3.088980 
DOK3 7.252802 8.350839 NCAPH2 8.343024 8.653922 TRNE 10.862485 11.117640 
DOPEY1 7.085241 7.536941 NCF4 8.031550 8.842358 TRNK 10.138304 10.360791 
DOPEY2 7.414728 7.747716 NCOA2 9.446978 9.715040 TRNL1 8.525660 8.906082 
DPAGT1 7.422328 8.036582 NCOA3 12.022518 12.260819 TRNP 9.682068 10.159892 
DPEP2 8.158205 9.457162 NDRG1 9.231521 10.389891 TRNS1 10.385581 10.708783 
DPH1 6.396205 6.863350 NDRG2 4.961433 5.532992 TRPS1 6.522564 7.095143 
DPH7 8.777561 9.052198 NDUFC1 5.557943 6.199728 TRPV1 7.119320 7.664875 
DPM3 9.537961 9.884789 NDUFS2 6.712081 7.194987 TSC1 9.436286 9.761052 
DSTYK 8.342426 8.695858 NEK7 9.788055 10.317744 TSC22D1 8.083693 8.759188 
DUOX2 2.817827 4.347256 NFATC1 10.013658 10.911003 TSC22D3 11.069814 12.573865 
DUSP26 3.424331 4.339244 NFATC3 9.993900 10.332279 TSEN54 8.064295 8.542318 
DUSP7 6.893286 7.318115 NFX1 9.420908 9.739283 TSHZ1 7.801659 8.377940 
DYRK1B 7.694156 8.141150 NHLRC3 7.807673 8.225800 TSHZ2 4.670996 5.876824 
DYRK2 9.044329 9.495965 NIPSNAP3B 6.117727 6.811343 TSPAN32 4.879388 5.481705 
E2F7 4.334582 5.163247 NISCH 10.730802 11.149138 TSPYL2 12.303171 12.804712 
E4F1 8.565077 8.818447 NKD1 4.769105 5.706008 TSSK3 7.070533 7.887918 
ECI1 7.734652 8.068989 NKTR 10.837553 11.249229 TSTD1 8.370253 8.787073 
EFCAB12 3.759928 4.798152 NLRC3 8.464577 9.086152 TTC13 7.167589 7.554917 
EFCAB13 5.918720 6.403375 NLRP1 9.370604 10.429823 TTC21A 5.345863 6.601337 
EFCAB4A 6.137706 7.189506 NLRP6 6.644224 7.259681 TTC24 6.151279 6.771111 
EFHC1 6.817567 7.223731 NMB 7.818529 8.500635 TTC28-AS1 7.528578 7.878194 
EFNA3 5.483622 6.047499 NMT2 6.438364 7.125066 TTC3 9.402826 10.183319 
EGLN1 9.259990 9.606053 NNT 7.711213 8.009091 TTC3P1 8.523507 9.278461 
EHD3 8.689564 9.732482 NOSIP 7.150039 7.956460 TTC9 8.630043 9.290719 
EHMT1 10.491950 10.975356 NPHP3 6.859570 7.376316 TTYH3 9.769446 10.371268 
EHMT2 8.401280 8.893189 NPR2 4.842691 5.294674 TUBA4A 9.909297 10.820228 
ELF1 11.328869 11.560383 NPRL2 7.096046 7.629903 TUBB4A 4.862251 5.548730 
ELFN2 3.576182 4.577458 NQO2 6.391782 7.164977 TUBG2 6.014518 6.483178 
254 
 
ELMSAN1 9.909607 10.492647 NR1D1 6.712072 7.228343 TUFT1 5.044166 5.466953 
ELOF1 9.628449 9.917285 NR1D2 9.302866 9.869768 TULP4 8.505039 8.913630 
EML4 9.579058 9.923017 NR3C1 11.529748 11.815130 TXNDC15 9.161677 9.436777 
EMR4P 6.261451 7.080459 NR3C2 4.661574 5.182179 TXNDC16 5.654069 6.209626 
ENC1 8.326696 9.912481 NR4A1 10.457055 10.835300 TXNIP 12.189966 13.126286 
ENDOV 6.939221 7.355566 NR4A2 9.924593 10.665573 U2AF1L4 8.174223 8.657763 
ENGASE 9.783274 10.148196 NSUN7 4.011925 4.750853 UBA7 7.884058 8.451952 
ENPP2 4.727364 5.852979 NT5C2 9.687179 9.993980 UBAC2 8.835503 9.294945 
ENTHD2 10.198218 10.666820 NT5E 2.653821 3.366242 UBALD1 8.656408 9.031562 
EP400 10.369762 10.813033 NTN5 2.736008 3.205833 UBAP1L 5.203255 5.767372 
EPB41 10.767210 10.994680 NUAK2 10.683458 10.956307 UBE2G1 9.562473 9.951837 
EPB41L4A-
AS1 
8.790712 9.147921 NUB1 8.352424 8.757364 UBE2H 10.640243 10.929215 
EPHB6 8.195338 8.657045 NUDT17 5.740746 6.270163 UBL4A 8.872394 9.184188 
EPHX1 7.017937 8.220787 NUMA1 10.899880 11.432127 UBN2 8.882831 9.250013 
EPS15L1 8.364827 8.771379 NUMBL 6.616713 7.267147 UBR2 8.800645 9.080573 
EPS8L2 7.662902 8.892119 NUP85 7.549594 7.986614 UBTF 10.872049 11.102501 
ERBB2IP 10.073792 10.332255 NXF1 10.571878 11.051442 UBXN11 6.986321 7.399203 
ERCC6 7.215803 7.550205 OAS2 8.837370 9.496462 UCKL1 7.923836 8.644657 
ERF 10.424454 10.901599 OBSCN 7.176507 7.940133 UCKL1-AS1 5.992437 6.620474 
ERMN 5.696187 6.495164 ODF2L 6.870189 7.197889 UCN 4.626888 5.521500 
ERMP1 7.339954 7.706900 OGFOD2 7.757489 8.179343 UHRF2 9.233554 9.644783 
ERP29 10.083042 10.836218 OGFR 10.621915 10.836956 ULK1 9.225187 9.909288 
ESYT1 9.392782 9.969350 OGFR-AS1 4.615748 5.248875 UNC5CL 6.835747 7.425221 
EVI5L 7.512667 7.830653 OGT 11.851027 12.165607 UNC93B1 9.392033 9.779728 
EVL 8.554424 9.044601 ORAI2 12.312134 13.081224 UNKL 9.084015 9.434910 
EYS 4.044213 4.549849 ORAI3 9.214082 9.472470 UPF3A 7.912754 8.330122 
EZR 13.060175 13.496880 ORM2 3.749554 4.386349 UQCRB 7.740910 8.106981 
FAIM3 10.881011 12.147648 OSBPL11 9.018254 9.357289 USF1 9.431646 9.958842 
FAM102A 10.105261 10.707639 OSBPL3 6.648385 7.236814 USP11 8.606994 8.925301 
FAM102B 7.734864 8.576748 OSBPL7 7.697280 8.174353 USP13 7.589933 7.938866 
FAM111A 9.051653 9.643364 OSBPL8 9.073585 9.388564 USP15 8.698260 8.953256 
FAM111B 6.296707 7.990343 OSER1-AS1 6.809008 7.250031 USP20 8.862110 9.254765 
FAM117A 9.777709 10.060223 OTUD1 9.796865 10.349405 USP21 8.772061 9.146895 
FAM117B 7.966368 8.849904 OVGP1 6.037259 6.538790 USP28 8.026320 8.505633 
FAM120C 6.326657 6.995432 OXR1 8.032750 8.372178 USP3 9.178885 9.407013 
FAM129C 9.023210 10.333919 P2RX1 6.949101 8.113017 USP48 8.359561 8.651220 
FAM134A 10.517393 10.768226 P2RX5 5.633269 6.374442 USP53 7.232655 7.581664 
FAM134C 9.907202 10.311827 P4HTM 8.730420 9.418310 USP6NL 8.635418 8.999053 
FAM13A-
AS1 
4.644562 5.242985 PACS2 8.307973 8.672479 USP8 8.818162 9.167869 
FAM159A 6.839793 7.330614 PAIP2 10.173342 10.458602 USPL1 9.490136 9.814636 
FAM167B 4.084406 4.765177 PAIP2B 7.466622 8.163529 UTRN 7.771586 8.387835 
FAM178A 9.105286 9.436315 PAN2 8.709327 9.300514 VAMP1 9.347425 10.212651 
FAM193B 10.001108 10.527868 PANK1 5.647662 6.359120 VAMP2 10.494623 10.922091 
FAM20A 3.925545 4.468174 PAPD5 8.292226 8.569102 VAMP4 8.504742 8.825564 
FAM210B 7.245459 7.793391 PAPD7 9.129675 9.680712 VAMP5 7.372925 7.701464 
FAM214A 8.605546 9.676050 PAPOLG 8.271844 8.573335 VASH1 7.634636 8.007980 
FAM217B 8.370932 8.703073 PARD6A 7.671486 8.443828 VAT1 10.136745 10.693485 
FAM26F 5.500341 6.192759 PARP15 10.407021 10.716140 VAV1 7.193247 7.637508 
FAM43A 8.761940 10.090857 PARP16 7.345006 7.733422 VGLL4 8.029868 8.358128 
FAM46A 7.106163 7.521119 PARP4 8.718416 9.087352 VIPR1 6.653476 7.175961 
FAM46C 10.462108 11.444296 PARVG 8.564574 9.421165 VNN2 6.693436 7.258470 
FAM63B 6.923214 7.590654 PATL2 6.654172 7.182981 VPREB3 6.158349 7.371381 
FAM65B 9.820740 10.910179 PBXIP1 11.063074 12.348149 VPS11 8.857144 9.153330 
FAM73B 9.556967 9.801155 PCBP4 7.876326 8.184956 VPS13C 10.132376 10.352360 
FAM76A 7.656214 8.019732 PCDH9 5.037308 5.962840 VPS26B 7.769576 8.606204 
FAM76B 8.854390 9.153176 PCF11 10.442840 10.675817 VWA5A 4.986424 5.485415 
FAM78A 9.454377 10.136842 PCM1 9.052248 9.282706 WASH2P 5.293496 5.730648 
FAM89B 9.566585 9.974526 PCMTD2 9.759498 10.200278 WBP2 10.172821 10.452324 
FAM8A1 7.488678 8.425106 PCOLCE 5.012493 5.682989 WDR19 5.716763 6.498161 
FARP2 7.459994 7.806834 PCP2 5.007082 5.639200 WDR34 7.945039 8.382785 
FAXDC2 4.729495 6.504227 PCSK7 9.483444 9.948045 WDR37 8.435207 8.813055 
255 
 
FBXL16 5.937166 6.450378 PCYOX1 8.295183 8.948464 WDR52 6.825240 7.305678 
FBXL20 8.814698 9.424835 PDE4A 8.352960 9.223207 WDR54 6.535852 7.118899 
FBXL3 10.365904 10.615842 PDE4B 11.357694 11.777547 WDR74 7.983100 8.291068 
FBXO10 9.191486 10.294236 PDE7B 4.754555 6.298709 WDR90 7.433413 7.766255 
FBXO15 3.215359 4.048794 PDGFD 6.938982 7.420570 WFIKKN1 4.016317 4.916781 
FBXO18 9.386447 9.632113 PDIK1L 7.678689 8.065567 WHSC1 9.552048 9.839877 
FBXO21 9.430987 9.819747 PDK3 8.308838 8.758424 WIPF1 11.487602 11.952482 
FBXO32 6.666385 7.917332 PDK4 6.294045 7.319272 WNT16 5.836915 6.264780 
FBXO33 8.930994 9.382873 PDLIM1 8.562436 9.498229 WNT3 9.327378 9.967734 
FBXO44 9.170375 9.537249 PDP1 8.692799 9.370561 WSB1 10.459574 10.743654 
FBXO9 8.579870 9.013078 PDPK1 10.100798 10.498426 XAB2 8.513218 8.786079 
FCGR2B 8.078852 8.782827 PDPR 9.918845 10.206283 XAF1 7.895972 8.578882 
FCGR3A 6.152125 6.665864 PDXDC2P 6.321283 6.896840 XKRX 6.269214 7.241268 
FCGRT 8.521760 9.115571 PDXK 8.788124 9.210474 XPC 9.724890 10.061000 
FCHO2 6.999559 7.509603 PECAM1 9.511264 10.503156 XXYLT1-AS2 6.758202 7.651515 
FCHSD1 8.350814 8.766951 PEG10 8.801794 10.154407 XYLT1 9.465020 10.111011 
FCRL1 7.728396 8.160657 PELI2 7.039963 7.467473 XYLT2 7.718274 8.150806 
FCRL2 8.068538 8.845014 PER1 9.688571 10.299158 YPEL1 7.942245 8.605516 
FCRLA 9.644855 10.678799 PEX1 7.771925 8.188685 YPEL2 9.969722 10.884158 
FCRLB 5.667689 6.392084 PEX5L 2.648191 3.156667 YPEL3 10.524072 11.227572 
FER1L4 4.010051 4.643179 PEX6 8.770280 9.066273 YPEL4 3.321757 4.276776 
FGD3 8.468591 9.448254 PFKFB3 8.843424 9.359292 YPEL5 10.956567 11.507696 
FGF22 2.587078 3.245644 PGAM2 7.857143 8.396992 ZBED6 8.347691 8.660097 
FGFR1 7.682941 8.202146 PGBD2 8.280659 8.557514 ZBP1 5.677379 7.218432 
FGFR1OP 7.398192 7.766971 PGM2L1 8.016898 8.450413 ZBTB1 10.955731 11.270760 
FGL2 6.222558 6.601358 PGPEP1 8.172682 9.126190 ZBTB11 9.145998 9.445513 
FHDC1 5.501349 6.237076 PHC3 10.339676 10.773814 ZBTB14 8.530060 8.849880 
FLI1 9.264164 9.833435 PHF1 10.261433 10.623586 ZBTB18 10.569639 11.135100 
FLJ10038 7.424381 7.915273 PHF10 6.874529 7.341400 ZBTB2 9.085511 9.366880 
FLJ32255 7.744199 8.489583 PHF12 9.641911 10.042149 ZBTB20 8.604613 9.101418 
FLJ42258 5.947016 6.801358 PHF19 8.388283 8.823753 ZBTB38 10.543435 10.851378 
FLJ44342 6.376689 7.230382 PHF2 9.236882 9.482758 ZBTB4 11.009518 11.734646 
FLT1 5.505945 5.957103 PHF3 10.289628 10.589862 ZBTB40 10.313517 10.572185 
FLYWCH1 9.347118 9.702207 PHF7 6.038726 6.992684 ZBTB41 8.193699 8.530404 
FMR1 8.897438 9.205902 PHIP 9.552442 9.829743 ZBTB44 10.270798 10.674770 
FN3K 3.855339 4.444605 PHKB 8.573794 9.082301 ZC3H11A 10.302267 10.625848 
FN3KRP 8.613282 8.887707 PHKG2 8.023116 8.346852 ZC3H3 8.778419 9.185062 
FNBP4 10.732871 11.045661 PHTF2 8.637925 8.880933 ZC3H6 7.643649 8.048756 
FOLR2 2.511209 3.140909 PI4KA 7.278949 7.653162 ZC4H2 6.366650 6.737372 
FOSB 10.218175 10.471421 PIDD 8.226646 8.675113 ZCCHC11 9.685899 10.061754 
FOSL2 8.712739 9.314652 PIH1D1 8.766341 9.011632 ZCCHC14 6.998694 7.484478 
FOXJ2 9.163383 9.446977 PIK3IP1 9.953773 10.760814 ZCCHC18 7.415280 8.190439 
FOXO3 7.710509 8.254120 PIK3R1 9.020786 9.334805 ZCCHC2 8.979175 9.360559 
FOXO4 9.321751 9.844210 PIP5KL1 4.954323 5.750413 ZDHHC20 10.819577 11.057106 
FRAT1 7.887102 8.763219 PITPNM1 10.144960 10.553227 ZDHHC8 9.674896 9.909633 
FRAT2 8.405748 9.047434 PITPNM2 9.613802 10.806899 ZER1 9.079020 9.507271 
FRMD8 9.846276 10.065080 PKIA 7.181023 7.774241 ZFAND2B 8.059587 8.537627 
FRMD8P1 8.697389 8.988543 PKN2 8.519805 8.771001 ZFP14 7.930833 8.362674 
FRY 7.683655 8.451528 PLA2G15 7.108969 7.641015 ZFP30 7.815103 8.141721 
FUCA1 9.080911 9.452319 PLA2G4B 4.499828 5.170232 ZFP36L2 11.806513 12.986661 
FUZ 6.728539 7.528590 PLA2G6 7.223059 7.568510 ZFP64 7.829307 8.324548 
FXYD1 3.112946 3.627917 PLAC9 3.650455 4.208004 ZHX2 10.897864 11.338397 
FXYD5 7.782667 8.355873 PLCB2 8.498381 9.015550 ZHX3 6.912212 7.780314 
FXYD7 4.086196 5.481156 PLCD1 4.792269 5.417205 ZIK1 8.249636 8.690029 
FZD3 7.223813 7.896181 PLCG1 9.064017 9.427354 ZKSCAN8 9.843298 10.054972 
GAA 8.243748 8.642256 PLCG2 8.154647 9.115745 ZMYM3 8.342762 8.910024 
GAB2 9.696769 10.489925 PLCH2 6.490566 7.170513 ZMYND15 3.547227 4.204713 
GAB3 7.096943 7.428629 PLCL2 10.211708 10.549660 ZMYND8 8.030524 8.438943 
GABARAPL
1 
8.234491 8.777779 PLCXD1 7.916426 8.181930 ZNF10 7.653888 8.286307 
GABARAPL
3 
6.184529 6.616750 PLD3 8.563995 8.887936 ZNF101 8.590284 9.066579 
GAK 9.678003 10.044604 PLD4 2.865686 3.456299 ZNF107 11.076054 11.910763 
256 
 
GAL3ST4 3.124887 3.645709 PLEKHA2 11.534749 12.498465 ZNF137P 7.392978 7.726225 
GALK1 6.095605 6.491927 PLEKHA3 8.560613 8.915017 ZNF14 8.304603 8.601256 
GALM 5.559671 6.233197 PLEKHG7 2.156266 2.756356 ZNF181 8.086832 8.360869 
GALNS 8.464871 8.848253 PLEKHM1 8.847815 9.131169 ZNF182 8.077200 8.357461 
GALNT3 5.860723 6.323214 PLEKHM1P 6.966586 7.366811 ZNF184 8.082250 8.422018 
GALR2 3.730343 4.510656 PLK1S1 6.244892 6.723819 ZNF211 9.060520 9.498993 
GAPDH 11.652124 11.888623 PLK2 6.835149 7.241420 ZNF224 7.084624 7.480551 
GAS7 6.825376 7.396223 PLP2 10.286080 10.699349 ZNF248 7.950252 8.476661 
GATAD1 9.678920 9.898051 PLXND1 8.766234 10.413918 ZNF250 7.575379 7.952059 
GATM 6.628605 7.121469 PMM1 6.606709 7.014373 ZNF266 10.979972 11.492441 
GATS 8.201142 8.506439 PNMA5 5.787281 6.559524 ZNF273 7.489178 7.809169 
GCC2 9.105312 9.420436 PNOC 5.919688 6.572153 ZNF275 9.149077 9.371756 
GCHFR 7.601200 8.137797 PNPLA2 10.337295 10.990806 ZNF30 5.500866 5.983478 
GCLC 8.866777 9.138254 PNPLA7 6.181029 7.413247 ZNF304 8.708785 8.977223 
GCNT2 7.354434 7.791559 PNPLA8 8.972647 9.534749 ZNF318 9.716905 10.032923 
GDE1 9.076656 9.349398 PNRC1 11.671833 12.052963 ZNF324 7.577579 7.952447 
GDF11 6.821368 7.238410 POFUT2 9.554029 9.856417 ZNF331 9.858796 10.850839 
GDF7 7.223427 7.830254 POLI 8.078500 8.375220 ZNF335 8.533672 8.875345 
GDPD1 4.836868 5.504822 POLR2A 11.202887 11.523289 ZNF362 7.476166 7.901811 
GDPD3 5.701194 6.434117 POLR3GL 8.218894 8.579793 ZNF367 6.292707 6.797933 
GFOD1 8.026594 9.059989 PP7080 8.241461 8.579391 ZNF394 9.850628 10.110642 
GGA2 11.843252 12.947867 PPARD 9.071386 9.824898 ZNF395 10.522494 11.336246 
GGA3 10.281704 10.786848 PPM1D 8.682267 9.048631 ZNF420 7.723749 8.024885 
GH1 3.673550 4.324812 PPM1J 4.555932 5.374052 ZNF439 8.084138 8.709601 
GHDC 8.517712 8.897716 PPM1K 11.094791 11.705290 ZNF441 7.800679 8.234593 
GIGYF1 10.930393 11.141058 PPOX 7.414564 7.892039 ZNF443 4.961438 5.522535 
GIPR 3.496856 4.149104 PPP1R12B 7.797324 8.184707 ZNF487 4.480348 5.116777 
GIT2 9.378430 9.913214 PPP1R32 4.789603 5.597100 ZNF510 8.462734 8.719863 
GKAP1 5.101303 5.674361 PPP1R37 8.863519 9.121753 ZNF540 5.794655 6.656633 
GLCCI1 7.612058 8.244544 PPP1R3E 7.908267 8.751273 ZNF548 8.872817 9.205345 
GLI1 4.861096 5.476480 PPP2R5A 9.931140 10.205015 ZNF569 7.484048 8.083320 
GLIPR1 7.806639 8.800315 PPP2R5C 10.369936 10.898137 ZNF575 4.803644 5.503796 
GM2A 10.246113 10.955648 PPP6R2 9.025896 9.322870 ZNF589 8.898818 9.194138 
GMCL1 7.419958 7.768913 PRC1 6.504971 7.054445 ZNF592 10.254471 10.512368 
GMEB2 9.595595 9.984911 PRDM2 12.422987 12.772597 ZNF595 7.297537 7.939653 
GMFG 6.413312 6.814777 PRICKLE1 4.628682 5.720444 ZNF615 7.860302 8.211976 
GNA13 11.637537 11.881008 PRICKLE2 2.261932 2.787186 ZNF627 7.970662 8.278136 
GNAO1 6.134217 7.114427 PRKAR2A 9.445878 9.711862 ZNF652 8.647479 9.157508 
GNAZ 6.826825 7.796849 PRKCB 11.069654 11.474835 ZNF654 8.377947 8.687484 
GNB5 9.000790 9.988991 PRKCE 8.534402 9.622876 ZNF667 5.793637 6.189179 
GNG7 7.391989 9.699179 PRKCSH 9.109237 9.575673 ZNF671 8.685030 9.018308 
GNL1 9.668105 9.970507 PRKD2 8.436242 8.827700 ZNF675 8.270327 8.522476 
GNPTAB 10.412407 10.728793 PRKX 8.974264 9.645325 ZNF699 7.357948 7.830270 
GNRH1 5.004545 5.546131 PROC 3.268809 3.865955 ZNF700 8.288623 8.705352 
GOLGA1 7.331251 7.831958 PRR12 9.502627 9.967238 ZNF75D 7.764135 8.102414 
GOLGA2P5 7.591021 8.569150 PRUNE 8.708390 8.938574 ZNF763 6.047648 6.478341 
GOLGA8B 9.247623 9.548564 PRX 6.820117 7.500682 ZNF767 8.709459 9.066665 
GORASP1 8.806483 9.345344 PTAR1 10.035614 10.366047 ZNF776 9.238460 9.474932 
GPATCH11 8.617671 8.910654 PTCH1 4.683725 5.283571 ZNF791 8.069907 8.424502 
GPCPD1 9.202075 9.722096 PTP4A1 10.256683 10.476113 ZNF792 6.561854 6.968390 
GPLD1 5.685776 6.527283 PTPN12 9.680322 10.005813 ZNF815P 4.129018 5.025899 
GPM6A 6.838589 7.639325 PTPN18 10.291396 10.774095 ZNF821 7.153703 7.898698 
GPR152 2.272336 2.846027 PTPN22 8.068919 9.076870 ZNF831 7.759459 8.762444 
GPR155 7.031886 8.595968 PTPN7 10.791922 11.053745 ZNF862 8.978615 9.380629 
GPR18 6.843750 8.444761 PTPRC 10.591800 11.306562 ZNF92 8.913216 9.698205 
GPRASP1 7.996842 8.698931 PTPRCAP 10.503651 11.914591 ZSCAN18 9.841149 10.138604 
GPRIN3 5.610673 6.023336 PTPRE 8.269751 8.743076 ZSWIM6 8.100975 8.535029 
GPT2 9.118758 10.817960 PTPRVP 4.417513 5.199809 
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Appendix 6. Significantly up-regulated genes induced by the soluble CD40 ligand in 




















A1BG 7.953602 7.591251 GPSM3 11.135677 10.772795 PSD 6.837553 6.255325 
AAGAB 9.188062 8.913403 GPX4 9.674541 9.234401 PSIMCT-1 5.673029 5.066073 
AAR2 9.379451 9.095487 GRHPR 9.092238 7.690434 PSMA1 9.015821 8.502967 
AARS 10.214361 9.682146 GRIK4 4.809248 2.879310 PSMA4 9.211167 8.650856 
ABCC4 8.064724 6.619467 GRIN1 3.559553 2.351340 PSMA7 9.060082 8.672845 
ABCD2 7.182471 6.394765 GRINA 10.993166 10.123794 PSMB1 7.950799 7.572439 
ABCE1 9.516025 8.979339 GRN 11.771573 11.278014 PSMB2 9.177748 8.698735 
ABCF1 9.549374 9.109554 GRSF1 10.046311 9.260831 PSMB5 9.051453 8.375940 
ABCF2 8.969114 8.487731 GRWD1 9.341053 8.883131 PSMC2 7.624181 7.284260 
ABHD17C 6.641581 5.957670 GSTP1 11.256427 10.884975 PSMC4 8.181014 7.814791 
ABTB2 10.037128 7.339014 GTDC1 7.203960 6.505307 PSMD1 7.204116 6.586985 
AC058791.1 4.574611 3.922992 GTF2H3 8.807539 8.484859 PSMD11 9.897823 9.503473 
AC147651.4 8.123056 7.268723 GTF2H5 7.849693 7.484557 PSMD12 7.253541 6.816966 
ACACA 7.589446 7.207003 GTF3C4 8.852180 8.545375 PSMD14 7.276049 6.530631 
ACAD9 7.207953 6.774966 GTF3C6 7.522765 6.709447 PSMD3 10.230640 9.814660 
ACADVL 11.532584 11.149527 GTPBP4 8.542398 8.071243 PSMD7 9.900365 9.502075 
ACBD6 8.226261 7.710660 GTPBP6 9.919791 9.671483 PSME3 11.002021 10.496613 
ACHE 6.768688 4.742802 GYS1 9.005394 8.694453 PSMG3 9.374916 8.886819 
ACKR3 6.692507 5.580341 H6PD 10.655701 10.370266 PTEN 10.667304 10.433113 
ACOT2 8.416423 8.005588 HAPLN3 7.242398 4.912322 PTGER4 10.310253 9.410302 
ACOT4 6.553445 5.451856 HBS1L 8.417542 7.998345 PTGES2 9.894379 9.079558 
ACSL1 9.613888 8.765114 HCG26 8.331340 7.701408 PTGES3 11.490620 11.201296 
ACSL4 9.967204 9.063832 HCLS1 10.366310 9.919086 PTGIR 9.973834 7.084023 
ACTB 16.011360 14.509096 HCN3 8.408519 7.803331 PTK2B 10.750176 9.969431 
ACTG1 13.975809 12.978394 HCP5 11.339949 10.391123 PTMS 9.291615 8.484564 
ACTN4 10.010649 9.531149 HDAC9 9.388910 8.592509 PTP4A3 6.623716 5.344837 
ACTR1B 10.146929 9.763903 HEATR1 7.392285 6.956633 PTPN1 12.385055 11.838354 
ACTR2 12.782099 12.498458 HEATR2 7.961268 7.454270 PTPN11 10.479156 10.181199 
ACTR3 11.924207 11.182534 HEG1 8.341664 7.791966 PTPRF 4.666223 4.049622 
ACTR3B 6.788065 5.768757 HELLS 4.860758 4.331003 PTPRO 7.416406 6.998408 
ADA 7.878489 6.952115 HERPUD1 11.654757 10.669929 PTRH1 5.462714 4.932335 
ADAM8 9.882809 9.422415 HIGD1A 8.722714 8.192657 PTRH2 8.187149 7.718312 
ADAMDEC1 8.108818 6.232325 HIGD2A 8.918177 8.616641 PUF60 9.388272 9.003443 
ADAMTS7 8.326577 6.992316 HILPDA 7.294816 6.412307 PUS7 6.357719 5.509326 
ADAT2 7.674849 7.130231 HIRA 9.583283 9.134908 PVR 7.247235 6.661869 
ADCY3 7.382646 6.624957 HIVEP1 11.591735 11.140702 PVRL1 10.027763 8.200008 
ADIRF 6.080527 4.557205 HIVEP3 8.068183 7.339419 PYCR1 8.260983 6.064941 
ADM2 7.381417 5.716318 HK2 8.429150 7.651651 QSER1 8.908262 8.603950 
ADNP 11.195404 10.957899 HLA-A 13.401634 13.136565 QTRT1 9.142368 8.651669 
ADO 10.396168 10.010414 HLA-B 14.013841 13.672862 QTRTD1 9.471702 9.103348 
ADPRH 10.896998 10.045864 HLA-C 12.883030 12.561046 RAB10 11.161529 10.774853 
ADSL 7.320443 6.719633 HLA-
DPA1 
12.509490 12.033920 RAB11A 10.275003 9.534631 
AEBP2 9.405431 9.124496 HLA-
DQA1 
9.750306 8.769536 RAB13 9.623606 8.262157 
AGFG1 10.040350 9.716423 HLA-
DQA2 
7.516829 6.666058 RAB21 10.663142 9.962045 
AGL 8.655202 8.365370 HLA-
DQB1 
11.089092 10.437605 RAB39A 6.978702 6.321346 
AGMAT 7.469726 6.370287 HLA-
DRB1 
10.204951 9.534120 RAB3GAP2 10.167510 9.616959 
AGPAT3 11.333868 10.598322 HLA-E 14.287375 13.991160 RAB3IP 8.595232 8.258827 
AGPAT6 10.812414 10.549432 HLA-F 11.900973 10.939797 RAB44 3.997764 2.934756 
AGRN 7.645800 6.789048 HLA-L 7.877141 6.794364 RAB7L1 11.767513 10.560577 
AGTRAP 7.629613 7.182788 HMGA1 11.214332 10.222061 RAB8B 11.436951 10.855283 
AHCY 8.931351 8.477557 HMGCR 8.771814 8.252869 RAB9A 9.989506 8.411926 
AIFM2 8.231195 7.827311 HMGCS1 9.903464 9.121187 RABGGTB 8.324886 8.023890 
AIMP2 7.462382 6.420642 HMGN1 10.215162 9.949769 RABL3 8.495328 8.060644 
AIRE 3.452527 2.193258 HN1L 10.419693 9.768490 RAC1 10.320348 10.009101 
AK2 10.438867 10.072937 HNF1B 4.957731 3.753008 RAD23B 10.720336 10.424021 
AKAP12 8.203482 7.732816 HNRNPA
1 
10.543968 10.082707 RAD50 8.973068 8.560301 
258 
 
AKR1A1 8.789518 8.184293 HNRNPC 11.312624 11.103650 RAD51B 6.299134 5.327946 
ALCAM 9.230131 8.433582 HNRNPF 12.385032 12.145393 RAD51D 7.998153 7.328008 
ALDH18A1 8.606723 8.317696 HNRNPK 11.638322 11.404710 RAET1K 4.719089 3.764198 
ALDH1B1 9.005862 7.955346 HNRNPM 11.612016 11.013579 RALA 9.832778 9.267196 
ALDH2 7.176307 5.949927 HNRNPR 10.861054 10.383544 RAN 10.145716 9.710003 
ALDH4A1 7.005663 6.245962 HNRNPU 12.378062 12.014735 RANGAP1 10.975680 10.560294 
ALKBH2 7.500857 6.915137 HOMEZ 9.094890 8.321394 RAP1A 9.500058 9.172359 
ALPK1 7.904115 7.337242 HOXB9 4.581664 2.984829 RAP1B 8.612859 8.301324 
ALYREF 8.330915 7.865124 HPRT1 7.189994 6.755705 RAP1GAP 3.321751 2.691571 
AMMECR1L 9.370920 9.106913 HSD17B1
0 
8.035130 7.628584 RAP2A 10.270108 9.331164 
AMPD3 9.872936 9.488498 HSF5 7.324718 6.973520 RAPGEF1 13.248279 12.889253 
AMZ1 6.294603 5.625254 HSP90AA
1 
12.548079 12.196879 RARA 10.513489 10.011484 
ANAPC16 11.296770 10.994903 HSP90AB
1 
12.314392 11.562649 RASGRF1 10.836455 10.442816 
ANAPC7 9.327347 8.948659 HSP90B1 9.296806 8.837077 RASGRP3 10.171754 9.541075 
ANKLE2 12.021287 10.871417 HSP90B2
P 
10.032137 9.479475 RASSF2 12.456385 11.721278 
ANKRD10 11.890276 10.883952 HSPA5 11.804135 11.144612 RASSF4 9.871375 8.032284 
ANKRD27 8.184743 7.826271 HSPA8 12.400208 11.864253 RAVER1 10.440696 9.869810 
ANKRD33B 11.139125 8.218603 HSPA9 9.932558 9.615700 RBBP9 9.707895 8.885143 
ANO9 10.858147 9.867610 HSPB7 2.670670 2.122148 RBM12 10.755761 10.211914 
ANP32A 10.748163 10.018870 HSPBP1 8.242288 7.553472 RBM19 9.800825 9.201659 
ANP32AP1 9.286902 8.651712 HTRA2 9.973806 9.042910 RBM20 7.249210 6.079333 
ANP32C 6.675776 6.060284 HUS1 7.527147 7.134973 RBM3 11.328704 10.511416 
ANP32E 11.333460 10.940295 HUWE1 10.950328 10.500300 RBM45 6.188943 5.738012 
ANXA2 8.724797 8.195545 HYAL2 8.012983 7.450556 RBMXL1 9.590626 9.307357 
ANXA2P2 11.914294 11.317552 HYLS1 7.942028 7.261607 RBPJ 11.353922 10.566045 
ANXA5 9.646031 9.102403 HYOU1 11.511247 10.224233 RCC2 11.122618 10.713460 
ANXA6 7.985273 6.696232 IARS 8.422468 7.872966 RCCD1 8.300561 7.822372 
ANXA7 10.015786 8.976671 IARS2 8.588394 8.284148 RCL1 7.067901 6.611755 
AP1AR 9.222218 8.835470 ICAM1 11.410798 9.076789 RCN1 7.093702 5.373989 
AP1S1 8.986207 8.645087 ICAM4 5.491791 4.917147 RELB 11.458717 10.545069 
AP1S3 10.979358 10.274773 ICAM5 6.848085 5.433557 RELT 10.572859 9.849657 
AP2B1 11.018343 10.766864 ICOSLG 5.269345 4.615022 REXO4 9.489454 9.146673 
APEX1 11.005438 10.633308 IER2 12.275053 11.771473 RFC2 7.252233 6.696947 
API5 10.555976 10.235367 IER3 10.794818 9.285861 RFC3 6.166268 5.657307 
APITD1 3.761836 3.132643 IER5 13.514664 12.822380 RFFL 7.536187 6.835488 
APLF 5.966964 5.356468 IFFO2 9.347917 8.953580 RFK 8.289172 7.958123 
APOBEC3C 11.059527 10.434204 IFIH1 9.393138 8.598635 RFTN1 11.813577 9.827169 
APOBEC3G 11.210267 10.593039 IFNGR1 9.763201 9.346301 RFX5 11.475747 10.587760 
APOL1 8.846609 8.088551 IFNGR2 10.780364 10.100596 RGS1 8.959302 8.054632 
APOOL 7.443268 7.083600 IFNLR1 10.922159 10.417373 RHBDF1 6.025289 5.224910 
APPL1 10.673339 10.251585 IFRD2 7.276652 6.905462 RHBDF2 9.590654 9.182923 
APRT 8.808586 8.340067 IGF2BP3 5.472191 4.663039 RHEB 6.468299 6.069171 
AREL1 9.577296 9.212915 IGSF3 11.656065 10.033678 RHOF 6.047007 4.355731 
ARF3 11.611093 11.064610 IKBKE 7.546157 6.847147 RHOG 11.143218 10.286219 
ARFRP1 9.054112 8.732964 IKZF1 12.265137 11.757679 RIMS3 8.079275 6.973859 
ARHGAP17 10.328129 9.490501 IKZF4 7.243872 6.813610 RIOK1 7.851200 7.360997 
ARHGAP23 5.647904 4.441719 IL10 7.086514 6.314350 RIPK2 7.667464 7.224282 
ARHGAP24 10.911241 10.522226 IL13RA1 10.566159 8.618030 RND1 7.764950 7.002037 
ARHGAP31 10.810990 9.313572 IL15RA 7.014825 6.564333 RNF115 8.304450 7.888037 
ARHGDIA 12.182496 11.848816 IL17REL 8.423473 5.468503 RNF145 10.600670 9.445000 
ARHGEF12 9.569177 9.205075 IL1B 6.749199 6.130541 RNF182 2.601409 1.992390 
ARHGEF2 11.512911 10.896419 IL21R 11.810773 9.905667 RNF19B 10.064001 9.302498 
ARID5A 10.731250 9.928932 IL21R-
AS1 
5.032682 3.902798 RNF207 6.995711 4.745560 
ARL1 8.988852 8.627915 IL2RG 12.086532 11.452626 RNF208 5.442153 3.761991 
ARL2 8.098157 7.606917 IL4I1 9.527967 7.216275 RNF215 6.601413 6.148230 
ARMC6 8.106244 7.461291 IL4R 12.719160 12.470609 RNU105A 3.628224 2.744276 
ARNTL2 8.498157 5.300441 IL6R 10.428230 9.308310 ROMO1 8.573124 8.056302 
ARPC2 10.498219 9.943726 IL7 8.189277 7.073533 RP1-249H1.4 4.628848 2.829985 
ARPC4 11.511566 10.965202 ILDR1 3.973019 3.262706 RP11-290F5.2 6.310941 5.255382 
ARPC5 11.473633 10.827694 ILF2 9.663101 9.348415 RP11-356I2.4 6.618250 5.390153 
ARPP19 12.148530 11.765525 IMPDH2 8.423418 8.099304 RP11-3P17.4 13.638275 13.429107 
259 
 
ARRDC3-AS1 5.114430 4.371524 INADL 8.317792 8.052028 RP11-
465B22.5 
4.679204 3.291198 
ARSB 8.261271 7.774163 INSL3 3.643327 3.019264 RP11-536C5.7 5.142525 4.519127 
ASAP1 8.340180 7.956147 INSM1 6.583691 5.264408 RP11-
538P18.2 
6.353958 5.866697 
ASB2 4.288624 3.616974 INSRR 1.782933 1.268095 RP11-87E22.2 4.400496 3.126149 
ASCC3 8.433754 8.014500 INTS3 9.404100 8.754706 RP3-
395M20.9 
7.157037 6.274172 
ASNA1 8.198430 7.783191 INTS6 9.775688 8.928177 RP4-
794H19.4 
3.263373 2.700392 
ASUN 6.857551 6.382267 INTS9 7.567917 7.136101 RPAP3 7.373702 7.001978 
ASXL1 12.098316 11.639824 IPO4 6.455161 6.000686 RPEL1 7.197457 6.690161 
ATAD2B 9.212634 8.922296 IPO5 9.812190 9.216624 RPF2 7.115596 6.160861 
ATAD3A 8.030086 7.664174 IPO7 9.897482 9.549128 RPIA 8.437565 8.107845 
ATF5 11.879009 10.556126 IQSEC1 11.774107 10.255995 RPL10 9.903455 9.581177 
ATF7IP 11.243586 10.726702 IRAK1 11.068272 10.468975 RPL10A 9.542559 9.268882 
ATG7 6.765557 6.349219 IRF2BP2 12.274639 11.958229 RPL13 10.519326 10.046809 
ATIC 7.280811 6.785505 IRF4 12.626079 11.276572 RPL23A 6.979419 6.537247 
ATOH8 3.567482 2.704664 IRF5 12.125198 11.048608 RPL23P8 9.263394 8.965291 
ATP2B1 10.546738 10.072132 IRGQ 9.334378 9.052990 RPL29 12.721501 12.473222 
ATP2C1 8.046513 7.716500 ISOC2 7.392895 6.501594 RPL36AL 10.750207 10.511685 
ATP5B 11.093055 10.770413 ITFG3 9.386246 8.832176 RPL4 10.538156 10.180273 
ATP5EP2 11.316277 10.961029 ITIH1 3.038724 2.283052 RPL7L1 10.559447 10.211236 
ATP5G1 7.258256 6.780906 ITPA 8.456971 7.983761 RPLP0 10.100347 9.681470 
ATP5G2 7.983415 7.560760 ITPKC 8.718697 8.416923 RPLP1 10.013713 9.674591 
ATP6V0A2 9.269476 8.996934 ITPR1 9.025708 8.669258 RPS14P3 12.074066 11.814551 
ATP6V0E1 10.534356 10.039391 IWS1 8.654431 8.371764 RPS2 10.513381 10.021096 
ATXN1 11.185682 10.877902 IZUMO4 9.841516 8.867929 RPS27A 8.591690 7.883617 
AURKAPS1 6.238717 5.488641 JADE2 12.251599 12.025805 RPS6 11.417879 11.077320 
AVEN 7.407921 6.780420 JADE3 10.290708 9.721067 RPS6KA1 10.045625 9.305438 
B3GALT6 9.941047 8.992557 JAGN1 9.450964 8.980003 RPS6KC1 8.251239 7.810793 
B3GNT7 8.275147 7.548849 JAK3 11.108855 9.586581 RPS6KL1 4.473933 3.368396 
B4GALNT1 4.062392 2.883996 JAM2 5.955225 5.138586 RPSA 6.596267 6.114268 
B4GALT2 7.615176 7.135456 JAZF1 10.202301 9.751484 RPSAP58 12.148064 11.728933 
B4GALT5 10.484103 8.907964 JMJD4 6.455379 5.952648 RPSAP9 3.718654 3.164912 
B4GALT7 8.113070 7.690219 JPH4 6.439699 3.243410 RPTOR 9.362913 8.682687 
BAHD1 10.168699 9.857148 JRK 9.877125 9.580698 RPUSD2 9.138040 8.561813 
BAI2 3.151312 2.184390 JUN 12.996036 12.379234 RQCD1 9.965768 9.497832 
BAIAP2L1 4.488149 3.621163 JUNB 14.086714 13.351132 RRP1 8.051443 7.705651 
BANF1 9.351906 8.778517 KCNC3 8.150285 7.776745 RRP12 7.397526 6.744615 
BASP1 13.272714 10.851975 KCNH3 5.653749 4.707706 RRP15 8.278223 7.818586 
BATF 8.917502 7.997360 KCNN1 8.511966 5.248535 RRS1 9.092649 8.022408 
BATF3 6.833039 4.885071 KCP 4.280979 3.569228 RSL1D1 10.946226 10.464287 
BAZ1A 9.961502 9.386272 KCTD10 9.805545 9.480084 RSL24D1 9.699376 9.447976 
BCAR3 8.369939 7.582849 KDM2B 12.268910 10.714558 RSU1 8.942696 8.546183 
BCAT1 9.309865 7.757046 KHDRBS1 11.652400 10.967165 RTCB 9.538481 8.726300 
BCCIP 7.720163 7.301681 KIAA0020 5.902294 5.224695 RTFDC1 9.577629 9.160482 
BCKDHB 6.778784 6.248323 KIAA0391 8.311961 7.824285 RTKN 6.481769 5.501242 
BCL2 14.198866 13.221322 KIAA1045 2.664470 2.104108 RUFY3 10.298589 9.186544 
BCL2A1 9.392760 7.820882 KIAA1191 10.435796 10.025585 RUNX3 12.596069 11.756227 
BCL2L1 11.493424 9.135548 KIAA1211 4.338624 2.991933 RUVBL1 7.573473 6.696404 
BCL7A 9.111780 8.329193 KIAA1430 10.298336 9.903549 S100A10 8.714577 8.121591 
BEND3 7.257881 6.709128 KIF13A 8.575798 8.253213 S100A14 7.223578 3.868838 
BHLHE40 12.544377 11.275516 KIF1C 11.276370 9.933755 S100A2 4.122547 3.530971 
BID 8.367325 7.678342 KIF21B 9.413559 9.035801 S100A6 10.467818 9.901778 
BIRC3 13.052305 12.315273 KIF26B 5.150088 3.503692 S1PR2 8.149520 7.573102 
BLK 12.368407 12.050104 KIF3B 10.090637 9.163625 SAMD14 7.524524 5.007918 
BLMH 7.944299 7.425929 KLC2 9.069490 8.619309 SAMSN1 10.431034 9.625640 
BLVRA 6.678430 5.619401 KLF6 12.656963 12.362437 SAMSN1-AS1 5.376193 3.741976 
BMP1 5.805288 5.262282 KLF7 8.471615 8.017316 SAP30 5.253952 4.570271 
BMP2K 9.541088 8.969050 KLHL42 8.370961 8.042674 SCARF1 6.332898 5.568616 
BNIP1 6.506248 6.023196 KNOP1 7.788044 7.165746 SCD 8.820482 8.127994 
BNIP3 7.176892 6.819566 KPNA6 10.665557 10.371578 SCFD2 7.398097 6.292158 
BRI3 9.713801 9.169265 KRAS 11.288874 10.971437 SCLT1 6.250410 5.780682 
BRIX1 8.014112 7.654140 KREMEN
2 
5.510570 4.471036 SCOC 9.198322 8.931367 
260 
 
BRPF3 10.412945 9.995979 L1CAM 8.918726 7.857928 SCRN1 11.557863 11.306716 
BSG 11.599480 11.294517 L3MBTL4 5.575276 5.036345 SDF2L1 8.507634 7.823733 
BSPRY 8.615770 7.981703 LACTB 9.719532 8.703973 SDF4 10.640890 10.345442 
BST2 9.680979 9.233069 LAGE3 8.726482 8.391347 SDR42E1 6.251427 5.816878 
BTBD19 7.432743 6.569788 LAMP1 11.292403 10.931516 SEC11C 6.228411 5.526326 
BTF3 9.331644 8.970954 LARP1 11.218238 10.968893 SEC13 8.670902 8.354378 
BTG3 7.778639 7.313267 LARP4 9.410389 8.971292 SEC14L1 10.705399 10.355784 
BTLA 10.762009 10.358610 LARS 8.977550 8.384273 SEC22A 7.692742 7.292941 
BTN2A2 10.445081 9.024415 LARS2 7.517846 6.981058 SEC23B 8.114213 7.789182 
BYSL 7.944979 6.792926 LAS1L 8.628135 8.294985 SEC61A2 8.458106 7.792157 
BZRAP1-AS1 9.723518 8.611387 LAT2 10.330119 9.191869 SEC61B 7.444333 6.853811 
BZW2 6.200291 5.594327 LCAT 7.045089 6.572970 SEH1L 8.709331 8.333180 
C10orf10 7.822418 6.104466 LCMT2 8.346444 7.800231 SEL1L 10.136026 9.883401 
C10orf2 9.140223 8.427869 LCP1 14.157744 12.285062 SEMA4C 7.799256 6.027704 
C10orf32 8.303047 8.003915 LDHA 10.236663 9.535798 SEMA7A 11.003286 8.985579 
C10orf55 4.511275 2.830362 LDHB 8.066238 7.386818 SENP1 8.677877 8.357190 
C11orf31 8.884223 8.471332 LHFP 5.925815 4.102411 SEPT11 9.756610 8.750257 
C11orf82 5.881863 5.401111 LHX2 3.622940 2.626554 SEPT5-GP1BB 3.034781 2.174196 
C11orf95 8.666916 7.973348 LIG3 7.829841 7.019258 SEPT8 8.573040 7.496849 
C12orf43 8.059812 7.618953 LILRB4 9.082356 7.743070 SERBP1 11.179379 10.838959 
C12orf77 5.049610 3.866476 LINC0015
8 
5.815112 3.647209 SERPINB9 11.594833 11.160468 
C14orf1 8.482813 7.938300 LINC0017
3 
5.714353 4.403198 SERPINE2 4.011177 3.295255 
C14orf166 7.466282 7.000882 LINC0026
5 
7.416980 6.841520 SET 12.516851 11.895729 
C14orf169 9.372301 8.969259 LINC0033
8 
8.124814 7.089845 SF3B3 10.156046 9.802861 
C14orf80 8.185197 7.396758 LINC0051
5 
4.114114 3.281087 SF3B4 8.741027 8.419412 
C15orf57 10.589128 9.603219 LINC0098
4 
8.974505 8.622160 SFPQ 11.947009 11.534271 
C17orf89 6.401457 5.888603 LINC0099
8 
8.336538 7.959765 SFT2D1 8.567571 7.892011 
C17orf96 8.203131 6.720264 LINC0110
4 
4.001038 2.763155 SFXN1 9.282866 8.750944 
C17orf99 7.287339 4.563586 LINC0116
0 
4.201704 3.048852 SFXN2 6.867724 6.001226 
C19orf12 9.319003 9.087586 LITAF 12.434706 11.985278 SGCA 4.061217 3.389853 
C19orf24 8.677582 8.363457 LLPH 8.335882 7.939998 SGPP2 11.199077 10.021414 
C19orf70 8.048328 7.417836 LMNB2 11.615476 10.076240 SH2B3 11.001734 10.415952 
C1QBP 8.338885 7.631167 LOC1001
29034 
10.630176 9.951731 SH2D3A 8.366765 7.716548 
C1QTNF1 3.465747 2.356049 LOC1001
29361 
9.200580 8.709067 SH3BP1 9.068065 8.721831 
C1orf186 8.858338 8.324919 LOC1001
29697 
6.272497 5.489784 SH3KBP1 10.174902 9.735481 
C1orf200 6.325141 5.399718 LOC1001
30458 
8.933209 7.787680 SHFM1 6.477378 5.864859 
C1orf86 8.806632 8.497204 LOC1001
30744 
8.784828 8.134899 SHISA8 5.231134 4.283978 
C21orf67 4.249848 3.503518 LOC1001
32111 
5.766741 4.242214 SHMT2 9.436222 9.086987 
C22orf34 6.865515 6.127635 LOC1001
32831 
5.095900 4.415323 SIAH2 10.794560 10.184566 
C2orf16 3.819208 3.274989 LOC1001
33445 
7.181492 6.689643 SIRPA 10.794584 9.607924 
C3orf38 9.141322 8.834557 LOC1002
68168 
4.611713 3.901168 SIRT6 7.967322 7.551424 
C4orf46 8.148278 7.113655 LOC1002
88175 
8.424403 7.481713 SLAMF1 8.327258 6.621369 
C5orf30 7.661271 7.179371 LOC1005
05650 
9.211494 8.906990 SLAMF7 11.361824 9.122259 
C6orf222 6.388092 5.429877 LOC1005
07634 
5.764861 5.086807 SLC12A3 5.392142 3.998781 
C6orf223 2.106453 1.592190 LOC1005
07656 
6.557749 5.846712 SLC12A4 9.303069 8.683257 
C7orf73 8.591247 8.216109 LOC1009
96573 
7.088988 6.067210 SLC15A4 10.006976 9.632488 
C8orf33 9.516507 9.217284 LOC1010
60264 
5.674149 3.435746 SLC16A9 3.268723 2.552510 
C9orf64 8.604541 8.340379 LOC1019
27686 
4.720274 3.273982 SLC1A4 9.966951 9.404181 
CA2 5.609804 4.891981 LOC1019
27696 
4.600329 2.977562 SLC1A5 10.249016 9.626715 
CACNA1G 4.603383 3.390988 LOC1019
27971 
4.584538 2.951310 SLC20A1 10.187021 9.374367 
CAD 8.444592 8.092975 LOC1019
28433 
7.572771 7.093581 SLC24A1 8.106206 7.466238 
CALM3 11.158910 10.811147 LOC1019
28485 
6.173001 5.356958 SLC25A11 8.639399 8.152269 
CALR 12.626098 11.741731 LOC1019
28673 
4.618436 4.094097 SLC25A15 6.581229 6.113477 
CAMSAP3 5.867303 4.965287 LOC1019
29272 
3.071862 2.280516 SLC25A23 8.246838 7.847384 
CAND1 10.463160 10.174110 LOC1019
29340 
5.302177 4.020667 SLC25A25 9.218836 8.844971 
CANX 11.705785 11.222020 LOC1019
29758 
6.846600 6.171484 SLC25A39 9.456361 9.077371 
CAP1 11.169937 10.815333 LOC1019
29759 
2.811435 2.098308 SLC25A43 9.003165 8.390473 
CAPG 8.715512 8.240410 LOC1027
23625 
4.176273 3.334876 SLC25A6 12.471555 12.153506 
CAPN2 9.638868 9.317650 LOC1027
23726 
7.507497 4.997806 SLC27A4 7.764237 7.256371 
CAPNS1 10.390149 9.975554 LOC1027
23766 
3.767447 2.851139 SLC29A1 8.976710 7.904880 
CAPRIN1 10.598411 10.379790 LOC1027
23826 
5.239223 2.978049 SLC2A13 8.778194 7.769419 
261 
 
CAPZA1 11.481159 11.144503 LOC1027
23996 
7.256461 6.418571 SLC2A6 9.175845 7.963926 
CAPZB 9.520476 9.148075 LOC1027
24301 
3.089498 2.675014 SLC30A9 8.331182 8.020838 
CARM1 9.814978 9.105947 LOC1027
24536 
9.470493 8.794283 SLC35A4 10.728173 10.346561 
CASP7 9.393260 8.744881 LOC1027
24545 
3.494412 2.590908 SLC35B2 11.695293 10.636735 
CAST 9.959532 9.717281 LOC1151
10 
7.179445 6.361784 SLC35F2 9.790013 8.922853 
CASZ1 9.819394 8.648408 LOC1522
25 
3.068965 2.259602 SLC37A1 9.666444 9.010784 
CAV1 9.341877 6.987543 LOC3391
92 
13.247178 12.384287 SLC38A1 13.074333 12.654633 
CBFA2T3 11.288445 10.977795 LOC3888
13 
5.713336 3.712012 SLC38A7 7.925877 7.527687 
CBX1 10.188892 9.532883 LOC3898
34 
6.407863 5.762117 SLC39A1 11.127842 10.461976 
CBX6 11.845521 11.078819 LOC6441
89 
4.750638 4.038190 SLC39A14 9.168908 8.449448 
CCDC102A 6.240188 5.208173 LOC7301
01 
7.713049 6.433161 SLC39A6 9.456755 9.119328 
CCDC103 4.876476 3.393288 LOC8015
4 
6.879704 6.200797 SLC41A2 8.121338 7.165818 
CCDC106 9.066360 8.540694 LOC9078
4 
7.865736 7.556029 SLC43A3 10.185178 8.169521 
CCDC12 8.279608 7.656416 LONP2 9.242088 8.995059 SLC45A3 8.063136 5.923671 
CCDC124 9.596485 8.890022 LONRF1 8.791004 8.344453 SLC50A1 10.001130 9.547619 
CCDC141 6.948607 6.533315 LPCAT1 11.355819 10.382481 SLC6A6 12.208553 11.236378 
CCDC167 6.478796 5.579804 LPP-AS1 2.683619 1.979767 SLC7A1 10.787451 9.944271 
CCDC28B 7.917564 6.789111 LPP-AS2 4.990305 4.481924 SLC9A7 12.240234 11.461486 
CCDC50 12.170925 10.965191 LRCH3 8.986462 8.548406 SLC9A7P1 6.503839 5.735416 
CCDC71 8.750833 8.062651 LRP4 2.601126 2.005358 SLC9A8 9.947234 9.561050 
CCDC82 8.789498 8.511295 LRP8 8.296582 6.847032 SLCO5A1 5.594875 4.282219 
CCDC86 8.481129 7.589879 LRPPRC 8.535209 8.116338 SMARCA4 8.812218 8.547144 
CCDC94 7.891740 7.578746 LRRC26 3.224873 1.917604 SMARCC1 10.477291 10.188316 
CCL17 6.092118 3.230058 LRRC41 9.304003 9.009577 SMC6 8.947372 8.565225 
CCL22 12.668254 8.194835 LRRC57 7.929529 7.621628 SMG1 12.020902 11.375825 
CCL24 5.827783 4.962395 LRRFIP2 8.637428 7.855030 SMG7 10.401506 10.061761 
CCND1 9.814171 8.206277 LSM6 6.845759 6.355912 SMG9 8.926757 8.504020 
CCND2 10.879597 10.098483 LSP1 11.941956 10.767040 SMIM12 9.944179 9.497801 
CCNI2 6.673379 5.720699 LSP1P3 6.112828 5.408166 SMIM15 9.032649 8.717686 
CCR7 14.789242 13.672239 LSS 9.298652 8.890232 SMKR1 5.241108 4.652760 
CCT3 9.804482 9.126152 LTA 8.529837 7.204848 SMO 4.921032 4.055190 
CCT4 9.391023 9.076716 LTV1 7.544290 7.056399 SMPD2 7.197873 6.712547 
CCT5 8.387743 7.834906 LY75 10.386110 9.369329 SMPD5 4.750706 3.844699 
CCT6A 9.727002 9.278320 LYPLA2 9.347404 9.039746 SMS 7.750231 7.161475 
CCT7 10.296253 9.692355 LYPLAL1 6.642090 6.095040 SMYD5 8.980703 8.451516 
CD1C 4.396649 3.490266 LYRM2 9.446194 9.082567 SNAP23 10.706049 10.400538 
CD200 11.030507 10.373927 LYRM4 8.077523 7.251943 SNAP47 9.223785 8.854853 
CD40 11.534593 9.810700 MAATS1 5.340486 4.395465 SND1 9.537265 9.086820 
CD58 9.505495 8.173851 MACF1 10.380762 9.531165 SNF8 7.876747 7.448690 
CD59 10.554165 9.822915 MALSU1 7.448230 6.938983 SNHG16 9.007607 8.176152 
CD70 9.835922 8.715651 MAML2 9.498283 8.952241 SNHG3 9.538158 8.900614 
CD74 14.497895 14.066901 MANBAL 8.040053 7.696889 SNHG4 6.836550 5.717510 
CD80 7.667405 5.771856 MANF 7.995998 7.580982 SNN 12.898935 11.363079 
CD82 12.637159 11.577043 MAP3K13 7.867132 7.511523 SNORA73A 4.153938 3.379051 
CD83 13.308793 12.021020 MAP3K8 9.682477 8.539663 SNORD80 6.031671 5.555513 
CD84 11.926531 11.583100 MAP4 11.533107 10.677504 SNRPD1 7.096244 6.394598 
CD86 8.799380 7.647640 MAP6 6.935215 6.137012 SNRPD3 10.913850 10.614957 
CD97 11.352271 10.348227 MAPK11 8.712058 7.248237 SNX11 11.812194 9.567149 
CDC42 11.841224 11.057363 MAPK13 10.280873 9.811360 SNX12 9.687112 9.402701 
CDC42EP2 7.080565 5.857928 MAPKAP
1 
10.470859 10.004471 SNX17 9.719376 9.281714 
CDC42EP3 10.769459 10.437082 MAPKBP
1 
9.583109 8.718776 SNX20 10.168775 9.341466 
CDC42EP5 2.664137 1.928244 MAPRE1 10.408562 9.889636 SNX8 11.394601 11.086672 
CDC42SE1 12.105565 11.496130 MARCKS 11.679886 9.817279 SNX9 11.098790 10.672767 
CDH22 2.024944 1.479020 MARCKSL
1 
11.908468 10.593525 SOCS1 9.594919 7.781802 
CDK17 9.888664 9.485166 MARS2 8.738997 8.439851 SOCS2 4.513999 3.536134 
CDK18 6.845537 5.099665 MARVEL
D2 
5.407525 4.767621 SP2 9.534290 9.260610 
CDK2 8.957970 8.673715 MAT2A 10.723302 10.471975 SPAG7 8.220232 7.898086 
CDK2AP1 8.969894 8.498836 MATR3 11.774953 11.560317 SPATA24 6.425116 5.895691 
CDK4 8.841566 8.277300 MB21D1 8.189145 7.767485 SPATA31D1 3.539993 2.278301 
CDKAL1 7.279457 6.918695 MCCC2 9.436617 8.774579 SPATS2 8.498204 8.051663 
CDKN1A 12.031648 10.829380 MCL1 13.500600 13.243667 SPDYE3 6.929736 6.425122 
262 
 
CDKN2A 7.736886 7.031619 MCM3AP
-AS1 
4.988807 4.456693 SPECC1 7.259613 5.864901 
CDKN2B 7.301119 6.543264 MCOLN2 10.021575 9.613968 SPHK1 7.275416 6.793675 
CDYL2 6.186658 5.615564 MCOLN3 2.907361 2.399498 SPI1 10.523073 10.197785 
CEBPG 10.797983 10.427928 MCRS1 8.187665 7.914586 SPIB 11.988670 10.843813 
CEP135 8.403790 7.371395 MDFIC 12.276155 11.367507 SPIN3 9.225114 8.871072 
CEP19 7.900799 7.438851 MDH2 8.718175 8.368267 SPINT1 8.992087 8.435186 
CEP78 7.325591 6.943163 MED1 10.737255 10.497846 SPINT2 11.131217 10.618761 
CERS4 8.660782 7.322158 MED14 8.846640 8.473905 SPN 11.418648 10.980221 
CETN2 7.289656 6.881196 MED19 7.271978 6.790520 SPPL2A 8.121444 7.551839 
CETP 5.719091 4.784837 MED22 10.306701 9.624732 SPR 6.290335 5.424845 
CFL1 12.519633 11.994344 MEF2BN
B 
6.731621 6.204200 SPRYD3 9.239665 8.970191 
CFLAR 13.608410 12.277976 MEF2C 11.196847 10.584444 SPRYD4 7.885642 7.427227 
CFLAR-AS1 5.221013 4.268974 MEGF8 9.031735 8.765617 SQLE 9.954796 8.439803 
CFP 5.983891 4.856617 MESDC1 11.112655 10.641382 SQRDL 7.881218 7.518491 
CGN 3.717528 3.020615 METAP1
D 
5.027514 4.282596 SRC 10.121322 9.162560 
CHAC1 6.583815 5.471676 METAP2 8.916329 8.603783 SREBF2 11.462777 10.989311 
CHAC2 6.010173 5.247957 METTL1 6.493107 5.204620 SRFBP1 7.611511 7.055999 
CHAF1B 5.015002 4.477831 METTL10 6.681130 6.292443 SRGN 13.682865 12.161971 
CHCHD3 8.551335 8.019293 METTL21
A 
8.674809 8.307471 SRM 7.513651 6.879680 
CHCHD6 3.831021 3.054542 MEX3C 12.334423 12.052005 SRP14 10.767247 10.482463 
CHML 8.823891 8.471805 MFI2 6.536731 5.858704 SRP72 9.165052 8.911784 
CHMP4A 8.455797 8.142906 MFN2 10.359174 10.030459 SRP9 10.011892 9.710680 
CHMP4B 11.607510 10.447964 MFSD10 9.590740 9.201500 SRPK1 9.878828 9.246642 
CHMP6 7.941653 7.485625 MFSD2A 6.815323 5.703461 SRSF1 11.989553 11.603490 
CHRNA6 6.773219 4.646282 MGAT2 11.079864 10.584718 SRSF3 11.583964 11.267951 
CHST10 8.685332 8.203622 MGAT3 5.605551 4.914558 SSNA1 10.521427 10.075770 
CHST7 9.829457 7.928500 MGC708
70 
6.674419 5.411652 SSRP1 9.687863 9.165313 
CHTOP 10.870733 10.631817 MGLL 10.663509 8.477564 SSTR2 3.594907 2.429830 
CIAPIN1 8.040379 7.679931 MGRN1 10.073213 9.775712 ST13 10.064867 9.800159 
CIB2 6.711000 5.999986 MICAL3 10.709531 10.182653 ST3GAL1 10.986346 10.300497 
CINP 7.644849 7.160125 MIIP 10.156774 9.058871 ST3GAL2 10.646583 10.107513 
CISD3 6.997685 6.623133 MINA 7.222425 6.655518 ST3GAL5 10.530533 10.016114 
CKB 8.974726 7.152464 MIR155H
G 
12.907790 10.004295 ST8SIA4 10.537679 9.417279 
CLCF1 6.223747 5.436035 MIR17HG 7.055611 5.924536 STAP2 3.668425 2.975640 
CLCN5 7.998736 7.001415 MIR21 4.344983 3.734492 STARD10 9.002322 8.010391 
CLECL1 8.778888 8.417246 MIR22HG 8.295670 7.890238 STAT1 9.935369 9.443659 
CLIC2 6.255091 4.539876 MIR3654 13.337313 13.049240 STAT5A 11.290817 9.977508 
CLIP2 9.987514 7.585678 MIR4444-
2 
8.846359 8.426913 STAT6 12.492624 12.239493 
CLN6 8.994240 8.257652 MIR497H
G 
4.307308 3.565208 STEAP3 6.386256 5.005016 
CLNS1A 8.769329 8.292723 MKL1 9.867952 9.495254 STOML1 6.890216 5.931248 
CLPB 6.989751 6.473624 MKNK2 13.304230 12.519412 STOML2 7.256802 6.922063 
CLPTM1 10.271562 9.935670 MLH1 7.492326 7.041913 STPG1 7.357077 6.617532 
CLSPN 5.231883 4.556089 MLLT11 6.663882 6.031382 STX11 9.663538 9.034849 
CLTA 9.909421 9.550972 MLST8 8.227149 7.696026 SUB1 8.759635 8.263845 
CLTC 10.180966 9.923349 MMAB 6.953990 6.418230 SUMO2 10.196871 9.872388 
CLTCL1 5.107843 4.521598 MMD 9.464756 8.255330 SUMO3 10.086692 9.724191 
CMAS 8.289670 8.013097 MMRN2 7.108313 5.954388 SUPT16H 10.192546 9.790139 
CMTM6 11.813486 10.972872 MNAT1 6.284586 5.862100 SUPT3H 6.495574 5.862931 
CNN3 7.417174 6.856768 MON1A 7.193688 6.754319 SWAP70 12.808022 12.190991 
CNOT11 9.770683 9.379909 MORF4L1 10.448895 10.051168 SYBU 5.983792 5.229991 
CNP 11.214670 10.513341 MOSPD2 7.824352 7.410548 SYCE2 5.006044 4.497154 
CNTNAP1 8.481074 7.895106 MPC1 8.979210 8.446777 SYMPK 9.648007 9.250217 
COA3 8.345816 7.900714 MPDU1 8.274138 7.948898 SYNCRIP 10.566291 10.283210 
COA4 8.807218 8.305453 MREG 7.971909 5.521629 SYNE3 8.583435 8.228668 
COA7 7.657207 7.144646 MRP63 9.437891 9.067680 SYNGR2 13.380578 12.300491 
COBLL1 9.540771 8.883899 MRPL11 8.055803 7.716037 SYNJ2 7.715490 6.712407 
COCH 9.252136 7.901357 MRPL12 8.011146 7.261570 SYNPO 11.025539 6.323091 
COL19A1 7.939462 7.444749 MRPL14 8.832552 7.929503 SYT17 9.407469 8.437999 
COL1A1 7.629171 5.117609 MRPL16 8.802281 8.507309 SZRD1 11.198975 10.791518 
COL9A2 10.270022 9.866758 MRPL17 8.046787 7.655030 TAB2 11.553687 11.223011 
COLGALT2 5.210730 4.390427 MRPL19 8.957190 8.683135 TAF15 10.069282 9.802790 
263 
 
COMMD1 8.993205 7.648802 MRPL24 7.576342 6.928469 TAF4B 8.028766 7.420561 
COMMD5 9.775343 9.447461 MRPL27 7.599070 6.980424 TAF5L 9.493696 9.183214 
COMT 8.715150 8.296035 MRPL28 8.555566 8.031914 TAF9 9.177985 8.821669 
COPRS 7.741211 7.340373 MRPL3 8.584175 7.900647 TAF9B 8.099539 7.786539 
CORO6 11.864646 9.593335 MRPL32 8.657064 8.301490 TAGAP 12.071207 11.718208 
COX17 5.615030 5.113404 MRPL37 9.422928 8.992084 TAGLN2 13.617466 12.122300 
COX5A 6.954684 6.486773 MRPL39 6.624917 5.975292 TANK 10.217328 9.772231 
CPEB1 7.427411 6.936547 MRPL40 7.942541 7.486570 TAP1 11.071466 10.425583 
CPNE2 7.302622 5.142851 MRPL45 7.637088 7.210470 TAP2 10.828102 10.293474 
CPNE5 9.726883 7.964174 MRPS10 9.397562 9.047628 TAPBP 12.207179 11.665484 
CPNE7 5.142090 4.360138 MRPS11 6.939326 6.530366 TARS 8.776039 8.238759 
CPSF2 9.579927 9.203885 MRPS14 8.565994 8.161508 TBC1D17 8.253803 7.828656 
CR2 7.628683 7.038069 MRPS16 9.654813 9.291228 TBC1D22B 8.512978 8.132941 
CRIP1 9.455016 8.440499 MRPS17 6.920477 6.440778 TBC1D2B 10.219667 9.234209 
CRIP2 9.249701 7.385702 MRPS23 7.386555 7.012722 TBCEL 8.060485 7.701068 
CRTC2 10.635525 10.335107 MRPS28 7.595000 6.873471 TBL1XR1 11.150652 10.776738 
CSF1 8.885294 7.203217 MRPS33 7.616966 7.039984 TBRG4 9.613552 9.281102 
CSF2 2.073407 1.481129 MRTO4 9.081578 8.133592 TCEAL3 8.846994 8.577637 
CSF2RB 10.152559 9.256732 MS4A1 12.507295 11.796376 TCEB1 7.141575 6.715236 
CSK 11.818491 11.281720 MSANTD
4 
8.782911 8.339895 TCEB3 9.408874 9.058029 
CSNK1G3 9.520561 8.949075 MSMO1 9.390022 8.585485 TCF7 10.947356 9.473242 
CSNK2A1 9.655232 9.431295 MST1R 7.678711 4.570930 TCFL5 10.975638 10.118637 
CSNK2A3 9.948822 9.654310 MTA1 9.677694 9.237356 TCTN1 8.306627 7.059413 
CSRP1 8.834306 8.515968 MTAP 8.316077 7.964437 TCTN3 7.623013 7.259493 
CSTF2T 10.487570 10.232049 MTCH2 7.613151 7.224868 TDRD7 8.238374 7.638845 
CTPS1 7.112944 6.166866 MTERF 7.862287 7.547290 TDRKH 6.478735 5.955987 
CTSC 9.547249 8.996951 MTFP1 8.086604 7.106995 TELO2 8.946880 8.541920 
CTSH 11.380326 10.420333 MTHFD1L 5.908789 5.210805 TES 8.559992 8.093958 
CTTN 6.341524 5.919034 MTHFD2 9.325535 8.512286 TET3 10.310335 9.757883 
CTTNBP2NL 7.844100 7.132932 MTMR12 9.330666 9.036675 TFAM 9.718268 9.404374 
CX3CL1 2.519949 1.712950 MTMR2 8.272547 7.842252 TFDP1 8.551536 8.040328 
CYB561 7.271512 6.081993 MTMR4 11.435499 10.079325 TFEB 11.210961 10.418445 
CYB5A 6.675070 5.489653 MTMR9 9.753843 8.789365 TFG 8.865984 8.390251 
CYB5B 10.210656 9.712040 MTSS1 10.593960 10.026656 TFRC 10.872786 10.238087 
CYB5R2 7.353256 5.369088 MVP 10.916383 9.932245 TGIF2 10.663700 10.320166 
CYBRD1 10.859098 9.021554 MYB 7.738301 6.409937 THEM4 7.361773 6.856913 
CYC1 9.430389 8.999415 MYBBP1
A 
7.628226 7.111029 THEM5 8.400445 6.380402 
CYCS 9.875819 9.553078 MYBL2 8.901945 8.348308 THG1L 8.208517 7.292539 
CYFIP1 8.023921 7.453287 MYC 10.282933 8.578441 THOP1 10.278221 9.164835 
CYLD 11.966134 11.471752 MYEOV2 7.514197 7.084359 THTPA 7.856317 7.527029 
CYP51A1 9.699267 9.037231 MYH11 7.596932 6.812436 THUMPD3-
AS1 
8.282229 7.913040 
CYS1 4.737226 2.423151 MYH9 12.637713 12.021796 TICAM1 10.299337 9.708186 
CYTH1 13.297281 13.012785 MYL12B 10.489797 10.236769 TIFA 10.279154 9.890726 
DACT3 4.365874 3.749365 MYL9 8.899777 7.768959 TIGD2 6.500526 5.998579 
DAD1 10.251737 9.892459 MYO1C 10.590553 9.192320 TIGIT 10.541265 9.948040 
DAP 10.801027 10.400093 MYO1D 7.943252 7.340057 TIMM23 7.801453 7.126639 
DARS 9.053949 8.581492 MYO1E 9.081245 8.671471 TIMMDC1 9.816092 9.366931 
DARS2 8.087212 7.562617 MYO1G 8.264033 7.531546 TINF2 10.668253 10.304810 
DAZAP1 10.448031 10.045281 MYOCD 5.429135 3.168388 TIPRL 9.408526 8.977484 
DBI 10.118624 8.859756 NAA15 9.446886 9.170263 TJAP1 9.847695 9.509343 
DBNL 9.972295 9.561625 NAA20 8.137951 7.801628 TJP2 7.795970 6.414936 
DCAF11 10.238501 9.959131 NABP1 9.155892 8.513928 TK1 7.311623 6.611742 
DCAF16 9.645327 9.336359 NABP2 8.040419 7.713393 TLCD1 6.116277 5.179699 
DCAF7 11.261622 10.944941 NACAD 4.981287 4.245515 TLE1 9.363125 8.455130 
DCPS 7.386787 7.016623 NAGLU 9.049834 8.505751 TLR10 9.251322 8.062609 
DCTD 10.089044 9.744656 NAMPT 9.577653 9.051504 TLR6 9.627146 9.203461 
DCTN1 9.069439 8.812467 NAP1L1 11.225195 10.556249 TMA16 8.318990 7.704358 
DCTPP1 9.503838 9.010212 NARS2 7.505315 7.038664 TMCC1-AS1 5.269900 4.766179 
DDHD1 10.472514 10.122160 NAT10 8.764464 8.318090 TMCC3 9.608815 8.624612 
DDHD2 8.395533 7.921495 NAT9 9.378129 9.132007 TMED3 9.201927 8.909204 
DDOST 8.555019 8.246635 NBEAL2 11.189095 9.441445 TMEM102 8.521444 8.225746 
264 
 
DDR1 10.377260 9.289402 NBN 9.689224 8.754780 TMEM106A 8.159463 7.784784 
DDR2 5.117448 4.325234 NCBP2 10.451974 10.221198 TMEM120A 8.499654 6.679126 
DDX21 11.059120 10.288843 NCF2 11.113571 8.841371 TMEM120B 8.624884 7.826387 
DDX47 8.568462 8.237490 NCK2 10.802134 9.982300 TMEM136 5.819658 5.211356 
DENND4A 10.280267 9.180465 NCL 11.842902 11.433179 TMEM14A 6.891340 6.181505 
DENND5A 9.354418 8.357638 NCLN 10.169707 9.953693 TMEM14B 8.370639 8.047480 
DFFA 8.639306 8.194692 NCOA5 10.060597 9.787313 TMEM164 8.754255 7.867608 
DGAT2 8.360501 7.278527 NDE1 10.674845 8.970843 TMEM168 8.826621 8.426639 
DHCR24 8.269132 6.795008 NDFIP1 10.241461 9.830353 TMEM170B 9.280859 8.261823 
DHCR7 7.901455 7.159500 NDFIP2 7.834734 7.442664 TMEM177 6.804431 6.013245 
DHTKD1 9.983723 9.632976 NDUFAF1 8.126916 7.806624 TMEM185B 9.885074 9.497928 
DHX33 8.633483 8.216421 NDUFB9 7.784829 7.433067 TMEM205 9.326121 8.801284 
DHX34 8.663760 8.348095 NDUFS6 6.364928 5.823944 TMEM230 10.404062 10.028212 
DHX37 8.636601 7.977375 NEAT1 13.371420 12.825499 TMEM241 5.778585 5.119292 
DLD 8.281915 7.695376 NECAP2 10.762162 9.930065 TMEM254 7.706092 7.213030 
DLGAP3 8.054068 6.426028 NEDD1 8.534176 8.120368 TMEM261 8.264440 7.862872 
DLGAP4 11.369441 10.878491 NEDD8 8.025124 7.660446 TMEM54 5.664094 4.029716 
DNAJA1 9.302810 8.762652 NEDD9 9.125081 8.062612 TMEM57 8.988358 8.500850 
DNAJB5 7.182959 6.310761 NEIL2 8.188232 7.760702 TMEM63B 8.395882 7.483385 
DNAJC14 9.934358 9.710543 NEK6 9.325184 8.278282 TMEM69 8.479523 8.022991 
DNAJC30 8.550951 7.912632 NEK9 10.796179 10.574614 TMEM97 7.317336 6.551007 
DNM1L 9.080609 8.820099 NENF 7.649064 7.277867 TMOD3 10.149088 9.868521 
DNMT3A 9.611954 8.665284 NET1 4.848338 4.244529 TMPO 11.302528 11.016913 
DNPH1 7.784866 7.136846 NETO2 8.274082 7.916143 TMSB4X 13.414419 12.676827 
DOCK10 10.282608 9.239791 NFAT5 11.213010 10.689407 TNF 8.949074 8.370173 
DOCK2 8.681681 8.378734 NFE2L1 12.373860 11.562258 TNFAIP2 10.736036 8.068215 
DOK4 5.391410 4.538502 NFIC 9.463345 9.105619 TNFAIP3 12.860713 11.035707 
DOT1L 10.429126 10.027518 NFIX 6.217070 5.378633 TNFAIP8 12.050378 11.306214 
DPCR1 2.630762 2.018774 NFKB1 11.396952 10.158563 TNFRSF10B 11.681169 11.011731 
DPH2 9.544898 8.997128 NFKB2 11.682414 10.198854 TNFRSF14 11.426021 10.478213 
DPH3P1 7.486890 6.589820 NFKBIA 13.224680 11.114822 TNFRSF18 10.763610 9.066918 
DPH6 5.746192 5.025908 NFKBID 10.354533 9.813712 TNFRSF19 2.515885 1.995011 
DPP3 7.784413 7.247810 NFKBIE 11.603261 10.178613 TNFRSF1B 13.188299 12.552761 
DRAM1 8.610334 7.898749 NFKBIZ 11.632246 10.479588 TNFRSF4 9.161512 6.680438 
DRAM2 9.510078 9.139333 NHP2 8.989614 8.411086 TNFRSF8 8.367201 5.933219 
DSE 7.861168 7.360637 NIFK 7.728039 7.243500 TNFRSF9 11.109620 7.540847 
DTD1 6.871372 6.475212 NIP7 8.645556 8.114729 TNFSF14 7.404509 6.429335 
DTD2 8.286415 7.605375 NIPAL2 9.827578 9.326254 TNFSF4 10.006048 7.109514 
DTNB 6.029604 5.469451 NIPAL4 6.464801 5.439813 TNIP1 11.167061 10.707889 
DTX2 7.928169 7.444255 NIPSNAP
3A 
7.519953 7.112906 TNIP2 10.597779 9.610075 
DUSP2 10.835306 10.399224 NKIRAS2 9.348468 8.974161 TNKS1BP1 9.423985 8.200423 
DUSP22 11.551397 10.619131 NKX3-1 6.785522 6.368362 TOMM22 9.381762 8.625239 
DUSP5 10.511688 9.499164 NLGN4Y 4.057044 2.954845 TOMM34 8.469328 8.133450 
DYNC1I2 6.554107 6.177822 NLN 8.473221 8.013981 TOMM40 8.596682 8.143274 
DYNLT3 8.969401 8.615046 NLRC5 11.455330 10.921271 TOMM6 9.269566 8.823066 
DZIP3 6.581985 5.975435 NME1 6.520077 4.944918 TOR3A 10.182884 9.668716 
E2F3 8.844789 8.413429 NME3 9.395136 8.811668 TOR4A 9.837392 9.547233 
EARS2 8.153320 7.153925 NOB1 8.599525 8.083376 TP53 9.929461 9.431482 
EBI3 9.549301 4.994158 NOC3L 8.563918 8.196723 TP53BP2 9.650856 9.163370 
EBNA1BP2 7.093238 6.633015 NOD2 10.852268 10.203598 TP53I11 11.358691 10.502516 
ECE1 12.043981 11.065352 NOL3 4.937946 4.221725 TP53I3 6.849350 6.355810 
ECE2 6.039201 5.186806 NOL6 8.856735 8.416611 TP63 4.491767 3.691883 
ECHDC2 7.907906 7.572098 NOLC1 10.384707 9.825684 TPI1 10.099443 9.789299 
ECHDC3 6.080794 5.109297 NONO 11.417875 11.141408 TPRN 8.984444 8.296761 
EDARADD 11.426088 10.390748 NOP10 8.854083 8.382442 TPT1-AS1 6.799949 6.194052 
EDC3 9.184250 8.859769 NOP14 8.229804 7.604613 TRADD 10.335622 9.521030 
EED 8.279121 7.859700 NOP14-
AS1 
7.227355 6.790656 TRAF1 14.239337 11.126570 
EEF1A1 9.729582 8.758479 NOP16 7.448759 6.846314 TRAF2 9.418814 9.008460 
EEF1E1 6.053783 5.297491 NPAT 9.481252 8.825183 TRAF3 11.571085 11.080722 
EEF2K 10.359934 9.601840 NPB 4.275929 3.670489 TRAF4 11.846510 10.928163 
EEFSEC 7.889330 7.567017 NPLOC4 11.187575 10.904465 TRAF7 8.470279 8.011289 
265 
 
EFHD2 11.559802 10.838838 NPM1 8.671944 8.258706 TRANK1 11.398120 11.057652 
EFNA1 4.544565 3.769976 NPR1 2.145329 1.522160 TRAPPC12 9.251092 8.985530 
EFNB1 7.531296 6.874857 NPRL3 7.697240 7.137706 TRDMT1 6.681462 6.067615 
EFTUD2 8.118211 7.765573 NPTX1 7.695826 5.891081 TRIM2 5.990787 5.487060 
EGOT 4.881449 2.965081 NR1I2 3.017019 2.520790 TRIM44 11.460265 11.207808 
EHD1 13.121143 12.150206 NR5A2 4.167623 3.606298 TRIP10 10.523760 8.607190 
EHD4 10.334731 9.712130 NR6A1 6.180024 3.912186 TRIP12 10.589256 10.267871 
EHF 3.207745 2.481609 NRAS 10.746205 9.910396 TRIP13 3.670005 3.089365 
EIF1 12.235142 11.991569 NRBF2 8.958663 8.510911 TRIP6 6.565267 6.131789 
EIF2A 8.680959 8.413282 NRP2 8.573846 6.809732 TRMT10C 8.801477 8.495932 
EIF2B1 8.817632 8.550130 NRXN2 5.199100 3.558150 TRMT2A 8.794459 8.466017 
EIF2D 7.666707 7.131550 NSDHL 6.840670 6.311140 TRMT5 7.944793 7.479397 
EIF2S1 9.636031 9.255287 NSRP1 9.011324 8.706040 TRMT61A 9.478528 8.560524 
EIF2S3 10.853582 10.443470 NSUN2 9.907858 9.624865 TRMT61B 7.629207 7.313661 
EIF3A 11.685291 11.409324 NSUN4 9.392408 9.047290 TRPM7 10.314735 9.960888 
EIF3B 10.042093 9.670602 NT5DC1 8.810870 8.173716 TRUB2 7.717603 7.276478 
EIF3I 9.120304 8.811257 NT5DC3 8.237786 7.737772 TSC22D2 10.470967 9.893867 
EIF4E2 9.654951 9.383192 NTNG1 4.865111 4.108177 TSEN15 9.329475 8.560993 
EIF4G1 10.665817 10.161265 NUCKS1 11.378474 11.096994 TSG101 7.959336 7.596389 
EIF5A 10.361440 9.771761 NUDC 8.986567 8.627461 TSPAN18 7.215250 5.561910 
EIF5B 9.269656 8.823374 NUDCD1 7.300307 6.917339 TSPAN31 7.959147 7.594450 
EIF6 8.610946 8.135765 NUDT18 7.438680 6.967176 TSPAN33 12.153355 10.074833 
ELAC1 6.770431 6.256236 NUDT19 8.397237 7.948102 TSR1 8.357539 7.835232 
ELAVL1 10.650562 10.117339 NUDT9P1 5.113263 4.408849 TTC1 9.205493 8.877264 
ELK1 9.544339 9.079623 NUP153 10.539777 10.113302 TTC27 6.425149 5.832760 
ELK3 9.666049 8.852139 NUP35 5.614720 5.114088 TTC39A 2.649169 1.982649 
ELL 9.766777 9.497437 NUP62 12.326875 11.441255 TTC7A 10.468069 10.068534 
ELL2 9.009600 8.389734 NUP93 7.018251 6.417975 TTF2 9.178933 8.275701 
ELMO2 8.831698 8.538192 NUPL1 9.103464 8.752006 TTLL4 7.906704 7.561971 
ELOVL1 9.513471 9.231591 NUS1 7.971071 7.593307 TTPAL 9.508952 9.156705 
ELP6 7.240933 6.881468 NUTF2 9.119548 8.512166 TUBA1A 10.220039 9.895335 
EMC3-AS1 7.136169 6.643308 NXPH3 5.342064 3.099890 TUBA1B 11.053368 10.242069 
EMG1 7.055070 6.566244 OAS3 9.311947 8.426734 TUBA1C 9.294054 8.129300 
EMILIN2 10.531309 9.703746 ODF3B 8.830132 8.157529 TUBB 13.137887 11.796779 
EMP3 9.217676 8.688157 OLA1 7.066930 6.629421 TUBB2A 6.430803 5.899914 
EMX1 2.654611 1.847335 OPA3 10.036918 9.516814 TUBB2B 3.264386 2.290128 
ENO1 10.870377 9.823198 ORAI1 11.177884 10.168751 TUBB4B 11.355809 10.894341 
ENPP4 9.533601 8.815892 ORMDL2 7.987625 7.439559 TVP23A 7.538027 6.081265 
ENPP5 4.997864 4.441407 OSBPL9 8.236468 7.657378 TWISTNB 8.732566 8.143546 
ENSA 10.919083 10.312115 OSGIN2 9.112446 8.773687 TXLNA 10.948077 10.617696 
EPM2AIP1 11.108246 10.351719 OSM 5.716694 5.116151 TXLNB 9.331443 8.735489 
EPRS 9.148911 8.799417 OTUD4 10.376022 10.029684 TXN 6.890421 5.584555 
EPS15 11.375262 10.190938 OTUD6B 7.676393 7.122848 TXNDC17 6.430715 5.954911 
ERAL1 8.700640 8.181161 OTUD7B 7.265234 6.420167 TXNL4A 10.042779 9.735640 
ERH 9.811060 9.350398 OXTR 6.089772 4.085986 TYK2 11.239448 10.570181 
ERI3 8.417545 8.095982 P2RY8 10.979301 10.553048 TYMP 10.039502 9.388983 
ESAM 6.807532 4.952602 PA2G4P4 9.887557 9.528241 TYW3 8.683810 8.336469 
ESF1 7.982055 7.450989 PAICS 9.067145 7.752368 UBAP2 7.980203 7.648359 
ESPL1 6.809637 5.630699 PAIP1 8.140297 7.829822 UBAP2L 9.408087 9.152711 
ESR1 6.533200 6.102701 PAK1 8.859267 8.046870 UBB 12.870243 12.473779 
ETFA 6.971312 6.225890 PAK1IP1 6.350293 5.509655 UBE2A 9.549611 9.237902 
ETFDH 6.639269 6.139359 PAK4 8.175213 7.800723 UBE2E2 6.441767 5.830951 
ETS1 12.867632 12.614606 PANDAR 9.241723 8.932151 UBE2G2 10.619140 10.273282 
ETV3 10.534527 10.000196 PANX1 8.939493 8.522510 UBE2N 10.094096 9.719263 
ETV3L 4.440082 3.034766 PAOX 8.075254 7.595720 UBE2Z 12.403095 11.604389 
EXOC4 8.854383 8.454182 PAQR7 9.041791 8.462287 UBE3A 10.530541 10.152699 
EXOSC4 8.117078 7.713219 PAQR8 9.663384 9.007410 UBE3C 9.639318 9.365406 
EXOSC5 6.057405 5.459068 PARK7 9.817258 8.970118 UBFD1 10.041359 9.607904 
EZH2 8.330396 7.006177 PARP1 10.026364 9.594607 UBLCP1 8.886889 8.268077 
F13A1 6.160437 5.084891 PARP12 9.896268 9.523114 UBR4 10.324268 9.974731 
FAHD1 8.704235 8.374553 PARP14 11.904127 11.360569 UBTD2 8.502680 8.224583 
266 
 
FAIM 6.011184 5.522033 PASK 10.981400 10.289553 UCK2 9.193717 8.303090 
FAM104B 6.386895 5.930823 PATL1 9.468229 9.119959 UEVLD 8.437504 7.952828 
FAM105B 10.341602 9.513963 PAX5 13.637816 12.338171 UFC1 9.420276 9.080400 
FAM109B 7.380307 6.844794 PCBD1 7.674704 7.313836 UGDH 8.708307 8.173577 
FAM114A1 6.765384 6.313198 PCED1B 9.799304 9.366962 ULBP1 4.093235 3.481660 
FAM118A 9.269946 8.885551 PCK2 8.614841 7.872326 UMPS 8.968923 8.497001 
FAM129A 8.742699 6.823768 PDAP1 9.900779 9.489182 UNC119 9.700245 9.009050 
FAM136A 9.668411 9.311970 PDCD11 8.737544 8.302187 UNQ6494 4.048135 2.522928 
FAM168A 10.339164 9.915241 PDCD4 11.831086 10.969703 UPF3B 8.564150 8.180017 
FAM174B 7.950876 7.520882 PDCD4-
AS1 
9.021450 8.583927 UPP1 6.619601 5.949520 
FAM195B 9.718966 9.085751 PDE7A 10.992366 10.499812 UQCRFS1 8.266017 7.950399 
FAM212A 4.027605 3.282434 PDF 6.670219 5.722115 URB1 8.163000 7.500788 
FAM213A 4.529831 3.896224 PDGFA 7.565219 6.727757 URB2 8.564399 7.703297 
FAM213B 9.872143 8.744736 PDIA3 10.155595 9.725938 URM1 9.809513 9.501099 
FAM3C 8.026517 7.659854 PDIA3P1 11.970199 11.462478 USP10 10.082444 9.724278 
FAM49A 9.034372 7.532904 PDIA4 9.741226 9.354672 USP12 11.476549 10.738323 
FAM60A 11.798208 10.761792 PDLIM4 2.251483 1.633625 USP14 8.954172 8.599662 
FAM83H 6.770438 6.109423 PDLIM5 8.624422 8.181209 USP24 10.555240 10.301722 
FAM98A 8.630511 8.339721 PEA15 12.475233 11.568256 USP46-AS1 4.406383 3.873363 
FAM98B 8.611977 7.905655 PEAK1 10.743976 10.413774 USP5 8.952762 8.581884 
FARSB 6.497199 5.989119 PEF1 10.145381 9.557935 UST 6.871780 5.990801 
FAS 9.830704 7.626175 PELP1 9.767877 9.457179 UTP15 7.684877 7.175897 
FASN 9.420824 8.515989 PEPD 8.258703 7.822845 UTP20 7.008165 6.499428 
FASTKD2 8.418093 7.930419 PES1 8.765752 8.127120 UTP3 10.344422 10.058909 
FBRS 11.790294 11.373890 PEX10 6.976420 6.315641 UVRAG 10.615780 10.048344 
FBRSL1 11.003170 10.482407 PEX26 10.030065 9.628677 VAMP8 9.854073 9.518776 
FBXL15 9.878689 9.477920 PFAS 8.731693 7.927263 VANGL2 4.733683 3.819186 
FBXL19-AS1 7.258007 6.805217 PFDN1 9.461585 9.161235 VARS 9.101573 8.192714 
FBXL8 5.355026 4.563678 PFKM 8.025312 7.171070 VASH2 4.492879 3.577930 
FBXO22 7.595360 7.070393 PFN1 13.372133 12.084521 VASP 10.251792 9.937944 
FBXO45 8.338523 8.017156 PGAM1 8.112403 7.622913 VBP1 8.969110 8.474776 
FBXW4 9.856618 9.547038 PGBD4 6.864357 6.475077 VCP 11.309590 10.864838 
FBXW4P1 8.034030 7.675593 PGD 8.978863 8.505778 VDAC1 10.214788 9.315996 
FBXW5 10.939534 10.621010 PGK1 9.567916 9.177667 VIM 11.524659 10.094935 
FBXW7 9.032337 8.566542 PGLS 8.789199 8.370619 VKORC1 9.372896 9.116591 
FCER2 10.562832 10.059279 PGM2 7.262273 6.847716 VMP1 9.729424 9.292584 
FCHSD2 10.999991 10.259340 PHAX 9.216365 8.920846 VOPP1 11.026579 10.365345 
FDFT1 10.113665 9.713110 PHB 9.900722 8.941577 VPS13A 8.467441 7.900280 
FDX1L 6.850569 6.120239 PHLDA2 5.925498 4.951819 VPS25 7.860396 7.418834 
FDXACB1 6.909728 6.355560 PHLDA3 5.142452 4.523687 VPS26A 9.148112 8.842783 
FEN1 8.594279 8.221496 PHLDB1 6.337751 5.474311 VPS29 9.543081 9.152989 
FGF2 5.413179 4.394963 PHPT1 8.601101 8.067807 VPS37C 8.445513 8.072400 
FH 6.418058 5.971228 PIGQ 8.949934 8.598714 VPS41 8.605028 8.253017 
FHOD1 9.578191 8.588910 PIGR 7.937257 7.384607 VWA7 5.427171 4.825719 
FILIP1L 10.356479 9.356375 PIGV 8.385064 7.881258 WAC-AS1 8.658474 8.245668 
FJX1 2.977266 2.460644 PIGW 7.755283 6.994328 WARS 11.288968 10.142710 
FKBP1A 10.128705 9.707040 PIK3CA 9.010215 8.604648 WARS2 7.389678 6.851963 
FKBP2 8.528406 8.183359 PIK3CD 11.917771 11.237567 WDFY1 10.819912 10.382353 
FKBP5 10.266723 9.420411 PIM1 13.059208 12.730878 WDR1 11.303678 10.723318 
FKRP 8.797542 8.510844 PIM2 12.745028 12.219786 WDR12 6.444299 5.830514 
FKTN 8.232403 7.648974 PIM3 11.938148 11.522207 WDR17 7.341882 6.678853 
FLJ13224 4.536501 3.719678 PINX1 7.332696 6.846480 WDR3 7.313354 6.722232 
FLNA 12.444029 12.078200 PIPSL 11.594161 11.086015 WDR36 9.057770 8.769552 
FLNB 9.903276 8.659727 PISD 9.507718 9.160570 WDR4 7.776993 7.095887 
FLOT1 9.507440 8.884688 PITPNB 10.016098 9.474371 WDR43 9.008932 8.432003 
FLOT2 11.688314 11.382168 PKIG 10.106541 9.407670 WDR44 8.217935 7.923502 
FLVCR2 7.144065 6.180121 PKM 12.931438 11.655070 WDR48 9.619798 9.356308 
FMNL1 12.437402 12.074592 PKN3 8.408078 7.301871 WDR5 9.621988 9.382540 
FMNL3 10.983661 10.020052 PLA2G4C 7.279877 6.208017 WDR77 8.904595 8.211805 
FMOD 13.243699 12.700689 PLAGL1 9.372387 8.192631 WDR89 9.284126 8.977215 
FNBP1 13.341354 11.893311 PLAGL2 9.634309 9.291964 WHAMMP3 6.697101 5.649219 
267 
 
FNDC3B 7.133154 6.612047 PLAU 7.794186 5.472298 WIZ 9.278124 8.837292 
FOXC1 5.756841 4.870722 PLCB3 8.429388 7.291601 WNT10B 5.144813 4.230550 
FOXN3-AS1 5.122823 4.151894 PLD2 8.105361 7.684142 WNT4 6.944027 4.843146 
FOXP1 12.136943 11.717704 PLEK 12.355095 9.902443 WSB2 10.010132 9.652488 
FOXP4 11.613187 9.829255 PLEKHA7 8.316508 7.718625 XBP1 10.160644 9.712154 
FPGS 9.602099 9.030815 PLEKHF1 8.329375 7.954924 XPO1 10.599384 10.256652 
FRK 4.717449 3.537603 PLEKHF2 11.266619 11.030991 XPO4 9.744651 9.354172 
FSCN1 9.600285 7.044685 PLEKHG4 4.385146 3.841998 XPO5 8.211772 7.866963 
FSD1L 8.549462 7.187813 PLEKHG5 4.998221 4.181173 XRCC5 10.021571 9.720843 
FSTL3 6.905159 5.327823 PLEKHM2 11.214887 10.794330 XRCC6 9.558492 9.140925 
FUNDC2 8.145428 7.649637 PLEKHO2 10.395716 10.084185 YARS 9.626249 9.102831 
FUOM 5.491880 4.753862 PLGRKT 6.312396 5.436987 YARS2 8.309586 8.019093 
FUS 10.423547 10.104296 PLIN3 10.185125 9.168749 YBX1 10.659890 10.276401 
FUT10 6.477369 5.468036 PLLP 5.357140 3.326359 YWHAB 11.954201 11.604477 
FUT4 9.226678 8.456433 PLXNA1 10.823242 9.136363 YWHAE 11.085052 10.430100 
FUT8 7.997890 7.560004 PML 9.846005 9.552496 YWHAG 11.714281 11.372897 
FXN 7.265689 6.787700 PMM2 9.198181 8.775496 YWHAQ 11.063740 10.721554 
FXYD2 3.506452 2.636457 PNO1 8.293581 7.600141 ZBED4 9.473163 9.158002 
FXYD6 8.049348 6.442875 PNPO 8.013158 7.559609 ZBTB10 11.173173 10.155414 
FZD6 5.945903 5.398161 PNPT1 7.583083 7.114070 ZBTB11-AS1 5.528837 4.924855 
G3BP1 11.391581 10.795282 POFUT1 9.434810 9.014447 ZBTB17 9.641504 9.183090 
G6PC3 8.083269 7.678325 POLA2 7.852898 7.040349 ZBTB32 11.686935 10.237519 
GABPB1 8.946818 8.430093 POLD2 9.697772 9.176237 ZBTB46 7.638151 6.640016 
GADD45GIP
1 
9.884543 9.475281 POLDIP2 9.442185 9.045882 ZBTB5 11.124582 10.282840 
GALNT10 9.463449 9.005468 POLDIP3 11.260636 11.014942 ZC3H4 10.044466 9.649573 
GALNT11 7.223165 6.742078 POLK 9.241800 8.979511 ZC3H7A 9.889884 9.530099 
GALNT16 4.308810 3.719120 POLR1B 8.543267 8.103450 ZC3H7B 11.673579 10.615865 
GALNT2 11.905478 11.193128 POLR3H 8.615201 8.109964 ZC3HC1 6.777675 6.317674 
GAR1 7.853477 7.328341 POP1 6.806970 6.239227 ZCCHC7 10.279679 9.638488 
GAREML 5.883480 5.305227 POP5 7.480235 7.049401 ZDHHC16 7.834317 7.406161 
GARS 8.119946 7.443759 POPDC2 6.016003 5.545090 ZDHHC18 10.899137 10.117134 
GART 8.923299 8.287375 POR 9.275222 8.530944 ZDHHC23 9.045300 8.717801 
GAS5 6.650326 6.254304 POU2F1 10.137552 9.815397 ZFAND3 10.758141 10.453399 
GATSL3 6.832459 6.138036 POU3F1 7.915312 6.144523 ZFHX2 7.527393 5.495155 
GBE1 7.172272 6.560243 PPA1 6.117443 5.335224 ZFHX3 9.554635 9.172524 
GBGT1 8.719648 7.532264 PPAP2A 6.422194 5.948769 ZFP36L1 14.378966 13.264840 
GBP1 5.467442 4.773312 PPARA 10.164272 9.376872 ZFYVE26 9.660477 9.022516 
GBP4 8.325968 7.748049 PPDPF 9.851421 9.561321 ZMAT3 9.681354 9.277620 
GCDH 8.144650 7.418193 PPFIA3 5.443813 4.869245 ZMIZ2 12.061715 11.351671 
GCGR 4.483258 2.794604 PPIA 10.470663 10.139280 ZMYM4 8.968046 8.719715 
GCN1L1 9.713355 9.428282 PPID 8.390168 7.789071 ZMYM6NB 8.379615 8.083632 
GEMIN4 9.154737 8.798989 PPIF 10.076440 9.278107 ZNF135 6.503097 6.034965 
GEMIN5 7.754269 7.312029 PPIL1 8.668263 8.012260 ZNF154 9.576726 9.188953 
GEMIN8 8.118855 7.596194 PPIP5K1 8.121953 7.726730 ZNF207 9.810543 9.302862 
GEN1 9.205402 8.788348 PPP1R14
B 
9.318734 8.083467 ZNF22 10.610312 10.104256 
GFI1 8.214589 7.324693 PPP1R15
B 
11.772253 11.493898 ZNF239 6.275331 5.422537 
GFM1 7.702974 7.288409 PPP1R7 7.665812 7.178673 ZNF260 9.921369 9.422770 
GGACT 7.086148 6.637489 PPP1R9B 13.152565 12.006304 ZNF267 10.451991 9.844640 
GGCT 7.843461 7.255475 PPP2R1A 9.309932 9.003669 ZNF281 9.748361 9.262862 
GGNBP2 9.161077 8.846246 PPP2R2D 9.343802 9.025824 ZNF282 9.393259 9.036816 
GHRL 5.337353 3.846749 PPP3CB 8.977501 8.537384 ZNF292 10.758186 10.509023 
GINS4 7.289893 6.794527 PPP5C 7.679915 7.074323 ZNF295-AS1 1.971144 1.497409 
GIPC1 8.418452 7.987438 PPRC1 10.219939 9.656591 ZNF296 8.915596 8.649528 
GJD3 7.069320 6.200616 PPT1 9.605580 9.352472 ZNF33B 8.599696 8.259510 
GLB1 7.907000 7.486299 PRCC 10.346203 10.082666 ZNF385C 6.901386 5.994654 
GLRX3 7.482780 7.071085 PRDX1 9.107393 8.367075 ZNF506 9.693350 9.242355 
GLYR1 10.758236 10.445629 PRDX3 9.317650 8.998659 ZNF512 8.963276 8.622157 
GMEB1 7.785704 7.399022 PRDX4 6.449152 5.753889 ZNF544 8.636854 8.314212 
GMFB 9.875280 9.507838 PRELID1 8.166251 7.849291 ZNF563 7.291101 6.821836 
GNAI3 9.677917 9.362094 PREX1 10.880736 10.118751 ZNF593 7.360259 6.797689 
GNB2L1 12.356545 12.130135 PRKAG2-
AS1 
6.038361 5.316568 ZNF598 9.830369 9.565500 
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GNG2 11.761042 11.394173 PRKAR1B 8.013317 7.227849 ZNF629 8.055181 7.598060 
GNG8 8.316874 5.585427 PRKCD 9.058549 8.166394 ZNF660 6.438243 5.758802 
GNL3L 9.809861 9.495302 PRKDC 9.723252 9.325586 ZNF70 6.166508 5.688498 
GNPDA1 9.527696 9.097681 PRMT1 9.070204 8.667742 ZNF706 8.498422 8.014149 
GORAB 8.304638 7.994270 PRMT2 10.203759 9.932595 ZNF710 10.701054 10.096776 
GOSR1 9.739977 9.468126 PRMT6 9.783213 9.491477 ZNF717 6.392040 5.960938 
GOSR2 9.975070 9.624911 PROB1 7.970000 7.408640 ZNF770 11.012646 10.734881 
GOT2 9.608301 8.590016 PROSER1 9.752252 9.446514 ZNF780B 8.572998 8.130140 
GPATCH4 9.288679 8.203503 PRPF19 9.633366 9.329745 ZNF788 6.458067 5.239809 
GPC5 2.006063 1.453279 PRPF40B 8.049812 7.470888 ZNF865 9.928260 9.641350 
GPR132 10.860224 9.708898 PRR18 8.060311 6.602980 ZNF878 4.421757 3.666537 
GPR137 9.887429 9.088088 PRRC2C 12.014769 11.684178 ZNFX1 11.273591 10.507499 
GPR137B 8.551395 7.857030 PRRG4 5.168425 4.207953 ZNHIT6 8.921738 8.540174 
GPR153 7.628139 6.106295 PRRT2 7.264727 5.988507 ZRANB2 10.280468 9.942858 
GPR157 8.086005 7.216365 PRRT3 8.723047 6.460573 ZSCAN2 9.968385 8.584235 
GPR55 6.678010 5.270696 PSAT1 5.278874 4.532170 ZSWIM4 9.940780 8.436791 
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Appendix 7. Significantly down-regulated genes induced by the soluble CD40 ligand in 



















AATK 6.395418 7.030075 GORASP1 9.126231 9.594865 PRKX 8.759110 9.236867 
ABCA1 6.256439 6.898599 GPATCH11 8.677886 9.019521 PROC 2.923686 3.781168 
ABCA2 5.485456 6.233520 GPCPD1 9.366557 9.795156 PRR12 9.939384 10.344527 
ABCA7 8.843768 9.745234 GPLD1 6.155997 6.699796 PRR7-AS1 3.918917 4.726744 
ABCA9 8.232258 8.524437 GPM6A 7.247556 8.098215 PRX 6.894216 7.515213 
ABCB1 4.882726 6.131992 GPNMB 6.776718 7.488496 PSD3 5.318696 5.860159 
ABCB8 7.834352 8.132824 GPR135 5.185373 5.709049 PTAR1 10.112285 10.533664 
ABCC2 4.326928 4.950671 GPR152 2.115878 2.799027 PTCH1 4.652244 5.115034 
ABCC5 7.255076 7.692944 GPR155 6.854244 8.664547 PTDSS1 9.652372 9.976897 
ABCD1 6.157117 6.825752 GPR160 4.813742 5.538552 PTGER2 5.835644 6.274452 
ABCG1 7.276963 7.797616 GPR18 6.929675 8.451116 PTP4A1 9.935972 10.213170 
ABHD14A 5.562153 6.317231 GPRASP1 8.496170 9.119963 PTPN12 9.784555 10.128484 
ABHD15 9.812938 10.717085 GPT2 9.012525 10.669549 PTPN18 10.467096 10.926565 
ABHD17A 8.949018 9.414940 GRAP 8.105331 8.664518 PTPN22 8.171906 9.163121 
ABHD3 8.030321 8.438978 GRB7 5.337344 5.798560 PTPN4 7.422296 7.854383 
ABHD4 9.108055 9.456928 GRIK3 6.276278 7.020193 PTPN7 10.734058 10.984009 
ABI3 3.944110 4.635091 GRK5 6.990143 7.891176 PTPRC 10.799966 11.547440 
ABLIM1 10.092356 10.970915 GRK6 8.394555 8.949055 PTPRCAP 10.754415 11.955962 
ABR 11.654113 11.929546 GSAP 8.478876 8.753476 PTPRE 8.452598 9.084693 
AC074289.1 7.192166 7.913105 GSDMB 7.693521 8.536267 PTPRVP 4.977871 5.796248 
ACACB 6.045251 7.325650 GSE1 9.607137 10.147011 PURA 9.591146 9.837469 
ACAD8 8.010394 8.384588 GSTM4 5.379444 5.874380 PUS7L 7.553271 7.892979 
ACAP1 8.388434 9.081230 GTPBP1 10.378433 10.736987 PVRIG 7.724398 8.357316 
ACAP2 9.894377 10.135100 GUCA1B 5.461303 5.976747 PXK 9.044449 9.579333 
ACAP3 6.378818 7.031814 GUCY2C 4.819611 5.622388 PYCARD 6.178746 7.013052 
ACBD4 7.825061 8.188332 GUSBP11 7.979067 8.429769 PYGM 4.887214 5.485969 
ACD 7.869561 8.208897 GYLTL1B 8.312880 8.952028 PYHIN1 5.735157 6.281363 
ACRBP 4.672360 5.281954 H1FX-AS1 5.547807 6.051611 PYROXD2 6.855000 7.244541 
ACRC 5.765498 6.451927 HAS3 5.136938 5.777864 QPCTL 8.027818 8.845425 
ACSF2 6.364827 7.046712 HAVCR2 5.146921 5.855253 QRICH2 6.282826 6.715580 
ACSM1 5.293030 6.035918 HBP1 8.671168 8.968944 QRSL1 7.941463 8.439541 
ACSM3 3.966996 4.796097 HCG23 4.662017 5.643581 QSOX1 8.630469 9.015820 
ACSS1 9.179775 9.826222 HCG27 5.670936 6.392131 QSOX2 10.231489 11.456212 
ACSS2 6.472960 6.960094 HCN2 4.315146 4.970507 RAB11FIP4 8.513825 9.553294 
ADAM10 9.673262 9.898947 HDAC10 8.378730 8.882557 RAB24 7.864374 8.244718 
ADAM28 10.109104 10.559521 HDAC5 8.438317 9.034893 RAB30 10.902198 11.346713 
ADAM29 5.261535 6.256614 HDAC7 11.360111 12.005918 RAB33B 8.530067 8.945635 
ADAMTS6 7.274429 8.023850 HEATR6 7.990930 8.416845 RAB37 7.340829 8.329629 
ADARB2 2.484420 2.884187 HECA 10.295887 10.738373 RAB40B 4.919110 5.620674 
ADCK2 8.175520 8.719729 HELZ2 9.760824 10.221220 RAB6A 10.160087 10.401060 
ADCK3 8.876563 9.246434 HERC3 7.739111 8.341326 RABAC1 7.793428 8.212685 
ADCK4 6.806512 7.169606 HEXA 7.989821 8.329329 RABEP2 8.502708 8.920099 
ADCY10P1 5.989137 6.540513 HHEX 8.923402 9.932439 RAD9A 8.246969 8.859558 
ADCY4 4.452749 5.098705 HIP1R 6.816270 8.244923 RAI1 9.881592 10.213644 
ADD3 9.386089 10.024704 HIRIP3 7.249788 7.695591 RALB 8.704546 9.049586 
ADHFE1 4.896612 5.609940 HIST1H1C 8.240793 8.618919 RALGDS 9.132162 9.679314 
ADM 7.180728 7.842494 HIST1H2AC 7.665345 8.112919 RALGPS2 11.243613 11.551449 
ADPGK 10.271180 10.636446 HIST1H2BD 6.959192 7.352832 RAMP1 3.260026 3.984930 
ADPRM 7.591603 7.998259 HIST1H2BK 8.563546 8.900916 RANBP10 9.506174 9.795030 
ADRB2 7.699567 8.467680 HIST1H2BN 2.758215 3.282642 RAP1GAP2 5.634464 6.959252 
ADRBK1 11.461303 11.914380 HIST2H2AC 5.053345 5.526842 RAPGEF2 8.645985 9.162584 
AES 12.048377 12.433644 HIST3H2A 4.002524 4.565631 RAPGEF3 8.255901 9.057488 
AFAP1L2 3.943945 4.790073 HLA-DMA 10.456342 11.018305 RARRES3 4.619669 5.160308 
AFF1 9.127347 9.439158 HMCES 8.052303 8.731648 RASA2 8.614141 8.952377 
AFF3 10.948211 11.306171 HMGB1 10.617118 10.899922 RASA3 7.950057 9.200090 
AFF4 10.359436 10.679825 HMGB2 8.410322 8.780171 RASAL1 5.864504 6.867719 
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AGAP7 2.445025 2.968782 HMOX1 9.801652 10.635216 RASGRP2 9.027097 10.183792 
AGFG2 7.743343 8.156418 HOMER2 7.909671 8.683635 RASSF1 9.325585 9.839632 
AGPAT5 10.696147 11.340269 HOXB2 6.410722 6.853893 RASSF1-AS1 3.438131 4.142104 
AHCYL1 9.786836 10.047527 HPCAL1 9.736406 10.590558 RASSF7 8.827168 9.237666 
AHCYL2 7.551935 7.914782 HPS3 7.690205 8.110360 RB1CC1 9.270930 9.561196 
AHDC1 9.106710 9.553466 HRK 5.150665 6.291363 RBL2 9.942703 10.200393 
AHI1 7.520659 8.127525 HS2ST1 8.778920 9.193386 RBM15 9.673159 9.954687 
AK1 7.592721 8.710655 HS3ST1 8.803833 9.170148 RBM33 10.548237 10.967140 
AKAP8L 9.327288 9.640337 HSD17B11 8.619757 9.156749 RBM38 11.771662 12.594194 
AKAP9 9.606988 9.898903 HSD17B13 2.996720 3.559572 RBM43 6.314499 6.873946 
AKNA 11.409311 11.745449 HSDL1 8.685066 9.163611 RBM5 10.185001 10.480373 
AKT1 9.858591 10.074194 HSH2D 10.957417 11.333713 RBM5-AS1 6.068502 6.504751 
AKT2 10.950797 11.200572 HSPA6 11.198634 11.560057 RBMS2 6.528711 7.250683 
ALAD 8.357744 9.211547 HSPA7 5.517267 6.364163 RCBTB2 6.605430 7.122831 
ALDH3A2 8.269665 8.846314 HSPBAP1 7.215851 7.552616 RCN3 5.832074 6.431481 
ALDH3B1 5.429586 6.004102 HSPG2 5.687725 6.437324 RCOR1 8.818772 9.269649 
ALDH5A1 10.144505 10.790915 HTATSF1P2 7.308144 8.220164 RCSD1 11.835860 12.728604 
ALDH9A1 8.565912 8.838463 HTRA3 4.779088 6.703531 RDH10 5.943171 6.632941 
ALKBH4 7.290960 7.854145 HTRA4 2.585942 3.196916 REEP5 9.380685 9.661982 
ALKBH5 10.659283 11.176200 ID3 12.043270 12.948612 REM2 6.013330 7.146756 
ALKBH6 7.734364 8.063508 IDS 11.814965 12.313892 RERE 10.305561 10.728946 
ALOX15P1 4.701698 5.487667 IER5L 6.706005 7.309385 REST 9.796425 10.047206 
ALOX5 10.477338 11.119090 IFFO1 8.862875 9.214676 REV3L 8.921205 9.527644 
ALOX5AP 7.747270 8.349553 IFI16 10.210428 10.548953 RFX1 7.607511 8.044191 
AMDHD2 8.004455 8.473937 IFIT2 6.761660 7.397793 RGCC 7.592945 9.109637 
AMFR 10.368222 10.908530 IFITM1 6.560899 7.138391 RGL2 8.690447 9.102764 
AMH 4.478103 5.178181 IFNAR2 9.410428 9.825531 RGL4 8.517806 8.826386 
AMN 5.776360 6.267648 IFT57 8.897559 9.336568 RGMB 6.970624 7.621245 
AMN1 6.943270 7.339767 IGBP1 7.913664 8.228168 RGS14 8.334398 8.871305 
AMT 6.541335 7.001831 IGF1R 6.043082 6.515709 RGS2 9.840677 11.173795 
AMZ2 9.670973 10.103572 IGIP 7.200791 7.701359 RGS3 5.776434 6.346626 
ANK1 5.107590 6.327090 IGSF8 8.051942 8.643015 RHBDD1 9.557100 9.870598 
ANKMY1 7.048322 7.602932 IKZF3 12.397704 12.674418 RHBDL1 4.879181 5.911237 
ANKRA2 7.965718 8.466941 IKZF5 8.999149 9.318984 RHOB 9.375745 9.788793 
ANKRD13A 10.529777 10.856107 IL10RB 8.934115 9.282664 RHOH 11.076360 11.778292 
ANKRD13D 8.021832 8.344469 IL11RA 7.228070 7.777637 RHPN1 9.491038 10.398168 
ANKRD16 6.621212 7.151929 IL16 10.824063 11.538315 RHPN2 4.841388 5.465901 
ANKRD34A 4.551209 5.280431 IL17RA 9.399500 9.768585 RILPL1 5.147351 6.136909 
ANKRD42 7.289971 7.860576 IL1R1 4.735437 5.392156 RIN2 5.524847 6.140270 
ANKRD44 10.256249 10.755752 IL1RAP 6.224708 6.858959 RIN3 10.440367 10.865066 
ANKZF1 9.451734 10.099253 IL24 6.496065 7.673981 RITA1 8.119818 8.596125 
ANO8 6.114635 7.139521 IL2RB 9.294908 9.683061 RMRP 5.165192 5.665629 
ANPEP 6.082408 6.575388 ILF3-AS1 8.109414 8.509020 RN7SK 8.043687 8.605502 
ANTXR2 7.994781 9.246622 IMPA2 5.896393 6.371219 RNASE1 6.788214 7.554883 
ANTXRLP1 3.020921 4.140298 INF2 8.616586 9.338698 RNASE4 4.736444 5.345926 
ANXA2R 5.704643 6.692838 ING1 9.542173 9.961553 RNASE6 6.591018 8.014642 
AP001258.4 5.740823 6.382658 ING2 7.025842 7.469613 RNASEL 8.253550 8.786235 
AP1B1 10.175314 10.649775 ING4 8.036174 8.373566 RNASET2 8.936069 10.716693 
AP3S1 7.310418 7.754809 INPP5A 7.736778 8.426302 RNF113A 9.113534 9.604264 
APAF1 8.828296 9.263119 INPP5D 10.599369 10.901420 RNF125 6.624881 7.108357 
APBB2 8.363016 10.153228 INSIG2 8.064825 8.517080 RNF13 8.727299 8.994124 
APCDD1 2.998136 3.968540 IP6K2 9.643425 10.055092 RNF130 8.121179 8.711474 
APLN 2.452398 2.968170 IPW 5.586360 6.462062 RNF135 7.943318 8.257098 
APOE 4.774806 5.387606 IQCD 2.757942 3.388080 RNF149 9.266066 9.792161 
APOLD1 5.390534 5.966057 IQCE 8.102048 8.434424 RNF166 8.460120 9.300145 
AQP3 4.515602 5.501889 IQGAP2 5.558504 6.564573 RNF19A 9.488776 9.910715 
ARAP1 9.647126 10.129645 IQSEC2 4.724852 5.310697 RNF213 10.954108 11.250063 
ARHGAP12 8.136183 8.511152 IRAK4 9.429520 9.750539 RNF24 6.923183 7.830520 
ARHGAP18 6.322242 6.734140 IRF2BPL 10.627850 11.440333 RNF38 9.844227 10.160676 
ARHGAP27 10.048922 10.559210 IRF3 10.287918 10.810910 RNF39 4.848799 5.534243 
ARHGAP4 9.875725 10.294411 IRF8 11.726170 12.196400 RNF41 10.443513 11.350604 
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ARHGAP6 4.712496 5.723432 IRS1 8.455834 9.162577 RNF44 10.508411 10.961987 
ARHGAP9 9.086764 10.166427 IRS2 9.495150 10.195661 RNFT2 5.042492 5.565963 
ARHGEF1 9.820955 10.316981 ISCA1 8.299877 8.657130 RNR1 13.149383 13.551023 
ARHGEF10L 7.676954 8.172796 ISYNA1 7.025898 7.674093 RNR2 15.951059 16.408030 
ARHGEF3 8.986087 9.669455 ITGAL 8.014857 9.325902 ROR1 9.701462 10.223515 
ARHGEF6 8.683484 9.063994 ITGB1 9.266772 9.904997 RP11-
142C4.6 
3.269322 4.582335 
ARID4A 8.823706 9.180782 ITGB7 8.336727 9.226981 RP11-
197N18.7 
2.321653 2.871465 
ARID5B 10.257514 11.022225 ITIH4 6.807900 7.397711 RP11-
430B1.2 
4.314264 5.169819 
ARL15 7.032487 7.542531 ITK 5.299641 5.846308 RP11-
452H21.4 
3.905608 4.961280 
ARL3 6.537084 6.988326 ITM2B 10.291375 10.677996 RP11-
563J2.2 
2.853107 3.455770 
ARL4C 9.999293 10.479715 ITPR2 9.534660 9.942694 RP11-
685M7.3 
4.419534 4.950604 
ARL6IP6 8.789372 9.074846 ITPRIP 9.218866 9.526143 RP5-
1021I20.1 
4.177226 4.916115 
ARMCX3 9.843858 10.133312 ITPRIPL1 6.926112 7.415771 RPPH1 6.109375 6.641505 
ARRB2 8.509338 9.091170 JDP2 8.448662 8.958076 RPRD2 9.507221 10.221384 
ARRDC2 11.345343 11.899657 JHDM1D-
AS1 
7.140427 7.911219 RPS11 9.567449 9.798914 
ARRDC3 9.301082 10.035318 JMJD1C 10.641363 11.171572 RPS27 8.247769 8.749132 
ARSK 5.553493 6.234027 JMJD7 6.005464 6.732103 RRAD 6.604655 7.063558 
AS3MT 3.670703 4.201309 JPH3 3.886623 4.541485 RRM2B 10.038173 10.499535 
ASAH1 8.730791 9.211946 JUND 12.794435 13.347067 RSBN1L 8.545347 8.825445 
ASF1A 8.965203 9.516688 KANK1 7.140753 7.773340 RTN3 9.205397 9.574898 
ASIC3 5.466519 6.343984 KANK2 5.366386 6.578058 RUNDC1 9.079524 9.652979 
ASTE1 7.125498 7.565499 KANSL2 8.315496 8.593461 RUNX1 9.310675 9.620814 
ATG12 9.246471 9.500526 KAT2A 8.803109 9.226645 S100A8 6.530682 6.956673 
ATG16L2 7.691230 8.251515 KAT2B 8.389604 8.769542 S1PR1 8.130991 9.453501 
ATG2B 9.232239 9.514951 KAT6B 9.070928 9.738844 S1PR4 9.284737 9.987333 
ATG9A 9.251425 9.574716 KBTBD6 7.762504 8.120103 SAFB2 9.358158 9.838844 
ATHL1 11.444196 12.159769 KBTBD7 7.330424 7.708051 SAP25 7.922977 8.568321 
ATL1 4.837723 5.409893 KCNA3 9.861488 11.136006 SAR1B 8.573465 8.899841 
ATM 10.352203 10.949158 KCNAB1 4.476278 4.958251 SAT1 9.963238 10.667609 
ATP13A1 8.992689 9.312971 KCND1 6.135476 6.805181 SAT2 8.738391 9.146222 
ATP2A1 4.698385 5.209540 KCNH2 5.604407 6.895948 SATB1 7.316871 7.972088 
ATP2A3 11.236258 12.463152 KCNJ11 8.498063 9.357947 SBDSP1 8.213995 8.524619 
ATP2B4 9.751450 10.854757 KCNQ1 3.700447 4.845017 SBF1 10.092046 10.475467 
ATP6V0C 10.973211 11.308956 KCTD12 6.943319 7.421399 SBK1 6.407822 7.129983 
ATP6V0E2 7.391622 8.031688 KCTD7 8.868869 9.475538 SBNO1 9.969515 10.222814 
ATP6V1G2 3.949697 4.699441 KDM1A 8.507948 8.790771 SCAI 7.820607 8.248796 
ATP7A 7.248878 7.616963 KDM3A 8.483040 8.975571 SCAMP1 7.577791 8.303452 
ATRN 8.290592 8.625859 KDM7A 9.673821 10.485249 SCARB2 8.276720 8.820977 
ATXN1L 10.360744 10.596677 KIAA0040 10.818142 11.614126 SCARF2 4.061969 4.900934 
AUP1 9.315461 9.551820 KIAA0226 11.028149 11.617364 SCART1 5.504117 6.205561 
AVIL 5.531140 6.082160 KIAA0226L 11.676238 11.908172 SCIMP 7.738148 9.488922 
AVP 1.588880 2.216552 KIAA0355 9.235952 9.507379 SCN4A 4.050504 5.147213 
AVPI1 5.135086 6.091066 KIAA0430 11.396654 11.680009 SCXB 6.526931 7.801395 
AVPR2 3.995314 4.557381 KIAA0513 6.555805 7.177738 SDCCAG3 9.320394 9.632748 
AXIN1 9.975606 10.397190 KIAA0586 6.761769 7.220159 SDK2 6.696515 7.647547 
B3GNT1 6.817269 7.468649 KIAA0930 8.801875 9.259849 SDR39U1 8.149195 8.542468 
B4GALT1 10.967041 11.625391 KIAA1328 6.404417 6.828266 SEC11A 9.037741 9.422083 
B4GALT3 8.958051 9.352824 KIAA1377 5.535246 6.440427 SEC31B 7.822762 8.208001 
BACE2 8.518601 8.851603 KIAA1407 9.165321 9.891931 SEC62 10.822670 11.110443 
BAG1 9.169674 9.536637 KIAA1432 9.239228 9.597828 SECISBP2L 10.444074 10.703673 
BAIAP3 6.850395 8.783832 KIAA1551 11.970275 12.430520 SEL1L3 9.724406 10.490161 
BANP 8.011047 8.710515 KIAA1683 6.838206 8.010652 SELO 8.929264 9.571980 
BBS2 7.565368 7.940960 KIAA1731 8.013333 8.376328 SELPLG 8.709877 9.440677 
BBX 10.242521 10.482108 KIAA2018 8.937392 9.251863 SEMA4B 9.061353 10.323491 
BCAS4 8.725506 9.125478 KIF20B 7.260239 7.695693 SEMA4D 9.652432 10.247564 
BCL11A 10.012169 10.705268 KIF22 7.538899 8.024629 SEMA6B 7.974200 8.301527 
BCR 7.659998 8.368065 KIF3C 6.451392 7.083228 SENP7 7.731986 8.224299 
BCRP3 1.921886 2.400524 KIFC2 8.926664 9.452492 SEPHS2 10.345781 10.707790 
BEST4 5.747724 6.281174 KISS1R 5.388100 6.024426 SEPN1 9.235163 9.631146 
BET1L 10.144261 10.417977 KLC4 6.766554 7.382174 SEPT6 10.990917 11.590322 
BFSP2 2.088639 2.555296 KLF10 9.770456 10.497591 SEPT9 12.976477 13.584720 
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BICD2 10.099176 10.756823 KLF16 9.819618 10.050890 SEPW1 8.055486 8.562667 
BIN1 7.767954 8.217637 KLF2 9.089364 10.370057 SERINC1 10.841249 11.132702 
BLCAP 9.877528 10.149382 KLF3 6.905642 7.461007 SERINC3 9.188736 9.493336 
BLNK 8.011656 8.478442 KLF9 9.272505 9.735240 SERINC4 7.473286 8.363514 
BMP6 4.076647 5.118873 KLHDC3 8.730100 9.019466 SERINC5 8.963282 9.444904 
BMPR2 10.317434 10.995691 KLHL14 7.949151 8.952131 SERPINF1 7.323334 7.887106 
BNIP3L 9.792192 10.093615 KLHL15 8.378203 8.742605 SESN1 7.739341 8.370537 
BOD1L1 10.927060 11.147994 KLHL2 8.229519 8.864046 SESN3 11.548346 12.590470 
BPTF 10.326464 10.617905 KLHL24 9.755932 10.409325 SESTD1 7.892097 8.694297 
BREA2 4.482367 5.055226 KLHL3 4.867085 5.517437 SETBP1 9.225334 9.642663 
BRICD5 5.889593 6.577696 KLHL32 3.890924 4.769450 SETD7 7.825092 8.446356 
BROX 9.346735 9.581885 KLHL8 8.013917 8.313764 SETDB2 8.497578 8.944987 
BRWD1 9.633751 10.058149 KMT2E 10.820742 11.085417 SFI1 7.708316 8.039504 
BSCL2 4.436340 5.310890 KMT2E-AS1 7.978778 8.357688 SFMBT1 10.092218 10.613237 
BTBD2 9.980792 10.283150 KSR2 7.199616 8.006079 SFTPB 5.567586 7.516210 
BTBD6 8.980059 9.431602 L3HYPDH 7.767666 8.228133 SFXN3 8.277845 9.333770 
BTG2 12.948087 13.709580 LAG3 6.588067 7.173393 SGK223 10.271691 10.647524 
BTN1A1 3.078725 3.699601 LAIR1 6.462664 7.172418 SGPP1 11.451474 11.884652 
BTN3A1 9.624240 10.045156 LAMA5 6.959960 8.089597 SGSH 8.213197 8.741278 
BTN3A2 9.796434 10.051441 LAPTM4A 9.432439 9.871077 SGSM2 9.966520 10.519142 
BTNL2 2.649853 3.618768 LAPTM5 13.377488 13.910181 SH3BGRL2 7.139015 7.752409 
BZRAP1 6.497954 7.425404 LATS2 7.726183 8.117174 SH3BP5 8.427641 8.926284 
C11orf21 7.211460 7.788500 LAX1 9.109487 10.266651 SH3BP5-AS1 7.593665 8.082182 
C11orf24 8.075065 8.539547 LBR 9.038036 9.326807 SH3TC1 9.932518 10.442274 
C11orf30 8.117839 8.440865 LCK 7.249719 8.138273 SHISA5 10.090849 10.760795 
C11orf35 6.819308 7.830480 LCN10 6.614869 7.279522 SIDT1 8.235446 9.134933 
C11orf80 6.389284 6.758084 LCN8 4.551383 5.740031 SIDT2 8.610723 9.285658 
C12orf23 9.375258 9.649277 LCORL 6.460622 6.853348 SIGIRR 7.983964 8.402222 
C12orf42 4.453859 5.056993 LCP2 6.269479 6.858250 SIGLEC10 7.529566 8.767223 
C14orf182 4.043320 4.636365 LDB1 10.648618 11.185988 SIK3 9.850357 10.315585 
C16orf54 7.848766 8.890279 LDLRAD4 8.751854 9.793863 SIMC1 7.900926 8.260477 
C16orf74 7.472204 8.731724 LDLRAP1 8.173324 9.034210 SIPA1L1 10.272902 10.696232 
C16orf86 6.869750 7.398254 LEPRE1 8.422284 8.773977 SIPA1L3 10.363168 11.172901 
C17orf103 8.146644 8.871803 LEPREL4 5.219057 5.828273 SIRT1 9.606016 9.859534 
C17orf59 9.400952 9.811043 LEPROTL1 8.548540 8.940429 SIRT2 8.086991 8.467848 
C17orf72 5.017916 5.535219 LGALS8 7.589219 8.084781 SIRT5 7.290979 7.658043 
C19orf35 4.940447 5.452136 LGMN 5.988662 6.767947 SIT1 8.415964 9.043230 
C19orf38 4.781081 5.708354 LGR4 4.291582 5.135501 SKIL 10.550244 10.867713 
C1QTNF6 6.974032 7.975910 LHB 3.123872 3.642334 SKOR1 3.669010 4.616919 
C1orf162 7.348386 8.192275 LHFPL2 9.739010 10.163908 SLA 9.663789 10.631162 
C1orf228 5.415359 6.065200 LHPP 7.518831 8.714397 SLA2 5.571644 6.189420 
C1orf56 7.061631 7.508517 LIG1 7.164222 8.150585 SLAMF6 10.055669 10.545962 
C20orf195 6.502128 6.977422 LIMD1 9.495730 9.974733 SLBP 8.512722 8.875367 
C2CD2L 6.868470 7.333760 LIME1 6.697297 7.717232 SLC12A6 10.647875 11.121173 
C2orf81 7.100308 7.506412 LIMK2 8.798395 9.405065 SLC13A5 3.674848 4.842823 
C3AR1 5.840674 6.352879 LIMS1 9.865646 10.253800 SLC14A1 4.157956 5.811666 
C3orf58 8.072489 8.581097 LIN7B 5.615402 6.187989 SLC16A4 4.909738 5.570232 
C3orf62 6.996719 7.452280 LINC-PINT 8.158372 8.830674 SLC16A7 7.882846 8.732587 
C5 3.699492 4.446087 LINC00202-1 3.324573 4.025811 SLC17A5 6.814294 7.210060 
C5orf45 6.647343 7.423865 LINC00304 3.829501 4.729280 SLC17A9 7.483152 8.053159 
C5orf56 5.262823 5.800600 LINC00339 6.924797 7.717363 SLC18B1 6.451783 7.623174 
C6orf48 10.436577 11.133273 LINC00426 4.796303 5.763221 SLC22A17 3.736625 4.518560 
C9orf72 7.844689 8.356547 LINC00525 3.823289 4.737353 SLC22A18 3.890213 4.546393 
C9orf89 6.858108 7.497833 LINC00565 2.341869 3.117499 SLC23A1 5.287884 6.235518 
CA11 7.103690 7.953880 LINC00674 9.976394 10.406303 SLC25A28 9.367031 9.878048 
CA14 4.489231 5.342208 LINC00847 8.814578 9.553966 SLC25A29 10.053197 10.479911 
CABIN1 9.375611 9.678846 LINC00886 4.672159 5.607497 SLC25A30 8.055032 8.395470 
CABLES1 10.744323 11.240470 LINC00888 6.590012 6.959993 SLC25A36 9.813671 10.096948 
CABP4 3.685375 4.980961 LINC00921 6.465957 7.031824 SLC25A42 7.387258 8.509341 
CACNA2D2 5.458325 6.232223 LINC00926 11.736551 12.138081 SLC25A53 6.050293 6.791997 
CACNB2 5.407468 6.036902 LINC01004 6.654596 7.592882 SLC26A11 7.489250 8.089992 
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CALCOCO1 9.545607 10.131400 LINC01011 4.071474 4.957334 SLC26A6 6.593648 7.123861 
CALHM2 8.860245 9.321787 LINC01023 5.086736 5.622674 SLC27A1 7.118829 7.553313 
CALM1 11.647266 12.017028 LINC01089 8.633949 8.977588 SLC27A3 7.470585 7.932882 
CAMKK1 6.498301 8.087640 LINGO3 6.393066 8.515320 SLC2A11 7.206182 8.004108 
CAPN3 8.106952 8.533877 LMNB1 7.069209 7.777846 SLC2A3 7.896609 8.572017 
CAPN7 8.892653 9.218785 LMO4 8.707082 9.300859 SLC2A4RG 7.575036 8.368327 
CAPRIN2 8.198220 8.655374 LMO7 7.939159 8.500931 SLC30A1 7.790274 8.218337 
CAPS 7.849466 8.281951 LMTK2 8.483564 8.990212 SLC35A1 7.818015 8.186576 
CARD11 9.916779 10.348547 LOC1001284
94 
5.184460 5.800793 SLC35D1 8.101107 8.404925 
CARD14 6.152607 7.143547 LOC1001286
53 
6.479857 6.984796 SLC35E2B 10.026203 10.404924 
CARD8 9.926632 10.315717 LOC1001292
03 
5.569287 6.364707 SLC37A2 7.513993 8.100582 
CARF 7.285783 7.696965 LOC1001295
50 
6.887545 7.906764 SLC39A10 7.957452 8.500259 
CARHSP1 8.565632 9.283102 LOC1001296
37 
8.849328 9.312752 SLC39A3 9.065786 9.348713 
CARNS1 7.747301 8.400880 LOC1001309
87 
4.934597 5.498275 SLC39A8 7.112510 7.496610 
CARS2 7.555786 8.100717 LOC1002407
35 
4.553488 5.105124 SLC44A2 9.732831 10.380943 
CASP10 5.741245 6.405615 LOC1002870
72 
2.175200 2.982703 SLC46A1 5.314071 6.003086 
CASP8 9.351259 9.831208 LOC1002871
75 
3.928075 4.630470 SLC48A1 8.905297 9.441941 
CASP9 7.844387 8.305281 LOC1002886
37 
5.212647 5.796024 SLC6A16 7.823547 8.145527 
CBFA2T2 9.297450 9.715371 LOC1005055
64 
6.397300 7.383986 SLC7A7 8.844911 9.293844 
CBFB 10.312700 10.550459 LOC1005055
85 
3.464460 4.233627 SLC7A8 5.320661 5.866936 
CBLB 8.651811 9.160367 LOC1005057
71 
8.130389 9.493771 SLC8A1 3.885695 4.404265 
CBX3P2 5.128894 5.669815 LOC1005061
27 
3.996271 4.503506 SLC8B1 7.634956 8.014071 
CBX4 9.918741 10.737451 LOC1005065
48 
8.933317 9.227142 SLC9A1 8.849334 9.446378 
CBX8 4.830437 5.863510 LOC1005066
34 
7.328824 7.751721 SLC9A3R1 9.096664 9.357511 
CCBL1 5.446968 6.056830 LOC1005069
22 
6.553869 7.017022 SLFN11 7.795332 8.404536 
CCDC109B 6.936096 7.688928 LOC1005072
17 
9.694506 10.052320 SMAD3 7.345431 7.845603 
CCDC114 4.661389 5.399291 LOC1005075
30 
3.494890 4.726740 SMARCD3 5.681771 6.354845 
CCDC126 6.314832 6.775560 LOC1005076
16 
8.611708 9.151815 SMC4 7.992769 8.333281 
CCDC134 4.801231 5.474765 LOC1005077
47 
2.671181 3.418856 SMCHD1 10.237605 10.939665 
CCDC163P 5.551014 6.083174 LOC1006527
68 
6.509437 7.565468 SMPD1 7.872393 8.290513 
CCDC42B 3.398519 4.418573 LOC1009962
73 
6.375557 7.231112 SNAI3 5.262436 6.572043 
CCDC64 10.165428 10.642306 LOC1009965
06 
6.433918 6.923757 SNED1 8.178133 8.935983 
CCDC68 5.239630 6.254075 LOC1009967
56 
3.839186 4.493553 SNPH 6.743273 7.380021 
CCDC88C 10.128250 10.362788 LOC1014092
56 
2.936901 3.597665 SNTB2 7.533622 8.592835 
CCL5 8.852615 9.215583 LOC1019271
21 
1.679845 2.254230 SNX2 8.051428 8.400359 
CCM2 8.980456 9.395871 LOC1019272
45 
3.488531 4.409296 SNX25 7.640059 7.980199 
CCND3 10.087483 10.425960 LOC1019273
82 
6.026821 6.430672 SNX27 8.974628 9.258913 
CCNDBP1 8.894049 9.255255 LOC1019274
02 
7.246861 7.721586 SNX30 8.253005 9.370797 
CCNL1 10.903555 11.155307 LOC1019277
59 
3.338261 4.393703 SOBP 5.307162 5.933279 
CCNL2 11.769129 12.173898 LOC1019277
75 
4.210670 5.046960 SORBS3 7.857946 8.485777 
CCP110 7.998261 8.423346 LOC1019279
02 
6.648306 8.008487 SOS1 9.341176 9.622321 
CCPG1 6.617615 7.090001 LOC1019280
92 
3.759232 4.449543 SOS2 9.228843 9.545079 
CCR6 5.680125 7.932199 LOC1019284
65 
6.730628 7.905249 SOWAHC 7.211835 7.549064 
CD14 7.622521 8.344490 LOC1019285
72 
2.703403 3.420304 SOWAHD 8.472437 9.278972 
CD163 7.410952 8.183209 LOC1019287
19 
6.578304 7.266313 SOX12 9.350224 10.208641 
CD1D 4.696880 6.076630 LOC1019289
23 
2.443281 3.003616 SP100 10.253388 10.476736 
CD24 8.805358 10.120671 LOC1019289
81 
3.070620 3.837968 SP110 7.254929 8.119601 
CD244 5.263982 6.087438 LOC1019290
05 
4.633524 5.720038 SP140 8.216088 8.781481 
CD248 2.044783 2.797795 LOC1019290
72 
5.374444 5.993478 SP4 9.641103 9.979752 
CD27 7.727936 9.651220 LOC1019296
34 
2.411557 3.309496 SPAG4 6.367972 7.158355 
CD27-AS1 5.619597 6.393238 LOC1019296
98 
3.115029 4.356992 SPATA13 8.006288 8.416709 
CD300A 5.562232 6.103284 LOC1024671
47 
1.745146 2.171493 SPATA2L 8.255877 8.833536 
CD300E 6.231633 6.710014 LOC1027233
98 
3.912671 4.522760 SPIN4 7.781651 8.586318 
CD320 7.549064 8.043831 LOC1027235
21 
10.234895 10.550649 SPPL2B 8.563640 8.973433 
CD36 5.295502 5.888762 LOC1027235
40 
4.117698 4.805532 SPSB3 10.057121 10.405510 
CD3E 5.620751 6.100139 LOC1027237
55 
5.182775 5.789020 SPTAN1 9.343236 9.665072 
CD47 10.875664 11.193560 LOC1027238
01 
4.785755 5.518208 SPTBN1 10.309498 10.904814 
CD48 10.014178 10.490740 LOC1027238
37 
3.026343 3.576099 SPTBN5 6.432046 7.373992 
CD5 9.895290 11.082186 LOC1027238
78 
3.063160 3.623777 SRGAP3 4.958419 5.874607 
CD52 9.589450 10.505004 LOC1027240
59 
3.490203 4.267983 SRMS 6.771200 7.326973 
CD53 10.865756 11.127069 LOC1027242
33 
4.665818 5.329898 SRP14-AS1 6.617434 7.105288 
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CD6 9.138656 10.453531 LOC1027242
48 
5.557133 6.383908 SRPK2 8.713984 8.984036 
CD7 4.751448 5.433895 LOC1027242
50 
3.000819 3.549051 SRRM2 13.765376 14.092242 
CD79A 11.898030 12.324810 LOC1027243
23 
6.591723 7.176717 SRSF8 10.015421 10.300127 
CD79B 10.293798 11.541910 LOC1027243
25 
2.487621 3.089650 SS18L1 8.105452 8.456299 
CD8A 7.280422 7.830405 LOC1027244
66 
6.205074 7.095411 SSBP2 4.094892 4.831876 
CD96 5.162466 5.670434 LOC1027245
43 
8.225311 9.678249 SSH2 10.567843 11.288230 
CDC25B 8.743952 9.905667 LOC1027246
18 
3.711550 4.318736 SSR1 10.377257 10.579904 
CDC40 8.571545 8.911820 LOC113230 4.974542 5.558770 SSTR3 5.875134 7.039146 
CDC42BPG 5.426698 6.070811 LOC146880 8.425923 8.928384 ST6GAL1 12.569707 12.891632 
CDCA7L 7.743647 8.531603 LOC202181 6.710886 7.278177 ST6GALNAC
4 
9.822347 10.533524 
CDHR1 3.718610 4.560075 LOC220729 6.140974 6.841530 ST6GALNAC
6 
11.384609 11.839570 
CDIP1 9.575410 9.947260 LOC284023 6.839952 7.215027 STAB1 6.035959 6.478919 
CDIPT 9.768760 10.142412 LOC390937 4.345044 5.289497 STAMBPL1 8.399246 8.793938 
CDK11A 7.720670 8.083503 LOC400685 2.790152 3.284459 STAP1 7.593264 7.973286 
CDK19 9.069831 9.448115 LOC440461 4.758730 6.336821 STARD5 7.568176 8.109065 
CDKL1 7.252225 7.698201 LOC441204 3.159428 3.947673 STARD9 7.824442 8.391399 
CDKN1B 10.928588 11.462065 LOC645638 6.660390 7.991341 STAT2 10.336414 10.921601 
CDKN1C 5.945054 6.393034 LOC648987 7.097404 7.519748 STIM1 9.581612 10.019388 
CDKN2AIP 9.728091 10.105811 LOC652276 6.876208 7.393582 STIM2 9.446419 9.851619 
CDKN2D 7.379842 8.407598 LOC728392 7.623809 8.916263 STK24 9.654438 10.085111 
CDS2 9.912146 10.167939 LOC728743 8.892246 9.782442 STMN1 8.235535 8.589955 
CEACAM21 6.618246 7.430917 LOC728752 5.658964 6.283539 STMN3 7.656546 9.194236 
CEBPD 4.882320 5.665798 LOC93622 7.595694 7.927770 STOX1 4.281798 4.901982 
CEBPE 2.228886 2.811497 LPAR5 9.363437 9.707253 STRN 9.224838 9.554081 
CECR1 7.951117 9.605400 LPCAT4 7.250888 8.145532 STX10 8.135257 8.489784 
CELF6 6.561885 7.308043 LPIN2 9.600280 10.025828 STX16 10.377212 10.646278 
CEMP1 7.042352 7.572072 LPP 9.039088 9.714461 STX7 10.373253 10.725319 
CENPM 4.520792 5.063276 LRCH4 9.619687 10.069984 SUFU 7.163531 7.588962 
CENPT 8.617404 9.052086 LRFN1 6.211094 7.149607 SUMF2 8.433772 8.739778 
CEP85L 8.150218 8.955542 LRIG1 8.632913 9.229752 SUN2 10.794412 11.226315 
CEP95 7.829186 8.229762 LRMP 8.748860 9.190499 SUSD3 5.898272 7.437791 
CEP97 7.372359 7.780572 LRP1 6.399326 7.075435 SUV420H2 6.932752 7.522321 
CERK 9.795266 10.774838 LRP10 11.830262 12.052420 SVILP1 4.026000 5.137475 
CERS2 10.080509 10.341164 LRRC25 7.103794 7.984280 SYCE1L 5.348601 5.983671 
CES3 2.923329 3.517070 LRRC34 4.964471 5.573814 SYCP3 4.154866 4.878362 
CHAD 4.399739 5.222210 LRRC37A3 4.236966 4.817541 SYK 12.024369 12.463342 
CHD9 9.253044 9.603312 LRRC37A4P 7.291323 7.868732 SYNE2 10.613964 11.212752 
CHIT1 3.641550 4.539599 LRRC37B 6.088435 6.518142 SYNGAP1 8.673794 9.034056 
CHMP1B 10.907701 11.207218 LRRC45 6.636263 7.124655 SYNRG 10.142777 10.438959 
CHPT1 7.818354 8.907990 LRRC56 6.121375 7.293685 SYPL1 9.346570 9.744487 
CHST11 10.238116 10.985108 LRRC58 9.433841 9.689760 SYTL1 8.930233 10.217913 
CHST12 7.882563 8.276353 LRRC6 2.793388 3.504919 SYTL3 4.415617 5.015246 
CHST15 9.697758 10.774881 LRRC8A 8.337331 8.675525 SYVN1 9.645725 10.023337 
CIB1 7.908354 8.610106 LRRC8C 7.032033 7.420391 TACC3 7.309471 8.801061 
CIPC 9.424793 9.945081 LRRK2 7.941073 8.567653 TAF1 8.839251 9.154716 
CITED2 8.597511 9.037107 LRRN2 5.831552 6.635127 TAF1L 9.714126 10.067300 
CKAP2 7.551719 8.041626 LRWD1 7.449766 8.224466 TAF5 6.352175 6.855815 
CKAP4 10.696489 11.077660 LSM4 9.087894 9.389547 TAGLN 7.248603 8.393940 
CLASRP 9.039680 9.413856 LTBP3 8.300550 9.120787 TAOK2 9.981022 10.251660 
CLDN15 8.343006 8.745523 LUC7L 9.550481 9.921450 TAPSAR1 7.351725 7.823782 
CLDN23 6.224232 7.202645 LUC7L3 10.758309 11.082746 TAPT1 7.979985 8.473822 
CLDND2 4.561052 5.069234 LY9 9.374260 10.563596 TARSL2 6.657129 7.120445 
CLEC2B 5.137201 5.692642 LYL1 8.442916 9.024322 TAS1R3 3.784685 4.349204 
CLEC4C 3.531764 4.350432 LYPD3 4.996770 5.559790 TAZ 8.835198 9.162874 
CLK1 10.097726 10.655823 LZTS2 9.546963 10.086621 TBC1D1 9.828270 10.172878 
CLMN 8.427053 10.040462 MAD1L1 7.687900 8.617529 TBC1D10C 9.319610 10.168267 
CLSTN1 10.390421 10.712002 MADD 9.239668 9.697150 TBC1D2 6.336769 6.829140 
CLSTN3 8.561800 9.209258 MAF 5.624019 6.316036 TBC1D20 9.602517 9.945509 
CMIP 9.361247 9.910637 MAFB 8.545007 9.178205 TBC1D22A 9.370203 9.680473 
CMKLR1 6.145227 6.615621 MAFK 10.132249 10.622015 TBC1D27 8.428611 9.966118 
CMTM1 5.318873 5.927105 MAGEE1 6.790568 7.232653 TBC1D9 9.675472 11.080486 
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CNNM3 9.835701 10.190451 MAML3 3.034209 3.707938 TBKBP1 7.631753 8.113300 
CNNM4 8.028763 8.464320 MAN1A1 9.762530 10.318670 TBL1X 9.285456 9.711830 
CNOT6L 9.639092 10.002059 MAN1B1 8.784305 9.258356 TBX19 6.409449 6.860982 
CNOT8 9.640700 9.913192 MAN1C1 3.628016 4.364870 TBX21 8.134936 8.542361 
CNR2 10.169803 10.616198 MAN2A1 9.854490 10.270385 TBXA2R 4.320663 5.033753 
CNTD2 3.597377 4.408369 MAN2A2 9.704721 10.377377 TCAP 5.090281 5.759582 
CNTRL 9.016369 9.293026 MAP1LC3B 9.923358 10.172486 TCEA2 6.889174 7.552375 
COG4 7.611337 7.972585 MAP2K3 8.981426 9.275695 TCEAL1 7.828529 8.547109 
COL18A1 4.714264 6.185639 MAP2K6 2.752027 3.575704 TCF25 8.933071 9.362641 
COL4A3 6.734507 7.944816 MAP3K1 10.979571 11.942678 TCF3 11.007463 11.277524 
COL4A4 6.657558 7.693414 MAP3K12 6.217259 6.757018 TCF4 12.724598 12.972933 
COL6A4P2 2.901860 3.681030 MAP3K14-
AS1 
6.276886 6.751689 TCL1A 11.304128 11.586886 
COL9A3 9.743529 11.133198 MAP3K2 10.401757 10.788376 TCL1B 3.192431 3.831049 
COLCA1 4.683561 5.311332 MAP3K3 9.253931 9.589936 TCL6 4.058425 4.833158 
COLGALT1 9.979780 10.379175 MAP3K7CL 6.543587 7.075592 TCP11L2 8.031323 8.814209 
COQ10A 7.715125 8.099016 MAP3K9 8.900146 9.625101 TDRD6 5.797336 6.277943 
CORO1B 9.165370 9.729567 MAP4K1 7.234958 7.680668 TECR 5.724376 6.396180 
COTL1 11.994459 12.326597 MAP4K2 7.823454 8.309981 TERF2IP 10.944661 11.289378 
CPEB2 7.599910 8.168982 MAPK1 11.314028 11.551544 TEX264 8.483978 8.784776 
CPLX1 2.056607 2.623418 MAPK8IP3 11.288326 12.066466 TFAP4 6.880585 7.364877 
CPNE1 9.530608 9.839229 MAPKAPK5-
AS1 
7.994919 8.345862 TGFBI 7.700485 8.989465 
CRAMP1L 10.131504 10.537242 MAPRE2 9.403390 10.090307 THAP11 10.132285 10.666443 
CRAT 6.903379 7.258645 Mar-01 8.373827 9.855849 THAP9-AS1 9.021103 9.354337 
CREB3L2 11.009259 11.558102 MAST3 8.365227 9.323571 THBS1 10.841095 11.343066 
CREBRF 10.135709 10.428355 MAST4 7.233216 7.975496 THBS4 3.545118 4.476264 
CREBZF 10.957731 11.297122 MAX 10.128969 10.375736 THEM6 7.113098 7.575312 
CREM 8.448056 9.443216 MAZ 11.102672 11.319787 THEMIS2 10.628006 11.120084 
CRKL 11.174666 11.377139 MBD4 9.442027 10.101687 THRA 6.722015 7.757711 
CRLF3 9.512989 9.986451 MBLAC2 7.221683 7.608518 TIA1 10.390164 10.700016 
CRTAP 8.976252 9.580253 MBNL3 10.000443 10.505757 TIAL1 9.726499 9.992786 
CRTC1 8.627252 9.084244 MBOAT1 7.187643 7.680679 TIGD3 5.400945 5.953023 
CRYM 3.985289 5.631930 MBOAT7 8.988812 9.304397 TIMP2 9.522702 10.103726 
CRYM-AS1 4.687099 5.655133 MBP 11.364118 11.882163 TINCR 3.311175 3.853448 
CSNK1G2 10.367142 10.614454 MBTPS1 9.303948 9.605106 TIPARP 8.178529 8.903067 
CTBP1 10.022548 10.353466 MC1R 5.977481 6.897504 TIRAP 7.653649 8.050578 
CTD-
2201I18.1 
3.159939 3.791243 MCM6 7.227696 7.800285 TK2 6.849481 7.358460 
CTDSP2 11.585286 11.964716 MECP2 10.925197 11.230799 TLR4 6.670294 7.318699 
CTLA4 8.029285 9.429742 MEGF6 8.855803 9.697757 TLR7 7.442059 8.192947 
CTNNBIP1 7.021525 7.693168 MEN1 9.790537 10.023803 TLR9 9.592265 10.232564 
CTSB 11.687008 12.013009 MERTK 5.554860 6.168423 TM7SF2 6.024067 6.505109 
CTSF 7.350237 8.486117 METRNL 7.233310 8.074132 TMED5 10.381161 10.696294 
CTSK 4.782733 5.678871 METTL7A 9.777490 11.148077 TMED8 10.131261 10.402745 
CTSS 11.513208 11.828049 MFHAS1 10.836023 11.127359 TMEM107 6.189454 6.841385 
CUL4B 9.278644 9.615705 MFN1 7.708640 8.143230 TMEM109 10.218445 10.983652 
CUTA 9.339315 9.700984 MFSD8 8.071802 8.401284 TMEM110 8.901565 9.250655 
CXCL16 8.493280 9.587144 MGAT1 11.555503 12.086707 TMEM123 11.672215 12.162647 
CXCR4 13.284547 14.384836 MGAT5 10.040352 10.518437 TMEM127 10.645660 10.912657 
CXXC1 9.357277 9.662271 MGEA5 11.655112 11.892324 TMEM129 9.604929 10.005718 
CXXC11 2.636247 3.237587 MGME1 8.996103 9.489921 TMEM134 7.792584 8.572692 
CXXC5 11.353295 11.622855 MIA3 9.615370 9.943856 TMEM140 9.418989 9.894215 
CYBA 9.184877 9.555047 MIAT 7.813520 8.300539 TMEM143 5.996477 6.769607 
CYFIP2 10.867847 11.505499 MIB2 8.988336 9.510109 TMEM154 9.001641 9.268518 
CYP27A1 7.079387 7.432517 MIDN 9.829455 10.729734 TMEM156 5.757804 6.313412 
CYP4V2 7.973522 8.332763 MIF4GD 8.841012 9.737938 TMEM159 7.925526 8.447837 
CYSLTR1 6.934135 7.770708 MINK1 9.031135 9.491465 TMEM175 7.682755 8.340551 
CYTH2 8.545192 8.961677 MIR1914 4.967396 5.728424 TMEM187 6.599544 6.990598 
CYTIP 10.049779 11.060102 MIR223 2.862711 3.444218 TMEM191A 3.822607 4.435065 
D2HGDH 8.051592 8.582566 MIR378I 7.685665 9.035887 TMEM2 8.074942 9.224763 
DAAM1 7.188216 7.637586 MIR600HG 9.414306 9.968163 TMEM219 8.319117 8.674634 
DAB2IP 6.182002 7.056810 MIR8071-2 7.692078 8.161457 TMEM229B 4.442508 5.064983 
DACT1 6.394281 7.568404 MIS18BP1 8.231951 8.774139 TMEM236 5.095447 5.738664 
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DAGLB 7.567608 7.896387 MKRN1 10.261089 10.566869 TMEM259 12.264799 12.541342 
DAPK2 6.392188 7.992411 MLKL 6.363046 7.000753 TMEM38A 5.068577 6.118614 
DBNDD1 5.739029 6.663768 MLXIP 8.524282 8.875463 TMEM56 5.531333 6.766886 
DBP 6.989077 7.898600 MMP17 6.143143 7.109871 TMEM59 8.560756 9.036256 
DCAF15 9.028888 9.291330 MN1 3.013219 3.723968 TMEM62 7.279155 7.801419 
DCLRE1C 8.781290 9.307969 MNT 8.654979 9.270621 TMEM63A 8.477263 9.447280 
DCST2 3.331548 4.011227 MOAP1 9.210208 9.627890 TMEM65 7.364358 7.799601 
DCUN1D4 7.451922 7.758355 MORC3 10.356114 10.699920 TMEM66 11.540077 12.336078 
DDAH2 8.126293 8.764535 MPEG1 10.248675 10.778626 TMEM71 5.604772 7.457221 
DDX12P 4.931712 5.528053 MPHOSPH8 10.178394 10.561849 TMEM79 7.440534 7.950850 
DDX26B 8.168815 8.574381 MPP1 5.765175 6.288386 TMEM80 7.926562 8.571958 
DEAF1 7.116614 7.564987 MPP7 5.255350 5.934594 TMEM81 5.448664 6.007544 
DEDD2 10.328413 10.629182 MPPE1 6.102498 6.521396 TMEM86B 7.387979 7.934024 
DEF6 8.580418 9.088795 MPRIP 9.901067 10.348345 TMF1 9.860863 10.144283 
DEF8 9.792752 10.463040 MPZ 5.434542 6.243002 TMX4 8.788761 9.775367 
DEGS2 7.304103 8.506103 MR1 9.106677 9.505630 TNFRSF13B 8.973391 10.147623 
DENND5B 9.146946 9.586050 MRI1 9.523043 9.833661 TNFRSF13C 8.945277 10.245787 
DENND6A 7.939243 8.377578 MRO 2.321199 3.138831 TNFSF10 5.673886 6.497303 
DENND6B 6.052940 6.921239 MROH1 8.037656 8.391944 TNFSF12 7.878202 8.635935 
DEPDC5 7.638060 8.311261 MROH6 6.842118 8.055834 TNFSF8 4.254971 5.094799 
DERL3 7.238436 7.820135 MRPL55 6.881970 7.391285 TNFSF9 8.930702 9.496531 
DFFB 7.007984 7.425403 MS4A7 6.763860 7.335748 TNK1 5.826921 6.292120 
DGCR2 9.945576 10.234010 MSI2 11.871465 12.577444 TNK2 10.346642 11.128173 
DGCR9 2.856033 3.769550 MSL2 10.453777 10.809672 TNKS2 9.785942 10.094983 
DGKA 8.463061 9.458801 MSL3 8.989121 9.398132 TNNI2 4.744582 5.348879 
DGKD 9.892872 10.274904 MST4 8.873736 9.239526 TNNT3 3.522569 4.320684 
DGKE 8.343834 8.770977 MSTO2P 6.479902 7.054533 TNRC6B 9.707594 10.391339 
DICER1-AS1 5.941747 6.434062 MTERFD3 7.232620 7.602865 TNRC6C 8.733517 9.001551 
DIP2C 5.568864 6.874664 MTHFR 9.461566 9.747288 TNS3 8.936322 9.445506 
DIRAS1 5.473606 6.287349 MTIF3 8.236158 8.614518 TNXB 4.840840 5.534729 
DIRC2 5.692154 6.472345 MTMR3 10.043727 10.267911 TOB1 8.783893 9.212989 
DISP1 6.092208 6.740849 MTMR9LP 7.311212 8.095549 TOM1 8.245750 8.829681 
DLG2 3.573237 4.559998 MTSS1L 6.584055 8.029707 TOP1MT 8.140624 8.810838 
DLL1 6.187223 6.680314 MTURN 8.372052 9.025540 TP53I13 10.722344 11.532560 
DMPK 8.987053 9.345187 MUC20 4.939339 5.754773 TPCN1 9.666835 10.655153 
DMXL1 9.307493 9.648442 MX2 7.863202 8.563851 TPK1 6.427669 7.023828 
DNAH10 5.333076 5.809189 MXD1 8.966126 9.284227 TPP1 10.862474 11.226210 
DNAJB13 6.080440 6.930441 MXD3 6.467638 6.902545 TRABD 9.313293 10.602861 
DNAJB14 9.563721 9.803935 MXD4 9.443670 10.028944 TRABD2A 6.680121 7.099083 
DNAJB9 8.754212 9.146872 MXI1 9.418147 9.977367 TRAF3IP2 7.739271 8.300707 
DNAJC1 6.785346 7.290289 MYBL1 4.593968 5.201493 TRAF3IP3 8.738340 9.270622 
DNAJC4 8.463367 8.993828 MYH7B 5.869798 6.330438 TRAF5 9.218242 9.961192 
DNASE2 8.424411 8.849104 MYO15B 8.509126 8.893083 TRAM2 9.500472 10.187215 
DNHD1 9.079607 9.556107 MYO1F 7.624625 7.957989 TRAPPC2L 8.126663 9.404619 
DNMBP 9.510519 10.128206 MYO9B 11.160162 11.478778 TRIB1 9.997695 10.791891 
DOK2 7.963769 8.374373 MYOM1 5.645049 6.430859 TRIM14 8.623463 8.990823 
DOK3 7.843948 9.051374 MZB1 8.248792 8.797089 TRIM22 10.330237 10.749775 
DOPEY1 7.316055 7.787419 N4BP2 8.792009 9.083815 TRIM23 7.227246 7.590308 
DPAGT1 7.471688 8.092263 NAA16 7.975625 8.340480 TRIM38 9.701218 10.199097 
DPEP2 8.610359 9.801387 NAA40 9.442017 9.744612 TRIM39 8.471847 8.765032 
DPH1 6.165365 6.669119 NAAA 7.474532 8.098652 TRIM52 8.444723 8.851701 
DPH7 8.716168 9.107704 NAALADL1 7.193896 7.532949 TRIM65 8.964412 9.389587 
DPM3 9.355394 9.765414 NAB2 8.587100 9.747255 TRIM7 5.284978 6.661681 
DSTYK 8.415409 8.838957 NADK 9.771897 10.138840 TRIM8 10.173709 10.567343 
DUSP26 3.651864 4.650479 NAGPA 7.749139 8.105223 TRNAA26 2.644382 3.489077 
DYNLL2 10.045351 10.351739 NAPRT1 8.877364 9.339383 TRNP 9.637186 10.172156 
DYRK1B 7.638027 8.029286 NBPF11 7.532379 8.073686 TRNS1 10.500912 10.818819 
DYRK2 9.351066 9.869504 NCAPD2 7.357574 7.731127 TRPS1 6.928769 7.529539 
E2F5 7.007129 7.397827 NCEH1 7.292422 7.769000 TRPV1 7.303117 7.870477 
EFCAB12 3.660744 4.582015 NCF4 7.862387 8.709950 TSC1 9.527696 9.838653 
EFCAB13 6.043420 6.742029 NCOA3 12.288167 12.543751 TSC22D1 8.209094 8.975399 
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EFCAB4A 6.241756 7.685981 NDRG1 9.108193 10.236159 TSC22D1-
AS1 
3.759527 4.282536 
EFNA3 5.366420 5.937036 NDRG2 5.181540 5.844291 TSC22D3 10.406757 12.138526 
EGLN1 9.266610 9.625277 NDST1 8.168375 8.550029 TSEN54 7.860275 8.375223 
EHD3 9.477890 10.102200 NDUFC1 5.437137 6.137905 TSHZ1 7.931629 8.406368 
EHMT1 10.499702 11.048358 NEK7 9.694979 10.250481 TSHZ2 4.877615 6.153797 
EHMT2 8.619016 9.039174 NFATC1 10.199776 10.825943 TSPYL2 11.934315 12.529008 
EID2 8.883358 9.156341 NFATC3 10.123845 10.440490 TSSK3 7.089877 7.958089 
ELF1 11.296970 11.558821 NFX1 9.588715 9.910684 TSSK6 6.349239 6.760412 
ELF2 8.874453 9.179513 NGLY1 8.299492 8.583822 TTC13 7.091905 7.539082 
ELFN2 3.414589 4.733303 NHLRC3 8.063355 8.432093 TTC21A 5.962863 7.259952 
ELMSAN1 10.183042 10.599192 NIPSNAP3B 6.286516 6.743305 TTC24 5.871724 6.576931 
ELOF1 9.550026 9.857473 NISCH 10.905388 11.283938 TTC28-AS1 7.506025 7.941323 
EMB 9.731617 10.015394 NKD1 5.217355 5.902183 TTC3 9.584619 10.349392 
EML4 9.748099 10.043944 NKG7 5.698522 6.223601 TTC3P1 8.728531 9.474671 
ENC1 8.338260 9.846181 NKTR 11.096560 11.549911 TTC9 8.535120 9.192509 
ENGASE 9.879921 10.260262 NLRC3 8.867943 9.436065 TTYH3 10.188284 10.679737 
ENKD1 6.680041 7.042754 NLRP1 9.572145 10.693312 TUBA4A 9.945519 10.809196 
ENPP2 5.488165 6.417453 NLRP6 6.299750 7.152057 TUBG2 6.364057 6.769225 
ENTHD2 10.149090 10.580741 NMRK1 5.954146 6.475361 TULP4 8.831309 9.225127 
EOMES 5.827830 6.364241 NMT2 6.725901 7.545298 TXNDC12 9.302051 9.609866 
EP300 10.955658 11.193741 NOSIP 7.566908 8.408514 TXNDC15 9.061187 9.370379 
EP400 10.608443 11.108309 NPHP3 7.094849 7.545313 TXNIP 12.228137 13.293390 
EPB41 10.900554 11.292405 NPIPB11 3.365294 3.886833 U2AF1L4 8.067362 8.592130 
EPB41L3 5.732439 6.185456 NPRL2 6.983450 7.610359 UBA7 8.112605 8.451289 
EPB41L4A-
AS1 
8.666009 9.123639 NQO2 6.629807 7.406055 UBAC2 8.825228 9.345526 
EPHB6 8.062361 8.656597 NR1D1 7.112680 7.626657 UBAP1L 5.211278 5.718925 
EPHX1 7.395412 8.641725 NR1D2 9.550598 10.123178 UBE2G1 9.577204 10.032559 
EPS15L1 8.362089 8.800623 NR3C1 11.332695 11.642809 UBE2H 10.715925 10.981374 
EPS8L2 7.524945 8.495698 NR3C2 4.836796 5.512551 UBN1 9.965082 10.191962 
ERBB2IP 10.246764 10.500673 NR4A2 9.065984 9.824129 UBN2 9.023235 9.336591 
ERCC6 7.316886 7.688584 NSUN6 7.148256 7.618561 UBR2 8.924589 9.233922 
ERF 10.112764 10.624854 NSUN7 4.605438 5.278193 UBXN11 6.907211 7.557599 
ERMN 5.878481 6.803392 NT5C2 9.888270 10.260654 UCKL1 7.900662 8.704584 
ERP29 10.282332 10.995020 NT5C3A 6.978778 7.332968 UCKL1-AS1 6.179417 6.780808 
ESYT1 9.524273 10.079573 NUAK2 10.650583 10.933336 UCN 4.827511 5.434219 
ETV5 4.639207 5.388185 NUMA1 11.311746 11.735133 UCP3 5.346556 5.842702 
EVL 8.640385 9.181450 NUMBL 6.521791 7.177986 UHRF2 9.028370 9.390215 
EZR 12.781126 13.202409 NUP85 7.590405 8.009195 ULK1 9.292309 9.991702 
F2R 6.127746 6.685938 NXF1 10.293368 10.753920 UNC5CL 6.719168 7.638509 
FAIM3 11.119867 12.355144 OAS2 9.211423 9.858793 UNC93B1 9.466687 9.902647 
FAM102A 10.341497 10.937852 OBSCN 8.116449 8.936374 UNKL 9.356099 9.623296 
FAM102B 7.718320 8.397291 OGFOD2 7.811898 8.156005 UPF3A 8.017272 8.415733 
FAM111A 9.372875 9.910182 OGT 12.103622 12.439197 UQCRB 7.583610 8.111980 
FAM111B 6.111105 8.102586 OR13A1 4.147824 4.846070 USF1 9.373610 9.930341 
FAM117B 7.966549 8.844644 OR52N4 2.957009 3.774176 USP11 8.324955 8.703336 
FAM120C 6.475219 7.049753 ORAI2 12.260660 13.188449 USP20 8.921391 9.237514 
FAM129C 9.433547 10.807706 ORM2 3.639565 4.549160 USP21 8.754581 9.195226 
FAM134A 10.482331 10.751867 ORMDL1 9.933611 10.277057 USP28 8.082237 8.615363 
FAM134C 9.978079 10.281434 OSBP2 6.228814 6.667281 USP53 7.311125 7.685499 
FAM13B 9.112022 9.344954 OSBPL11 8.903670 9.405955 USP6NL 8.499918 8.830184 
FAM159A 6.310339 7.127835 OSBPL3 7.043130 7.672355 USP8 8.932668 9.240681 
FAM167B 4.467881 5.256468 OSBPL5 4.167870 4.719014 USPL1 9.485585 9.775383 
FAM178A 9.220089 9.546463 OSBPL7 7.872578 8.280606 UTRN 8.392128 8.993422 
FAM193B 10.058542 10.618791 OSBPL8 9.303331 9.575750 VAMP1 9.667474 10.329868 
FAM198B 5.941870 6.544739 OSER1-AS1 7.069771 7.489522 VAMP2 10.651979 11.074938 
FAM210B 7.820457 8.269177 OTUD1 9.598571 10.198729 VAMP4 8.576634 9.016879 
FAM214A 8.902602 9.833293 OVGP1 6.176328 6.978294 VASH1 7.738165 8.369080 
FAM217B 8.422453 8.822935 OVOL1 5.371710 5.932278 VAT1 10.202331 10.750358 
FAM220A 8.348472 8.680600 OXR1 8.242246 8.542509 VAV1 7.315939 7.760534 
FAM222A 5.159251 5.674080 P2RX1 7.718576 9.098444 VGLL4 7.933878 8.244934 
FAM26F 5.764647 6.700957 P2RX5 5.406615 6.064706 VIPR1 6.980081 7.525785 
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FAM43A 9.198136 10.414334 P2RY6 4.613647 5.184825 VMO1 4.596811 5.186683 
FAM46A 7.128823 7.634702 P4HTM 8.581332 9.220505 VNN2 7.164540 7.726892 
FAM46C 10.285919 11.306376 PACSIN1 2.364067 2.967517 VPREB3 6.303873 7.724564 
FAM63B 7.191132 7.874161 PAIP2B 7.816772 8.583296 VPS26B 7.857605 8.802069 
FAM65B 9.999721 11.138137 PAN2 8.907627 9.431786 VWA3A 4.046714 4.746794 
FAM73B 9.493783 9.744204 PANK1 5.427118 6.259314 WBP2 10.177474 10.530766 
FAM76B 8.843599 9.235256 PAPD7 8.990527 9.516953 WDFY4 10.761716 11.022791 
FAM78A 9.684060 10.336331 PAPSS2 4.554894 5.333824 WDR19 5.746516 6.427240 
FAM89B 9.448111 9.937195 PAQR6 4.846727 5.387192 WDR37 8.703911 8.989303 
FAM8A1 7.665836 8.658751 PARD6A 7.732405 8.373995 WDR47 7.206921 7.600586 
FAXDC2 5.610566 7.514959 PARP16 7.371225 7.778387 WDR52 6.937653 7.408268 
FBXL14 9.645589 9.932894 PARP4 9.031390 9.424764 WDR54 6.639192 7.149698 
FBXL16 5.666518 6.369652 PARVG 8.693674 9.608204 WDR74 7.711435 8.047635 
FBXL20 9.090698 9.529145 PATL2 7.072288 7.765082 WFIKKN1 3.592566 4.167677 
FBXL3 10.214564 10.494303 PBXIP1 11.216156 12.440093 WHSC1 9.692928 9.908316 
FBXO10 9.227814 10.018003 PCDH9 4.937854 6.243122 WHSC1L1 10.847592 11.103146 
FBXO15 3.197147 4.102268 PCF11 10.359286 10.695989 WIPF1 11.587507 12.176966 
FBXO18 9.418454 9.805117 PCMTD2 10.099492 10.473703 WNT3 9.021342 9.920469 
FBXO21 9.390026 9.752127 PCOLCE 4.925128 5.632224 WSB1 10.346040 10.647629 
FBXO32 7.096601 8.225684 PCP2 4.980941 5.737681 XAF1 8.468052 8.920375 
FBXO44 9.311084 9.585862 PCSK7 9.410816 9.927430 XKRX 6.401226 7.337313 
FBXO9 8.657897 9.150880 PCYOX1 8.519777 9.150720 XPC 9.708936 10.201474 
FCGR2B 8.136848 8.893917 PDE1B 5.801025 6.497324 XXYLT1-AS2 7.004557 7.915926 
FCGR2C 2.779775 3.526659 PDE4A 8.044267 8.756800 XYLT1 9.567547 10.267923 
FCGR3A 6.388435 7.241791 PDE4B 11.150356 11.588118 XYLT2 7.988640 8.339547 
FCGRT 8.935369 9.524448 PDE7B 5.110307 6.752688 YPEL1 8.227148 8.804941 
FCHO2 7.181985 7.690181 PDGFD 7.555172 7.954650 YPEL2 9.995632 10.983065 
FCHSD1 8.397352 8.779830 PDK3 8.697286 9.108292 YPEL3 10.551439 11.298464 
FCRL1 8.071989 8.536621 PDK4 7.068839 8.328900 YPEL4 3.518267 4.397661 
FCRL2 7.922816 8.701414 PDLIM1 8.921107 9.653152 YPEL5 10.958313 11.309596 
FCRLA 9.842865 10.939973 PDP1 8.597513 9.270187 ZBED6 8.415356 8.879194 
FCRLB 5.775447 6.405606 PDPR 10.143027 10.355644 ZBP1 5.415750 7.239335 
FGD1 7.885756 8.281740 PDXDC2P 6.140324 6.697397 ZBTB1 10.887841 11.229709 
FGD3 8.555568 9.584428 PDXK 8.701011 9.232471 ZBTB11 9.030798 9.448235 
FGFBP2 5.363135 6.013487 PECAM1 9.903126 10.698074 ZBTB14 8.725897 8.996061 
FGFR1 7.205856 7.595832 PEG10 8.509555 10.152779 ZBTB18 10.531926 11.135647 
FGFR1OP 7.373117 7.761230 PELI2 6.942838 7.570142 ZBTB2 9.034452 9.343934 
FHDC1 5.254053 6.167901 PER1 9.458995 10.071561 ZBTB20 8.785204 9.443875 
FLI1 9.487765 10.033405 PEX1 7.858219 8.380608 ZBTB38 10.543266 10.889219 
FLJ10038 7.231803 7.830100 PEX6 8.776091 9.090305 ZBTB4 11.242166 11.939125 
FLJ20021 5.008668 5.566601 PFKFB3 8.793985 9.348616 ZBTB40 10.515879 10.821621 
FLJ32255 7.972495 8.741436 PGAM2 8.091290 8.717409 ZBTB41 8.192995 8.578554 
FLJ38379 3.280222 3.857871 PGM2L1 7.692699 8.395057 ZBTB44 10.232701 10.768645 
FLJ42258 6.315870 7.211709 PGPEP1 8.598089 9.468764 ZC3H11A 10.389790 10.725385 
FLJ44342 6.673149 7.493969 PHC3 10.528370 11.000181 ZC3H3 8.877373 9.340307 
FLT1 5.996407 6.609605 PHF1 9.970966 10.467423 ZC3H6 8.075339 8.503513 
FLYWCH1 9.528906 9.849177 PHF10 6.843299 7.321238 ZCCHC11 9.722018 10.197974 
FMR1 9.004822 9.277543 PHF12 9.700796 10.038594 ZCCHC14 7.313456 7.881238 
FN3K 3.769217 4.409465 PHF13 9.242392 9.505813 ZCCHC18 7.353233 8.447805 
FNBP4 10.787241 11.126503 PHF19 8.376921 8.785115 ZCCHC2 8.949510 9.413396 
FOLR2 2.367216 3.370751 PHF2 9.223254 9.495065 ZCCHC24 6.194732 6.609896 
FOPNL 8.604013 8.897461 PHF3 10.471190 10.740470 ZDHHC20 10.780803 11.067276 
FOS 9.056495 9.446771 PHF7 6.128468 6.984191 ZER1 9.277133 9.624907 
FOSB 9.314267 9.713014 PHIP 9.709664 9.991177 ZFAND2B 7.929458 8.355842 
FOSL2 7.985485 8.570636 PHKB 8.615470 9.002847 ZFP14 8.218628 8.561345 
FOXJ2 9.310313 9.649870 PHKG2 8.032771 8.332195 ZFP36L2 11.875325 13.127658 
FOXN2 9.093369 9.350617 PHLDA1 7.895883 8.251404 ZFP64 8.045202 8.510551 
FOXO3 7.961128 8.462227 PI4K2A 10.140662 10.402749 ZFYVE28 6.326622 6.704644 
FOXO4 9.317650 9.881645 PI4KA 7.548581 7.869357 ZHX2 10.945892 11.447311 
FPR3 7.392129 7.925276 PID1 5.593082 6.178429 ZHX3 6.949804 7.877903 
FRAT1 7.734172 8.599465 PIK3IP1 10.065277 10.871641 ZIK1 8.497347 8.864694 
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FRAT2 8.320765 8.950476 PIK3R1 9.228085 9.561986 ZKSCAN8 9.987509 10.265291 
FRY 8.254513 9.010353 PIP4K2B 9.853952 10.115641 ZMYM3 8.657682 9.104494 
FTL 12.515462 12.865330 PIP5KL1 5.213565 6.045408 ZMYM6 8.279882 8.573234 
FUCA1 9.676688 10.221398 PITPNC1 7.294052 7.861024 ZMYND10 3.247814 3.951346 
FUZ 6.774066 7.572011 PITPNM1 10.087828 10.458500 ZMYND15 3.862105 4.569945 
FXYD1 2.864990 3.474882 PITPNM2 10.063453 11.038609 ZMYND8 8.182959 8.627261 
FXYD5 7.688616 8.354854 PKD1 9.736438 10.020999 ZNF10 7.486255 8.029936 
FXYD7 4.366889 6.010721 PKIA 7.171588 7.793120 ZNF101 8.682461 9.204554 
FYB 6.013826 6.656049 PKN2 8.449712 8.779303 ZNF107 10.966446 11.904860 
FZD3 7.490647 8.064051 PLA2G15 7.407978 7.850018 ZNF14 8.066692 8.480796 
GAA 8.516936 8.970294 PLA2G4B 4.560664 5.138546 ZNF211 9.064781 9.517581 
GAB2 9.695725 10.502598 PLAC9 4.095594 4.878264 ZNF219 8.894310 9.189978 
GABARAPL1 8.325228 8.941389 PLCB2 9.071073 9.421348 ZNF224 7.252344 7.674999 
GABARAPL3 6.171091 6.805819 PLCD1 4.618811 5.544858 ZNF248 8.195289 8.566882 
GABRB2 2.530571 3.109537 PLCG2 8.409509 9.214869 ZNF250 7.211458 7.829392 
GAK 9.685898 10.125891 PLCH2 7.261830 8.016683 ZNF266 10.794692 11.385694 
GALM 6.175972 6.816030 PLCL2 10.284755 10.582316 ZNF273 7.433128 7.792494 
GALNS 8.402671 8.843310 PLD3 8.691768 9.144492 ZNF30 5.336340 5.956362 
GALNT3 5.519971 6.092381 PLD4 2.984497 3.571469 ZNF304 8.658793 8.990512 
GAPT 7.309832 7.755506 PLEKHA2 11.768944 12.585679 ZNF318 9.881901 10.245270 
GATAD1 9.794561 10.151914 PLEKHA3 8.442948 8.814856 ZNF331 9.307067 10.276127 
GATM 7.042889 7.489733 PLEKHB1 6.316772 6.874143 ZNF335 8.347985 8.795930 
GCC2 9.299545 9.555372 PLEKHM1 8.892714 9.178884 ZNF34 6.890517 7.287990 
GCHFR 7.805465 8.189154 PLEKHM1P 7.007212 7.418798 ZNF367 6.073740 6.674884 
GCLC 9.021459 9.393953 PLK1S1 6.560459 6.974730 ZNF395 10.782825 11.558307 
GCNT2 7.374358 7.867151 PLP2 9.896804 10.471979 ZNF439 8.018791 8.786358 
GDE1 8.969255 9.305518 PLXND1 9.726213 11.128400 ZNF441 7.924118 8.317246 
GDF11 6.921180 7.436380 PMEL 4.034936 4.680156 ZNF487 4.310473 5.170751 
GDF7 7.718463 8.612699 PNMA5 5.390997 6.321755 ZNF490 7.131681 7.501887 
GDPD1 4.688770 5.221307 PNPLA2 10.216288 10.956675 ZNF516 7.200737 7.788919 
GDPD3 5.949021 6.830994 PNPLA7 6.535310 8.074559 ZNF540 5.845400 6.845934 
GFOD1 8.037557 8.984444 PNPLA8 9.026886 9.532733 ZNF548 8.811509 9.154550 
GGA2 12.043555 12.959809 PNRC1 11.491310 11.887465 ZNF566 7.393226 7.923050 
GGA3 10.382535 10.795589 POFUT2 9.369069 9.648037 ZNF569 7.511167 8.131843 
GH1 3.525882 4.411478 POLM 9.117723 9.373317 ZNF575 5.003248 5.510336 
GHDC 8.558782 9.043320 POLR3GL 8.220264 8.596098 ZNF595 8.133504 8.981992 
GIPR 3.679387 4.404236 PPAP2B 5.480715 6.047320 ZNF615 7.931536 8.255725 
GIT2 9.558193 10.025268 PPARD 9.059911 9.779642 ZNF627 7.942776 8.263055 
GKAP1 4.682013 5.381104 PPM1D 8.400431 8.765148 ZNF652 8.934573 9.411741 
GLCCI1 7.719510 8.344246 PPM1J 4.371531 5.476421 ZNF654 8.257681 8.639784 
GLI1 4.939790 5.794795 PPM1K 11.293611 11.930100 ZNF667 5.747674 6.088915 
GLIPR1 7.695390 8.837542 PPP1R12B 7.937717 8.393019 ZNF671 8.742671 8.988737 
GLTSCR2 10.216956 10.433053 PPP1R32 4.643154 5.405927 ZNF699 7.243557 7.885497 
GM2A 10.760522 11.321828 PPP1R3E 8.183909 9.041793 ZNF700 8.507417 8.863217 
GMCL1 7.473887 7.889810 PPP2R5C 10.544418 11.077917 ZNF703 5.135007 5.793945 
GMEB2 9.534705 9.878198 PPP3CA 9.295837 9.630359 ZNF704 3.017126 3.634068 
GMFG 6.486907 6.954804 PRC1 6.435888 6.913528 ZNF721 9.712045 9.973855 
GNA13 11.534620 11.817368 PRDM2 12.518563 12.833009 ZNF791 7.927168 8.325819 
GNAO1 5.164637 6.382627 PRICKLE1 5.182319 6.241397 ZNF815P 4.263324 5.072533 
GNAZ 7.084189 8.085829 PRKAR2A 9.389050 9.654574 ZNF821 7.094282 7.739871 
GNB5 8.942027 9.790116 PRKCA 5.165391 5.780434 ZNF823 5.555208 5.980860 
GNG7 7.413585 9.873069 PRKCB 11.348785 11.908393 ZNF831 7.889246 9.018884 
GNL1 9.440126 9.820509 PRKCE 8.913912 9.968235 ZNF853 7.585817 7.991584 
GNPTAB 10.597070 10.864116 PRKCH 5.801053 6.242240 ZNF862 9.257505 9.731329 
GNPTG 6.099040 6.540563 PRKCSH 9.315728 9.684751 ZNF92 9.126394 10.095460 
GOLGA1 7.489169 7.945890 PRKD2 8.457707 8.861025 ZSCAN18 10.012435 10.275554 
GOLGA2P5 8.012281 8.878062 PRKD3 9.742707 10.028493 ZSWIM6 7.743843 8.301334 
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Appendix 8. 158 differentially expressed proteins induced by the soluble CD40 ligand in primary CLL cells at 12h time point 
Protein Accession p-value(12h stim 
vs. 12h unstim) 
Fold-Change(12h stim 
vs. 12h unstim) 
TNF receptor-associated factor 1 Q13077 1.95E-05 8.34834 
Beta-galactosidase P16278 0.0180556 3.8089 
Serine/threonine-protein phosphatase 4 regulatory subunit 1 Q8TF05 0.0359863 3.0761 
Putative ribosome-binding factor A, mitochondrial Q8N0V3 0.00321725 2.95393 
Raftlin Q14699 0.0468653 2.87343 
ATP-dependent RNA helicase DDX50 Q9BQ39 0.00141214 2.78484 
Anaphase-promoting complex subunit 7 Q9UJX3 0.010285 2.78484 
Charged multivesicular body protein 4b Q9H444 0.0200121 2.70396 
Isopentenyl-diphosphate Delta-isomerase 1 Q13907 0.0154446 2.46604 
Protein fosB P53539 0.0321401 2.4615 
Pyridoxal kinase O00764 0.00214469 2.37247 
Importin subunit alpha-5 P52294 0.0277964 2.35505 
UPF0668 protein C10orf76 Q5T2E6 0.0318233 2.35072 
Importin subunit alpha-1 P52292 0.00340447 2.3206 
Interferon regulatory factor 5 Q13568 0.029128 2.25736 
Thiamine-triphosphatase Q9BU02 0.0086693 2.2532 
RalBP1-associated Eps domain-containing protein 1 Q96D71 0.00302813 2.18776 
CD44 antigen P16070 0.0302177 2.15179 
HLA class I histocompatibility antigen, alpha chain E P13747 0.0466695 2.13206 
Exocyst complex component 5 O00471 0.00844907 2.07014 
rRNA-processing protein FCF1 homolog Q9Y324 0.0283591 2.05116 
Coiled-coil domain-containing protein 50 Q8IVM0 0.010825 2.00632 
Nardilysin O43847 0.040561 1.96607 
Vacuolar protein sorting-associated protein 41 homolog P49754 0.0247649 1.89496 
NADH dehydrogenase [ubiquinone] 1 subunit C2 O95298 0.0105793 1.88799 
Ferredoxin-2, mitochondrial Q6P4F2 0.0215064 1.88452 
Mitogen-activated protein kinase kinase kinase kinase 1 Q92918 0.0157866 1.87413 
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BAG family molecular chaperone regulator 1 Q99933 0.0246946 1.8197 
Mitofusin-1 Q8IWA4 0.0369386 1.80634 
28S ribosomal protein S5, mitochondrial P82675 0.0425243 1.7997 
PH and SEC7 domain-containing protein 4 Q8NDX1 0.0313628 1.79639 
Eukaryotic translation initiation factor 3 subunit K Q9UBQ5 0.0379199 1.77337 
Pre-mRNA-processing factor 17 O60508 0.01962 1.76035 
Sequestosome-1 Q13501 0.0444721 1.7378 
Nuclear factor NF-kappa-B p105 subunit P19838 0.000268062 1.73141 
Fibronectin P02751 0.0138861 1.71238 
Nucleolar RNA helicase 2 Q9NR30 0.0456201 1.70608 
Pre-mRNA-splicing factor 38A Q8NAV1 0.0110474 1.69044 
Formin-binding protein 1 Q96RU3 0.0107497 1.65653 
DNA replication licensing factor MCM7 P33993 0.0487353 1.64437 
Coatomer subunit epsilon O14579 0.0191017 1.6293 
CD97 antigen P48960 0.0146525 1.62032 
NADH-cytochrome b5 reductase 2 Q6BCY4 0.0393652 1.62032 
Elongator complex protein 1 O95163 0.0314496 1.58782 
N6-adenosine-methyltransferase 70 kDa subunit Q86U44 0.0361988 1.58782 
39S ribosomal protein L16, mitochondrial Q9NX20 0.0374456 1.57906 
Axin interactor, dorsalization-associated protein Q96BJ3 0.0174278 1.56459 
40S ribosomal protein S20 P60866 0.0329154 1.55597 
Triokinase/FMN cyclase Q3LXA3 0.0402704 1.54739 
Telomeric repeat-binding factor 2-interacting protein 1 Q9NYB0 0.04825 1.5332 
S-adenosylmethionine synthase isoform type-2 P31153 0.0208195 1.52757 
Ral GTPase-activating protein subunit beta Q86X10 0.0485136 1.52475 
Ras-related GTP-binding protein A Q7L523 0.0444937 1.50245 
Ribosome biogenesis protein BOP1 Q14137 0.0348412 1.49968 
Centrosome-associated protein CEP250 Q9BV73 0.0150552 1.4642 
GPN-loop GTPase 1 Q9HCN4 0.0195359 1.45613 
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U4/U6 small nuclear ribonucleoprotein Prp4 O43172 0.012533 1.45345 
Alanine--tRNA ligase, cytoplasmic P49588 0.0380601 1.44544 
Signal transducer and activator of transcription 3 P40763 0.0357639 1.44278 
Nuclear pore complex protein Nup155 O75694 0.0269057 1.42955 
Lymphocyte antigen 75 O60449 0.0362861 1.41906 
Forkhead box protein P1 Q9H334 0.0207763 1.41384 
Regulator of nonsense transcripts 1 Q92900 0.00995453 1.38803 
Transcription factor ETV6 P41212 0.0368435 1.33783 
E3 ubiquitin-protein ligase CHIP Q9UNE7 0.0417096 1.24509 
60S ribosomal protein L12 P30050 0.031156 1.2314 
Centromere/kinetochore protein zw10 homolog O43264 0.022832 -1.28469 
Alpha-actinin-4 O43707 0.0297568 -1.2942 
Ribonuclease P protein subunit p40 O75818 0.0465094 -1.34029 
Peptidyl-prolyl cis-trans isomerase-like 1 Q9Y3C6 0.0383708 -1.35769 
Eukaryotic translation initiation factor 4 gamma 2 P78344 0.0269089 -1.38293 
U5 small nuclear ribonucleoprotein 200 kDa helicase O75643 0.0152873 -1.39059 
Nuclear pore complex protein Nup98-Nup96 P52948 0.0193335 -1.40088 
Coiled-coil domain-containing protein 58 Q4VC31 0.0214045 -1.41124 
Early endosome antigen 1 Q15075 0.0391155 -1.42692 
N6-adenosine-methyltransferase subunit METTL14 Q9HCE5 0.0368163 -1.43747 
LDLR chaperone MESD Q14696 0.0439465 -1.45613 
Neutral alpha-glucosidase AB Q14697 0.0150213 -1.4642 
Peroxisomal membrane protein 11B O96011 0.041299 -1.4642 
LIM and senescent cell antigen-like-containing domain protein 1 P48059 0.0273038 -1.47503 
Diphosphomevalonate decarboxylase P53602 0.0497517 -1.49968 
Mitochondrial antiviral-signaling protein Q7Z434 0.0172114 -1.51635 
Nucleoporin NUP188 homolog Q5SRE5 0.0375278 -1.52475 
Nuclear autoantigenic sperm protein P49321 0.0179607 -1.5332 
Regulation of nuclear pre-mRNA domain-containing protein 1B Q9NQG5 0.0223404 -1.54454 
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Zinc finger protein 22 P17026 0.0270537 -1.5531 
Presequence protease, mitochondrial Q5JRX3 0.0233727 -1.56747 
NAD-dependent malic enzyme, mitochondrial P23368 0.0220016 -1.57036 
Apoptosis-inducing factor 1, mitochondrial O95831 0.00163427 -1.57906 
Nucleoprotein TPR P12270 0.0112538 -1.57907 
Glutaredoxin-related protein 5, mitochondrial Q86SX6 0.0460222 -1.58489 
Striatin-3 Q13033 0.0276508 -1.59074 
GrpE protein homolog 1, mitochondrial Q9HAV7 0.0332458 -1.59956 
Protein disulfide-isomerase A3 P30101 0.046373 -1.60251 
Calcium-independent phospholipase A2-gamma Q9NP80 0.0420105 -1.60842 
Regulator of microtubule dynamics protein 1 Q96DB5 0.049153 -1.61139 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 P61803 0.0499472 -1.61734 
Cytochrome b-245 heavy chain P04839 0.0253985 -1.63531 
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide Q9UN19 0.0293618 -1.63531 
Bromodomain adjacent to zinc finger domain protein 1A Q9NRL2 0.0337885 -1.63531 
Death-inducer obliterator 1 Q9BTC0 0.00266131 -1.64437 
Cytochrome b-c1 complex subunit 2, mitochondrial P22695 0.0151215 -1.65348 
Metalloendopeptidase OMA1, mitochondrial Q96E52 0.041772 -1.65959 
Translation factor GUF1, mitochondrial Q8N442 0.00550369 -1.67494 
GDP-D-glucose phosphorylase 1 Q6ZNW5 0.0396605 -1.67803 
m-AAA protease-interacting protein 1, mitochondrial Q8WWC4 0.0356438 -1.68112 
Zinc finger protein 800 Q2TB10 0.0175112 -1.68422 
Ribosome biogenesis protein BMS1 homolog Q14692 0.0359627 -1.68422 
RNA-binding protein 45 Q8IUH3 0.00569016 -1.69044 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial Q16795 0.0462323 -1.69356 
CD2-associated protein Q9Y5K6 0.0481226 -1.7187 
Tyrosine-protein phosphatase non-receptor type 2 P17706 0.00419286 -1.72504 
Transmembrane emp24 domain-containing protein 1 Q13445 0.0071266 -1.7378 
Mitochondrial fission factor Q9GZY8 0.00360017 -1.741 
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Mitogen-activated protein kinase 1 P28482 0.0477138 -1.74421 
Required for meiotic nuclear division protein 1 homolog Q9NWS8 0.00564363 -1.75388 
TBC1 domain family member 5 Q92609 0.0268271 -1.75388 
Transmembrane protein 126A Q9H061 0.0486999 -1.7636 
Ubiquitin carboxyl-terminal hydrolase 47 Q96K76 0.0194067 -1.77337 
SRSF protein kinase 2 P78362 0.0208254 -1.7997 
Ubiquitin carboxyl-terminal hydrolase 8 P40818 0.0349134 -1.80967 
Nucleoporin p58/p45 Q9BVL2 0.024014 -1.81301 
Cyclin-L1 Q9UK58 0.0354552 -1.82978 
CD2 antigen cytoplasmic tail-binding protein 2 O95400 0.020144 -1.83992 
Transcription initiation factor TFIID subunit 7 Q15545 0.0127683 -1.84672 
Chromobox protein homolog 5 P45973 0.0159766 -1.87413 
Lysine-specific demethylase PHF2 O75151 0.0373017 -1.89496 
Selenoprotein T P62341 0.0121287 -1.89845 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial O00217 0.01561 -1.90546 
Abl interactor 1 Q8IZP0 0.0133336 -1.91955 
Ras GTPase-activating protein 2 Q15283 0.0352427 -1.92309 
39S ribosomal protein L27, mitochondrial Q9P0M9 0.0306971 -1.93731 
Inactive phospholipase C-like protein 2 Q9UPR0 0.0283558 -1.94446 
E3 ubiquitin-protein ligase ARIH1 Q9Y4X5 0.0366734 -1.96246 
Hermansky-Pudlak syndrome 3 protein Q969F9 0.0428015 -1.98061 
Biogenesis of lysosome-related organelles complex 1 subunit 4 Q9NUP1 0.0303338 -1.98793 
Ribosomal protein S6 kinase beta-1 P23443 0.0330079 -2.00263 
ADP-ribosylation factor-binding protein GGA3 Q9NZ52 0.0230564 -2.02488 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 O96000 0.0400584 -2.02862 
Cytochrome c oxidase subunit 5A, mitochondrial P20674 0.0331083 -2.05494 
Small glutamine-rich tetratricopeptide repeat-containing protein alpha O43765 0.0336517 -2.06253 
HLA class II histocompatibility antigen, DO alpha chain P06340 0.0413405 -2.08545 
Zinc finger and BTB domain-containing protein 20 Q9HC78 0.0162387 -2.10087 
285 
 
52 kDa repressor of the inhibitor of the protein kinase O43422 0.0316094 -2.12422 
Lysine-specific demethylase 4B O94953 0.000432156 -2.13993 
PC4 and SFRS1-interacting protein O75475 0.0328843 -2.15973 
E3 ubiquitin/ISG15 ligase TRIM25 Q14258 0.00757154 -2.22433 
F-actin-uncapping protein LRRC16A Q5VZK9 0.00414821 -2.31206 
Histone-lysine N-methyltransferase EZH1 Q92800 0.028239 -2.31633 
Fc receptor-like protein 3 Q96P31 0.0353818 -2.33346 
Probable leucine--tRNA ligase, mitochondrial Q15031 0.00950692 -2.35072 
RAD50-interacting protein 1 Q6NUQ1 0.0322799 -2.36374 
Malectin Q14165 0.0401762 -2.53046 
Nicotinate phosphoribosyltransferase Q6XQN6 0.0365203 -2.57276 
F-box only protein 4 Q9UKT5 0.0371546 -2.76439 
Serum albumin P02768 0.0245536 -2.93224 
Stromal interaction molecule 2 Q9P246 0.0366994 -2.99226 













Appendix 9. 552 differentially expressed proteins induced by the soluble CD40 ligand in primary CLL cells at 24h time point 
Protein Accession p-value(24h stim vs. 
24h unstim) 
Fold-Change(24h 
stim vs. 24h unstim) 
Biotinidase P43251 0.0290927 18.1301 
Probable RNA polymerase II nuclear localization protein SLC7A6OS Q96CW6 0.0144067 10.4906 
TNF receptor-associated factor 1 Q13077 1.80E-05 10.0956 
PHD finger protein 14 O94880 0.00204098 6.35916 
Uncharacterized protein C15orf57 Q9BV29 0.0122798 5.95662 
Glutamine-rich protein 1 Q2TAL8 0.00380146 4.99728 
Glutathione S-transferase theta-1 P30711 0.0430604 4.7665 
Leukosialin P16150 0.0265614 4.55477 
Maspardin Q9NZD8 0.0245251 4.28023 
MKI67 FHA domain-interacting nucleolar phosphoprotein Q9BYG3 0.00184687 4.20017 
Raftlin Q14699 0.0190648 4.04824 
Cleavage sulation factor subunit 2 P33240 0.00216336 4.01667 
Nucleoside diphosphate kinase 6 O75414 0.00954956 3.98229 
28S ribosomal protein S26, mitochondrial Q9BYN8 0.00300268 3.8259 
OTU domain-containing protein 6B Q8N6M0 0.0369902 3.78617 
Charged multivesicular body protein 4b Q9H444 0.00717986 3.67451 
Poly [ADP-ribose] polymerase 4 Q9UKK3 0.00643273 3.63971 
Coiled-coil domain-containing protein 124 Q96CT7 0.0321343 3.5986 
Interferon regulatory factor 2-binding protein 2 Q7Z5L9 0.00948054 3.57987 
Nucleoporin NDC1 Q9BTX1 0.00928962 3.46364 
Myristoylated alanine-rich C-kinase substrate P29966 0.0155395 3.38272 
Cytoplasmic FMR1-interacting protein 1 Q7L576 0.0178261 3.34298 
Transmembrane protein 256 Q8N2U0 0.0297293 3.32762 
Calcium-binding mitochondrial carrier protein Aralar2 Q9UJS0 0.0074247 3.21909 
Ubiquitin-conjugating enzyme E2 variant 2 Q15819 0.0449567 3.21613 
SCY1-like protein 2 Q6P3W7 0.0476614 3.20529 
Prefoldin subunit 3 P61758 0.0136794 3.19644 
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Kynurenine--oxoglutarate transaminase 1 Q16773 0.0459935 3.15017 
Ras-related protein Rab-9A P51151 0.0152817 3.09504 
EF-hand domain-containing protein D2 Q96C19 0.00773858 3.09077 
Glucose-induced degradation protein 8 homolog Q9NWU2 0.0147596 3.08935 
Armadillo repeat-containing X-linked protein 3 Q9UH62 0.0248214 3.05398 
U3 small nucleolar RNA-associated protein 6 homolog Q9NYH9 0.0480777 3.05117 
Phosphoglucomutase-1 P36871 0.00327416 3.04322 
Histone-arginine methyltransferase CARM1 Q86X55 0.00771575 3.01949 
Protein PBDC1 Q9BVG4 0.0313902 3.01902 
WASH complex subunit 4 Q2M389 0.00301707 3.00423 
Epimerase family protein SDR39U1 Q9NRG7 0.0149061 3.00193 
60S acidic ribosomal protein P0 P05388 0.00118466 2.96438 
MOB kinase activator 3A Q96BX8 0.0055357 2.95393 
TBC1 domain family member 15 Q8TC07 0.00390331 2.92236 
Procollagen galactosyltransferase 1 Q8NBJ5 0.0162711 2.89423 
ATP-dependent RNA helicase DDX3X O00571 0.00446091 2.89379 
Ubiquitin-associated and SH3 domain-containing protein B Q8TF42 0.0153909 2.89024 
Ras-related protein Rab-8B Q92930 0.0291229 2.88669 
Galectin-3 P17931 0.0071113 2.88315 
Sorting nexin-29 Q8TEQ0 0.0121247 2.8655 
Ufm1-specific protease 2 Q9NUQ7 0.0455952 2.85102 
60S ribosomal protein L27a P46776 0.028205 2.84796 
ATP-dependent RNA helicase DDX3Y O15523 0.0427885 2.83835 
Rho GTPase-activating protein 24 Q8N264 0.0220466 2.82748 
Mini-chromosome maintenance complex-binding protein Q9BTE3 0.000800414 2.81536 
RNA-binding protein 3 P98179 0.0173307 2.80027 
Protein transport protein Sec24B O95487 0.00659407 2.79812 
Interferon regulatory factor 4 Q15306 0.0102352 2.79726 
RNA-binding protein NOB1 Q9ULX3 0.00977215 2.79383 
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Repressor of yield of DENV protein Q9NUL5 0.0243593 2.77843 
RNA-binding protein 5 P52756 0.0224248 2.76143 
Peflin Q9UBV8 0.00786793 2.75761 
Nuclear factor NF-kappa-B p105 subunit P19838 2.16E-06 2.74832 
Integrator complex subunit 6 Q9UL03 0.0165096 2.73863 
Proteasome activator complex subunit 3 P61289 0.00418539 2.72228 
Protein Dr1 Q01658 0.0170937 2.72228 
Protein preY, mitochondrial Q96I23 0.0198159 2.71727 
Phosphatidate cytidylyltransferase, mitochondrial Q96BW9 0.0308224 2.71477 
Telomere-associated protein RIF1 Q5UIP0 0.0365176 2.70188 
Neutrophil cytosol factor 2 P19878 0.00264348 2.6965 
UDP-glucose 4-epimerase Q14376 0.0463269 2.68658 
Regulator of G-protein signaling 10 O43665 0.000722122 2.68246 
Importin subunit alpha-1 P52292 0.00202849 2.67178 
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 0.014714 2.67055 
Target of Myb protein 1 O60784 0.034193 2.64931 
Ribosomal RNA-processing protein 7 homolog A Q9Y3A4 0.0173862 2.64566 
mRNA-capping enzyme O60942 0.0464419 2.62382 
Monoacylglycerol lipase ABHD12 Q8N2K0 0.0367521 2.60976 
Proto-oncogene c-Rel Q04864 0.0232571 2.59458 
RAS protein activator like-3 Q86YV0 0.0462434 2.59338 
Poly [ADP-ribose] polymerase 9 Q8IXQ6 0.00106029 2.5898 
28S ribosomal protein S16, mitochondrial Q9Y3D3 0.0217867 2.58107 
Eukaryotic translation initiation factor 4E P06730 0.0365969 2.57316 
COP9 signalosome complex subunit 5 Q92905 0.0183384 2.57079 
Elongator complex protein 2 Q6IA86 0.011456 2.56882 
Mitochondrial fission process protein 1 Q9UDX5 0.0443249 2.56724 
NADH-cytochrome b5 reductase 2 Q6BCY4 0.00146079 2.55741 
Unconventional myosin-Ic O00159 0.00791558 2.54957 
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NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial O43674 0.00827452 2.52038 
Serine/threonine-protein kinase 10 O94804 0.00365659 2.51497 
Cytohesin-1 Q15438 0.0382285 2.5142 
Interferon-induced GTP-binding protein Mx1 P20591 0.0161072 2.51382 
Ferritin heavy chain P02794 0.0211614 2.51073 
Tumor protein D54 O43399 0.0477613 2.50496 
2',5'-phosphodiesterase 12 Q6L8Q7 0.0190605 2.49766 
ADP-ribosylation factor-like protein 2 P36404 0.000712222 2.48618 
Nicotinamide phosphoribosyltransferase P43490 0.0101366 2.4858 
CD97 antigen P48960 0.00037752 2.48085 
Protein DJ-1 Q99497 0.0307982 2.47704 
Ankyrin repeat and MYND domain-containing protein 2 Q8IV38 0.0144246 2.47514 
T-cell surface glycoprotein CD5 P06127 0.00429851 2.4615 
Splicing factor U2AF 35 kDa subunit Q01081 0.0306915 2.45057 
Eukaryotic translation initiation factor 4 gamma 1 Q04637 0.00589011 2.44906 
THO complex subunit 3 Q96J01 0.0182285 2.44381 
Phospholysine phosphohistidine inorganic pyrophosphate phosphatase Q9H008 0.0159543 2.44118 
von Willebrand factor A domain-containing protein 8 A3KMH1 0.017688 2.43781 
Probable ATP-dependent RNA helicase DDX60 Q8IY21 0.0334052 2.43781 
Electron transfer flavoprotein subunit alpha, mitochondrial P13804 0.0100192 2.42959 
Alanine--tRNA ligase, cytoplasmic P49588 0.000279067 2.42066 
Biliverdin reductase A P53004 0.0474096 2.40991 
Importin subunit alpha-5 P52294 0.0352416 2.40215 
Gasdermin-D P57764 0.0390553 2.37648 
Pyridoxal kinase O00764 0.00362713 2.36774 
Asparagine--tRNA ligase, cytoplasmic O43776 0.00620722 2.36701 
39S ribosomal protein L16, mitochondrial Q9NX20 0.00170604 2.36084 
CD44 antigen P16070 0.0258337 2.35613 
Calcineurin subunit B type 1 P63098 0.0380566 2.34387 
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Tryptophan--tRNA ligase, cytoplasmic P23381 0.00214031 2.34315 
Nuclear factor NF-kappa-B p100 subunit Q00653 0.0191842 2.33382 
Solute carrier family 15 member 4 Q8N697 0.0281797 2.33238 
Ribosome biogenesis protein BOP1 Q14137 0.00069963 2.33203 
Fragile X mental retardation syndrome-related protein 1 P51114 0.0332517 2.32238 
Tricarboxylate transport protein, mitochondrial P53007 0.0213412 2.31846 
2'-5'-oligoadenylate synthase 1 P00973 0.0340321 2.31597 
DNA-directed RNA polymerase II subunit RPB7 P62487 0.0281001 2.3142 
40S ribosomal protein S25 P62851 0.0141602 2.31171 
Carnitine O-palmitoyltransferase 2, mitochondrial P23786 0.00182727 2.30958 
Acidic leucine-rich nuclear phosphoprotein 32 family member B Q92688 0.0178166 2.30569 
Tubulin-specific chaperone D Q9BTW9 9.65E-05 2.30427 
60S ribosomal protein L7a P62424 0.00624446 2.30215 
Fatty acid synthase P49327 0.00369533 2.30109 
Basic leucine zipper and W2 domain-containing protein 2 Q9Y6E2 0.0320287 2.29968 
Adaptin ear-binding coat-associated protein 2 Q9NVZ3 0.0262408 2.2751 
Lactation elevated protein 1 Q8WV93 0.0272305 2.27405 
Dedicator of cytokinesis protein 2 Q92608 0.00626283 2.26917 
Eukaryotic translation initiation factor 4B P23588 0.0371005 2.26882 
Anaphase-promoting complex subunit 7 Q9UJX3 0.0431568 2.26604 
ATP-dependent RNA helicase DDX39A O00148 0.0335678 2.26499 
Trifunctional purine biosynthetic protein adenosine-3 P22102 0.0165164 2.2643 
Proteasome activator complex subunit 1 Q06323 0.0142096 2.26325 
Protein FAM160B1 Q5W0V3 0.04093 2.26325 
26S proteasome non-ATPase regulatory subunit 8 P48556 0.0168302 2.26256 
Beta-2-microglobulin P61769 0.0477731 2.2577 
Wiskott-Aldrich syndrome protein family member 2 Q9Y6W5 0.00128296 2.25251 
Anamorsin Q6FI81 0.0133017 2.25182 
Bifunctional purine biosynthesis protein PURH P31939 0.000317104 2.2494 
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Eukaryotic peptide chain release factor GTP-binding subunit ERF3A P15170 0.00220808 2.2494 
Heat shock protein 105 kDa Q92598 0.00343374 2.24182 
Mitochondrial import inner membrane translocase subunit Tim23 O14925 0.0241978 2.24078 
FYVE, RhoGEF and PH domain-containing protein 2 Q7Z6J4 0.0280965 2.23872 
mRNA turnover protein 4 homolog Q9UKD2 0.00795814 2.23563 
Ran GTPase-activating protein 1 P46060 0.000646979 2.22468 
60S ribosomal protein L13a P40429 0.0312392 2.22468 
Heterogeneous nuclear ribonucleoprotein L-like Q8WVV9 0.0292327 2.22399 
2',3'-cyclic-nucleotide 3'-phosphodiesterase P09543 0.0028444 2.22058 
Septin-7 Q16181 0.00261056 2.21752 
ATP-dependent RNA helicase SUPV3L1, mitochondrial Q8IYB8 0.0113837 2.20326 
HLA class II histocompatibility antigen, DP alpha 1 chain P20036 0.0272825 2.20056 
Glucose-6-phosphate 1-dehydrogenase P11413 0.0033012 2.19853 
Tyrosine-protein kinase Lyn P07948 0.00349719 2.19786 
Sequestosome-1 Q13501 0.0123562 2.19516 
Polypeptide N-acetylgalactosaminyltransferase 2 Q10471 0.0360772 2.19213 
Elongation factor 1-alpha 1 P68104 0.0314047 2.18911 
Cytochrome b5 type B O43169 0.0109012 2.18776 
Adenosine deaminase P00813 0.0452616 2.18608 
14-3-3 protein epsilon P62258 0.0132332 2.16504 
Nuclear pore complex protein Nup50 Q9UKX7 0.0138637 2.16504 
B-cell receptor-associated protein 31 P51572 0.0222612 2.16405 
Major vault protein Q14764 0.00215666 2.1594 
Astrocytic phosphoprotein PEA-15 Q15121 0.00144226 2.15443 
Multifunctional protein ADE2 P22234 0.0138977 2.15146 
Chloride intracellular channel protein 4 Q9Y696 0.00887074 2.1475 
NADH dehydrogenase [ubiquinone] 1 subunit C2 O95298 0.00570676 2.14684 
Peptidyl-prolyl cis-trans isomerase FKBP5 Q13451 0.0151974 2.14223 
Rho GTPase-activating protein 4 P98171 0.0217678 2.13862 
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Exocyst complex component 5 O00471 0.0102886 2.13567 
Calcium-binding mitochondrial carrier protein Aralar1 O75746 0.000786399 2.1337 
Elongation factor 1-gamma P26641 0.000134342 2.13075 
RNA demethylase ALKBH5 Q6P6C2 0.0497164 2.12292 
Probable tRNA N6-adenosine threonylcarbamoyltransferase Q9NPF4 0.00939343 2.11836 
Tubulin beta chain P07437 0.0236466 2.10766 
Peptidyl-prolyl cis-trans isomerase CWC27 homolog Q6UX04 0.0149023 2.10539 
Glutaredoxin-3 O76003 0.0158272 2.10249 
Methionine--tRNA ligase, cytoplasmic P56192 0.00822424 2.09894 
Dehydrogenase/reductase SDR family member 4 Q9BTZ2 0.016434 2.09443 
Low affinity immunoglobulin gamma Fc region receptor II-b P31994 0.0212317 2.09443 
[Protein ADP-ribosylarginine] hydrolase P54922 0.0158958 2.09283 
Mitochondrial import inner membrane translocase subunit TIM50 Q3ZCQ8 0.00221948 2.0909 
Maleylacetoacetate isomerase O43708 0.0446711 2.09058 
Thymidine phosphorylase P19971 0.00198262 2.08673 
Myelin expression factor 2 Q9P2K5 0.00295331 2.08577 
Nardilysin O43847 0.0394559 2.08577 
Beta-adrenergic receptor kinase 1 P25098 0.0153114 2.08065 
Aspartate aminotransferase, cytoplasmic P17174 0.00983462 2.08002 
Heterogeneous nuclear ribonucleoprotein A0 Q13151 0.00343533 2.07714 
Transcription factor BTF3 homolog 4 Q96K17 0.014218 2.07173 
Core-binding factor subunit beta Q13951 0.0174339 2.07109 
Lysine-specific demethylase 6A O15550 0.0327617 2.07078 
40S ribosomal protein S19 P39019 0.0259886 2.0676 
Telomerase Cajal body protein 1 Q9BUR4 0.0496106 2.06601 
Chromatin complexes subunit BAP18 Q8IXM2 0.0147403 2.06475 
Peptidyl-prolyl cis-trans isomerase D Q08752 0.0166786 2.05715 
5'-AMP-activated protein kinase catalytic subunit alpha-1 Q13131 0.0287486 2.05715 
Vacuolar protein sorting-associated protein 18 homolog Q9P253 0.0125296 2.05368 
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Tyrosine-protein kinase JAK1 P23458 0.0451761 2.04676 
Platelet-activating factor acetylhydrolase IB subunit beta P68402 0.00920454 2.03986 
Proteasomal ubiquitin receptor ADRM1 Q16186 0.0412679 2.03955 
Hepatoma-derived growth factor-related protein 2 Q7Z4V5 0.0251773 2.03767 
Suppressor of SWI4 1 homolog Q9NQ55 0.0355644 2.03236 
DNA-directed RNA polymerase III subunit RPC1 O14802 0.0280364 2.02862 
39S ribosomal protein L19, mitochondrial P49406 0.0323636 2.02147 
Nuclear pore complex protein Nup133 Q8WUM0 0.00236503 2.02054 
FACT complex subunit SSRP1 Q08945 0.00893353 2.01837 
F-box only protein 7 Q9Y3I1 0.00723759 2.00909 
Pre-mRNA-processing factor 17 O60508 0.0098051 2.00909 
E3 SUMO-protein ligase RanBP2 P49792 0.00746106 1.99741 
Alpha-ketoglutarate-dependent dioxygenase FTO Q9C0B1 0.00206533 1.99557 
Activating signal cointegrator 1 complex subunit 3 Q8N3C0 0.0113618 1.9922 
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 O43598 0.0224039 1.99128 
Lysophospholipase-like protein 1 Q5VWZ2 0.00424669 1.99006 
Conserved oligomeric Golgi complex subunit 8 Q96MW5 0.00898122 1.98945 
Protein MEMO1 Q9Y316 0.0195282 1.98854 
Thymidylate kinase P23919 0.0175527 1.98001 
Adenine phosphoribosyltransferase P07741 0.0105071 1.97818 
Heterogeneous nuclear ribonucleoprotein A3 P51991 0.0341586 1.97515 
Tubulin beta-1 chain Q9H4B7 0.0276088 1.9697 
Cell division cycle protein 123 homolog O75794 0.00180055 1.96698 
Galectin-1 P09382 0.0462744 1.96607 
Polyadenylate-binding protein 1 P11940 0.00172285 1.96065 
Proteasome assembly chaperone 1 O95456 0.00314153 1.96065 
BRISC complex subunit Abro1 Q15018 0.0120702 1.96005 
Peptidyl-prolyl cis-trans isomerase FKBP4 Q02790 0.00505917 1.95854 
E3 SUMO-protein ligase ZNF451 Q9Y4E5 0.0194907 1.95434 
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Coiled-coil domain-containing protein 50 Q8IVM0 0.0197118 1.95374 
Metastasis suppressor protein 1 O43312 0.0205979 1.95044 
Sorting nexin-11 Q9Y5W9 0.00795026 1.94865 
L-lactate dehydrogenase B chain P07195 0.00855459 1.94835 
Serpin B6 P35237 0.0336292 1.94655 
THO complex subunit 4 Q86V81 0.0148275 1.94059 
Threonine--tRNA ligase, cytoplasmic P26639 0.0240553 1.93761 
Integrator complex subunit 2 Q9H0H0 0.000811417 1.93672 
Ubiquitin-like modifier-activating enzyme 1 P22314 0.00685712 1.93523 
Pleckstrin P08567 0.0341085 1.93434 
Putative RNA-binding protein 15B Q8NDT2 0.0019431 1.93315 
Mitofusin-1 Q8IWA4 0.0324807 1.93138 
Rab GDP dissociation inhibitor alpha P31150 0.0108754 1.92989 
39S ribosomal protein L45, mitochondrial Q9BRJ2 0.0300575 1.92634 
Beta-centractin P42025 0.0168534 1.92398 
ATPase family AAA domain-containing protein 3B Q5T9A4 0.0456528 1.92339 
Rab GDP dissociation inhibitor beta P50395 0.0006762 1.92309 
Heat shock protein HSP 90-beta P08238 0.0070492 1.91543 
Protein kinase C beta type P05771 0.0368698 1.91396 
Eukaryotic translation initiation factor 3 subunit H O15372 0.000777776 1.91191 
Transcription factor BTF3 P20290 0.0104558 1.91103 
Schlafen family member 5 Q08AF3 0.00717867 1.91073 
Ubiquitin-like modifier-activating enzyme 5 Q9GZZ9 0.0427907 1.91015 
Cleft lip and palate transmembrane protein 1-like protein Q96KA5 0.047828 1.91015 
Tyrosine-protein phosphatase non-receptor type 23 Q9H3S7 0.0415599 1.90956 
Proteasome subunit beta type-3 P49720 0.00494703 1.90927 
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 Q92620 0.0152423 1.90108 
Alpha-mannosidase 2C1 Q9NTJ4 0.02874 1.89904 
Protein MAK16 homolog Q9BXY0 0.0132827 1.89496 
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Integrin-linked protein kinase Q13418 0.000957061 1.89467 
Protein phosphatase 1B O75688 0.0252751 1.8906 
Phosphoglucomutase-2 Q96G03 0.0125834 1.88886 
Ras-related protein Rab-21 Q9UL25 0.0478096 1.88365 
CDGSH iron-sulfur domain-containing protein 2 Q8N5K1 0.0176341 1.88105 
Rab3 GTPase-activating protein non-catalytic subunit Q9H2M9 0.0367308 1.87932 
SNW domain-containing protein 1 Q13573 0.025919 1.87874 
Profilin-1 P07737 0.0122101 1.87528 
Acylamino-acid-releasing enzyme P13798 0.0199854 1.87241 
RNA-binding protein 39 Q14498 0.045919 1.8704 
E3 ubiquitin-protein ligase Itchy homolog Q96J02 0.0292376 1.86839 
Coatomer subunit epsilon O14579 0.00770775 1.8681 
SUMO-activating enzyme subunit 1 Q9UBE0 0.00544303 1.86781 
Proteasome-associated protein ECM29 homolog Q5VYK3 0.00985895 1.86638 
Formin-binding protein 1 Q96RU3 0.00503173 1.86123 
Protein TASOR Q9UK61 0.0227575 1.85866 
N-acetyl-D-glucosamine kinase Q9UJ70 0.0468806 1.85467 
N-alpha-acetyltransferase 15, NatA auxiliary subunit Q9BXJ9 0.0180138 1.85353 
Formin-like protein 1 O95466 0.0109605 1.84927 
60S ribosomal protein L7 P18124 0.0184711 1.84927 
Eukaryotic translation initiation factor 3 subunit D O15371 0.0234629 1.84927 
Serine/threonine-protein phosphatase 6 catalytic subunit O00743 0.0245194 1.84842 
Elongation factor Tu, mitochondrial P49411 0.0163921 1.84728 
Sorting nexin-8 Q9Y5X2 0.0119933 1.84473 
TBC1 domain family member 1 Q86TI0 0.0328476 1.8436 
Heterogeneous nuclear ribonucleoprotein A1 P09651 0.0318222 1.83964 
Vacuolar protein sorting-associated protein 29 Q9UBQ0 0.0283354 1.83597 
Elongator complex protein 1 O95163 0.0126985 1.82642 
Hydroxymethylglutaryl-CoA lyase, mitochondrial P35914 0.0212215 1.82642 
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Ras-related protein Rab-43 Q86YS6 0.00915302 1.81858 
Ras-related protein Rab-7a P51149 0.0125488 1.81496 
Cysteine--tRNA ligase, cytoplasmic P49589 0.0424746 1.81273 
DnaJ homolog subfamily A member 1 P31689 0.000795578 1.81162 
Echinoderm microtubule-associated protein-like 4 Q9HC35 0.0343062 1.81106 
Tripeptidyl-peptidase 1 O14773 0.0203784 1.81051 
Density-regulated protein O43583 0.0432634 1.80662 
E3 ubiquitin-protein ligase UHRF2 Q96PU4 0.0376525 1.80302 
Signal transducer and activator of transcription 6 P42226 0.0431805 1.80274 
Ras suppressor protein 1 Q15404 0.0123313 1.80246 
Eukaryotic translation initiation factor 2 subunit 2 P20042 0.00310808 1.80136 
Eukaryotic translation initiation factor 3 subunit E P60228 0.00324461 1.79694 
Glutaminase kidney isoform, mitochondrial O94925 0.0115175 1.79418 
Macrophage-capping protein P40121 0.0362662 1.79006 
Glycine--tRNA ligase P41250 0.0387423 1.78402 
Charged multivesicular body protein 7 Q8WUX9 0.000547605 1.78101 
TAR DNA-binding protein 43 Q13148 0.0322718 1.78101 
Glia maturation factor gamma O60234 0.0186017 1.77855 
Vacuolar protein sorting-associated protein 4A Q9UN37 0.0370589 1.77746 
Microtubule-associated protein RP/EB family member 1 Q15691 0.0263022 1.77637 
BAG family molecular chaperone regulator 5 Q9UL15 0.0159067 1.77364 
Heterogeneous nuclear ribonucleoprotein Q O60506 0.0112182 1.77256 
Elongin-A Q14241 0.0421967 1.77201 
Ena/VASP-like protein Q9UI08 0.00879917 1.77147 
Protein-glutamate O-methyltransferase Q9H993 0.0282543 1.77147 
Mitogen-activated protein kinase kinase kinase kinase 1 Q92918 0.0359439 1.76577 
WASH complex subunit 2A Q641Q2 0.0434773 1.7636 
Basic leucine zipper and W2 domain-containing protein 1 Q7L1Q6 0.0222605 1.76035 
Protein MIS12 homolog Q9H081 0.045057 1.76008 
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Hypoxanthine-guanine phosphoribosyltransferase P00492 0.0441949 1.75954 
Atlastin-3 Q6DD88 0.0370933 1.75873 
eIF-2-alpha kinase activator GCN1 Q92616 0.00140335 1.75846 
Epidermal growth factor receptor substrate 15 P42566 0.0201482 1.75388 
Sorting nexin-9 Q9Y5X1 0.0390693 1.75119 
Trifunctional enzyme subunit alpha, mitochondrial P40939 0.0048547 1.73807 
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Q9HCC0 0.00110568 1.7354 
Proteasome activator complex subunit 2 Q9UL46 0.0289715 1.72849 
Thioredoxin domain-containing protein 17 Q9BRA2 0.0499216 1.7269 
HEAT repeat-containing protein 5B Q9P2D3 0.0274267 1.72372 
Sorting nexin-5 Q9Y5X3 0.0356887 1.72134 
Nucleosome assembly protein 1-like 4 Q99733 0.0465261 1.72081 
CTP synthase 2 Q9NRF8 0.0439451 1.71817 
Dipeptidyl peptidase 3 Q9NY33 0.00752285 1.71238 
Dedicator of cytokinesis protein 11 Q5JSL3 0.0353968 1.7087 
Actin-related protein 2/3 complex subunit 5-like protein Q9BPX5 0.0329746 1.70818 
Non-structural maintenance of chromosomes element 3 homolog Q96MG7 0.0192634 1.70634 
Protein FAM49B Q9NUQ9 0.0268192 1.70608 
Cohesin subunit SA-1 Q8WVM7 0.0124597 1.70504 
Heterogeneous nuclear ribonucleoprotein F P52597 0.0358193 1.70347 
Bromodomain adjacent to zinc finger domain protein 1A Q9NRL2 0.0338605 1.70059 
Selenide, water dikinase 1 P49903 0.0291028 1.70007 
Serine--tRNA ligase, cytoplasmic P49591 0.0148983 1.69877 
Serpin B9 P50453 0.00267377 1.6972 
Lymphocyte antigen 75 O60449 0.00667511 1.69668 
Proteasome subunit beta type-2 P49721 0.0082958 1.69564 
Carbonyl reductase [NADPH] 1 P16152 0.015069 1.69122 
Triokinase/FMN cyclase Q3LXA3 0.0254454 1.68888 
COP9 signalosome complex subunit 1 Q13098 0.0492772 1.68863 
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Puromycin-sensitive aminopeptidase P55786 0.0166645 1.68526 
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 Q9Y6D5 0.0215852 1.685 
Phosducin-like protein 3 Q9H2J4 0.0305924 1.685 
Palmitoyl-protein thioesterase 1 P50897 0.0175423 1.67984 
Vesicle-associated membrane protein 7 P51809 0.00667651 1.6788 
Leupaxin O60711 0.0230223 1.67597 
Alpha-enolase P06733 0.0166598 1.6752 
5'-nucleotidase domain-containing protein 3 Q86UY8 0.0336886 1.67186 
L-lactate dehydrogenase A chain P00338 0.0333437 1.6693 
BSD domain-containing protein 1 Q9NW68 0.0285431 1.66392 
Inositol monophosphatase 1 P29218 0.0124463 1.66341 
MIF4G domain-containing protein A9UHW6 0.0165722 1.66316 
Protein diaphanous homolog 1 O60610 0.00653377 1.66188 
Apoptosis inhibitor 5 Q9BZZ5 0.0339207 1.65755 
Gamma-enolase P09104 0.0138555 1.65679 
26S protease regulatory subunit 6A P17980 0.0041091 1.65628 
U4/U6 small nuclear ribonucleoprotein Prp4 O43172 0.00340333 1.65501 
Vesicle-trafficking protein SEC22b O75396 0.0485943 1.65196 
6-phosphogluconolactonase O95336 0.0488833 1.64715 
Isocitrate dehydrogenase [NADP] cytoplasmic O75874 0.0402149 1.64462 
Pyruvate kinase PKM P14618 0.0135798 1.64286 
Enoyl-CoA delta isomerase 2, mitochondrial O75521 0.0169667 1.64059 
Nucleosome assembly protein 1-like 1 P55209 0.00911904 1.63858 
Staphylococcal nuclease domain-containing protein 1 Q7KZF4 0.0171574 1.63807 
Programmed cell death protein 4 Q53EL6 0.00213305 1.63631 
Aminopeptidase B Q9H4A4 0.0245548 1.63531 
GEM-interacting protein Q9P107 0.0389433 1.63506 
Ral GTPase-activating protein subunit beta Q86X10 0.0358136 1.63406 
8-oxo-dGDP phosphatase NUDT18 Q6ZVK8 0.0207259 1.6318 
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Serine/threonine-protein kinase 4 Q13043 0.0356113 1.63155 
Septin-1 Q8WYJ6 0.0479714 1.6308 
Inorganic pyrophosphatase Q15181 0.00983852 1.63055 
Heat shock protein HSP 90-alpha P07900 0.0213684 1.63055 
Transcription elongation factor SPT5 O00267 0.00711501 1.62805 
Hsc70-interacting protein P50502 0.0155641 1.6243 
Phosphofurin acidic cluster sorting protein 1 Q6VY07 0.0310635 1.62306 
Intron-binding protein aquarius O60306 0.0277945 1.62281 
RAC-alpha serine/threonine-protein kinase P31749 0.0344816 1.62231 
Transgelin-2 P37802 0.00258991 1.62131 
Amino-terminal enhancer of split Q08117 0.0458774 1.61907 
Eukaryotic translation initiation factor 5B O60841 0.0276076 1.61659 
Ubiquitin-conjugating enzyme E2 variant 1 Q13404 0.0403794 1.61535 
Heat shock 70 kDa protein 4 P34932 0.0342404 1.60966 
40S ribosomal protein SA P08865 0.0125821 1.60892 
Dual specificity mitogen-activated protein kinase kinase 4 P45985 0.0381785 1.60645 
Translin Q15631 0.0228205 1.60472 
Leucine--tRNA ligase, cytoplasmic Q9P2J5 0.0463193 1.59612 
Trafficking protein particle complex subunit 4 Q9Y296 0.00643442 1.5949 
U3 small nucleolar RNA-associated protein 18 homolog Q9Y5J1 0.0196483 1.59465 
Polyadenylate-binding protein 2 Q86U42 0.0345797 1.59417 
Helicase SKI2W Q15477 0.012688 1.59294 
Valine--tRNA ligase P26640 0.0119959 1.58757 
Purine nucleoside phosphorylase P00491 0.017869 1.58125 
Alpha-actinin-4 O43707 0.00179521 1.57834 
N-alpha-acetyltransferase 50 Q9GZZ1 0.0298238 1.57398 
Enhancer of mRNA-decapping protein 4 Q6P2E9 0.010955 1.56723 
Receptor of activated protein C kinase 1 P63244 0.0102207 1.56699 
Eukaryotic translation initiation factor 5 P55010 0.0341293 1.56579 
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26S proteasome non-ATPase regulatory subunit 5 Q16401 0.024703 1.56387 
Aspartate--tRNA ligase, cytoplasmic P14868 0.0368339 1.56123 
26S protease regulatory subunit 8 P62195 0.0352535 1.55501 
Rho GTPase-activating protein 17 Q68EM7 0.00433029 1.55406 
U6 snRNA-associated Sm-like protein LSm1 O15116 0.0203529 1.55024 
Probable ATP-dependent RNA helicase DDX6 P26196 0.0167281 1.55001 
S-adenosylmethionine synthase isoform type-2 P31153 0.0278382 1.53721 
Cytochrome c oxidase assembly protein COX15 homolog Q7KZN9 0.0475679 1.53532 
GMP synthase [glutamine-hydrolyzing] P49915 0.0179324 1.53203 
Non-POU domain-containing octamer-binding protein Q15233 0.028354 1.52031 
Protein ABHD16A O95870 0.0401581 1.52031 
Protein NipSnap homolog 2 O75323 0.0355826 1.51891 
Transitional endoplasmic reticulum ATPase P55072 0.0064814 1.50962 
Gamma-parvin Q9HBI0 0.0365916 1.50823 
Serine/threonine-protein kinase Nek9 Q8TD19 0.0446036 1.508 
Poly(A) polymerase alpha P51003 0.0215819 1.50776 
14-3-3 protein gamma P61981 0.0371538 1.50753 
Signal transducer and activator of transcription 1-alpha/beta P42224 0.0338373 1.50638 
Forkhead box protein P1 Q9H334 0.0149217 1.49142 
WW domain-binding protein 11 Q9Y2W2 0.0195123 1.48982 
Angio-associated migratory cell protein Q13685 0.0299831 1.48343 
Rho guanine nucleotide exchange factor 6 Q15052 0.0464864 1.48161 
Signal transducer and activator of transcription 3 P40763 0.0410562 1.46667 
Glycogen phosphorylase, brain form P11216 0.0346353 1.45479 
Tyrosine--tRNA ligase, cytoplasmic P54577 0.0485097 1.45457 
Mediator of RNA polymerase II transcription subunit 19 A0JLT2 0.0444333 1.45367 
Tyrosine-protein phosphatase non-receptor type 6 P29350 0.0457777 1.44566 
Ribonucleoprotein PTB-binding 1 Q8IY67 0.0311609 1.44455 
Probable ATP-dependent RNA helicase DDX46 Q7L014 0.0333495 1.43263 
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Syntaxin-7 O15400 0.0226319 1.42867 
Nuclear pore complex protein Nup155 O75694 0.0431222 1.41297 
Nuclear migration protein nudC Q9Y266 0.024221 1.4108 
T-complex protein 1 subunit zeta P40227 0.0457964 1.38123 
RNA 3'-terminal phosphate cyclase O00442 0.00804896 1.38102 
Tropomodulin-3 Q9NYL9 0.0207673 1.37446 
Regulator of nonsense transcripts 1 Q92900 0.0183592 1.37046 
28S ribosomal protein S31, mitochondrial Q92665 0.0498167 1.3692 
Protein transport protein Sec31A O94979 0.0246082 1.35477 
Cell division cycle protein 16 homolog Q13042 0.0319791 1.3471 
Importin subunit beta-1 Q14974 0.0123401 1.34359 
Alcohol dehydrogenase [NADP(+)] P14550 0.0467433 1.30898 
T-complex protein 1 subunit beta P78371 0.0395673 1.29837 
Signal recognition particle subunit SRP72 O76094 0.0366254 1.23804 
60S ribosomal protein L12 P30050 0.0451538 1.22838 
ATP synthase subunit beta, mitochondrial P06576 0.00819788 -1.02266 
NIF3-like protein 1 Q9GZT8 0.0238727 -1.32069 
Transcription factor ETV6 P41212 0.0363868 -1.37067 
NFATC2-interacting protein Q8NCF5 0.00820104 -1.38038 
U3 small nucleolar ribonucleoprotein protein MPP10 O00566 0.019745 -1.38463 
Protein PAT1 homolog 1 Q86TB9 0.0176136 -1.45904 
Early endosome antigen 1 Q15075 0.0416146 -1.45971 
Histidine triad nucleotide-binding protein 2, mitochondrial Q9BX68 0.0174388 -1.46442 
Nuclear autoantigenic sperm protein P49321 0.0409821 -1.46893 
E3 ubiquitin-protein ligase BRE1A Q5VTR2 0.0345769 -1.48206 
Treacle protein Q13428 0.0200764 -1.49211 
Microtubule-associated proteins 1A/1B light chain 3B Q9GZQ8 0.0259131 -1.49257 
Putative RNA-binding protein Luc7-like 2 Q9Y383 0.0251501 -1.49394 
Chromodomain-helicase-DNA-binding protein 2 O14647 0.0181627 -1.49738 
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General transcription factor 3C polypeptide 4 Q9UKN8 0.0181051 -1.51985 
DNA-directed DNA/RNA polymerase mu Q9NP87 0.0313207 -1.54739 
Putative ATP-dependent RNA helicase DHX57 Q6P158 0.0346027 -1.55907 
Endoplasmic reticulum-Golgi intermediate compartment protein 1 Q969X5 0.0345031 -1.57471 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 Q16718 0.0200973 -1.5998 
Protein RUBCNL-like Q9H714 0.0427755 -1.61585 
Thioredoxin domain-containing protein 5 Q8NBS9 0.0280112 -1.62306 
TRAF family member-associated NF-kappa-B activator Q92844 0.0497264 -1.62955 
NFU1 iron-sulfur cluster scaffold homolog, mitochondrial Q9UMS0 0.0128814 -1.64462 
Ras-related protein R-Ras2 P62070 0.0265708 -1.64665 
MICOS complex subunit MIC27 Q6UXV4 0.0213123 -1.67186 
PHD finger protein 10 Q8WUB8 0.047776 -1.67803 
Mitochondrial import inner membrane translocase subunit Tim29 Q9BSF4 0.023455 -1.68061 
Non-receptor tyrosine-protein kinase TYK2 P29597 0.0253325 -1.68138 
Sec1 family domain-containing protein 2 Q8WU76 0.0143412 -1.70033 
Proline-, glutamic acid- and leucine-rich protein 1 Q8IZL8 0.0412083 -1.70085 
Hemoglobin subunit beta P68871 0.0155362 -1.70713 
Stromal interaction molecule 1 Q13586 0.0295351 -1.71501 
MICOS complex subunit MIC60 Q16891 0.006552 -1.72743 
Microsomal glutathione S-transferase 2 Q99735 0.028978 -1.73061 
HAUS augmin-like complex subunit 5 O94927 0.0414767 -1.7346 
KH domain-containing, RNA-binding, signal transduction-associated protein 1 Q07666 0.0322671 -1.77883 
Striatin-3 Q13033 0.0136901 -1.78457 
Mitochondrial import inner membrane translocase subunit Tim10 P62072 0.047086 -1.79171 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 P61803 0.0276378 -1.81914 
General transcription factor IIE subunit 1 P29083 0.00365695 -1.84049 
Diphosphoinositol polyphosphate phosphohydrolase 1 O95989 0.0263519 -1.8578 
RNA-binding protein 33 Q96EV2 0.00835339 -1.87384 
Factor VIII intron 22 protein P23610 0.0372488 -1.87384 
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Epididymis-specific alpha-mannosidase Q9Y2E5 0.0481366 -1.8851 
Histone-lysine N-methyltransferase EHMT1 Q9H9B1 0.0304833 -1.89205 
Putative uncharacterized protein LOC100996504 I3L1I5 0.0305771 -1.90049 
RNA binding motif protein, X-linked-like-1 Q96E39 0.0107249 -1.90341 
GrpE protein homolog 1, mitochondrial Q9HAV7 0.00968424 -1.91837 
Translation factor GUF1, mitochondrial Q8N442 0.00196922 -1.92103 
F-actin-uncapping protein LRRC16A Q5VZK9 0.0245803 -1.92309 
Ras-related protein Rab-22A Q9UL26 0.0221436 -1.96065 
HMG box transcription factor BBX Q8WY36 0.0197771 -1.96185 
Ribosomal protein S6 kinase beta-1 P23443 0.0490742 -1.97545 
PAX-interacting protein 1 Q6ZW49 0.0466401 -1.97727 
Beta-soluble NSF attachment protein Q9H115 0.0474986 -1.99434 
Zinc finger protein 592 Q92610 0.0265116 -1.99465 
Aminoacylase-1 Q03154 0.0167017 -1.99587 
Probable leucine--tRNA ligase, mitochondrial Q15031 0.0378347 -2.00386 
Mitotic checkpoint protein BUB3 O43684 0.0272537 -2.02488 
H/ACA ribonucleoprotein complex subunit 4 O60832 0.0377822 -2.05305 
Coiled-coil domain-containing protein 47 Q96A33 0.040189 -2.05589 
Cytochrome c oxidase subunit 5A, mitochondrial P20674 0.0441697 -2.06633 
BLOC-1-related complex subunit 7 Q96B45 0.0371582 -2.07874 
RNA-binding protein Raly Q9UKM9 0.00770624 -2.1096 
DIS3-like exonuclease 2 Q8IYB7 0.044843 -2.1252 
Syntaxin-8 Q9UNK0 0.0495931 -2.13468 
Zinc fingers and homeoboxes protein 2 Q9Y6X8 0.0148283 -2.14289 
Stromal cell-derived factor 2-like protein 1 Q9HCN8 0.0157369 -2.14454 
Polycomb protein SUZ12 Q15022 0.028815 -2.15642 
Selenoprotein T P62341 0.00630183 -2.1757 
Serine/threonine-protein phosphatase PP1-gamma catalytic subunit P36873 0.0263746 -2.19483 
PC4 and SFRS1-interacting protein O75475 0.0402789 -2.20902 
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Hydroxyacyl-thioester dehydratase type 2, mitochondrial P86397 0.0406166 -2.25286 
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Q13627 0.00240256 -2.2737 
Cyclin-L1 Q9UK58 0.0108579 -2.30074 
Ribosome biogenesis regulatory protein homolog Q15050 0.0498251 -2.30144 
Negative elongation factor A Q9H3P2 0.00129793 -2.30781 
28S ribosomal protein S18b, mitochondrial Q9Y676 0.0451601 -2.31882 
Glutaredoxin-related protein 5, mitochondrial Q86SX6 0.00292082 -2.32024 
Ankyrin repeat domain-containing protein 12 Q6UB98 0.0201826 -2.38086 
Ribonuclease K6 Q93091 0.0319991 -2.38525 
E3 ubiquitin-protein ligase CBL-B Q13191 0.00594154 -2.40917 
Sideroflexin-3 Q9BWM7 0.0302124 -2.41324 
Protein PRRC1 Q96M27 0.0219153 -2.43968 
Biogenesis of lysosome-related organelles complex 1 subunit 4 Q9NUP1 0.0119026 -2.45622 
Thrombospondin-1 P07996 0.0231613 -2.48161 
HAUS augmin-like complex subunit 8 Q9BT25 0.00824208 -2.49153 
Coiled-coil domain-containing protein 6 Q16204 0.0406977 -2.51884 
Pyridoxine-5'-phosphate oxidase Q9NVS9 0.0165005 -2.53357 
Periodic tryptophan protein 1 homolog Q13610 0.0248347 -2.65746 
Fc receptor-like protein 3 Q96P31 0.0238681 -2.71769 
Hermansky-Pudlak syndrome 3 protein Q969F9 0.00999746 -2.72187 
Guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase MESH1 Q8N4P3 0.0255024 -2.77332 
60S ribosomal protein L21 P46778 0.00397915 -2.81882 
Sphingosine-1-phosphate phosphatase 1 Q9BX95 0.031117 -2.82705 
Histone H1.5 P16401 0.0180346 -2.82835 
Sphingomyelin phosphodiesterase 2 O60906 0.013748 -2.84228 
Hemoglobin subunit alpha P69905 0.00139377 -2.94171 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 Q9UI09 0.0183695 -3.03762 
PHD and RING finger domain-containing protein 1 Q9P1Y6 0.0051797 -3.05633 
Dihydroorotate dehydrogenase (quinone), mitochondrial Q02127 0.0346953 -3.09409 
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Serum albumin P02768 0.0196412 -3.37961 
Coagulation factor V P12259 0.00551603 -3.77514 
Serine/threonine-protein kinase 38-like Q9Y2H1 0.0109114 -4.10204 
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Appendix 10. The DAVID functional annotation categories (with FDR<0.5) of the 2046 statistically significantly up-regulated genes induced 





     





84 4.24 YWHAE, OXTR, TES, HSP90AB1, YWHAB, OLA1, PARK7, ENO1, BZW2, PVR, BAIAP2L1, ATIC, CAPZB, 
RUVBL1, BSG, EFHD2, FLOT1, FLOT2, TNKS1BP1, TMPO, EIF2A, CAST, LYPLA2, NUDC, DBNL, ANXA2, 
SWAP70, TMOD3, RANGAP1, SND1, PLCB3, PKM, CTTN, FSCN1, MYH9, CHMP4B, PLIN3, TAGLN2, 
MAPRE1, RPL29, PFN1, MACF1, SRC, CAPG, ASAP1, UBFD1, CNN3, LDHA, KLC2, LARP1, PUF60, 
COBLL1, PRDX1, FLNA, FLNB, SNX9, RPS2, TIGIT, PDLIM5, EPS15, PAK4, VASP, PTPN1, HSPA8, HSPA5, 
STAT1, RPL23A, CGN, PAICS, RAB10, EHD1, RSL1D1, EIF2S3, HNRNPK, EHD4, GIPC1, FASN, CAPZA1, 






76 3.83 YWHAE, TES, HSP90AB1, YWHAB, OLA1, PARK7, ENO1, BZW2, BAIAP2L1, ATIC, CAPZB, RUVBL1, BSG, 
EFHD2, TNKS1BP1, TMPO, EIF2A, CAST, LYPLA2, NUDC, DBNL, ANXA2, SWAP70, TMOD3, RANGAP1, 
SND1, PLCB3, PKM, CTTN, FSCN1, ELMO2, CHMP4B, PLIN3, TAGLN2, MAPRE1, RPL29, PFN1, MACF1, 
CAPG, ASAP1, UBFD1, CNN3, LDHA, KLC2, LARP1, PUF60, COBLL1, PRDX1, FLNB, SNX9, RPS2, PDLIM5, 
EPS15, PAK4, VASP, PTPN1, HSPA8, HSPA5, STAT1, RPL23A, CGN, PAICS, RAB10, EHD1, RSL1D1, 





binding involved in cell-
cell adhesion 
78 3.94 YWHAE, TES, HSP90AB1, YWHAB, OLA1, PARK7, ENO1, BZW2, BAIAP2L1, ATIC, CAPZB, RUVBL1, BSG, 
EFHD2, TNKS1BP1, TMPO, EIF2A, CAST, LYPLA2, NUDC, DBNL, ANXA2, SWAP70, TMOD3, RANGAP1, 
SND1, PLCB3, PKM, CTTN, FSCN1, MYH9, CHMP4B, PLIN3, TAGLN2, MAPRE1, RPL29, PFN1, MACF1, 
SRC, CAPG, ASAP1, UBFD1, CNN3, LDHA, KLC2, LARP1, PUF60, COBLL1, PRDX1, FLNA, FLNB, SNX9, 
RPS2, PDLIM5, EPS15, PAK4, VASP, PTPN1, HSPA8, HSPA5, STAT1, RPL23A, CGN, PAICS, RAB10, EHD1, 
RSL1D1, EIF2S3, HNRNPK, EHD4, GIPC1, FASN, CAPZA1, SERBP1, UBAP2, RAN, EIF4G1, TJP2 
0.00 0.00 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Mitochondrion 178 8.98 TDRKH, MTCH2, CLPB, PARK7, YARS2, CISD3, TOMM22, LACTB, CHCHD3, MPC1, CHCHD6, FPGS, 
NARS2, SLC25A43, EARS2, MCCC2, ACSL1, TOMM34, ACSL4, LIG3, ATAD3A, PISD, LARS2, MTHFD2, 
PPIF, ACOT2, TFAM, VDAC1, TP53, GCDH, SHMT2, MRPL19, COX17, MRPL16, AK2, HTRA2, MRPL17, 
ARL2, MRPL14, PHB, MRPL12, HIGD1A, MRPL11, PRDX3, NLN, ATP5B, MAATS1, SNN, THEM5, THEM4, 
CYC1, MCL1, PCK2, COA4, HSPA9, COA3, PRELID1, PNPT1, APOOL, GOT2, MRPL27, MRPL28, PYCR1, 
ERAL1, KIAA0391, MRPL24, HIGD2A, BCL2, CYCS, ECHDC2, SFXN1, ECHDC3, NDUFAF1, SFXN2, 
ALDH18A1, GRSF1, BCL2L1, MRPS17, ACADVL, FEN1, GFM1, MRPS16, FASTKD2, MRPS14, MRPS11, 
MRPL39, MRPS10, ETFA, MRPL37, SQRDL, ATP5G2, ATP5G1, HK2, MRPL32, DHTKD1, C7ORF73, 
MRPL3, MRPL40, ALDH2, AIFM2, OPA3, C1QBP, UQCRFS1, C19ORF12, DNM1L, COA7, MRPS28, 
NSUN4, GPX4, MARS2, ACAD9, BCKDHB, MRPS23, TIMM23, DARS2, MRPL45, QTRT1, SLC25A15, 
TRAF3, NDUFS6, PTRH2, HCLS1, GARS, FXN, DLD, SLC25A11, SLC25A6, NDUFB9, FH, STOML2, 
TOMM40, ATP5EP2, MTFP1, SRC, GSTP1, MRPS33, ETFDH, MALSU1, NOL3, COX5A, HSD17B10, 
TBRG4, C19ORF70, PDF, MTHFD1L, ALDH1B1, BNIP1, C10ORF2, MFN2, ROMO1, IARS2, BID, 




MDH2, MMAB, BNIP3, LRPPRC, WARS2, FDX1L, AGMAT, ALDH4A1, DNAJA1, SLC25A39, LYRM4, 
APEX1, TRMT5, CIAPIN1, ABCE1, TRMT61B, TOMM6 
UP_KEYWO
RDS 
Transit peptide 93 4.69 MRPS17, ACADVL, GFM1, MRPS16, CLPB, FASTKD2, MRPS11, ETFA, MRPL37, SQRDL, ATP5G2, 
ATP5G1, YARS2, CISD3, MRPL32, DHTKD1, LACTB, MRPL40, ALDH2, C1QBP, FPGS, NARS2, UQCRFS1, 
EARS2, MRPS28, MCCC2, NSUN4, GPX4, MARS2, ACAD9, BCKDHB, DARS2, LIG3, MRPL45, PISD, 
LARS2, MTHFD2, NDUFS6, PTRH2, ACOT2, PPIF, TFAM, DLD, FXN, GCDH, FH, STOML2, SHMT2, 
MRPL19, MRPL16, ETFDH, MRPL17, HTRA2, MRPL14, MRPL12, COX5A, TBRG4, MRPL11, PRDX3, NLN, 
ATP5B, PDF, MTHFD1L, ALDH1B1, THEM4, C10ORF2, IARS2, CYC1, PCK2, HSPA9, PRELID1, METAP1D, 
PNPT1, TRMT10C, FAHD1, APOOL, MDH2, MMAB, GOT2, MRPL28, ERAL1, KIAA0391, MRPL24, 






84 4.24 MRPS17, ACADVL, GFM1, MRPS16, MRPS11, ETFA, MRPL37, SQRDL, ATP5G2, ATP5G1, YARS2, CISD3, 
MRPL32, DHTKD1, LACTB, CHCHD3, MRPL40, ALDH2, C1QBP, FPGS, NARS2, NUDT19, UQCRFS1, 
EARS2, MRPS28, MCCC2, GPX4, MARS2, ACAD9, BCKDHB, DARS2, MRPL45, LARS2, MTHFD2, NDUFS6, 
PTRH2, ACOT2, PPIF, TFAM, DLD, FXN, GCDH, FH, SHMT2, MRPL19, MRPL16, ETFDH, MRPL17, HTRA2, 
MRPL14, MRPL12, COX5A, MRPL11, PRDX3, NLN, ATP5B, PDF, MTHFD1L, ALDH1B1, C10ORF2, IARS2, 
CYC1, DTD1, ISOC2, PCK2, HSPA9, PRELID1, METAP1D, PNPT1, TRMT10C, MDH2, MMAB, GOT2, 







58 2.93 ACADVL, GFM1, ETFA, PARK7, YARS2, DHTKD1, ALDH2, C1QBP, FPGS, NARS2, EARS2, MCCC2, MARS2, 
BCKDHB, DARS2, LARS2, MTHFD2, ACOT2, PPIF, TFAM, GARS, DLD, FXN, TP53, GCDH, FH, SHMT2, 
ETFDH, ARL2, MALSU1, HSD17B10, PRDX3, ATP5B, MTHFD1L, ALDH1B1, THEM5, THEM4, C10ORF2, 
IARS2, MCL1, PCK2, GADD45GIP1, TRMT10C, MDH2, MMAB, GOT2, PYCR1, TDRD7, ERAL1, KIAA0391, 
FDX1L, WARS2, ALDH4A1, LYRM4, TRMT5, ABCE1, TRMT61B, BCL2L1 
0.00 0.00 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Ribonucleoprotein 63 3.18 MRPS17, RPL4, MRPS16, MRPS14, RPLP1, MRPS11, RPLP0, MRPL39, MRPS10, HNRNPU, HNRNPR, 
MRPL37, RPL10A, SRP14, MRPL32, EFTUD2, MRPL3, SYNCRIP, MRPL40, RPL36AL, SNRPD1, SNRPD3, 
MRPS28, RPS6KL1, RPS6, MRPS23, RPSA, MRPL45, SRP9, RBMXL1, RPL7L1, NHP2, RPL29, RPL10, 
MRPS33, MVP, MRPL19, HEATR1, MRPL16, MRPL17, MRPL14, MRPL12, ZFP36L1, MRPL11, PUF60, 
SRP72, RPS6KC1, GAR1, RPL13, RPS2, RPS27A, HNRNPA1, MRPL27, MRPL28, RPL23A, MRPL24, 




GO:0006412~translation 55 2.77 MRPS17, RPL4, HBS1L, MRPS16, MRPS14, RPLP1, MRPS11, RPLP0, MRPL37, RPL10A, YARS2, MRPL32, 
EFTUD2, MRPL3, RPL36AL, SLC25A43, WARS, RPS6, MRPS23, RPSA, SLC25A15, NHP2, RPL29, 
SLC25A11, SLC25A6, RPL10, MRPS33, MRPL19, MRPL16, MRPL17, TARS, MRPL14, MRPL11, PDF, 
RPL13, IGF2BP3, RPS2, RPS27A, SLC25A23, SLC25A25, ABCF1, EEFSEC, DARS, MRPL27, MRPL28, 




GO:0005840~ribosome 39 1.97 RPL4, MRPS17, MRPS16, RPL10, MRPS14, MRPS33, MRPS11, RPLP1, MRPL19, RPLP0, MRPL16, 
MRPL17, MRPS10, MRPL14, MRPL37, RPL10A, TMA16, MRPL32, MRPL11, MRPL3, RPS6KC1, RPL13, 
RPS2, RPS27A, ABCF1, MRPS28, RPS6KL1, MRPS23, RPS6, MRPL27, RPL23A, MRPL45, MRPL24, 






Ribosomal protein 39 1.97 RPL4, MRPS17, MRPS16, RPL10, MRPS14, MRPS33, MRPS11, RPLP1, MRPL19, RPLP0, MRPL16, 
MRPL17, MRPL39, MRPS10, MRPL14, MRPL37, RPL10A, MRPL12, MRPL32, MRPL11, MRPL3, MRPL40, 
RPL36AL, RPS6KC1, RPL13, RPS2, RPS27A, MRPS28, RPS6KL1, MRPS23, RPS6, MRPL27, MRPL28, 





al translational elongation 
25 1.26 MRPS17, GFM1, MRPS16, MRPS14, MRPS33, MRPS11, MRPL19, MRPL16, MRPL17, MRPL39, 
MRPS10, MRPL14, MRPL37, MRPL12, MRPL32, MRPL11, MRPL3, MRPL40, MRPS28, GADD45GIP1, 







24 1.21 MRPS17, GADD45GIP1, MRPS28, MRPS16, MRPS14, MRPS33, MRPS11, MRPS23, MRPL19, MRPL27, 
MRPL16, MRPL17, MRPL39, MRPS10, MRPL28, MRPL14, MRPL37, MRPL12, MRPL45, MRPL24, 





constituent of ribosome 
41 2.07 RPL4, MRPS17, MRPS16, RPL10, MRPS14, MRPS33, MRPS11, RPLP1, MRPL19, RPLP0, MRPL16, 
MRPL17, MRPL14, MRPL37, RPL10A, MRPL12, MRPL32, MRPL11, MRPL3, RPL36AL, RPL13, SLC25A43, 
RPS2, RPS27A, SLC25A23, SLC25A25, MRPS23, RPS6, MRPL27, MRPL28, RPL23A, RPSA, MRPL24, 





al large ribosomal subunit 
14 0.71 NSUN4, MRPL19, MRPL27, MRPL16, MRPL17, MRPL39, MRPL28, MRPL14, MRPL37, MRPL12, 




hsa03010:Ribosome 30 1.51 RPL4, MRPS17, MRPS16, RPL10, MRPS14, MRPS11, RPLP1, MRPL19, RPLP0, MRPL16, MRPL17, 
MRPS10, MRPL14, RPL10A, MRPL12, MRPL32, MRPL11, MRPL3, RPL36AL, RPL13, RPS2, RPS27A, 
RPS6, MRPL27, MRPL28, RPL23A, RPSA, MRPL24, RPL29, RSL24D1 
0.01 0.01 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Protein biosynthesis 45 2.27 HBS1L, GFM1, VARS, TARS, EPRS, YARS2, LARP1, PDF, LARS, NARS2, TCEB3, TCEB1, EIF2D, IARS2, 
EIF2B1, EARS2, EIF2A, EIF5A, EEFSEC, YARS, EIF5B, DARS, WARS, MARS2, DARS2, ELL2, EIF2S1, EIF1, 
WARS2, EEF1A1, AIMP2, LARS2, EIF2S3, EIF6, EIF3I, TAF4B, GARS, IARS, EEF1E1, EIF4E2, EIF3A, FARSB, 







22 1.11 YARS, DARS, WARS, VARS, MARS2, MRPL39, TARS, DARS2, EPRS, YARS2, WARS2, LARS2, AIMP2, LARS, 






19 0.96 YARS, DARS, WARS, VARS, MARS2, TARS, DARS2, EPRS, YARS2, WARS2, LARS2, LARS, NARS2, IARS2, 











11 0.55 YARS, LARS2, WARS, VARS, LARS, MARS2, IARS2, IARS, EPRS, YARS2, EARS2 0.00 0.00 
INTERPRO IPR001412:Aminoacyl-
tRNA synthetase, class I, 
conserved site 






tRNA editing activity 










of translational fidelity 





19 0.96 YARS, DARS, WARS, VARS, MARS2, TARS, DARS2, EPRS, YARS2, WARS2, LARS2, LARS, NARS2, IARS2, 




Ligase 51 2.57 VARS, RTCB, TNFAIP3, UBE3A, EPRS, PRPF19, PFAS, YARS2, RNF115, TRIM2, FPGS, NARS2, EARS2, 
MCCC2, WARS, ACSL1, MARS2, CAD, DARS2, ACSL4, LIG3, TRAF2, CTPS1, TRAF7, LARS2, TRAF3, GARS, 
GART, SLC27A4, MGRN1, UBR4, TARS, DTX2, ACACA, MTHFD1L, LARS, IARS2, DPH6, RFFL, YARS, 




class Ia, editing domain 
5 0.25 LARS2, VARS, LARS, IARS2, IARS 0.26 0.26 
INTERPRO IPR013155:Valyl/Leucyl/Is
oleucyl-tRNA synthetase, 
class I, anticodon-binding 
5 0.25 LARS2, VARS, LARS, IARS2, IARS 0.26 0.26 
INTERPRO IPR002300:Aminoacyl-
tRNA synthetase, class Ia 




tRNA ligase activity 
7 0.35 YARS, WARS, VARS, LARS, NARS2, DARS2, IARS 0.23 0.23 





     





28 1.41 HSP90AB1, HTRA2, HSP90B1, CHAF1B, HSP90B2P, DNAJB5, CCT7, CCT5, CCT4, CCT3, HSPA9, HSPA8, 
NPM1, NUDC, HSP90AA1, HSPA5, ST13, PTGES3, TTC1, TUBB4B, TAPBP, CCT6A, DNAJA1, CANX, 




Chaperone 39 1.97 SET, HSP90AB1, COX17, HSPB7, PARK7, HSP90B1, HSP90B2P, DNAJB5, CCT7, CCT5, CCT4, CCT3, BTF3, 
HSPA9, CD74, HSPA8, NPM1, HSP90AA1, TIMMDC1, ST13, VBP1, ALYREF, PTGES3, TOMM34, 
DNAJC14, CCT6A, DNAJA1, NPLOC4, DNAJC30, CANX, ANP32E, PSMG3, PFDN1, HYOU1, NDUFAF1, 






38 1.92 FKBP2, HSP90AB1, FUT10, GNAI3, TXN, HSPBP1, HSP90B1, HSP90B2P, GNG2, DNAJB5, CCT7, CCT5, 
CCT4, MPDU1, CCT3, PDIA3, HSPA9, HSPA8, NUDC, HSP90AA1, PPIL1, CSNK2A1, ST13, VBP1, SPHK1, 
TTC1, PDIA4, CCT6A, DNAJA1, FKBP1A, CANX, PPIF, PFDN1, CALR, PPIA, PPID, AARS, FKBP5 
0.01 0.01 







     






41 2.07 PSMD12, CD40, PSMD11, PSMD14, TRADD, TNF, PSMA7, TXNDC17, PSMD7, PSMB5, UBB, PSMB2, 
PSMD3, PSMB1, PTK2B, PSMD1, TNFRSF8, TNFRSF14, RPS27A, RELT, TNFRSF4, EDARADD, TNFSF14, 
CD70, STAT1, TNFRSF18, TNFRSF9, TNFRSF19, TNFRSF10B, TRAF2, TNFRSF1B, PSMA4, PSMA1, 




Proteasome 20 1.01 USP14, PSMD12, PSMD11, PSMD14, UBE3C, SHFM1, UBE3A, RAD23B, PSMA7, PSMD7, PSMA4, 






22 1.11 USP14, PSMD12, VCP, PSMD11, PSMD14, UBE3C, SHFM1, UBE3A, RAD23B, PSMA7, PSMD7, PSMA4, 





of mRNA stability 
30 1.51 PSMD12, SET, PSMD11, PSMD14, ANP32A, YWHAB, ELAVL1, PSMA7, ZFP36L1, EXOSC5, PSMD7, 
XPO1, EXOSC4, PSMB5, UBB, PSMB2, PSMD3, PSMB1, PSMD1, RPS27A, HSPA8, PRKCD, PSMA4, 






22 1.11 PSMD12, PSMD11, PSMD14, NFKB1, PSMA7, RELB, NFKB2, PSMD7, PSMA4, PSMB5, PSMA1, UBB, 








antigen via MHC class I, 
TAP-dependent 
21 1.06 PSMD12, PSMD11, PSMD14, NCF2, HLA-B, HLA-C, HLA-A, HLA-F, PSMA7, HLA-E, PSMD7, PSMA4, 







34 1.72 PSMD12, STOML2, PSMD11, PSMD14, PTEN, PIK3CD, PSMA7, PAK1, PSMD7, PSMB5, UBB, PSMB2, 
PSMD3, PSMB1, PSMD1, CSK, RPS27A, HLA-DQA2, HLA-DQA1, HLA-DPA1, RIPK2, RFTN1, NFKB1, 





C-type lectin receptor 
signaling pathway 
27 1.36 PSMD12, PSMD11, PSMD14, SRC, PSMA7, RELB, PAK1, NRAS, PSMD7, PSMB5, UBB, PSMB2, PSMD3, 







protein ligase activity 
involved in mitotic cell 
cycle 
20 1.01 PSMD12, PSMD11, PSMD14, ANAPC7, ANAPC16, PSMA7, PSMD7, PSMA4, PSMB5, PSMA1, UBB, 




hsa03050:Proteasome 16 0.81 PSMD12, PSMD11, PSMD14, SHFM1, PSMA7, PSMD7, PSMA4, PSMB5, PSMA1, PSMB2, PSMC4, 






37 1.87 PSMD12, PSMD11, UBE3C, PSMD14, MGRN1, RNF19B, PRPF19, FBXO22, PSMA7, RNF115, PSMD7, 









signaling pathway, planar 
cell polarity pathway 
23 1.16 PSMD12, PSMD11, PSMD14, FZD6, CLTC, AP2B1, PSMA7, CDC42, PSMD7, PSMA4, PSMB5, PSMA1, 





of cellular amino acid 
metabolic process 
15 0.76 PSMD12, PSMD11, PSMD14, PSMA7, PSMD7, PSMA4, PSMB5, PSMA1, PSMB2, PSMC4, PSME3, 






protein ligase activity 
involved in regulation of 
mitotic cell cycle 
transition 
19 0.96 PSMD12, PSMD11, PSMD14, ANAPC7, ANAPC16, PSMA7, PSMD7, PSMA4, PSMB5, PSMA1, UBB, 






45 2.27 PSMD12, PSMD11, CSF2, PSMD14, YWHAB, RASGRF1, PDGFA, CSF2RB, IL2RG, FGF2, TNF, PSMA7, 
ZFP36L1, RASGRP3, PAK1, NRAS, PSMD7, PSMB5, UBB, PSMB2, MYC, PSMD3, PEA15, PSMB1, PTK2B, 
PSMD1, RPS27A, JAK3, DUSP5, MEF2C, CAV1, GRIN1, MAPK13, EFNA1, MAPK11, PPP5C, PSMA4, 








19 0.96 PSMD12, PSMD11, PSMD14, ANAPC7, ANAPC16, PSMA7, PSMD7, PSMA4, PSMB5, PSMA1, UBB, 








36 1.82 PSMD12, VCP, PSMD11, ANAPC16, PSMD14, FBXO45, PSMA7, RNF115, PSMD7, MTA1, PSMB5, UBB, 
PSMB2, PSMD3, PSMB1, PSMD1, RFFL, RPS27A, FBXW5, ANAPC7, SIAH2, UBE2A, RAD23B, PML, 





regulation of canonical 
Wnt signaling pathway 
24 1.21 WNT10B, PSMD12, PSMD11, PSMD14, SRC, CAV1, FGF2, NFKB1, PSMA7, COL1A1, PSMD7, PSMA4, 







30 1.51 PSMD12, PSMD11, PSMD14, PSMA7, PAK1, PPP3CB, NRAS, PSMD7, PSMB5, UBB, PSMB2, PSMD3, 
PSMB1, PSMD1, RAC1, RPS27A, JUN, NFKB1, LAT2, NFKBIA, PSMA4, PIK3CA, PSMA1, PSMC4, PSME3, 





regulation of canonical 
Wnt signaling pathway 
28 1.41 PSMD12, PSMD11, PSMD14, PTPRO, LRP4, PSMA7, PSMD7, PSMB5, UBB, PSMB2, PSMD3, G3BP1, 
PSMB1, DACT3, PSMD1, RPS27A, WNT4, SIAH2, CAV1, FZD6, KREMEN2, CYLD, PSMA4, PSMA1, 
PSMC4, PSME3, PSMC2, RAPGEF1 
0.43 0.43 







     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
DNA repair 51 2.57 SMG1, FEN1, CETN2, BCCIP, SMC6, PRPF19, ALKBH2, CHAF1B, ZFYVE26, RUVBL1, NBN, POLK, PRMT6, 
GEN1, SUPT16H, PARP1, LIG3, RAD23B, RAD51B, MORF4L1, RAD51D, SFPQ, NEIL2, CINP, VCP, 
PSMD14, USP10, PRKDC, ASCC3, CLSPN, UVRAG, XRCC6, XRCC5, MCRS1, INTS3, NONO, HUWE1, 





DNA damage 56 2.83 SMG1, FEN1, CETN2, BCCIP, SMC6, PRPF19, ALKBH2, CHAF1B, ZFYVE26, CCND1, RUVBL1, NBN, POLK, 
IKBKE, PRMT6, GEN1, SUPT16H, PARP1, HUS1, LIG3, RAD23B, RAD51B, MORF4L1, RAD51D, SFPQ, 
NEIL2, CINP, VCP, PSMD14, USP10, PRKDC, TANK, ZMAT3, ASCC3, CLSPN, UVRAG, XRCC6, XRCC5, 
MCRS1, INTS3, NONO, HUWE1, UBE2A, SSRP1, GTF2H3, MLH1, GTF2H5, PPP5C, RAD50, APEX1, APLF, 
CDK2, UBE2N, NABP2, NABP1, TRIP12 
0.00 0.00 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
repeat:WD 3 45 2.27 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, EIF2A, FBXW4, 
UTP15, WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, 




repeat:WD 4 43 2.17 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, FBXW4, UTP15, 
WDR17, WDR36, SEC13, TLE1, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, NEDD1, 




WD repeat 45 2.27 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, EIF2A, FBXW4, 
UTP15, WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, 




repeat:WD 5 40 2.02 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR89, PRPF19, TAF5L, WDR43, 
WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, UTP15, WDR17, WDR36, SEC13, 
TLE1, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, NEDD1, TBL1XR1, EIF3I, GRWD1, 




repeat:WD 1 45 2.27 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, EIF2A, FBXW4, 
UTP15, WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, 




repeat:WD 2 45 2.27 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, EIF2A, FBXW4, 
UTP15, WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, 




SMART SM00320:WD40 43 2.17 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, FBXW4, UTP15, 
WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, NEDD1, 




49 2.47 MAPKBP1, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, WDR43, DCAF7, WDR44, 
RPTOR, CHAF1B, WDR5, MLST8, KIF21B, EIF2A, UTP15, FBXW4, WDR36, SEC13, TLE1, FBXW5, WSB2, 
EED, FBXW7, WDR77, TRAF7, TBL1XR1, GRWD1, WDFY1, GEMIN5, DYNC1I2, SEH1L, SF3B3, GTF3C4, 
UBR4, TAF5L, HIRA, DCAF11, WDR17, NBEAL2, WDR12, NEDD1, EIF3I, PPP2R2D, VPS41, CORO6, EIF3B 
0.24 0.24 
INTERPRO IPR001680:WD40 repeat 43 2.17 MAPKBP1, DYNC1I2, SEH1L, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, TAF5L, 
WDR43, DCAF7, WDR44, RPTOR, HIRA, CHAF1B, WDR5, MLST8, KIF21B, DCAF11, FBXW4, UTP15, 
WDR17, WDR36, SEC13, TLE1, FBXW5, WSB2, EED, FBXW7, NBEAL2, WDR12, WDR77, TRAF7, NEDD1, 
TBL1XR1, EIF3I, GRWD1, PPP2R2D, CORO6, WDFY1, GEMIN5 
0.27 0.27 
INTERPRO IPR020472:G-protein beta 
WD-40 repeat 
20 1.01 WDR17, SEH1L, WDR48, WSB2, WDR1, FBXW7, WDR3, PAK1IP1, PRPF19, WDR12, TAF5L, WDR44, 





50 2.52 MAPKBP1, WDR48, WDR1, WDR3, PAK1IP1, WDR4, WDR89, PRPF19, WDR43, DCAF7, WDR44, 
RPTOR, CHAF1B, WDR5, MLST8, KIF21B, EIF2A, UTP15, FBXW4, WDR36, SEC13, TLE1, FBXW5, WSB2, 
EED, FBXW7, WDR77, TRAF7, TBL1XR1, GRWD1, WDFY1, GEMIN5, DYNC1I2, SEMA7A, SEH1L, MST1R, 
TAF5L, HIRA, PLXNA1, DCAF11, WDR17, SEMA4C, NBEAL2, WDR12, NEDD1, EIF3I, PPP2R2D, VPS41, 
CORO6, EIF3B 
0.33 0.33 
INTERPRO IPR019775:WD40 repeat, 
conserved site 
29 1.46 WDR48, WDR1, WDR3, PAK1IP1, PRPF19, TAF5L, DCAF7, HIRA, CHAF1B, WDR5, MLST8, KIF21B, 
UTP15, WDR17, WDR36, TLE1, WSB2, EED, FBXW7, WDR12, WDR77, TRAF7, NEDD1, TBL1XR1, EIF3I, 
GRWD1, CORO6, WDFY1, GEMIN5 
0.41 0.41 





     






11 0.55 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B, RELT, 
TNFRSF4 
0.01 0.01 
SMART SM00208:TNFR 10 0.50 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B, TNFRSF4 0.06 0.06 
INTERPRO IPR001368:TNFR/NGFR 
cysteine-rich region 
10 0.50 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B, TNFRSF4 0.24 0.24 
UP_SEQ_FE
ATURE 
repeat:TNFR-Cys 1 10 0.50 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B, TNFRSF4 0.12 0.12 
UP_SEQ_FE
ATURE 
repeat:TNFR-Cys 2 10 0.50 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B, TNFRSF4 0.12 0.12 
UP_SEQ_FE
ATURE 
repeat:TNFR-Cys 3 9 0.45 CD40, TNFRSF18, TNFRSF9, TNFRSF19, FAS, TNFRSF10B, TNFRSF8, TNFRSF14, TNFRSF1B 0.28 0.28 







     





48 2.42 ARF3, HBS1L, RALA, GFM1, ARL1, GNAI3, ARL2, RAP1GAP, RND1, RAP1B, RAB21, CDC42, EFTUD2, 
ARFRP1, TUBA1C, TUBA1B, RAP1A, TUBA1A, NKIRAS2, MFN2, GNG8, RAC1, DNM1L, GBP1, GBP4, 
RAB8B, EEFSEC, EIF5B, TUBB, RHOG, ERAL1, RHOF, TUBB4B, GTPBP4, RAB11A, RAB10, EEF1A1, 




GTP-binding 56 2.83 ARF3, HBS1L, GFM1, RTKN, RND1, THG1L, EFTUD2, TUBA1C, RAB44, TUBA1B, TUBA1A, NKIRAS2, 
RAC1, DNM1L, RAB8B, MB21D1, EIF5B, TUBB, RHOG, GTPBP6, RHOF, GTPBP4, EEF1A1, RAP2A, 
TUBB2B, TUBB2A, RABL3, RALA, NPR1, ARL1, GNAI3, NOLC1, ARL2, RAP1B, RAB21, CDC42, ARFRP1, 
NRAS, RAP1A, MFN2, GBP1, GBP4, PCK2, EEFSEC, RAB39A, ERAL1, TUBB4B, RAB11A, RAB10, GNL3L, 




GO:0005525~GTP binding 65 3.28 ARF3, HBS1L, GFM1, RTKN, HSP90AB1, OLA1, RND1, THG1L, EFTUD2, TUBA1C, RAB44, TUBA1B, 
TUBA1A, NKIRAS2, ANXA6, RAC1, DNM1L, RAB8B, MB21D1, EIF5B, HSP90AA1, TUBB, RHOG, GTPBP6, 
RHOF, GTPBP4, NME1, EEF1A1, RAP2A, TUBB2B, TUBB2A, RABL3, RALA, NPR1, ARL1, GNAI3, NOLC1, 
ARL2, RAP1B, RAB21, CDC42, ARFRP1, NRAS, RAP1A, MFN2, GBP1, GBP4, PCK2, EEFSEC, RAB39A, 







51 2.57 ARF3, HBS1L, GFM1, RND1, EFTUD2, TUBA1C, RAB44, TUBA1B, TUBA1A, NKIRAS2, RAC1, DNM1L, 
RAB8B, EIF5B, TUBB, RHOG, GTPBP6, RHOF, GTPBP4, EEF1A1, RAP2A, TUBB2B, TUBB2A, RABL3, 
RALA, ARL1, GNAI3, ARL2, RAP1B, RAB21, CDC42, ARFRP1, NRAS, RAP1A, MFN2, GBP1, GBP4, PCK2, 




Prenylation 30 1.51 RALA, CNP, LMNB2, RND1, RAP1B, RAB21, CDC42, RAB44, NRAS, RAP1A, GNG2, GNG8, RAC1, GBP1, 
RAB8B, PTGIR, PLA2G4C, RHOG, RAB39A, NAP1L1, RHOF, RAB11A, RAB10, DNAJA1, PTP4A3, RAP2A, 
RHEB, RAB13, RAB9A, KRAS 
0.01 0.01 
INTERPRO IPR005225:Small GTP-
binding protein domain 
31 1.56 ARF3, RALA, GFM1, ARL1, ARL2, RND1, RAP1B, RAB21, CDC42, EFTUD2, ARFRP1, RAB44, NRAS, 
RAP1A, NKIRAS2, RAC1, RAB8B, EIF5B, RHOG, RAB39A, ERAL1, RHOF, GTPBP4, RAB11A, RAB10, 
RAP2A, RHEB, RAB13, RAB9A, KRAS, RAN 
0.24 0.24 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
RNA-binding 110 5.55 TDRKH, SPI1, HNRNPU, PHAX, HNRNPR, PARK7, EPRS, SRP14, C14ORF166, EDC3, RAVER1, SNRPD3, 
EARS2, KDM2B, METTL1, RBMXL1, NCL, NHP2, SRSF3, GEMIN5, MATR3, KHDRBS1, CNP, TRMT2A, 
ZFP36L1, EMG1, LARP1, ATXN1, ZMAT3, DHX34, G3BP1, GAR1, RBM12, YARS, CHTOP, PNPT1, 
ZRANB2, PNO1, FUS, ALYREF, NONO, CPSF2, UPF3B, TDRD7, SYNJ2, ERAL1, LARP4, MEX3C, EIF2S1, 
HNRNPM, CPEB1, HNRNPK, LSM6, HNRNPF, CAPRIN1, HNRNPC, GRSF1, DZIP3, AARS, EIF4G1, 
MRPS17, DAZAP1, DDX47, FASTKD2, YBX1, ELAVL1, RBM3, IFIH1, SYNCRIP, XPO1, XPO5, EIF5A, 
NSUN4, ANXA2, NCBP2, NSUN2, RBM19, PPRC1, SRP9, PATL1, SFPQ, OAS3, RBM20, NSRP1, EIF4E2, 
SF3B4, POLDIP3, NIP7, SRSF1, DDX21, CSTF2T, NOL6, EXOSC5, EXOSC4, PUF60, IGF2BP3, HNRNPA1, 






binding, alpha-beta plait 
44 2.22 SF3B4, DAZAP1, TMEM63B, POLDIP3, SRSF1, DDX21, CSTF2T, TRMT2A, HNRNPR, ELAVL1, RBM3, 
SYNCRIP, PUF60, RAVER1, G3BP1, IGF2BP3, RBM12, HNRNPA1, TAF15, NIFK, NCBP2, FUS, ALYREF, 
NONO, RBM19, UPF3B, RPL23A, SYNJ2, LARP4, PPRC1, HNRNPM, SFPQ, CPEB1, RBMXL1, NCL, 
HNRNPF, SRSF3, RBM20, NUP35, MATR3, HNRNPC, RBM45, GRSF1, EIF3B 
0.24 0.24 
INTERPRO IPR000504:RNA 
recognition motif domain 
38 1.92 SF3B4, DAZAP1, POLDIP3, SRSF1, CSTF2T, TRMT2A, HNRNPR, ELAVL1, RBM3, SYNCRIP, PUF60, 
RAVER1, G3BP1, IGF2BP3, RBM12, HNRNPA1, TAF15, NIFK, NCBP2, FUS, ALYREF, NONO, RBM19, 
SYNJ2, PPRC1, HNRNPM, SFPQ, CPEB1, RBMXL1, NCL, HNRNPF, SRSF3, RBM20, MATR3, HNRNPC, 
RBM45, GRSF1, EIF3B 
0.26 0.26 
SMART SM00360:RRM 35 1.77 SF3B4, DAZAP1, POLDIP3, SRSF1, CSTF2T, HNRNPR, ELAVL1, RBM3, SYNCRIP, PUF60, RAVER1, G3BP1, 
IGF2BP3, RBM12, HNRNPA1, TAF15, NIFK, NCBP2, FUS, ALYREF, NONO, RBM19, PPRC1, HNRNPM, 






53 2.67 DAZAP1, MRPL39, HNRNPR, ELAVL1, RBM3, SYNCRIP, RAVER1, HSP90AA1, NCBP2, RBM19, PPRC1, 
SFPQ, RBMXL1, NCL, SRSF3, RBM20, MATR3, HPRT1, SLC27A4, SF3B4, TMEM63B, NPR1, POLDIP3, 
SRSF1, ADCY3, CSTF2T, TRMT2A, PUF60, G3BP1, IGF2BP3, RBM12, HNRNPA1, TAF15, NIFK, FUS, 
ALYREF, NONO, UPF3B, RPL23A, SYNJ2, ATP2B1, LARP4, HNRNPM, CPEB1, IMPDH2, HNRNPF, APLF, 
NUP35, HNRNPC, RBM45, GRSF1, ITPA, EIF3B 
0.18 0.18 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa05140:Leishmaniasis 21 1.06 IL10, JUN, MARCKSL1, IFNGR1, NCF2, STAT1, IFNGR2, ELK1, TNF, NFKB1, MAPK13, NFKBIA, MAPK11, 




hsa05145:Toxoplasmosis 26 1.31 CD40, GNAI3, TNF, SOCS1, IRAK1, HLA-DQA2, HLA-DQA1, HLA-DPA1, IL10, HSPA8, IFNGR1, STAT1, 





hsa05164:Influenza A 34 1.72 PIK3CD, TNF, ACTB, ACTG1, ICAM1, IFIH1, XPO1, IKBKE, HLA-DQA2, HLA-DQA1, AGFG1, HLA-DPA1, 
HSPA8, JUN, IFNGR1, STAT1, IFNGR2, TNFRSF10B, TYK2, TICAM1, EIF2S1, NFKB1, PML, MAPK13, 




hsa05152:Tuberculosis 34 1.72 SRC, TRADD, CEBPG, LSP1, NOD2, TNF, PPP3CB, IRAK1, LAMP1, ATP6V0A2, BID, HLA-DQA2, HLA-
DQA1, HLA-DPA1, IL10, HSPA9, CD74, ARHGEF12, IFNGR1, STAT1, RIPK2, IFNGR2, SPHK1, NFKB1, 
MAPK13, MAPK11, IL1B, RFX5, BCL2, CYCS, CALM3, TLR6, HLA-DRB1, HLA-DQB1 
0.05 0.04 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa04210:Apoptosis 20 1.01 DFFA, TRADD, PIK3CD, TNFRSF10B, TRAF2, CSF2RB, CFLAR, TNF, NFKB1, NFKBIA, CASP7, PIK3CA, 
BCL2, CAPN2, FAS, CYCS, BID, TP53, BIRC3, BCL2L1 
0.00 0.00 
BIOCARTA h_hivnefPathway:HIV-I 
Nef: negative effector of 
Fas and TNF 
20 1.01 DFFA, PARP1, PRKDC, TRADD, PRKCD, TRAF2, CFLAR, TRAF1, TNFRSF1B, TNF, NFKB1, LMNB2, ACTG1, 





n of apoptosis through 
DR3 and DR4/5 Death 
Receptors 
12 0.61 NFKBIA, CASP7, DFFA, TRADD, BCL2, TNFRSF10B, CYCS, TRAF2, CFLAR, BID, NFKB1, BIRC3 0.47 0.47 





     











IMP biosynthetic process 
5 0.25 ADSL, ATIC, GART, PFAS, PAICS 0.13 0.13 
UP_KEYWO
RDS 
Purine biosynthesis 6 0.30 ADSL, ATIC, IMPDH2, GART, PFAS, PAICS 0.04 0.03 





     




component of lumenal 
side of endoplasmic 
reticulum membrane 
15 0.76 CD74, SPPL2A, HLA-B, HLA-C, HLA-A, HLA-F, TAPBP, HLA-E, CANX, CALR, HLA-DQA2, HLA-DQA1, HLA-






23 1.16 CD86, CD40, CD80, CAV1, HLA-B, HLA-C, HLA-A, HLA-F, ACTB, ACTG1, ICAM1, HLA-E, SGCA, CCND1, 






16 0.81 IL10, CD86, CD40, CD80, HLA-B, HLA-C, HLA-A, HLA-F, TNF, HLA-E, FAS, HLA-DQA2, HLA-DQA1, HLA-













presentation of peptide 
antigen via MHC class I 








23 1.16 PDIA3, CD74, HSPA8, HSP90AA1, HSP90AB1, HLA-B, TAP2, HLA-C, TAP1, HLA-A, HLA-F, TNF, TAPBP, 











hsa04940:Type I diabetes 
mellitus 
16 0.81 CD86, CD80, HLA-B, HLA-C, HLA-A, HLA-F, TNF, HLA-E, IL1B, LTA, FAS, HLA-DQA2, HLA-DQA1, HLA-







20 1.01 IFNGR1, STAT1, IFNGR2, PRKCD, HLA-B, HLA-C, HLA-A, HLA-F, PML, ICAM1, HLA-E, IRF4, OAS3, IRF5, 
GBP1, HLA-DQA2, HLA-DQA1, HLA-DRB1, HLA-DPA1, HLA-DQB1 
0.02 0.02 
INTERPRO IPR010579:MHC class I, 
alpha chain, C-terminal 
6 0.30 HLA-B, HLA-C, HLA-A, HLA-F, HLA-E, HLA-DQB1 0.14 0.14 
UP_SEQ_FE
ATURE 
region of interest:Alpha-1 8 0.40 HLA-B, HLA-C, HLA-A, HLA-F, HLA-DQA2, HLA-DQA1, HLA-DPA1, HLA-E 0.12 0.12 
UP_SEQ_FE
ATURE 
region of interest:Alpha-2 8 0.40 HLA-B, HLA-C, HLA-A, HLA-F, HLA-DQA2, HLA-DQA1, HLA-DPA1, HLA-E 0.12 0.12 
GOTERM_C
C_DIRECT 
GO:0012507~ER to Golgi 
transport vesicle 
membrane 
15 0.76 CD74, SEC13, GOSR2, HLA-B, HLA-C, HLA-A, HLA-F, SREBF2, HLA-E, CD59, HLA-DQA2, HLA-DQA1, HLA-
DRB1, HLA-DPA1, HLA-DQB1 
0.01 0.01 
INTERPRO IPR001039:MHC class I, 
alpha chain, 
alpha1/alpha2 
7 0.35 HLA-B, HLA-C, HLA-A, HLA-F, HLA-DRB1, HLA-E, HLA-DQB1 0.24 0.24 
UP_SEQ_FE
ATURE 






11 0.55 PLAU, HLA-B, HLA-C, HLA-A, HLA-F, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DPA1, HLA-E, HLA-DQB1 0.22 0.22 
UP_KEYWO
RDS 






15 0.76 CD74, HLA-B, HLA-C, HLA-A, RELB, HLA-E, RAB10, CTSH, ULBP1, HLA-DQA2, HLA-DQA1, HLA-DRB1, 











GO:0042612~MHC class I 
protein complex 
6 0.30 HLA-B, HLA-C, HLA-A, HLA-F, HLA-E, HLA-DQB1 0.06 0.06 
318 
 
INTERPRO IPR011162:MHC classes 
I/II-like antigen 
recognition protein 





GO:0042613~MHC class II 
protein complex 
8 0.40 CD74, HLA-C, HLA-A, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DPA1, HLA-DQB1 0.08 0.08 
INTERPRO IPR011161:MHC class I-
like antigen recognition 







antigen via MHC class I, 
TAP-independent 




from natural killer cell 
mediated cytotoxicity 
4 0.20 HLA-B, SERPINB9, HLA-A, HLA-E 0.43 0.43 
GOTERM_M
F_DIRECT 
GO:0032395~MHC class II 
receptor activity 





27 1.36 CD86, CNTNAP1, CD40, CD80, NRXN2, PVR, PTPRF, ICAM1, SPN, ALCAM, CD58, TIGIT, HLA-DQA2, 






coated endocytic vesicle 
membrane 




immune network for IgA 
production 














12 0.61 RAB10, ATP6V0E1, HLA-B, ATP6V0A2, RAB39A, HLA-C, RAB9A, HLA-A, TLR6, HLA-F, RAB8B, HLA-E 0.34 0.32 
KEGG_PATH
WAY 
hsa05310:Asthma 8 0.40 IL10, CD40, TNF, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DPA1, HLA-DQB1 0.24 0.20 
UP_KEYWO
RDS 







15 0.76 CD86, JUN, ATP6V0E1, CSF2, CSF1, CD80, TNF, ICAM1, IL1B, ATP6V0A2, HLA-DQA2, HLA-DQA1, HLA-
DRB1, HLA-DPA1, HLA-DQB1 
0.49 0.41 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 




initiation factor activity 
14 0.71 EIF5B, EIF2S1, EIF1, EIF2S3, EIF6, EIF3I, TAF4B, EIF2D, EIF2B1, EIF4E2, EIF3A, EIF2A, EIF3B, EIF4G1 0.32 0.32 





     




of tumor necrosis factor-
mediated signaling 
pathway 




of necrotic cell death 
6 0.30 UBB, TRADD, PPIF, TRAF2, RPS27A, BIRC3 0.31 0.31 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Sterol biosynthesis 10 0.50 CYB5R2, NSDHL, HMGCS1, C14ORF1, CYP51A1, MSMO1, DHCR24, HMGCR, DHCR7, FDFT1 0.00 0.00 
UP_KEYWO
RDS 
Steroid biosynthesis 11 0.55 CYB5R2, NSDHL, HMGCS1, C14ORF1, CYP51A1, MSMO1, DHCR24, HMGCR, DHCR7, LSS, FDFT1 0.01 0.01 
UP_KEYWO
RDS 





8 0.40 SQLE, NSDHL, CYP51A1, MSMO1, DHCR24, DHCR7, LSS, FDFT1 0.05 0.04 
UP_KEYWO
RDS 
Sterol metabolism 14 0.71 CETP, HMGCS1, CYP51A1, LCAT, MSMO1, DHCR24, HMGCR, SREBF2, CYB5R2, NSDHL, C14ORF1, 






Lipid biosynthesis 25 1.26 LPCAT1, MSMO1, HMGCR, ACACA, AGPAT3, CYB5R2, NSDHL, FAM213B, C14ORF1, FDFT1, ELOVL1, 







10 0.50 SQLE, NSDHL, HMGCS1, CYP51A1, MSMO1, DHCR24, HMGCR, DHCR7, LSS, FDFT1 0.55 0.55 
UP_KEYWO
RDS 
Cholesterol metabolism 11 0.55 CETP, NSDHL, HMGCS1, CYP51A1, LCAT, DHCR24, HMGCR, DHCR7, APOL1, SREBF2, FDFT1 0.20 0.18 
UP_KEYWO
RDS 
Steroid metabolism 14 0.71 CETP, HMGCS1, CYP51A1, LCAT, MSMO1, DHCR24, HMGCR, SREBF2, CYB5R2, NSDHL, C14ORF1, 
DHCR7, APOL1, FDFT1 
0.27 0.23 





     




into host cell 
17 0.86 CD86, UVRAG, CR2, TFRC, CD80, RPSA, NUP153, SLC1A5, PVR, ICAM1, VAMP8, LAMP1, HYAL2, 




Host cell receptor for 
virus entry 
13 0.66 CD86, CR2, TFRC, CD80, RPSA, SLC1A5, PVR, ICAM1, LAMP1, TNFRSF14, TNFRSF4, HLA-DRB1, SLAMF1 0.09 0.08 





     





10 0.50 EEFSEC, EEF1A1, EFTUD2, EIF5B, MRPL3, HBS1L, GFM1, EIF2S3, GAR1, AARS 0.30 0.30 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 





9 0.45 EFTUD2, SYNCRIP, HNRNPM, HNRNPK, SNRPD1, HNRNPF, HNRNPR, HNRNPC, HNRNPA1 0.09 0.08 
UP_KEYWO
RDS 
Spliceosome 21 1.06 SF3B4, HSPA8, PPIL1, SF3B3, ALYREF, SRSF1, HNRNPU, HNRNPR, TTF2, PRPF19, EFTUD2, SYNCRIP, 







step 2 spliceosome 
16 0.81 PPIL1, SF3B3, ALYREF, SRSF1, HNRNPU, HNRNPR, PRPF19, EFTUD2, SYNCRIP, HNRNPM, HNRNPK, 
SNRPD1, HNRNPF, SNRPD3, HNRNPC, HNRNPA1 
0.40 0.38 





     










3 0.15 TAP2, TAP1, TAPBP 0.34 0.32 





     




regulation of protein 
insertion into 
mitochondrial membrane 
involved in apoptotic 
signaling pathway 
10 0.50 YWHAE, TFDP1, YWHAQ, YWHAB, BCL2, TP53BP2, BID, TP53, TP63, YWHAG 0.19 0.19 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR013024:Butirosin 
biosynthesis, BtrG-like 






4 0.20 GGCT, CHAC2, CHAC1, GGACT 0.19 0.18 





     

















telomerase RNP complex 










3 0.15 GAR1, NHP2, NOP10 0.47 0.45 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Nucleotide-binding 248 12.51 CLPB, VARS, RTCB, HNRNPU, SMC6, EPRS, ACTB, RPS6KA1, LONP2, KIF21B, EARS2, MCCC2, CSNK2A1, 
ACSL1, CSNK2A3, PRKCD, GTPBP6, ACSL4, PASK, GTPBP4, LARS2, PRKAR1B, RABL3, HPRT1, PRKDC, 
NOLC1, MST1R, ACTR3B, ATP5B, DHX33, LARS, DHX34, DHX37, TRPM7, DPH6, PCK2, CDK17, CDK18, 
XRCC6, XRCC5, RAB39A, ERAL1, PAICS, SRPK1, SMARCA4, EHD1, CCT6A, UCK2, EHD4, HYOU1, 
ALDH18A1, ITPA, AARS, FARSB, DDR1, ARF3, HBS1L, SMG1, GFM1, OLA1, NAT10, PFAS, IFIH1, 
TUBA1C, TUBA1B, TUBA1A, ACTR1B, RFK, NKIRAS2, KIF13A, KIF1C, RAC1, RIOK1, TK1, JAK3, IKBKE, 
RAB8B, CCT3, HELLS, RPS6KL1, WARS, RIPK2, SPHK1, TUBB, INSRR, RHOG, NME3, TYK2, RHOF, NME1, 
RAD51B, ITPKC, TUBB2B, RAD51D, RAP2A, TUBB2A, GARS, GART, DDR2, TOR4A, PKN3, GNAI3, 
ADCY3, ARFRP1, NRAS, PAK1, MTHFD1L, ASNA1, MFN2, C10ORF2, CKB, CCT7, CCT5, PAK4, CCT4, 
UBE2G2, TUBB4B, RAB11A, TTLL4, PSMC4, KIF26B, PSMC2, RAB9A, TRIP13, FRK, RTKN, TTF2, UBE2Z, 
YARS2, ACTG1, THG1L, EFTUD2, RAB44, PPIP5K1, FPGS, NARS2, RUVBL1, PIM1, MAP3K8, PIM3, PIM2, 
MB21D1, TOR3A, CSNK1G3, TAP2, UBE2E2, TAP1, LIG3, ATAD3A, EEF1A1, SLC27A4, BLK, VCP, NPR1, 
AK2, ARL1, TARS, ARL2, ACACA, HSP90B1, RAP1B, RAP1A, IRAK1, KIF3B, G3BP1, PGK1, MYH11, 
HSPA9, EEFSEC, YARS, DARS, NEK9, HSPA8, HSPA5, NEK6, UBE2A, GNL3L, EIF2S3, RHEB, CDK4, CDK2, 
UBE2N, IARS, MAP3K13, ABCD2, HSP90AB1, DDX47, PIK3CD, HK2, RND1, EEF2K, DNM1L, ACTR3, 
ABCC4, ACTR2, EIF5B, HSP90AA1, RFC2, MARS2, CAD, DARS2, CTPS1, PKM, PIK3CA, PEAK1, OAS3, 
BMP2K, MYH9, DCTPP1, HCN3, RALA, SRC, NLRC5, DDX21, NOD2, ATP2C1, ATAD2B, RAB21, CDC42, 
MAT2A, RPS6KC1, MKNK2, PTK2B, IARS2, CSK, ASCC3, ABCF2, GBP1, GBP4, ABCF1, MMAB, ATP2B1, 
WARS2, MAPK13, MYO1D, RAB10, MYO1E, MAPK11, CLCN5, RAD50, MYO1C, RAB13, APLF, KRAS, 




ATP-binding 188 9.49 CLPB, VARS, RTCB, HNRNPU, TTF2, SMC6, EPRS, UBE2Z, YARS2, ACTB, ACTG1, PPIP5K1, RPS6KA1, 
FPGS, NARS2, RUVBL1, PIM1, LONP2, MAP3K8, PIM3, KIF21B, PIM2, EARS2, MB21D1, MCCC2, 
CSNK1G3, TOR3A, CSNK2A1, ACSL1, CSNK2A3, PRKCD, TAP2, UBE2E2, TAP1, ACSL4, LIG3, PASK, 
ATAD3A, LARS2, BLK, VCP, PRKDC, AK2, NOLC1, TARS, MST1R, ACTR3B, ACACA, HSP90B1, ATP5B, 
IRAK1, DHX33, KIF3B, LARS, DHX34, G3BP1, DHX37, PGK1, MYH11, TRPM7, DPH6, CDK17, YARS, 




CCT6A, EHD1, UCK2, EHD4, CDK4, CDK2, UBE2N, HYOU1, IARS, ALDH18A1, MAP3K13, AARS, FARSB, 
DDR1, SMG1, ABCD2, HSP90AB1, DDX47, OLA1, PIK3CD, NAT10, PFAS, HK2, IFIH1, ACTR1B, EEF2K, 
RFK, KIF13A, KIF1C, RIOK1, TK1, JAK3, IKBKE, CCT3, ACTR3, ABCC4, ACTR2, HELLS, RPS6KL1, 
HSP90AA1, WARS, RIPK2, RFC2, MARS2, SPHK1, CAD, INSRR, DARS2, NME3, CTPS1, TYK2, NME1, 
RAD51B, ITPKC, RAD51D, PKM, PIK3CA, PEAK1, OAS3, BMP2K, MYH9, GARS, GART, DDR2, TOR4A, 
SRC, PKN3, NLRC5, ADCY3, DDX21, NOD2, ATP2C1, ATAD2B, PAK1, MTHFD1L, MAT2A, RPS6KC1, 
ASNA1, MKNK2, C10ORF2, PTK2B, IARS2, CSK, CKB, ASCC3, ABCF2, CCT7, CCT5, ABCF1, PAK4, CCT4, 
MMAB, UBE2G2, ATP2B1, WARS2, MAPK13, MYO1D, MYO1E, MAPK11, RAD50, CLCN5, MYO1C, 
TTLL4, PSMC4, KIF26B, PSMC2, KRAS, TRIP13, ABCE1, PFKM, FRK, MYO1G 
GOTERM_M
F_DIRECT 
GO:0005524~ATP binding 201 10.14 CLPB, VARS, RTCB, HNRNPU, SMC6, EPRS, ACTB, RPS6KA1, LONP2, KIF21B, EARS2, MCCC2, CSNK2A1, 
ACSL1, CSNK2A3, PRKCD, ACSL4, PASK, RUNX3, LARS2, ALPK1, TP53, PRKDC, NOLC1, MST1R, ACTR3B, 
ATP5B, DHX33, LARS, DHX34, DHX37, TRPM7, DPH6, CDK17, CDK18, XRCC6, XRCC5, PAICS, SRPK1, 
SMARCA4, EHD1, CCT6A, UCK2, PPP5C, EHD4, HYOU1, ALDH18A1, AARS, FARSB, DDR1, SMG1, OLA1, 
NAT10, PFAS, IFIH1, ACTR1B, RFK, KIF13A, KIF1C, RIOK1, TK1, JAK3, IKBKE, CCT3, HELLS, RPS6KL1, 
WARS, RIPK2, SPHK1, INSRR, NME3, TYK2, NME1, RAD51B, ITPKC, RAD51D, GARS, GART, DDR2, 
TOR4A, PKN3, ADCY3, PAK1, MTHFD1L, ASNA1, C10ORF2, CKB, CCT7, CCT5, PAK4, CCT4, UBE2G2, 
MLH1, TTLL4, PSMC4, KIF26B, PSMC2, TRIP13, FRK, TTF2, UBE2Z, YARS2, ACTG1, THG1L, PPIP5K1, 
FPGS, NARS2, RUVBL1, PIM1, MAP3K8, PIM3, PIM2, MB21D1, TOR3A, CSNK1G3, SWAP70, TAP2, 
UBE2E2, TAP1, LIG3, ILF2, ATAD3A, TXLNB, BLK, VCP, NPR1, AK2, TARS, ACACA, HSP90B1, IRAK1, 
KIF3B, G3BP1, PGK1, MYH11, HSPA9, YARS, DARS, NEK9, HSPA8, HSPA5, NEK6, UBE2A, CDK4, CDK2, 
UBE2N, IARS, MAP3K13, ABCD2, HSP90AB1, DDX47, PIK3CD, HK2, HSP90B2P, EEF2K, ACTR3, ABCC4, 
ACTR2, HSP90AA1, RFC2, MARS2, CAD, DARS2, CTPS1, PKM, PIK3CA, PEAK1, OAS3, BMP2K, MYH9, 
SRC, NLRC5, DDX21, NOD2, ATP2C1, ATAD2B, MAT2A, RPS6KC1, MKNK2, PTK2B, IARS2, CSK, ASCC3, 
ABCF2, ABCF1, FDXACB1, MMAB, ATP2B1, WARS2, MAPK13, MYO1D, DNAJA1, MYO1E, MAPK11, 




Kinase 78 3.94 DDR1, MAPKBP1, CDKN1A, SMG1, SH3KBP1, PIK3CD, HK2, EEF2K, PPIP5K1, PLAU, RFK, RPS6KA1, 
PIM1, PIM3, MAP3K8, RIOK1, PIM2, TK1, JAK3, IKBKE, CSNK1G3, RPS6KL1, CSNK2A1, RIPK2, SPHK1, 
CSNK2A3, INSRR, PRKCD, NME3, TYK2, PASK, NME1, ITPKC, PKM, PIK3CA, PRKAR1B, PEAK1, CINP, 
BMP2K, ALPK1, DDR2, BLK, SRC, PRKDC, PKN3, MAPKAP1, AK2, MST1R, PAK1, IRAK1, RPS6KC1, 
MKNK2, PGK1, PTK2B, CSK, TRPM7, CKB, PAK4, PCK2, CDK17, CDK18, NEK9, CDKN2B, CDKN2A, NEK6, 
SRPK1, MAPK13, MAPK11, UCK2, CDK4, CDK2, CALM3, TAB2, ALDH18A1, PKIG, MAP3K13, PFKM, FRK 
0.48 0.43 
       





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
mRNA processing 50 2.52 DDX47, TSEN15, HNRNPU, HNRNPR, TTF2, YBX1, PRPF19, EFTUD2, SYNCRIP, SNRPD1, C1QBP, 
SNRPD3, TXNL4A, NCBP2, PRPF40B, SFPQ, RBMXL1, GEMIN4, SRSF3, GEMIN5, RBM20, GEMIN8, 
NSRP1, SF3B4, KHDRBS1, SF3B3, SRSF1, CSTF2T, NOL3, IWS1, ZFP36L1, PUF60, SYMPK, HNRNPA1, 
DCPS, HSPA8, PPIL1, PNPT1, ZRANB2, ALYREF, NONO, CPSF2, SRPK1, HNRNPM, CPEB1, LSM6, 




mRNA splicing 41 2.07 SF3B4, SF3B3, DDX47, SRSF1, HNRNPU, HNRNPR, TTF2, YBX1, PRPF19, NOL3, IWS1, EFTUD2, 




ALYREF, NONO, PRPF40B, SRPK1, HNRNPM, SFPQ, LSM6, RBMXL1, HNRNPK, HNRNPF, GEMIN4, 
GEMIN5, SRSF3, RBM20, HNRNPC, GEMIN8, NSRP1 
UP_KEYWO
RDS 
Spliceosome 21 1.06 SF3B4, HSPA8, PPIL1, SF3B3, ALYREF, SRSF1, HNRNPU, HNRNPR, TTF2, PRPF19, EFTUD2, SYNCRIP, 





step 2 spliceosome 
16 0.81 PPIL1, SF3B3, ALYREF, SRSF1, HNRNPU, HNRNPR, PRPF19, EFTUD2, SYNCRIP, HNRNPM, HNRNPK, 




hsa03040:Spliceosome 23 1.16 SF3B4, HSPA8, PPIL1, SF3B3, CCDC12, NCBP2, ALYREF, SRSF1, PRPF40B, HNRNPU, PRPF19, EFTUD2, 
HNRNPM, RBMXL1, LSM6, HNRNPK, PUF60, SNRPD1, SRSF3, SNRPD3, HNRNPC, HNRNPA1, TXNL4A 
0.27 0.23 





     





28 1.41 RPL4, RPL10, RPLP1, RPLP0, RPL10A, LARP1, RPL13, RPS2, RPS27A, EIF2B1, ABCF1, EIF2A, PAIP1, 






large ribosomal subunit 
14 0.71 RPL4, RPL10, RPLP1, RPLP0, RPL23A, RPL10A, RSL1D1, RPL36AL, RPL7L1, MRTO4, NHP2, RPL13, 
RPL29, RSL24D1 
0.25 0.24 





     
Category Term Count % Genes Benjamini FDR 
BIOCARTA h_cdc42racPathway:Role 
of PI3K subunit p85 in 
regulation of Actin 
Organization and Cell 
Migration 





6 0.30 ACTR3, ACTR2, ARPC2, ARPC4, ARPC5, ACTR3B 0.08 0.08 
BIOCARTA h_salmonellaPathway:Ho
w does salmonella hijack 
a cell 
7 0.35 ACTR3, CDC42, ACTR2, ARPC2, ARPC4, RAC1, ARPC5 0.47 0.47 





     













5 0.25 PRMT6, PRMT2, PRMT1, CARM1, WDR77 0.34 0.34 





     




Escherichia coli infection 
18 0.91 TUBB, ARPC4, ARPC5, TUBB4B, ACTB, ACTG1, CDC42, TUBA1C, TUBA1B, TUBB2B, TUBA1A, TUBB2A, 







7 0.35 TUBA1C, TUBA1B, TUBA1A, KIF26B, TUBB, KIF13A, KIF1C 0.39 0.39 
KEGG_PATH
WAY 
hsa04540:Gap junction 15 0.76 SRC, TUBB, GNAI3, ITPR1, PDGFA, ADCY3, TUBB4B, TUBA1C, TUBA1B, TUBB2B, PLCB3, NRAS, 
TUBA1A, TUBB2A, KRAS 
0.49 0.41 





     





6 0.30 SNRPD1, PRMT1, CLNS1A, ERH, SNRPD3, WDR77 0.08 0.08 





     




regulation of telomerase 
RNA localization to Cajal 
body 




regulation of protein 
localization to Cajal body 













4 0.20 CCT3, CCT7, CCT5, CCT4 0.47 0.45 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa05161:Hepatitis B 30 1.51 CDKN1A, YWHAB, SRC, PTEN, PIK3CD, ELK1, TNF, IFIH1, NRAS, CCND1, YWHAQ, MYC, PTK2B, E2F3, 





hsa05222:Small cell lung 
cancer 
20 1.01 CDKN2B, PTEN, PIK3CD, TRAF2, TRAF1, NFKB1, NFKBIA, PIK3CA, TRAF4, CCND1, TRAF3, CDK4, MYC, 




hsa05215:Prostate cancer 20 1.01 CDKN1A, HSP90AA1, HSP90AB1, TCF7, INSRR, PTEN, PDGFA, PIK3CD, NFKB1, HSP90B1, NFKBIA, 






14 0.71 STAT5A, SPI1, TCF7, PIK3CD, NFKB1, PML, NRAS, PIK3CA, CCND1, MYC, PIM1, RARA, KRAS, PIM2 0.08 0.06 
KEGG_PATH
WAY 





16 0.81 STAT5A, CDKN1A, CDKN2A, PIK3CD, PTPN11, NFKB1, NFKBIA, NRAS, PIK3CA, CCND1, CDK4, MYC, 













13 0.66 JUN, TCF7, PIK3CD, MLH1, PIK3CA, CCND1, MYC, BCL2, CYCS, KRAS, RAC1, TP53, APPL1 0.24 0.20 
KEGG_PATH
WAY 





11 0.55 NRAS, CCND1, PIK3CA, MYC, TCF7, PTEN, PIK3CD, KRAS, MLH1, ELK1, TP53 0.31 0.25 
KEGG_PATH
WAY 
hsa05216:Thyroid cancer 7 0.35 NRAS, CCND1, TFG, MYC, TCF7, KRAS, TP53 0.40 0.34 
KEGG_PATH
WAY 
hsa05218:Melanoma 13 0.66 CDKN1A, CDKN2A, PTEN, PDGFA, PIK3CD, FGF2, NRAS, PIK3CA, CCND1, CDK4, KRAS, E2F3, TP53 0.43 0.36 
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Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Immunity 70 3.53 CD86, CD84, CD40, CSF1, PIK3CD, RNF19B, OTUD7B, ETS1, PTMS, IFIH1, ALCAM, NUDCD1, C1QBP, 
MAP3K8, JAK3, ICOSLG, HLA-DPA1, MB21D1, JAGN1, CR2, DBNL, IL4R, RIPK2, TFEB, HLA-B, TAP2, 
HLA-C, TAP1, CTPS1, HLA-A, TICAM1, HLA-F, HLA-E, LAT2, PSMA1, TRAF3, OAS3, ORAI1, TLR10, IRF5, 
ARHGEF2, TLR6, HLA-DQB1, SRC, NLRC5, MST1R, NOD2, CD1C, CFP, SEC14L1, IRAK1, BTLA, PTK2B, 
SLAMF7, CSK, HLA-DQA2, GBP1, HLA-DQA1, SLAMF1, APOBEC3C, CD74, APOBEC3G, LILRB4, PML, 
BST2, CYLD, LOC102723996, POLR3H, HLA-DRB1, MYO1G 
0.01 0.01 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Cell cycle 86 4.34 CDKN1A, STEAP3, ANKLE2, CETN2, CCDC124, CLTC, BCCIP, CLTA, IKZF1, CHAF1B, ZFYVE26, RASSF2, 
CCND2, CCND1, RASSF4, RUVBL1, RPS6KA1, KIF13A, ENSA, PIM1, ZNF207, PIM3, MAP3K8, PIM2, 
NBN, TXNL4A, TP63, APPL1, HELLS, NUDC, CSNK2A1, ANAPC7, DYNLT3, NSUN2, PRKCD, LIG3, KLHL42, 
TFDP1, PSME3, CINP, ERH, ARHGEF2, MAPRE1, TP53, KHDRBS1, RALA, SEH1L, TSG101, ANAPC16, 
SRC, PRCC, GNAI3, NEDD9, ARL2, ARPP19, CDC42, SYCE2, NPAT, ASUN, TP53BP2, E2F3, SNX9, CLSPN, 
PAK4, GADD45GIP1, NEK9, CDKN2B, CDKN2A, NEK6, NDE1, SIAH2, RCC2, MLH1, RAB11A, MAPK13, 




Cell division 44 2.22 RALA, ANKLE2, SEH1L, TSG101, ANAPC16, CETN2, CCDC124, CLTC, GNAI3, NEDD9, CLTA, ARPP19, 
CDC42, SYCE2, ZFYVE26, CCND2, CCND1, ASUN, RUVBL1, KIF13A, ENSA, ZNF207, SNX9, TXNL4A, 
NEK9, HELLS, NUDC, ANAPC7, DYNLT3, NEK6, NDE1, NSUN2, RCC2, LIG3, KLHL42, ZC3HC1, NEDD1, 




Mitosis 31 1.56 ANKLE2, SEH1L, ANAPC16, CETN2, CLTC, NEDD9, CLTA, ARPP19, ASUN, RUVBL1, ENSA, ZNF207, SNX9, 
TXNL4A, NEK9, HELLS, NUDC, ANAPC7, DYNLT3, NEK6, NDE1, NSUN2, RCC2, KLHL42, ZC3HC1, NEDD1, 
PPP2R2D, CDK2, ARHGEF2, MAPRE1, RAN 
0.48 0.42 





     




necrosis factor receptor 
binding 





7 0.35 CDC42, TRAF4, TRAF3, TRAF2, CALM3, TRAF1, RAC1 0.10 0.09 
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Category Term Count % Genes Benjamini FDR 
BIOCARTA h_tnfr2Pathway:TNFR2 
Signaling Pathway 
9 0.45 NFKBIA, TRAF3, LTA, TNFAIP3, TRAF2, TRAF1, TNFRSF1B, TANK, NFKB1 0.35 0.35 





     




regulation of anoikis 





pathway in response to 
DNA damage 





7 0.35 AIFM2, CDKN2A, PPIF, BID, HK2, BCL2L1, MCL1 0.44 0.44 





     









regulatory particle, lid 
subcomplex 
5 0.25 PSMD12, PSMD11, PSMD14, SHFM1, PSMD3 0.09 0.09 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Cell shape 6 0.30 CDC42SE1, CYFIP1, CDC42EP5, CDC42EP3, CDC42EP2, MYH9 0.34 0.30 





     





9 0.45 NFKBIA, TRAF3, LTA, TNFAIP3, TRAF2, TRAF1, TNFRSF1B, TANK, NFKB1 0.35 0.35 





     






11 0.55 ELOVL1, ACSL1, SCD, FASN, PPT1, THEM5, ACOT2, THEM4, ACSL4, ACOT4, ACACA 0.43 0.43 





     




necrosis factor receptor 
binding 
11 0.55 TRAF4, TNFSF14, TRAF3, STAT1, CD70, TNFSF4, TRADD, LTA, TRAF2, TRAF1, TNF 0.03 0.03 





     






















18 0.91 FH, H6PD, TPI1, RPEL1, SHMT2, MDH2, PGAM1, GOT2, ENO1, PGD, HK2, RPIA, PKM, PSAT1, PGK1, 
PGLS, DLD, PFKM 
0.55 0.46 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
S-adenosyl-L-methionine 24 1.21 PRMT6, TRMT10C, PRMT2, NSUN4, METTL1, PRMT1, SMYD5, NSUN2, TYW3, DNMT3A, DOT1L, 







Methyltransferase 25 1.26 SHMT2, SMYD5, DOT1L, TRMT2A, ECE2, METTL21A, COMT, EMG1, METTL10, LCMT2, TRDMT1, 
PRMT6, TRMT10C, PRMT2, NSUN4, METTL1, PRMT1, TYW3, NSUN2, DNMT3A, CARM1, TRMT5, 
TRMT61A, TRMT61B, EZH2 
0.35 0.31 





     






10 0.50 UBB, PARP1, SUMO3, CETN2, SUMO2, UBE2N, GTF2H3, RPS27A, RAD23B, GTF2H5 0.26 0.26 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
mRNA transport 24 1.21 EIF5A, CHTOP, SEC13, SEH1L, NCBP2, POLDIP3, MVP, ALYREF, SRSF1, UPF3B, NUP153, NUTF2, 




Translocation 15 0.76 EIF5A, SEC13, SEH1L, MVP, TIMM23, NUP153, NUTF2, TOMM22, SEC61A2, NUP93, MYO1C, ZMAT3, 




Nuclear pore complex 10 0.50 EIF5A, NUP93, SEC13, MYO1C, SEH1L, MVP, NUP62, NUP35, NUP153, NUTF2 0.22 0.19 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
NAD 25 1.26 H6PD, AHCY, MSMO1, HSD17B10, CYB5R2, LDHB, LDHA, NSDHL, ALDH2, ALDH1B1, SDR42E1, PARP1, 
MDH2, SIRT6, PARP14, PARP12, ALDH4A1, UEVLD, UGDH, MTHFD2, FASN, IMPDH2, DLD, BLVRA, 
GLYR1 
0.20 0.17 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
SH2 domain 17 0.86 BLK, STAT5A, BCAR3, STAT1, SRC, SH2D3A, PTPN11, TYK2, SOCS2, SOCS1, NCK2, STAP2, CSK, STAT6, 
SH2B3, JAK3, FRK 
0.22 0.20 







     




regulation of extrinsic 
apoptotic signaling 
pathway via death 
domain receptors 
10 0.50 TRADD, PEA15, FAS, TNFAIP3, TNFRSF10B, TRAF2, CFLAR, ARHGEF2, RFFL, ICAM1 0.31 0.31 





     





6 0.30 ACTR3, ACTR2, ARPC2, ARPC4, ARPC5, ACTR3B 0.08 0.08 





     





5 0.25 XRCC6, FEN1, RAD50, XRCC5, PRKDC 0.24 0.20 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 





6 0.30 PSMA4, PSMB5, PSMA1, PSMB2, PSMB1, PSMA7 0.47 0.45 





     




protein S5 domain 2-type 
fold 
12 0.61 EFTUD2, EXOSC5, GFM1, HSP90AA1, EXOSC4, HSP90B2P, PNPT1, HSP90AB1, LONP2, RPS2, MLH1, 
HSP90B1 
0.41 0.41 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Flavoprotein 18 0.91 GCDH, ACADVL, STEAP3, ACAD9, MICAL3, ETFDH, DHCR24, ETFA, SQRDL, CYB5R2, IL4I1, SQLE, POR, 




FAD 16 0.81 GCDH, ACADVL, STEAP3, ACAD9, MICAL3, ETFDH, DHCR24, ETFA, SQRDL, CYB5R2, IL4I1, SQLE, POR, 






     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
SH3-binding 12 0.61 VASP, KHDRBS1, FUT8, CNTNAP1, SH3BP1, SH3KBP1, TP53BP2, RAPGEF1, SIRPA, ELMO2, ARHGAP17, 
EPS15 
0.18 0.16 





     





10 0.50 EIF5A, NPM1, SET, MYBBP1A, ANP32A, ANP32E, ANP32C, NSRP1, FBXO22, RAN 0.08 0.08 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa03060:Protein export 7 0.35 SEC61A2, SRP72, HSPA5, SEC61B, SRP14, SRP9, SEC11C 0.21 0.17 
UP_KEYWO
RDS 
Signal recognition particle 3 0.15 SRP72, SRP14, SRP9 0.40 0.35 





     


















     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 





5 0.25 ANXA2, ANXA5, ANXA6, ANXA7, ANXA2P2 0.24 0.21 





     
Category Term Count % Genes Benjamini FDR 
BIOCARTA h_npcPathway:Mechanis
m of Protein Import into 
the Nucleus 
7 0.35 IL4I1, NUP62, NUP153, NUTF2, RANGAP1, RAN, SNHG3 0.47 0.47 





     











4 0.20 ACSL1, FASN, ACSL4, ACACA 0.55 0.46 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 






pool by folate 
5 0.25 ATIC, MTHFD1L, SHMT2, MTHFD2, GART 0.55 0.46 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
domain:Leucine-zipper 22 1.11 HOMEZ, XBP1, JUN, BATF3, XRCC5, PRKDC, API5, CEBPG, TFEB, FOXP4, SREBF2, BATF, FOXP1, RELB, 
MYC, MYB, GEMIN4, E2F3, ATF5, IKBKE, JUNB, NFE2L1 
0.43 0.43 





     











dependent protein kinase 
holoenzyme complex 
5 0.25 CDKN1A, CCND2, CCND1, CDK4, CDK2 0.48 0.46 
KEGG_PATH
WAY 
hsa04110:Cell cycle 19 0.96 YWHAE, ZBTB17, CDKN1A, CDKN2B, ANAPC7, CDKN2A, YWHAB, PRKDC, TFDP1, CCND2, ESPL1, 
CCND1, YWHAQ, CDK4, MYC, CDK2, E2F3, TP53, YWHAG 
0.57 0.47 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
TPR repeat 23 1.16 ANAPC7, ST13, NCF2, PRKDC, TOMM34, TRANK1, VPS13A, TTC1, TTC7A, SMG7, TTC27, RPAP3, 
TTC39A, PPP5C, KLC2, ZC3H7A, SRP72, ZC3H7B, TRAPPC12, NAA15, LONRF1, PPID, FKBP5 
0.28 0.25 





     
Category Term Count % Genes Benjamini FDR 
GOTERM_C
C_DIRECT 
GO:0005874~microtubule 42 2.12 MACF1, DYNC1I2, CNP, DCTN1, WDR43, TUBA1C, TUBA1B, KLC2, MTA1, TUBA1A, KIF3B, KIF13A, 
ZNF207, MAP6, KIF1C, KIF21B, MAP4, DNM1L, CCT7, CCDC50, SYBU, CCT5, CCT4, CCT3, NUDC, 
DYNLT3, NEK6, NDE1, RCC2, TUBB, TUBB4B, LRPPRC, CCT6A, CAMSAP3, CYLD, TUBB2B, TUBB2A, 
TTLL4, KIF26B, ARHGEF2, MAPRE1, EIF3A 
0.40 0.38 







     





5 0.25 XRCC6, FEN1, RAD50, XRCC5, PRKDC 0.24 0.20 





     





18 0.91 HSPA8, JUN, HSP90AA1, HSP90AB1, SRC, PRKCD, GNAI3, ITPR1, ADCY3, PIK3CD, ESR1, HSP90B1, 






16 0.81 JUN, SRC, PRKCD, PLA2G4C, ITPR1, ADCY3, ELK1, MAPK13, PLD2, CDC42, MAPK11, PLCB3, NRAS, 
PTK2B, KRAS, CALM3 
0.40 0.34 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa04660:T cell receptor 
signaling pathway 
20 1.01 IL10, JUN, CSF2, PIK3CD, TNF, NFKB1, MAPK13, CDC42, NFKBIA, MAPK11, PAK1, PPP3CB, NRAS, 






12 0.61 CDC42, MAPK11, PPP3CB, NRAS, PIK3CA, SRC, SPHK1, PLA2G4C, PIK3CD, KRAS, RAC1, MAPK13 0.36 0.30 
KEGG_PATH
WAY 
hsa04662:B cell receptor 
signaling pathway 
12 0.61 NFKBIA, CR2, PPP3CB, NRAS, JUN, PIK3CA, PIK3CD, KRAS, RAC1, NFKBIE, NFKB1, RASGRP3 0.55 0.46 





     




id biosynthesis - ganglio 
series 
5 0.25 GLB1, ST3GAL5, B4GALNT1, ST3GAL1, ST3GAL2 0.33 0.27 





     





Electron transport 15 0.76 CYB5B, NDUFB9, CYB5A, ETFDH, CYBRD1, ETFA, TXN, HIGD1A, FDX1L, HIGD2A, NDUFS6, UQCRFS1, 
CYCS, CYC1, CYB561 
0.47 0.41 





     





6 0.30 ACSL1, GOT2, ACSL4, PPARA, SLC27A4, MFSD2A 0.31 0.31 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Redox-active center 10 0.50 PRDX3, VKORC1, PDIA3, PRDX4, PRDX1, TXN, FAM213A, DLD, TXNDC17, PDIA4 0.20 0.18 





     





cytoplasmic side of 
plasma membrane 
13 0.66 BLK, SRC, TYK2, CYLD, RGS1, S100A6, PTK2B, CSK, SNX9, KRAS, JAK3, FRK, CYTH1 0.39 0.37 





     





10 0.50 ALDH4A1, ALDH2, ALDH1B1, GOT2, SMS, PYCR1, CKB, ALDH18A1, SRM, AGMAT 0.43 0.36 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 










     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Rotamase 7 0.35 FKBP1A, PPIL1, FKBP2, PPIF, PPIA, PPID, FKBP5 0.48 0.43 





     





7 0.35 GALNT11, GALNT16, GALNT2, ST3GAL1, GALNT10, ST3GAL2, B4GALT5 0.49 0.40 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Transcription 243 12.26 ZNF296, EHF, SPI1, MAML2, GFI1, ZNF292, IKZF1, ENO1, RBPJ, GABPB1, C14ORF166, ELK1, 
C14ORF169, IKZF4, ELK3, SPIB, MYC, ZMIZ2, SPATA24, MYB, JUNB, TP63, MED1, MEF2C, SMARCC1, 
CSNK2A1, ZNF282, ZNF281, HNF1B, RUNX3, SND1, HOXB9, ZNF717, SUB1, RFX5, VOPP1, TFAM, 
SRFBP1, ZNF710, ATF5, VPS25, TP53, ZNF154, CASZ1, ANP32A, AIRE, ZNF22, TXN, ZBTB5, HIVEP1, 
HIVEP3, NRBF2, ZNF267, STAT5A, BTF3, JUN, XBP1, XRCC6, XRCC5, ZNF260, IRF2BP2, SNF8, MINA, 
PARP14, ELL2, SMARCA4, HNRNPK, TRIP6, ZNF135, EZH2, GMEB1, ELL, ADIRF, MED19, LITAF, 
CHAF1B, MED14, C1QBP, PRMT6, HELLS, BATF3, PARP1, NCOA5, TFEB, COMMD1, BAZ1A, PAX5, 
PPRC1, CBFA2T3, SREBF2, SUPT3H, COMMD5, MED22, NR5A2, AEBP2, MDFIC, RARA, ZNF239, 
ZNF780B, PPARA, FOXC1, ZNF593, NFIX, NR1I2, ARNTL2, FSTL3, RELB, HIRA, TCEAL3, PLAGL1, 
TWISTNB, TCEB3, PLAGL2, STAT6, TCEB1, HSF5, TAF9B, CDKN2A, STAT1, MCRS1, GTF2H3, ELP6, 
GTF2H5, LRPPRC, BATF, ZNF33B, NR6A1, ZNF70, MYBBP1A, NFIC, APEX1, CRTC2, TTF2, ETS1, 
CHCHD3, CCND1, RUVBL1, ZNF563, SLC30A9, SUPT16H, TLE1, KDM2B, ARID5A, ZBTB32, POU3F1, 
FOXP4, ILF2, SAP30, FOXP1, EEF1A1, MORF4L1, TBL1XR1, ADNP, HOMEZ, KHDRBS1, TCF7, TAF5L, 
NPAT, ATXN1, ZNF788, ZNF544, ZBTB17, ZNF660, HSPA8, CBX6, ZFHX3, CHTOP, POU2F1, ZFHX2, 
DENND4A, NONO, HMGA1, ZBTB10, ESR1, NFKB1, NFKB2, COPRS, SP2, LHX2, CNOT11, BHLHE40, 
TAF4B, MNAT1, NFE2L1, ZSCAN2, ZNF770, YBX1, NFKBIZ, WDR5, MYBL2, NKX3-1, PELP1, MYOCD, 
TGIF2, EED, MKL1, ETV3, TRAF7, SFPQ, ETV3L, TFDP1, IRF4, POLR1B, ZNF878, IRF5, ZNF512, L3MBTL4, 
NFAT5, GTF3C4, GTF3C6, ZBTB46, CEBPG, TAF9, DDX21, HDAC9, IWS1, MTA1, PUF60, ZNF629, 
ZNF506, BAHD1, ATOH8, BEND3, E2F3, ZNF865, PCBD1, ASCC3, JAZF1, TCFL5, ATF7IP, SSRP1, PML, 




Transcription regulation 236 11.91 ZNF296, EHF, SPI1, MAML2, GFI1, ZNF292, IKZF1, ENO1, RBPJ, GABPB1, C14ORF166, ELK1, 
C14ORF169, IKZF4, ELK3, SPIB, MYC, ZMIZ2, SPATA24, MYB, JUNB, TP63, MED1, MEF2C, SMARCC1, 




SRFBP1, ZNF710, ATF5, VPS25, TP53, ZNF154, CASZ1, ANP32A, AIRE, ZNF22, TXN, ZBTB5, HIVEP1, 
HIVEP3, NRBF2, ZNF267, STAT5A, BTF3, JUN, XBP1, XRCC6, XRCC5, ZNF260, IRF2BP2, SNF8, MINA, 
PARP14, ELL2, SMARCA4, HNRNPK, TRIP6, ZNF135, EZH2, GMEB1, ELL, ADIRF, MED19, LITAF, 
CHAF1B, MED14, C1QBP, PRMT6, HELLS, BATF3, PARP1, NCOA5, TFEB, COMMD1, BAZ1A, PAX5, 
PPRC1, CBFA2T3, SREBF2, SUPT3H, COMMD5, MED22, NR5A2, AEBP2, MDFIC, RARA, ZNF239, 
ZNF780B, PPARA, FOXC1, ZNF593, NFIX, NR1I2, ARNTL2, FSTL3, RELB, HIRA, TCEAL3, PLAGL1, TCEB3, 
PLAGL2, STAT6, TCEB1, HSF5, TAF9B, CDKN2A, STAT1, MCRS1, GTF2H3, ELP6, GTF2H5, LRPPRC, BATF, 
ZNF33B, NR6A1, ZNF70, MYBBP1A, NFIC, APEX1, CRTC2, TTF2, ETS1, CHCHD3, CCND1, RUVBL1, 
ZNF563, SLC30A9, SUPT16H, TLE1, KDM2B, ARID5A, ZBTB32, POU3F1, FOXP4, ILF2, SAP30, FOXP1, 
EEF1A1, MORF4L1, TBL1XR1, ADNP, HOMEZ, KHDRBS1, TCF7, TAF5L, NPAT, ATXN1, ZNF788, ZNF544, 
ZBTB17, ZNF660, HSPA8, CBX6, ZFHX3, CHTOP, POU2F1, ZFHX2, DENND4A, NONO, HMGA1, ZBTB10, 
ESR1, NFKB1, NFKB2, COPRS, SP2, LHX2, CNOT11, BHLHE40, TAF4B, MNAT1, NFE2L1, ZSCAN2, 
ZNF770, YBX1, NFKBIZ, WDR5, MYBL2, NKX3-1, MYOCD, TGIF2, EED, MKL1, ETV3, TRAF7, SFPQ, 
ETV3L, TFDP1, IRF4, ZNF878, IRF5, ZNF512, L3MBTL4, NFAT5, ZBTB46, CEBPG, TAF9, HDAC9, IWS1, 
MTA1, PUF60, ZNF629, ZNF506, BAHD1, ATOH8, BEND3, E2F3, ZNF865, PCBD1, ASCC3, JAZF1, TCFL5, 





     
Category Term Count % Genes Benjamini FDR 
GOTERM_C
C_DIRECT 






Appendix 11. The DAVID functional annotation categories (with FDR<0.5) of the 1986 statistically significantly down-regulated gene 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR001849:Pleckstrin 
homology domain 
66 3.48 ARHGAP9, ITK, DGKD, IRS1, PLEKHB1, IRS2, OSBPL11, SYNGAP1, MPRIP, AKT2, PSD3, AKT1, SBF1, 
PHLDA1, RALGPS2, GAB2, ARAP1, VAV1, BCR, ACAP3, TBC1D2, DOK2, ACAP2, ACAP1, DOK3, OBSCN, 
RASA3, PRKD3, RASA2, SPATA13, ARHGEF3, PRKD2, ARHGEF1, SOS1, SOS2, OSBP2, ARHGEF6, GRB7, 
SPTBN5, RASAL1, FGD1, FAM129C, ARHGAP12, FGD3, ABR, CYTH2, PLCG2, STAP1, SPTBN1, OSBPL8, 
AFAP1L2, OSBPL7, IQSEC2, OSBPL5, PLEKHA2, CDC42BPG, OSBPL3, PLCL2, DAB2IP, PLEKHA3, 




88 4.64 ARHGAP9, ITK, DGKD, PID1, IRS1, PLEKHB1, IRS2, ARHGEF10L, OSBPL11, CMIP, RGS3, SYNGAP1, 
MPRIP, AKT2, PSD3, AKT1, LDLRAP1, SBF1, PHLDA1, TNS3, RALGPS2, GAB2, ARAP1, VAV1, BCR, 
TBC1D1, ACAP3, TBC1D2, DOK2, ACAP2, ACAP1, DOK3, OBSCN, RASA3, PRKD3, RASA2, SPATA13, 
ARHGEF3, PRKD2, EVL, ARHGEF1, EZR, SOS1, PLCB2, WDFY4, SOS2, OSBP2, ARHGEF6, GRB7, SPTBN5, 
NUMBL, MTMR3, WBP2, EPB41, RASAL1, FGD1, FAM129C, ARHGAP12, FGD3, ABR, CYTH2, EPB41L3, 
PLCG2, STAP1, EPS8L2, APBB2, FAM43A, SPTBN1, OSBPL8, AFAP1L2, OSBPL7, IQSEC2, OSBPL5, 
PLEKHA2, HOMER2, CDC42BPG, OSBPL3, PLCL2, DAB2IP, PLEKHA3, ARHGAP27, DEF6, PLEKHM1, 
CCM2, PLCH2, PTPN4, PLCD1, SNTB2 
0.00 0.00 
SMART SM00233:PH 66 3.48 ARHGAP9, ITK, DGKD, IRS1, PLEKHB1, IRS2, OSBPL11, SYNGAP1, MPRIP, AKT2, PSD3, AKT1, SBF1, 
PHLDA1, RALGPS2, GAB2, ARAP1, VAV1, BCR, ACAP3, TBC1D2, DOK2, ACAP2, ACAP1, DOK3, OBSCN, 
RASA3, PRKD3, RASA2, SPATA13, ARHGEF3, PRKD2, ARHGEF1, SOS1, SOS2, OSBP2, ARHGEF6, GRB7, 
SPTBN5, RASAL1, FGD1, FAM129C, ARHGAP12, FGD3, ABR, CYTH2, PLCG2, STAP1, SPTBN1, OSBPL8, 
AFAP1L2, OSBPL7, IQSEC2, OSBPL5, PLEKHA2, CDC42BPG, OSBPL3, PLCL2, DAB2IP, PLEKHA3, 




domain:PH 58 3.06 ARHGAP9, ITK, DGKD, IRS1, PLEKHB1, IRS2, OSBPL11, CMIP, SYNGAP1, AKT2, PSD3, AKT1, SBF1, 
PHLDA1, RALGPS2, GAB2, VAV1, BCR, ACAP3, TBC1D2, DOK2, ACAP2, ACAP1, DOK3, OBSCN, RASA3, 
PRKD3, RASA2, SPATA13, ARHGEF3, PRKD2, ARHGEF1, SOS1, SOS2, OSBP2, ARHGEF6, GRB7, SPTBN5, 
RASAL1, ARHGAP12, ABR, CYTH2, PLCG2, STAP1, SPTBN1, OSBPL8, OSBPL7, IQSEC2, OSBPL5, 
CDC42BPG, OSBPL3, PLCL2, DAB2IP, PLEKHA3, ARHGAP27, DEF6, PLCH2, PLCD1 
0.00 0.00 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Zinc 295 15.54 ZMYND8, EHMT2, JMJD1C, EHMT1, CBLB, ADARB2, IKZF3, IKZF5, ZFYVE28, RASSF1, PEG10, ANPEP, 
TNFSF10, ZNF721, TNS3, TRIM22, AGFG2, TRIM23, PRKCH, SP110, PRKCB, PRKCE, ZNF10, PRKCA, 
OVOL1, ZNF14, RUNX1, RNF125, PRKD3, ZC3H11A, TRIM14, PRKD2, ZNF831, FLYWCH1, ADPRM, 
ZNF395, ZNF273, MTMR3, TSHZ1, SP140, TSHZ2, ZBTB1, ZBTB4, ZBTB2, HELZ2, RNF213, ZNF704, 
ZNF703, ZNF823, AMZ2, ZNF821, ZNF700, ZBED6, ZNF266, ZSCAN18, BCL11A, TIPARP, SNAI3, 
SETDB2, NR1D2, NR1D1, ZNF34, PHC3, THAP11, RPS27, ZNF30, SLC2A4RG, PHF3, ITK, PHF2, COL18A1, 
ZCCHC11, GMEB2, ZNF250, ZNF490, PHF1, ZFAND2B, ZCCHC18, GLI1, LIMD1, PHF7, ING1, ZCCHC14, 




ZNF487, ZIK1, ZCCHC24, ZHX2, ZHX3, KCND1, SLC39A10, SIRT5, CBFA2T2, SIRT1, VAV1, SIRT2, 
NAALADL1, MBLAC2, NFX1, MMP17, RNF166, PPARD, ZNF595, SP100, RNASEL, ELOF1, PRICKLE1, 
FGD1, FGD3, RNF135, ADAM28, ZFP14, STAMBPL1, ZNF107, ZSWIM6, MBNL3, RNF130, ZNF224, 
ANKMY1, ZNF101, EGLN1, GIT2, NQO2, MAP3K1, MIB2, SYVN1, MYO9B, DEF8, RNF149, ZNF219, 
TTC3, YPEL1, TCEA2, ZNF699, ZNF335, YPEL5, YPEL4, ZNF575, YPEL3, ZNF211, YPEL2, LIMS1, ZNF331, 
DGKE, DGKD, DGKA, ZBTB20, PRDM2, NR3C1, NR3C2, RNF19A, ENPP2, ZNF569, EP300, SLC39A8, 
ZNF566, CA14, WHSC1L1, SLC39A3, ZNF441, RNF44, MORC3, LMO4, ZBTB38, ADAM10, SLC30A1, 
LMO7, RNF41, ACAP3, ACAP2, ACAP1, ZNF92, KAT6B, ZNF318, ZNF439, DPEP2, UTRN, CARS2, 
S100A8, KMT2E, ZNF671, ZNF791, MAZ, RASAL1, UBR2, RASGRP2, LPP, ZFP36L2, RAI1, MAN2A2, 
MAN2A1, DEAF1, ZKSCAN8, TMEM129, ZNF548, ZNF667, ZNF304, ANKZF1, BPTF, ZBTB18, ZNF540, 
SMAD3, ZBTB14, PHF10, PHF12, ZBTB11, NR4A2, GH1, SP4, MKRN1, ZFP64, PLEKHM1, PHF13, XAF1, 
ZNF654, ZCCHC2, ZNF652, PHF19, ZMYND15, RERE, RNF13, THRA, ZC3H3, AKAP8L, NGLY1, ZC3H6, 
SOBP, IRF2BPL, ALAD, TRPS1, GATAD1, WHSC1, TRIM65, UNKL, ADAMTS6, RBM5, KLF10, MSL2, 
ARAP1, KSR2, KLF16, RASA3, TRAF5, RASA2, ZNF516, ZMYND10, KDM7A, RNFT2, HDAC5, KDM3A, 
PDXK, TRIM52, UHRF2, RNF38, CXXC1, ZBTB44, CXXC5, ZBTB41, U2AF1L4, ZBTB40, HDAC7, CECR1, 
PDLIM1, RNF113A, ABLIM1, TNKS2, ZNF627, RNF39, ZNF862, USP20, RNF24, USP21, QPCTL, 
CDC42BPG, AMFR, LIMK2, KLF3, KLF2, REST, TRIM39, KLF9, ZNF615, TRIM38, ZNF853 
UP_KEYWO
RDS 
Zinc-finger 233 12.28 ZMYND8, JMJD1C, CBLB, IKZF3, IKZF5, ZFYVE28, RASSF1, PEG10, ZNF721, TRIM22, AGFG2, TRIM23, 
PRKCH, SP110, PRKCB, PRKCE, ZNF10, PRKCA, OVOL1, ZNF14, RUNX1, RNF125, PRKD3, ZC3H11A, 
TRIM14, PRKD2, ZNF831, FLYWCH1, ZNF395, ZNF273, MTMR3, TSHZ1, SP140, TSHZ2, ZBTB1, ZBTB4, 
ZBTB2, HELZ2, RNF213, ZNF704, ZNF703, ZNF823, ZNF821, ZNF700, ZBED6, ZNF266, ZSCAN18, 
BCL11A, TIPARP, SNAI3, NR1D2, NR1D1, ZNF34, PHC3, THAP11, RPS27, ZNF30, SLC2A4RG, PHF3, ITK, 
PHF2, ZCCHC11, ZNF250, ZNF490, PHF1, ZFAND2B, ZCCHC18, GLI1, PHF7, ING1, ZCCHC14, TRIM8, 
ING4, ING2, TRIM7, ZMYM3, ZMYM6, REV3L, ZNF248, ZNF367, ZNF487, ZIK1, ZCCHC24, ZHX2, ZHX3, 
CBFA2T2, VAV1, NFX1, RNF166, PPARD, ZNF595, SP100, RNASEL, ELOF1, FGD1, FGD3, RNF135, 
ZFP14, ZNF107, ZSWIM6, MBNL3, RNF130, ZNF224, ANKMY1, ZNF101, EGLN1, GIT2, MAP3K1, MIB2, 
SYVN1, MYO9B, DEF8, RNF149, ZNF219, TTC3, TCEA2, ZNF699, ZNF335, ZNF575, ZNF211, ZNF331, 
DGKE, DGKD, DGKA, ZBTB20, PRDM2, NR3C1, NR3C2, RNF19A, ZNF569, EP300, ZNF566, WHSC1L1, 
ZNF441, RNF44, MORC3, ZBTB38, RNF41, ACAP3, ACAP2, ACAP1, ZNF92, KAT6B, ZNF318, ZNF439, 
UTRN, KMT2E, ZNF671, ZNF791, MAZ, RASAL1, UBR2, RASGRP2, ZFP36L2, RAI1, DEAF1, ZKSCAN8, 
TMEM129, ZNF548, ZNF667, ZNF304, ANKZF1, BPTF, ZBTB18, ZNF540, ZBTB14, PHF10, PHF12, 
ZBTB11, NR4A2, SP4, MKRN1, ZFP64, PLEKHM1, PHF13, XAF1, ZNF654, ZCCHC2, ZNF652, PHF19, 
ZMYND15, RERE, RNF13, THRA, ZC3H3, AKAP8L, ZC3H6, SOBP, IRF2BPL, TRPS1, GATAD1, WHSC1, 
TRIM65, UNKL, RBM5, KLF10, MSL2, ARAP1, KSR2, KLF16, RASA3, TRAF5, RASA2, ZNF516, ZMYND10, 
KDM7A, RNFT2, KDM3A, TRIM52, UHRF2, RNF38, CXXC1, ZBTB44, CXXC5, ZBTB41, U2AF1L4, ZBTB40, 
RNF113A, ZNF627, RNF39, ZNF862, USP20, RNF24, CDC42BPG, AMFR, KLF3, KLF2, REST, TRIM39, 




Metal-binding 410 21.60 EHMT2, EHMT1, ADARB2, ALKBH6, ZFYVE28, ALKBH5, ALKBH4, PRKCH, PRKCB, PRKCE, HPCAL1, 
CACNA2D2, ZNF10, PRKCA, HSPG2, ZNF14, RNF125, PRKD3, ZC3H11A, PRKD2, MPPE1, ADPRM, 
ZNF395, ZNF273, MTMR3, SAR1B, RNF213, HMOX1, AMZ2, ZSCAN18, ZNF266, LHPP, DMPK, TIPARP, 
SNAI3, NR1D2, NR1D1, ZNF34, PHC3, THAP11, EHD3, ZNF30, PLCH2, PHF3, PHF2, ITK, GMEB2, 
ZNF250, ZNF490, PHF1, PHF7, GLI1, ING1, TRIM8, ING4, ING2, TRIM7, IMPA2, SMPD1, TIMP2, 
ZNF248, ZNF367, ZNF487, ZIK1, HAVCR2, CNOT6L, KCND1, SIRT5, EPS15L1, SIRT1, SUMF2, SIRT2, 
PGM2L1, MBLAC2, MMP17, PLCB2, RNF166, PPARD, ZNF595, RNASEL, ELOF1, ADCY4, FGD1, RNF135, 
FGD3, ADAM28, ALOX5, CARNS1, ZNF107, ZSWIM6, MBNL3, P4HTM, RNF130, ZNF224, ZNF101, 




YPEL3, ZNF211, YPEL2, LIMS1, ZNF331, DGKE, DGKD, DGKA, GUCA1B, ZBTB20, SLC8A1, RNF19A, 
ZNF569, ZNF566, WHSC1L1, ZNF441, RNF44, ZBTB38, RNF41, ACAP3, ACAP2, OBSCN, ACAP1, STIM1, 
STIM2, KAT6B, ZNF439, ZNF318, TSSK6, TSSK3, UTRN, S100A8, TRABD2A, FTL, KMT2E, ZNF671, 
ZNF791, ARL3, MAZ, RASAL1, UBR2, AMDHD2, ZKSCAN8, ZNF548, ZNF667, ZNF304, NADK, ZBTB18, 
ZNF540, ZBTB14, TNK2, NEK7, ZBTB11, STK24, SP4, ZFP64, PLEKHM1, TPP1, CNOT8, XAF1, ZNF654, 
ZNF652, ITGB1, BMPR2, RNF13, ADPGK, ZC3H3, AKAP8L, ZC3H6, EFCAB12, ITGAL, ALAD, ITGB7, 
ATP7A, UNKL, TRIM65, ADAMTS6, MSL2, KSR2, NT5C3A, RRM2B, PAPD7, CTDSP2, TRAF5, ZNF516, 
DAGLB, RNFT2, HDAC5, TRIM52, UHRF2, LRP1, RNF38, CXXC1, PPM1K, ZBTB44, PPM1D, CXXC5, 
ZBTB41, HDAC7, ZBTB40, CECR1, ABLIM1, ZNF627, RNF39, ZNF862, RNF24, CDC42BPG, AMFR, KLF3, 
KLF2, TRIM39, KLF9, ZNF615, TRIM38, ZNF853, ISCA1, ACSM3, ZMYND8, ACSM1, GDE1, JMJD1C, 
CBLB, ANTXR2, IKZF3, IKZF5, RASSF1, ANPEP, PEG10, OGFOD2, TNFSF10, ZNF721, TNS3, TRIM22, 
AGFG2, TRIM23, SP110, OVOL1, RUNX1, CYP27A1, SIK3, TRIM14, FLYWCH1, ZNF831, PDE1B, TSHZ1, 
SP140, TSHZ2, ZBTB1, ZBTB4, ZBTB2, HELZ2, NUAK2, ZNF704, ARSK, ZNF703, ZNF823, ZNF821, 
ZNF700, ZBED6, RAB11FIP4, BCL11A, SETDB2, RPS27, CALM1, SLC2A4RG, COL18A1, ZCCHC11, 
ZFAND2B, ZCCHC18, LIMD1, ZCCHC14, PPP3CA, ZMYM3, NMRK1, ZMYM6, REV3L, IDS, SPTAN1, 
ZCCHC24, ZHX2, ZHX3, CBFA2T2, VAV1, NAALADL1, PITPNM1, NFX1, PITPNM2, SP100, GDPD1, 
GDPD3, PRICKLE1, NKD1, ZFP14, STAMBPL1, MGAT1, ANKMY1, MAP3K2, MAP3K3, GIT2, NQO2, 
MAP3K1, MIB2, MYO9B, PDP1, TTC3, TCEA2, ESYT1, CAPS, CIB1, PRDM2, NR3C1, NR3C2, GNPTAB, 
ENPP2, CAPN3, EP300, CA14, MORC3, LIG1, LMO4, ADAM10, CYBA, LMO7, ZNF92, DPEP2, CARS2, 
GNAZ, CABP4, RASGRP2, ACACB, LPP, ZFP36L2, RAI1, MAN2A2, MAN2A1, DEAF1, TMEM129, ANKZF1, 
BPTF, SMAD3, PHF10, PHF12, TRPV1, GNAO1, NR4A2, GH1, MKRN1, PHF13, ZCCHC2, PHF19, 
ZMYND15, RERE, B4GALT3, B4GALT1, MAST4, THRA, PRKCSH, NGLY1, ATP2A3, ATP2A1, SOBP, SGSH, 
IRF2BPL, TRPS1, CYP4V2, GATAD1, PDE4B, PDE4A, WHSC1, RBM5, KLF10, PLA2G4B, ARAP1, KLF16, 
RCN3, LATS2, RASA3, OAS2, RASA2, ZMYND10, MAN1B1, KDM7A, PDXK, KDM3A, NT5C2, U2AF1L4, 
GNA13, PDLIM1, RNF113A, TNKS2, MAN1C1, GALNT3, USP20, USP21, POLM, ATP13A1, QPCTL, 





241 12.70 ACSM3, ACSM1, GDE1, JMJD1C, ADARB2, ANTXR2, IKZF3, IKZF5, ZFYVE28, ALKBH5, RASSF1, ALKBH4, 
TNFSF10, ZNF721, TNS3, AGFG2, PRKCH, PRKCE, CACNA2D2, ZNF10, PRKCA, OVOL1, ZNF14, RUNX1, 
PRKD3, ZC3H11A, PRKD2, ZNF831, FLYWCH1, ADPRM, ZNF395, ZNF273, MTMR3, PDE1B, SAR1B, 
TSHZ1, TSHZ2, ZBTB1, ZBTB4, ZBTB2, HELZ2, ZNF704, ARSK, ZNF703, ZNF823, HMOX1, ZNF821, 
ZNF700, ZBED6, ZNF266, ZSCAN18, DMPK, BCL11A, TIPARP, ADHFE1, ZNF34, ZNF30, SLC2A4RG, ITK, 
COL18A1, GMEB2, ZNF250, ZNF490, GLI1, NMRK1, REV3L, TIMP2, IDS, ZNF248, ZNF367, ZNF487, 
ZIK1, HAVCR2, ZHX2, ZHX3, KCND1, CNOT6L, CBFA2T2, SIRT1, PGM2L1, VAV1, SUMF2, NAALADL1, 
MBLAC2, PITPNM1, PITPNM2, ZNF595, RNASEL, ELOF1, GDPD1, ADCY4, GDPD3, FGD1, FGD3, 
ADAM28, ZFP14, STAMBPL1, CARNS1, ZNF107, MGAT1, MBNL3, ZNF224, ANKMY1, ZNF101, MAP3K2, 
GIT2, MAP3K3, NQO2, MIB2, MYO9B, DEF8, PDP1, ZNF219, YPEL1, ZNF699, ESYT1, ZNF335, YPEL5, 
YPEL4, ZNF575, YPEL3, ZNF211, YPEL2, ZNF331, DGKE, DGKD, ZBTB20, PRDM2, ENPP2, ZNF569, 
ZNF566, CA14, ZNF441, LIG1, ZBTB38, ADAM10, CYBA, ACAP3, ACAP2, ACAP1, OBSCN, ZNF92, 
ZNF439, DPEP2, CARS2, TRABD2A, ZNF671, GNAZ, ZNF791, ARL3, MAZ, RASAL1, ACACB, ZFP36L2, 
DEAF1, AMDHD2, ZKSCAN8, TMEM129, ZNF548, ZNF667, ZNF304, NADK, ANKZF1, ZBTB18, ZNF540, 
ZBTB14, TNK2, NEK7, TRPV1, ZBTB11, GNAO1, GH1, STK24, SP4, MKRN1, ZFP64, PLEKHM1, TPP1, 
CNOT8, ZNF654, ZNF652, ITGB1, ZMYND15, B4GALT3, BMPR2, ADPGK, ZC3H3, AKAP8L, NGLY1, 
ATP2A3, ATP2A1, ZC3H6, ITGAL, SOBP, IRF2BPL, SGSH, ALAD, TRPS1, PDE4B, PDE4A, ITGB7, KLF10, 
ARAP1, KSR2, KLF16, LATS2, PAPD7, RASA3, RRM2B, OAS2, CTDSP2, RASA2, ZNF516, ZMYND10, 




ZNF627, ZNF862, POLM, ATP13A1, USP21, ATP2B4, KLF3, KLF2, GALNS, REST, KLF9, ZNF615, CHPT1, 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
GTPase activation 41 2.16 ARHGAP9, USP6NL, RGS14, FAM13B, NPRL2, LRRK2, ARHGAP18, RASAL1, ARHGAP6, SIPA1L3, 
ARHGAP4, ARHGAP12, ABR, RGS2, SIPA1L1, SYNGAP1, TBC1D10C, SRGAP3, TBC1D22A, RAP1GAP2, 
GIT2, DAB2IP, TBC1D9, MYO9B, ARHGAP27, ARAP1, BCR, TBC1D1, ACAP3, ACAP2, TBC1D2, ACAP1, 






50 2.63 ARHGAP9, USP6NL, FAM13B, LRRK2, ARHGEF10L, ARHGAP6, SIPA1L3, ARHGAP4, RGS2, SIPA1L1, 
RGS3, SYNGAP1, TBC1D10C, TBC1D22A, AGFG2, AXIN1, TBC1D9, ARAP1, BCR, TBC1D1, ACAP3, 
TBC1D2, ACAP2, ACAP1, RABEP2, RASA3, TBC1D20, RASA2, RAPGEF2, RIN3, ARHGEF1, DEPDC5, 
SOS1, RIN2, ARHGEF6, RGS14, NPRL2, ARHGAP18, RASAL1, ARHGAP12, ABR, SRGAP3, RAP1GAP2, 





regulation of GTPase 
activity 
83 4.37 ARHGAP9, ITGB1, FAM13B, DENND5B, IRS1, LRRK2, IRS2, ARHGEF10L, ARHGAP6, SIPA1L3, ARHGAP4, 
RCBTB2, RGS2, RGS3, SYNGAP1, PSD3, SBF1, SPTAN1, AGFG2, RALGPS2, AXIN1, ARAP1, VAV1, BCR, 
ACAP3, TBC1D2, ACAP2, ACAP1, OBSCN, RABEP2, RASA3, TBC1D20, AKAP9, RASA2, MADD, SPATA13, 
ARHGEF3, RAPGEF2, RIN3, ARHGEF1, DENND6B, DENND6A, DEPDC5, SOS1, RIN2, SOS2, RAPGEF3, 
ARHGEF6, SPTBN5, RGS14, NPRL2, ARHGAP18, RASAL1, RASGRP2, FGD1, ARHGAP12, FGD3, ABR, 
CYTH2, TBXA2R, CCL5, S1PR1, EPS8L2, SRGAP3, RALGDS, SPTBN1, RAP1GAP2, GIT2, SEMA4D, IQSEC2, 
DAB2IP, MYO9B, ARHGAP27, GNAO1, DNMBP, SGSM2, IL2RB, GNB5, RGL4, CALM1, RGL2, LIMS1, 
FGFR1 
0.04 0.04 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Kinase 115 6.06 DGKE, DGKD, CERK, PANK1, DGKA, IGF1R, AKT2, PDK4, PDK3, AKT1, PIP4K2B, MAP3K9, SEPHS2, 
MAP2K3, PRKCH, PRKCB, DAPK2, PRKCE, LMTK2, DYRK1B, PRKCA, MAPK8IP3, BCR, DOK2, OBSCN, 
PRKD3, AKAP9, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, PI4K2A, CSNK1G2, CDKL1, PXK, PFKFB3, AK1, 
PIK3R1, NUAK2, GRK5, PRKAR2A, GRK6, NADK, PACSIN1, MAP2K6, IP6K2, SRPK2, FN3K, CDK19, 
SRMS, DMPK, TNK2, TNK1, NEK7, PHKB, UCKL1, CLK1, ADCK2, STK24, GKAP1, PKIA, PI4KA, ATM, 
CALM1, MAP3K12, FGFR1, CDKN1C, ITK, CDKN1B, FLT1, BMPR2, DYRK2, MAST4, PRKCSH, ADPGK, 
MAST3, LRRK2, AKAP8L, AATK, DSTYK, PIP5KL1, NMRK1, TK2, MAP4K1, MAP4K2, SYK, MINK1, KSR2, 
IRAK4, GAK, SGK223, LATS2, LCK, PDXK, PRKX, CAMKK1, PAPSS2, PHKG2, MAPK1, CDKN2D, MAP3K2, 




domain:Protein kinase 76 4.00 EPHB6, ITK, FLT1, BMPR2, DYRK2, MAST4, MAST3, LRRK2, AATK, IGF1R, DSTYK, AKT2, AKT1, MAP3K9, 
MAP4K1, MAP2K3, MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, 
KSR2, IRAK4, GAK, SGK223, LATS2, PRKD3, LCK, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, TRIB1, 
CSNK1G2, CDKL1, GUCY2C, RNASEL, PXK, PRKX, CAMKK1, NUAK2, GRK5, PHKG2, GRK6, MAPK1, 
MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, SRMS, MAP3K1, MLKL, DMPK, CDC42BPG, 




INTERPRO IPR000719:Protein kinase, 
catalytic domain 
77 4.06 EPHB6, ITK, FLT1, BMPR2, DYRK2, MAST4, MAST3, LRRK2, AATK, IGF1R, DSTYK, AKT2, AKT1, MAP3K9, 
MAP4K1, MAP2K3, MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, 
KSR2, IRAK4, GAK, SGK223, LATS2, OBSCN, PRKD3, LCK, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, 
TRIB1, CSNK1G2, CDKL1, GUCY2C, RNASEL, PXK, PRKX, CAMKK1, NUAK2, GRK5, PHKG2, GRK6, 
MAPK1, MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, SRMS, MAP3K1, MLKL, DMPK, 







63 3.32 BMPR2, DYRK2, MAST4, MAST3, LRRK2, AATK, DSTYK, AKT2, AKT1, MAP3K9, MAP4K1, MAP2K3, 
MAP4K2, PRKCH, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, KSR2, IRAK4, GAK, BCR, 
LATS2, OBSCN, PRKD3, SIK3, TSSK6, PRKD2, ULK1, TSSK3, CSNK1G2, CDKL1, PRKX, CAMKK1, NUAK2, 
GRK5, PHKG2, GRK6, MAPK1, MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, MAP3K1, DMPK, 




80 4.21 EPHB6, ITK, FLT1, BMPR2, DYRK2, MAST4, MAST3, LRRK2, AATK, IGF1R, DSTYK, AKT2, AKT1, MAP3K9, 
MAP4K1, MAP2K3, MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, 
KSR2, IRAK4, GAK, SGK223, LATS2, OBSCN, PRKD3, LCK, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, 
TRIB1, CSNK1G2, CDKL1, GUCY2C, RNASEL, PXK, PRKX, CAMKK1, NUAK2, GRK5, PHKG2, GRK6, 
MAPK1, MAP2K6, SRPK2, MAP3K2, FN3K, MAP3K3, CDK19, CDK11A, SRMS, MAP3K1, MLKL, DMPK, 
CDC42BPG, LIMK2, TNK2, TNK1, NEK7, MERTK, CLK1, SBK1, ADCK2, STK24, TAOK2, PI4KA, PKN2, 






72 3.79 EPHB6, DYRK2, LRRK2, GMFG, AATK, PDK4, AKT1, MAP3K9, MAP4K1, MAP4K2, MORC3, PRKCH, SYK, 
PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, ADAM10, PRKCA, KSR2, CDC25B, GAK, BCR, LATS2, 
OBSCN, PRKD3, LCK, SIK3, TSSK6, PRKD2, ULK1, TSSK3, TRIB1, CSNK1G2, CDKL1, GUCY2C, RNASEL, 
PXK, CTBP1, NPRL2, TAF1L, PIK3R1, CAMKK1, FYB, NUAK2, PHKG2, GRK6, MAPK1, C19ORF35, SRPK2, 
MAP3K2, CDK19, CDK11A, MAP3K1, MLKL, DMPK, CDC42BPG, LIMK2, TNK1, NEK7, PHKB, MERTK, 







62 3.27 DYRK2, MAST4, MAST3, LRRK2, AATK, DSTYK, AKT2, PDK3, AKT1, MAP3K9, MAP4K1, MAP2K3, 
MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, KSR2, IRAK4, GAK, 
BCR, LATS2, OBSCN, SIK3, TSSK6, PRKD2, ULK1, TSSK3, CSNK1G2, CDKL1, TAF1L, PRKX, CAMKK1, 
NUAK2, GRK5, PHKG2, MAPK1, MAP2K6, SRPK2, MAP3K2, CDK19, CDK11A, MAP3K1, DMPK, 




binding site:ATP 79 4.16 ITK, FLT1, BMPR2, DYRK2, ACSM3, MAST4, MAST3, ACSM1, LRRK2, ATP2A3, AATK, IGF1R, DSTYK, 
NMRK1, AKT2, PDK4, PDK3, AKT1, MAP3K9, MAP4K1, MAP2K3, MAP4K2, PRKCH, LIG1, SYK, PRKCB, 
DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, IRAK4, SGK223, LATS2, OBSCN, PRKD3, LCK, SIK3, 
TSSK6, PRKD2, ROR1, ULK1, TSSK3, CARS2, CSNK1G2, CDKL1, PRKX, CAMKK1, NUAK2, GRK5, PHKG2, 
GRK6, MAPK1, MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, SRMS, MAP3K1, DMPK, 
CDC42BPG, LIMK2, TNK2, TNK1, NEK7, MERTK, ACSF2, CLK1, EHD3, SBK1, ADCK2, STK24, TAOK2, 






28 1.48 MAST4, MAST3, LRRK2, PRKX, PKD1, AKT2, AKT1, MAPK1, PDK3, MAP4K1, MORC3, PRKCH, SYK, 
DMPK, PRKCB, PRKCE, LMTK2, PRKCA, CLK1, LATS2, PRKD3, PRKD2, PKN2, ULK1, ATM, CSNK1G2, 
TAF1, MAP3K12 
0.04 0.04 
INTERPRO IPR017441:Protein kinase, 
ATP binding site 
59 3.11 ITK, FLT1, BMPR2, DYRK2, LRRK2, AATK, IGF1R, DSTYK, AKT2, AKT1, MAP3K9, MAP4K1, MAP2K3, 
MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, LMTK2, PRKCA, LATS2, OBSCN, PRKD3, 
LCK, SIK3, TSSK6, PRKD2, ULK1, TSSK3, CSNK1G2, CDKL1, PRKX, CAMKK1, NUAK2, GRK5, PHKG2, 
GRK6, MAPK1, MAP2K6, SRPK2, MAP3K2, CDK19, SRMS, MAP3K1, DMPK, CDC42BPG, LIMK2, TNK2, 






Transferase 192 10.12 DPAGT1, DGKE, DGKD, CERK, PANK1, DGKA, EHMT2, XYLT2, XYLT1, EHMT1, SAT2, PRDM2, SAT1, 
IGF1R, NDST1, AS3MT, PTAR1, HERC3, POFUT2, GNPTAB, RNF19A, AKT2, PDK4, PDK3, AKT1, EP300, 
PIP4K2B, MAP3K9, SEPHS2, WHSC1L1, MAP2K3, ST6GAL1, PRKCH, PRKCB, DAPK2, PRKCE, GPT2, 
LMTK2, DYRK1B, PRKCA, MAPK8IP3, BCR, PLA2G15, DOK2, OBSCN, PRKD3, KAT6B, AKAP9, SIK3, 
TSSK6, PRKD2, ROR1, ULK1, TSSK3, PI4K2A, CSNK1G2, CDKL1, KMT2E, PXK, PFKFB3, AK1, PIK3R1, 
PTDSS1, NUAK2, GRK5, CHST11, CHST12, PRKAR2A, GRK6, CHST15, NADK, PACSIN1, MAP2K6, IP6K2, 
SRPK2, FN3K, GSTM4, CDK19, UBE2H, SRMS, DMPK, TIPARP, TNK2, TNK1, NEK7, SETDB2, PHKB, 
PARP16, UCKL1, CLK1, ADCK2, STK24, GKAP1, PKIA, PI4KA, NMT2, ATM, CALM1, OGT, CDS2, 
MAP3K12, FGFR1, CDKN1C, ITK, B4GALT3, ZCCHC11, CDKN1B, FLT1, B4GALT1, BMPR2, NAA40, 
DYRK2, MAST4, PRKCSH, ADPGK, MAST3, LRRK2, AKAP8L, SETD7, AATK, PYGM, HS2ST1, DSTYK, 
PIP5KL1, NMRK1, REV3L, TK2, WHSC1, COLGALT1, MAP4K1, MAP4K2, PARP4, SYK, NCOA3, MINK1, 
AMT, NSUN6, KSR2, NSUN7, IRAK4, PGM2L1, GAK, NT5C3A, SGK223, KAT2B, KAT2A, LATS2, PAPD7, 
OAS2, LCK, ST6GALNAC4, ST6GALNAC6, AGPAT5, PDXK, ZDHHC20, PRKX, CAMKK1, PAPSS2, TNKS2, 
MGAT5, PHKG2, GCNT2, HAS3, MAPK1, MGAT1, METTL7A, CDIPT, CDKN2D, MAP3K2, GIT2, MAP3K3, 
MAP3K1, GALNT3, POLM, TPK1, CDC42BPG, AMFR, QPCTL, MBOAT7, LIMK2, MBOAT1, UBE2G1, 






57 3.00 EPHB6, LRRK2, AATK, AKT2, PDK4, PDK3, AKT1, MAP3K9, MAP4K1, MAP2K3, MAP4K2, PRKCH, SYK, 
PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, PRKCA, KSR2, IRAK4, GAK, SGK223, OBSCN, SIK3, TSSK6, 
PRKD2, ROR1, AVP, TRIB1, CSNK1G2, CDKL1, GUCY2C, RNASEL, PXK, NPRL2, CCL5, PHKG2, C19ORF35, 
MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, MAP3K1, MLKL, DMPK, LIMK2, TNK2, NEK7, 




ATP-binding 160 8.43 EPHB6, DGKE, DGKD, CERK, ACSM3, PANK1, ACSM1, DGKA, SMC4, IGF1R, AKT2, PDK4, PDK3, AKT1, 
PIP4K2B, MAP3K9, SEPHS2, MAP2K3, PRKCH, LIG1, FBXO18, PRKCB, DAPK2, PRKCE, STARD9, LMTK2, 
DYRK1B, PRKCA, BCR, OBSCN, SLFN11, PRKD3, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, KIF20B, 
CARS2, PI4K2A, ABCG1, CSNK1G2, CDKL1, PFKFB3, ABCB1, UBA7, TARSL2, AK1, ABCB8, ACACB, 
HELZ2, NUAK2, GRK5, NLRP6, GRK6, EP400, NLRP1, KIF3C, N4BP2, NADK, MAP2K6, IP6K2, ABCA1, 
SRPK2, ABCA2, MYH7B, CDK19, UBE2H, DNAH10, SRMS, MLKL, DMPK, TNK2, HSPA7, TNK1, NEK7, 
HSPA6, ABCA9, ABCA7, TRPV1, ACSF2, UCKL1, CLK1, EHD3, GCLC, ADCK2, STK24, PI4KA, ATM, 
MAP3K12, FGFR1, ITK, FLT1, BMPR2, DYRK2, MAST4, CHD9, MAST3, LRRK2, DDX12P, ATP2A3, AATK, 
ATP2A1, DSTYK, PIP5KL1, NMRK1, TK2, ATP7A, ABCD1, MAP4K1, MAP4K2, ABCC2, APAF1, SYK, 
ABCC5, MINK1, KSR2, PEX1, IRAK4, KIF22, QRSL1, GAK, SGK223, LATS2, KIFC2, OAS2, LCK, PEX6, 
MCM6, PDXK, RNASEL, ACSS2, ADCY4, NLRC3, PRKX, CAMKK1, PAPSS2, PHKG2, CARNS1, MAPK1, 
ACSS1, MAP3K2, MAP3K3, CDK11A, MAP3K1, ATP13A1, TPK1, CDC42BPG, LIMK2, ATP2B4, MYO9B, 




Nucleotide-binding 197 10.38 EPHB6, ACSM3, CERK, PANK1, ACSM1, SMC4, AKT2, PDK4, PDK3, AKT1, PIP4K2B, SEPHS2, TRIM23, 
PRKCH, ARL15, PRKCB, DAPK2, PRKCE, STARD9, PRKCA, GTPBP1, BCR, PRKD3, SIK3, ULK1, PRKD2, 
KIF20B, PI4K2A, ABCB1, RRAD, TARSL2, SAR1B, ABCB8, HELZ2, NUAK2, PRKAR2A, N4BP2, ABCA1, 
SRPK2, ABCA2, MYH7B, CDK19, SRMS, DNAH10, DMPK, ABCA9, ABCA7, EHD3, ADCK2, ATM, ITK, 
DIRAS1, DDX12P, AATK, PYGM, DSTYK, NMRK1, TK2, MAP4K1, MAP4K2, SYK, MINK1, RHOH, TUBG2, 
KIF22, GNL1, RHOB, RAB33B, GAK, KIFC2, RAPGEF3, GUCY2C, RNASEL, ATL1, ADCY4, PRKX, CAMKK1, 
PAPSS2, CARNS1, MFN1, REM2, MAP3K2, MAP3K3, MAP3K1, TPK1, MYO9B, UBE2G1, TAOK2, PKN2, 
SLC27A1, DGKE, DGKD, DGKA, IGF1R, MAP3K9, MAP2K3, LIG1, FBXO18, LMTK2, DYRK1B, TUBA4A, 
RAB30, OBSCN, SLFN11, RAB37, TSSK6, TSSK3, ROR1, SLC27A3, CARS2, ABCG1, CSNK1G2, CDKL1, 
GNAZ, PFKFB3, UBA7, ARL3, AK1, ACACB, GRK5, NLRP6, GRK6, EP400, KIF3C, NLRP1, RAB6A, NADK, 




GNAO1, GCLC, STK24, PI4KA, MAFK, MAP3K12, FGFR1, BMPR2, DYRK2, FLT1, MAST4, CHD9, MAST3, 
LRRK2, ATP2A3, ATP2A1, PIP5KL1, ATP7A, ABCD1, ABCC2, APAF1, ABCC5, PEX1, KSR2, IRAK4, QRSL1, 
NT5C3A, ARL4C, SGK223, LATS2, OAS2, LCK, PEX6, MCM6, PDXK, ACSS2, RALB, NLRC3, NT5C2, 
GNA13, RAB40B, PHKG2, RAB24, MAPK1, ACSS1, CDK11A, ATP13A1, CDC42BPG, LIMK2, MX2, 





87 4.58 ITK, FLT1, BMPR2, DYRK2, MAST4, ADPGK, MAST3, LRRK2, AATK, IGF1R, DSTYK, NMRK1, AKT2, AKT1, 
MAP3K9, L3HYPDH, ACAD8, MAP4K1, MAP2K3, MAP4K2, PRKCH, SYK, PRKCB, DAPK2, PRKCE, MINK1, 
RNASE6, DYRK1B, LMTK2, SIRT5, RNASE4, PRKCA, IRAK4, RNASE1, SIRT1, SIRT2, GAK, SGK223, LATS2, 
OBSCN, ALDH5A1, PRKD3, LCK, SIK3, TSSK6, PRKD2, ROR1, ULK1, TSSK3, CSNK1G2, ALDH9A1, CDKL1, 
HSD17B13, PRKX, HSD17B11, CAMKK1, NUAK2, GRK5, RDH10, PHKG2, GRK6, MAPK1, MAP2K6, 
SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, SRMS, MAP3K1, DMPK, CDC42BPG, QPCTL, TNK2, TNK1, 
NEK7, MERTK, CLK1, SBK1, ADCK2, STK24, TAOK2, GALM, PKN2, CRAT, FGFR1, MAP3K12 
0.08 0.08 
SMART SM00220:S_TKc 57 3.00 DYRK2, MAST4, MAST3, LRRK2, DSTYK, AKT2, AKT1, MAP3K9, MAP4K1, MAP2K3, MAP4K2, PRKCH, 
PRKCB, DAPK2, PRKCE, MINK1, DYRK1B, PRKCA, KSR2, IRAK4, GAK, SGK223, LATS2, OBSCN, PRKD3, 
SIK3, TSSK6, PRKD2, ULK1, TSSK3, TRIB1, CSNK1G2, CDKL1, RNASEL, PRKX, CAMKK1, NUAK2, GRK5, 
PHKG2, GRK6, MAPK1, MAP2K6, SRPK2, MAP3K2, MAP3K3, CDK19, CDK11A, MAP3K1, DMPK, 
CDC42BPG, NEK7, CLK1, SBK1, STK24, TAOK2, PKN2, MAP3K12 
0.07 0.07 
INTERPRO IPR008271:Serine/threoni
ne-protein kinase, active 
site 
46 2.42 DYRK2, MAST4, MAST3, LRRK2, PRKX, CAMKK1, DSTYK, NUAK2, AKT2, PHKG2, GRK6, AKT1, MAPK1, 
MAP3K9, MAP2K6, SRPK2, MAP2K3, CDK11A, CDK19, PRKCH, MAP3K1, DMPK, PRKCB, CDC42BPG, 
PRKCE, DAPK2, NEK7, MINK1, DYRK1B, PRKCA, KSR2, GAK, CLK1, OBSCN, SBK1, LATS2, PRKD3, TAOK2, 






113 5.95 EPHB6, ACSM3, ACSM1, SMC4, IGF1R, AKT2, PDK4, PDK3, AKT1, MAP3K9, SEPHS2, MAP2K3, PRKCH, 
PRKCB, DAPK2, PRKCE, STARD9, LMTK2, DYRK1B, PRKCA, OBSCN, SLFN11, PRKD3, SIK3, TSSK6, 
PRKD2, ROR1, ULK1, TSSK3, KIF20B, ABCG1, CSNK1G2, CDKL1, PFKFB3, UBA7, AK1, ABCB8, ACACB, 
HELZ2, NUAK2, GRK5, NLRP6, GRK6, EP400, NLRP1, KIF3C, N4BP2, MAP2K6, SRPK2, MYH7B, CDK19, 
DNAH10, SRMS, DMPK, TNK2, TNK1, NEK7, ACSF2, UCKL1, CLK1, EHD3, ADCK2, STK24, MAP3K12, 
FGFR1, ITK, FLT1, BMPR2, DYRK2, MAST4, CHD9, MAST3, LRRK2, DDX12P, AATK, DSTYK, NMRK1, 
ABCD1, MAP4K1, MAP4K2, APAF1, SYK, MINK1, PEX1, IRAK4, KIF22, SGK223, LATS2, KIFC2, LCK, PEX6, 
MCM6, PDXK, NLRC3, PRKX, CAMKK1, PAPSS2, PHKG2, CARNS1, MAPK1, MAP3K2, MAP3K3, CDK11A, 




GO:0005524~ATP binding 171 9.01 EPHB6, DGKE, DGKD, CERK, ACSM3, PANK1, ACSM1, DGKA, SMC4, IGF1R, SMCHD1, AKT2, PDK4, 
PDK3, AKT1, PIP4K2B, MAP3K9, SEPHS2, MAP2K3, PRKCH, LIG1, FBXO18, PRKCB, DAPK2, PRKCE, 
STARD9, LMTK2, DYRK1B, PRKCA, RUNX1, BCR, OBSCN, SLFN11, PRKD3, SIK3, TSSK6, PRKD2, ROR1, 
ULK1, TSSK3, KIF20B, TRIB1, CARS2, PI4K2A, ABCG1, CSNK1G2, CDKL1, PXK, PFKFB3, ABCB1, UBA7, 
TARSL2, AK1, ABCB8, ACACB, HELZ2, NUAK2, GRK5, NLRP6, GRK6, EP400, NLRP1, KIF3C, N4BP2, 
NADK, MAP2K6, IP6K2, ABCA1, SRPK2, ABCA2, MYH7B, CDK19, UBE2H, DNAH10, SRMS, MLKL, DMPK, 
TNK2, HSPA7, TNK1, NEK7, HSPA6, ABCA9, ABCA7, TRPV1, ACSF2, UCKL1, CLK1, EHD3, GCLC, ADCK2, 
STK24, PI4KA, ATM, ITM2B, MAP3K12, FGFR1, ITK, FLT1, BMPR2, DYRK2, MAST4, CHD9, MAST3, 
LRRK2, DDX12P, ATP2A3, AATK, ATP2A1, DSTYK, PIP5KL1, NMRK1, TK2, ATP7A, ABCD1, MAP4K1, 
MAP4K2, ABCC2, APAF1, SYK, ABCC5, MINK1, KSR2, PEX1, IRAK4, KIF22, QRSL1, GAK, SGK223, LATS2, 
KIFC2, OAS2, LCK, PEX6, MCM6, GUCY2C, PDXK, RNASEL, ACSS2, ADCY4, NLRC3, PRKX, CAMKK1, 
PAPSS2, PHKG2, CARNS1, MAPK1, ACSS1, MAP3K2, MAP3K3, CDK11A, MAP3K1, KCNJ11, ATP13A1, 
TPK1, PNPLA8, CDC42BPG, LIMK2, ATP2B4, MYO9B, UBE2G1, MERTK, P2RX5, SBK1, MYO15B, P2RX1, 
TAOK2, PKN2, ERCC6, MYO1F, TAF1 
0.28 0.27 







     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR019787:Zinc finger, 
PHD-finger 
23 1.21 KMT2E, PHF3, PHF2, SP100, UHRF2, PHF10, SP110, PHF1, PHF12, ZMYND8, SP140, CXXC1, ING1, 
ING4, ING2, KAT6B, NFX1, PHF13, WHSC1, KDM7A, WHSC1L1, PHF19, BPTF 
0.00 0.00 
INTERPRO IPR001965:Zinc finger, 
PHD-type 
24 1.26 KMT2E, PHF3, PHF2, SP100, UHRF2, PHF10, SP110, PHF1, PHF12, ZMYND8, SP140, CXXC1, PHF7, 
ING1, ING4, RAI1, ING2, KAT6B, PHF13, WHSC1, KDM7A, WHSC1L1, PHF19, BPTF 
0.00 0.00 
SMART SM00249:PHD 24 1.26 KMT2E, PHF3, PHF2, SP100, UHRF2, PHF10, SP110, PHF1, PHF12, ZMYND8, SP140, CXXC1, PHF7, 
ING1, ING4, RAI1, ING2, KAT6B, PHF13, WHSC1, KDM7A, WHSC1L1, PHF19, BPTF 
0.00 0.00 
INTERPRO IPR019786:Zinc finger, 
PHD-type, conserved site 
19 1.00 KMT2E, PHF3, PHF2, SP100, SP110, PHF1, PHF12, ZMYND8, SP140, CXXC1, ING1, ING4, ING2, NFX1, 
WHSC1, KDM7A, WHSC1L1, PHF19, BPTF 
0.01 0.01 
INTERPRO IPR011011:Zinc finger, 
FYVE/PHD-type 
28 1.48 KMT2E, PHF3, PHF2, SP100, MTMR3, UHRF2, PHF1, ZMYND8, SP140, CXXC1, PHF7, ING1, ZFYVE28, 







14 0.74 KMT2E, PHF3, PHF2, UHRF2, SP110, ZMYND8, SP140, CXXC1, ING1, ING4, RAI1, ING2, PHF13, KDM7A 0.12 0.12 
INTERPRO IPR013083:Zinc finger, 
RING/FYVE/PHD-type 
62 3.27 PHF3, PHF2, RNF13, PHF1, ZMYND8, CBLB, PHF7, ING1, ZFYVE28, TRIM8, ING4, ING2, TRIM7, 
RNF19A, WHSC1, TRIM65, TRIM22, WHSC1L1, TRIM23, RNF44, SP110, SYTL1, NOSIP, SYTL3, RNF41, 
RNF125, KAT6B, TRAF5, RNF166, KDM7A, RNFT2, KMT2E, SP100, MTMR3, TRIM52, UHRF2, SP140, 
RNF38, CXXC1, FGD1, RNF135, FGD3, RNF113A, RNF213, RNF39, RNF130, BPTF, MAP3K1, RNF24, 
PHF10, USP20, AMFR, PHF12, MIB2, SYVN1, TRIM39, RNF149, MKRN1, TTC3, PHF13, TRIM38, PHF19 
0.11 0.11 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
SH3 domain 40 2.11 ARHGAP9, ITK, NCF4, SLA, MIA3, PIK3R1, SLA2, FYB, ARHGAP4, CRKL, ARHGAP12, SH3TC1, PLCG2, 
EPS8L2, MAP3K9, SRGAP3, SPTAN1, PACSIN1, MPP1, SRMS, TNK2, TNK1, ARHGAP27, SORBS3, VAV1, 





domain:SH3 34 1.79 ARHGAP9, ITK, NCF4, SLA, MIA3, PIK3R1, SLA2, FYB, ARHGAP4, ARHGAP12, SH3TC1, PLCG2, EPS8L2, 
MAP3K9, SRGAP3, SPTAN1, PACSIN1, MPP1, LOC440461, SRMS, TNK2, TNK1, ARHGAP27, MPP7, 




40 2.11 ARHGAP9, ITK, NCF4, SLA, MIA3, PIK3R1, SLA2, FYB, ARHGAP4, CRKL, ARHGAP12, SH3TC1, PLCG2, 
EPS8L2, MAP3K9, SRGAP3, SPTAN1, PACSIN1, MPP1, SRMS, TNK2, TNK1, ARHGAP27, SORBS3, VAV1, 
MPP7, FCHSD1, CACNB2, AHI1, OBSCN, DLG2, DNMBP, MYO15B, BIN1, ABI3, LCK, SPATA13, GRAP, 
MYO1F, ARHGEF6 
0.01 0.01 
SMART SM00326:SH3 36 1.90 ITK, NCF4, SLA, PIK3R1, SLA2, FYB, ARHGAP4, CRKL, ARHGAP12, SH3TC1, PLCG2, EPS8L2, MAP3K9, 
SRGAP3, SPTAN1, PACSIN1, MPP1, SRMS, TNK2, TNK1, SORBS3, VAV1, MPP7, FCHSD1, CACNB2, 
AHI1, DLG2, DNMBP, MYO15B, BIN1, ABI3, LCK, SPATA13, GRAP, MYO1F, ARHGEF6 
0.13 0.12 







     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Transcription regulation 265 13.96 HDAC10, JMJD1C, IKZF3, IKZF5, ALKBH4, CREB3L2, CPNE1, BBX, CCNL2, ZNF721, CCNL1, TRIM22, 
TSPYL2, SFMBT1, SP110, PRKCB, ZNF10, SOX12, RFX1, OVOL1, ZNF14, RUNX1, EID2, TXNIP, HOXB2, 
MAML3, ASF1A, ZNF395, ZNF273, CTBP1, TSHZ1, TSHZ2, ZBTB1, ZBTB4, DEDD2, ZBTB2, HELZ2, 
ZNF703, ZNF823, ZNF821, ZNF700, ZBED6, SCAI, ZNF266, BANP, ZSCAN18, JUND, BCL11A, SNAI3, 
SS18L1, NFATC3, NFATC1, NR1D2, NR1D1, ZNF34, FLI1, FOSL2, THAP11, ZNF30, CREBRF, ID3, HBP1, 
RCOR1, SLC2A4RG, PHF2, BTG2, GMEB2, ZNF250, CITED2, TCF25, ZNF490, PHF1, SETD7, GLI1, LIMD1, 
MECP2, ING2, ZNF248, ZNF367, ZNF487, ZIK1, ACAD8, ZHX2, ZHX3, CNOT6L, TSC22D1, NCOA3, IL16, 
CBFA2T2, SIRT1, SIRT2, AES, KAT2B, MN1, KAT2A, NFX1, JDP2, VGLL4, PPARD, ZNF595, KANK2, 
KANK1, SP100, ELOF1, TMF1, SATB1, CIPC, PURA, MNT, ZFP14, TCEAL1, ZNF107, TBL1X, ZNF224, 
ZNF101, STAT2, PER1, TFAP4, ZNF219, TCEA2, PKN2, ZNF699, ZNF335, MPHOSPH8, ZNF575, ZNF211, 
ZNF331, KDM1A, CRTC1, NAB2, ZBTB20, ARID4A, PRDM2, NR3C1, CARF, NR3C2, ZNF569, EP300, 
MAP3K9, ZNF566, WHSC1L1, MEN1, ZNF441, EOMES, LMO4, ZBTB38, ARID5B, ZNF92, MAF, SAP25, 
KAT6B, ZNF318, ZNF439, ERF, KMT2E, ZNF671, ZNF791, AKNA, MAX, MAZ, CREM, FOXO4, FOXO3, 
DEAF1, ZKSCAN8, ZNF548, SAFB2, ZNF667, ZNF304, BPTF, MAP2K6, ZBTB18, ZNF540, CBX8, SMAD3, 
CBX4, ZBTB14, PHF10, PHF12, ZBTB11, FOXN2, NR4A2, MAFB, SP4, ZFP64, TCF4, MAFK, TCF3, CNOT8, 
BRWD1, ZNF654, MXD1, MXD3, ZNF652, PHF19, FGFR1, MXD4, CREBZF, ZMYND15, RERE, CALCOCO1, 
THRA, CHD9, CDCA7L, AKAP8L, HMGB2, AFF3, AFF4, LYL1, HHEX, DBP, TRPS1, RB1CC1, WHSC1, IFT57, 
MYBL1, KLF10, MSL3, KLF16, RBL2, ELF1, ELF2, IRF3, ZNF516, TERF2IP, IRF8, LCORL, KDM7A, HDAC5, 
KDM3A, SMARCD3, CEBPD, CEBPE, CXXC1, TAF1L, ZBTB44, ZBTB41, ZBTB40, HDAC7, IFI16, ELMSAN1, 
ZNF627, TBX21, ATXN1L, MXI1, MAPK1, E2F5, ZNF862, STOX1, MLXIP, SKOR1, USP21, FOXJ2, KLF3, 




Transcription 266 14.01 HDAC10, JMJD1C, IKZF3, IKZF5, ALKBH4, CREB3L2, CPNE1, BBX, CCNL2, ZNF721, CCNL1, TRIM22, 
TSPYL2, SFMBT1, SP110, PRKCB, ZNF10, SOX12, RFX1, OVOL1, ZNF14, RUNX1, EID2, TXNIP, HOXB2, 
MAML3, ASF1A, ZNF395, ZNF273, CTBP1, TSHZ1, TSHZ2, ZBTB1, ZBTB4, DEDD2, ZBTB2, HELZ2, 
ZNF703, ZNF823, ZNF821, ZNF700, ZBED6, SCAI, ZNF266, BANP, ZSCAN18, JUND, BCL11A, SNAI3, 
SS18L1, NFATC3, NFATC1, NR1D2, NR1D1, ZNF34, FLI1, FOSL2, THAP11, ZNF30, CREBRF, ID3, HBP1, 
RCOR1, SLC2A4RG, PHF2, BTG2, GMEB2, ZNF250, CITED2, TCF25, ZNF490, PHF1, SETD7, GLI1, LIMD1, 
MECP2, ING2, ZNF248, ZNF367, ZNF487, ZIK1, ACAD8, ZHX2, ZHX3, CNOT6L, TSC22D1, NCOA3, IL16, 
CBFA2T2, SIRT1, SIRT2, AES, KAT2B, MN1, KAT2A, NFX1, JDP2, VGLL4, PPARD, ZNF595, KANK2, 
KANK1, SP100, ELOF1, TMF1, SATB1, CIPC, PURA, MNT, ZFP14, TCEAL1, ZNF107, TBL1X, ZNF224, 
ZNF101, STAT2, PER1, TFAP4, ZNF219, TCEA2, PKN2, ZNF699, ZNF335, MPHOSPH8, ZNF575, ZNF211, 
ZNF331, KDM1A, CRTC1, NAB2, ZBTB20, ARID4A, PRDM2, NR3C1, CARF, NR3C2, ZNF569, EP300, 
MAP3K9, ZNF566, WHSC1L1, MEN1, ZNF441, EOMES, LMO4, ZBTB38, ARID5B, ZNF92, MAF, SAP25, 
KAT6B, ZNF318, ZNF439, ERF, KMT2E, ZNF671, ZNF791, AKNA, MAX, MAZ, CREM, FOXO4, FOXO3, 
DEAF1, ZKSCAN8, ZNF548, SAFB2, ZNF667, ZNF304, BPTF, MAP2K6, ZBTB18, ZNF540, CBX8, SMAD3, 
CBX4, ZBTB14, PHF10, PHF12, ZBTB11, FOXN2, NR4A2, MAFB, SP4, ZFP64, TCF4, MAFK, TCF3, CNOT8, 
BRWD1, ZNF654, MXD1, MXD3, ZNF652, PHF19, FGFR1, MXD4, CREBZF, ZMYND15, RERE, CALCOCO1, 
THRA, CHD9, CDCA7L, AKAP8L, HMGB2, AFF3, AFF4, LYL1, HHEX, DBP, TRPS1, RB1CC1, WHSC1, IFT57, 
MYBL1, KLF10, MSL3, KLF16, RBL2, ELF1, ELF2, IRF3, ZNF516, TERF2IP, IRF8, LCORL, KDM7A, HDAC5, 




ELMSAN1, ZNF627, TBX21, ATXN1L, MXI1, MAPK1, E2F5, ZNF862, STOX1, MLXIP, SKOR1, USP21, 
FOXJ2, KLF3, TBX19, KLF2, PNRC1, USF1, REST, KLF9, ZNF615, ERCC6, TAF5, LPIN2, TAF1 
UP_KEYWO
RDS 
Nucleus 513 27.03 CYFIP2, EHMT2, EHMT1, ADARB2, SMC4, ALKBH6, TSEN54, ALKBH5, ALKBH4, AKT2, CREB3L2, AKT1, 
BBX, PIP4K2B, TSPYL2, PRKCB, PRKCE, STARD9, WDR74, ZNF10, PRKCA, SOX12, RFX1, ZNF14, EID2, 
BIN1, HOXB2, PRKD2, MAML3, ASF1A, SLBP, ZNF395, ZNF273, CTBP1, XPC, C9ORF72, DEDD2, NUP85, 
ZSCAN18, ZNF266, LHPP, ACD, JUND, DMPK, SNAI3, NFATC3, UPF3A, NFATC1, NR1D2, NR1D1, ZNF34, 
PHC3, FLI1, FOSL2, THAP11, FAM220A, FAM111A, ZNF30, HBP1, CDKN1C, PHF2, CDKN1B, GMEB2, 
ZNF250, TCF25, ZNF490, PHF1, DDX12P, SETD7, PHF7, GLI1, ING1, HIST2H2AC, MECP2, ING4, ING2, 
SH3BGRL2, ZNF248, ZNF367, ZNF487, ZIK1, TIGD3, DFFB, CNOT6L, SIRT5, EPS15L1, FOS, SIRT1, SIRT2, 
AES, GCHFR, KAT2B, KAT2A, JDP2, PPARD, ZNF595, KANK1, ELOF1, TMF1, CIPC, CCNDBP1, ALOX5, 
UBN1, ZNF107, MBNL3, ZNF224, ZNF101, CDKN2D, CENPT, EGLN1, MBD4, CARD8, STAT2, DEF6, 
ZNF219, TAOK2, YPEL1, CENPM, FOSB, PKN2, NCAPD2, ZNF699, ZNF335, YPEL4, ZNF575, YPEL3, 
ZNF211, YPEL2, ZNF331, GHDC, FMR1, CLSTN1, NAB2, ZBTB20, PYCARD, SESN1, ZNF569, ZNF566, 
PHLDA1, WHSC1L1, MEN1, ZNF441, BNIP3L, USP8, FBXO18, ZBTB38, CTNNBIP1, DYRK1B, MAF, 
SAP25, KAT6B, ZNF439, ZNF318, ERF, PHIP, MAD1L1, SRSF8, CDKL1, KMT2E, ZNF671, ZNF791, CBFB, 
MAX, ARL3, MAZ, CREM, MRI1, UBR2, FOXO4, FOXO3, BAG1, ZKSCAN8, ZNF548, SAFB2, MBP, 
ZNF667, ZNF304, IP6K2, MAP2K6, ZBTB18, ZNF540, OSBPL8, TIA1, ZBTB14, OSBPL3, TNK2, NEK7, 
RITA1, ZBTB11, FBXO32, FOXN2, LSM4, UCKL1, RGCC, MAFB, STK24, SP4, ZFP64, MAFK, CNOT8, XAF1, 
ZNF654, OGT, ZNF652, RAD9A, CALCOCO1, RNF13, NUMA1, CDCA7L, ZC3H3, AKAP8L, CELF6, LRMP, 
ARRB2, SYNE2, HHEX, UNKL, LBR, MSL3, DUSP26, PATL2, DNAJC1, RRM2B, PAPD7, CTDSP2, ZNF516, 
MCM6, LCORL, CERS2, HDAC5, SMARCD3, CEBPD, UHRF2, LRP1, CEBPE, RNF38, CXXC1, PBXIP1, 
ZBTB44, CXXC5, ACRC, FYB, ZBTB41, HDAC7, ZBTB40, HIRIP3, IFI16, ELMSAN1, ZNF627, RSBN1L, 
ATXN1L, E2F5, ZNF862, STOX1, MLXIP, PTPN18, SKOR1, FOXJ2, CABLES1, KLF3, KLF2, PNRC1, PRC1, 
KLF9, ZNF615, SYCP3, CUL4B, HDAC10, JMJD1C, IKZF3, IKZF5, TIAL1, RASSF1, TCL1A, PEG10, CPNE1, 
CCNL2, ZNF721, CCNL1, TRIM22, SRRM2, SFMBT1, SP110, OVOL1, MIF4GD, CDC40, RUNX1, FAM76B, 
FLYWCH1, KIF20B, EPB41, TSHZ1, SP140, TSHZ2, ZBTB1, ZBTB4, CDKN2AIP, GMCL1, ZBTB2, HELZ2, 
DPH1, ZNF703, ZNF823, ZNF821, ZNF700, ZBED6, RALGDS, SCAI, BANP, SRPK2, MAGEE1, BCL11A, 
PYHIN1, SS18L1, SETDB2, RANBP10, CREBRF, ID3, ATM, FBXL3, SLC2A4RG, RCOR1, ZCCHC11, USPL1, 
CITED2, LIMD1, PPP3CA, ZMYM3, MIS18BP1, PCF11, SUFU, ENC1, PRX, ZMYM6, REV3L, QSOX2, ZHX2, 
PARP4, ZHX3, TSC22D1, NCOA3, TSC22D3, IL16, KIF22, CBFA2T2, GLTSCR2, RHOB, NFX1, FAM193B, 
VGLL4, SP100, SATB1, PRKX, PRICKLE1, CAMKK1, PURA, MNT, ZFP14, TCEAL1, TBL1X, MAP3K2, 
PNPLA7, PLEKHA2, SORBS3, PER1, HIST3H2A, TFAP4, TTC3, TCEA2, MPHOSPH8, MIDN, DCLRE1C, 
KDM1A, CRTC1, ARID4A, CIB1, PRDM2, NR3C1, CARF, CMIP, NR3C2, RGS2, CCND3, RGS3, CAPN7, 
COTL1, EP300, TMEM38A, SBF1, HIST1H2AC, EOMES, MORC3, LIG1, SHISA5, ARID5B, NOSIP, ZNF92, 
SLFN11, HIST1H2BD, AKNA, MRO, ACACB, NDRG1, LPP, ZFP36L2, RAI1, NLRP6, GRK5, DEAF1, EP400, 
STAP1, NLRP1, BPTF, CBX8, MGEA5, SMAD3, CBX4, PHF10, PHF12, CLK1, PAN2, NR4A2, PHF13, TCF4, 
TCF3, CLASRP, BRWD1, MXD1, MXD3, FGFR1, MXD4, PHF19, CREBZF, ZMYND15, RERE, DYRK2, LDB1, 
THRA, CHD9, HMGB2, ATP2A3, HMGB1, AFF3, AFF4, AFF1, IRF2BPL, LMNB1, CABIN1, LYL1, DBP, 
TRPS1, RB1CC1, GATAD1, TMEM109, WHSC1, MYBL1, RBM5, DACT1, HIST1H1C, KLF10, SUN2, 
RBM15, AXIN1, PPP2R5C, ETV5, KLF16, RBL2, TBC1D1, HSH2D, ELF1, LATS2, ELF2, SETBP1, IRF3, 
OAS2, TERF2IP, IRF8, LUC7L3, RBMS2, KDM7A, AGPAT5, HIST1H2BN, KDM3A, RGS14, USP11, 
HIST1H2BK, TAF1L, TOB1, U2AF1L4, GNA13, NXF1, TNKS2, TBX21, MXI1, MAPK1, RBM38, CDK11A, 
USP21, POLM, MX2, LIMK2, LRWD1, USP28, TBX19, USF1, REST, KANSL2, ALOX5AP, ERCC6, TAF5, 







n factor activity, 
sequence-specific DNA 
binding 
120 6.32 KDM1A, ARID4A, PRDM2, NR3C1, IKZF3, CARF, IKZF5, NR3C2, CREB3L2, TRIM22, EOMES, LMO4, 
ZBTB38, OVOL1, RUNX1, ZNF92, MAF, ERF, HOXB2, ZNF831, CBFB, MAX, CTBP1, SP140, CREM, 
FOXO4, FOXO3, ZFP36L2, RAI1, DEAF1, ZKSCAN8, ZNF548, ZNF821, ZNF304, ZBED6, ZSCAN18, 
ZNF540, ZBTB18, JUND, SMAD3, ZBTB14, NFATC3, NFATC1, NR1D2, NR1D1, ZBTB11, FOXN2, FLI1, 
FOSL2, SP4, ZNF30, CREBRF, ID3, TCF4, MAFK, TCF3, CNOT8, MXD1, SLC2A4RG, CREBZF, RERE, 
ZNF250, THRA, CITED2, TCF25, ZNF490, PHF1, HMGB2, HMGB1, AFF4, AFF1, MECP2, DBP, TRPS1, 
GATAD1, ZNF367, ZIK1, KLF10, ZHX2, ZHX3, TSC22D1, TSC22D3, FOS, CBFA2T2, ETV5, VAV1, ELF1, 
ELF2, IRF3, NFX1, ZNF516, IRF8, JDP2, PPARD, ZNF595, KDM3A, CEBPD, TULP4, PURA, ZFP14, MNT, 
ELMSAN1, TBX21, TCEAL1, UBN1, E2F5, ZNF224, MLXIP, STAT2, KLF3, TBX19, KLF2, REST, ZNF219, 






222 11.70 HDAC10, JMJD1C, IKZF5, ALKBH4, CPNE1, BBX, CCNL2, ZNF721, CCNL1, TRIM22, TSPYL2, SFMBT1, 
SP110, PRKCB, ZNF10, RFX1, OVOL1, ZNF14, EID2, TXNIP, HOXB2, ASF1A, ZNF395, ZNF273, CTBP1, 
TSHZ1, TSHZ2, ZBTB4, DEDD2, ZBTB2, HELZ2, ZNF703, ZNF823, ZNF821, ZNF700, ZBED6, SCAI, 
ZNF266, BANP, ZSCAN18, BCL11A, SNAI3, SS18L1, NR1D2, NR1D1, ZNF34, FOSL2, THAP11, ZNF30, 
CREBRF, ID3, HBP1, RCOR1, SLC2A4RG, PHF3, PHF2, BTG2, ZNF250, CITED2, TCF25, ZNF490, PHF1, 
SETD7, GLI1, LIMD1, MECP2, ING2, ZNF248, ZNF367, ZNF487, ZIK1, ACAD8, ZHX2, ZHX3, CNOT6L, 
NCOA3, IL16, CBFA2T2, SIRT1, SIRT2, AES, MN1, JDP2, VGLL4, PPARD, ZNF595, KANK2, KANK1, SP100, 
SATB1, CIPC, PURA, ZFP14, TCEAL1, ZNF107, TBL1X, ZNF224, ZNF101, STAT2, PER1, ZNF219, TCEA2, 
PKN2, ZNF699, ZNF335, MPHOSPH8, ZNF575, ZNF211, ZNF331, KDM1A, CRTC1, NAB2, ZBTB20, 
PRDM2, NR3C1, NR3C2, ZNF569, MAP3K9, ZNF566, WHSC1L1, MEN1, ZNF441, EOMES, ZBTB38, 
ARID5B, ZNF92, MAF, SAP25, KAT6B, ZNF318, ZNF439, ERF, KMT2E, ZNF671, ZNF791, CREM, 
ZKSCAN8, ZNF548, SAFB2, ZNF667, ZNF304, BPTF, MAP2K6, ZBTB18, ZNF540, CBX8, SMAD3, CBX4, 
ZBTB14, PHF10, PHF12, ZBTB11, FOXN2, NR4A2, SP4, ZFP64, MAFK, TCF3, CNOT8, BRWD1, ZNF654, 
MXD1, MXD3, ZNF652, PHF19, FGFR1, MXD4, CREBZF, ZMYND15, RERE, CALCOCO1, LDB1, THRA, 
CHD9, CDCA7L, AKAP8L, HMGB2, AFF3, LYL1, HHEX, RB1CC1, WHSC1, IFT57, KLF10, MSL3, KLF16, 
RBL2, ELF2, TERF2IP, IRF8, KDM7A, HDAC5, KDM3A, SMARCD3, CEBPD, CXXC1, ZBTB44, CXXC5, 
ZBTB41, ZBTB40, HDAC7, IFI16, ELMSAN1, ZNF627, TBX21, ATXN1L, MXI1, MAPK1, E2F5, ZNF862, 




DNA-binding 215 11.33 IKZF3, IKZF5, PEG10, CREB3L2, BBX, ZNF721, SP110, ZNF10, SOX12, RFX1, OVOL1, ZNF14, RUNX1, 
HOXB2, FLYWCH1, ZNF395, ZNF273, TSHZ1, SP140, TSHZ2, ZBTB1, XPC, ZBTB4, DEDD2, ZBTB2, HELZ2, 
ZNF823, ZNF821, ZNF700, ZBED6, ZNF266, BANP, ZSCAN18, ACD, JUND, SNAI3, NFATC3, NFATC1, 
NR1D2, NR1D1, ZNF34, PHC3, FLI1, FOSL2, THAP11, ZNF30, HBP1, ATM, SLC2A4RG, GMEB2, ZNF250, 
TCF25, ZNF490, DDX12P, GLI1, HIST2H2AC, MECP2, MIS18BP1, REV3L, ZNF248, ZNF367, ZNF487, 
ZIK1, TIGD3, ZHX2, ZHX3, KIF22, FOS, NFX1, JDP2, PPARD, ZNF595, SP100, TMF1, SATB1, PURA, MNT, 
ZFP14, UBN1, ZNF107, ZNF224, ZNF101, CENPT, MBD4, STAT2, HIST3H2A, TFAP4, ZNF219, TCEA2, 
FOSB, ZNF699, ZNF335, ZNF575, ZNF211, ZNF331, ZBTB20, PRDM2, NR3C1, CARF, NR3C2, HMCES, 
ZNF569, ZNF566, HIST1H2AC, MEN1, ZNF441, EOMES, ZBP1, FBXO18, ZBTB38, ARID5B, ZNF92, MAF, 
ZNF439, ERF, HIST1H2BD, ZNF671, ZNF791, AKNA, MAX, MAZ, CREM, FOXO4, FOXO3, ZFP36L2, 
DEAF1, ZKSCAN8, ZNF548, EP400, SAFB2, ZNF667, ZNF304, ZBTB18, ZNF540, SMAD3, ZBTB14, 
ZBTB11, FOXN2, NR4A2, MAFB, SP4, ZFP64, TCF4, MAFK, TCF3, ZNF654, MXD1, MXD3, ZNF652, 
MXD4, THRA, CHD9, ZC3H3, HMGB2, HMGB1, AFF3, LYL1, HHEX, DBP, TRPS1, TOP1MT, WHSC1, 
IFT57, LBR, MYBL1, HIST1H1C, KLF10, MSL3, ETV5, KLF16, RBL2, DNAJC1, ELF1, ELF2, IRF3, PAPD7, 
SETBP1, ZNF516, LUC7L3, IRF8, MCM6, LCORL, AHDC1, CERS2, HIST1H2BN, CEBPD, UHRF2, CEBPE, 
HIST1H2BK, CXXC1, TAF1L, ZBTB44, ZBTB41, ZBTB40, IFI16, ELMSAN1, ZNF627, TBX21, ATXN1L, MXI1, 







GO:0005634~nucleus 523 27.56 CYFIP2, EHMT2, EHMT1, ADARB2, SMC4, ALKBH6, ALKBH5, ALKBH4, AKT2, CREB3L2, AKT1, TSPYL2, 
PRKCB, PRKCE, STARD9, WDR74, ZNF10, RFX1, ZNF14, PRKD3, CDIP1, TXNIP, HOXB2, PRKD2, MAML3, 
ASF1A, SLBP, ZNF395, ZNF273, CTBP1, SDR39U1, XPC, ABCB8, C9ORF72, RDH10, HMOX1, ZSCAN18, 
ZNF266, LHPP, ACD, CDK19, JUND, HOMER2, TIPARP, SNAI3, NFATC3, UPF3A, NFATC1, NR1D2, 
NR1D1, ZNF34, PHC3, FLI1, FOSL2, FAM220A, FAM111A, EHD3, PKIA, ZNF30, CPEB2, CDKN1C, PHF2, 
CDKN1B, GMEB2, ZNF250, TCF25, ZNF490, PHF1, DDX12P, PHF7, GLI1, ING1, HIST2H2AC, MECP2, 
ING4, ING2, TRIM7, ZNF248, ZNF367, ZNF487, ZIK1, TIGD3, DFFB, CNTD2, CNOT6L, SLC2A11, PGAM2, 
SIRT5, EPS15L1, FOS, DYNLL2, GNL1, SIRT1, SIRT2, AES, GCHFR, KAT2B, KAT2A, JDP2, PPARD, ZNF595, 
KANK1, TMF1, CIPC, CCNDBP1, UBN2, UBN1, ZNF107, MBNL3, RNF130, ZNF224, ZNF101, CDKN2D, 
CENPT, EGLN1, MBD4, CARD8, STAT2, DEF6, ZNF219, TAOK2, YPEL1, FOSB, PKN2, NCAPD2, ZNF699, 
ZNF335, ZNF575, ZNF211, ZNF331, DGKD, IRS1, FMR1, CLSTN1, NAB2, MAP3K7CL, ZBTB20, PYCARD, 
SESN3, SESN1, ZNF569, SLC25A42, ZNF566, WHSC1L1, MEN1, ZNF441, FBXO18, ZBTB38, CTNNBIP1, 
DYRK1B, MAF, SAP25, KAT6B, ZNF439, ERF, TSSK6, TSSK3, PHIP, S100A8, MAD1L1, CSNK1G2, SRSF8, 
CDKL1, ZNF671, ZNF791, CBFB, MAX, ARL3, MAZ, CREM, FOXO4, FOXO3, SLC9A3R1, AMDHD2, BAG1, 
ZKSCAN8, ZNF548, SAFB2, MBP, ZNF667, ZNF304, SKIL, IP6K2, ZBTB18, ZNF540, ZBTB14, TNK2, RITA1, 
FBXO32, FOXN2, UCKL1, PTPRE, RGCC, MAFB, STK24, SP4, ZFP64, FGFR1OP, MAFK, CNOT8, XAF1, 
ZNF654, OGT, ZNF652, RAD9A, CALCOCO1, NUMA1, CDCA7L, ZC3H3, AKAP8L, EFCAB13, CELF6, 
PTPN22, ARRB2, SYNE2, ALAD, HHEX, UNKL, APAF1, MSL3, DUSP26, PATL2, PTP4A1, ARL4C, DNAJC1, 
PAPD7, ZNF516, MCM6, LCORL, HDAC5, SMARCD3, CEBPD, UHRF2, RNF38, CXXC1, PBXIP1, ZBTB44, 
PPM1D, ACRC, FYB, ZBTB41, HDAC7, ZBTB40, HIRIP3, PARD6A, IFI16, ELMSAN1, ZNF627, RSBN1L, 
ATXN1L, TNNI2, E2F5, ZNF862, STOX1, MLXIP, PTPN18, SKOR1, AMFR, FOXJ2, CABLES1, KIAA1683, 
KLF3, KLF2, PNRC1, PRC1, KLF9, ZNF615, SYCP3, HDAC10, PANK1, ZMYND8, JMJD1C, CBLB, IKZF3, 
AQP3, IKZF5, TIAL1, HERC3, RASSF1, TCL1A, PEG10, CPNE1, CCNL2, ZNF721, CCNL1, TRIM22, TRIM23, 
SFMBT1, SP110, OVOL1, ANK1, RUNX1, FAM76B, HECA, ZNF831, KIF20B, ANKRA2, TRIB1, EPB41, 
TSHZ1, SP140, TSHZ2, DCUN1D4, ZBTB1, PIK3R1, ZBTB4, GMCL1, ZBTB2, NUAK2, DPH1, ZNF704, 
ZNF703, ZNF823, ZNF821, ZNF700, APOE, ZBED6, RALGDS, SCAI, SPTBN1, SRPK2, MAGEE1, BCL11A, 
SS18L1, SETDB2, RPS27, RANBP10, ID3, CD27, ATM, FBXL3, CALM1, SLC2A4RG, RCOR1, ZCCHC11, 
CITED2, TECR, LIMD1, PPP3CA, SUFU, ENC1, PRX, REV3L, ZHX2, PARP4, ZHX3, TSC22D1, SYK, NCOA3, 
TSC22D3, IL16, KIF22, CBFA2T2, RHOB, NFX1, FAM193B, VGLL4, SP100, SATB1, PRKX, PRICKLE1, 
CAMKK1, PURA, MNT, ZFP14, TCEAL1, APBB2, TBL1X, PLEKHA2, SORBS3, PER1, TFAP4, THEMIS2, 
TTC3, TCEA2, MPHOSPH8, CAPS, KDM1A, CRTC1, ARID4A, CIB1, PRDM2, NR3C1, ACRBP, CARF, CMIP, 
NR3C2, RGS2, CCND3, COTL1, CAPN3, EP300, SBF1, HIST1H2AC, EOMES, ZBP1, LIG1, ADAM10, 
ARID5B, NOSIP, TSC1, CYBA, LMO7, ZNF92, SLFN11, HIST1H2BD, PXK, AKNA, UBA7, PLD4, ADRB2, 
ACACB, NDRG1, LPP, ZFP36L2, SEL1L3, RAI1, GRK5, DEAF1, STAP1, FOPNL, NLRP1, BPTF, CBX8, 
MGEA5, SMAD3, CBX4, PHF10, PHF12, ARHGAP27, CLK1, PAN2, NR4A2, CAPRIN2, PHF13, TCF4, 
GNB5, TCF3, CLASRP, BRWD1, MXD1, MXD3, FGFR1, MXD4, CREBZF, ZMYND15, RERE, DYRK2, LDB1, 
THRA, CHD9, NGLY1, HMGB2, HMGB1, TAZ, SOBP, AFF3, PKD1, IRF2BPL, CABIN1, CASP9, LYL1, 
SENP7, DBP, TRPS1, TOP1MT, GATAD1, WHSC1, MYBL1, RBM5, DACT1, HIST1H1C, KLF10, AXIN1, 
PPP2R5C, IRAK4, ETV5, KLF16, RBL2, TBC1D1, HSH2D, ELF1, LATS2, ELF2, SETBP1, IRF3, OAS2, 
TERF2IP, LUC7L3, RBMS2, KDM7A, HIST1H2BN, LAMA5, PDXK, KDM3A, RGS14, USP11, HIST1H2BK, 
TOB1, GNA13, NXF1, TNKS2, FAM120C, TBX21, MXI1, MAPK1, CRYM, RBM38, CDK11A, POLM, MX2, 







149 7.85 ZNF331, HDAC10, ZMYND8, JMJD1C, PRDM2, NR3C1, IKZF5, NR3C2, ALKBH4, CPNE1, ZNF569, BBX, 
EP300, CCNL2, MAP3K9, ZNF721, ZNF566, TRIM22, WHSC1L1, TSPYL2, ZNF441, RNF44, SFMBT1, 
SP110, ZNF10, ZNF14, CARHSP1, ZNF92, SAP25, KAT6B, ZNF318, ZNF439, HOXB2, ZNF831, ABCG1, 




SBNO1, ZNF703, ZKSCAN8, ZNF823, ZNF548, ZNF667, ZNF700, ZNF304, SCAI, ZNF266, BPTF, MAP2K6, 
ZNF540, SMAD3, PHF10, NR1D2, ZNF34, ZBTB11, THAP11, ZFP64, ZNF30, CREBRF, HBP1, TCF3, 
CNOT8, ZNF654, ZNF652, SLC2A4RG, PHF19, ZNF250, THRA, LDB1, CHD9, CITED2, ZNF490, PHF1, 
CDCA7L, SETD7, HMGB2, LIMD1, AFF3, AFF4, AFF1, LYL1, ING2, RB1CC1, SUFU, GATAD1, ZNF248, 
IFT57, MYBL1, ZNF487, ZIK1, ACAD8, CNOT6L, TSC22D1, NCOA3, TSC22D3, RHOH, MSL3, IL16, VAV1, 
MN1, KAT2A, IRF3, TERF2IP, VGLL4, ZNF595, KANK1, TMF1, SATB1, RNF38, CXXC1, TULP4, ZBTB44, 
ZBTB41, HDAC7, ZBTB40, PDLIM1, ZFP14, ZNF627, TBX21, MXI1, ZNF107, APBB2, ZNF862, ZNF224, 
ZNF101, CDK11A, SKOR1, KLF3, PNRC1, REST, ZNF219, ZNF615, PKN2, ZNF699, TAF5, SSBP2, ZNF335, 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
domain:PDZ 25 1.32 MAST4, MAST3, HTRA3, HTRA4, LIN7B, SIPA1L3, PDLIM1, PARD6A, RGS3, SIPA1L1, SNX27, PRX, 
RHPN1, RHPN2, CYTIP, MPP1, LIMK2, LMO7, MPP7, GORASP1, RAPGEF2, PTPN4, CARD14, CARD11, 
SNTB2 
0.02 0.02 
INTERPRO IPR001478:PDZ domain 28 1.48 MAST4, MAST3, HTRA3, HTRA4, LIN7B, SIPA1L3, PDLIM1, SLC9A3R1, PARD6A, RGS3, SIPA1L1, SNX27, 
PRX, RHPN1, RHPN2, CYTIP, MPP1, LIMK2, IL16, LMO7, MPP7, DLG2, GORASP1, RAPGEF2, PTPN4, 
CARD14, CARD11, SNTB2 
0.08 0.08 
SMART SM00228:PDZ 25 1.32 MAST4, MAST3, HTRA3, HTRA4, LIN7B, SIPA1L3, PDLIM1, SLC9A3R1, PARD6A, RGS3, SIPA1L1, SNX27, 
PRX, RHPN1, RHPN2, CYTIP, MPP1, LIMK2, IL16, LMO7, MPP7, DLG2, RAPGEF2, PTPN4, SNTB2 
0.39 0.39 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Immunity 72 3.79 ITK, IFITM1, DCLRE1C, TNFRSF13B, HMGB2, LRMP, PTPN22, TNFRSF13C, HMGB1, IL1RAP, CD3E, IFIT2, 
PYCARD, SIT1, CTLA4, HAVCR2, EOMES, ZBP1, MAP4K2, SYK, BTN3A1, CD300A, PRKCB, PRKCE, IRAK4, 
BTN3A2, LIME1, MR1, LAX1, SIRT2, TIRAP, ATG12, CLEC4C, RNF125, SLFN11, IRF3, CD8A, OAS2, TLR9, 
CD300E, PRKD2, TLR7, TLR4, S100A8, UNC93B1, ZBTB1, CD1D, LY9, RNF135, CD79B, CD79A, HLA-
DMA, C5, IFI16, NLRP6, INPP5D, SLAMF6, CD14, NLRP1, LAIR1, MX2, DAB2IP, SCART1, THEMIS2, CD6, 




Innate immunity 42 2.21 IFITM1, UNC93B1, HMGB2, ZBTB1, HMGB1, CD1D, IL1RAP, LY9, IFIT2, PYCARD, RNF135, C5, IFI16, 
NLRP6, SLAMF6, NLRP1, CD14, HAVCR2, ZBP1, MAP4K2, SYK, MX2, DAB2IP, IRAK4, MR1, SIRT2, 
TIRAP, ATG12, CLEC4C, IRF3, CD6, OAS2, TLR9, TLR7, TBKBP1, TRIM38, SERINC3, TLR4, LGR4, S100A8, 
SERINC5, CD244 
0.00 0.00 





     










domain:Leucine-zipper 23 1.21 CREBZF, MLXIP, JUND, TSC22D1, CEBPD, MAX, CEBPE, TSC22D3, CREM, FOS, USF1, FOSL2, MNT, 






27 1.42 CREBZF, CEBPD, CEBPE, MAX, CREM, LYL1, MNT, DBP, MXI1, CREB3L2, MLXIP, JUND, NCOA3, FOS, 
USF1, FOSL2, MAFB, TFAP4, MAF, FOSB, TCF4, MAFK, TCF3, MXD1, MXD3, JDP2, MXD4 
0.41 0.41 
SMART SM00338:BRLZ 13 0.68 JUND, CEBPD, CEBPE, CREM, FOS, FOSL2, MAFB, DBP, MAF, CREB3L2, FOSB, MAFK, JDP2 0.20 0.20 





     












10 0.53 DGKE, DGKD, PRKCH, PRKD3, PRKCB, DGKA, PRKCE, PRKD2, PRKCA, DEF8 0.02 0.02 




18 0.95 DGKE, DGKD, PRKCH, PRKCB, DGKA, CDC42BPG, PRKCE, MYO9B, PRKCA, KSR2, DEF8, RASGRP2, VAV1, 
RASSF1, PRKD3, PLEKHM1, PRKD2, TNS3 
0.01 0.01 
SMART SM00109:C1 18 0.95 DGKE, DGKD, PRKCH, PRKCB, DGKA, CDC42BPG, PRKCE, MYO9B, PRKCA, KSR2, DEF8, RASGRP2, VAV1, 





kinase C activity 
7 0.37 PRKCH, PRKD3, PRKCB, PRKCE, PKN2, PRKD2, PRKCA 0.17 0.17 





     










15 0.79 PRKCH, DMPK, MAST4, PRKCB, MAST3, CDC42BPG, PRKCE, PRKCA, PRKX, LATS2, GRK5, AKT2, GRK6, 
AKT1, PKN2 
0.05 0.05 
SMART SM00133:S_TK_X 13 0.68 PRKCH, DMPK, PRKCB, CDC42BPG, PRKCE, PRKCA, PRKX, LATS2, GRK5, AKT2, GRK6, AKT1, PKN2 0.20 0.20 







     




d biosynthetic process 










Phospholipid biosynthesis 12 0.63 AGPAT5, ISYNA1, PTDSS1, LPCAT4, MBOAT7, MBOAT1, CHPT1, SERINC1, CDIPT, SERINC5, CDS2, 
SERINC4 
0.02 0.02 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
domain:C2 17 0.90 PRKCH, PRKCB, PRKCE, PLA2G4B, PLCL2, DAB2IP, PRKCA, JMJD7, BCR, ABR, RGS3, SYNGAP1, PLCG2, 





27 1.42 RASAL1, ABR, RGS3, SYNGAP1, CPNE1, PLCG2, TNS3, PRKCH, PRKCB, PRKCE, PLA2G4B, PLCL2, 
DAB2IP, SYTL1, PRKCA, SYTL3, BAIAP3, GAK, BCR, RASA3, RASA2, PKN2, ESYT1, PLCH2, PLCB2, PLCD1, 
C2CD2L 
0.23 0.23 
SMART SM00239:C2 24 1.26 PRKCH, PRKCB, PRKCE, PLA2G4B, PLCL2, DAB2IP, SYTL1, PRKCA, RASAL1, SYTL3, BAIAP3, BCR, ABR, 
RGS3, SYNGAP1, RASA3, RASA2, CPNE1, PLCG2, PKN2, ESYT1, PLCH2, PLCB2, PLCD1 
0.20 0.20 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
domain:Ras-associating 11 0.58 GRB7, RASSF1, SNX27, RASSF7, RAPGEF2, RIN3, MYO9B, ARAP1, RIN2, RGL2, RALGDS 0.12 0.12 
INTERPRO IPR000159:Ras-
association 
11 0.58 GRB7, RASSF1, SNX27, RASSF7, RAPGEF2, RIN3, MYO9B, ARAP1, RIN2, RGL2, RALGDS 0.22 0.22 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
SH2 domain 21 1.11 GRB7, ITK, SRMS, SYK, STAT2, SLA, PIK3R1, SLA2, VAV1, CRKL, HSH2D, LCK, INPP5D, BLNK, PLCG2, 




INTERPRO IPR000980:SH2 domain 22 1.16 GRB7, ITK, SRMS, SYK, STAT2, SLA, CBLB, PIK3R1, SLA2, VAV1, CRKL, HSH2D, LCK, INPP5D, BLNK, 
PLCG2, STAP1, LCP2, RIN3, GRAP, RIN2, TNS3 
0.12 0.11 
SMART SM00252:SH2 20 1.05 GRB7, ITK, SRMS, SYK, STAT2, SLA, PIK3R1, SLA2, VAV1, CRKL, HSH2D, LCK, INPP5D, BLNK, PLCG2, 
STAP1, LCP2, RIN3, GRAP, TNS3 
0.27 0.27 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR008936:Rho GTPase 
activation protein 
20 1.05 ARHGAP9, FAM13B, PLXND1, DAB2IP, ARHGAP18, MYO9B, RASAL1, PIK3R1, ARAP1, ARHGAP27, 
IQGAP2, ARHGAP6, ARHGAP4, ARHGAP12, BCR, ABR, SYNGAP1, RASA3, RASA2, SRGAP3 
0.06 0.06 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR010919:SAND domain-
like 
7 0.37 SP100, SKOR1, GMEB2, SP110, DEAF1, SP140, SKIL 0.05 0.05 
UP_SEQ_FE
ATURE 
domain:SAND 5 0.26 SP100, GMEB2, SP110, DEAF1, SP140 0.49 0.49 
INTERPRO IPR000770:SAND domain 5 0.26 SP100, GMEB2, SP110, DEAF1, SP140 0.23 0.23 
SMART SM00258:SAND 5 0.26 SP100, GMEB2, SP110, DEAF1, SP140 0.23 0.23 





     





26 1.37 DENND5B, ARHGEF10L, RASGRP2, FGD1, FGD3, ABR, CYTH2, PSD3, SBF1, RALGDS, RALGPS2, VAV1, 
BCR, MADD, SPATA13, ARHGEF3, RAPGEF2, DENND6B, ARHGEF1, DENND6A, RGL4, SOS1, RGL2, 








9 0.47 RAPGEF2, RGL4, RASGRP2, SOS1, RGL2, RALGDS, SOS2, RAPGEF3, RALGPS2 0.26 0.26 
INTERPRO IPR023578:Ras guanine 
nucleotide exchange 
factor, domain 
9 0.47 RAPGEF2, RGL4, RASGRP2, SOS1, RGL2, RALGDS, SOS2, RAPGEF3, RALGPS2 0.26 0.26 
355 
 
SMART SM00147:RasGEF 9 0.47 RAPGEF2, RGL4, RASGRP2, SOS1, RGL2, RALGDS, SOS2, RAPGEF3, RALGPS2 0.30 0.30 
SMART SM00229:RasGEFN 7 0.37 RAPGEF2, RASGRP2, SOS1, RGL2, RALGDS, SOS2, RAPGEF3 0.35 0.34 





     





26 1.37 DENND5B, ARHGEF10L, RASGRP2, FGD1, FGD3, ABR, CYTH2, PSD3, SBF1, RALGDS, RALGPS2, VAV1, 
BCR, MADD, SPATA13, ARHGEF3, RAPGEF2, DENND6B, ARHGEF1, DENND6A, RGL4, SOS1, RGL2, 







17 0.90 ARHGEF10L, FGD1, VAV1, ARHGAP4, BCR, FGD3, ABR, OBSCN, DNMBP, SPATA13, ARHGEF3, 
ARHGEF1, EPS8L2, SOS1, RGL2, SOS2, ARHGEF6 
0.17 0.17 
SMART SM00325:RhoGEF 14 0.74 ARHGEF10L, FGD1, VAV1, BCR, FGD3, ABR, OBSCN, DNMBP, SPATA13, ARHGEF3, ARHGEF1, SOS1, 
SOS2, ARHGEF6 
0.42 0.42 





     




ositol signaling system 
21 1.11 DGKE, MTMR3, DGKD, PRKCB, DGKA, ITPR2, PRKCA, PIK3R1, INPP5A, IMPA2, INPP5D, PI4KA, PLCG2, 






14 0.74 ISYNA1, MTMR3, INPP5A, IMPA2, INPP5D, PIP5KL1, PI4KA, PLCG2, PIP4K2B, PLCH2, CDIPT, PLCB2, 
PI4K2A, PLCD1 
0.21 0.20 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR001487:Bromodomain 12 0.63 KAT2B, SP100, KAT2A, SP110, ZMYND8, SP140, EP300, TAF1L, PHIP, BRWD1, TAF1, BPTF 0.12 0.12 
UP_KEYWO
RDS 
Bromodomain 11 0.58 KAT2B, KAT2A, SP110, ZMYND8, SP140, EP300, TAF1L, PHIP, BRWD1, TAF1, BPTF 0.02 0.02 
SMART SM00297:BROMO 12 0.63 KAT2B, SP100, KAT2A, SP110, ZMYND8, SP140, EP300, TAF1L, PHIP, BRWD1, TAF1, BPTF 0.18 0.17 
INTERPRO IPR018359:Bromodomain, 
conserved site 
8 0.42 KAT2B, KAT2A, EP300, TAF1L, PHIP, BRWD1, TAF1, BPTF 0.37 0.37 







     




9 0.47 PLCL2, GDPD1, GDE1, PLCG2, GDPD3, PLCH2, GPCPD1, PLCB2, PLCD1 0.12 0.12 





     




6 0.32 OSBPL8, OSBPL7, OSBPL5, OSBPL3, OSBPL11, OSBP2 0.23 0.23 
INTERPRO IPR000648:Oxysterol-
binding protein 
6 0.32 OSBPL8, OSBPL7, OSBPL5, OSBPL3, OSBPL11, OSBP2 0.23 0.23 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Calmodulin-binding 23 1.21 PDE1B, EPB41, RRAD, DAPK2, ATP2B4, PHKB, MYO9B, TRPV1, IQGAP2, ADD3, SLC8A1, CAMKK1, 
SLC9A1, PPP3CA, OBSCN, KCNQ1, PHKG2, STRN, CEP97, SPTAN1, SPTBN1, MYO1F, SNTB2 
0.12 0.11 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
domain:BTB 25 1.32 KLHL14, KLHL15, KLHL32, ZBTB1, ZBTB20, ZBTB44, ZBTB4, GMCL1, ZBTB41, ZBTB40, ZBTB2, BTBD2, 
ENC1, ZBTB18, ZBTB14, ZBTB38, KLHL2, KLHL3, KLHL24, BTBD6, ZBTB11, KCTD7, KBTBD6, KLHL8, 
KBTBD7 
0.37 0.37 
INTERPRO IPR000210:BTB/POZ-like 29 1.53 KLHL14, KLHL15, KCNA3, KLHL32, ZBTB1, ZBTB20, ZBTB44, ZBTB4, GMCL1, ZBTB41, ZBTB40, RCBTB2, 
ZBTB2, BTBD2, ENC1, ZBTB18, KCND1, ZBTB14, ZBTB38, KLHL2, KLHL3, KLHL24, BTBD6, ZBTB11, 




14 0.74 KLHL14, KLHL15, KLHL32, KLHL2, KLHL3, KLHL24, BTBD6, GMCL1, RCBTB2, KBTBD6, KLHL8, ENC1, 
BTBD2, KBTBD7 
0.23 0.23 
INTERPRO IPR011333:BTB/POZ fold 29 1.53 KLHL14, KLHL15, KCNA3, KLHL32, ZBTB1, ZBTB20, ZBTB44, ZBTB4, GMCL1, ZBTB41, ZBTB40, RCBTB2, 
ZBTB2, BTBD2, ENC1, ZBTB18, KCND1, ZBTB14, ZBTB38, KLHL2, KLHL3, KLHL24, BTBD6, ZBTB11, 




SMART SM00225:BTB 29 1.53 KLHL14, KLHL15, KCNA3, KLHL32, ZBTB1, ZBTB20, ZBTB44, ZBTB4, GMCL1, ZBTB41, ZBTB40, RCBTB2, 
ZBTB2, BTBD2, ENC1, ZBTB18, KCND1, ZBTB14, ZBTB38, KLHL2, KLHL3, KLHL24, BTBD6, ZBTB11, 
KCTD7, KBTBD6, KLHL8, KCTD12, KBTBD7 
0.32 0.31 





Kelch repeat 12 0.63 ATRN, KLHDC3, KBTBD6, KLHL14, KLHL15, KLHL8, ENC1, KLHL32, KLHL2, KLHL3, KLHL24, KBTBD7 0.32 0.29 





     




mediator regulation of 
TRP channels 
18 0.95 MAP2K3, PRKCH, IL1R1, PRKCB, PTGER2, PRKCE, PLA2G4B, ADCY4, ITPR2, PRKCA, IL1RAP, PIK3R1, 






16 0.84 MAP2K3, MAP3K2, MAP3K3, MAP3K1, PRKCB, PLA2G4B, LHB, ADCY4, ITPR2, PRKCA, MAPK1, CALM1, 
SOS1, PLCB2, SOS2, MAP2K6 
0.27 0.26 





     










11 0.58 ISYNA1, INPP5A, IMPA2, INPP5D, PLCG2, PLD4, PLCH2, CALM1, PLCB2, PLCD1, IP6K2 0.92 0.92 
UP_KEYWO
RDS 
Lipid degradation 17 0.90 ABHD4, RARRES3, PNPLA8, PLA2G4B, PLCL2, PLD4, PLD3, PLA2G15, BSCL2, NCEH1, ENPP2, PLCG2, 
PLCH2, DAGLB, PLCB2, PLCD1, PNPLA2 
0.18 0.16 





     
Category Term Count % Genes Benjamini FDR 
UP_SEQ_FE
ATURE 
repeat:LRR 11 19 1.00 LRRC37A3, DNAH10, LINGO3, LRRN2, LRRK2, NLRC3, SYNE2, FBXL20, MFHAS1, CHAD, CNTRL, LRIG1, 






Leucine-rich repeat 40 2.11 LRRC58, LRRC56, LRRC34, LRRK2, LRRC6, NLRC3, ELFN2, PKD1, CMIP, FBXL20, NXF1, NLRP6, CHAD, 
CNTRL, LRRC8C, LRIG1, LRRC8A, NLRP1, CD14, CEP97, LRRC25, LRRC37A3, LRRC45, ZER1, LINGO3, 
CNOT6L, LRRN2, LRWD1, FBXL16, FBXL14, LRRC37B, NISCH, MFHAS1, LRFN1, TLR9, TLR7, FBXL3, 
LRCH4, TLR4, LGR4 
0.12 0.11 





     




6 0.32 SYNGAP1, RASA3, RASA2, DAB2IP, RASAL1, IQGAP2 0.35 0.35 
SMART SM00323:RasGAP 6 0.32 SYNGAP1, RASA3, RASA2, DAB2IP, RASAL1, IQGAP2 0.32 0.31 





     






4 0.21 SERINC1, SERINC3, SERINC5, SERINC4 0.36 0.36 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR025110:Domain of 
unknown function 
DUF4009 
7 0.37 SLC27A1, ACSS2, ACSM3, ACSM1, ACSS1, SLC27A3, ACSF2 0.32 0.31 





     






18 0.95 MAP2K3, IFNAR2, PIK3R1, FOS, IRAK4, TIRAP, CASP8, IRF3, CTSK, AKT2, CCL5, TLR9, AKT1, MAPK1, 






hsa05164:Influenza A 24 1.26 MAP2K3, IFNAR2, RNASEL, PRKCB, STAT2, HSPA6, PRKCA, PIK3R1, IRAK4, CASP9, PYCARD, NXF1, HLA-
DMA, IRF3, OAS2, AKT2, CCL5, TNFSF10, AKT1, EP300, MAPK1, TLR7, TLR4, MAP2K6 
0.48 0.45 





     
Category Term Count % Genes Benjamini FDR 
INTERPRO IPR013083:Zinc finger, 
RING/FYVE/PHD-type 
62 3.27 PHF3, PHF2, RNF13, PHF1, ZMYND8, CBLB, PHF7, ING1, ZFYVE28, TRIM8, ING4, ING2, TRIM7, 
RNF19A, WHSC1, TRIM65, TRIM22, WHSC1L1, TRIM23, RNF44, SP110, SYTL1, NOSIP, SYTL3, RNF41, 
RNF125, KAT6B, TRAF5, RNF166, KDM7A, RNFT2, KMT2E, SP100, MTMR3, TRIM52, UHRF2, SP140, 
RNF38, CXXC1, FGD1, RNF135, FGD3, RNF113A, RNF213, RNF39, RNF130, BPTF, MAP3K1, RNF24, 




Ligase 42 2.21 SLC27A1, ACSS2, RNF13, UBA7, ACSM3, UHRF2, TARSL2, ACSM1, RNF38, PELI2, UBR2, CBLB, ACACB, 
TRIM8, RNF135, RNF213, TMEM129, CARNS1, ACSS1, RNF130, UNKL, TRIM22, TRIM23, LIG1, CBX4, 
MIB2, SYVN1, MSL2, NOSIP, QRSL1, ACSF2, RNF41, GCLC, RNF125, TRIM39, RNF149, NFX1, TTC3, 
MKRN1, TRIM38, SLC27A3, CARS2 
0.20 0.18 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
cAMP 8 0.42 PDE1B, PRKAR2A, PDE4B, PDE4A, PRKX, PDE7B, HCN2, RAPGEF3 0.24 0.22 
       





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Ubl conjugation pathway 70 3.69 DYRK2, RNF13, CBLB, AUP1, FBXO21, TRIM8, SENP7, HERC3, MAP1LC3B, RNF19A, UNKL, TRIM22, 
FBXO9, TRIM23, USP8, WSB1, ZER1, FBXO18, MSL2, FBXO15, NOSIP, FBXO10, ATG12, RNF41, 
RNF125, NFX1, NUMBL, UBA7, UHRF2, KLHL15, USP11, RNF38, PELI2, TULP4, UBR2, FBXO44, DCAF15, 
RNF135, FBXL20, RNF213, RAB40B, STAMBPL1, TMEM129, FAM63B, TBL1X, RNF130, UBE2H, CBX4, 
MAGEE1, USP20, USP21, AMFR, MIB2, SYVN1, KLHL2, KLHL3, UBE2G1, FBXL16, USP28, FBXO32, 
FBXL14, TRIM39, RNF149, MKRN1, KLHL8, TTC3, FBXL3, TRIM38, OTUD1, CUL4B 
0.52 0.48 





     





protein kinase catalytic 
domain 
24 1.26 EPHB6, GUCY2C, ITK, SRMS, FLT1, SYK, MLKL, TNK2, LIMK2, NEK7, TNK1, LMTK2, AATK, KSR2, IRAK4, 




Tyrosine-protein kinase 17 0.90 MAP2K3, ITK, SRMS, FLT1, DYRK2, SYK, TNK2, TNK1, DYRK1B, MERTK, IGF1R, CLK1, SGK223, DSTYK, 
LCK, MAP2K6, FGFR1 
0.23 0.21 





     




regulation of cholesterol 
efflux 
7 0.37 ABCA1, LRP1, PTCH1, ABCA7, APOE, SIRT1, ABCG1 0.37 0.37 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Membrane 746 39.30 XYLT2, XYLT1, EHMT1, NPIPB11, SLA2, FAM159A, ZFYVE28, FAM134C, NDST1, FAM134A, AKT2, 
CREB3L2, C3AR1, AKT1, PIP4K2B, CEP95, CMKLR1, GABARAPL3, GABARAPL1, PRKCB, DAPK2, PRKCE, 
HPCAL1, SYTL1, CACNA2D2, PRKCA, SCAMP1, TMEM80, TMEM81, SYTL3, ATG12, LRRC37B, BCR, 
SIGIRR, NISCH, RNF125, PRKD3, TMEM79, GPR160, ORAI2, PRKD2, MPPE1, ADPRM, PI4K2A, ABCB1, 
MTMR3, TTYH3, SAR1B, FAXDC2, FPR3, LYPD3, ABCB8, VPS26B, LY9, KIAA0040, XKRX, CHST11, 
NUP85, CHST12, PRKAR2A, RDH10, EPB41L3, CHST15, HMOX1, SSR1, C19ORF38, RHBDL1, ABCA1, 
LRRC37A3, ABCA2, MYH7B, GSDMB, FZD3, DNAH10, DMPK, HOMER2, ABCA9, ABCA7, EHD3, FXYD1, 
SFXN3, NMT2, TNFSF9, FXYD7, STRN, TNFSF8, PLCH2, FXYD5, GPR18, GAPT, ATG2B, HRK, GABRB2, 
OSBPL11, TMEM187, DSTYK, JPH3, C1QTNF6, SMPD1, CTLA4, AP3S1, EMB, GPR135, C11ORF24, 
HAVCR2, FCRL1, FCRL2, KCND1, SLC2A11, SLC39A10, EPS15L1, TMEM175, SIRT2, COQ10A, FAM210B, 
GCHFR, BACE2, SLC7A7, SLC7A8, MMP17, RAPGEF2, VAMP1, SLC18B1, VAMP4, RAPGEF3, VAMP2, 
KANK1, ASAH1, CLDND2, TP53I13, TMF1, ATL1, PELI2, ADCY4, KCNA3, APOLD1, TMEM71, GPR152, 
GGA2, ADAM29, HLA-DMA, ADAM28, GGA3, GPNMB, SLC17A9, TMEM65, SNX27, UCP3, ALOX5, 
SNX25, MFN1, GCNT2, SLC17A5, HAS3, METTL7A, RABAC1, GPR155, P4HTM, RNF130, NKTR, LRRC25, 
COLCA1, IL10RB, SYVN1, DAB2IP, LAPTM5, TMEM62, CRYM-AS1, SLC8B1, BLCAP, DEF6, TMEM154, 
TMEM156, TMEM59, GATM, TMEM159, RNF149, LPCAT4, TMEM56, TAOK2, PKN2, PLP2, CRLF3, 
CRAT, LGR4, TMEM229B, LIMS1, DGKE, SLC27A1, DGKD, ANKRD13D, PLXND1, CLSTN3, FMR1, 
CLSTN1, NCF4, GUCA1B, IL1RAP, AUP1, SLC8A1, CXCL16, TM7SF2, BEST4, LAPTM4A, CYSLTR1, 
SMCHD1, FCGRT, RNF19A, TOM1, SLC16A7, SLC26A11, SLC39A8, MAP3K9, SLC25A42, ZNF566, 
ANKRD13A, SLC16A4, SLC39A3, SEMA6B, IFNAR2, KCNH2, BNIP3L, USP8, LAG3, FBXO18, BTN1A1, 
F2R, STX7, DISP1, ARMCX3, BSCL2, CACNB2, CLEC4C, RAB30, ACAP2, ACAP1, STIM1, SYPL1, STIM2, 
MADD, ROR1, SLC25A53, PTPRCAP, UTRN, SLC27A3, FAM8A1, S100A8, OSBP2, TRABD2A, KMT2E, 




RAB6A, OSBPL8, SLC14A1, CD163, OSBPL7, SLC37A2, OSBPL5, OSBPL3, TNK2, TNK1, PHKB, PTPRE, 
BFSP2, PTPRC, STK24, REEP5, LRFN1, PLEKHM1, SERINC1, FAM26F, OR13A1, SERINC3, LRCH4, OGT, 
SLC26A6, SERINC5, MAP3K12, SERINC4, SLC48A1, ITGB1, FLT1, BMPR2, RNF13, ADPGK, LRRK2, 
CDCA7L, LRMP, ARRB2, ELFN2, ITGAL, NAGPA, SYNE2, FCGR3A, PIP5KL1, PSD3, ITGB7, ATP7A, LBR, 
TAPT1, DGCR2, AMN, APAF1, PVRIG, AVPR2, NDUFC1, KCNAB1, C1ORF162, KSR2, BET1L, TIRAP, 
PTP4A1, ARL4C, ATRN, DNAJC1, RRM2B, SNPH, LCK, DNAJC4, PECAM1, PPP1R12B, DAGLB, 
ST6GALNAC4, ST6GALNAC6, CERS2, RNFT2, LRP1, UNC93B1, PBXIP1, SLC25A29, P2RY6, PARD6A, 
SLC25A28, RAB24, FCHO2, LRRC8C, CEACAM21, LRRC8A, SLC13A5, E2F5, CNNM3, SEC11A, CNNM4, 
MLXIP, SLC35A1, LINGO3, SEMA4D, KCNJ11, RNF24, PCDH9, AMFR, SEMA4B, MBOAT7, SPAG4, 
MBOAT1, HIP1R, MERTK, TPCN1, SCART1, P2RX5, CLEC2B, P2RX1, IL2RB, SLC25A30, CD248, FCGR2B, 
FOLR2, PTPN4, FCGR2C, CD244, SLC25A36, EPHB6, VIPR1, IFITM1, SLC46A1, TRAF3IP3, AHCYL1, CERK, 
ACSM1, SLC23A1, PLEKHB1, GDE1, GCC2, LDLRAD4, ANTXR2, AQP3, TXNDC15, OR52N4, ANPEP, 
GOLGA1, TNFSF10, CPNE1, FAM65B, SLC12A6, SEC62, BRICD5, TRIM23, ARL6IP6, PAQR6, ST6GAL1, 
SLC6A16, IL1R1, COG4, BROX, ARRDC3, AP1B1, ANK1, RUNX1, CYP27A1, KCNQ1, SPATA13, FAM76B, 
KCTD12, EZR, ANKRA2, CUTA, IGSF8, GPM6A, GRB7, TMEM63A, SLC35D1, RRAD, GIPR, EPB41, CD1D, 
APCDD1, CD79B, CD79A, PTDSS1, SNX2, INPP5A, INPP5D, ARSK, SLAMF6, CD14, SEC31B, RAB11FIP4, 
SCAI, SPTBN1, BANP, VAT1, BBS2, TMEM86B, MAGEE1, LRRN2, SYNRG, TNFSF12, SIGLEC10, PARP16, 
UBAC2, MC1R, NCEH1, PARVG, VNN2, LPAR5, ADCK2, CD27, CD24, ITM2B, C2CD2L, CD320, CDS2, 
TNFRSF13B, SLC44A2, DIRAS1, TECR, GRIK3, AATK, MIA3, TNFRSF13C, PCSK7, CD3E, TRAM2, SIPA1L3, 
PPP3CA, MAP1LC3B, GLIPR1, SIPA1L1, SLC22A17, CHMP1B, SLC22A18, PRX, STAB1, CLDN23, QSOX1, 
CCR6, QSOX2, CD36, DIRC2, TMED5, RALGPS2, CD53, CD52, MAP4K2, SYK, BTN3A1, GAA, MINK1, 
ANO8, RHOH, GAB2, BTN3A2, RGMB, LIME1, IL17RA, RHOB, RAB33B, NAALADL1, PITPNM1, CLDN15, 
PITPNM2, TLR9, TLR7, ARHGEF1, CD48, CD47, ATP6V0C, TLR4, GUCY2C, SELPLG, STX16, ZDHHC20, 
DERL3, PTGER2, GDPD1, CXCR4, GDPD3, PRICKLE1, NKD1, STX10, DCST2, ZFP14, MGAT5, KISS1R, 
SUSD3, MGAT1, ATP6V0E2, REM2, LAIR1, MPP1, PNPLA7, PNPLA8, PLEKHA2, KLHL2, ORMDL1, 
PLEKHA3, LHFPL2, MPP7, KBTBD6, ESYT1, RAMP1, PNPLA2, DPAGT1, SCARB2, ITPRIP, DENND5B, 
SPPL2B, CIB1, TMEM140, NR3C2, IGF1R, TMEM143, RGS2, CCND3, RGS3, GNPTAB, SIT1, MPZ, 
FAM198B, ENPP2, TMEM38A, CA14, CD96, UNC5CL, CD300A, IL11RA, ATG9A, SHISA5, ADAM10, 
LMTK2, TSC1, DNAJB14, CYBA, SLC30A1, LMO7, MR1, LAX1, ERMN, MPEG1, KCTD7, PLA2G15, 
ALDH3A2, TMEM134, DPM3, TMX4, DOK3, TBC1D20, TMEM259, CD8A, SIDT1, DPEP2, CD300E, 
WDFY4, ABCG1, CARD11, SIDT2, RTN3, PMEL, GNAZ, PXK, KLHL14, PLD4, ADRB2, NDRG2, RASGRP2, 
ACACB, NDRG1, LPP, PLD3, SEL1L3, TMEM123, CALHM2, MAN2A2, NLRP6, GRK5, MAN2A1, 
TMEM127, ALDH3B1, TMEM129, GRK6, ASIC3, C16ORF54, PACSIN1, ACBD4, MLKL, RARRES3, 
RHBDD1, PTCH1, EPHX1, NKG7, TRPV1, ARHGAP27, BTNL2, TMEM110, GNAO1, GCLC, EFNA3, DLG2, 
TMEM236, CCPG1, PI4KA, DEGS2, GNB5, LRP10, MUC20, SDK2, SLC35E2B, FGFR1, B4GALT3, DYRK2, 
B4GALT1, MS4A7, ATP2A3, SLC2A3, ATP2A1, HMGB1, TMEM191A, TAZ, PKD1, HS2ST1, LMNB1, 
MFSD8, CYP4V2, TMEM107, BLNK, PDE4A, TMEM109, MAN1A1, SCARF2, ABCD1, SUN2, ABCC2, 
RBM15, PLA2G4B, ABCC5, AXIN1, ABHD14A, PEX1, ARAP1, SSTR3, CKAP4, TMEM2, RASA3, CDHR1, 
PEX6, GORASP1, TMEM219, SCN4A, MAN1B1, AGPAT5, RALB, RGS14, ADD3, DLL1, GNA13, CYTH2, 
RAB40B, CNR2, TNKS2, CLMN, GNG7, LEPROTL1, LRIG1, MAN1C1, S1PR1, CDIPT, S1PR4, TAS1R3, 
MBTPS1, GALNT3, ATP13A1, QPCTL, ATP2B4, SCIMP, SGPP1, PIK3IP1, CD6, CD5, ALOX5AP, CD7, 
CHPT1, CMTM1, LPIN2, HCN2, SNTB2 
UP_KEYWO
RDS 
Transmembrane helix 526 27.71 XYLT2, XYLT1, EHMT1, NPIPB11, FAM159A, FAM134C, NDST1, FAM134A, CREB3L2, C3AR1, CEP95, 
CMKLR1, DAPK2, CACNA2D2, SCAMP1, TMEM80, TMEM81, LRRC37B, SIGIRR, TMEM79, GPR160, 
ORAI2, MPPE1, ADPRM, ABCB1, TTYH3, FAXDC2, FPR3, ABCB8, VPS26B, LY9, KIAA0040, XKRX, 




ABCA2, FZD3, DNAH10, DMPK, ABCA9, ABCA7, FXYD1, SFXN3, TNFSF9, FXYD7, TNFSF8, FXYD5, 
GPR18, GAPT, HRK, GABRB2, TMEM187, JPH3, C1QTNF6, SMPD1, CTLA4, EMB, GPR135, C11ORF24, 
HAVCR2, FCRL1, FCRL2, KCND1, SLC2A11, SLC39A10, TMEM175, FAM210B, BACE2, SLC7A7, SLC7A8, 
VAMP1, SLC18B1, VAMP4, VAMP2, ASAH1, CLDND2, TP53I13, ATL1, PELI2, ADCY4, KCNA3, APOLD1, 
TMEM71, GPR152, ADAM29, HLA-DMA, ADAM28, GPNMB, SLC17A9, TMEM65, UCP3, MFN1, GCNT2, 
SLC17A5, HAS3, METTL7A, RABAC1, GPR155, P4HTM, RNF130, LRRC25, COLCA1, IL10RB, SYVN1, 
LAPTM5, TMEM62, CRYM-AS1, SLC8B1, BLCAP, TMEM154, TMEM156, TMEM59, TMEM159, RNF149, 
LPCAT4, TMEM56, TAOK2, PKN2, PLP2, CRLF3, LGR4, TMEM229B, DGKE, SLC27A1, PLXND1, CLSTN3, 
CLSTN1, IL1RAP, AUP1, SLC8A1, CXCL16, TM7SF2, BEST4, LAPTM4A, CYSLTR1, SMCHD1, FCGRT, 
RNF19A, SLC16A7, SLC26A11, SLC39A8, MAP3K9, SLC25A42, ZNF566, SLC16A4, SLC39A3, SEMA6B, 
IFNAR2, KCNH2, BNIP3L, LAG3, FBXO18, BTN1A1, F2R, STX7, DISP1, ARMCX3, BSCL2, CLEC4C, STIM1, 
SYPL1, STIM2, ROR1, SLC25A53, PTPRCAP, SLC27A3, FAM8A1, TRABD2A, LCN8, ABHD3, INSIG2, 
ITPR2, SLC9A1, ITPRIPL1, TBXA2R, OSBPL8, SLC14A1, CD163, SLC37A2, OSBPL5, PTPRE, PTPRC, REEP5, 
LRFN1, SERINC1, FAM26F, OR13A1, SERINC3, LRCH4, SLC26A6, SERINC5, SERINC4, SLC48A1, ITGB1, 
FLT1, BMPR2, RNF13, ADPGK, CDCA7L, LRMP, ELFN2, ITGAL, NAGPA, SYNE2, FCGR3A, ITGB7, ATP7A, 
LBR, TAPT1, DGCR2, AMN, APAF1, PVRIG, AVPR2, NDUFC1, C1ORF162, BET1L, ATRN, DNAJC1, 
RRM2B, SNPH, DNAJC4, PECAM1, PPP1R12B, DAGLB, ST6GALNAC4, ST6GALNAC6, CERS2, RNFT2, 
LRP1, UNC93B1, PBXIP1, SLC25A29, P2RY6, SLC25A28, LRRC8C, CEACAM21, LRRC8A, SLC13A5, E2F5, 
CNNM3, SEC11A, CNNM4, SLC35A1, LINGO3, SEMA4D, KCNJ11, RNF24, PCDH9, AMFR, SEMA4B, 
MBOAT7, SPAG4, MBOAT1, MERTK, TPCN1, SCART1, P2RX5, CLEC2B, P2RX1, IL2RB, SLC25A30, 
CD248, FCGR2B, FCGR2C, CD244, SLC25A36, EPHB6, VIPR1, IFITM1, SLC46A1, TRAF3IP3, ACSM1, 
SLC23A1, GDE1, LDLRAD4, ANTXR2, AQP3, TXNDC15, OR52N4, ANPEP, TNFSF10, SLC12A6, SEC62, 
BRICD5, ARL6IP6, PAQR6, ST6GAL1, SLC6A16, IL1R1, KCNQ1, FAM76B, CUTA, IGSF8, GPM6A, 
TMEM63A, SLC35D1, GIPR, EPB41, CD1D, APCDD1, CD79B, CD79A, PTDSS1, ARSK, SLAMF6, SCAI, 
BANP, TMEM86B, LRRN2, TNFSF12, SIGLEC10, PARP16, UBAC2, MC1R, NCEH1, LPAR5, ADCK2, CD27, 
ITM2B, C2CD2L, CD320, CDS2, TNFRSF13B, SLC44A2, TECR, GRIK3, AATK, MIA3, TNFRSF13C, PCSK7, 
CD3E, TRAM2, GLIPR1, SLC22A17, SLC22A18, STAB1, CLDN23, QSOX1, CCR6, QSOX2, CD36, DIRC2, 
TMED5, CD53, CD52, MAP4K2, BTN3A1, GAA, ANO8, BTN3A2, LIME1, IL17RA, NAALADL1, CLDN15, 
TLR9, TLR7, CD48, CD47, ATP6V0C, TLR4, GUCY2C, SELPLG, STX16, ZDHHC20, DERL3, PTGER2, GDPD1, 
CXCR4, GDPD3, STX10, DCST2, ZFP14, MGAT5, KISS1R, SUSD3, MGAT1, ATP6V0E2, LAIR1, PNPLA7, 
PNPLA8, KLHL2, ORMDL1, LHFPL2, KBTBD6, ESYT1, RAMP1, PNPLA2, DPAGT1, SCARB2, DENND5B, 
SPPL2B, TMEM140, IGF1R, TMEM143, GNPTAB, SIT1, MPZ, FAM198B, ENPP2, TMEM38A, CA14, 
CD96, UNC5CL, CD300A, IL11RA, ATG9A, SHISA5, ADAM10, LMTK2, DNAJB14, CYBA, SLC30A1, LMO7, 
MR1, LAX1, ERMN, MPEG1, ALDH3A2, TMEM134, DPM3, TMX4, TBC1D20, TMEM259, CD8A, SIDT1, 
CD300E, WDFY4, ABCG1, SIDT2, RTN3, PMEL, PLD4, ADRB2, NDRG2, PLD3, SEL1L3, TMEM123, 
CALHM2, MAN2A2, MAN2A1, TMEM127, TMEM129, ASIC3, C16ORF54, ACBD4, RARRES3, RHBDD1, 
PTCH1, EPHX1, NKG7, TRPV1, BTNL2, TMEM110, GCLC, TMEM236, CCPG1, DEGS2, LRP10, SDK2, 
SLC35E2B, FGFR1, B4GALT3, DYRK2, B4GALT1, MS4A7, ATP2A3, SLC2A3, ATP2A1, TMEM191A, TAZ, 
PKD1, HS2ST1, MFSD8, CYP4V2, TMEM107, TMEM109, MAN1A1, SCARF2, ABCD1, SUN2, ABCC2, 
ABCC5, ABHD14A, SSTR3, CKAP4, TMEM2, CDHR1, TMEM219, SCN4A, MAN1B1, AGPAT5, DLL1, 
CNR2, CLMN, LEPROTL1, LRIG1, MAN1C1, S1PR1, CDIPT, S1PR4, TAS1R3, MBTPS1, GALNT3, ATP13A1, 
QPCTL, ATP2B4, SCIMP, SGPP1, PIK3IP1, CD6, CD5, ALOX5AP, CD7, CHPT1, CMTM1, HCN2 
UP_KEYWO
RDS 
Transmembrane 527 27.77 XYLT2, XYLT1, EHMT1, NPIPB11, FAM159A, FAM134C, NDST1, FAM134A, CREB3L2, C3AR1, CEP95, 
CMKLR1, DAPK2, CACNA2D2, SCAMP1, TMEM80, TMEM81, LRRC37B, SIGIRR, TMEM79, GPR160, 
ORAI2, MPPE1, ADPRM, ABCB1, TTYH3, FAXDC2, FPR3, ABCB8, VPS26B, LY9, KIAA0040, XKRX, 




ABCA2, FZD3, DNAH10, DMPK, ABCA9, ABCA7, FXYD1, SFXN3, TNFSF9, FXYD7, TNFSF8, FXYD5, 
GPR18, GAPT, HRK, GABRB2, TMEM187, JPH3, C1QTNF6, SMPD1, CTLA4, EMB, GPR135, C11ORF24, 
HAVCR2, FCRL1, FCRL2, KCND1, SLC2A11, SLC39A10, TMEM175, FAM210B, BACE2, SLC7A7, SLC7A8, 
VAMP1, SLC18B1, VAMP4, VAMP2, ASAH1, CLDND2, TP53I13, ATL1, PELI2, ADCY4, KCNA3, APOLD1, 
TMEM71, GPR152, ADAM29, HLA-DMA, ADAM28, GPNMB, SLC17A9, TMEM65, UCP3, MFN1, GCNT2, 
SLC17A5, HAS3, METTL7A, RABAC1, GPR155, P4HTM, RNF130, LRRC25, COLCA1, IL10RB, SYVN1, 
LAPTM5, TMEM62, CRYM-AS1, SLC8B1, BLCAP, TMEM154, TMEM156, TMEM59, TMEM159, RNF149, 
LPCAT4, TMEM56, TAOK2, PKN2, PLP2, CRLF3, LGR4, TMEM229B, DGKE, SLC27A1, PLXND1, CLSTN3, 
CLSTN1, IL1RAP, AUP1, SLC8A1, CXCL16, TM7SF2, BEST4, LAPTM4A, CYSLTR1, SMCHD1, FCGRT, 
RNF19A, SLC16A7, SLC26A11, SLC39A8, MAP3K9, SLC25A42, ZNF566, SLC16A4, SLC39A3, SEMA6B, 
IFNAR2, KCNH2, BNIP3L, LAG3, FBXO18, BTN1A1, F2R, STX7, DISP1, ARMCX3, BSCL2, CLEC4C, STIM1, 
SYPL1, STIM2, ROR1, SLC25A53, PTPRCAP, SLC27A3, FAM8A1, TRABD2A, LCN8, ABHD3, INSIG2, 
ITPR2, SLC9A1, ITPRIPL1, TBXA2R, OSBPL8, SLC14A1, CD163, SLC37A2, OSBPL5, PTPRE, PTPRC, REEP5, 
LRFN1, SERINC1, FAM26F, OR13A1, SERINC3, LRCH4, SLC26A6, SERINC5, SERINC4, SLC48A1, ITGB1, 
FLT1, BMPR2, RNF13, ADPGK, CDCA7L, LRMP, ELFN2, ITGAL, NAGPA, SYNE2, FCGR3A, ITGB7, ATP7A, 
LBR, TAPT1, DGCR2, AMN, APAF1, PVRIG, AVPR2, NDUFC1, C1ORF162, BET1L, ATRN, DNAJC1, 
RRM2B, SNPH, DNAJC4, PECAM1, PPP1R12B, DAGLB, ST6GALNAC4, ST6GALNAC6, CERS2, RNFT2, 
LRP1, UNC93B1, PBXIP1, SLC25A29, P2RY6, SLC25A28, LRRC8C, CEACAM21, LRRC8A, SLC13A5, E2F5, 
CNNM3, SEC11A, CNNM4, SLC35A1, LINGO3, SEMA4D, KCNJ11, RNF24, PCDH9, AMFR, SEMA4B, 
MBOAT7, SPAG4, MBOAT1, MERTK, TPCN1, SCART1, P2RX5, CLEC2B, P2RX1, IL2RB, SLC25A30, 
CD248, FCGR2B, FCGR2C, CD244, SLC25A36, EPHB6, VIPR1, IFITM1, SLC46A1, TRAF3IP3, ACSM1, 
SLC23A1, GDE1, LDLRAD4, ANTXR2, AQP3, TXNDC15, OR52N4, ANPEP, TNFSF10, SLC12A6, SEC62, 
BRICD5, ARL6IP6, PAQR6, ST6GAL1, SLC6A16, IL1R1, RUNX1, KCNQ1, FAM76B, CUTA, IGSF8, GPM6A, 
TMEM63A, SLC35D1, GIPR, EPB41, CD1D, APCDD1, CD79B, CD79A, PTDSS1, ARSK, SLAMF6, SCAI, 
BANP, TMEM86B, LRRN2, TNFSF12, SIGLEC10, PARP16, UBAC2, MC1R, NCEH1, LPAR5, ADCK2, CD27, 
ITM2B, C2CD2L, CD320, CDS2, TNFRSF13B, SLC44A2, TECR, GRIK3, AATK, MIA3, TNFRSF13C, PCSK7, 
CD3E, TRAM2, GLIPR1, SLC22A17, SLC22A18, STAB1, CLDN23, QSOX1, CCR6, QSOX2, CD36, DIRC2, 
TMED5, CD53, CD52, MAP4K2, BTN3A1, GAA, ANO8, BTN3A2, LIME1, IL17RA, NAALADL1, CLDN15, 
TLR9, TLR7, CD48, CD47, ATP6V0C, TLR4, GUCY2C, SELPLG, STX16, ZDHHC20, DERL3, PTGER2, GDPD1, 
CXCR4, GDPD3, STX10, DCST2, ZFP14, MGAT5, KISS1R, SUSD3, MGAT1, ATP6V0E2, LAIR1, PNPLA7, 
PNPLA8, KLHL2, ORMDL1, LHFPL2, KBTBD6, ESYT1, RAMP1, PNPLA2, DPAGT1, SCARB2, DENND5B, 
SPPL2B, TMEM140, IGF1R, TMEM143, GNPTAB, SIT1, MPZ, FAM198B, ENPP2, TMEM38A, CA14, 
CD96, UNC5CL, CD300A, IL11RA, ATG9A, SHISA5, ADAM10, LMTK2, DNAJB14, CYBA, SLC30A1, LMO7, 
MR1, LAX1, ERMN, MPEG1, ALDH3A2, TMEM134, DPM3, TMX4, TBC1D20, TMEM259, CD8A, SIDT1, 
CD300E, WDFY4, ABCG1, SIDT2, RTN3, PMEL, PLD4, ADRB2, NDRG2, PLD3, SEL1L3, TMEM123, 
CALHM2, MAN2A2, MAN2A1, TMEM127, TMEM129, ASIC3, C16ORF54, ACBD4, RARRES3, RHBDD1, 
PTCH1, EPHX1, NKG7, TRPV1, BTNL2, TMEM110, GCLC, TMEM236, CCPG1, DEGS2, LRP10, SDK2, 
SLC35E2B, FGFR1, B4GALT3, DYRK2, B4GALT1, MS4A7, ATP2A3, SLC2A3, ATP2A1, TMEM191A, TAZ, 
PKD1, HS2ST1, MFSD8, CYP4V2, TMEM107, TMEM109, MAN1A1, SCARF2, ABCD1, SUN2, ABCC2, 
ABCC5, ABHD14A, SSTR3, CKAP4, TMEM2, CDHR1, TMEM219, SCN4A, MAN1B1, AGPAT5, DLL1, 
CNR2, CLMN, LEPROTL1, LRIG1, MAN1C1, S1PR1, CDIPT, S1PR4, TAS1R3, MBTPS1, GALNT3, ATP13A1, 
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Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa04662:B cell receptor 
signaling pathway 
19 1.00 SYK, NFATC3, NFATC1, PIK3R1, FOS, VAV1, CD79B, CD79A, PPP3CA, AKT2, INPP5D, BLNK, PLCG2, 




14 0.74 MAP3K1, SYK, PRKCB, NFATC3, NFATC1, PRKCA, FOS, VAV1, CD79B, CD79A, PPP3CA, BLNK, CALM1, 
SOS1 
0.02 0.02 
BIOCARTA h_tcrPathway:T Cell 
Receptor Signaling 
Pathway 





hsa04660:T cell receptor 
signaling pathway 
19 1.00 ITK, NFATC3, NFATC1, PIK3R1, FOS, CD3E, VAV1, PPP3CA, PTPRC, LCK, CD8A, AKT2, AKT1, CTLA4, 
MAPK1, LCP2, SOS1, SOS2, CARD11 
0.10 0.10 
BIOCARTA h_fcer1Pathway:Fc 
Epsilon Receptor I 
Signaling in Mast Cells 




cell mediated cytotoxicity 
19 1.00 IFNAR2, SYK, PRKCB, NFATC1, PRKCA, PIK3R1, ITGAL, VAV1, PPP3CA, FCGR3A, LCK, TNFSF10, PLCG2, 
MAPK1, LCP2, CD48, SOS1, SOS2, CD244 
0.39 0.37 





     





10 0.53 ABCA1, ABCA2, ABCB1, ABCC2, ABCC5, ABCA9, ABCB8, ABCA7, ABCD1, ABCG1 0.26 0.24 





     





10 0.53 ALDH3A2, KMT2E, EHMT2, SETD7, SETDB2, EHMT1, WHSC1, COLGALT1, WHSC1L1, ALDH9A1 0.48 0.45 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Glycogen metabolism 6 0.32 AKT2, PPP1R3E, PHKG2, AKT1, PHKB, PYGM 0.44 0.41 







     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Protein phosphatase 18 0.95 PTPN18, MTMR3, PPM1J, PTPN22, PTPN12, PPM1K, DUSP26, PPM1D, SSH2, CDC25B, PDP1, PTP4A1, 
PPP3CA, PTPRE, PTPRC, CTDSP2, PTPN7, PTPN4 
0.43 0.40 





     
Category Term Count % Genes Benjamini FDR 
KEGG_PATH
WAY 
hsa04664:Fc epsilon RI 
signaling pathway 
17 0.90 MAP2K3, SYK, PRKCB, PLA2G4B, PRKCA, PIK3R1, GAB2, VAV1, AKT2, INPP5D, PLCG2, AKT1, MAPK1, 






17 0.90 SYK, PRKCB, PRKCE, LIMK2, PRKCA, PIK3R1, GAB2, VAV1, CRKL, PTPRC, BIN1, AKT2, INPP5D, PLCG2, 










metabolism in cancer 
19 1.00 DGKE, DGKD, SLC44A2, PRKCB, DGKA, PLA2G4B, PRKCA, TSC1, PIK3R1, FOS, GPCPD1, AKT2, PDGFD, 











15 0.79 EGLN1, CDKN1B, FLT1, PFKFB3, PRKCB, PRKCA, PIK3R1, IGF1R, AKT2, PLCG2, AKT1, EP300, MAPK1, 
HMOX1, TLR4 
0.48 0.45 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Biological rhythms 17 0.90 KLF10, CRTC1, CIPC, CREM, NR1D2, NR1D1, SIRT1, PER1, KAT2B, RAI1, DBP, KLF9, ID3, EP300, FBXL3, 
OGT, LGR4 
0.46 0.42 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Cell cycle 75 3.95 CDKN1C, CDKN1B, NUMA1, CDCA7L, DDX12P, CIB1, NR3C1, ING1, SMC4, ING4, CCND3, RASSF1, 
RGS2, MIS18BP1, CHMP1B, RB1CC1, CNTRL, EP300, LZTS2, TSPYL2, USP8, LIG1, PRKCE, CKAP2, 
VASH1, SIRT2, CDC40, CDC25B, GAK, RBL2, PTP4A1, KAT2B, LATS2, PAPD7, TXNIP, MCM6, KIF20B, 




PPM1D, PARD6A, MAPK1, STOX1, BANP, CDKN2D, CENPT, RBM38, CDK19, CDK11A, PYHIN1, SETDB2, 
DAB2IP, CABLES1, BLCAP, RGCC, CCPG1, PRC1, TACC3, PHF13, NCAPD2, PKN2, ATM, SYCP3, CUL4B, 





     
Category Term Count % Genes Benjamini FDR 
UP_KEYWO
RDS 
Immunoglobulin domain 59 3.11 MYOM1, FLT1, WFIKKN1, IL1RAP, CD3E, FCRLA, VPREB3, FCRLB, FCGR3A, FCGRT, MPZ, CTLA4, EMB, 
HAVCR2, FCRL1, FCRL2, CD96, LAG3, BTN3A1, IL11RA, CD300A, IL1R1, BTN1A1, BTN3A2, HSPG2, 
MR1, TMEM81, SIGIRR, OBSCN, CD8A, PECAM1, CD300E, ROR1, CD48, CD47, IGSF8, CD1D, LY9, 
CD79B, CD79A, HLA-DMA, LRIG1, CEACAM21, SLAMF6, LAIR1, LINGO3, SEMA4D, LRRN2, SEMA4B, 
SIGLEC10, BTNL2, MERTK, LRFN1, CD7, FCGR2B, FCGR2C, SDK2, CD244, FGFR1 
0.39 0.36 
 
